No., subject, TM-score, RMSD, Sequence Identity, Subject length, Aligned length, Description
1, d3ikaB_, 1.0000, 0.00, 1.000, 310, 310, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M MUTANT COVALENTLY BINDING TO WZ4002
2, d2jitB_, 0.9691, 1.19, 0.987, 312, 308, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN T790M MUTATION
3, d5xgnB_, 0.9614, 1.10, 0.997, 308, 304, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M/C797S IN COMPLEX WITH GO6976
4, d2jiuB_, 0.9562, 0.75, 0.993, 309, 300, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN T790M MUTATION IN COMPLEX WITH AEE788
5, d4g5pB_, 0.9483, 1.16, 0.993, 303, 301, CRYSTAL STRUCTURE OF EGFR KINASE T790M IN COMPLEX WITH BIBW2992
6, d3w2rA_, 0.8823, 1.73, 0.872, 297, 290, EGFR KINASE DOMAIN T790M/L858R MUTANT WITH COMPOUND 4
7, d2jitA_, 0.8814, 1.89, 0.880, 299, 292, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN T790M MUTATION
8, d3w32A_, 0.8782, 2.49, 0.836, 317, 299, EGFR KINASE DOMAIN COMPLEXED WITH COMPOUND 20A
9, d3ikaA_, 0.8746, 2.35, 0.834, 310, 296, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M MUTANT COVALENTLY BINDING TO WZ4002
10, d4g5pA_, 0.8724, 2.05, 0.863, 299, 292, CRYSTAL STRUCTURE OF EGFR KINASE T790M IN COMPLEX WITH BIBW2992
11, d3pp0B_, 0.8716, 2.10, 0.704, 296, 291, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN HER2 (ERBB2).
12, d2jiuA_, 0.8710, 2.02, 0.862, 303, 290, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN T790M MUTATION IN COMPLEX WITH AEE788
13, d5xgnA_, 0.8662, 2.26, 0.842, 302, 292, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M/C797S IN COMPLEX WITH GO6976
14, d1xkkA_, 0.8489, 2.34, 0.829, 289, 286, EGFR KINASE DOMAIN COMPLEXED WITH A QUINAZOLINE INHIBITOR- GW572016
15, d3w2sA_, 0.8450, 2.60, 0.856, 307, 291, EGFR KINASE DOMAIN WITH COMPOUND4
16, d3w33A_, 0.8408, 2.28, 0.883, 297, 283, EGFR KINASE DOMAIN COMPLEXED WITH COMPOUND 19B
17, d3pozA_, 0.8392, 2.47, 0.877, 293, 285, EGFR KINASE DOMAIN COMPLEXED WITH TAK-285
18, d2rgpA_, 0.8382, 2.20, 0.843, 284, 280, STRUCTURE OF EGFR IN COMPLEX WITH HYDRAZONE A POTENT DUAL INHIBITOR
19, d5hg5A_, 0.8379, 2.43, 0.806, 302, 284, EGFR (L858R T790M V948R) IN COMPLEX WITH N-{3-[(2-{[4-(4- METHYLPIPERAZIN-1-YL)PHENYL]AMINO}-7H-PYRROLO[23-D]PYRIMIDIN-4-YL) OXY]PHENYL}PROP-2-ENAMIDE
20, d5hg8A_, 0.8371, 2.56, 0.804, 300, 285, EGFR (L858R T790M V948R) IN COMPLEX WITH N-[3-({2-[(1-METHYL-1H- PYRAZOL-4-YL)AMINO]-7H-PYRROLO[23-D]PYRIMIDIN-4-YL}OXY)PHENYL]PROP- 2-ENAMIDE
21, d3pp0A_, 0.8347, 2.21, 0.707, 286, 280, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN HER2 (ERBB2).
22, d5cnnB_, 0.8282, 2.35, 0.842, 304, 279, CRYSTAL STRUCTURE OF THE EGFR KINASE DOMAIN MUTANT I682Q
23, d3belA_, 0.8273, 2.19, 0.844, 280, 276, X-RAY STRUCTURE OF EGFR IN COMPLEX WITH OXIME INHIBITOR
24, d2r4bA_, 0.8261, 2.00, 0.696, 292, 273, ERBB4 KINASE DOMAIN COMPLEXED WITH A THIENOPYRIMIDINE INHIBITOR
25, d4zseA_, 0.8258, 2.40, 0.828, 297, 279, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M/V948R CRYSTAL FORM II
26, d5d41B_, 0.8251, 2.30, 0.830, 302, 277, EGFR KINASE DOMAIN IN COMPLEX WITH MUTANT SELECTIVE ALLOSTERIC INHIBITOR
27, d2gs7B_, 0.8241, 2.36, 0.812, 288, 277, CRYSTAL STRUCTURE OF THE INACTIVE EGFR KINASE DOMAIN IN COMPLEX WITH AMP-PNP
28, d2r4bB_, 0.8236, 1.99, 0.699, 291, 272, ERBB4 KINASE DOMAIN COMPLEXED WITH A THIENOPYRIMIDINE INHIBITOR
29, d4zseB_, 0.8234, 2.68, 0.839, 313, 280, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M/V948R CRYSTAL FORM II
30, d4i24B_, 0.8230, 2.38, 0.855, 304, 276, STRUCTURE OF T790M EGFR KINASE DOMAIN CO-CRYSTALLIZED WITH DACOMITINIB
31, d4riyD_, 0.8216, 2.43, 0.854, 297, 281, CRYSTAL STRUCTURE OF AN EGFR/HER3 KINASE DOMAIN HETERODIMER CONTAINING THE CANCER-ASSOCIATED HER3-E909G MUTATION
32, d2gs6A2, 0.8203, 3.08, 0.852, 308, 291, CRYSTAL STRUCTURE OF THE ACTIVE EGFR KINASE DOMAIN IN COMPLEX WITH AN ATP ANALOG-PEPTIDE CONJUGATE
33, d2j5eA_, 0.8195, 3.03, 0.849, 309, 291, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN IN COMPLEX WITH AN IRREVERSIBLE INHIBITOR 13-JAB
34, d4rixD_, 0.8194, 2.49, 0.854, 297, 281, CRYSTAL STRUCTURE OF AN EGFR/HER3 KINASE DOMAIN HETERODIMER CONTAINING THE CANCER-ASSOCIATED HER3-Q790R MUTATION
35, d4riwD_, 0.8189, 2.48, 0.854, 297, 281, CRYSTAL STRUCTURE OF AN EGFR/HER3 KINASE DOMAIN HETERODIMER
36, d5d41A_, 0.8187, 2.28, 0.818, 300, 275, EGFR KINASE DOMAIN IN COMPLEX WITH MUTANT SELECTIVE ALLOSTERIC INHIBITOR
37, d5gnkA_, 0.8186, 2.06, 0.867, 277, 271, CRYSTAL STRUCTURE OF EGFR 696-988 T790M IN COMPLEX WITH LXX-6-34
38, d3gt8C_, 0.8186, 2.37, 0.851, 296, 275, CRYSTAL STRUCTURE OF THE INACTIVE EGFR KINASE DOMAIN IN COMPLEX WITH AMP-PNP
39, d5hibA_, 0.8184, 3.27, 0.791, 314, 296, EGFR KINASE DOMAIN MUTANT TMLR WITH A PYRAZOLOPYRIMIDINE INHIBITOR
40, d5cnoA_, 0.8169, 2.32, 0.839, 300, 274, CRYSTAL STRUCTURE OF THE EGFR KINASE DOMAIN MUTANT V924R
41, d4zseD_, 0.8167, 2.37, 0.836, 297, 275, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M/V948R CRYSTAL FORM II
42, d4zseC_, 0.8166, 2.41, 0.840, 301, 275, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M/V948R CRYSTAL FORM II
43, d3gt8A_, 0.8166, 2.33, 0.829, 300, 275, CRYSTAL STRUCTURE OF THE INACTIVE EGFR KINASE DOMAIN IN COMPLEX WITH AMP-PNP
44, d3gt8B_, 0.8158, 2.31, 0.825, 292, 274, CRYSTAL STRUCTURE OF THE INACTIVE EGFR KINASE DOMAIN IN COMPLEX WITH AMP-PNP
45, d2itpA_, 0.8158, 3.18, 0.777, 305, 291, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN G719S MUTATION IN COMPLEX WITH AEE788
46, d5xdkA_, 0.8155, 3.17, 0.856, 307, 291, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M IN COMPLEX WITH CO-1686
47, d5cnoB_, 0.8155, 2.50, 0.833, 302, 276, CRYSTAL STRUCTURE OF THE EGFR KINASE DOMAIN MUTANT V924R
48, d5cnnA_, 0.8153, 2.41, 0.840, 300, 275, CRYSTAL STRUCTURE OF THE EGFR KINASE DOMAIN MUTANT I682Q
49, d5em8A_, 0.8152, 3.14, 0.841, 303, 290, EGFR KINASE DOMAIN WITH PYRIDONE COMPOUND 13: 4-[(2-METHOXYPHENYL) AMINO]-~{N}-[4-(4-METHYLPIPERAZIN-1-YL)PHENYL]-2-OXIDANYLIDENE-1~{H}- PYRIDINE-3-CARBOXAMIDE
50, d4li5A1, 0.8150, 2.66, 0.812, 303, 282, EGFR-K IN COMPLEX WITH N-[3-[[5-CHLORO-4-(1H-INDOL-3-YL)PYRIMIDIN-2- YL]AMINO]-4-METHOXY-PHENYL] PROP-2-ENAMIDE
51, d2j6mA_, 0.8150, 3.10, 0.772, 306, 289, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN IN COMPLEX WITH AEE788
52, d3gt8D_, 0.8137, 2.21, 0.845, 295, 271, CRYSTAL STRUCTURE OF THE INACTIVE EGFR KINASE DOMAIN IN COMPLEX WITH AMP-PNP
53, d5gtyA_, 0.8128, 2.31, 0.861, 300, 273, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M IN COMPLEX WITH LXX-6-26
54, d5gtzA_, 0.8127, 3.46, 0.826, 317, 298, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M IN COMPLEX WITH JTS-1-39
55, d2gs2A_, 0.8121, 3.23, 0.849, 305, 291, CRYSTAL STRUCTURE OF THE ACTIVE EGFR KINASE DOMAIN
56, d3w2qA1, 0.8110, 3.28, 0.808, 306, 292, EGFR KINASE DOMAIN T790M/L858R MUTANT WITH HKI-272
57, d5cavA_, 0.8108, 3.17, 0.786, 306, 290, EGFR KINASE DOMAIN WITH COMPOUND 41A
58, d5gtyB_, 0.8107, 2.33, 0.853, 299, 272, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M IN COMPLEX WITH LXX-6-26
59, d4riyB_, 0.8105, 2.41, 0.852, 293, 277, CRYSTAL STRUCTURE OF AN EGFR/HER3 KINASE DOMAIN HETERODIMER CONTAINING THE CANCER-ASSOCIATED HER3-E909G MUTATION
60, d2itxA_, 0.8105, 3.34, 0.829, 307, 292, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN IN COMPLEX WITH AMP- PNP
61, d4lqmA_, 0.8097, 3.14, 0.828, 305, 290, EGFR L858R IN COMPLEX WITH PD168393
62, d5gtyH_, 0.8093, 2.32, 0.867, 300, 271, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M IN COMPLEX WITH LXX-6-26
63, d2j5fA_, 0.8093, 3.19, 0.814, 308, 291, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN IN COMPLEX WITH AN IRREVERSIBLE INHIBITOR 34-JAB
64, d5ugbA_, 0.8092, 2.94, 0.837, 307, 283, CRYSTAL STRUCTURE OF THE EGFR KINASE DOMAIN IN COMPLEX WITH 4-(4-{[2- {[(3S)-1-ACETYLPYRROLIDIN-3-YL]AMINO}-9-(PROPAN-2-YL)-9H-PURIN-6- YL]AMINO}PHENYL)-1-METHYLPIPERAZIN-1-IUM
65, d5gtyG_, 0.8091, 2.39, 0.867, 299, 271, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M IN COMPLEX WITH LXX-6-26
66, d4i22A_, 0.8085, 2.33, 0.852, 297, 271, STRUCTURE OF THE MONOMERIC (V948R)GEFITINIB/ERLOTINIB RESISTANT DOUBLE MUTANT (L858R+T790M) EGFR KINASE DOMAIN CO-CRYSTALLIZED WITH GEFITINIB
67, d4rixB_, 0.8082, 2.47, 0.852, 293, 277, CRYSTAL STRUCTURE OF AN EGFR/HER3 KINASE DOMAIN HETERODIMER CONTAINING THE CANCER-ASSOCIATED HER3-Q790R MUTATION
68, d2eb2A_, 0.8081, 3.14, 0.854, 305, 288, CRYSTAL STRUCTURE OF MUTATED EGFR KINASE DOMAIN (G719S)
69, d2itqA_, 0.8074, 3.09, 0.819, 300, 287, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN G719S MUTATION IN COMPLEX WITH AFN941
70, d2gs7A_, 0.8073, 2.33, 0.819, 281, 271, CRYSTAL STRUCTURE OF THE INACTIVE EGFR KINASE DOMAIN IN COMPLEX WITH AMP-PNP
71, d3w2oA1, 0.8070, 3.32, 0.808, 304, 292, EGFR KINASE DOMAIN T790M/L858R MUTANT WITH TAK-285
72, d5gtyF_, 0.8069, 2.31, 0.856, 297, 270, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M IN COMPLEX WITH LXX-6-26
73, d4hjoA_, 0.8069, 2.16, 0.825, 278, 268, CRYSTAL STRUCTURE OF THE INACTIVE EGFR TYROSINE KINASE DOMAIN WITH ERLOTINIB
74, d4riwB_, 0.8068, 2.48, 0.852, 293, 277, CRYSTAL STRUCTURE OF AN EGFR/HER3 KINASE DOMAIN HETERODIMER
75, d3w2pA1, 0.8064, 3.33, 0.810, 307, 290, EGFR KINASE DOMAIN T790M/L858R MUTANT WITH COMPOUND 2
76, d5j9yA_, 0.8058, 3.02, 0.856, 300, 285, EGFR-T790M IN COMPLEX WITH PYRAZOLOPYRIMIDINE INHIBITOR 1B
77, d4wkqA1, 0.8045, 2.77, 0.871, 294, 280, 1.85 ANGSTROM STRUCTURE OF EGFR KINASE DOMAIN WITH GEFITINIB
78, d3ug2A_, 0.8043, 3.03, 0.874, 299, 285, CRYSTAL STRUCTURE OF THE MUTATED EGFR KINASE DOMAIN (G719S/T790M) IN COMPLEX WITH GEFITINIB
79, d3bceB_, 0.8042, 2.62, 0.705, 286, 278, CRYSTAL STRUCTURE OF THE ERBB4 KINASE
80, d3bceC_, 0.8038, 2.63, 0.698, 286, 278, CRYSTAL STRUCTURE OF THE ERBB4 KINASE
81, d4i24A_, 0.8034, 2.24, 0.869, 295, 267, STRUCTURE OF T790M EGFR KINASE DOMAIN CO-CRYSTALLIZED WITH DACOMITINIB
82, d5gtyC_, 0.8031, 2.26, 0.859, 295, 269, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M IN COMPLEX WITH LXX-6-26
83, d2itwA_, 0.8028, 3.16, 0.815, 300, 287, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN IN COMPLEX WITH AFN941
84, d5gtyE_, 0.8022, 2.35, 0.859, 297, 270, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M IN COMPLEX WITH LXX-6-26
85, d3vjnA_, 0.8020, 3.13, 0.863, 297, 285, CRYSTAL STRUCTURE OF THE MUTATED EGFR KINASE DOMAIN (G719S/T790M) IN COMPLEX WITH AMPPNP.
86, d5gtyD_, 0.8018, 2.31, 0.862, 297, 269, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M IN COMPLEX WITH LXX-6-26
87, d4i23A_, 0.8017, 3.00, 0.851, 304, 281, CRYSTAL STRUCTURE OF THE WILD-TYPE EGFR KINASE DOMAIN IN COMPLEX WITH DACOMITINIB (SOAKED)
88, d3ug1A_, 0.8017, 3.01, 0.799, 296, 283, CRYSTAL STRUCTURE OF THE MUTATED EGFR KINASE DOMAIN (G719S/T790M) IN THE APO FORM
89, d2itzA_, 0.8002, 3.28, 0.765, 302, 289, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN L858R MUTATION IN COMPLEX WITH IRESSA
90, d1m17A_, 0.7999, 2.90, 0.807, 312, 280, EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE DOMAIN WITH 4-ANILINOQUINAZOLINE INHIBITOR ERLOTINIB
91, d3vjoA_, 0.7998, 2.99, 0.873, 298, 283, CRYSTAL STRUCTURE OF THE WILD-TYPE EGFR KINASE DOMAIN IN COMPLEX WITH AMPPNP.
92, d4jq8A_, 0.7996, 2.87, 0.796, 303, 279, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN IN COMPLEX WITH COMPOUND 4B
93, d3bceA_, 0.7984, 2.67, 0.697, 285, 277, CRYSTAL STRUCTURE OF THE ERBB4 KINASE
94, d4jrvA_, 0.7967, 2.81, 0.853, 300, 278, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN IN COMPLEX WITH COMPOUND 4C
95, d3kexA_, 0.7958, 2.35, 0.504, 292, 270, CRYSTAL STRUCTURE OF THE CATALYTICALLY INACTIVE KINASE DOMAIN OF THE HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 3 (HER3)
96, d4jr3A_, 0.7957, 2.99, 0.800, 303, 280, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN IN COMPLEX WITH COMPOUND 3G
97, d2ittA_, 0.7957, 3.26, 0.767, 302, 287, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN L858R MUTATION IN COMPLEX WITH AEE788
98, d4jq7A_, 0.7956, 2.99, 0.800, 303, 280, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN IN COMPLEX WITH COMPOUND 2A
99, d3kexB_, 0.7955, 2.36, 0.504, 283, 270, CRYSTAL STRUCTURE OF THE CATALYTICALLY INACTIVE KINASE DOMAIN OF THE HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 3 (HER3)
100, d2rfeD_, 0.7935, 2.55, 0.867, 278, 270, CRYSTAL STRUCTURE OF THE COMPLEX BETWEEN THE EGFR KINASE DOMAIN AND A MIG6 PEPTIDE
101, d5gmpA_, 0.7934, 3.47, 0.769, 305, 290, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M IN COMPLEX WITH XTF-262
102, d5fedA_, 0.7932, 2.91, 0.875, 288, 279, EGFR KINASE DOMAIN IN COMPLEX WITH A COVALENT AMINOBENZIMIDAZOLE INHIBITOR.
103, d2itnA_, 0.7932, 3.36, 0.767, 304, 288, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN G719S MUTATION IN COMPLEX WITH AMP-PNP
104, d4g5jA_, 0.7931, 2.58, 0.867, 307, 271, CRYSTAL STRUCTURE OF EGFR KINASE IN COMPLEX WITH BIBW2992
105, d2ityA1, 0.7923, 3.23, 0.849, 299, 285, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN IN COMPLEX WITH IRESSA
106, d1m14A_, 0.7920, 2.96, 0.802, 307, 278, TYROSINE KINASE DOMAIN FROM EPIDERMAL GROWTH FACTOR RECEPTOR
107, d2itvA_, 0.7918, 3.37, 0.764, 303, 288, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN L858R MUTATION IN COMPLEX WITH AMP-PNP
108, d5hicA_, 0.7917, 3.13, 0.859, 302, 283, EGFR KINASE DOMAIN MUTANT TMLR WITH A IMIDAZOPYRIDINYL- AMINOPYRIMIDINE INHIBITOR
109, d5hczA_, 0.7913, 2.98, 0.854, 300, 280, EGFR KINASE DOMAIN MUTANT TMLR WITH 3-AZETIDINYL AZAINDAZOLE COMPOUND 21
110, d5hcyA_, 0.7912, 3.03, 0.854, 302, 281, EGFR KINASE DOMAIN MUTANT TMLR WITH 3-CARBOXAMIDE AZAINDOLE COMPOUND 13
111, d5hcxA_, 0.7900, 2.92, 0.860, 298, 279, EGFR KINASE DOMAIN MUTANT TMLR WITH AZABENZIMIDAZOLE COMPOUND 7
112, d4otwA_, 0.7898, 2.15, 0.519, 272, 264, HER3 PSEUDOKINASE DOMAIN BOUND TO BOSUTINIB
113, d5lwmA_, 0.7891, 2.27, 0.295, 290, 268, CRYSTAL STRUCTURE OF JAK3 IN COMPLEX WITH COMPOUND 4 (FM381)
114, d2ituA_, 0.7890, 3.45, 0.765, 304, 289, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN L858R MUTATION IN COMPLEX WITH AFN941
115, d5lwnA_, 0.7889, 2.27, 0.295, 290, 268, CRYSTAL STRUCTURE OF JAK3 IN COMPLEX WITH COMPOUND 5 (FM409)
116, d3bbtB_, 0.7888, 2.34, 0.675, 274, 265, CRYSTAL STRUCTURE OF THE ERBB4 KINASE IN COMPLEX WITH LAPATINIB
117, d3q32B1, 0.7877, 2.29, 0.307, 293, 267, STRUCTURE OF JANUS KINASE 2 WITH A PYRROLOTRIAZINE INHIBITOR
118, d5em6A_, 0.7871, 3.02, 0.793, 301, 280, EGFR KINASE DOMAIN MUTANT TMLR WITH PYRIDONE COMPOUND 19: 4-[(2- AZANYLPYRIMIDIN-4-YL)AMINO]-~{N}-[4-(4-METHYLPIPERAZIN-1-YL)PHENYL]- 2-OXIDANYLIDENE-1~{H}-PYRIDINE-3-CARBOXAMIDE
119, d5calA_, 0.7868, 3.16, 0.851, 300, 281, EGFR KINASE DOMAIN MUTANT TMLR WITH COMPOUND 24
120, d5casA_, 0.7866, 3.03, 0.861, 299, 280, EGFR KINASE DOMAIN MUTANT TMLR WITH COMPOUND 41A
121, d5canA_, 0.7866, 3.07, 0.819, 301, 281, EGFR KINASE DOMAIN MUTANT TMLR WITH COMPOUND 27
122, d4rixA_, 0.7866, 2.29, 0.502, 269, 265, CRYSTAL STRUCTURE OF AN EGFR/HER3 KINASE DOMAIN HETERODIMER CONTAINING THE CANCER-ASSOCIATED HER3-Q790R MUTATION
123, d5tq5A_, 0.7859, 2.19, 0.294, 291, 265, DESIGN AND SYNTHESIS OF A PAN-JAK KINASE INHIBITOR CLINICAL CANDIDATE (PF-06263276) SUITABLE FOR INHALED AND TOPICAL DELIVERY FOR THE TREATMENT OF INFLAMMATORY DISEASES OF THE LUNGS AND SKIN
124, d5feeA_, 0.7859, 2.90, 0.888, 287, 276, EGFR KINASE DOMAIN T790M MUTANT IN COMPLEX WITH A COVALENT AMINOBENZIMIDAZOLE INHIBITOR.
125, d4rj7A_, 0.7858, 2.95, 0.863, 295, 278, EGFR KINASE (T790M/L858R) WITH INHIBITOR COMPOUND 1
126, d5cauA_, 0.7857, 3.00, 0.864, 297, 279, EGFR KINASE DOMAIN MUTANT TMLR WITH COMPOUND 41B
127, d4zauA_, 0.7857, 2.70, 0.861, 283, 273, AZD9291 COMPLEX WITH WILD TYPE EGFR
128, d5caqA_, 0.7856, 3.16, 0.851, 301, 282, EGFR KINASE DOMAIN MUTANT TMLR WITH COMPOUND 33
129, d5tq8A_, 0.7855, 2.19, 0.306, 291, 265, DESIGN AND SYNTHESIS OF A PAN-JAK KINASE INHIBITOR CLINICAL CANDIDATE (PF-06263276) SUITABLE FOR INHALED AND TOPICAL DELIVERY FOR THE TREATMENT OF INFLAMMATORY DISEASES OF THE LUNGS AND SKIN
130, d4riyA_, 0.7854, 2.27, 0.498, 269, 265, CRYSTAL STRUCTURE OF AN EGFR/HER3 KINASE DOMAIN HETERODIMER CONTAINING THE CANCER-ASSOCIATED HER3-E909G MUTATION
131, d5cf5B1, 0.7852, 2.33, 0.307, 292, 267, CRYSTAL STRUCTURE OF JANUS KINASE 2 IN COMPLEX WITH NN-DICYCLOPROPYL- 7-[(DIMETHYL-13-THIAZOL-2-YL)AMINO]-10-ETHYL-3-METHYL-35810- TETRAAZATRICYCLO[7.3.0.026] DODECA-1(9)2(6)4711-PENTAENE-11- CARBOXAMIDE
132, d5cf6B1, 0.7851, 2.23, 0.302, 288, 265, CRYSTAL STRUCTURE OF JANUS KINASE 2 IN COMPLEX WITH NN-DICYCLOPROPYL- 10-[(2S)-23-DIHYDROXYPROPYL]-3-METHYL-7-(METHYLAMINO)-35810- TETRAAZATRICYCLO [7.3.0.026]DODECA-1(9)2(6)4711-PENTAENE-11- CARBOXAMIDE
133, d5c8nA_, 0.7849, 3.21, 0.855, 300, 282, EGFR KINASE DOMAIN MUTANT TMLR WITH COMPOUND 23
134, d4rj6A_, 0.7848, 3.29, 0.858, 297, 282, EGFR KINASE (T790M/L858R) WITH INHIBITOR COMPOUND 4
135, d5em7A_, 0.7844, 3.05, 0.796, 300, 279, EGFR KINASE DOMAIN MUTANT TMLR WITH PYRIDONE COMPOUND 13: 4-[(2- METHOXYPHENYL)AMINO]-~{N}-[4-(4-METHYLPIPERAZIN-1-YL)PHENYL]-2- OXIDANYLIDENE-1~{H}-PYRIDINE-3-CARBOXAMIDE
136, d4riwA_, 0.7842, 2.30, 0.506, 269, 265, CRYSTAL STRUCTURE OF AN EGFR/HER3 KINASE DOMAIN HETERODIMER
137, d5cf4B_, 0.7840, 2.35, 0.307, 291, 267, CRYSTAL STRUCTURE OF JANUS KINASE 2 IN COMPLEX WITH NN-DICYCLOPROPYL- 10-ETHYL-7-[(3-METHOXYPROPYL)AMINO] -3-METHYL-35810- TETRAAZATRICYCLO[7.3.0.06] DODECA-1(9)2(6)4711-PENTAENE-11- CARBOXAMIDE
138, d5capA_, 0.7840, 3.27, 0.813, 303, 284, EGFR KINASE DOMAIN MUTANT TMLR WITH COMPOUND 30
139, d5c8kA_, 0.7840, 3.35, 0.845, 300, 284, EGFR KINASE DOMAIN MUTANT TMLR WITH COMPOUND 1
140, d4e6qB_, 0.7839, 2.43, 0.297, 296, 269, JAK2 KINASE (JH1 DOMAIN) TRIPLE MUTANT IN COMPLEX WITH COMPOUND 12
141, d4aqcB_, 0.7837, 2.31, 0.301, 295, 266, TRIAZOLOPYRIDINE-BASED INHIBITOR OF JANUS KINASE 2
142, d3lmgB_, 0.7834, 2.20, 0.521, 268, 263, CRYSTAL STRUCTURE OF THE ERBB3 KINASE DOMAIN IN COMPLEX WITH AMP-PNP
143, d3pjcA_, 0.7832, 2.31, 0.321, 286, 265, CRYSTAL STRUCTURE OF JAK3 COMPLEXED WITH A POTENT ATP SITE INHIBITOR SHOWING HIGH SELECTIVITY WITHIN THE JANUS KINASE FAMILY
144, d3fupB_, 0.7831, 2.31, 0.297, 287, 266, CRYSTAL STRUCTURES OF JAK1 AND JAK2 INHIBITOR COMPLEXES
145, d3lzbB_, 0.7829, 1.84, 0.857, 265, 258, EGFR KINASE DOMAIN COMPLEXED WITH AN IMIDAZO[21-B]THIAZOLE INHIBITOR
146, d3q32A_, 0.7828, 2.45, 0.301, 291, 269, STRUCTURE OF JANUS KINASE 2 WITH A PYRROLOTRIAZINE INHIBITOR
147, d4rj4A_, 0.7827, 3.10, 0.792, 299, 279, EGFR KINASE (T790M/L858R) WITH INHIBITOR COMPOUND 6
148, d4ivaA_, 0.7823, 2.40, 0.297, 290, 269, JAK2 KINASE (JH1 DOMAIN) IN COMPLEX WITH THE INHIBITOR TRANS-4-[(8AS)- 2-[(1R)-1-HYDROXYETHYL]IMIDAZO[45-D]PYRROLO[23-B]PYRIDIN-1(8AH)- YL]CYCLOHEXANECARBONITRILE
149, d2b7aB_, 0.7823, 2.34, 0.308, 287, 266, THE STRUCTURAL BASIS OF JANUS KINASE 2 INHIBITION BY A POTENT AND SPECIFIC PAN-JANUS KINASE INHIBITOR
150, d4zimB1, 0.7821, 2.40, 0.307, 292, 267, CRYSTAL STRUCTURE OF JANUS KINASE 2 IN COMPLEX WITH A 9H-CARBAZOLE-1- CARBOXAMIDE INHIBITOR
151, d4rj8A_, 0.7821, 3.04, 0.860, 298, 279, EGFR KINASE (T790M/L858R) WITH INHIBITOR COMPOUND 8
152, d4e6qA_, 0.7817, 2.48, 0.297, 296, 269, JAK2 KINASE (JH1 DOMAIN) TRIPLE MUTANT IN COMPLEX WITH COMPOUND 12
153, d3lmgA_, 0.7817, 2.18, 0.515, 268, 262, CRYSTAL STRUCTURE OF THE ERBB3 KINASE DOMAIN IN COMPLEX WITH AMP-PNP
154, d4p7eB_, 0.7816, 2.34, 0.308, 285, 266, TRIAZOLOPYRIDINE COMPOUNDS AS SELECTIVE JAK1 INHIBITORS: FROM HIT IDENTIFICATION TO GLPG0634
155, d5cf6A_, 0.7814, 2.22, 0.306, 285, 265, CRYSTAL STRUCTURE OF JANUS KINASE 2 IN COMPLEX WITH NN-DICYCLOPROPYL- 10-[(2S)-23-DIHYDROXYPROPYL]-3-METHYL-7-(METHYLAMINO)-35810- TETRAAZATRICYCLO [7.3.0.026]DODECA-1(9)2(6)4711-PENTAENE-11- CARBOXAMIDE
156, d4wrgA1, 0.7812, 2.83, 0.883, 287, 273, 1.9 ANGSTROM STRUCTURE OF EGFR KINASE DOMAIN
157, d3tjcB_, 0.7811, 2.35, 0.308, 287, 266, CO-CRYSTAL STRUCTURE OF JAK2 WITH THIENOPYRIDINE 8
158, d4ji9B_, 0.7810, 2.33, 0.308, 288, 266, JAK2 KINASE (JH1 DOMAIN) IN COMPLEX WITH TG101209
159, d4hvgA_, 0.7807, 2.35, 0.303, 281, 267, JAK3 KINASE DOMAIN IN COMPLEX WITH 2-CYCLOPROPYL-5H-PYRROLO[23- B]PYRAZINE-7-CARBOXYLIC ACID ((S)-2-HYDROXY-12-DIMETHYL-PROPYL)- AMIDE
160, d2fo0A3, 0.7807, 2.89, 0.327, 291, 275, ORGANIZATION OF THE SH3-SH2 UNIT IN ACTIVE AND INACTIVE FORMS OF THE C-ABL TYROSINE KINASE
161, d4e6dB_, 0.7803, 2.37, 0.300, 286, 267, JAK2 KINASE (JH1 DOMAIN) TRIPLE MUTANT IN COMPLEX WITH COMPOUND 7
162, d4aqcA_, 0.7803, 2.37, 0.303, 289, 267, TRIAZOLOPYRIDINE-BASED INHIBITOR OF JANUS KINASE 2
163, d4riyC_, 0.7800, 2.11, 0.513, 275, 261, CRYSTAL STRUCTURE OF AN EGFR/HER3 KINASE DOMAIN HETERODIMER CONTAINING THE CANCER-ASSOCIATED HER3-E909G MUTATION
164, d4f08B_, 0.7800, 2.35, 0.300, 288, 267, DISCOVERY AND OPTIMIZATION OF C-2 METHYL IMIDAZO-PYRROLOPYRIDINES AS POTENT AND ORALLY BIOAVAILABLE JAK1 INHIBITORS WITH SELECTIVITY OVER JAK2
165, d5cf5A1, 0.7799, 2.30, 0.309, 286, 265, CRYSTAL STRUCTURE OF JANUS KINASE 2 IN COMPLEX WITH NN-DICYCLOPROPYL- 7-[(DIMETHYL-13-THIAZOL-2-YL)AMINO]-10-ETHYL-3-METHYL-35810- TETRAAZATRICYCLO[7.3.0.026] DODECA-1(9)2(6)4711-PENTAENE-11- CARBOXAMIDE
166, d5c8mA_, 0.7799, 3.27, 0.777, 302, 282, EGFR KINASE DOMAIN MUTANT TMLR WITH COMPOUND 17
167, d4rixC_, 0.7798, 2.12, 0.513, 275, 261, CRYSTAL STRUCTURE OF AN EGFR/HER3 KINASE DOMAIN HETERODIMER CONTAINING THE CANCER-ASSOCIATED HER3-Q790R MUTATION
168, d4f08A_, 0.7798, 2.34, 0.300, 288, 267, DISCOVERY AND OPTIMIZATION OF C-2 METHYL IMIDAZO-PYRROLOPYRIDINES AS POTENT AND ORALLY BIOAVAILABLE JAK1 INHIBITORS WITH SELECTIVITY OVER JAK2
169, d3tjdB_, 0.7798, 2.38, 0.308, 287, 266, CO-CRYSTAL STRUCTURE OF JAK2 WITH THIENOPYRIDINE 19
170, d3krrA1, 0.7798, 2.36, 0.308, 290, 266, CRYSTAL STRUCTURE OF JAK2 COMPLEXED WITH A POTENT QUINOXALINE ATP SITE INHIBITOR
171, d3e62A_, 0.7795, 2.44, 0.303, 291, 267, FRAGMENT BASED DISCOVERY OF JAK-2 INHIBITORS
172, d5aepA_, 0.7794, 2.32, 0.302, 287, 265, NOVEL PYRROLE CARBOXAMIDE INHIBITORS OF JAK2 AS POTENTIAL TREATMENT OF MYELOPROLIFERATIVE DISORDERS
173, d3lzbA_, 0.7792, 1.92, 0.860, 265, 258, EGFR KINASE DOMAIN COMPLEXED WITH AN IMIDAZO[21-B]THIAZOLE INHIBITOR
174, d4riwC_, 0.7791, 2.18, 0.523, 275, 262, CRYSTAL STRUCTURE OF AN EGFR/HER3 KINASE DOMAIN HETERODIMER
175, d4hgeB_, 0.7791, 2.37, 0.308, 288, 266, JAK2 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 8
176, d3e64A_, 0.7788, 2.39, 0.308, 291, 266, FRAGMENT BASED DISCOVERY OF JAK-2 INHIBITORS
177, d4r5sA_, 0.7787, 3.44, 0.761, 299, 285, CRYSTAL STRUCTURE OF EGFR 696-1022 L858R IN COMPLEX WITH FIIN-3
178, d5cf8B1, 0.7786, 2.35, 0.309, 287, 265, CRYSTAL STRUCTURE OF JANUS KINASE 2 IN COMPLEX WITH NN-DICYCLOPROPYL- 10-ETHYL-7-[(3-METHOXYPROPYL)AMINO] -3-METHYL-35810- TETRAAZATRICYCLO[7.3.0.06] DODECA-1(9)2(6)4711-PENTAENE-11- CARBOXAMIDE
179, d4e6dA_, 0.7785, 2.39, 0.300, 286, 267, JAK2 KINASE (JH1 DOMAIN) TRIPLE MUTANT IN COMPLEX WITH COMPOUND 7
180, d3e63A_, 0.7783, 2.39, 0.308, 290, 266, FRAGMENT BASED DISCOVERY OF JAK-2 INHIBITORS
181, d4qpsC_, 0.7782, 2.01, 0.304, 276, 260, CRYSTAL STRUCTURE OF JAK3 COMPLEXED TO N-[3-(6-PHENYLAMINO-PYRAZIN-2- YL)-3H-BENZOIMIDAZOL-5-YL]-ACRYLAMIDE
182, d3hmiA_, 0.7782, 2.14, 0.351, 268, 262, THE CRYSTAL STRUCTURE OF HUMAN ABL2 IN COMPLEX WITH 5-AMINO-3-{[4- (AMINOSULFONYL)PHENYL]AMINO}-N-(26-DIFLUOROPHENYL)-1H-124- TRIAZOLE-1-CARBOTHIOAMIDE
183, d5caoA_, 0.7779, 3.17, 0.850, 300, 280, EGFR KINASE DOMAIN MUTANT TMLR WITH COMPOUND 29
184, d4f09A_, 0.7778, 2.44, 0.300, 288, 267, DISCOVERY AND OPTIMIZATION OF C-2 METHYL IMIDAZO-PYRROLOPYRIDINES AS POTENT AND ORALLY BIOAVAILABLE JAK1 INHIBITORS WITH SELECTIVITY OVER JAK2
185, d1yvjA_, 0.7778, 2.42, 0.300, 288, 267, CRYSTAL STRUCTURE OF THE JAK3 KINASE DOMAIN IN COMPLEX WITH A STAUROSPORINE ANALOGUE
186, d4zimA_, 0.7777, 2.25, 0.311, 285, 264, CRYSTAL STRUCTURE OF JANUS KINASE 2 IN COMPLEX WITH A 9H-CARBAZOLE-1- CARBOXAMIDE INHIBITOR
187, d4d0xA_, 0.7777, 2.40, 0.308, 291, 266, PYRROLE-3-CARBOXAMIDES AS POTENT AND SELECTIVE JAK2 INHIBITORS
188, d2eb3A_, 0.7776, 3.23, 0.804, 294, 280, CRYSTAL STRUCTURE OF MUTATED EGFR KINASE DOMAIN (L858R) IN COMPLEX WITH AMPPNP
189, d3dkcA1, 0.7775, 2.93, 0.331, 310, 269, STRUCTURE OF MET RECEPTOR TYROSINE KINASE IN COMPLEX WITH ATP
190, d4qt1A_, 0.7771, 2.23, 0.312, 277, 263, JAK3 KINASE DOMAIN IN COMPLEX WITH 1-[(3S)-1-ISOBUTYLSULFONYL-3- PIPERIDYL]-3-(5H-PYRROLO[23-B]PYRAZIN-2-YL)UREA
191, d4hvhA_, 0.7771, 2.24, 0.312, 278, 263, JAK3 KINASE DOMAIN IN COMPLEX WITH 2-CYCLOPROPYL-5H-PYRROLO[23- B]PYRAZINE-7-CARBOXYLIC ACID ((R)-2-HYDROXY-12-DIMETHYL-PROPYL
192, d4gfmA_, 0.7770, 2.35, 0.309, 289, 265, JAK2 KINASE (JH1 DOMAIN) WITH 26-DICHLORO-N-(2-OXO-25- DIHYDROPYRIDIN-4-YL)BENZAMIDE
193, d5tq3B_, 0.7769, 2.32, 0.311, 285, 264, DESIGN AND SYNTHESIS OF A PAN-JAK KINASE INHIBITOR CLINICAL CANDIDATE (PF-06263276) SUITABLE FOR THE TREATMENT OF INFLAMMATORY DISEASES OF THE LUNGS AND SKIN
194, d5xdlA_, 0.7766, 3.24, 0.864, 292, 280, CRYSTAL STRUCTURE OF EGFR 696-1022 L858R IN COMPLEX WITH CO-1686
195, d4ythA_, 0.7758, 2.34, 0.306, 287, 265, DISCOVERY OF VX-509 (DECERNOTINIB): A POTENT AND SELECTIVE JANUS KINASE (JAK) 3 INHIBITOR FOR THE TREATMENT OF AUTOIMMUNE DISEASES
196, d4e4mE_, 0.7757, 2.43, 0.301, 296, 266, JAK2 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 30
197, d4e4mA_, 0.7757, 2.42, 0.301, 296, 266, JAK2 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 30
198, d4py1A_, 0.7754, 2.45, 0.300, 289, 267, CRYSTAL STRUCTURE OF TYK2 IN COMPLEX WITH COMPOUND 15 6-((25- DIMETHOXYPHENYL)THIO)-3-(1-METHYL-1H-PYRAZOL-4-YL)-[124]TRIAZOLO[4 3-B]PYRIDAZINE
199, d3bbtD_, 0.7752, 1.98, 0.693, 259, 257, CRYSTAL STRUCTURE OF THE ERBB4 KINASE IN COMPLEX WITH LAPATINIB
200, d5j9zA_, 0.7750, 3.04, 0.830, 291, 276, EGFR-T790M IN COMPLEX WITH PYRAZOLOPYRIMIDINE INHIBITOR 1A
201, d4ji9A_, 0.7748, 2.38, 0.302, 284, 265, JAK2 KINASE (JH1 DOMAIN) IN COMPLEX WITH TG101209
202, d4rj5A_, 0.7747, 3.02, 0.862, 296, 275, EGFR KINASE (T790M/L858R) WITH INHIBITOR COMPOUND 5
203, d3lpbA_, 0.7746, 2.27, 0.308, 278, 263, CRYSTAL STRUCTURE OF JAK2 COMPLEXED WITH A POTENT 28-DIARYL- QUINOXALINE INHIBITOR
204, d4fk6B_, 0.7745, 2.27, 0.312, 284, 263, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 72
205, d4ytiA_, 0.7742, 2.37, 0.302, 284, 265, DISCOVERY OF VX-509 (DECERNOTINIB): A POTENT AND SELECTIVE JANUS KINASE (JAK) 3 INHIBITOR FOR THE TREATMENT OF AUTOIMMUNE DISEASE
206, d4p7eA_, 0.7740, 2.33, 0.307, 281, 264, TRIAZOLOPYRIDINE COMPOUNDS AS SELECTIVE JAK1 INHIBITORS: FROM HIT IDENTIFICATION TO GLPG0634
207, d3tjcA_, 0.7740, 2.37, 0.306, 284, 265, CO-CRYSTAL STRUCTURE OF JAK2 WITH THIENOPYRIDINE 8
208, d4d0wA_, 0.7739, 2.35, 0.311, 289, 264, PYRROLE-3-CARBOXAMIDES AS POTENT AND SELECTIVE JAK2 INHIBITORS
209, d3plsA_, 0.7736, 2.78, 0.310, 298, 268, RON IN COMPLEX WITH LIGAND AMP-PNP
210, d5cf8A1, 0.7731, 2.32, 0.300, 284, 263, CRYSTAL STRUCTURE OF JANUS KINASE 2 IN COMPLEX WITH NN-DICYCLOPROPYL- 10-ETHYL-7-[(3-METHOXYPROPYL)AMINO] -3-METHYL-35810- TETRAAZATRICYCLO[7.3.0.06] DODECA-1(9)2(6)4711-PENTAENE-11- CARBOXAMIDE
211, d4rioA_, 0.7731, 2.27, 0.304, 285, 263, CRYSTAL STRUCTURE OF JAK3 KINASE DOMAIN IN COMPLEX WITH A PYRROLOPYRIDAZINE CARBOXAMIDE INHIBITOR
212, d4i6qA_, 0.7730, 2.27, 0.313, 277, 262, JAK3 KINASE DOMAIN IN COMPLEX WITH 2-PHENOXY-5H-PYRROLO[23- B]PYRAZINE-7-CARBOXYLIC ACID ((S)-1-CYCLOPROPYL-ETHYL)-AMIDE
213, d3tjdA_, 0.7727, 2.39, 0.306, 284, 265, CO-CRYSTAL STRUCTURE OF JAK2 WITH THIENOPYRIDINE 19
214, d4hvdA_, 0.7726, 2.19, 0.314, 276, 261, JAK3 KINASE DOMAIN IN COMPLEX WITH 2-CYCLOPROPYL-5H-PYRROLO[23- B]PYRAZINE-7-CARBOXYLIC ACID ((S)-122-TRIMETHYL-PROPYL)-AMIDE
215, d4bbfD_, 0.7725, 2.28, 0.300, 288, 263, AMINOALKYLPYRIMIDINE INHIBITOR COMPLEXES WITH JAK2
216, d4bbfA_, 0.7725, 2.29, 0.300, 288, 263, AMINOALKYLPYRIMIDINE INHIBITOR COMPLEXES WITH JAK2
217, d3lzbD_, 0.7725, 1.80, 0.874, 261, 254, EGFR KINASE DOMAIN COMPLEXED WITH AN IMIDAZO[21-B]THIAZOLE INHIBITOR
218, d5edqA_, 0.7721, 3.41, 0.812, 298, 282, EGFR KINASE (T790M/L858R) WITH INHIBITOR COMPOUND 15: ~{N}-(7- CHLORANYL-1~{H}-INDAZOL-3-YL)-77-DIMETHYL-2-(1~{H}-PYRAZOL-4-YL)- 5~{H}-FURO[34-D]PYRIMIDIN-4-AMINE
219, d3fupA_, 0.7719, 2.45, 0.301, 284, 266, CRYSTAL STRUCTURES OF JAK1 AND JAK2 INHIBITOR COMPLEXES
220, d3dk7B_, 0.7719, 2.28, 0.331, 268, 263, CRYSTAL STRUCTURE OF MUTANT ABL KINASE DOMAIN IN COMPLEX WITH SMALL MOLECULE FRAGMENT
221, d2qohB2, 0.7719, 2.69, 0.335, 280, 266, CRYSTAL STRUCTURE OF ABL KINASE BOUND WITH PPY-A
222, d5tq3A_, 0.7717, 2.27, 0.303, 282, 261, DESIGN AND SYNTHESIS OF A PAN-JAK KINASE INHIBITOR CLINICAL CANDIDATE (PF-06263276) SUITABLE FOR THE TREATMENT OF INFLAMMATORY DISEASES OF THE LUNGS AND SKIN
223, d4hgeA_, 0.7716, 2.43, 0.302, 284, 265, JAK2 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 8
224, d3lzbC_, 0.7713, 1.77, 0.877, 259, 253, EGFR KINASE DOMAIN COMPLEXED WITH AN IMIDAZO[21-B]THIAZOLE INHIBITOR
225, d4e4mD_, 0.7710, 2.71, 0.301, 296, 269, JAK2 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 30
226, d4e4mB_, 0.7709, 2.71, 0.301, 296, 269, JAK2 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 30
227, d5cf4A_, 0.7708, 2.38, 0.303, 283, 264, CRYSTAL STRUCTURE OF JANUS KINASE 2 IN COMPLEX WITH NN-DICYCLOPROPYL- 10-ETHYL-7-[(3-METHOXYPROPYL)AMINO] -3-METHYL-35810- TETRAAZATRICYCLO[7.3.0.06] DODECA-1(9)2(6)4711-PENTAENE-11- CARBOXAMIDE
228, d3dk3B_, 0.7708, 2.30, 0.335, 269, 263, CRYSTAL STRUCTURE OF MUTANT ABL KINASE DOMAIN IN COMPLEX WITH SMALL MOLECULE FRAGMENT
229, d2g2hB_, 0.7706, 2.59, 0.333, 272, 267, A SRC-LIKE INACTIVE CONFORMATION IN THE ABL TYROSINE KINASE DOMAIN
230, d2b7aA_, 0.7705, 2.46, 0.302, 284, 265, THE STRUCTURAL BASIS OF JANUS KINASE 2 INHIBITION BY A POTENT AND SPECIFIC PAN-JANUS KINASE INHIBITOR
231, d3nyxA1, 0.7697, 2.27, 0.299, 285, 261, NON-PHOSPHORYLATED TYK2 JH1 DOMAIN WITH QUINOLINE-THIADIAZOLE- THIOPHENE INHIBITOR
232, d3lpbB1, 0.7697, 2.29, 0.299, 283, 261, CRYSTAL STRUCTURE OF JAK2 COMPLEXED WITH A POTENT 28-DIARYL- QUINOXALINE INHIBITOR
233, d5edrA_, 0.7696, 3.21, 0.849, 299, 278, EGFR KINASE (T790M/L858R) WITH INHIBITOR COMPOUND 27: ~{N}-(1~{H}- INDAZOL-3-YL)-77-DIMETHYL-2-(2-METHYLPYRAZOL-3-YL)-5~{H}-FURO[34- D]PYRIMIDIN-4-AMINE
234, d1u59A1, 0.7695, 2.88, 0.299, 276, 271, CRYSTAL STRUCTURE OF THE ZAP-70 KINASE DOMAIN IN COMPLEX WITH STAUROSPORINE
235, d5edpA_, 0.7693, 3.36, 0.804, 295, 280, EGFR KINASE (T790M/L858R) APO
236, d4fk6A_, 0.7693, 2.28, 0.314, 285, 261, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 72
237, d4e1zA_, 0.7692, 2.49, 0.282, 288, 266, STRUCTURE OF MOUSE TYK-2 COMPLEXED TO A 3-AMINOINDAZOLE INHIBITOR
238, d5eg3A_, 0.7690, 3.20, 0.296, 301, 274, CRYSTAL STRUCTURE OF THE ACTIVATED FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN IN COMPLEX WITH THE CSH2 DOMAIN OF PHOSPHOLIPASE C GAMMA (PLCGAMMA)
239, d4ehzD_, 0.7686, 2.26, 0.307, 280, 261, THE JAK1 KINASE DOMAIN IN COMPLEX WITH INHIBITOR
240, d5e1eB_, 0.7684, 2.25, 0.307, 280, 261, HUMAN JAK1 KINASE IN COMPLEX WITH COMPOUND 30 AT 2.30 ANGSTROMS RESOLUTION
241, d5wo4A_, 0.7682, 2.33, 0.305, 292, 262, JAK1 COMPLEXED WITH COMPOUND 28
242, d4e5wA1, 0.7680, 2.26, 0.307, 291, 261, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 26
243, d2w1iA_, 0.7679, 2.47, 0.307, 284, 264, STRUCTURE DETERMINATION OF AURORA KINASE IN COMPLEX WITH INHIBITOR
244, d3rvgA_, 0.7678, 2.32, 0.290, 285, 262, CRYSTALS STRUCTURE OF JAK2 WITH A 1-AMINO-5H-PYRIDO[43-B]INDOL-4- CARBOXAMIDE INHIBITOR
245, d4ivbB_, 0.7677, 2.28, 0.307, 280, 261, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH THE INHIBITOR TRANS-4-{2- [(1R)-1-HYDROXYETHYL]IMIDAZO[45-D]PYRROLO[23-B]PYRIDIN-1(6H)- YL}CYCLOHEXANECARBONITRILE
246, d4gmyA_, 0.7676, 2.60, 0.307, 298, 267, JAK2 KINASE (JH1 DOMAIN) IN COMPLEX WITH 26-DICHLORO-N-{2- [(CYCLOPROPYLCARBONYL)AMINO]PYRIDIN-4-YL}BENZAMIDE
247, d2w1iB_, 0.7675, 2.48, 0.307, 284, 264, STRUCTURE DETERMINATION OF AURORA KINASE IN COMPLEX WITH INHIBITOR
248, d5tozA_, 0.7674, 2.38, 0.309, 278, 262, JAK3 WITH COVALENT INHIBITOR PF-06651600
249, d3dqwD_, 0.7674, 2.96, 0.293, 276, 273, C-SRC KINASE DOMAIN THR338ILE MUTANT IN COMPLEX WITH ATPGS
250, d5ttvA_, 0.7671, 2.30, 0.318, 280, 261, JAK3 WITH COVALENT INHIBITOR 6
251, d3dqwC_, 0.7671, 2.88, 0.280, 275, 271, C-SRC KINASE DOMAIN THR338ILE MUTANT IN COMPLEX WITH ATPGS
252, d4ehzB_, 0.7670, 2.29, 0.310, 280, 261, THE JAK1 KINASE DOMAIN IN COMPLEX WITH INHIBITOR
253, d4ytcA_, 0.7669, 2.36, 0.298, 284, 262, DISCOVERY OF VX-509 (DECERNOTINIB): A POTENT AND SELECTIVE JANUS KINASE (JAK) 3 INHIBITOR FOR THE TREATMENT OF AUTOIMMUNE DISEASE
254, d5wo4B_, 0.7668, 2.30, 0.307, 280, 261, JAK1 COMPLEXED WITH COMPOUND 28
255, d3jy9A_, 0.7668, 2.31, 0.303, 282, 261, JANUS KINASE 2 INHIBITORS
256, d5hx8A_, 0.7666, 2.37, 0.305, 291, 262, JAK1 COMPLEX WITH 4-[(4-AMINOCYCLOHEXYL)AMINO]-3-(1H-BENZIMIDAZOL-2- YL)-1H-PYRIDIN-2-ONE
257, d3clyA_, 0.7666, 3.12, 0.293, 289, 273, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAINS TRAPPED IN TRANS-PHOSPHORYLATION REACTION
258, d4z16B_, 0.7665, 2.46, 0.312, 276, 263, CRYSTAL STRUCTURE OF THE JAK3 KINASE DOMAIN COVALENTLY BOUND TO N-(3- (((5-CHLORO-2-((2-METHOXY-4-(4-METHYLPIPERAZIN-1-YL)PHENYL)AMINO) PYRIMIDIN-4-YL)AMINO)METHYL)PHENYL)ACRYLAMIDE
259, d5cy3A1, 0.7663, 2.72, 0.332, 274, 268, SYK CATALYTIC DOMAIN COMPLEXED WITH A POTENT AND ORALLY BIOAVAILABLE BENZISOTHIAZOLE INHIBITOR
260, d4hviA_, 0.7662, 2.21, 0.317, 274, 259, JAK3 KINASE DOMAIN IN COMPLEX WITH 2-CYCLOPROPYL-5H-PYRROLO[23- B]PYRAZINE-7-CARBOXYLIC ACID ((R)-1-METHYL-2-OXO-2-PIPERIDIN-1-YL- ETHYL)-AMIDE
261, d4ei4B_, 0.7662, 2.31, 0.307, 280, 261, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 20
262, d3r7oA1, 0.7662, 2.91, 0.327, 295, 269, STRUCTURE OF DUALLY PHOSPHORYLATED C-MET RECEPTOR KINASE IN COMPLEX WITH AN MK-2461 ANALOG
263, d2z60A1, 0.7662, 2.86, 0.326, 280, 267, CRYSTAL STRUCTURE OF THE T315I MUTANT OF ABL KINASE BOUND WITH PPY-A
264, d1opkA3, 0.7662, 3.01, 0.326, 291, 273, STRUCTURAL BASIS FOR THE AUTO-INHIBITION OF C-ABL TYROSINE KINASE
265, d5tq6A_, 0.7661, 2.34, 0.303, 274, 261, DESIGN AND SYNTHESIS OF A PAN-JAK KINASE INHIBITOR CLINICAL CANDIDATE (PF-06263276) SUITABLE FOR INHALED AND TOPICAL DELIVERY FOR THE TREATMENT OF INFLAMMATORY DISEASES OF THE LUNGS AND SKIN
266, d4ehzA_, 0.7658, 2.31, 0.310, 290, 261, THE JAK1 KINASE DOMAIN IN COMPLEX WITH INHIBITOR
267, d4ivcB_, 0.7657, 2.30, 0.307, 280, 261, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH THE INHIBITOR (TRANS-4-{2- [(1R)-1-HYDROXYETHYL]IMIDAZO[45-D]PYRROLO[23-B]PYRIDIN-1(6H)- YL}CYCLOHEXYL)ACETONITRILE
268, d4ytfA_, 0.7656, 2.37, 0.309, 283, 262, DISCOVERY OF VX-509 (DECERNOTINIB): A POTENT AND SELECTIVE JANUS KINASE (JAK) 3 INHIBITOR FOR THE TREATMENT OF AUTOIMMUNE DISEASES
269, d3lxnA_, 0.7656, 2.43, 0.300, 287, 263, STRUCTURAL AND THERMODYNAMIC CHARACTERIZATION OF THE TYK2 AND JAK3 KINASE DOMAINS IN COMPLEX WITH CP-690550 AND CMP-6
270, d3lxlA_, 0.7655, 2.44, 0.309, 281, 262, STRUCTURAL AND THERMODYNAMIC CHARACTERIZATION OF THE TYK2 AND JAK3 KINASE DOMAINS IN COMPLEX WITH CP-690550 AND CMP-6
271, d1oplA3, 0.7655, 3.02, 0.326, 291, 273, STRUCTURAL BASIS FOR THE AUTO-INHIBITION OF C-ABL TYROSINE KINASE
272, d3gqiA_, 0.7653, 2.85, 0.311, 304, 267, CRYSTAL STRUCTURE OF ACTIVATED RECEPTOR TYROSINE KINASE IN COMPLEX WITH SUBSTRATES
273, d5flfD_, 0.7652, 2.89, 0.310, 290, 268, DISEASE LINKED MUTATION IN FGFR
274, d3io7A_, 0.7652, 2.41, 0.304, 282, 263, 2-AMINOPYRAZOLO[15-A]PYRIMIDINES AS POTENT AND SELECTIVE INHIBITORS OF JAK2
275, d4e4lD_, 0.7651, 2.26, 0.312, 281, 260, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 30
276, d5tq7A_, 0.7650, 2.39, 0.302, 275, 262, DESIGN AND SYNTHESIS OF A PAN-JAK KINASE INHIBITOR CLINICAL CANDIDATE (PF-06263276) SUITABLE FOR INHALED AND TOPICAL DELIVERY FOR THE TREATMENT OF INFLAMMATORY DISEASES OF THE LUNGS AND SKIN
277, d4ivbA1, 0.7650, 2.28, 0.308, 290, 260, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH THE INHIBITOR TRANS-4-{2- [(1R)-1-HYDROXYETHYL]IMIDAZO[45-D]PYRROLO[23-B]PYRIDIN-1(6H)- YL}CYCLOHEXANECARBONITRILE
278, d3q6wA1, 0.7648, 2.88, 0.323, 293, 269, STRUCTURE OF DUALLY-PHOSPHORYLATED MET RECEPTOR KINASE IN COMPLEX WITH AN MK-2461 ANALOG WITH SPECIFICITY FOR THE ACTIVATED RECEPTOR
279, d4k77A_, 0.7647, 2.39, 0.305, 282, 262, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 6
280, d3lxkA_, 0.7645, 2.32, 0.319, 279, 260, STRUCTURAL AND THERMODYNAMIC CHARACTERIZATION OF THE TYK2 AND JAK3 KINASE DOMAINS IN COMPLEX WITH CP-690550 AND CMP-6
281, d4jiaA_, 0.7644, 2.65, 0.311, 298, 267, JAK2 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 9
282, d4ivdB_, 0.7644, 2.33, 0.307, 280, 261, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 34
283, d4ewhA_, 0.7644, 2.78, 0.335, 274, 266, CO-CRYSTAL STRUCTURE OF ACK1 WITH INHIBITOR
284, d4ehzC_, 0.7643, 2.29, 0.315, 278, 260, THE JAK1 KINASE DOMAIN IN COMPLEX WITH INHIBITOR
285, d5em5A_, 0.7642, 3.22, 0.830, 298, 276, EGFR KINASE DOMAIN MUTANT TMLR WITH PYRIDONE COMPOUND 2: 4-[2-(4- CHLOROPHENYL)ETHYLAMINO]-~{N}-[4-(4-METHYLPIPERAZIN-1-YL)PHENYL]-2- OXIDANYLIDENE-1~{H}-PYRIDINE-3-CARBOXAMIDE
286, d4e4lE_, 0.7641, 2.29, 0.312, 280, 260, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 30
287, d4bbeC_, 0.7641, 2.44, 0.300, 288, 263, AMINOALKYLPYRIMIDINE INHIBITOR COMPLEXES WITH JAK2
288, d5ttsA_, 0.7639, 2.27, 0.313, 274, 259, JAK3 WITH COVALENT INHIBITOR 4
289, d4zogB_, 0.7638, 2.38, 0.332, 268, 262, VX-680/MK-0457 BINDS TO HUMAN ABL1 ALSO IN INACTIVE DFG CONFORMATIONS.
290, d4gj2A1, 0.7638, 2.48, 0.300, 287, 263, TYK2 (JH1) IN COMPLEX WITH 26-DICHLORO-N-[2-({[(1R2R)-2- FLUOROCYCLOPROPYL]CARBONYL}AMINO)PYRIDIN-4-YL]BENZAMIDE
291, d2x2kA1, 0.7638, 2.70, 0.332, 284, 265, CRYSTAL STRUCTURE OF PHOSPHORYLATED RET TYROSINE KINASE DOMAIN WITH INHIBITOR
292, d4e20A_, 0.7637, 2.47, 0.293, 282, 263, STRUCTURE OF MOUSE TYK-2 COMPLEXED TO A 3-AMINOINDAZOLE INHIBITOR
293, d5hx8B_, 0.7634, 2.31, 0.312, 279, 260, JAK1 COMPLEX WITH 4-[(4-AMINOCYCLOHEXYL)AMINO]-3-(1H-BENZIMIDAZOL-2- YL)-1H-PYRIDIN-2-ONE
294, d4e4lB_, 0.7634, 2.24, 0.313, 279, 259, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 30
295, d1m52A_, 0.7634, 2.76, 0.335, 271, 266, CRYSTAL STRUCTURE OF THE C-ABL KINASE DOMAIN IN COMPLEX WITH PD173955
296, d4gvjA1, 0.7633, 2.44, 0.305, 288, 262, TYK2 (JH1) IN COMPLEX WITH ADENOSINE DI-PHOSPHATE
297, d3kulA_, 0.7633, 2.53, 0.304, 267, 263, KINASE DOMAIN OF HUMAN EPHRIN TYPE-A RECEPTOR 8 (EPHA8)
298, d3kckA_, 0.7633, 2.46, 0.304, 285, 263, A NOVEL CHEMOTYPE OF KINASE INHIBITORS
299, d3iokA_, 0.7631, 2.40, 0.309, 285, 262, 2-AMINOPYRAZOLO[15-A]PYRIMIDINES AS POTENT AND SELECTIVE INHIBITORS OF JAK2
300, d5flfA_, 0.7630, 2.91, 0.311, 296, 267, DISEASE LINKED MUTATION IN FGFR
301, d4ivcA1, 0.7630, 2.30, 0.308, 290, 260, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH THE INHIBITOR (TRANS-4-{2- [(1R)-1-HYDROXYETHYL]IMIDAZO[45-D]PYRROLO[23-B]PYRIDIN-1(6H)- YL}CYCLOHEXYL)ACETONITRILE
302, d4bbeB_, 0.7630, 2.46, 0.300, 288, 263, AMINOALKYLPYRIMIDINE INHIBITOR COMPLEXES WITH JAK2
303, d4k77B_, 0.7629, 2.37, 0.310, 280, 261, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 6
304, d4gihA1, 0.7627, 2.55, 0.303, 287, 264, TYK2 (JH1) IN COMPLEX WITH 26-DICHLORO-N-{2-[(CYCLOPROPYLCARBONYL) AMINO]PYRIDIN-4-YL}BENZAMIDE
305, d4e5wB_, 0.7626, 2.26, 0.297, 278, 259, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 26
306, d4e4lA_, 0.7626, 2.20, 0.314, 277, 258, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 30
307, d3kulB_, 0.7625, 2.65, 0.295, 271, 264, KINASE DOMAIN OF HUMAN EPHRIN TYPE-A RECEPTOR 8 (EPHA8)
308, d2ivuA1, 0.7625, 2.77, 0.332, 283, 265, CRYSTAL STRUCTURE OF PHOSPHORYLATED RET TYROSINE KINASE DOMAIN COMPLEXED WITH THE INHIBITOR ZD6474
309, d4e4nB_, 0.7623, 2.40, 0.310, 280, 261, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 49
310, d3nz0A1, 0.7619, 2.60, 0.307, 283, 264, NON-PHOSPHORYLATED TYK2 KINASE WITH CMP6
311, d5u6bB1, 0.7618, 2.85, 0.327, 289, 266, STRUCTURE OF THE AXL KINASE DOMAIN IN COMPLEX WITH A MACROCYCLIC INHIBITOR
312, d4i5cA_, 0.7615, 2.32, 0.304, 279, 260, THE JAK1 KINASE DOMAIN IN COMPLEX WITH INHIBITOR
313, d4gj3A1, 0.7614, 2.53, 0.300, 287, 263, TYK2 (JH1) IN COMPLEX WITH 26-DICHLORO-4-CYANO-N-[2-({[(1R2R)-2- FLUOROCYCLOPROPYL]CARBONYL}AMINO)PYRIDIN-4-YL]BENZAMIDE
314, d5walA1, 0.7613, 2.55, 0.307, 285, 264, IDENTIFICATION OF AN IMIDAZOPYRIDINE SCAFFOLD TO GENERATE POTENT AND SELECTIVE TYK2 INHIBITORS THAT DEMONSTRATE ACTIVITY IN AN IN VIVO PSORIASIS MODEL
315, d5tq6B_, 0.7612, 2.22, 0.306, 271, 258, DESIGN AND SYNTHESIS OF A PAN-JAK KINASE INHIBITOR CLINICAL CANDIDATE (PF-06263276) SUITABLE FOR INHALED AND TOPICAL DELIVERY FOR THE TREATMENT OF INFLAMMATORY DISEASES OF THE LUNGS AND SKIN
316, d1m52B_, 0.7612, 2.81, 0.335, 272, 266, CRYSTAL STRUCTURE OF THE C-ABL KINASE DOMAIN IN COMPLEX WITH PD173955
317, d5tq7B_, 0.7611, 2.17, 0.305, 269, 256, DESIGN AND SYNTHESIS OF A PAN-JAK KINASE INHIBITOR CLINICAL CANDIDATE (PF-06263276) SUITABLE FOR INHALED AND TOPICAL DELIVERY FOR THE TREATMENT OF INFLAMMATORY DISEASES OF THE LUNGS AND SKIN
318, d4bbfB_, 0.7611, 2.49, 0.300, 288, 263, AMINOALKYLPYRIMIDINE INHIBITOR COMPLEXES WITH JAK2
319, d5e1eA_, 0.7610, 2.32, 0.308, 279, 260, HUMAN JAK1 KINASE IN COMPLEX WITH COMPOUND 30 AT 2.30 ANGSTROMS RESOLUTION
320, d1y57A3, 0.7609, 3.00, 0.280, 285, 271, STRUCTURE OF UNPHOSPHORYLATED C-SRC IN COMPLEX WITH AN INHIBITOR
321, d5tq4A_, 0.7607, 2.63, 0.308, 290, 266, DESIGN AND SYNTHESIS OF A PAN-JAK KINASE INHIBITOR CLINICAL CANDIDATE (PF-06263276) SUITABLE FOR INHALED AND TOPICAL DELIVERY FOR THE TREATMENT OF INFLAMMATORY DISEASES OF THE LUNGS AND SKIN
322, d5u6bD1, 0.7606, 2.96, 0.326, 289, 267, STRUCTURE OF THE AXL KINASE DOMAIN IN COMPLEX WITH A MACROCYCLIC INHIBITOR
323, d4ckjA1, 0.7606, 2.85, 0.331, 287, 266, CRYSTAL STRUCTURE OF RET TYROSINE KINASE DOMAIN BOUND TO ADENOSINE
324, d4bbeD_, 0.7605, 2.50, 0.300, 288, 263, AMINOALKYLPYRIMIDINE INHIBITOR COMPLEXES WITH JAK2
325, d2ivtA1, 0.7605, 2.70, 0.333, 283, 264, CRYSTAL STRUCTURE OF PHOSPHORYLATED RET TYROSINE KINASE DOMAIN
326, d4bbfC_, 0.7604, 2.50, 0.300, 288, 263, AMINOALKYLPYRIMIDINE INHIBITOR COMPLEXES WITH JAK2
327, d4ckiA1, 0.7601, 2.72, 0.326, 288, 264, CRYSTAL STRUCTURE OF ONCOGENIC RET TYROSINE KINASE M918T BOUND TO ADENOSINE
328, d5l3aA_, 0.7600, 2.60, 0.298, 290, 265, FRAGMENT-BASED DISCOVERY OF 6-ARYLINDAZOLE JAK INHIBITORS
329, d4zogA_, 0.7600, 2.59, 0.342, 269, 263, VX-680/MK-0457 BINDS TO HUMAN ABL1 ALSO IN INACTIVE DFG CONFORMATIONS.
330, d4ewhB_, 0.7599, 2.81, 0.336, 273, 265, CO-CRYSTAL STRUCTURE OF ACK1 WITH INHIBITOR
331, d4i5cB1, 0.7598, 2.37, 0.308, 290, 260, THE JAK1 KINASE DOMAIN IN COMPLEX WITH INHIBITOR
332, d5flfB_, 0.7597, 2.96, 0.313, 292, 268, DISEASE LINKED MUTATION IN FGFR
333, d5f1zA1, 0.7596, 2.16, 0.312, 280, 256, STRUCTURE OF TYK2 WITH INHIBITOR 16: 3-AZANYL-5-[(2~{S})-3- METHYLBUTAN-2-YL]-7-[1-METHYL-5-(2-OXIDANYLPROPAN-2-YL)PYRAZOL-3-YL]- 1~{H}-PYRAZOLO[43-C]PYRIDIN-4-ONE
334, d2ivsA_, 0.7594, 2.73, 0.337, 284, 264, CRYSTAL STRUCTURE OF NON-PHOSPHORYLATED RET TYROSINE KINASE DOMAIN
335, d4uy9A_, 0.7593, 2.77, 0.250, 313, 268, STRUCTURE OF MLK1 KINASE DOMAIN WITH LEUCINE ZIPPER 1
336, d4iwdA1, 0.7593, 3.03, 0.327, 295, 269, STRUCTURE OF DUALLY PHOSPHORYLATED C-MET RECEPTOR KINASE IN COMPLEX WITH AN MK-8033 ANALOG
337, d4giiA1, 0.7592, 2.60, 0.307, 287, 264, TYK2 (JH1) IN COMPLEX WITH 26-DICHLORO-4-CYANO-N-{2- [(CYCLOPROPYLCARBONYL)AMINO]PYRIDIN-4-YL}BENZAMIDE
338, d3ue4A_, 0.7592, 2.85, 0.342, 270, 266, STRUCTURAL AND SPECTROSCOPIC ANALYSIS OF THE KINASE INHIBITOR BOSUTINIB BINDING TO THE ABL TYROSINE KINASE DOMAIN
339, d4bbeA_, 0.7591, 2.53, 0.300, 288, 263, AMINOALKYLPYRIMIDINE INHIBITOR COMPLEXES WITH JAK2
340, d2g2hA_, 0.7591, 2.79, 0.338, 272, 266, A SRC-LIKE INACTIVE CONFORMATION IN THE ABL TYROSINE KINASE DOMAIN
341, d4ivdA1, 0.7590, 2.33, 0.313, 289, 259, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 34
342, d4ei4A1, 0.7590, 2.27, 0.314, 288, 258, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 20
343, d5xgmA_, 0.7588, 3.24, 0.803, 288, 274, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M IN COMPLEX WITH GO6976
344, d2hziB_, 0.7588, 2.30, 0.344, 264, 259, ABL KINASE DOMAIN IN COMPLEX WITH PD180970
345, d4e4nA1, 0.7587, 2.41, 0.308, 290, 260, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 49
346, d5usyA_, 0.7580, 2.52, 0.302, 287, 262, JAK2 JH1 IN COMPLEX WITH JNJ-7706621
347, d3dqwA_, 0.7579, 3.09, 0.279, 278, 272, C-SRC KINASE DOMAIN THR338ILE MUTANT IN COMPLEX WITH ATPGS
348, d3eqrA_, 0.7577, 2.70, 0.346, 270, 263, CRYSTAL STRUCTURE OF ACK1 WITH COMPOUND T74
349, d2qohA2, 0.7577, 2.46, 0.331, 270, 260, CRYSTAL STRUCTURE OF ABL KINASE BOUND WITH PPY-A
350, d3dk3A_, 0.7574, 2.51, 0.342, 266, 260, CRYSTAL STRUCTURE OF MUTANT ABL KINASE DOMAIN IN COMPLEX WITH SMALL MOLECULE FRAGMENT
351, d5khxA_, 0.7573, 2.13, 0.306, 276, 255, CRYSTAL STRUCTURE OF JAK1 IN COMPLEX WITH PF-4950736
352, d4j96B_, 0.7573, 3.06, 0.313, 305, 268, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC GAIN-OF-FUNCTION K659M MUTATION IDENTIFIED IN CERVICAL CANCER.
353, d3dqwB_, 0.7573, 3.04, 0.280, 278, 271, C-SRC KINASE DOMAIN THR338ILE MUTANT IN COMPLEX WITH ATPGS
354, d3eqpB_, 0.7571, 2.61, 0.347, 270, 262, CRYSTAL STRUCTURE OF ACK1 WITH COMPOUND T95
355, d5f20A_, 0.7558, 2.21, 0.306, 274, 255, STRUCTURE OF TYK2 WITH INHIBITOR 4: 3-AZANYL-5-(2-METHYLPHENYL)-7-(1- METHYLPYRAZOL-3-YL)-1~{H}-PYRAZOLO[43-C]PYRIDIN-4-ONE
356, d4k6zA_, 0.7558, 2.45, 0.308, 279, 260, THE JAK1 KINASE DOMAIN IN COMPLEX WITH COMPOUND 37
357, d3eqrB_, 0.7558, 2.85, 0.341, 271, 264, CRYSTAL STRUCTURE OF ACK1 WITH COMPOUND T74
358, d3dk7A_, 0.7558, 2.53, 0.338, 265, 260, CRYSTAL STRUCTURE OF MUTANT ABL KINASE DOMAIN IN COMPLEX WITH SMALL MOLECULE FRAGMENT
359, d2hziA_, 0.7557, 2.46, 0.341, 268, 261, ABL KINASE DOMAIN IN COMPLEX WITH PD180970
360, d2f4jA_, 0.7557, 3.10, 0.323, 287, 269, STRUCTURE OF THE KINASE DOMAIN OF AN IMATINIB-RESISTANT ABL MUTANT IN COMPLEX WITH THE AURORA KINASE INHIBITOR VX-680
361, d4j98B_, 0.7556, 2.96, 0.316, 304, 266, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE GAIN-OF-FUNCTION K659Q MUTATION.
362, d3l8pA_, 0.7556, 2.45, 0.314, 292, 258, CRYSTAL STRUCTURE OF CYTOPLASMIC KINASE DOMAIN OF TIE2 COMPLEXED WITH INHIBITOR CEP11207
363, d4uy9B_, 0.7553, 2.84, 0.254, 315, 268, STRUCTURE OF MLK1 KINASE DOMAIN WITH LEUCINE ZIPPER 1
364, d5ui0B_, 0.7552, 3.02, 0.315, 304, 267, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FGF RECEPTOR 2 HARBORING AN E565A/K659M DOUBLE GAIN-OF-FUNCTION MUTATION
365, d5ttuA_, 0.7550, 2.27, 0.316, 271, 256, JAK3 WITH COVALENT INHIBITOR 7
366, d5usyB_, 0.7546, 2.59, 0.302, 287, 262, JAK2 JH1 IN COMPLEX WITH JNJ-7706621
367, d3eqpA_, 0.7545, 2.61, 0.350, 268, 260, CRYSTAL STRUCTURE OF ACK1 WITH COMPOUND T95
368, d5wevA_, 0.7544, 2.53, 0.313, 293, 262, IDENTIFICATION OF AN IMIDAZOPYRIDINE SCAFFOLD TO GENERATE POTENT AND SELECTIVE TYK2 INHIBITORS THAT DEMONSTRATE ACTIVITY IN AN IN VIVO PSORIASIS MODEL
369, d4cnhB_, 0.7544, 3.16, 0.262, 293, 271, STRUCTURE OF THE HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH THE INHIBITOR 3-((1R)-1-(5-FLUORO-2- METHOXYPHENYL)ETHOXY)-5-(1-METHYL-1H-123-TRIAZOL-5-YL) PYRIDIN-2-AMINE
370, d5cxhA1, 0.7543, 3.01, 0.331, 273, 266, SYK CATALYTIC DOMAIN COMPLEXED WITH A POTENT ORALLY BIOAVAILABLE THIAZOLE INHIBITOR
371, d4twpA_, 0.7543, 2.52, 0.331, 266, 260, THE CRYSTAL STRUCTURE OF HUMAN ABL1 T315I GATEKEEPER MUTANT KINASE DOMAIN IN COMPLEX WITH AXITINIB
372, d4z16A_, 0.7542, 2.42, 0.310, 271, 258, CRYSTAL STRUCTURE OF THE JAK3 KINASE DOMAIN COVALENTLY BOUND TO N-(3- (((5-CHLORO-2-((2-METHOXY-4-(4-METHYLPIPERAZIN-1-YL)PHENYL)AMINO) PYRIMIDIN-4-YL)AMINO)METHYL)PHENYL)ACRYLAMIDE
373, d3eyhA_, 0.7542, 2.39, 0.322, 285, 258, CRYSTAL STRUCTURES OF JAK1 AND JAK2 INHIBITOR COMPLEXES
374, d2x2lA1, 0.7540, 2.72, 0.336, 282, 262, CRYSTAL STRUCTURE OF PHOSPHORYLATED RET TYROSINE KINASE DOMAIN WITH INHIBITOR
375, d3eygA_, 0.7539, 2.45, 0.322, 280, 258, CRYSTAL STRUCTURES OF JAK1 AND JAK2 INHIBITOR COMPLEXES
376, d1fvrB_, 0.7539, 3.05, 0.299, 300, 268, TIE2 KINASE DOMAIN
377, d5khwB_, 0.7538, 2.29, 0.316, 276, 256, CRYSTAL STRUCTURE OF JAK1 IN COMPLEX WITH ADP
378, d1xbcA1, 0.7538, 2.71, 0.345, 267, 261, CRYSTAL STRUCTURE OF THE SYK TYROSINE KINASE DOMAIN WITH STAUROSPORIN
379, d3kf4A_, 0.7536, 3.00, 0.327, 281, 266, STRUCTURAL ANALYSIS OF DFG-IN AND DFG-OUT DUAL SRC-ABL INHIBITORS SHARING A COMMON VINYL PURINE TEMPLATE
380, d4gfgA1, 0.7533, 2.95, 0.340, 273, 265, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH R9021
381, d3lxpA_, 0.7533, 2.64, 0.307, 285, 261, STRUCTURAL AND THERMODYNAMIC CHARACTERIZATION OF THE TYK2 AND JAK3 KINASE DOMAINS IN COMPLEX WITH CP-690550 AND CMP-6
382, d1k9aB3, 0.7532, 2.27, 0.312, 267, 256, CRYSTAL STRUCTURE ANALYSIS OF FULL-LENGTH CARBOXYL-TERMINAL SRC KINASE AT 2.5 A RESOLUTION
383, d2x2mA1, 0.7531, 2.89, 0.326, 281, 264, CRYSTAL STRUCTURE OF PHOSPHORYLATED RET TYROSINE KINASE DOMAIN WITH INHIBITOR
384, d4wnmA1, 0.7528, 2.88, 0.346, 269, 263, SYK CATALYTIC DOMAIN IN COMPLEX WITH A POTENT TRIAZOLOPYRIDINE INHIBITOR
385, d5tr6A1, 0.7527, 2.75, 0.344, 268, 262, DISCOVERY OF TAK-659 AN ORALLY AVAILABLE INVESTIGATIONAL INHIBITOR OF SPLEEN TYROSINE KINASE (SYK)
386, d5ui0A_, 0.7526, 3.05, 0.318, 301, 267, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FGF RECEPTOR 2 HARBORING AN E565A/K659M DOUBLE GAIN-OF-FUNCTION MUTATION
387, d5u6bC_, 0.7526, 2.71, 0.310, 270, 258, STRUCTURE OF THE AXL KINASE DOMAIN IN COMPLEX WITH A MACROCYCLIC INHIBITOR
388, d2j0lA_, 0.7525, 3.10, 0.333, 274, 270, CRYSTAL STRUCTURE OF A THE ACTIVE CONFORMATION OF THE KINASE DOMAIN OF FOCAL ADHESION KINASE WITH A PHOSPHORYLATED ACTIVATION LOOP.
389, d4z16C_, 0.7523, 2.46, 0.310, 271, 258, CRYSTAL STRUCTURE OF THE JAK3 KINASE DOMAIN COVALENTLY BOUND TO N-(3- (((5-CHLORO-2-((2-METHOXY-4-(4-METHYLPIPERAZIN-1-YL)PHENYL)AMINO) PYRIMIDIN-4-YL)AMINO)METHYL)PHENYL)ACRYLAMIDE
390, d5vo6A_, 0.7521, 2.12, 0.316, 271, 253, CRYSTAL STRUCTURE OF JAK3 KINASE DOMAIN IN COMPLEX WITH A PYRROLOPYRIDAZINE INHIBITOR
391, d4twpB_, 0.7520, 2.78, 0.322, 271, 264, THE CRYSTAL STRUCTURE OF HUMAN ABL1 T315I GATEKEEPER MUTANT KINASE DOMAIN IN COMPLEX WITH AXITINIB
392, d4k33A_, 0.7520, 2.97, 0.313, 293, 265, CRYSTAL STRUCTURE OF FGF RECEPTOR 3 (FGFR3) KINASE DOMAIN HARBORING THE K650E MUTATION A GAIN-OF-FUNCTION MUTATION RESPONSIBLE FOR THANATOPHORIC DYSPLASIA TYPE II AND SPERMATOCYTIC SEMINOMA
393, d5cxzA1, 0.7518, 2.85, 0.340, 267, 262, SYK CATALYTIC DOMAIN COMPLEXED WITH NAPHTHYRIDINE INHIBITOR
394, d3vf8A_, 0.7516, 2.66, 0.346, 265, 260, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE SYK CATALYTIC DOMAIN WITH PYRAZOLYLBENZIMIDAZOLE INHIBITOR 416
395, d1oplB2, 0.7514, 2.52, 0.342, 267, 260, STRUCTURAL BASIS FOR THE AUTO-INHIBITION OF C-ABL TYROSINE KINASE
396, d2xa4A_, 0.7512, 2.28, 0.298, 276, 255, INHIBITORS OF JAK2 KINASE DOMAIN
397, d1xbaA1, 0.7510, 2.66, 0.346, 265, 260, CRYSTAL STRUCTURE OF APO SYK TYROSINE KINASE DOMAIN
398, d3zepC_, 0.7508, 2.38, 0.319, 276, 257, CRYSTAL STRUCTURE OF JAK3 KINASE DOMAIN IN COMPLEX WITH A PYRROLOPYRAZINE-2-PHENYL ETHER INHIBITOR
399, d3zepA_, 0.7508, 2.48, 0.319, 274, 257, CRYSTAL STRUCTURE OF JAK3 KINASE DOMAIN IN COMPLEX WITH A PYRROLOPYRAZINE-2-PHENYL ETHER INHIBITOR
400, d4z16D_, 0.7506, 2.50, 0.310, 271, 258, CRYSTAL STRUCTURE OF THE JAK3 KINASE DOMAIN COVALENTLY BOUND TO N-(3- (((5-CHLORO-2-((2-METHOXY-4-(4-METHYLPIPERAZIN-1-YL)PHENYL)AMINO) PYRIMIDIN-4-YL)AMINO)METHYL)PHENYL)ACRYLAMIDE
401, d2ivvA1, 0.7505, 2.63, 0.338, 277, 260, CRYSTAL STRUCTURE OF PHOSPHORYLATED RET TYROSINE KINASE DOMAIN COMPLEXED WITH THE INHIBITOR PP1
402, d3zepD_, 0.7503, 2.44, 0.312, 272, 256, CRYSTAL STRUCTURE OF JAK3 KINASE DOMAIN IN COMPLEX WITH A PYRROLOPYRAZINE-2-PHENYL ETHER INHIBITOR
403, d4yhfB_, 0.7502, 2.46, 0.300, 269, 257, BRUTON S TYROSINE KINASE IN COMPLEX WITH A T-BUTYL CYANOACRYLAMIDE INHIBITOR
404, d2v7aA_, 0.7502, 2.91, 0.328, 269, 265, CRYSTAL STRUCTURE OF THE T315I ABL MUTANT IN COMPLEX WITH THE INHIBITOR PHA-739358
405, d3lcdA_, 0.7501, 2.86, 0.285, 290, 263, INHIBITOR BOUND TO A DFG-IN STRUCTURE OF THE KINASE DOMAIN OF CSF-1R
406, d5lmbA_, 0.7500, 2.61, 0.335, 264, 260, HUMAN SPLEEN TYROSINE KINASE KINASE DOMAIN IN COMPLEX WITH AZANAPHTHYRIDINE INHIBITOR
407, d5flfC_, 0.7498, 2.99, 0.313, 283, 265, DISEASE LINKED MUTATION IN FGFR
408, d1k9aA3, 0.7498, 2.32, 0.316, 267, 256, CRYSTAL STRUCTURE ANALYSIS OF FULL-LENGTH CARBOXYL-TERMINAL SRC KINASE AT 2.5 A RESOLUTION
409, d1fvrA_, 0.7496, 3.05, 0.300, 299, 267, TIE2 KINASE DOMAIN
410, d5u6bA_, 0.7495, 2.83, 0.317, 270, 259, STRUCTURE OF THE AXL KINASE DOMAIN IN COMPLEX WITH A MACROCYCLIC INHIBITOR
411, d4xeyB2, 0.7495, 2.63, 0.344, 264, 259, CRYSTAL STRUCTURE OF AN SH2-KINASE DOMAIN CONSTRUCT OF C-ABL TYROSINE KINASE
412, d2xa4B_, 0.7495, 2.23, 0.307, 275, 254, INHIBITORS OF JAK2 KINASE DOMAIN
413, d4xeyA_, 0.7493, 2.83, 0.342, 269, 263, CRYSTAL STRUCTURE OF AN SH2-KINASE DOMAIN CONSTRUCT OF C-ABL TYROSINE KINASE
414, d3mftA_, 0.7493, 3.02, 0.198, 302, 268, CASK-4M CAM KINASE DOMAIN MN2+
415, d3dk6A_, 0.7493, 2.56, 0.336, 262, 259, CRYSTAL STRUCTURE OF MUTANT ABL KINASE DOMAIN IN COMPLEX WITH SMALL MOLECULE FRAGMENT
416, d2pvfA_, 0.7493, 2.96, 0.314, 285, 264, CRYSTAL STRUCTURE OF TYROSINE PHOSPHORYLATED ACTIVATED FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN IN COMPLEX WITH ATP ANALOG AND SUBSTRATE PEPTIDE
417, d3aglA_, 0.7490, 3.47, 0.167, 338, 276, COMPLEX OF PKA WITH THE BISUBSTRATE PROTEIN KINASE INHIBITOR ARC-1039
418, d4rx7A1, 0.7488, 3.02, 0.345, 270, 264, SYK CATALYTIC DOMAIN COMPLEXED WITH A POTENT TRIAZINE INHIBITOR
419, d4xg3B_, 0.7487, 2.68, 0.342, 267, 260, CRYSTAL STRUCTURE OF AN INHIBITOR-BOUND SYK
420, d4at5A1, 0.7484, 3.00, 0.277, 291, 264, CRYSTAL STRUCTURE OF TRKB KINASE DOMAIN IN COMPLEX WITH GW2580
421, d5khwA_, 0.7483, 2.40, 0.316, 276, 256, CRYSTAL STRUCTURE OF JAK1 IN COMPLEX WITH ADP
422, d5hezC_, 0.7482, 2.67, 0.308, 289, 260, JAK2 KINASE (JH1 DOMAIN) MUTANT P1057A IN COMPLEX WITH TG101209
423, d4j96A_, 0.7482, 3.04, 0.320, 302, 266, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC GAIN-OF-FUNCTION K659M MUTATION IDENTIFIED IN CERVICAL CANCER.
424, d4c61B_, 0.7482, 2.19, 0.308, 274, 253, INHIBITORS OF JAK2 KINASE DOMAIN
425, d3dk6B_, 0.7480, 2.40, 0.342, 259, 257, CRYSTAL STRUCTURE OF MUTANT ABL KINASE DOMAIN IN COMPLEX WITH SMALL MOLECULE FRAGMENT
426, d1u4dB_, 0.7480, 2.43, 0.344, 262, 256, STRUCTURE OF THE ACK1 KINASE DOMAIN BOUND TO DEBROMOHYMENIALDISINE
427, d1pkgA_, 0.7480, 2.72, 0.296, 290, 260, STRUCTURE OF A C-KIT KINASE PRODUCT COMPLEX
428, d3zmmB_, 0.7477, 2.20, 0.308, 274, 253, INHIBITORS OF JAK2 KINASE DOMAIN
429, d2ckeD_, 0.7476, 3.16, 0.170, 300, 270, HUMAN DEATH-ASSOCIATED DRP-1 KINASE IN COMPLEX WITH INHIBITOR
430, d5hezA_, 0.7474, 2.71, 0.308, 287, 260, JAK2 KINASE (JH1 DOMAIN) MUTANT P1057A IN COMPLEX WITH TG101209
431, d3c0gB_, 0.7474, 3.04, 0.190, 320, 268, CASK CAM-KINASE DOMAIN- 3 -AMP COMPLEX P1 FORM
432, d2ckeA_, 0.7473, 3.26, 0.173, 301, 271, HUMAN DEATH-ASSOCIATED DRP-1 KINASE IN COMPLEX WITH INHIBITOR
433, d4u5jA_, 0.7472, 2.80, 0.285, 267, 263, C-SRC IN COMPLEX WITH RUXOLITINIB
434, d2ckeC_, 0.7471, 3.18, 0.174, 300, 270, HUMAN DEATH-ASSOCIATED DRP-1 KINASE IN COMPLEX WITH INHIBITOR
435, d4xg3A_, 0.7470, 2.55, 0.350, 262, 257, CRYSTAL STRUCTURE OF AN INHIBITOR-BOUND SYK
436, d2f7eE_, 0.7470, 3.53, 0.173, 336, 277, PKA COMPLEXED WITH (S)-2-(1H-INDOL-3-YL)-1-(5-ISOQUINOLIN-6- YL-PYRIDIN-3-YLOXYMETHYL-ETYLAMINE
437, d5xp7B_, 0.7468, 2.75, 0.284, 267, 261, C-SRC IN COMPLEX WITH ATP-CHCL
438, d2a2aA_, 0.7468, 3.15, 0.174, 304, 270, HIGH-RESOLUTION CRYSTALLOGRAPHIC ANALYSIS OF THE AUTOINHIBITED CONFORMATION OF A HUMAN DEATH-ASSOCIATED PROTEIN KINASE
439, d4j98A_, 0.7467, 3.03, 0.321, 304, 265, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE GAIN-OF-FUNCTION K659Q MUTATION.
440, d3srvA_, 0.7467, 2.56, 0.337, 262, 258, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE (SYK) IN COMPLEX WITH A DIAMINOPYRIMIDINE CARBOXAMIDE INHIBITOR
441, d3idcA_, 0.7466, 3.54, 0.170, 341, 276, CRYSTAL STRUCTURE OF (102-265)RIIB:C HOLOENZYME OF CAMP- DEPENDENT PROTEIN KINASE
442, d2ojfE_, 0.7466, 3.61, 0.173, 336, 278, CRYSTAL STRUCTURE OF PROTEIN KINASE A IN COMPLEX WITH PYRIDINE-PYRAZOLOPYRIDINE BASED INHIBITORS
443, d3fhiA_, 0.7465, 3.46, 0.167, 336, 275, CRYSTAL STRUCTURE OF A COMPLEX BETWEEN THE CATALYTIC AND REGULATORY (RI{ALPHA}) SUBUNITS OF PKA
444, d2ckeB_, 0.7464, 3.19, 0.174, 300, 270, HUMAN DEATH-ASSOCIATED DRP-1 KINASE IN COMPLEX WITH INHIBITOR
445, d2oh0E_, 0.7463, 3.54, 0.173, 336, 277, CRYSTAL STRUCTURE OF PROTEIN KINASE A IN COMPLEX WITH PYRIDINE-PYRAZOLOPYRIDINE BASED INHIBITORS
446, d2a2aD_, 0.7463, 3.27, 0.170, 303, 271, HIGH-RESOLUTION CRYSTALLOGRAPHIC ANALYSIS OF THE AUTOINHIBITED CONFORMATION OF A HUMAN DEATH-ASSOCIATED PROTEIN KINASE
447, d3mfrA_, 0.7462, 2.98, 0.199, 302, 267, CASK-4M CAM KINASE DOMAIN NATIVE
448, d3aglB_, 0.7462, 3.52, 0.181, 335, 276, COMPLEX OF PKA WITH THE BISUBSTRATE PROTEIN KINASE INHIBITOR ARC-1039
449, d2uzuE_, 0.7462, 3.53, 0.173, 336, 277, PKA STRUCTURES OF INDAZOLE-PYRIDINE SERIES OF AKT INHIBITORS
450, d2f7xE_, 0.7462, 3.45, 0.174, 336, 276, PROTEIN KINASE A BOUND TO (S)-2-(1H-INDOL-3-YL)-1-[5-((E)-2- PYRIDIN-4-YL-VINYL)-PYRIDIN-3-YLOXYMETHYL]-ETHYLAMINE
451, d3mvjE_, 0.7461, 3.42, 0.178, 334, 275, HUMAN CYCLIC AMP-DEPENDENT PROTEIN KINASE PKA INHIBITOR COMPLEX
452, d2gqgB1, 0.7461, 2.59, 0.331, 270, 260, X-RAY CRYSTAL STRUCTURE OF DASATINIB (BMS-354825) BOUND TO ACTIVATED ABL KINASE DOMAIN
453, d4j97C_, 0.7459, 2.89, 0.321, 283, 262, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC GAIN-OF-FUNCTION K659E MUTATION IDENTIFIED IN ENDOMETRIAL CANCER.
454, d3c0gA_, 0.7459, 3.02, 0.184, 309, 267, CASK CAM-KINASE DOMAIN- 3 -AMP COMPLEX P1 FORM
455, d2gnfA_, 0.7459, 3.52, 0.174, 339, 276, PROTEIN KINASE A FIVEFOLD MUTANT MODEL OF RHO-KINASE WITH Y- 27632
456, d1jbpE_, 0.7457, 3.52, 0.170, 339, 276, CRYSTAL STRUCTURE OF THE CATALYTIC SUBUNIT OF CAMP- DEPENDENT PROTEIN KINASE COMPLEXED WITH A SUBSTRATE PEPTIDE ADP AND DETERGENT
457, d3qamE_, 0.7456, 3.49, 0.174, 348, 276, CRYSTAL STRUCTURE OF GLU208ALA MUTANT OF CATALYTIC SUBUNIT OF CAMP- DEPENDENT PROTEIN KINASE
458, d3e8eE_, 0.7456, 3.52, 0.163, 341, 276, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
459, d3cc6A_, 0.7456, 3.02, 0.311, 269, 264, CRYSTAL STRUCTURE OF KINASE DOMAIN OF PROTEIN TYROSINE KINASE 2 BETA (PTK2B)
460, d1re8A_, 0.7455, 3.46, 0.160, 337, 275, CRYSTAL STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE COMPLEXED WITH BALANOL ANALOG 2
461, d5tt7A1, 0.7454, 2.87, 0.341, 270, 261, DISCOVERY OF TAK-659 AN ORALLY AVAILABLE INVESTIGATIONAL INHIBITOR OF SPLEEN TYROSINE KINASE (SYK)
462, d2a2aC_, 0.7454, 3.28, 0.173, 303, 271, HIGH-RESOLUTION CRYSTALLOGRAPHIC ANALYSIS OF THE AUTOINHIBITED CONFORMATION OF A HUMAN DEATH-ASSOCIATED PROTEIN KINASE
463, d1u7eA_, 0.7454, 3.35, 0.176, 338, 273,  
464, d4x6qC_, 0.7453, 3.50, 0.175, 334, 275, AN ISOFORM-SPECIFIC MYRISTYLATION SWITCH TARGETS RIIB PKA HOLOENZYMES TO MEMBRANES
465, d3b2tA_, 0.7453, 3.24, 0.313, 288, 268, STRUCTURE OF PHOSPHOTRANSFERASE
466, d4j99B_, 0.7452, 3.11, 0.305, 291, 266, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE GAIN-OF-FUNCTION K659T MUTATION.
467, d4j95B_, 0.7452, 3.03, 0.309, 282, 265, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC K659N MUTATION RESPONSIBLE FOR AN UNCLASSIFIED CRANIOSYNOSTOSIS SYNDROME IN SPACE GROUP C2.
468, d3c0hA_, 0.7452, 3.02, 0.187, 300, 267, CASK CAM-KINASE DOMAIN- AMPPNP COMPLEX P1 FORM
469, d2a2aB_, 0.7452, 3.29, 0.173, 303, 271, HIGH-RESOLUTION CRYSTALLOGRAPHIC ANALYSIS OF THE AUTOINHIBITED CONFORMATION OF A HUMAN DEATH-ASSOCIATED PROTEIN KINASE
470, d1bkxA_, 0.7452, 3.49, 0.178, 337, 276, A BINARY COMPLEX OF THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE AND ADENOSINE FURTHER DEFINES CONFORMATIONAL FLEXIBILITY
471, d2gngA_, 0.7451, 3.52, 0.178, 338, 276, PROTEIN KINASE A FIVEFOLD MUTANT MODEL OF RHO-KINASE
472, d1apmE_, 0.7451, 3.53, 0.174, 338, 276, 2.0 ANGSTROM REFINED CRYSTAL STRUCTURE OF THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE COMPLEXED WITH A PEPTIDE INHIBITOR AND DETERGENT
473, d5amnA1, 0.7450, 2.93, 0.338, 282, 263, THE DISCOVERY OF 2-SUBSTITUTED PHENOL QUINAZOLINES AS POTENT AND SELECTIVE RET KINASE INHIBITORS
474, d3c0hB_, 0.7450, 3.01, 0.184, 300, 267, CASK CAM-KINASE DOMAIN- AMPPNP COMPLEX P1 FORM
475, d3tnpF_, 0.7449, 3.42, 0.175, 334, 274, STRUCTURE AND ALLOSTERY OF THE PKA RIIB TETRAMERIC HOLOENZYME
476, d3tnpC_, 0.7449, 3.42, 0.175, 334, 274, STRUCTURE AND ALLOSTERY OF THE PKA RIIB TETRAMERIC HOLOENZYME
477, d3geqB1, 0.7449, 3.00, 0.292, 270, 264, STRUCTURAL BASIS FOR THE CHEMICAL RESCUE OF SRC KINASE ACTIVITY
478, d2uzvA_, 0.7449, 3.49, 0.174, 336, 276, PKA STRUCTURES OF INDAZOLE-PYRIDINE SERIES OF AKT INHIBITORS
479, d2gniA_, 0.7449, 3.55, 0.170, 338, 276, PKA FIVEFOLD MUTANT MODEL OF RHO-KINASE WITH INHIBITOR FASUDIL (HA1077)
480, d3ue4B_, 0.7448, 2.95, 0.341, 268, 264, STRUCTURAL AND SPECTROSCOPIC ANALYSIS OF THE KINASE INHIBITOR BOSUTINIB BINDING TO THE ABL TYROSINE KINASE DOMAIN
481, d3e8eL_, 0.7448, 3.46, 0.167, 336, 275, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
482, d3e8eB_, 0.7448, 3.45, 0.167, 337, 275, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
483, d3c0iA_, 0.7448, 3.05, 0.187, 298, 267, CASK CAM-KINASE DOMAIN- 3 -AMP COMPLEX P212121 FORM
484, d2gfcA_, 0.7448, 3.55, 0.174, 335, 276, CAMP-DEPENDENT PROTEIN KINASE PKA CATALYTIC SUBUNIT WITH PKI-5-24
485, d5ng0B_, 0.7447, 3.01, 0.234, 282, 265, STRUCTURE OF RIP2K(L294F) WITH BOUND AMPPCP
486, d3e8eA_, 0.7447, 3.46, 0.171, 341, 275, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
487, d3mfuA_, 0.7446, 3.02, 0.195, 302, 267, CASK-4M CAM KINASE DOMAIN AMPPNP-MN2+
488, d3fjqE_, 0.7446, 3.49, 0.181, 334, 276, CRYSTAL STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT ALPHA IN COMPLEX WITH PEPTIDE INHIBITOR PKI ALPHA (6-25)
489, d5ar5A_, 0.7445, 2.94, 0.231, 284, 264, RIP2 KINASE CATALYTIC DOMAIN (1 - 310) COMPLEX WITH BENZIMIDAZOLE
490, d1jluE_, 0.7445, 3.54, 0.170, 337, 276, CRYSTAL STRUCTURE OF THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE COMPLEXED WITH A PHOSPHORYLATED SUBSTRATE PEPTIDE AND DETERGENT
491, d1fmoE_, 0.7445, 3.47, 0.175, 336, 275, CRYSTAL STRUCTURE OF A POLYHISTIDINE-TAGGED RECOMBINANT CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE COMPLEXED WITH THE PEPTIDE INHIBITOR PKI(5-24) AND ADENOSINE
492, d1cdkB_, 0.7445, 3.47, 0.178, 342, 275, CAMP-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT (E.C.2.7.1.37) (PROTEIN KINASE A) COMPLEXED WITH PROTEIN KINASE INHIBITOR PEPTIDE FRAGMENT 5-24 (PKI(5-24) ISOELECTRIC VARIANT CA) AND MN2+ ADENYLYL IMIDODIPHOSPHATE (MNAMP-PNP) AT PH 5.6 AND 7C AND 4C
493, d3e8eP_, 0.7444, 3.46, 0.167, 341, 275, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
494, d5ar2B_, 0.7443, 2.95, 0.223, 285, 264, RIP2 KINASE CATALYTIC DOMAIN (1 - 310)
495, d4puzB_, 0.7443, 2.82, 0.342, 265, 260, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE (SYK) IN COMPLEX WITH GS- 9973
496, d4j97A_, 0.7443, 2.83, 0.322, 282, 261, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC GAIN-OF-FUNCTION K659E MUTATION IDENTIFIED IN ENDOMETRIAL CANCER.
497, d2gnjA_, 0.7443, 3.54, 0.178, 335, 276, PKA THREE FOLD MUTANT MODEL OF RHO-KINASE WITH Y-27632
498, d2f7zE_, 0.7443, 3.48, 0.174, 336, 276, PROTEIN KINASE A BOUND TO (R)-1-(1H-INDOL-3-YLMETHYL)-2-(2- PYRIDIN-4-YL-[17]NAPHTYRIDIN-5-YLOXY)-EHYLAMINE
499, d4rx8A1, 0.7442, 2.88, 0.345, 266, 261, SYK CATALYTIC DOMAIN COMPLEXED WITH A POTENT TRIAZINE INHIBITOR2
500, d2dq7X_, 0.7442, 2.60, 0.287, 262, 258, CRYSTAL STRUCTURE OF FYN KINASE DOMAIN COMPLEXED WITH STAUROSPORINE
501, d1q24A_, 0.7442, 3.44, 0.172, 335, 274, PKA DOUBLE MUTANT MODEL OF PKB IN COMPLEX WITH MGATP
502, d5hezD_, 0.7441, 2.77, 0.303, 289, 261, JAK2 KINASE (JH1 DOMAIN) MUTANT P1057A IN COMPLEX WITH TG101209
503, d5hezB_, 0.7441, 2.77, 0.303, 289, 261, JAK2 KINASE (JH1 DOMAIN) MUTANT P1057A IN COMPLEX WITH TG101209
504, d4j99C_, 0.7441, 3.08, 0.306, 291, 265, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE GAIN-OF-FUNCTION K659T MUTATION.
505, d3zepB_, 0.7441, 2.37, 0.311, 268, 254, CRYSTAL STRUCTURE OF JAK3 KINASE DOMAIN IN COMPLEX WITH A PYRROLOPYRAZINE-2-PHENYL ETHER INHIBITOR
506, d1rekA_, 0.7441, 3.53, 0.166, 336, 277, CRYSTAL STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE COMPLEXED WITH BALANOL ANALOG 8
507, d2h8hA3, 0.7440, 2.44, 0.294, 280, 255, SRC KINASE IN COMPLEX WITH A QUINAZOLINE INHIBITOR
508, d3vf9A_, 0.7439, 2.86, 0.346, 265, 260, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE SYK CATALYTIC DOMAIN WITH THIENOPYRAZOLYLINDOLE INHIBITOR 027
509, d3dneA_, 0.7439, 3.54, 0.174, 336, 276, CAMP-DEPENDENT PROTEIN KINASE PKA CATALYTIC SUBUNIT WITH PKI-5-24
510, d1rejA_, 0.7439, 3.48, 0.167, 333, 275, CRYSTAL STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE COMPLEXED WITH BALANOL ANALOG 1
511, d5c26A1, 0.7438, 3.08, 0.337, 271, 264, CRYSTAL STRUCTURE OF SYK IN COMPLEX WITH COMPOUND 1
512, d4u5jB_, 0.7438, 2.87, 0.299, 267, 264, C-SRC IN COMPLEX WITH RUXOLITINIB
513, d3oogA_, 0.7438, 3.47, 0.175, 333, 275, HUMAN CAMP-DEPENDENT PROTEIN KINASE IN COMPLEX WITH A SMALL FRAGMENT
514, d3a4pA_, 0.7438, 3.06, 0.331, 285, 263, HUMAN C-MET KINASE DOMAIN COMPLEXED WITH 6-BENZYLOXYQUINOLINE INHIBITOR
515, d2xuuA_, 0.7438, 3.17, 0.175, 301, 269, CRYSTAL STRUCTURE OF A DAP-KINASE 1 MUTANT
516, d3srvB_, 0.7437, 2.57, 0.346, 263, 257, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE (SYK) IN COMPLEX WITH A DIAMINOPYRIMIDINE CARBOXAMIDE INHIBITOR
517, d3oxtA_, 0.7437, 3.47, 0.175, 335, 274, HUMAN CAMP-DEPENDENT PROTEIN KINASE IN COMPLEX WITH AN INHIBITOR
518, d3e8cA_, 0.7437, 3.48, 0.167, 341, 275, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
519, d4k11A3, 0.7436, 2.46, 0.290, 282, 255, THE STRUCTURE OF 1NA IN COMPLEX WITH SRC T338G
520, d4d1sA_, 0.7436, 2.52, 0.306, 280, 258, PYRROLE-3-CARBOXAMIDES AS POTENT AND SELECTIVE JAK2 INHIBITORS
521, d2hz0A_, 0.7436, 2.66, 0.327, 265, 260, ABL KINASE DOMAIN IN COMPLEX WITH NVP-AEG082
522, d5c27A1, 0.7435, 3.04, 0.337, 271, 264, CRYSTAL STRUCTURE OF SYK IN COMPLEX WITH COMPOUND 2
523, d4o21A_, 0.7435, 3.45, 0.175, 333, 274, PRODUCT COMPLEX OF METAL-FREE PKAC ATP-GAMMA-S AND SP20.
524, d3zmmA_, 0.7435, 2.32, 0.296, 273, 253, INHIBITORS OF JAK2 KINASE DOMAIN
525, d3e8cF_, 0.7435, 3.48, 0.167, 341, 275, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
526, d2c1aA_, 0.7435, 3.54, 0.174, 335, 276, STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE COMPLEXED WITH ISOQUINOLINE-5-SULFONIC ACID (2-(2-(4-CHLOROBENZYLOXY) ETHYLAMINO)ETHYL)AMIDE
527, d3e8cB_, 0.7434, 3.48, 0.167, 344, 275, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
528, d2uw8A_, 0.7434, 3.51, 0.178, 334, 275, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH 2-(4-CHLORO- PHENYL)-2-PHENYL-ETHYLAMINE
529, d3u4wA_, 0.7433, 2.85, 0.290, 275, 262, SRC IN COMPLEX WITH DNA-TEMPLATED MACROCYCLIC INHIBITOR MC4B
530, d3mdyC_, 0.7433, 2.88, 0.176, 320, 262, CRYSTAL STRUCTURE OF THE CYTOPLASMIC DOMAIN OF THE BONE MORPHOGENETIC PROTEIN RECEPTOR TYPE-1B (BMPR1B) IN COMPLEX WITH FKBP12 AND LDN- 193189
531, d3e8cD_, 0.7433, 3.48, 0.167, 344, 275, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
532, d2yaaB_, 0.7433, 3.18, 0.171, 299, 269, CRYSTAL STRUCTURE OF THE AUTOINHIBITED FORM OF MOUSE DAPK2 IN COMPLEX WITH ATP
533, d1q62A_, 0.7433, 3.49, 0.178, 336, 275, PKA DOUBLE MUTANT MODEL OF PKB
534, d5ugxA_, 0.7432, 3.11, 0.317, 297, 265, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FGF RECEPTOR 2 HARBORING A E565A/D650V DOUBLE GAIN-OF-FUNCTION MUTATION
535, d3qalE_, 0.7432, 3.41, 0.161, 339, 274, CRYSTAL STRUCTURE OF ARG280ALA MUTANT OF CATALYTIC SUBUNIT OF CAMP- DEPENDENT PROTEIN KINASE
536, d2yaaA_, 0.7431, 3.11, 0.172, 300, 268, CRYSTAL STRUCTURE OF THE AUTOINHIBITED FORM OF MOUSE DAPK2 IN COMPLEX WITH ATP
537, d4yxrA_, 0.7430, 3.48, 0.178, 334, 275, CRYSTAL STRUCTURE OF PKA IN COMPLEX WITH INHIBITOR.
538, d3zewA_, 0.7430, 2.86, 0.295, 269, 264, CRYSTAL STRUCTURE OF EPHB4 IN COMPLEX WITH STAUROSPORINE
539, d3mfsA_, 0.7430, 3.06, 0.195, 303, 267, CASK-4M CAM KINASE DOMAIN AMPPNP
540, d3e8cE_, 0.7430, 3.48, 0.167, 336, 275, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
541, d3fqeA1, 0.7429, 2.86, 0.342, 265, 260, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH YM193306
542, d3e8eI_, 0.7429, 3.55, 0.167, 345, 276, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
543, d2yabB_, 0.7429, 3.20, 0.175, 299, 269, CRYSTAL STRUCTURE OF THE AUTOINHIBITED FORM OF MOUSE DAPK2 IN COMPLEX WITH AMP
544, d1cdkA_, 0.7429, 3.44, 0.185, 342, 275, CAMP-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT (E.C.2.7.1.37) (PROTEIN KINASE A) COMPLEXED WITH PROTEIN KINASE INHIBITOR PEPTIDE FRAGMENT 5-24 (PKI(5-24) ISOELECTRIC VARIANT CA) AND MN2+ ADENYLYL IMIDODIPHOSPHATE (MNAMP-PNP) AT PH 5.6 AND 7C AND 4C
545, d4xg4A_, 0.7428, 2.78, 0.347, 264, 259, CRYSTAL STRUCTURE OF AN INHIBITOR-BOUND SYK
546, d3e8cC_, 0.7428, 3.66, 0.173, 341, 278, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
547, d2uzwE_, 0.7428, 3.58, 0.173, 336, 277, PKA STRUCTURES OF INDAZOLE-PYRIDINE SERIES OF AKT INHIBITORS
548, d4xg6A1, 0.7427, 3.02, 0.335, 270, 263, CRYSTAL STRUCTURE OF AN INHIBITOR-BOUND SYK
549, d3geqA1, 0.7427, 3.00, 0.297, 269, 263, STRUCTURAL BASIS FOR THE CHEMICAL RESCUE OF SRC KINASE ACTIVITY
550, d2yabA_, 0.7427, 3.18, 0.171, 299, 269, CRYSTAL STRUCTURE OF THE AUTOINHIBITED FORM OF MOUSE DAPK2 IN COMPLEX WITH AMP
551, d2gnhA_, 0.7427, 3.56, 0.178, 338, 276, PKA FIVE FOLD MUTANT MODEL OF RHO-KINASE WITH H1152P
552, d1qpjA_, 0.7427, 2.79, 0.294, 265, 262, CRYSTAL STRUCTURE OF THE LYMPHOCYTE-SPECIFIC KINASE LCK IN COMPLEX WITH STAUROSPORINE.
553, d1l3rE_, 0.7427, 3.43, 0.168, 338, 273, CRYSTAL STRUCTURE OF A TRANSITION STATE MIMIC OF THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE
554, d2qurA_, 0.7426, 3.61, 0.170, 338, 277, CRYSTAL STRUCTURE OF F327A/K285P MUTANT OF CAMP-DEPENDENT PROTEIN KINASE
555, d4j97B_, 0.7425, 2.86, 0.326, 283, 261, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC GAIN-OF-FUNCTION K659E MUTATION IDENTIFIED IN ENDOMETRIAL CANCER.
556, d3mvjA_, 0.7425, 3.38, 0.179, 334, 273, HUMAN CYCLIC AMP-DEPENDENT PROTEIN KINASE PKA INHIBITOR COMPLEX
557, d2jdtA_, 0.7425, 3.55, 0.174, 334, 276, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH ISOQUINOLINE-5- SULFONIC ACID (2-(2-(4-CHLOROBENZYLOXY) ETHYLAMINO)ETHYL) AMIDE
558, d1atpE_, 0.7425, 3.52, 0.181, 334, 276, 2.2 ANGSTROM REFINED CRYSTAL STRUCTURE OF THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE COMPLEXED WITH MNATP AND A PEPTIDE INHIBITOR
559, d4j99D_, 0.7424, 2.97, 0.309, 281, 262, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE GAIN-OF-FUNCTION K659T MUTATION.
560, d1svgA_, 0.7424, 3.51, 0.171, 338, 275, CRYSTAL STRUCTURE OF PROTEIN KINASE A IN COMPLEX WITH AZEPANE DERIVATIVE 4
561, d1rdqE_, 0.7424, 3.44, 0.175, 340, 274, HYDROLYSIS OF ATP IN THE CRYSTAL OF Y204A MUTANT OF CAMP-DEPENDENT PROTEIN KINASE
562, d1qcfA3, 0.7424, 2.54, 0.298, 281, 255, CRYSTAL STRUCTURE OF HCK IN COMPLEX WITH A SRC FAMILY- SELECTIVE TYROSINE KINASE INHIBITOR
563, d4xg9B_, 0.7423, 2.78, 0.342, 265, 260, CRYSTAL STRUCTURE OF AN INHIBITOR-BOUND SYK
564, d4xliB_, 0.7422, 2.70, 0.342, 264, 260, CRYSTAL STRUCTURE OF ABL2/ARG KINASE IN COMPLEX WITH DASATINIB
565, d5mjbA_, 0.7421, 3.21, 0.301, 276, 269, KINASE DOMAIN OF HUMAN EPHB1 G703C MUTANT COVALENTLY BOUND TO A QUINAZOLINE-BASED INHIBITOR
566, d4xliA_, 0.7421, 2.67, 0.342, 264, 260, CRYSTAL STRUCTURE OF ABL2/ARG KINASE IN COMPLEX WITH DASATINIB
567, d4pv0A1, 0.7421, 2.86, 0.338, 266, 260, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE (SYK) IN COMPLEX WITH AN IMIDAZOPYRAZINE INHIBITOR
568, d4o22A1, 0.7420, 3.52, 0.171, 333, 275, BINARY COMPLEX OF METAL-FREE PKAC WITH SP20.
569, d4c62A_, 0.7420, 2.36, 0.296, 273, 253, INHIBITORS OF JAK2 KINASE DOMAIN
570, d2uvxA_, 0.7420, 3.55, 0.178, 335, 276, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH 7-AZAINDOLE
571, d1ydsE_, 0.7420, 3.56, 0.170, 334, 276, STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE ALPHA-CATALYTIC SUBUNIT IN COMPLEX WITH H8 PROTEIN KINASE INHIBITOR [N-(2-METHYLAMINO)ETHYL]-5- ISOQUINOLINESULFONAMIDE
572, d4x6rA_, 0.7419, 3.36, 0.169, 347, 272, AN ISOFORM-SPECIFIC MYRISTYLATION SWITCH TARGETS RIIB PKA HOLOENZYMES TO MEMBRANES
573, d6aywB_, 0.7418, 3.18, 0.157, 293, 268, THE STRUCTURE OF HUMAN CAMKII WITH BOUND INHIBITOR
574, d2vo7A_, 0.7418, 3.49, 0.178, 335, 275, STRUCTURE OF PKA COMPLEXED WITH 4-(4-CHLOROBENZYL)-1-(7H- PYRROLO(23-D)PYRIMIDIN-4-YL)PIPERIDIN-4-YLAMINE
575, d2srcA3, 0.7418, 2.49, 0.290, 284, 255, CRYSTAL STRUCTURE OF HUMAN TYROSINE-PROTEIN KINASE C-SRC IN COMPLEX WITH AMP-PNP
576, d2erzE_, 0.7418, 3.56, 0.174, 334, 276, CRYSTAL STRUCTURE OF C-AMP DEPENDENT KINASE (PKA) BOUND TO HYDROXYFASUDIL
577, d4i0sA1, 0.7417, 2.74, 0.345, 263, 258, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH 2-(6- CHLORO-1-METHYL-1H-INDAZOL-3-YL)-5H-PYRROLO[23-B]PYRAZINE-7- CARBOXYLIC ACID ISOPROPYLAMIDE
578, d6aywA_, 0.7416, 3.06, 0.154, 293, 267, THE STRUCTURE OF HUMAN CAMKII WITH BOUND INHIBITOR
579, d4ybkA_, 0.7416, 2.83, 0.281, 266, 260, C-HELIX-OUT DASATINIB ANALOG CRYSTALLIZED WITH C-SRC KINASE
580, d5ng3A_, 0.7415, 2.63, 0.218, 283, 257, STRUCTURE OF INACTIVE KINASE RIP2K(K47R)
581, d3amaA_, 0.7415, 3.57, 0.170, 342, 276, PROTEIN KINASE A SIXFOLD MUTANT MODEL OF AURORA B WITH INHIBITOR JNJ- 7706621
582, d2jdsA_, 0.7415, 3.54, 0.175, 334, 275, STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE COMPLEXED WITH A- 443654
583, d1ydrE_, 0.7415, 3.56, 0.174, 334, 276, STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE ALPHA-CATALYTIC SUBUNIT IN COMPLEX WITH H7 PROTEIN KINASE INHIBITOR 1-(5- ISOQUINOLINESULFONYL)-2-METHYLPIPERAZINE
584, d1q8tA_, 0.7415, 3.65, 0.177, 338, 277, THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE (PKA) IN COMPLEX WITH RHO-KINASE INHIBITOR Y-27632
585, d1yi6B_, 0.7414, 3.20, 0.280, 274, 268, C-TERM TAIL SEGMENT OF HUMAN TYROSINE KINASE (258-533)
586, d2cpkE_, 0.7413, 3.45, 0.168, 333, 273, CRYSTAL STRUCTURE OF THE CATALYTIC SUBUNIT OF CYCLIC ADENOSINE MONOPHOSPHATE-DEPENDENT PROTEIN KINASE
587, d2c1bA_, 0.7413, 3.57, 0.178, 335, 276, STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE COMPLEXED WITH ( 4R2S)-5 -(4-(4-CHLOROBENZYLOXY)PYRROLIDIN-2- YLMETHANESULFONYL)ISOQUINOLINE
588, d4id7A_, 0.7412, 2.75, 0.347, 268, 259, ACK1 KINASE IN COMPLEX WITH THE INHIBITOR CIS-3-[8-AMINO-1-(4- PHENOXYPHENYL)IMIDAZO[15-A]PYRAZIN-3-YL]CYCLOBUTANOL
589, d4fyoA1, 0.7412, 2.77, 0.349, 263, 258, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH N-{(S)-1- [7-(34-DIMETHOXY-PHENYLAMINO)-THIAZOLO[54-D]PYRIMIDIN-5-YL]- PYRROLIDIN-3-YL}-TEREPHTHALAMIC ACID
590, d4c62B_, 0.7412, 2.25, 0.307, 271, 251, INHIBITORS OF JAK2 KINASE DOMAIN
591, d1oecA_, 0.7412, 3.04, 0.326, 280, 264, FGFR2 KINASE DOMAIN
592, d5vloB_, 0.7411, 3.01, 0.158, 293, 266, THE STRUCTURE OF HUMAN CAMKII WITH BOUND INHIBITOR
593, d4j95C_, 0.7411, 3.07, 0.314, 281, 264, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC K659N MUTATION RESPONSIBLE FOR AN UNCLASSIFIED CRANIOSYNOSTOSIS SYNDROME IN SPACE GROUP C2.
594, d3idbA_, 0.7411, 3.74, 0.189, 341, 280, CRYSTAL STRUCTURE OF (108-268)RIIB:C HOLOENZYME OF CAMP- DEPENDENT PROTEIN KINASE
595, d2uztA_, 0.7411, 3.70, 0.186, 336, 279, PKA STRUCTURES OF AKT INDAZOLE-PYRIDINE INHIBITORS
596, d1vebA_, 0.7411, 3.53, 0.171, 338, 275, CRYSTAL STRUCTURE OF PROTEIN KINASE A IN COMPLEX WITH AZEPANE DERIVATIVE 5
597, d1ad5B3, 0.7411, 2.40, 0.304, 271, 253, SRC FAMILY KINASE HCK-AMP-PNP COMPLEX
598, d2qcsA_, 0.7410, 3.44, 0.186, 335, 274, A COMPLEX STRUCTURE BETWEEN THE CATALYTIC AND REGULATORY SUBUNIT OF PROTEIN KINASE A THAT REPRESENTS THE INHIBITED STATE
599, d1q61A_, 0.7410, 3.72, 0.183, 335, 279, PKA TRIPLE MUTANT MODEL OF PKB
600, d2xynA_, 0.7409, 2.59, 0.345, 264, 258, HUMAN ABL2 IN COMPLEX WITH AURORA KINASE INHIBITOR VX-680
601, d1sveA_, 0.7409, 3.49, 0.175, 341, 275, CRYSTAL STRUCTURE OF PROTEIN KINASE A IN COMPLEX WITH AZEPANE DERIVATIVE 1
602, d5lmaA_, 0.7408, 2.90, 0.342, 267, 260, HUMAN SPLEEN TYROSINE KINASE KINASE DOMAIN IN COMPLEX WITH AZANAPHTHYRIDINE INHIBITOR
603, d4i0tA1, 0.7408, 2.70, 0.346, 262, 257, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH 2-(5678- TETRAHYDRO-IMIDAZO[15-A]PYRIDIN-1-YL)-5H-PYRROLO[23-B]PYRAZINE-7- CARBOXYLIC ACID TERT-BUTYLAMIDE
604, d3fqhA_, 0.7408, 2.68, 0.346, 262, 257, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH A 2-SUBSTITUTED 7-AZAINDOLE
605, d3ow3A_, 0.7407, 3.47, 0.172, 334, 274, DISCOVERY OF DIHYDROTHIENO- AND DIHYDROFUROPYRIMIDINES AS POTENT PAN AKT INHIBITORS
606, d2uw4A_, 0.7407, 3.55, 0.178, 334, 275, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH 2-(4-(5-METHYL- 1H-PYRAZOL-4-YL)-PHENYL)-ETHYLAMINE
607, d4puzA_, 0.7406, 2.72, 0.345, 263, 258, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE (SYK) IN COMPLEX WITH GS- 9973
608, d3nx8A_, 0.7406, 3.52, 0.175, 333, 275, HUMAN CAMP DEPENDENT PROTEIN KINASE IN COMPLEX WITH PHENOL
609, d1ydtE_, 0.7406, 3.58, 0.170, 334, 276, STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE ALPHA-CATALYTIC SUBUNIT IN COMPLEX WITH H89 PROTEIN KINASE INHIBITOR N-[2- (4-BROMOCINNAMYLAMINO)ETHYL]-5-ISOQUINOLINE
610, d1u4dA_, 0.7406, 2.40, 0.357, 258, 252, STRUCTURE OF THE ACK1 KINASE DOMAIN BOUND TO DEBROMOHYMENIALDISINE
611, d4b4lA_, 0.7405, 3.14, 0.175, 299, 268, CRYSTAL STRUCTURE OF AN ARD DAP-KINASE 1 MUTANT
612, d3bwjA_, 0.7405, 3.39, 0.183, 338, 273, COMPLEX OF PKA WITH THE BISUBSTRATE PROTEIN KINASE INHIBITOR LEAD COMPOUND ARC-1034
613, d4dfnA1, 0.7404, 2.94, 0.349, 268, 261, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH AN ADAMANTYLPYRAZINE INHIBITOR
614, d4c61A_, 0.7404, 2.33, 0.298, 272, 252, INHIBITORS OF JAK2 KINASE DOMAIN
615, d4bkjB1, 0.7404, 2.54, 0.293, 296, 256, CRYSTAL STRUCTURE OF THE HUMAN DDR1 KINASE DOMAIN IN COMPLEX WITH IMATINIB
616, d1u54A_, 0.7404, 2.48, 0.350, 262, 254, CRYSTAL STRUCTURES OF THE PHOSPHORYLATED AND UNPHOSPHORYLATED KINASE DOMAINS OF THE CDC42-ASSOCIATED TYROSINE KINASE ACK1 BOUND TO AMP-PCP
617, d5ghvB_, 0.7403, 2.90, 0.346, 265, 260, CRYSTAL STRUCTURE OF AN INHIBITOR-BOUND SYK
618, d4xg5B_, 0.7403, 2.90, 0.346, 265, 260,  
619, d3agmA_, 0.7403, 3.52, 0.175, 337, 275, COMPLEX OF PKA WITH THE BISUBSTRATE PROTEIN KINASE INHIBITOR ARC-670
620, d2x2mB1, 0.7403, 2.69, 0.339, 274, 257, CRYSTAL STRUCTURE OF PHOSPHORYLATED RET TYROSINE KINASE DOMAIN WITH INHIBITOR
621, d2hckB3, 0.7403, 2.42, 0.304, 271, 253, SRC FAMILY KINASE HCK-QUERCETIN COMPLEX
622, d1gjoA_, 0.7403, 3.05, 0.326, 280, 264, THE FGFR2 TYROSINE KINASE DOMAIN
623, d4gfoA1, 0.7402, 2.04, 0.319, 270, 248, TYK2 KINASE (JH1 DOMAIN) WITH 26-DICHLORO-N-(2-OXO-25- DIHYDROPYRIDIN-4-YL)BENZAMIDE
624, d4qpsA_, 0.7401, 2.09, 0.321, 270, 249, CRYSTAL STRUCTURE OF JAK3 COMPLEXED TO N-[3-(6-PHENYLAMINO-PYRAZIN-2- YL)-3H-BENZOIMIDAZOL-5-YL]-ACRYLAMIDE
625, d3d7uC1, 0.7401, 2.17, 0.319, 255, 251, STRUCTURAL BASIS FOR THE RECOGNITION OF C-SRC BY ITS INACTIVATOR CSK
626, d3d7uA1, 0.7401, 2.17, 0.319, 255, 251, STRUCTURAL BASIS FOR THE RECOGNITION OF C-SRC BY ITS INACTIVATOR CSK
627, d1xhaA_, 0.7401, 3.57, 0.174, 348, 276, CRYSTAL STRUCTURES OF PROTEIN KINASE B SELECTIVE INHIBITORS IN COMPLEX WITH PROTEIN KINASE A AND MUTANTS
628, d1u46B_, 0.7401, 2.24, 0.356, 257, 250, CRYSTAL STRUCTURE OF THE UNPHOSPHORYLATED KINASE DOMAIN OF THE TYROSINE KINASE ACK1
629, d3pooA_, 0.7400, 3.52, 0.175, 331, 275, HUMAN CAMP-DEPENDENT PROTEIN KINASE IN COMPLEX WITH AN INHIBITOR
630, d3nsvA_, 0.7400, 2.60, 0.345, 264, 258,  
631, d3dqxB_, 0.7400, 3.01, 0.284, 268, 264, CHICKEN C-SRC KINASE DOMAIN IN COMPLEX WITH ATPGS
632, d2pwlA_, 0.7400, 3.27, 0.316, 284, 266, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC N549H MUTATION RESPONSIBLE FOR CROUZON SYNDROME.
633, d3vs3B3, 0.7399, 2.45, 0.300, 271, 253, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR 7-[TRANS-4-(4-METHYLPIPERAZIN-1-YL)CYCLOHEXYL]-5-(4-PHENOXYPHENYL)- 7H-PYRROLO[23-D]PYRIMIDIN-4-AMINE
634, d1xh9A_, 0.7399, 3.63, 0.174, 336, 276, CRYSTAL STRUCTURES OF PROTEIN KINASE B SELECTIVE INHIBITORS IN COMPLEX WITH PROTEIN KINASE A AND MUTANTS
635, d1svhA_, 0.7399, 3.59, 0.174, 335, 276, CRYSTAL STRUCTURE OF PROTEIN KINASE A IN COMPLEX WITH AZEPANE DERIVATIVE 8
636, d3dndA_, 0.7398, 3.58, 0.174, 334, 276, CAMP-DEPENDENT PROTEIN KINASE PKA CATALYTIC SUBUNIT WITH PKI-5-24
637, d2uw3A_, 0.7398, 3.50, 0.175, 334, 274, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH 5-METHYL-4- PHENYL-1H-PYRAZOLE
638, d1u54B_, 0.7398, 2.48, 0.356, 261, 253, CRYSTAL STRUCTURES OF THE PHOSPHORYLATED AND UNPHOSPHORYLATED KINASE DOMAINS OF THE CDC42-ASSOCIATED TYROSINE KINASE ACK1 BOUND TO AMP-PCP
639, d1kswA3, 0.7398, 2.64, 0.289, 284, 256, STRUCTURE OF HUMAN C-SRC TYROSINE KINASE (THR338GLY MUTANT) IN COMPLEX WITH N6-BENZYL ADP
640, d1bx6A_, 0.7398, 3.53, 0.174, 337, 276, CRYSTAL STRUCTURE OF THE POTENT NATURAL PRODUCT INHIBITOR BALANOL IN COMPLEX WITH THE CATALYTIC SUBUNIT OF CAMP- DEPENDENT PROTEIN KINASE
641, d4j97D_, 0.7397, 2.82, 0.324, 285, 259, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC GAIN-OF-FUNCTION K659E MUTATION IDENTIFIED IN ENDOMETRIAL CANCER.
642, d3kcfD_, 0.7396, 2.88, 0.187, 330, 262, CRYSTAL STRUCTURE OF TGFBRI COMPLEXED WITH A PYRAZOLONE INHIBITOR
643, d5ghvA_, 0.7395, 2.90, 0.346, 265, 260, CRYSTAL STRUCTURE OF AN INHIBITOR-BOUND SYK
644, d4xg5A_, 0.7395, 2.90, 0.346, 265, 260,  
645, d3mdyA_, 0.7395, 2.72, 0.174, 320, 259, CRYSTAL STRUCTURE OF THE CYTOPLASMIC DOMAIN OF THE BONE MORPHOGENETIC PROTEIN RECEPTOR TYPE-1B (BMPR1B) IN COMPLEX WITH FKBP12 AND LDN- 193189
646, d3en4B_, 0.7395, 2.92, 0.294, 266, 262, TARGETED POLYPHARMACOLOGY: CRYSTAL STRUCTURE OF THE C-SRC KINASE DOMAIN IN COMPLEX WITH PP121 A MULTITARGETED KINASE INHIBITOR
647, d2uw7A_, 0.7395, 3.50, 0.175, 335, 275, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH  4-(4-CHLORO- PHENYL)-4-(4-(1H-PYRAZOL-4-YL)-PHENYL)-PIPERIDINE
648, d2hckA3, 0.7395, 2.43, 0.300, 271, 253, SRC FAMILY KINASE HCK-QUERCETIN COMPLEX
649, d2gu8A_, 0.7395, 3.52, 0.175, 335, 275, DISCOVERY OF 2-PYRIMIDYL-5-AMIDOTHIOPHENES AS NOVEL AND POTENT INHIBITORS FOR AKT: SYNTHESIS AND SAR STUDIES
650, d1ad5A3, 0.7395, 2.42, 0.304, 271, 253, SRC FAMILY KINASE HCK-AMP-PNP COMPLEX
651, d6babA_, 0.7394, 3.08, 0.158, 290, 266, THE STRUCTURE OF HUMAN CAMKII WITH BOUND INHIBITOR
652, d3kcfA_, 0.7394, 2.75, 0.192, 328, 261, CRYSTAL STRUCTURE OF TGFBRI COMPLEXED WITH A PYRAZOLONE INHIBITOR
653, d2w4kA_, 0.7394, 3.16, 0.179, 301, 268, X-RAY STRUCTURE OF A DAP-KINASE 2-302
654, d4l00B_, 0.7393, 2.78, 0.211, 278, 261, CRYSTAL STRUCTURE OF THE APO JAK1 PSEUDOKINASE DOMAIN
655, d2uw5A_, 0.7393, 3.50, 0.179, 333, 274, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH  (R)-2-(4- CHLORO-PHENYL)-2-(4-1H-PYRAZOL-4-YL)-PHENYL)-ETHYLAMINE
656, d2gnlA_, 0.7393, 3.59, 0.178, 338, 276, PKA THREEFOLD MUTANT MODEL OF RHO-KINASE WITH INHIBITOR H- 1152P
657, d1xh5A_, 0.7393, 3.59, 0.174, 335, 276, CRYSTAL STRUCTURES OF PROTEIN KINASE B SELECTIVE INHIBITORS IN COMPLEX WITH PROTEIN KINASE A AND MUTANTS
658, d4px6A1, 0.7392, 2.72, 0.346, 261, 257, SYK CATALYTIC DOMAIN IN COMPLEX WITH A POTENT PYRIDOPYRIMIDINONE INHIBITOR
659, d1k9aE3, 0.7392, 2.51, 0.309, 268, 256, CRYSTAL STRUCTURE ANALYSIS OF FULL-LENGTH CARBOXYL-TERMINAL SRC KINASE AT 2.5 A RESOLUTION
660, d5ng3D_, 0.7391, 2.71, 0.221, 278, 258, STRUCTURE OF INACTIVE KINASE RIP2K(K47R)
661, d2wd1A_, 0.7391, 3.02, 0.346, 289, 260, HUMAN C-MET KINASE IN COMPLEX WITH AZAINDOLE INHIBITOR
662, d2uvzA_, 0.7391, 3.49, 0.179, 334, 274, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH C-PHENYL-C-(4-( 9H-PURIN-6-YL)-PHENYL)-METHYLAMINE
663, d3vs4B3, 0.7390, 2.36, 0.299, 269, 251, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR 5-(4-PHENOXYPHENYL)-7-(TETRAHYDRO-2H-PYRAN-4-YL)-7H-PYRROLO[23- D]PYRIMIDIN-4-AMINE
664, d3vryA3, 0.7390, 2.36, 0.299, 269, 251, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR 4-AMINO-5-(4-PHENOXYPHENYL)-7H-PYRROLO[23-D]PYRIMIDIN-7-YL- CYCLOPENTANE
665, d2vnyA_, 0.7390, 3.57, 0.175, 334, 275, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH (1-(9H-PURIN-6- YL)PIPERIDIN-4-YL)AMINE
666, d2uvyA_, 0.7390, 3.56, 0.178, 333, 275, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH METHYL-(4-(9H- PURIN-6-YL)-BENZYL)-AMINE
667, d1iasA_, 0.7390, 3.06, 0.158, 330, 266, CYTOPLASMIC DOMAIN OF UNPHOSPHORYLATED TYPE I TGF-BETA RECEPTOR CRYSTALLIZED WITHOUT FKBP12
668, d3vs4A3, 0.7389, 2.44, 0.298, 270, 252, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR 5-(4-PHENOXYPHENYL)-7-(TETRAHYDRO-2H-PYRAN-4-YL)-7H-PYRROLO[23- D]PYRIMIDIN-4-AMINE
669, d3fqsA1, 0.7389, 2.91, 0.344, 264, 259, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH R406
670, d5wfjA_, 0.7388, 2.36, 0.313, 265, 252, THE JAK3 KINASE DOMAIN IN COMPLEX WITH A COVALENT INHIBITOR
671, d4mkcA_, 0.7388, 3.48, 0.256, 303, 273, CRYSTAL STRUCTURE OF ANAPLASTIC LYMPHOMA KINASE COMPLEXED WITH LDK378
672, d3vryB3, 0.7388, 2.38, 0.299, 269, 251, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR 4-AMINO-5-(4-PHENOXYPHENYL)-7H-PYRROLO[23-D]PYRIMIDIN-7-YL- CYCLOPENTANE
673, d3p0mA_, 0.7388, 3.59, 0.178, 335, 276, HUMAN CAMP-DEPENDENT PROTEIN KINASE IN COMPLEX WITH AN INHIBITOR
674, d3ambA_, 0.7388, 3.57, 0.174, 340, 276, PROTEIN KINASE A SIXFOLD MUTANT MODEL OF AURORA B WITH INHIBITOR VX- 680
675, d2ofuA_, 0.7388, 2.86, 0.294, 272, 262, X-RAY CRYSTAL STRUCTURE OF 2-AMINOPYRIMIDINE CARBAMATE 43 BOUND TO LCK
676, d4rx9A1, 0.7386, 2.97, 0.342, 264, 260, SYK CATALYTIC DOMAIN COMPLEXED WITH A POTENT PYRIMIDINE INHIBITOR
677, d2v7aB_, 0.7386, 2.98, 0.331, 268, 263, CRYSTAL STRUCTURE OF THE T315I ABL MUTANT IN COMPLEX WITH THE INHIBITOR PHA-739358
678, d1smhA_, 0.7386, 3.51, 0.175, 348, 275, PROTEIN KINASE A VARIANT COMPLEX WITH COMPLETELY ORDERED N- TERMINAL HELIX
679, d3kcfC_, 0.7385, 2.88, 0.172, 330, 262, CRYSTAL STRUCTURE OF TGFBRI COMPLEXED WITH A PYRAZOLONE INHIBITOR
680, d2pvyA_, 0.7384, 2.79, 0.326, 288, 258, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC K659N MUTATION RESPONSIBLE FOR AN UNCLASSIFIED CRANIOSYNOSTOSIS SYNDROME.
681, d1xbbA1, 0.7384, 3.01, 0.341, 266, 261, CRYSTAL STRUCTURE OF THE SYK TYROSINE KINASE DOMAIN WITH GLEEVEC
682, d5w86C_, 0.7383, 2.43, 0.316, 273, 253, CRYSTAL STRUCTURE OF JAK3 KINASE DOMAIN WITH A 46-DIAMINONICOTINAMIDE INHIBITOR (COMPOUND NUMBER 7)
683, d4mxzA_, 0.7383, 3.03, 0.289, 266, 263, SRC M314L T338M DOUBLE MUTANT BOUND TO KINASE INHIBITOR BOSUTINIB
684, d4mxyA_, 0.7383, 3.03, 0.289, 266, 263, SRC M314L T338M DOUBLE MUTANT BOUND TO KINASE INHIBITOR BOSUTINIB
685, d4e26A_, 0.7383, 2.70, 0.216, 270, 259, BRAF IN COMPLEX WITH AN ORGANIC INHIBITOR 7898734
686, d5w86D_, 0.7382, 2.35, 0.327, 272, 251, CRYSTAL STRUCTURE OF JAK3 KINASE DOMAIN WITH A 46-DIAMINONICOTINAMIDE INHIBITOR (COMPOUND NUMBER 7)
687, d5d7vC1, 0.7382, 2.32, 0.299, 262, 251, CRYSTAL STRUCTURE OF PTK6 KINASE DOMAIN
688, d4bkjA1, 0.7382, 2.59, 0.293, 294, 256, CRYSTAL STRUCTURE OF THE HUMAN DDR1 KINASE DOMAIN IN COMPLEX WITH IMATINIB
689, d3zfxA_, 0.7382, 2.88, 0.312, 267, 260, CRYSTAL STRUCTURE OF EPHB1
690, d2gqgA1, 0.7382, 2.89, 0.332, 271, 262, X-RAY CRYSTAL STRUCTURE OF DASATINIB (BMS-354825) BOUND TO ACTIVATED ABL KINASE DOMAIN
691, d1xh8A_, 0.7382, 3.52, 0.178, 337, 275, CRYSTAL STRUCTURES OF PROTEIN KINASE B SELECTIVE INHIBITORS IN COMPLEX WITH PROTEIN KINASE A AND MUTANTS
692, d2jdvA_, 0.7381, 3.62, 0.174, 334, 276, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH A-443654
693, d3zfxD_, 0.7380, 2.88, 0.312, 265, 260, CRYSTAL STRUCTURE OF EPHB1
694, d3kf4B_, 0.7380, 2.75, 0.331, 270, 260, STRUCTURAL ANALYSIS OF DFG-IN AND DFG-OUT DUAL SRC-ABL INHIBITORS SHARING A COMMON VINYL PURINE TEMPLATE
695, d2qu5A_, 0.7380, 3.13, 0.297, 292, 263, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A BENZIMIDAZOLE INHIBITOR
696, d3sxsA1, 0.7379, 2.73, 0.290, 261, 259, CRYSTAL STRUCTURE OF BMX NON-RECEPTOR TYROSINE KINASE COMPLEXED WITH PP2
697, d2vnwA_, 0.7379, 3.58, 0.175, 334, 275, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH (1-(9H-PURIN-6- YL)PIPERIDIN-4-YL)METHANAMINE
698, d1xh7A_, 0.7378, 3.58, 0.178, 337, 275, CRYSTAL STRUCTURES OF PROTEIN KINASE B SELECTIVE INHIBITORS IN COMPLEX WITH PROTEIN KINASE A AND MUTANTS
699, d1xh6A_, 0.7378, 3.62, 0.178, 331, 276, CRYSTAL STRUCTURES OF PROTEIN KINASE B SELECTIVE INHIBITORS IN COMPLEX WITH PROTEIN KINASE A AND MUTANTS
700, d5uhnA_, 0.7377, 3.18, 0.317, 282, 265, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FGF RECEPTOR 2 HARBORING A N549H/E565A DOUBLE GAIN-OF-FUNCTION MUTATION
701, d3kcfE_, 0.7377, 3.02, 0.159, 330, 264, CRYSTAL STRUCTURE OF TGFBRI COMPLEXED WITH A PYRAZOLONE INHIBITOR
702, d2a27C_, 0.7377, 3.28, 0.175, 303, 269, HUMAN DRP-1 KINASE W305S S308A D40 MUTANT CRYSTAL FORM WITH 8 MONOMERS IN THE ASYMMETRIC UNIT
703, d5mjbB_, 0.7376, 3.29, 0.301, 278, 269, KINASE DOMAIN OF HUMAN EPHB1 G703C MUTANT COVALENTLY BOUND TO A QUINAZOLINE-BASED INHIBITOR
704, d4dflA1, 0.7376, 2.74, 0.346, 262, 257, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH A SULFONAMIDOPYRAZINE PIPERIDINE INHIBITOR
705, d3zfxI_, 0.7376, 2.79, 0.313, 263, 259, CRYSTAL STRUCTURE OF EPHB1
706, d3zfxH_, 0.7376, 2.91, 0.310, 266, 261, CRYSTAL STRUCTURE OF EPHB1
707, d2vo6A_, 0.7376, 3.49, 0.182, 335, 274, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH  4-(4- CHLOROBENZYL)-1-(7H-PYRROLO(23-D)PYRIMIDIN-4-YL)PIPERIDIN- 4-YLAMINE
708, d5d7vB1, 0.7375, 2.34, 0.299, 262, 251, CRYSTAL STRUCTURE OF PTK6 KINASE DOMAIN
709, d4cd0A_, 0.7375, 3.42, 0.269, 295, 271, STRUCTURE OF L1196M MUTANT HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH 2-(5-(6-AMINO-5-((R)-1-(5-FLUORO-2-(2H-123-TRIAZOL-2-YL) PHENYL)ETHOXY)PYRIDIN-3-YL)-4-METHYLTHIAZOL-2-YL)PROPANE-12-DIOL
710, d2ya9A_, 0.7375, 3.18, 0.175, 299, 268, CRYSTAL STRUCTURE OF THE AUTOINHIBITED FORM OF MOUSE DAPK2
711, d2a27A_, 0.7375, 3.28, 0.175, 304, 269, HUMAN DRP-1 KINASE W305S S308A D40 MUTANT CRYSTAL FORM WITH 8 MONOMERS IN THE ASYMMETRIC UNIT
712, d1q8uA_, 0.7375, 3.62, 0.188, 341, 277, THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE IN COMPLEX WITH RHO-KINASE INHIBITOR H-1152P
713, d5eydA_, 0.7374, 3.14, 0.347, 289, 262, CRYSTAL STRUCTURE OF C-MET IN COMPLEX WITH AMG 337
714, d3vs6B3, 0.7374, 2.41, 0.299, 269, 251, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRAZOLO-PYRIMIDINE INHIBITOR TERT-BUTYL {4-[4-AMINO-1-(PROPAN-2-YL)-1H-PYRAZOLO[34- D]PYRIMIDIN-3-YL]-2-METHOXYPHENYL}CARBAMATE
715, d3fzrA_, 0.7374, 2.77, 0.318, 261, 258, CRYSTAL STRUCTURE OF PYK2 COMPLEXED WITH PF-431396
716, d2vo3A_, 0.7374, 3.51, 0.175, 334, 274, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH  C-(4-(4- CHLOROPHENYL)-1-(7H-PYRROLO(23-D)PYRIMIDIN-4-YL)PIPERIDIN- 4-YL)METHYLAMINE
717, d1iasE_, 0.7374, 3.13, 0.158, 330, 266, CYTOPLASMIC DOMAIN OF UNPHOSPHORYLATED TYPE I TGF-BETA RECEPTOR CRYSTALLIZED WITHOUT FKBP12
718, d1b6cH_, 0.7374, 3.05, 0.177, 326, 265, CRYSTAL STRUCTURE OF THE CYTOPLASMIC DOMAIN OF THE TYPE I TGF-BETA RECEPTOR IN COMPLEX WITH FKBP12
719, d5ng2B_, 0.7373, 2.88, 0.231, 278, 260, STRUCTURE OF RIP2K(D146N) WITH BOUND STAUROSPORINE
720, d4gu6A_, 0.7373, 2.94, 0.345, 271, 261, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH N-{3-[(5-CYANO- 2-PHENYL-1H-PYRROLO[23-B]PYRIDIN-4-YLAMINO)- METHYL]-PYRIDIN-2-YL}- N-METHYL-METHANESULFONAMIDE
721, d3f6xA_, 0.7373, 2.77, 0.291, 264, 258, C-SRC KINASE DOMAIN IN COMPLEX WITH SMALL MOLECULE INHIBITOR
722, d2a27E_, 0.7373, 3.28, 0.175, 303, 269, HUMAN DRP-1 KINASE W305S S308A D40 MUTANT CRYSTAL FORM WITH 8 MONOMERS IN THE ASYMMETRIC UNIT
723, d1xh4A_, 0.7373, 3.59, 0.178, 334, 275, CRYSTAL STRUCTURES OF PROTEIN KINASE B SELECTIVE INHIBITORS IN COMPLEX WITH PROTEIN KINASE A AND MUTANTS
724, d1stcE_, 0.7372, 3.56, 0.174, 334, 276, CAMP-DEPENDENT PROTEIN KINASE ALPHA-CATALYTIC SUBUNIT IN COMPLEX WITH STAUROSPORINE
725, d2vo0A_, 0.7371, 3.54, 0.178, 340, 275, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH  C-(4-(4- CHLOROPHENYL)-1-(7H-PYRROLO(23-D)PYRIMIDIN-4-YL)PIPERIDIN- 4-YL)METHYLAMINE
726, d1iasD_, 0.7371, 2.97, 0.159, 330, 264, CYTOPLASMIC DOMAIN OF UNPHOSPHORYLATED TYPE I TGF-BETA RECEPTOR CRYSTALLIZED WITHOUT FKBP12
727, d1iasC_, 0.7371, 2.96, 0.159, 330, 264, CYTOPLASMIC DOMAIN OF UNPHOSPHORYLATED TYPE I TGF-BETA RECEPTOR CRYSTALLIZED WITHOUT FKBP12
728, d5vndB_, 0.7370, 3.24, 0.331, 295, 266, CRYSTAL STRUCTURE OF FGFR1-Y563C (FGFR4 SURROGATE) COVALENTLY BOUND TO H3B-6527
729, d4hzrB_, 0.7370, 2.52, 0.357, 258, 252, CRYSTAL STRUCTURE OF ACK1 KINASE DOMAIN
730, d5d7vD1, 0.7369, 2.35, 0.299, 262, 251, CRYSTAL STRUCTURE OF PTK6 KINASE DOMAIN
731, d4tl0A_, 0.7369, 3.29, 0.175, 300, 269, CRYSTAL STRUCTURE OF DEATH-ASSOCIATED PROTEIN KINASE 1 WITH A CRUCIAL PHOSPHOMIMICKING MUTATION
732, d3l9lA_, 0.7369, 3.60, 0.174, 338, 276, CRYSTAL STRUCTURE OF PKA WITH COMPOUND 36
733, d1b6cD_, 0.7369, 3.04, 0.177, 326, 265, CRYSTAL STRUCTURE OF THE CYTOPLASMIC DOMAIN OF THE TYPE I TGF-BETA RECEPTOR IN COMPLEX WITH FKBP12
734, d5h09A3, 0.7368, 2.84, 0.296, 281, 257, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR (S)-ETHYL2-(((1R4S)-4-(4-AMINO-5-(4-PHENOXYPHENYL)-7H-PYRROLO[23- D]PYRIMIDIN-7-YL)CYCLOHEXYL)AMINO)-4-METHYLPENTANOATE
735, d5d7vA1, 0.7368, 2.46, 0.298, 262, 252, CRYSTAL STRUCTURE OF PTK6 KINASE DOMAIN
736, d2pvyD_, 0.7368, 2.92, 0.317, 283, 259, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC K659N MUTATION RESPONSIBLE FOR AN UNCLASSIFIED CRANIOSYNOSTOSIS SYNDROME.
737, d2gcdB_, 0.7368, 3.34, 0.187, 308, 273, TAO2 KINASE DOMAIN-STAUROSPORINE STRUCTURE
738, d5h0eA3, 0.7367, 2.84, 0.296, 281, 257, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR (S)-2-(((1R4S)-4-(4-AMINO-5-(4-PHENOXYPHENYL)-7H-PYRROLO[23- D]PYRIMIDIN-7-YL)CYCLOHEXYL)AMINO)-4-METHYLPENTANAMIDE
739, d3f6xC_, 0.7367, 2.71, 0.296, 265, 257, C-SRC KINASE DOMAIN IN COMPLEX WITH SMALL MOLECULE INHIBITOR
740, d1qpcA_, 0.7367, 2.93, 0.286, 270, 262, STRUCTURAL ANALYSIS OF THE LYMPHOCYTE-SPECIFIC KINASE LCK IN COMPLEX WITH NON-SELECTIVE AND SRC FAMILY SELECTIVE KINASE INHIBITORS
741, d3vs6A3, 0.7366, 2.41, 0.299, 269, 251, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRAZOLO-PYRIMIDINE INHIBITOR TERT-BUTYL {4-[4-AMINO-1-(PROPAN-2-YL)-1H-PYRAZOLO[34- D]PYRIMIDIN-3-YL]-2-METHOXYPHENYL}CARBAMATE
742, d3lcsA_, 0.7366, 3.53, 0.255, 304, 275, CRYSTAL STRUCTURE OF THE ANAPLASTIC LYMPHOMA KINASE CATALYTIC DOMAIN
743, d2uw6A_, 0.7365, 3.51, 0.179, 334, 274, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH  (S)-2-(4- CHLORO-PHENYL)-2-(4-1H-PYRAZOL-4-YL)-PHENYL)-ETHYLAMINE
744, d2pwlB_, 0.7365, 3.30, 0.320, 286, 266, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC N549H MUTATION RESPONSIBLE FOR CROUZON SYNDROME.
745, d1k2pA_, 0.7365, 2.69, 0.289, 258, 256, CRYSTAL STRUCTURE OF BRUTON S TYROSINE KINASE DOMAIN
746, d4uxlA_, 0.7364, 3.22, 0.321, 288, 268, STRUCTURE OF HUMAN ROS1 KINASE DOMAIN IN COMPLEX WITH PF-06463922
747, d4fynA1, 0.7364, 2.88, 0.341, 263, 258, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH 3-(8-{4- [ETHYL-(2-HYDROXY-ETHYL)-AMINO]-PHENYLAMINO}-IMIDAZO[12-A]PYRAZIN-5- YL)-PHENOL
748, d3tnqB_, 0.7362, 3.59, 0.171, 331, 275, STRUCTURE AND ALLOSTERY OF THE PKA RIIB TETRAMERIC HOLOENZYME
749, d3lctA_, 0.7362, 3.55, 0.258, 308, 275, CRYSTAL STRUCTURE OF THE ANAPLASTIC LYMPHOMA KINASE CATALYTIC DOMAIN
750, d2uw0A_, 0.7362, 3.52, 0.175, 334, 274, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH  6-(4-(4-(4- CHLORO-PHENYL)-PIPERIDIN-4-YL)-PHENYL)-9H-PURINE
751, d1qpdA_, 0.7362, 2.89, 0.294, 270, 262, STRUCTURAL ANALYSIS OF THE LYMPHOCYTE-SPECIFIC KINASE LCK IN COMPLEX WITH NON-SELECTIVE AND SRC FAMILY SELECTIVE KINASE INHIBITORS
752, d1koaA2, 0.7362, 3.71, 0.159, 350, 277, TWITCHIN KINASE FRAGMENT (C.ELEGANS) AUTOREGULATED PROTEIN KINASE AND IMMUNOGLOBULIN DOMAINS
753, d4aoiA_, 0.7361, 2.84, 0.346, 289, 257, CRYSTAL STRUCTURE OF C-MET KINASE DOMAIN IN COMPLEX WITH 4-( 3-((1H- PYRROLO(23-B)PYRIDIN-3-YL)METHYL)-(124)TRIAZOLO( 43-B)(124) TRIAZIN-6-YL)BENZONITRILE
754, d3zzeA_, 0.7361, 2.98, 0.347, 286, 259, CRYSTAL STRUCTURE OF C-MET KINASE DOMAIN IN COMPLEX WITH N - ((3Z)-4-CHLORO-7-METHYL-2-OXO-12-DIHYDRO-3H-INDOL-3- YLIDENE)-2-(4-HYDROXYPHENYL)PROPANOHYDRAZIDE
755, d4z55A_, 0.7360, 3.49, 0.261, 294, 272, ANAPLASTIC LYMPHOMA KINASE CATALYTIC DOMAIN COMPLEXED WITH PYRAZOLOPYRIMIDINE DERIVATIVE OF LDK378
756, d4rssA_, 0.7360, 3.06, 0.340, 269, 262, CRYSTAL STRUCTURE OF TYROSINE-PROTEIN KINASE SYK WITH AN INHIBITOR
757, d3vs3A3, 0.7360, 2.41, 0.299, 269, 251, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR 7-[TRANS-4-(4-METHYLPIPERAZIN-1-YL)CYCLOHEXYL]-5-(4-PHENOXYPHENYL)- 7H-PYRROLO[23-D]PYRIMIDIN-4-AMINE
758, d3g6hA_, 0.7360, 3.01, 0.297, 266, 263, SRC THR338ILE INHIBITED IN THE DFG-ASP-OUT CONFORMATION
759, d3b2tB_, 0.7360, 3.01, 0.318, 287, 261, STRUCTURE OF PHOSPHOTRANSFERASE
760, d2of4A_, 0.7360, 2.93, 0.289, 271, 263, CRYSTAL STRUCTURE OF FURANOPYRIMIDINE 1 BOUND TO LCK
761, d3kxzA_, 0.7359, 2.75, 0.296, 263, 260, THE COMPLEX CRYSTAL STRUCTURE OF LCK WITH A PROBE MOLECULE W259
762, d3zclA_, 0.7358, 2.86, 0.346, 289, 257, X-RAY STRUCTURE OF C-MET KINASE IN COMPLEX WITH INHIBITOR ( S)-3-(1-(1H-PYRROLO(23-B)PYRIDIN-3-YL)ETHYL)-N-ISOPROPYL-( 124)TRIAZOLO(43-B)PYRIDAZIN-6-AMINE
763, d2py3A_, 0.7358, 3.29, 0.314, 282, 264, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC E565G MUTATION RESPONSIBLE FOR PFEIFFER SYNDROME
764, d2g15A_, 0.7358, 3.19, 0.344, 301, 262, STRUCTURAL CHARACTERIZATION OF AUTOINHIBITED C-MET KINASE
765, d3et7A_, 0.7357, 2.82, 0.324, 261, 259, CRYSTAL STRUCTURE OF PYK2 COMPLEXED WITH PF-2318841
766, d2a27F_, 0.7357, 3.33, 0.175, 303, 269, HUMAN DRP-1 KINASE W305S S308A D40 MUTANT CRYSTAL FORM WITH 8 MONOMERS IN THE ASYMMETRIC UNIT
767, d3vs5B3, 0.7356, 2.36, 0.296, 268, 250, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR 7-(1-METHYLPIPERIDIN-4-YL)-5-(4-PHENOXYPHENYL)-7H-PYRROLO[23- D]PYRIMIDIN-4-AMINE
768, d3vrzB3, 0.7356, 2.42, 0.299, 269, 251, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR 1-[4-(4-AMINO-7-CYCLOPENTYL-7H-PYRROLO[23-D]PYRIMIDIN-5-YL)PHENYL]- 3-BENZYLUREA
769, d3l9lB_, 0.7356, 3.57, 0.188, 337, 276, CRYSTAL STRUCTURE OF PKA WITH COMPOUND 36
770, d3bymA_, 0.7356, 2.91, 0.294, 271, 262, X-RAY CO-CRYSTAL STRUCTURE AMINOBENZIMIDAZOLE TRIAZINE 1 BOUND TO LCK
771, d2a27B_, 0.7356, 3.31, 0.175, 303, 269, HUMAN DRP-1 KINASE W305S S308A D40 MUTANT CRYSTAL FORM WITH 8 MONOMERS IN THE ASYMMETRIC UNIT
772, d5h2uC1, 0.7355, 2.35, 0.295, 261, 251, CRYSTAL STRUCTURE OF PTK6 KINASE DOMAIN COMPLEXED WITH DASATINIB
773, d4yc8A_, 0.7355, 2.61, 0.357, 259, 255, C-HELIX-OUT BINDING OF DASATINIB ANALOG TO C-ABL KINASE
774, d3ad6A_, 0.7355, 2.92, 0.290, 272, 262, CRYSTAL STRUCTURE OF PYRAZOLO PYRIMIDINE DERIVATIVE BOUND TO THE KINASE DOMAIN OF HUMAN LCK (AUTO-PHOSPHORYLATED ON TYR394)
775, d2x9fA_, 0.7355, 2.87, 0.304, 265, 260, EPHB4 KINASE DOMAIN INHIBITOR COMPLEX
776, d4l00A_, 0.7354, 2.77, 0.200, 277, 260, CRYSTAL STRUCTURE OF THE APO JAK1 PSEUDOKINASE DOMAIN
777, d4i0rA1, 0.7354, 2.78, 0.344, 260, 256, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH 2-(345- TRIMETHOXY-PHENYL)-5H-PYRROLO[23-B]PYRAZINE-7-CARBOXYLIC ACID ISOPROPYLAMIDE
778, d4hzrA_, 0.7354, 2.61, 0.343, 261, 254, CRYSTAL STRUCTURE OF ACK1 KINASE DOMAIN
779, d5ng2A_, 0.7353, 2.70, 0.236, 274, 258, STRUCTURE OF RIP2K(D146N) WITH BOUND STAUROSPORINE
780, d4wa9B1, 0.7353, 2.66, 0.354, 263, 254, THE CRYSTAL STRUCTURE OF HUMAN ABL1 WILD TYPE KINASE DOMAIN IN COMPLEX WITH AXITINIB
781, d2z8cA1, 0.7353, 2.97, 0.302, 297, 262, PHOSPHORYLATED INSULIN RECEPTOR TYROSINE KINASE IN COMPLEX WITH (4-{[5-CARBAMOYL-4-(3-METHYLANILINO)PYRIMIDIN-2- YL]AMINO}PHENYL)ACETIC ACID
782, d2q0nA_, 0.7353, 3.31, 0.165, 293, 266, STRUCTURE OF HUMAN P21 ACTIVATING KINASE 4 (PAK4) IN COMPLEX WITH A CONSENSUS PEPTIDE
783, d5h0hA3, 0.7352, 2.68, 0.298, 281, 255, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR (S)-2-(((1R4S)-4-(4-AMINO-5-(4-PHENOXYPHENYL)-7H-PYRROLO[23- D]PYRIMIDIN-7-YL)CYCLOHEXYL)AMINO)-NN4-TRIMETHYLPENTANAMIDE
784, d4yc8B_, 0.7352, 2.88, 0.344, 264, 259, C-HELIX-OUT BINDING OF DASATINIB ANALOG TO C-ABL KINASE
785, d4fzaB1, 0.7352, 3.15, 0.234, 280, 265, CRYSTAL STRUCTURE OF MST4-MO25 COMPLEX
786, d3vs5A3, 0.7352, 2.38, 0.300, 268, 250, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR 7-(1-METHYLPIPERIDIN-4-YL)-5-(4-PHENOXYPHENYL)-7H-PYRROLO[23- D]PYRIMIDIN-4-AMINE
787, d2ya9B_, 0.7352, 3.16, 0.172, 299, 267, CRYSTAL STRUCTURE OF THE AUTOINHIBITED FORM OF MOUSE DAPK2
788, d2a27H_, 0.7352, 3.29, 0.171, 304, 269, HUMAN DRP-1 KINASE W305S S308A D40 MUTANT CRYSTAL FORM WITH 8 MONOMERS IN THE ASYMMETRIC UNIT
789, d5h0gA3, 0.7351, 2.93, 0.302, 281, 258, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR (S)-2-(((1R4S)-4-(4-AMINO-5-(4-PHENOXYPHENYL)-7H-PYRROLO[23- D]PYRIMIDIN-7-YL)CYCLOHEXYL)AMINO)-N4-DIMETHYLPENTANAMIDE
790, d4zsaA_, 0.7351, 3.12, 0.318, 289, 264, CRYSTAL STRUCTURE OF FGFR1 KINASE DOMAIN IN COMPLEX WITH 7N
791, d4dehA_, 0.7351, 2.99, 0.347, 286, 259, CRYSTAL STRUCTURE OF C-MET IN COMPLEX WITH TRIAZOLOPYRIDINONE INHIBITOR 3
792, d5ng3B_, 0.7350, 2.75, 0.227, 275, 256, STRUCTURE OF INACTIVE KINASE RIP2K(K47R)
793, d1u5qB_, 0.7350, 3.37, 0.190, 308, 273, CRYSTAL STRUCTURE OF THE TAO2 KINASE DOMAIN: ACTIVATION AND SPECIFITY OF A STE20P MAP3K
794, d5ia0C_, 0.7349, 3.09, 0.299, 269, 264, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH ALISERTIB (MLN8237)
795, d1iasB_, 0.7349, 2.90, 0.172, 324, 261, CYTOPLASMIC DOMAIN OF UNPHOSPHORYLATED TYPE I TGF-BETA RECEPTOR CRYSTALLIZED WITHOUT FKBP12
796, d1b6cB_, 0.7349, 3.08, 0.177, 326, 265, CRYSTAL STRUCTURE OF THE CYTOPLASMIC DOMAIN OF THE TYPE I TGF-BETA RECEPTOR IN COMPLEX WITH FKBP12
797, d5w5oM_, 0.7348, 2.86, 0.230, 276, 257, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
798, d5j79A_, 0.7348, 3.12, 0.217, 283, 263, THE IDENTIFICATION AND PHARMACOLOGICAL CHARACTERIZATION OF 6-(TERT- BUTYLSULFONYL)-N-(5-FLUORO-1H-INDAZOL-3-YL)QUINOLIN-4-AMINE (GSK583) A HIGHLY POTENT AND SELECTIVE INHIBITOR OF RIP2 KINASE COMPOUND 3 COMPLEX
799, d2hz4A_, 0.7348, 2.72, 0.329, 262, 258, ABL KINASE DOMAIN UNLIGATED AND IN COMPLEX WITH TETRAHYDROSTAUROSPORINE
800, d2a27G_, 0.7348, 3.30, 0.171, 303, 269, HUMAN DRP-1 KINASE W305S S308A D40 MUTANT CRYSTAL FORM WITH 8 MONOMERS IN THE ASYMMETRIC UNIT
801, d2a27D_, 0.7348, 3.40, 0.174, 304, 270, HUMAN DRP-1 KINASE W305S S308A D40 MUTANT CRYSTAL FORM WITH 8 MONOMERS IN THE ASYMMETRIC UNIT
802, d5eycA_, 0.7347, 3.10, 0.346, 288, 260, CRYSTAL STRUCTURE OF C-MET IN COMPLEX WITH NAPHTHYRIDINONE INHIBITOR 5
803, d4r1vA_, 0.7347, 3.04, 0.351, 289, 259, IDENTIFICATION AND OPTIMIZATION OF PYRIDAZINONES AS POTENT AND SELECTIVE C-MET KINASE INHIBITORS
804, d3fzoA_, 0.7347, 3.02, 0.319, 262, 260, CRYSTAL STRUCTURE OF PYK2-APO PROLINE-RICH TYROSINE KINASE
805, d1kobA_, 0.7347, 3.71, 0.152, 352, 276, TWITCHIN KINASE FRAGMENT (APLYSIA) AUTOREGULATED PROTEIN KINASE DOMAIN
806, d5h0bA3, 0.7346, 2.69, 0.298, 281, 255, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR (S)-2-(((1R4S)-4-(4-AMINO-5-(4-PHENOXYPHENYL)-7H-PYRROLO[23- D]PYRIMIDIN-7-YL)CYCLOHEXYL)AMINO)-4-METHYLPENTANOIC ACID
807, d4mneB_, 0.7346, 2.84, 0.212, 270, 259, CRYSTAL STRUCTURE OF THE BRAF:MEK1 COMPLEX
808, d3ppzA_, 0.7346, 2.58, 0.243, 264, 255, CRYSTAL STRUCTURE OF CTR1 KINASE DOMAIN IN COMPLEX WITH STAUROSPORINE
809, d3lckA_, 0.7346, 2.95, 0.286, 270, 262, THE KINASE DOMAIN OF HUMAN LYMPHOCYTE KINASE (LCK) ACTIVATED FORM (AUTO-PHOSPHORYLATED ON TYR394)
810, d3dqxA_, 0.7346, 3.00, 0.293, 267, 263, CHICKEN C-SRC KINASE DOMAIN IN COMPLEX WITH ATPGS
811, d3ac1A_, 0.7346, 2.94, 0.294, 270, 262, CRYSTAL STRUCTURE OF PYRAZIN DERIVATIVE BOUND TO THE KINASE DOMAIN OF HUMAN LCK (AUTO-PHOSPHORYLATED ON TYR394)
812, d4j99A_, 0.7343, 3.09, 0.305, 280, 262, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE GAIN-OF-FUNCTION K659T MUTATION.
813, d5h2uD1, 0.7342, 2.37, 0.295, 261, 251, CRYSTAL STRUCTURE OF PTK6 KINASE DOMAIN COMPLEXED WITH DASATINIB
814, d4gt4B_, 0.7342, 2.55, 0.304, 273, 253, STRUCTURE OF UNLIGANDED INACTIVE ROR2 KINASE DOMAIN
815, d3ad4A_, 0.7342, 2.90, 0.291, 270, 261, CRYSTAL STRUCTURE OF METHOXY BENZOFURAN DERIVATIVE BOUND TO THE KINASE DOMAIN OF HUMAN LCK (AUTO-PHOSPHORYLATED ON TYR394)
816, d3js2A_, 0.7341, 3.17, 0.321, 295, 265, CRYSTAL STRUCTURE OF MINIMAL KINASE DOMAIN OF FIBROBLAST GROWTH FACTOR RECEPTOR 1 IN COMPLEX WITH 5-(2-THIENYL) NICOTINIC ACID
817, d5uglA_, 0.7340, 3.23, 0.317, 285, 265, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 TYROSINE KINASE DOMAIN HARBORING THE D650V ACTIVATING MUTATION
818, d5ew8A_, 0.7340, 3.15, 0.318, 291, 264, FIBROBLAST GROWTH FACTOR RECEPTOR 1 IN COMPLEX WITH JNJ-4275693
819, d4wbbB_, 0.7340, 3.53, 0.179, 334, 274, SINGLE TURNOVER AUTOPHOSPHORYLATION CYCLE OF THE PKA RIIB HOLOENZYME
820, d4uv0A_, 0.7340, 3.32, 0.171, 300, 269, STRUCTURE OF A SEMISYNTHETIC PHOSPHORYLATED DAPK
821, d3zbxA_, 0.7340, 2.79, 0.344, 282, 256, X-RAY STRUCTURE OF C-MET KINASE IN COMPLEX WITH INHIBITOR 6- ((6-(4-FLUOROPHENYL)-(124)TRIAZOLO(43-B)(124)TRIAZIN- 3-YL)METHYL)QUINOLINE.
822, d5tiuA1, 0.7339, 2.89, 0.346, 262, 257, CRYSTAL STRUCTURE OF SYK KINASE DOMAIN WITH INHIBITOR
823, d4xyfA_, 0.7339, 3.04, 0.346, 290, 260, CRYSTAL STRUCTURE OF C-MET IN COMPLEX WITH (S)-5-(8-FLUORO-3-(1-(3-(2- METHOXYETHOXY)QUINOLIN-6-YL)ETHYL)-[124]TRIAZOLO[43-A]PYRIDIN-6- YL)-3-METHYLISOXAZOLE
824, d3kcfB_, 0.7339, 3.03, 0.163, 324, 263, CRYSTAL STRUCTURE OF TGFBRI COMPLEXED WITH A PYRAZOLONE INHIBITOR
825, d2psqA_, 0.7339, 3.41, 0.307, 287, 267, CRYSTAL STRUCTURE OF UNPHOSPHORYLATED UNACTIVATED WILD TYPE FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN
826, d1yi6A_, 0.7339, 3.34, 0.294, 274, 269, C-TERM TAIL SEGMENT OF HUMAN TYROSINE KINASE (258-533)
827, d5h2uB1, 0.7338, 2.38, 0.295, 261, 251, CRYSTAL STRUCTURE OF PTK6 KINASE DOMAIN COMPLEXED WITH DASATINIB
828, d3zxzA_, 0.7338, 2.80, 0.344, 289, 256, X-RAY STRUCTURE OF PF-04217903 BOUND TO THE KINASE DOMAIN OF C-MET
829, d3ppzB_, 0.7338, 2.70, 0.241, 264, 257, CRYSTAL STRUCTURE OF CTR1 KINASE DOMAIN IN COMPLEX WITH STAUROSPORINE
830, d3l9pA_, 0.7338, 3.55, 0.264, 303, 273, CRYSTAL STRUCTURE OF THE ANAPLASTIC LYMPHOMA KINASE CATALYTIC DOMAIN
831, d5vloA_, 0.7337, 3.07, 0.148, 290, 264, THE STRUCTURE OF HUMAN CAMKII WITH BOUND INHIBITOR
832, d4uwcA_, 0.7337, 3.10, 0.312, 300, 263, FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE IN COMPLEX WITH JK-P3
833, d3ac3A_, 0.7337, 2.90, 0.291, 270, 261, CRYSTAL STRUCTURE OF PYRAZOLO PYRIMIDINE DERIVATIVE BOUND TO THE KINASE DOMAIN OF HUMAN LCK (AUTO-PHOSPHORYLATED ON TYR394)
834, d3l9mB_, 0.7336, 3.79, 0.193, 336, 280, CRYSTAL STRUCTURE OF PKAB3 (PKA TRIPLE MUTANT V123A L173M Q181K) WITH COMPOUND 18
835, d3acjA_, 0.7335, 2.91, 0.291, 270, 261, CRYSTAL STRUCTURE OF IMIDAZO PYRIMIDINE DERIVATIVE BOUND TO THE KINASE DOMAIN OF HUMAN LCK (AUTO-PHOSPHORYLATED ON TYR394)
836, d3ac4A_, 0.7335, 2.91, 0.291, 270, 261, CRYSTAL STRUCTURE OF TRIAZOLO PYRIMIDINE DERIVATIVE BOUND TO THE KINASE DOMAIN OF HUMAN LCK (AUTO-PHOSPHORYLATED ON TYR394)
837, d5h2uA1, 0.7334, 2.38, 0.295, 261, 251, CRYSTAL STRUCTURE OF PTK6 KINASE DOMAIN COMPLEXED WITH DASATINIB
838, d4l01B_, 0.7334, 2.77, 0.212, 274, 259, CRYSTAL STRUCTURE OF THE V658F APO JAK1 PSEUDOKINASE DOMAIN
839, d2xvdA_, 0.7334, 2.94, 0.299, 270, 261, EPHB4 KINASE DOMAIN INHIBITOR COMPLEX
840, d6eixA_, 0.7333, 3.05, 0.174, 312, 264, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF THE Q207E MUTANT OF ACVR1 (ALK2) IN COMPLEX WITH A 2-AMINOPYRIDINE INHIBITOR K02288
841, d2zm4A_, 0.7333, 2.90, 0.291, 270, 261, CRYSTAL STRUCTURE OF IMIDAZO QUINOXALINE 1 BOUND TO THE KINASE DOMAIN OF HUMAN LCK ACTIVATED FORM (AUTO- PHOSPHORYLATED ON TYR394)
842, d3kmmA_, 0.7332, 2.91, 0.291, 270, 261, STRUCTURE OF HUMAN LCK KINASE WITH A SMALL MOLECULE INHIBITOR
843, d3c4fB_, 0.7332, 3.21, 0.321, 290, 265, FGFR TYROSINE KINASE DOMAIN IN COMPLEX WITH 3-(3- METHOXYBENZYL)-7-AZAINDOLE
844, d3bhhB1, 0.7332, 2.95, 0.145, 288, 262, CRYSTAL STRUCTURE OF HUMAN CALCIUM/CALMODULIN-DEPENDENT PROTEIN KINASE IIB ISOFORM 1 (CAMK2B)
845, d5w5oO_, 0.7331, 2.90, 0.230, 276, 257, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
846, d5vndA_, 0.7331, 3.16, 0.322, 302, 264, CRYSTAL STRUCTURE OF FGFR1-Y563C (FGFR4 SURROGATE) COVALENTLY BOUND TO H3B-6527
847, d5t0pA_, 0.7331, 2.97, 0.291, 264, 261, C-SRC KINASE DOMAIN IN COMPLEX WITH RAO-IV-151
848, d3ri1A_, 0.7331, 3.41, 0.307, 285, 267, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF FGFR2 KINASE IN COMPLEX WITH ARQ 069
849, d3ad5A_, 0.7331, 2.90, 0.287, 270, 261, CRYSTAL STRUCTURE OF TRIAZOLONE DERIVATIVE BOUND TO THE KINASE DOMAIN OF HUMAN LCK (AUTO-PHOSPHORYLATED ON TYR394)
850, d3ac2A_, 0.7331, 2.90, 0.287, 270, 261, CRYSTAL STRUCTURE OF PYRAZOLO PYRIMIDINE DERIVATIVE BOUND TO THE KINASE DOMAIN OF HUMAN LCK (AUTO-PHOSPHORYLATED ON TYR394)
851, d6babD_, 0.7330, 3.12, 0.158, 291, 266, THE STRUCTURE OF HUMAN CAMKII WITH BOUND INHIBITOR
852, d4l01A_, 0.7330, 2.87, 0.211, 274, 261, CRYSTAL STRUCTURE OF THE V658F APO JAK1 PSEUDOKINASE DOMAIN
853, d4fz7A1, 0.7330, 2.82, 0.344, 261, 256, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH 6-((1R2S)- 2-AMINO-CYCLOHEXYLAMINO)-4-(6-ETHYL-PYRIDIN-2-YLAMINO)-PYRIDAZINE-3- CARBOXYLIC ACID AMIDE
854, d4fl1A_, 0.7330, 3.16, 0.347, 268, 262, STRUCTURAL AND BIOPHYSICAL CHARACTERIZATION OF THE SYK ACTIVATION SWITCH
855, d5li1A1, 0.7329, 3.41, 0.166, 329, 271, STRUCTURE OF A PAR3-INHIBITORY PEPTIDE BOUND TO PKCIOTA CORE KINASE DOMAIN
856, d5aaaA_, 0.7329, 3.33, 0.257, 294, 268, STRUCTURE OF L1198F MUTANT HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH CRIZOTINIB
857, d2py3B_, 0.7329, 3.32, 0.311, 284, 264, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC E565G MUTATION RESPONSIBLE FOR PFEIFFER SYNDROME
858, d3ackA_, 0.7328, 2.91, 0.291, 270, 261, CRYSTAL STRUCTURE OF PYRROLO PYRAZINE DERIVATIVE BOUND TO THE KINASE DOMAIN OF HUMAN LCK (AUTO-PHOSPHORYLATED ON TYR394)
859, d2c0iA3, 0.7328, 2.41, 0.300, 268, 250, SRC FAMILY KINASE HCK WITH BOUND INHIBITOR A-420983
860, d4uwcB_, 0.7327, 3.12, 0.319, 301, 263, FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE IN COMPLEX WITH JK-P3
861, d3c4fA_, 0.7327, 3.16, 0.318, 290, 264, FGFR TYROSINE KINASE DOMAIN IN COMPLEX WITH 3-(3- METHOXYBENZYL)-7-AZAINDOLE
862, d2of2A_, 0.7327, 2.99, 0.289, 271, 263, CRYSTAL STRUCTURE OF FURANOPYRIMIDINE 8 BOUND TO LCK
863, d4yhfA_, 0.7326, 2.59, 0.299, 268, 254, BRUTON S TYROSINE KINASE IN COMPLEX WITH A T-BUTYL CYANOACRYLAMIDE INHIBITOR
864, d3vs2B3, 0.7326, 2.42, 0.300, 268, 250, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR 7-[CIS-4-(4-METHYLPIPERAZIN-1-YL)CYCLOHEXYL]-5-(4-PHENOXYPHENYL)-7H- PYRROLO[23-D]PYRIMIDIN-4-AMINE
865, d3ac5A_, 0.7326, 2.96, 0.294, 270, 262, CRYSTAL STRUCTURE OF TRIAZOLO PYRIMIDINE DERIVATIVE BOUND TO THE KINASE DOMAIN OF HUMAN LCK (AUTO-PHOSPHORYLATED ON TYR394)
866, d5tehB_, 0.7325, 2.88, 0.287, 262, 258, C-SRC V281C KINASE DOMAIN IN COMPLEX WITH RAO-IV-156
867, d3l9mA_, 0.7325, 3.67, 0.184, 338, 277, CRYSTAL STRUCTURE OF PKAB3 (PKA TRIPLE MUTANT V123A L173M Q181K) WITH COMPOUND 18
868, d2vz6A1, 0.7325, 2.93, 0.149, 285, 261, STRUCTURE OF HUMAN CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE TYPE II ALPHA (CAMK2A) IN COMPLEX WITH INDIRUBIN E804
869, d2gcdA_, 0.7325, 3.46, 0.198, 308, 273, TAO2 KINASE DOMAIN-STAUROSPORINE STRUCTURE
870, d5k9iB_, 0.7324, 2.93, 0.292, 262, 260, CRYSTAL STRUCTURE OF C-SRC IN COMPLEX WITH A COVALENT LYSINE PROBE
871, d5j87B_, 0.7324, 2.83, 0.307, 274, 257, DISCOVERY OF N-(3-(5-((3-ACRYLAMIDO-4-(MORPHOLINE-4-CARBONYL)PHENYL) AMINO)-1-METHYL-6-OXO-16-DIHYDROPYRIDIN-3-YL)-2-METHYLPHENYL)-4- (TERT-BUTYL)BENZAMIDE (CHMFL-BTK-01) AS A HIGHLY SELECTIVE IRREVERSIBLE BTK KINASE INHIBITOR
872, d1kobB_, 0.7324, 3.54, 0.146, 352, 274, TWITCHIN KINASE FRAGMENT (APLYSIA) AUTOREGULATED PROTEIN KINASE DOMAIN
873, d5k9iA_, 0.7323, 2.73, 0.285, 258, 256, CRYSTAL STRUCTURE OF C-SRC IN COMPLEX WITH A COVALENT LYSINE PROBE
874, d4v0gB_, 0.7323, 2.54, 0.317, 272, 252, JAK3 IN COMPLEX WITH A COVALENT EGFR INHIBITOR
875, d2y0aA_, 0.7323, 3.42, 0.174, 300, 270, STRUCTURE OF DAPK1 CONSTRUCT RESIDUES 1-304
876, d2oiqA_, 0.7323, 2.96, 0.288, 265, 260, CRYSTAL STRUCTURE OF CHICKEN C-SRC KINASE DOMAIN IN COMPLEX WITH THE CANCER DRUG IMATINIB.
877, d2c0oA3, 0.7323, 2.41, 0.296, 268, 250, SRC FAMILY KINASE HCK WITH BOUND INHIBITOR A-770041
878, d1u5rB_, 0.7323, 3.47, 0.186, 308, 274, CRYSTAL STRUCTURE OF THE TAO2 KINASE DOMAIN: ACTIVATION AND SPECIFITY OF A STE20P MAP3K
879, d4deiA_, 0.7322, 2.93, 0.346, 287, 257, CRYSTAL STRUCTURE OF C-MET IN COMPLEX WITH TRIAZOLOPYRIDINONE INHIBITOR 24
880, d3vs2A3, 0.7322, 2.44, 0.300, 268, 250, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR 7-[CIS-4-(4-METHYLPIPERAZIN-1-YL)CYCLOHEXYL]-5-(4-PHENOXYPHENYL)-7H- PYRROLO[23-D]PYRIMIDIN-4-AMINE
881, d4j95A_, 0.7321, 3.13, 0.313, 279, 262, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC K659N MUTATION RESPONSIBLE FOR AN UNCLASSIFIED CRANIOSYNOSTOSIS SYNDROME IN SPACE GROUP C2.
882, d4fz6A1, 0.7321, 2.90, 0.346, 262, 257, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH [6-((S)-2- METHYL-PYRROLIDIN-1-YL)-PYRIDIN-2-YL]-(6-PHENYL-IMIDAZO[12- B]PYRIDAZIN-8-YL)-AMINE
883, d4ap7A_, 0.7321, 2.92, 0.346, 289, 257, CRYSTAL STRUCTURE OF C-MET KINASE DOMAIN IN COMPLEX WITH 4-( (6-(4- FLUOROPHENYL)-(124)TRIAZOLO(43-B)(124)TRIAZIN-3-YL)METHYL) PHENOL
884, d3l9nA_, 0.7321, 3.53, 0.189, 332, 275, CRYSTAL STRUCTURE OF PKAB3 (PKA TRIPLE MUTANT V123A L173M Q181K) WITH COMPOUND 27
885, d1fmkA3, 0.7321, 2.39, 0.292, 270, 250, CRYSTAL STRUCTURE OF HUMAN TYROSINE-PROTEIN KINASE C-SRC
886, d3zc5A_, 0.7320, 2.83, 0.344, 289, 256, X-RAY STRUCTURE OF C-MET KINASE IN COMPLEX WITH INHIBITOR ( S)-6-(1-(6-(1-METHYL-1H-PYRAZOL-4-YL)-(124)TRIAZOLO(43- B)PYRIDAZIN-3-YL)ETHYL)QUINOLINE.
887, d2c0tA3, 0.7320, 2.43, 0.300, 268, 250, SRC FAMILY KINASE HCK WITH BOUND INHIBITOR A-641359
888, d4v0gA_, 0.7319, 2.55, 0.325, 267, 252, JAK3 IN COMPLEX WITH A COVALENT EGFR INHIBITOR
889, d3zfxE_, 0.7319, 2.89, 0.314, 262, 258, CRYSTAL STRUCTURE OF EPHB1
890, d3rhkA_, 0.7319, 3.01, 0.337, 298, 258, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF C-MET KINASE IN COMPLEX WITH ARQ 197
891, d4degA_, 0.7318, 3.00, 0.349, 286, 258, CRYSTAL STRUCTURE OF C-MET IN COMPLEX WITH TRIAZOLOPYRIDAZINE INHIBITOR 2
892, d3f6xD_, 0.7318, 3.13, 0.295, 267, 264, C-SRC KINASE DOMAIN IN COMPLEX WITH SMALL MOLECULE INHIBITOR
893, d2wgjA_, 0.7318, 2.84, 0.344, 289, 256, X-RAY STRUCTURE OF PF-02341066 BOUND TO THE KINASE DOMAIN OF C-MET
894, d5w5oK_, 0.7317, 2.90, 0.230, 275, 257, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
895, d3fqhB_, 0.7317, 2.68, 0.346, 258, 254, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH A 2-SUBSTITUTED 7-AZAINDOLE
896, d2oiqB_, 0.7317, 3.05, 0.294, 265, 262, CRYSTAL STRUCTURE OF CHICKEN C-SRC KINASE DOMAIN IN COMPLEX WITH THE CANCER DRUG IMATINIB.
897, d2j0mB_, 0.7317, 2.66, 0.343, 257, 254, CRYSTAL STRUCTURE A TWO-CHAIN COMPLEX BETWEEN THE FERM AND KINASE DOMAINS OF FOCAL ADHESION KINASE.
898, d1s9iA_, 0.7317, 3.59, 0.207, 303, 271, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 2 (MEK2)IN A COMPLEX WITH LIGAND AND MGATP
899, d1opjB1, 0.7317, 3.03, 0.323, 284, 260, STRUCTURAL BASIS FOR THE AUTO-INHIBITION OF C-ABL TYROSINE KINASE
900, d5jfsA_, 0.7316, 2.80, 0.306, 277, 258, CRYSTAL STRUCTURE OF TRKA IN COMPLEX WITH PF-00593174
901, d3byoA_, 0.7316, 2.95, 0.291, 270, 261, X-RAY CO-CRYSTAL STRUCTURE OF 2-AMINO-6-PHENYLPYRIMIDO[5  4 :56]PYRIMIDO[12-A]BENZIMIDAZOL-5(6H)-ONE 25 BOUND TO LCK
902, d2r2pA1, 0.7316, 3.27, 0.294, 276, 265, KINASE DOMAIN OF HUMAN EPHRIN TYPE-A RECEPTOR 5 (EPHA5)
903, d1u5qA_, 0.7316, 3.37, 0.199, 308, 272, CRYSTAL STRUCTURE OF THE TAO2 KINASE DOMAIN: ACTIVATION AND SPECIFITY OF A STE20P MAP3K
904, d4rwiA_, 0.7315, 3.10, 0.327, 305, 263, CRYSTAL STRUCTURE OF V561M FGFR1 GATEKEEPER MUTATION (C488A C584S V561M) APO
905, d4f4pA1, 0.7315, 2.79, 0.344, 260, 256, SYK IN COMPLEX WITH LIGAND LASW836
906, d3vs0B3, 0.7315, 2.42, 0.300, 268, 250, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR N-[4-(4-AMINO-7-CYCLOPENTYL-7H-PYRROLO[23-D]PYRIMIDIN-5-YL) PHENYL]BENZAMIDE
907, d5a46B_, 0.7314, 3.17, 0.318, 297, 264, FGFR1 IN COMPLEX WITH DOVITINIB
908, d1qpeA_, 0.7314, 2.92, 0.291, 270, 261, STRUCTURAL ANALYSIS OF THE LYMPHOCYTE-SPECIFIC KINASE LCK IN COMPLEX WITH NON-SELECTIVE AND SRC FAMILY SELECTIVE KINASE INHIBITORS
909, d4hctA_, 0.7313, 2.68, 0.312, 265, 253, CRYSTAL STRUCTURE OF ITK IN COMPLEX WITH COMPOUND 52
910, d5w5oB_, 0.7312, 2.86, 0.234, 275, 256, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
911, d2hz4C_, 0.7312, 2.56, 0.335, 259, 254, ABL KINASE DOMAIN UNLIGATED AND IN COMPLEX WITH TETRAHYDROSTAUROSPORINE
912, d1opjA1, 0.7312, 3.00, 0.327, 282, 260, STRUCTURAL BASIS FOR THE AUTO-INHIBITION OF C-ABL TYROSINE KINASE
913, d5w5oJ_, 0.7311, 2.78, 0.231, 275, 255, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
914, d5ig1B_, 0.7311, 3.44, 0.170, 304, 270, CRYSTAL STRUCTURE OF S. ROSETTA CAMKII KINASE DOMAIN
915, d1mqbB_, 0.7311, 3.00, 0.299, 265, 261, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE
916, d5lmbB_, 0.7310, 2.69, 0.335, 261, 254, HUMAN SPLEEN TYROSINE KINASE KINASE DOMAIN IN COMPLEX WITH AZANAPHTHYRIDINE INHIBITOR
917, d5j7hA_, 0.7310, 3.37, 0.266, 291, 267, CRYSTAL STRUCTURE OF ANAPLASTIC LYMPHOMA KINASE (ALK) BOUND BY BRIGATINIB
918, d5ar5B_, 0.7310, 2.93, 0.238, 279, 260, RIP2 KINASE CATALYTIC DOMAIN (1 - 310) COMPLEX WITH BENZIMIDAZOLE
919, d3nsvB_, 0.7310, 2.84, 0.344, 264, 259,  
920, d2xynC_, 0.7310, 2.67, 0.344, 262, 256, HUMAN ABL2 IN COMPLEX WITH AURORA KINASE INHIBITOR VX-680
921, d2c0iB3, 0.7310, 2.45, 0.300, 268, 250, SRC FAMILY KINASE HCK WITH BOUND INHIBITOR A-420983
922, d5w5oD_, 0.7309, 2.88, 0.234, 275, 256, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
923, d3bhhA1, 0.7309, 2.94, 0.142, 287, 261, CRYSTAL STRUCTURE OF HUMAN CALCIUM/CALMODULIN-DEPENDENT PROTEIN KINASE IIB ISOFORM 1 (CAMK2B)
924, d3ac8A_, 0.7309, 2.94, 0.291, 270, 261, CRYSTAL STRUCTURE OF PYRAZOLO PYRIMIDINE DERIVATIVE BOUND TO THE KINASE DOMAIN OF HUMAN LCK (AUTO-PHOSPHORYLATED ON TYR394)
925, d2zm1A_, 0.7309, 2.99, 0.294, 270, 262, CRYSTAL STRUCTURE OF IMIDAZO PYRAZIN 1 BOUND TO THE KINASE DOMAIN OF HUMAN LCK (AUTO-PHOSPHORYLATED ON TYR394)
926, d2x4fB_, 0.7309, 3.05, 0.177, 288, 265, THE CRYSTAL STRUCTURE OF THE HUMAN MYOSIN LIGHT CHAIN KINASE LOC340156.
927, d2x0gA_, 0.7309, 3.41, 0.164, 318, 269, X-RAY STRUCTURE OF A DAP-KINASE CALMODULIN COMPLEX
928, d4fobA_, 0.7308, 3.58, 0.265, 295, 272, CRYSTAL STRUCTURE OF HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH ACYLIMINOBENZIMIDAZOLE INHIBITOR 1
929, d4at3A1, 0.7308, 3.20, 0.281, 286, 263, CRYSTAL STRUCTURE OF TRKB KINASE DOMAIN IN COMPLEX WITH CPD5N
930, d5hesA_, 0.7307, 3.06, 0.256, 287, 258, HUMAN LEUCINE ZIPPER- AND STERILE ALPHA MOTIF-CONTAINING KINASE (ZAK MLT HCCS-4 MRK AZK MLTK) IN COMPLEX WITH VEMURAFENIB
931, d4h58A_, 0.7307, 2.59, 0.220, 263, 254, BRAF IN COMPLEX WITH COMPOUND 3
932, d4fvrA_, 0.7307, 2.56, 0.209, 274, 254, CRYSTAL STRUCTURE OF THE JAK2 PSEUDOKINASE DOMAIN MUTANT V617F (MG- ATP-BOUND FORM)
933, d4cmoA_, 0.7307, 3.38, 0.265, 295, 268, STRUCTURE OF THE HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH THE INHIBITOR 2-((1R)-1-((3-AMINO-6-(2- METHOXYPYRIDIN- -YL)PYRAZIN-2-YL)OXY)ETHYL)-4-FLUORO-N-METHYLBENZAMIDE
934, d4ccbA_, 0.7307, 3.38, 0.262, 287, 267, STRUCTURE OF THE HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH 3-((R)-1-(5-FLUORO-2-(2H-123-TRIAZOL-2-YL) PHENYL)ETHOXY)-5-(5-METHYL-1H-PYRAZOL-4-YL)PYRIDIN-2-AMINE
935, d3u6iA_, 0.7307, 2.99, 0.327, 281, 257, CRYSTAL STRUCTURE OF C-MET IN COMPLEX WITH PYRAZOLONE INHIBITOR 58A
936, d2xynB_, 0.7307, 2.83, 0.336, 264, 259, HUMAN ABL2 IN COMPLEX WITH AURORA KINASE INHIBITOR VX-680
937, d5w5oI_, 0.7306, 2.89, 0.230, 275, 256, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
938, d2v7oA1, 0.7306, 3.20, 0.139, 297, 266, CRYSTAL STRUCTURE OF HUMAN CALCIUM-CALMODULIN-DEPENDENT PROTEIN KINASE II GAMMA
939, d4mxoA_, 0.7305, 3.06, 0.280, 266, 261, HUMAN SRC KINASE BOUND TO KINASE INHIBITOR BOSUTINIB
940, d2c0oB3, 0.7304, 2.44, 0.296, 268, 250, SRC FAMILY KINASE HCK WITH BOUND INHIBITOR A-770041
941, d1u46A_, 0.7304, 2.52, 0.360, 255, 250, CRYSTAL STRUCTURE OF THE UNPHOSPHORYLATED KINASE DOMAIN OF THE TYROSINE KINASE ACK1
942, d5w5oA_, 0.7303, 2.89, 0.234, 275, 256, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
943, d4xg7A1, 0.7303, 3.05, 0.344, 265, 259, CRYSTAL STRUCTURE OF AN INHIBITOR-BOUND SYK
944, d5w5oL_, 0.7302, 2.88, 0.230, 275, 256, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
945, d5ng0A_, 0.7302, 2.78, 0.233, 274, 257, STRUCTURE OF RIP2K(L294F) WITH BOUND AMPPCP
946, d5kz0A_, 0.7302, 3.33, 0.262, 293, 267, STRUCTURE OF HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH 2-[(1R)- 1-{[2-AMINO-5-(13-DIMETHYL-1H-PYRAZOL-4-YL)PYRIDIN-3-YL]OXY}ETHYL]- 4-FLUORO-NN-DIMETHYLBENZAMIDE
947, d1b6cF_, 0.7302, 3.14, 0.174, 326, 265, CRYSTAL STRUCTURE OF THE CYTOPLASMIC DOMAIN OF THE TYPE I TGF-BETA RECEPTOR IN COMPLEX WITH FKBP12
948, d5w5oF_, 0.7301, 2.88, 0.234, 275, 256, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
949, d2zybA_, 0.7301, 2.95, 0.291, 270, 261, CRYSTAL STRUCTURE OF PHENYLIMIDAZO PYRAZIN 2 BOUND TO THE KINASE DOMAIN OF HUMAN LCK (AUTO-PHOSPHORYLATED ON TYR394)
950, d2q0bA_, 0.7301, 3.27, 0.317, 280, 262, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC E565A MUTATION RESPONSIBLE FOR PFEIFFER SYNDROME
951, d5ig1A_, 0.7300, 3.44, 0.174, 300, 270, CRYSTAL STRUCTURE OF S. ROSETTA CAMKII KINASE DOMAIN
952, d3nsvC_, 0.7300, 2.67, 0.344, 262, 256,  
953, d2pz5A_, 0.7300, 3.29, 0.317, 280, 262, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC N549T MUTATION RESPONSIBLE FOR PFEIFFER SYNDROME
954, d2rfsA_, 0.7299, 2.49, 0.349, 264, 249, X-RAY STRUCTURE OF SU11274 BOUND TO C-MET
955, d5w5oE_, 0.7298, 2.88, 0.234, 275, 256, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
956, d5nkhA_, 0.7298, 3.55, 0.311, 295, 273, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 3E
957, d5eobA_, 0.7298, 3.16, 0.350, 288, 260, CRYSTAL STRUCTURE OF CMET IN COMPLEX WITH NOVEL INHIBITOR
958, d5am6A1, 0.7298, 3.09, 0.318, 294, 261, NATIVE FGFR1 WITH AN INHIBITOR
959, d2pzpA_, 0.7298, 3.21, 0.322, 280, 261, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC K526E MUTATION RESPONSIBLE FOR CROUZON SYNDROME
960, d5w5oH_, 0.7297, 2.89, 0.238, 275, 256, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
961, d5w5oG_, 0.7297, 2.79, 0.231, 275, 255, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
962, d4fnyA_, 0.7297, 3.17, 0.245, 273, 261, CRYSTAL STRUCTURE OF THE R1275Q ANAPLASTIC LYMPHOMA KINASE CATALYTIC DOMAIN IN COMPLEX WITH A BENZOXAZOLE INHIBITOR
963, d5ar2A_, 0.7296, 2.85, 0.233, 277, 257, RIP2 KINASE CATALYTIC DOMAIN (1 - 310)
964, d5aabA_, 0.7296, 3.41, 0.261, 293, 268, STRUCTURE OF C1156YL1198F MUTANT HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH CRIZOTINIB
965, d5aa9A_, 0.7295, 3.36, 0.257, 295, 268, STRUCTURE OF L1198F MUTANT HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH PF-06463922 ((10R)-7-AMINO-12-FLUORO-210 16-TRIMETHYL-15-OXO-10151617-TETRAHYDRO-2H-84-(METHENO) PYRAZOLO(43-H)(2511)BENZOXADIAZACYCLOTETRADECINE-3- CARBONITRILE).
966, d4yjoA_, 0.7295, 3.13, 0.350, 267, 260, THE KINASE DOMAIN OF HUMAN SPLEEN TYROSINE (SYK) IN COMPLEX WITH GTC000222
967, d3l8vA_, 0.7295, 3.36, 0.326, 293, 264, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF THE HEPATOCYTE GROWTH FACTOR RECEPTOR C-MET IN COMPLEX WITH A BIARYLAMINE BASED INHIBITOR
968, d2pzpB_, 0.7295, 3.31, 0.317, 282, 262, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC K526E MUTATION RESPONSIBLE FOR CROUZON SYNDROME
969, d2pz5B_, 0.7295, 3.31, 0.317, 280, 262, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC N549T MUTATION RESPONSIBLE FOR PFEIFFER SYNDROME
970, d1o6kA_, 0.7295, 3.41, 0.163, 317, 270, STRUCTURE OF ACTIVATED FORM OF PKB KINASE DOMAIN S474D WITH GSK3 PEPTIDE AND AMP-PNP
971, d4cmuA_, 0.7294, 3.40, 0.261, 294, 268, STRUCTURE OF THE HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH THE INHIBITOR (10R)-7-AMINO-12-FLUORO-1310 16-TETRAMETHYL-1617-DIHYDRO-1H-84-(METHENO)PYRAZOLO(43- H)(2511)BENZOXADIAZACYCLOTETRADECIN-15(10H)-ONE
972, d5jfxA_, 0.7293, 2.82, 0.306, 277, 258, CRYSTAL STRUCTURE OF TRKA IN COMPLEX WITH PF-06273340
973, d5i4nA1, 0.7293, 2.55, 0.213, 273, 253, CRYSTAL STRUCTURE OF THE E596A V617F MUTANT JAK2 PSEUDOKINASE DOMAIN BOUND TO MG-ATP
974, d4tt7A_, 0.7293, 3.54, 0.264, 291, 269, CRYSTAL STRUCTURE OF HUMAN ALK WITH A COVALENT MODIFICATION
975, d3u51A_, 0.7293, 2.67, 0.291, 256, 254, SRC IN COMPLEX WITH DNA-TEMPLATED MACROCYCLIC INHIBITOR MC1
976, d2c0tB3, 0.7293, 2.47, 0.296, 268, 250, SRC FAMILY KINASE HCK WITH BOUND INHIBITOR A-641359
977, d5wr7A_, 0.7292, 2.95, 0.312, 301, 260, CRYSTAL STRUCTURE OF TRK-A COMPLEXED WITH A SELECTIVE INHIBITOR CH7057288
978, d4cliA_, 0.7292, 3.40, 0.261, 294, 268, STRUCTURE OF THE HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH PF-06463922 ((10R)-7-AMINO-12-FLUORO-21016-TRIMETHYL-15 -OXO-10151617-TETRAHYDRO-2H-84-(METHENO)PYRAZOLO(43-H) (2511)BENZOXADIAZACYCLOTETRADECINE-3-CARBONITRILE).
979, d1o6lA_, 0.7292, 3.42, 0.163, 316, 270, CRYSTAL STRUCTURE OF AN ACTIVATED AKT/PROTEIN KINASE B (PKB-PIF CHIMERA) TERNARY COMPLEX WITH AMP-PNP AND GSK3 PEPTIDE
980, d5jfwA_, 0.7291, 2.84, 0.306, 277, 258, CRYSTAL STRUCTURE OF TRKA IN COMPLEX WITH PF-05247452
981, d5ew8B_, 0.7291, 3.16, 0.323, 290, 263, FIBROBLAST GROWTH FACTOR RECEPTOR 1 IN COMPLEX WITH JNJ-4275693
982, d2q0bB_, 0.7290, 3.37, 0.316, 282, 263, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC E565A MUTATION RESPONSIBLE FOR PFEIFFER SYNDROME
983, d4mxxA_, 0.7289, 3.10, 0.294, 266, 262, HUMAN SRC A403T MUTANT BOUND TO KINASE INHIBITOR BOSUTINIB
984, d2vn9B_, 0.7289, 3.18, 0.154, 301, 266, CRYSTAL STRUCTURE OF HUMAN CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE II DELTA ISOFORM 1 CAMKD
985, d3pxkB_, 0.7288, 2.72, 0.350, 258, 254, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH PYRROLO[23- D]THIAZOLE
986, d3o7lB_, 0.7288, 3.52, 0.165, 326, 272, CRYSTAL STRUCTURE OF PHOSPHOLAMBAN (1-19):PKA C-SUBUNIT:AMP-PNP:MG2+ COMPLEX
987, d5w5oP_, 0.7287, 2.90, 0.230, 275, 256, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
988, d5w5oC_, 0.7287, 2.91, 0.234, 275, 256, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
989, d3vs0A3, 0.7287, 2.48, 0.296, 268, 250, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR N-[4-(4-AMINO-7-CYCLOPENTYL-7H-PYRROLO[23-D]PYRIMIDIN-5-YL) PHENYL]BENZAMIDE
990, d3rhxA_, 0.7287, 3.19, 0.319, 289, 263, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF FGFR1 KINASE IN COMPLEX WITH ARQ 069
991, d4focA_, 0.7286, 3.60, 0.258, 296, 271, CRYSTAL STRUCTURE OF HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH ACYLIMINOBENZIMIDAZOLE INHIBITOR 2
992, d3k5vB1, 0.7286, 2.90, 0.331, 279, 257, STRUCTURE OF ABL KINASE IN COMPLEX WITH IMATINIB AND GNF-2
993, d5am7A_, 0.7285, 3.07, 0.323, 294, 260, FGFR1 MUTANT WITH AN INHIBITOR
994, d4xg9A_, 0.7285, 2.72, 0.350, 259, 254, CRYSTAL STRUCTURE OF AN INHIBITOR-BOUND SYK
995, d2pvyB_, 0.7285, 2.93, 0.318, 286, 255, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC K659N MUTATION RESPONSIBLE FOR AN UNCLASSIFIED CRANIOSYNOSTOSIS SYNDROME.
996, d5ng3C_, 0.7284, 2.78, 0.221, 272, 253, STRUCTURE OF INACTIVE KINASE RIP2K(K47R)
997, d5j7bB_, 0.7284, 2.99, 0.208, 281, 259, THE IDENTIFICATION AND PHARMACOLOGICAL CHARACTERIZATION OF 6-(TERT- BUTYLSULFONYL)-N-(5-FLUORO-1H-INDAZOL-3-YL)QUINOLIN-4-AMINE (GSK583) A HIGHLY POTENT AND SELECTIVE INHIBITOR OF RIP2 KINASE GSK583 COMPLEX
998, d3vs1A3, 0.7284, 2.47, 0.296, 268, 250, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR 1-[4-(4-AMINO-7-CYCLOPENTYL-7H-PYRROLO[23-D]PYRIMIDIN-5-YL)PHENYL]- 3-PHENYLUREA
999, d3g6gB_, 0.7284, 3.00, 0.286, 263, 259, EQUALLY POTENT INHIBITION OF C-SRC AND ABL BY COMPOUNDS THAT RECOGNIZE INACTIVE KINASE CONFORMATIONS
1000, d2vn9A_, 0.7284, 3.19, 0.154, 301, 266, CRYSTAL STRUCTURE OF HUMAN CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE II DELTA ISOFORM 1 CAMKD
1001, d5mjaB_, 0.7283, 3.40, 0.310, 274, 268, KINASE DOMAIN OF HUMAN EPHB1 BOUND TO A QUINAZOLINE-BASED INHIBITOR
1002, d4xmoA_, 0.7283, 3.03, 0.349, 289, 258, CRYSTAL STRUCTURE OF C-MET IN COMPLEX WITH (R)-5-(8-FLUORO-3-(1- FLUORO-1-(3-METHOXYQUINOLIN-6-YL)ETHYL)-[124]TRIAZOLO[43- A]PYRIDIN-6-YL)-3-METHYLISOXAZOLE
1003, d4rx5A1, 0.7283, 2.71, 0.307, 264, 254, BRUTON S TYROSINE KINASE (BTK) WITH PYRIDAZINONE COMPOUND 23
1004, d2ivsB1, 0.7283, 2.77, 0.331, 272, 254, CRYSTAL STRUCTURE OF NON-PHOSPHORYLATED RET TYROSINE KINASE DOMAIN
1005, d4uwbA_, 0.7282, 3.21, 0.322, 299, 264, FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE IN COMPLEX WITH JK-P5
1006, d4ccuA_, 0.7282, 3.34, 0.263, 292, 266, STRUCTURE OF THE HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH 2-(5-(6-AMINO-5-((R)-1-(5-FLUORO-2-(2H-123-TRIAZOL-2-YL) PHENYL)ETHOXY)PYRIDIN-3-YL)-4-METHYLTHIAZOL-2-YL)PROPAN-2-OL
1007, d3js2B_, 0.7282, 3.12, 0.322, 291, 261, CRYSTAL STRUCTURE OF MINIMAL KINASE DOMAIN OF FIBROBLAST GROWTH FACTOR RECEPTOR 1 IN COMPLEX WITH 5-(2-THIENYL) NICOTINIC ACID
1008, d1q8wA_, 0.7282, 3.66, 0.188, 334, 276, THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE IN COMPLEX WITH RHO-KINASE INHIBITOR FASUDIL (HA-1077)
1009, d6babC_, 0.7281, 2.98, 0.158, 284, 260, THE STRUCTURE OF HUMAN CAMKII WITH BOUND INHIBITOR
1010, d4y95D_, 0.7280, 2.68, 0.311, 265, 254, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF BRUTON S TYROSINE KINASE WITH MUTATIONS IN THE ACTIVATION LOOP
1011, d4rwkA1, 0.7280, 3.23, 0.326, 307, 264, CRYSTAL STRUCTURE OF V561M FGFR1 GATEKEEPER MUTATION (C488A C584S V561M) IN COMPLEX WITH N-{3-[2-(35-DIMETHOXYPHENYL)ETHYL]-1H- PYRAZOL-5-YL}-4-[(3R5S)-35-DIMETHYLPIPERAZIN-1-YL]BENZAMIDE (AZD4547)
1012, d4mxzB_, 0.7280, 3.05, 0.287, 264, 261, SRC M314L T338M DOUBLE MUTANT BOUND TO KINASE INHIBITOR BOSUTINIB
1013, d4mxyB_, 0.7280, 3.05, 0.287, 264, 261, SRC M314L T338M DOUBLE MUTANT BOUND TO KINASE INHIBITOR BOSUTINIB
1014, d2pzrA_, 0.7280, 3.26, 0.314, 280, 261, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC K641R MUTATION RESPONSIBLE FOR PFEIFFER SYNDROME
1015, d2i0eA_, 0.7280, 3.41, 0.170, 326, 270, STRUCTURE OF CATALYTIC DOMAIN OF HUMAN PROTEIN KINASE C BETA II COMPLEXED WITH A BISINDOLYLMALEIMIDE INHIBITOR
1016, d4y95A1, 0.7279, 2.68, 0.311, 265, 254, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF BRUTON S TYROSINE KINASE WITH MUTATIONS IN THE ACTIVATION LOOP
1017, d4hcuA_, 0.7279, 2.69, 0.321, 263, 252, CRYSTAL STRUCTURE OF ITK IN COMPLEXT WITH COMPOUND 40
1018, d4cljA_, 0.7279, 3.44, 0.264, 295, 269, STRUCTURE OF L1196M MUTANT HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH PF-06463922 ((10R)-7-AMINO-12-FLUORO-210 16-TRIMETHYL-15-OXO-10151617-TETRAHYDRO-2H-84-(METHENO) PYRAZOLO(43-H)(2511)BENZOXADIAZACYCLOTETRADECINE-3- CARBONITRILE).
1019, d3vrzA3, 0.7279, 2.49, 0.296, 268, 250, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR 1-[4-(4-AMINO-7-CYCLOPENTYL-7H-PYRROLO[23-D]PYRIMIDIN-5-YL)PHENYL]- 3-BENZYLUREA
1020, d3u6hA_, 0.7279, 2.91, 0.325, 280, 255, CRYSTAL STRUCTURE OF C-MET IN COMPLEX WITH PYRAZOLONE INHIBITOR 26
1021, d3zosB1, 0.7278, 2.88, 0.296, 301, 257, STRUCTURE OF THE DDR1 KINASE DOMAIN IN COMPLEX WITH PONATINIB
1022, d3iw4A_, 0.7278, 3.55, 0.187, 330, 272, CRYSTAL STRUCTURE OF PKC ALPHA IN COMPLEX WITH NVP-AEB071
1023, d2pvyC_, 0.7278, 2.79, 0.331, 285, 254, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC K659N MUTATION RESPONSIBLE FOR AN UNCLASSIFIED CRANIOSYNOSTOSIS SYNDROME.
1024, d2psqB_, 0.7278, 3.49, 0.305, 286, 266, CRYSTAL STRUCTURE OF UNPHOSPHORYLATED UNACTIVATED WILD TYPE FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN
1025, d5mjaA_, 0.7277, 3.14, 0.300, 271, 263, KINASE DOMAIN OF HUMAN EPHB1 BOUND TO A QUINAZOLINE-BASED INHIBITOR
1026, d2yjrA_, 0.7277, 3.09, 0.262, 278, 260, STRUCTURE OF F1174L MUTANT ANAPLASTIC LYMPHOMA KINASE
1027, d4ckrA1, 0.7276, 2.73, 0.294, 294, 255, CRYSTAL STRUCTURE OF THE HUMAN DDR1 KINASE DOMAIN IN COMPLEX WITH DDR1-IN-1
1028, d5p9fA_, 0.7275, 2.71, 0.306, 266, 255, BTK IN COMPLEX WITH GDC-0834
1029, d4bkiA1, 0.7275, 2.73, 0.294, 294, 255,  
1030, d3d0eB_, 0.7275, 3.42, 0.160, 322, 269, CRYSTAL STRUCTURE OF HUMAN AKT2 IN COMPLEX WITH GSK690693
1031, d4qrcA_, 0.7274, 3.11, 0.330, 297, 261, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FGF RECEPTOR 4 IN COMPLEX WITH PONATINIB
1032, d4gt4A_, 0.7274, 2.55, 0.295, 274, 251, STRUCTURE OF UNLIGANDED INACTIVE ROR2 KINASE DOMAIN
1033, d3e88B_, 0.7274, 3.53, 0.159, 319, 271, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF AKT2 IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
1034, d3d0eA_, 0.7274, 3.42, 0.160, 322, 269, CRYSTAL STRUCTURE OF HUMAN AKT2 IN COMPLEX WITH GSK690693
1035, d5jfvA_, 0.7273, 2.88, 0.306, 277, 258, CRYSTAL STRUCTURE OF TRKA IN COMPLEX WITH PF-05206283
1036, d4uwbB_, 0.7273, 3.14, 0.324, 299, 262, FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE IN COMPLEX WITH JK-P5
1037, d3e88A_, 0.7273, 3.53, 0.159, 319, 271, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF AKT2 IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
1038, d2xzsA_, 0.7272, 3.54, 0.167, 301, 270, DEATH ASSOCIATED PROTEIN KINASE 1 RESIDUES 1-312
1039, d2pzrB_, 0.7272, 3.35, 0.305, 282, 262, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC K641R MUTATION RESPONSIBLE FOR PFEIFFER SYNDROME
1040, d5fd2A_, 0.7271, 2.70, 0.228, 264, 254, B-RAF WILD-TYPE KINASE DOMAIN IN COMPLEX WITH A PURINYLPYRIDINYLAMINO- BASED INHIBITOR
1041, d3ppkB_, 0.7271, 2.69, 0.228, 264, 254, HUMAN B-RAF KINASE IN COMPLEX WITH A NON-OXIME FUROPYRIDINE INHIBITOR
1042, d3ky2A1, 0.7271, 3.17, 0.324, 305, 262, CRYSTAL STRUCTURE OF FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN
1043, d2vz6B1, 0.7271, 3.07, 0.156, 288, 262, STRUCTURE OF HUMAN CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE TYPE II ALPHA (CAMK2A) IN COMPLEX WITH INDIRUBIN E804
1044, d3f6xB_, 0.7270, 3.12, 0.298, 267, 262, C-SRC KINASE DOMAIN IN COMPLEX WITH SMALL MOLECULE INHIBITOR
1045, d4at4A1, 0.7269, 3.30, 0.273, 289, 264, CRYSTAL STRUCTURE OF TRKB KINASE DOMAIN IN COMPLEX WITH EX429
1046, d3k5vA1, 0.7269, 3.01, 0.328, 281, 259, STRUCTURE OF ABL KINASE IN COMPLEX WITH IMATINIB AND GNF-2
1047, d2jdrA_, 0.7269, 3.45, 0.163, 316, 270, STRUCTURE OF PKB-BETA (AKT2) COMPLEXED WITH THE INHIBITOR A- 443654
1048, d4fvqA_, 0.7267, 2.63, 0.206, 274, 253, CRYSTAL STRUCTURE OF THE JAK2 PSEUDOKINASE DOMAIN (MG-ATP-BOUND FORM)
1049, d3kfaA1, 0.7267, 3.14, 0.340, 283, 259, STRUCTURAL ANALYSIS OF DFG-IN AND DFG-OUT DUAL SRC-ABL INHIBITORS SHARING A COMMON VINYL PURINE TEMPLATE
1050, d2x4fA_, 0.7267, 3.18, 0.169, 289, 266, THE CRYSTAL STRUCTURE OF THE HUMAN MYOSIN LIGHT CHAIN KINASE LOC340156.
1051, d4u8zA_, 0.7266, 3.39, 0.213, 289, 268, CRYSTAL STRUCTURE OF MST3 WITH A PYRROLOPYRIMIDINE INHIBITOR (PF- 06447475)
1052, d4bb4A_, 0.7266, 3.06, 0.308, 265, 260, EPHB4 KINASE DOMAIN INHIBITOR COMPLEX
1053, d3vs1B3, 0.7266, 2.49, 0.300, 268, 250, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR 1-[4-(4-AMINO-7-CYCLOPENTYL-7H-PYRROLO[23-D]PYRIMIDIN-5-YL)PHENYL]- 3-PHENYLUREA
1054, d3kfaB1, 0.7266, 3.15, 0.340, 283, 259, STRUCTURAL ANALYSIS OF DFG-IN AND DFG-OUT DUAL SRC-ABL INHIBITORS SHARING A COMMON VINYL PURINE TEMPLATE
1055, d5vgoA1, 0.7265, 2.70, 0.304, 264, 253, BRUTON S TYROSINE KINASE (BTK) WITH COMPOUND G-744
1056, d4rwlB_, 0.7265, 3.12, 0.308, 285, 260, CRYSTAL STRUCTURE OF FGFR1 (C488A C584C) IN COMPLEX WITH 6-(7-((1- AMINOCYCLOPROPYL) METHOXY)-6-METHOXYQUINOLIN-4-YLOXY)-N-METHYL-1- NAPHTHAMIDE (E3810)
1057, d4fodA_, 0.7265, 3.61, 0.262, 308, 271, CRYSTAL STRUCTURE OF HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH ACYLIMINOBENZIMIDAZOLE INHIBITOR 36
1058, d3tt0A_, 0.7265, 3.22, 0.322, 305, 264, CO-STRUCTURE OF FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN WITH 3-(26-DICHLORO-35-DIMETHOXY-PHENYL)-1-{6-[4-(4-ETHYL-PIPERAZIN-1- YL)-PHENYLAMINO]-PYRIMIDIN-4-YL}-1-METHYL-UREA (BGJ398)
1059, d2xb7A_, 0.7265, 3.34, 0.269, 286, 264, STRUCTURE OF HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH NVP- TAE684
1060, d2p2iA2, 0.7265, 3.03, 0.306, 283, 258, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A NICOTINAMIDE INHIBITOR
1061, d3thbA_, 0.7264, 3.21, 0.215, 287, 265, STRUCTURE OF PLK1 KINASE DOMAIN IN COMPLEX WITH A BENZOLACTAM-DERIVED INHIBITOR
1062, d3en5B_, 0.7264, 2.91, 0.288, 261, 257, TARGETED POLYPHARMACOLOGY: CRYSTAL STRUCTURE OF THE C-SRC KINASE DOMAIN IN COMPLEX WITH PP494 A MULTITARGETED KINASE INHIBITOR
1063, d3u51B_, 0.7263, 2.67, 0.292, 255, 253, SRC IN COMPLEX WITH DNA-TEMPLATED MACROCYCLIC INHIBITOR MC1
1064, d3iw4C_, 0.7263, 3.64, 0.187, 332, 273, CRYSTAL STRUCTURE OF PKC ALPHA IN COMPLEX WITH NVP-AEB071
1065, d3d4qB_, 0.7263, 2.74, 0.220, 264, 255, PYRAZOLE-BASED INHIBITORS OF B-RAF KINASE
1066, d5i9uA_, 0.7262, 3.23, 0.314, 281, 264, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE
1067, d3d4qA_, 0.7262, 2.74, 0.220, 264, 255, PYRAZOLE-BASED INHIBITORS OF B-RAF KINASE
1068, d4z3vA_, 0.7261, 2.85, 0.305, 271, 256, FRAGMENT-BASED DISCOVERY OF A SMALL MOLECULE REVERSIBLE INHIBITOR OF BRUTON S TYROSINE KINASE
1069, d4y95C1, 0.7261, 2.71, 0.311, 265, 254, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF BRUTON S TYROSINE KINASE WITH MUTATIONS IN THE ACTIVATION LOOP
1070, d4y95B1, 0.7261, 2.70, 0.311, 265, 254, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF BRUTON S TYROSINE KINASE WITH MUTATIONS IN THE ACTIVATION LOOP
1071, d4qmoA_, 0.7260, 3.46, 0.219, 288, 269, MST3 IN COMPLEX WITH IMIDAZOLO-OXINDOLE PKR INHIBITOR C16
1072, d4ludB3, 0.7260, 2.42, 0.298, 264, 248, CRYSTAL STRUCTURE OF HCK IN COMPLEX WITH THE FLUORESCENT COMPOUND SKF86002
1073, d1t46A_, 0.7260, 3.24, 0.286, 297, 262, STRUCTURAL BASIS FOR THE AUTOINHIBITION AND STI-571 INHIBITION OF C-KIT TYROSINE KINASE
1074, d5uafA_, 0.7259, 2.83, 0.345, 291, 252, MET TYROSINE KINASE INHIBITION ENHANCES THE ANTITUMOR EFFICACY OF AN HGF ANTIBODY
1075, d5uadA_, 0.7259, 2.83, 0.345, 291, 252, MET TYROSINE KINASE INHIBITION ENHANCES THE ANTITUMOR EFFICACY OF AN HGF ANTIBODY
1076, d5t68B_, 0.7258, 3.11, 0.344, 264, 259, CRYSTAL STRUCTURE OF SYK CATALYTIC DOMAIN IN COMPLEX WITH A FURO[32- D]PYRIMIDINE
1077, d5kupA1, 0.7258, 2.71, 0.304, 264, 253, BRUTON S TYROSINE KINASE (BTK) WITH PYRIDAZINONE COMPOUND 9
1078, d5j87D_, 0.7258, 2.68, 0.308, 263, 253, DISCOVERY OF N-(3-(5-((3-ACRYLAMIDO-4-(MORPHOLINE-4-CARBONYL)PHENYL) AMINO)-1-METHYL-6-OXO-16-DIHYDROPYRIDIN-3-YL)-2-METHYLPHENYL)-4- (TERT-BUTYL)BENZAMIDE (CHMFL-BTK-01) AS A HIGHLY SELECTIVE IRREVERSIBLE BTK KINASE INHIBITOR
1079, d4xg2A1, 0.7258, 2.95, 0.349, 258, 255, CRYSTAL STRUCTURE OF LIGAND-FREE SYK
1080, d4knbC_, 0.7258, 2.74, 0.347, 271, 251, C-MET IN COMPLEX WITH OSI LIGAND
1081, d4anqA_, 0.7258, 3.41, 0.262, 293, 267, STRUCTURE OF G1269A MUTANT ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH CRIZOTINIB
1082, d5ugxB_, 0.7257, 3.11, 0.314, 282, 258, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FGF RECEPTOR 2 HARBORING A E565A/D650V DOUBLE GAIN-OF-FUNCTION MUTATION
1083, d4xg8A_, 0.7257, 2.82, 0.353, 258, 255, CRYSTAL STRUCTURE OF AN INHIBITOR-BOUND SYK
1084, d4ot6A_, 0.7257, 2.69, 0.311, 265, 254, CRYSTAL STRUCTURE OF BTK KINASE DOMAIN COMPLEXED WITH 4- METHANESULFONYL-N-(3-{8-[4-(MORPHOLINE-4-CARBONYL)-PHENYLAMINO]- IMIDAZO[12-A]PYRAZIN-6-YL}-PHENYL)-BENZAMIDE
1085, d5t68A1, 0.7256, 3.10, 0.347, 264, 259, CRYSTAL STRUCTURE OF SYK CATALYTIC DOMAIN IN COMPLEX WITH A FURO[32- D]PYRIMIDINE
1086, d3efjA_, 0.7256, 2.86, 0.348, 276, 253, STRUCTURE OF C-MET WITH PYRIMIDONE INHIBITOR 7
1087, d1k2pB_, 0.7256, 2.85, 0.289, 258, 256, CRYSTAL STRUCTURE OF BRUTON S TYROSINE KINASE DOMAIN
1088, d4nkaB_, 0.7255, 3.05, 0.309, 287, 259, CRYSTAL STRUCTURE OF HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN IN COMPLEX WITH PYRAZOLAMINOPYRIMIDINE 2
1089, d5w86A_, 0.7254, 2.57, 0.321, 269, 249, CRYSTAL STRUCTURE OF JAK3 KINASE DOMAIN WITH A 46-DIAMINONICOTINAMIDE INHIBITOR (COMPOUND NUMBER 7)
1090, d2xp2A_, 0.7254, 3.41, 0.260, 285, 265, STRUCTURE OF THE HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH CRIZOTINIB (PF-02341066)
1091, d5dg5B_, 0.7253, 3.01, 0.341, 297, 258, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF THE HEPATOCYTE GROWTH FACTOR RECEPTOR C-MET IN COMPLEX WITH ALTIRATINIB ANALOG DP- 4157
1092, d5p9gA_, 0.7252, 2.71, 0.307, 265, 254, STRUCTURE OF BTK WITH RN486
1093, d2xzsB_, 0.7252, 3.36, 0.169, 293, 267, DEATH ASSOCIATED PROTEIN KINASE 1 RESIDUES 1-312
1094, d2ptkA3, 0.7252, 2.29, 0.290, 259, 245, CHICKEN SRC TYROSINE KINASE
1095, d5t0pB_, 0.7251, 3.08, 0.291, 263, 261, C-SRC KINASE DOMAIN IN COMPLEX WITH RAO-IV-151
1096, d4trlA_, 0.7251, 3.04, 0.309, 268, 259, STRUCTURE OF EPHRIN TYPE-A RECEPTOR 2
1097, d4qmpA_, 0.7251, 3.45, 0.219, 289, 269, MST3 IN COMPLEX WITH CDK1/2 INHIBITOR III 5-AMINO-3-{[4- (AMINOSULFONYL)PHENYL]AMINO}-N-(26-DIFLUOROPHENYL)-1H-124- TRIAZOLE-1-CARBOTHIOAMIDE
1098, d5j7bA_, 0.7250, 2.83, 0.207, 277, 256, THE IDENTIFICATION AND PHARMACOLOGICAL CHARACTERIZATION OF 6-(TERT- BUTYLSULFONYL)-N-(5-FLUORO-1H-INDAZOL-3-YL)QUINOLIN-4-AMINE (GSK583) A HIGHLY POTENT AND SELECTIVE INHIBITOR OF RIP2 KINASE GSK583 COMPLEX
1099, d4rwjA1, 0.7250, 3.19, 0.323, 306, 263, CRYSTAL STRUCTURE OF FGFR1 (C488A C584S) IN COMPLEX WITH AZD4547 (N- {3-[2-(35-DIMETHOXYPHENYL)ETHYL]-1H-PYRAZOL-5-YL}-4-[(3R5S)-35- DIMETHYLPIPERAZIN-1-YL]BENZAMIDE)
1100, d2cdzA_, 0.7250, 3.32, 0.175, 289, 263, CRYSTAL STRUCTURE OF THE HUMAN P21-ACTIVATED KINASE 4 IN COMPLEX WITH CGP74514A
1101, d5p9kA_, 0.7249, 2.80, 0.306, 271, 255, CRYSTAL STRUCTURE OF BTK WITH CNX 774
1102, d5ftoA1, 0.7249, 3.57, 0.256, 297, 270, CRYSTAL STRUCTURE OF THE ALK KINASE DOMAIN IN COMPLEX WITH ENTRECTINIB
1103, d4hcvA_, 0.7249, 2.64, 0.319, 263, 251, CRYSTAL STRUCTURE OF ITK IN COMPLEX WITH COMPOUND 53
1104, d5nkeA_, 0.7248, 3.42, 0.321, 292, 268, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 3A
1105, d4o2pB_, 0.7248, 3.01, 0.297, 265, 259, KINASE DOMAIN OF CSRC IN COMPLEX WITH A SUBSTITUTED PYRAZOLOPYRIMIDINE
1106, d3ocsA1, 0.7248, 2.62, 0.307, 262, 251, CRYSTAL STRUCTURE OF BRUTON S TYROSINE KINASE IN COMPLEX WITH INHIBITOR CGI1746
1107, d5w86B_, 0.7247, 2.43, 0.319, 267, 248, CRYSTAL STRUCTURE OF JAK3 KINASE DOMAIN WITH A 46-DIAMINONICOTINAMIDE INHIBITOR (COMPOUND NUMBER 7)
1108, d3iw4B_, 0.7247, 3.62, 0.180, 325, 272, CRYSTAL STRUCTURE OF PKC ALPHA IN COMPLEX WITH NVP-AEB071
1109, d5da3A1, 0.7246, 2.53, 0.296, 261, 250, CRYSTAL STRUCTURE OF PTK6 KINASE DOMAIN WITH INHIBITOR
1110, d4u0iA_, 0.7246, 3.18, 0.300, 297, 260, CRYSTAL STRUCTURE OF KIT IN COMPLEX WITH PONATINIB
1111, d4ctcA_, 0.7246, 3.42, 0.264, 288, 265, STRUCTURE OF THE HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH THE INHIBITOR 7-AMINO-3-CYCLOPROPYL-12-FLUORO- 11016-TRIMETHYL-1617-DIHYDRO-1H-84-(METHENO)PYRAZOLO(4 3-H)(2511)BENZOXADIAZACYCLOTETRADECIN-15(10H)-ONE
1112, d4zlzA_, 0.7245, 2.84, 0.306, 270, 255, CRYSTAL STRUCTURE OF BRUTON S TYROSINE KINASE IN COMPLEX WITH A SUBSTITUTED CINNOLINE
1113, d3vs7A3, 0.7245, 2.47, 0.301, 267, 249, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRAZOLO-PYRIMIDINE INHIBITOR 1-CYCLOPENTYL-3-(1H-PYRROLO[23-B]PYRIDIN-5-YL)-1H- PYRAZOLO[34-D]PYRIMIDIN-4-AMINE
1114, d3qlgB_, 0.7245, 2.75, 0.302, 260, 255, CRYSTAL STRUCTURE OF THE L317I MUTANT OF THE C-SRC TYROSINE KINASE DOMAIN COMPLEXED WITH DASATINIB
1115, d5ia2A_, 0.7244, 3.32, 0.287, 287, 265, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 66
1116, d3vntA_, 0.7244, 3.14, 0.305, 301, 259, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN VEGFR2 WITH A [1 3]THIAZOLO[54-B]PYRIDINE DERIVATIVE
1117, d3ri1B_, 0.7244, 3.55, 0.311, 283, 267, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF FGFR2 KINASE IN COMPLEX WITH ARQ 069
1118, d4o2pA_, 0.7243, 3.22, 0.286, 265, 262, KINASE DOMAIN OF CSRC IN COMPLEX WITH A SUBSTITUTED PYRAZOLOPYRIMIDINE
1119, d4ansA_, 0.7243, 3.44, 0.266, 293, 267, STRUCTURE OF L1196MG1269A DOUBLE MUTANT ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH CRIZOTINIB
1120, d5a46A_, 0.7242, 3.30, 0.333, 289, 264, FGFR1 IN COMPLEX WITH DOVITINIB
1121, d4knbA_, 0.7241, 2.77, 0.345, 273, 252, C-MET IN COMPLEX WITH OSI LIGAND
1122, d4f0iB_, 0.7241, 3.05, 0.299, 294, 261, CRYSTAL STRUCTURE OF APO TRKA
1123, d4d58B_, 0.7241, 3.02, 0.348, 261, 256, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH BIS- ANILINO PYRIMIDINE INHIBITOR
1124, d3mblA_, 0.7241, 3.21, 0.189, 290, 264, CRYSTAL STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK 1) IN COMPLEX WITH LIGAND AND MGADP
1125, d3el8B_, 0.7241, 2.83, 0.298, 259, 255, CRYSTAL STRUCTURE OF C-SRC IN COMPLEX WITH PYRAZOLOPYRIMIDINE 5
1126, d1u5rA_, 0.7241, 3.59, 0.186, 308, 274, CRYSTAL STRUCTURE OF THE TAO2 KINASE DOMAIN: ACTIVATION AND SPECIFITY OF A STE20P MAP3K
1127, d1fgiA_, 0.7241, 3.20, 0.322, 283, 261, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FIBROBLAST GROWTH FACTOR RECEPTOR 1 IN COMPLEX WITH SU5402 INHIBITOR
1128, d5p9jA_, 0.7240, 2.75, 0.291, 263, 254, BTK1 COCRYSTALLIZED WITH IBRUTINIB
1129, d5d12A_, 0.7239, 2.76, 0.310, 260, 255, KINASE DOMAIN OF CSRC IN COMPLEX WITH RL40
1130, d5a4cB1, 0.7239, 3.24, 0.324, 284, 262, FGFR1 LIGAND COMPLEX
1131, d3uqgA_, 0.7239, 3.07, 0.296, 263, 260, C-SRC KINASE DOMAIN IN COMPLEX WITH BUMPLESS BKI ANALOG UW1243
1132, d4u43A_, 0.7238, 2.90, 0.167, 287, 257, MAP4K4 IN COMPLEX WITH INHIBITOR (COMPOUND 6)
1133, d4jdiA_, 0.7238, 3.30, 0.182, 289, 264, CRYSTAL STRUCTURE OF SERINE/THREONINE-PROTEIN KINASE PAK 4 IN COMPLEX WITH PAKTIDE S PEPTIDE SUBSTRATE
1134, d5a9uA_, 0.7237, 3.41, 0.263, 292, 266, STRUCTURE OF C1156Y MUTANT HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH PF-06463922 ((10R)-7-AMINO-12-FLUORO-210 16-TRIMETHYL-15-OXO-10151617-TETRAHYDRO-2H-84-(METHENO) PYRAZOLO(43-H)(2511)BENZOXADIAZACYCLOTETRADECINE-3- CARBONITRILE).
1135, d3h3cA_, 0.7237, 3.07, 0.324, 263, 259, CRYSTAL STRUCTURE OF PYK2 IN COMPLEX WITH SULFOXIMINE- SUBSTITUTED TRIFLUOROMETHYLPYRIMIDINE ANALOG
1136, d3e8dB_, 0.7237, 3.46, 0.160, 317, 269, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF AKT2 IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
1137, d3pp1A1, 0.7236, 3.21, 0.189, 290, 264, CRYSTAL STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK 1) IN COMPLEX WITH LIGAND AND MGATP
1138, d3e8dA_, 0.7236, 3.46, 0.160, 315, 269, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF AKT2 IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
1139, d3bu6A_, 0.7236, 3.12, 0.299, 294, 261, CRYSTAL STRUCTURE OF THE INSULIN RECEPTOR KINASE IN COMPLEX WITH IRS2 KRLB PHOSPHOPEPTIDE
1140, d2yfxA_, 0.7236, 3.47, 0.266, 292, 267, STRUCTURE OF L1196M MUTANT ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH CRIZOTINIB
1141, d5imxA_, 0.7235, 2.70, 0.273, 266, 253, ANAPLASTIC LYMPHOMA KINASE (ALK) CATALYTIC DOMAIN COMPLEXED WITH NOVEL INHIBITOR 3-SULFONYLPYRAZOL-4-AMINO PYRIMIDINE
1142, d4w8dA_, 0.7235, 3.39, 0.217, 289, 267, CRYSTAL STRUCTURE OF MST3 WITH A PYRROLOPYRIMIDINE INHIBITOR (PF- 06454589).
1143, d4o0xA1, 0.7235, 3.39, 0.170, 289, 265, BACK POCKET FLEXIBILITY PROVIDES GROUP-II PAK SELECTIVITY FOR TYPE 1 KINASE INHIBITORS
1144, d4c02A_, 0.7235, 3.00, 0.181, 313, 259, CRYSTAL STRUCTURE OF HUMAN ACVR1 (ALK2) IN COMPLEX WITH FKBP12.6 AND DORSOMORPHIN
1145, d4asdA_, 0.7235, 3.14, 0.305, 305, 259, CRYSTAL STRUCTURE OF VEGFR2 (JUXTAMEMBRANE AND KINASE DOMAINS) IN COMPLEX WITH SORAFENIB (BAY 43-9006)
1146, d3f66B_, 0.7235, 2.87, 0.344, 269, 253, HUMAN C-MET KINASE IN COMPLEX WITH QUINOXALINE INHIBITOR
1147, d2etmB_, 0.7235, 3.23, 0.342, 263, 260, CRYSTAL STRUCTURE OF FOCAL ADHESION KINASE DOMAIN COMPLEXED WITH 7H-PYRROLO [23-D] PYRIMIDINE DERIVATIVE
1148, d4u7zA1, 0.7233, 3.33, 0.185, 290, 265, MITOGEN-ACTIVATED PROTEIN KINASE KINASE (MEK1) BOUND TO G805
1149, d3efjB_, 0.7233, 2.99, 0.328, 275, 253, STRUCTURE OF C-MET WITH PYRIMIDONE INHIBITOR 7
1150, d3svvA_, 0.7232, 3.01, 0.291, 261, 258, CRYSTAL STRUCTURE OF T338C C-SRC COVALENTLY BOUND TO VINYLSULFONAMIDE- PYRAZOLOPYRIMIDINE 9
1151, d3dkfA1, 0.7232, 3.25, 0.338, 293, 260, STRUCTURE OF MET RECEPTOR TYROSINE KINASE IN COMPLEX WITH INHIBITOR SGX-523
1152, d2hz4B1, 0.7232, 2.28, 0.343, 248, 245, ABL KINASE DOMAIN UNLIGATED AND IN COMPLEX WITH TETRAHYDROSTAUROSPORINE
1153, d5iuiA_, 0.7231, 3.63, 0.265, 303, 272, CRYSTAL STRUCTURE OF ANAPLASTIC LYPHOMA KINASE (ALK) IN COMPLEX WITH 4
1154, d5aa8A_, 0.7231, 3.47, 0.259, 292, 266, STRUCTURE OF C1156YL1198F MUTANT HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH PF-06463922 ((10R)-7-AMINO-12- FLUORO-21016-TRIMETHYL-15-OXO-10151617-TETRAHYDRO-2H- 84-(METHENO)PYRAZOLO(43-H)(2511) BENZOXADIAZACYCLOTETRADECINE-3-CARBONITRILE).
1155, d4v04B_, 0.7231, 3.12, 0.309, 287, 259, FGFR1 IN COMPLEX WITH PONATINIB.
1156, d4l7sA1, 0.7231, 2.25, 0.317, 248, 246, KINASE DOMAIN MUTANT OF HUMAN ITK IN COMPLEX WITH AN AMINOBENZOTHIAZOLE INHIBITOR
1157, d4v05B_, 0.7230, 3.12, 0.308, 286, 260, FGFR1 IN COMPLEX WITH AZD4547.
1158, d3e8nA1, 0.7230, 3.26, 0.186, 290, 264, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) COMPLEXED WITH A POTENT INHIBITOR RDEA119 AND MGATP
1159, d5j87A_, 0.7229, 2.70, 0.306, 263, 252, DISCOVERY OF N-(3-(5-((3-ACRYLAMIDO-4-(MORPHOLINE-4-CARBONYL)PHENYL) AMINO)-1-METHYL-6-OXO-16-DIHYDROPYRIDIN-3-YL)-2-METHYLPHENYL)-4- (TERT-BUTYL)BENZAMIDE (CHMFL-BTK-01) AS A HIGHLY SELECTIVE IRREVERSIBLE BTK KINASE INHIBITOR
1160, d5ftqA1, 0.7229, 3.47, 0.262, 292, 267, CRYSTAL STRUCTURE OF THE ALK KINASE DOMAIN IN COMPLEX WITH CMPD 17
1161, d5d7aA_, 0.7229, 3.14, 0.166, 289, 259, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF TRAF2 AND NCK-INTERACTING PROTEIN KINASE WITH NCB-0846
1162, d4u3yA_, 0.7229, 3.40, 0.211, 295, 266, APO MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE KINASE 4 (MAP4K4)
1163, d4o0vA1, 0.7229, 3.40, 0.181, 289, 265, BACK POCKET FLEXIBILITY PROVIDES GROUP-II PAK SELECTIVITY FOR TYPE 1 KINASE INHIBITORS
1164, d4fvpA_, 0.7229, 2.69, 0.206, 274, 253, CRYSTAL STRUCTURE OF THE JAK2 PSEUDOKINASE DOMAIN (APO FORM)
1165, d4ag8A_, 0.7229, 3.16, 0.305, 296, 259, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH AXITINIB (AG-013736) (N-METHYL-2-(3-((E)-2-PYRIDIN-2-YL-VINYL)-1H- INDAZOL-6- YLSULFANYL)-BENZAMIDE)
1166, d3e87B_, 0.7229, 3.53, 0.163, 321, 270, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF AKT2 IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
1167, d3e87A_, 0.7229, 3.53, 0.163, 321, 270, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF AKT2 IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
1168, d2x39A_, 0.7229, 3.41, 0.160, 316, 269, STRUCTURE OF 4-AMINO-N-(4-CHLOROBENZYL)-1-(7H-PYRROLO(23-D) PYRIMIDIN-4-YL)PIPERIDINE-4-CARBOXAMIDE BOUND TO PKB
1169, d2b4sB_, 0.7229, 3.02, 0.297, 294, 259, CRYSTAL STRUCTURE OF A COMPLEX BETWEEN PTP1B AND THE INSULIN RECEPTOR TYROSINE KINASE
1170, d1zwsD_, 0.7229, 3.16, 0.180, 278, 261, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN DRP-1 KINASE
1171, d5jsmA1, 0.7228, 2.59, 0.222, 262, 252, BRAFV600E KINASE DOMAIN IN COMPLEX WITH CHEMICALLY LINKED VEMURAFENIB INHIBITOR VEM-3-VEM
1172, d5i0bA_, 0.7228, 3.33, 0.163, 288, 264, STRUCTURE OF PAK4
1173, d4otdA_, 0.7228, 3.56, 0.181, 334, 271, CRYSTAL STRUCTURE OF PRK1 CATALYTIC DOMAIN
1174, d3eqgA_, 0.7228, 3.52, 0.186, 314, 269, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN A TERNARY COMPLEX WITH PD ADP AND MG2P
1175, d3cquA_, 0.7228, 3.44, 0.164, 318, 269, CRYSTAL STRUCTURE OF AKT-1 COMPLEXED WITH SUBSTRATE PEPTIDE AND INHIBITOR
1176, d2wkmA_, 0.7228, 3.15, 0.345, 286, 258, X-RAY STRUCTURE OF PHA-00665752 BOUND TO THE KINASE DOMAIN OF C-MET
1177, d4h1jA_, 0.7227, 3.12, 0.314, 263, 261, CRYSTAL STRUCTURE OF PYK2 WITH THE PYRAZOLE 13A
1178, d4dggA_, 0.7227, 2.98, 0.284, 261, 257, C-SRC KINASE DOMAIN IN COMPLEX WITH RM-1-176
1179, d5ut4A_, 0.7226, 2.63, 0.209, 273, 253, JAK2 JH2 IN COMPLEX WITH NVP-BSK805
1180, d5bpyA1, 0.7226, 2.71, 0.313, 262, 252, CRYSTAL STRUCTURE OF BRUTON AGAMMAGLOBULINEMIA TYROSINE KINASE COMPLEXED WITH BMS-824171 AKA 6-[(3R)-3-(4-TERT-BU TYLBENZAMIDO) PIPERIDIN-1-YL]-2-{[4-(MORPHOLINE-4-CARBONYL) PHENYL]AMINO}PYRIDINE- 3-CARBOXAMIDE
1181, d3ik3A1, 0.7226, 3.17, 0.333, 279, 258, AP24534 A PAN-BCR-ABL INHIBITOR FOR CHRONIC MYELOID LEUKEMIA POTENTLY INHIBITS THE T315I MUTANT AND OVERCOMES MUTATION-BASED RESISTANCE
1182, d4o0yA1, 0.7225, 3.41, 0.177, 289, 265, BACK POCKET FLEXIBILITY PROVIDES GROUP-II PAK SELECTIVITY FOR TYPE 1 KINASE INHIBITORS
1183, d3dv3A_, 0.7225, 3.31, 0.185, 288, 265, MEK1 WITH PF-04622664 BOUND
1184, d5xp7A_, 0.7224, 3.15, 0.291, 265, 261, C-SRC IN COMPLEX WITH ATP-CHCL
1185, d4a4oA_, 0.7224, 3.26, 0.211, 290, 265, CRYSTAL STRUCTURE OF POLO-LIKE KINASE 1 IN COMPLEX WITH A 2- (2-AMINO-PYRIMIDIN-4-YL)-1567-TETRAHYDRO-PYRROLOPYRIDIN- 4-ONE INHIBITOR
1186, d4qmmA_, 0.7223, 3.48, 0.231, 288, 268, MST3 IN COMPLEX WITH AT-9283 4-[(2-{4-[(CYCLOPROPYLCARBAMOYL)AMINO]- 1H-PYRAZOL-3-YL}-1H-BENZIMIDAZOL-6-YL)METHYL]MORPHOLIN-4-IUM
1187, d4dggB_, 0.7223, 2.86, 0.303, 259, 254, C-SRC KINASE DOMAIN IN COMPLEX WITH RM-1-176
1188, d4d4sB_, 0.7223, 3.01, 0.349, 260, 255, FOCAL ADHESION KINASE CATALYTIC DOMAIN
1189, d1zwsH_, 0.7223, 3.17, 0.180, 278, 261, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN DRP-1 KINASE
1190, d5t3qA1, 0.7222, 2.91, 0.332, 277, 253, CRYSTAL STRUCTURE OF THE C-MET KINASE DOMAIN IN COMPLEX WITH A PYRAZOLONE INHIBITOR
1191, d5p9iA_, 0.7222, 2.85, 0.298, 271, 255, BTK1 SOAKED WITH IBRUTINIB-REV
1192, d4lmnA1, 0.7222, 3.25, 0.186, 291, 264, CRYSTAL STRUCTURE OF MEK1 KINASE BOUND TO GDC0973
1193, d4v05A_, 0.7221, 3.19, 0.322, 287, 261, FGFR1 IN COMPLEX WITH AZD4547.
1194, d3eflA1, 0.7221, 2.87, 0.300, 279, 253, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH MOTESANIB
1195, d2jedA_, 0.7221, 3.47, 0.167, 324, 269, THE CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF THE PROTEIN KINASE C THETA IN COMPLEX WITH NVP-XAA228 AT 2.32A RESOLUTION.
1196, d2i0eB_, 0.7221, 3.16, 0.175, 300, 263, STRUCTURE OF CATALYTIC DOMAIN OF HUMAN PROTEIN KINASE C BETA II COMPLEXED WITH A BISINDOLYLMALEIMIDE INHIBITOR
1197, d1rqqA_, 0.7221, 3.22, 0.292, 294, 260, CRYSTAL STRUCTURE OF THE INSULIN RECEPTOR KINASE IN COMPLEX WITH THE SH2 DOMAIN OF APS
1198, d3beaA_, 0.7220, 3.49, 0.295, 310, 264, CFMS TYROSINE KINASE (TIE2 KID) IN COMPLEX WITH A PYRIMIDINOPYRIDONE INHIBITOR
1199, d4mxoB_, 0.7219, 3.15, 0.287, 264, 261, HUMAN SRC KINASE BOUND TO KINASE INHIBITOR BOSUTINIB
1200, d4arkA1, 0.7219, 3.31, 0.185, 290, 265, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN MAP KINASE KINASE 1 (MEK1) IN COMPLEX WITH  A SMALL MOLECULE INHIBITOR AND ADP
1201, d3oezB_, 0.7219, 3.00, 0.284, 261, 257, CRYSTAL STRUCTURE OF THE L317I MUTANT OF THE CHICKEN C-SRC TYROSINE KINASE DOMAIN COMPLEXED WITH IMATINIB
1202, d5w5oN_, 0.7218, 2.80, 0.230, 272, 252, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
1203, d5i9vA_, 0.7218, 3.13, 0.314, 279, 261, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH AGS
1204, d4ymjB1, 0.7218, 2.97, 0.297, 272, 256, (R)-2-PHENYLPYRROLIDINE SUBSTITUTE IMIDAZOPYRIDAZINES: A NEW CLASS OF POTENT AND SELECTIVE PAN-TRK INHIBITORS
1205, d4fijA_, 0.7218, 3.25, 0.183, 291, 263, CATALYTIC DOMAIN OF HUMAN PAK4
1206, d3slsB1, 0.7218, 3.48, 0.195, 291, 267, CRYSTAL STRUCTURE OF HUMAN MEK-1 KINASE IN COMPLEX WITH UCB1353770 AND AMPPNP
1207, d4mxxB_, 0.7217, 3.03, 0.287, 260, 258, HUMAN SRC A403T MUTANT BOUND TO KINASE INHIBITOR BOSUTINIB
1208, d3bu3A_, 0.7217, 3.18, 0.299, 294, 261, CRYSTAL STRUCTURE OF THE INSULIN RECEPTOR KINASE IN COMPLEX WITH IRS2 KRLB PEPTIDE
1209, d4qmqA_, 0.7216, 3.52, 0.219, 289, 269, MST3 IN COMPLEX WITH CP-673451
1210, d3el8A_, 0.7216, 3.10, 0.296, 263, 260, CRYSTAL STRUCTURE OF C-SRC IN COMPLEX WITH PYRAZOLOPYRIMIDINE 5
1211, d5ew3A_, 0.7215, 2.89, 0.303, 274, 254, HUMAN VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2 (KDR) KINASE DOMAIN IN COMPLEX WITH AAL993
1212, d4rwlA_, 0.7215, 3.06, 0.326, 282, 258, CRYSTAL STRUCTURE OF FGFR1 (C488A C584C) IN COMPLEX WITH 6-(7-((1- AMINOCYCLOPROPYL) METHOXY)-6-METHOXYQUINOLIN-4-YLOXY)-N-METHYL-1- NAPHTHAMIDE (E3810)
1213, d4apcB1, 0.7215, 2.83, 0.181, 291, 254, CRYSTAL STRUCTURE OF HUMAN NIMA-RELATED KINASE 1 (NEK1)
1214, d5iugA_, 0.7214, 3.21, 0.269, 285, 260, CRYSTAL STRUCTURE OF ANAPLASTIC LYMPHOMA KINASE (ALK) IN COMPLEX WITH 5A
1215, d4j95D_, 0.7214, 2.92, 0.319, 271, 254, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC K659N MUTATION RESPONSIBLE FOR AN UNCLASSIFIED CRANIOSYNOSTOSIS SYNDROME IN SPACE GROUP C2.
1216, d4a4lA_, 0.7214, 3.28, 0.211, 290, 265, CRYSTAL STRUCTURE OF POLO-LIKE KINASE 1 IN COMPLEX WITH A 5-(2-AMINO-PYRIMIDIN-4-YL)-1H-PYRROLE INHIBITOR
1217, d2uw9A_, 0.7214, 3.43, 0.160, 316, 269, STRUCTURE OF PKB-BETA (AKT2) COMPLEXED WITH 4-(4-CHLORO- PHENYL)-4-(4-(1H-PYRAZOL-4-YL)-PHENYL)-PIPERIDINE
1218, d2jkmA_, 0.7214, 2.94, 0.342, 260, 257, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH BIS- ANILINO PYRIMIDINE INHIBITOR
1219, d5j79B_, 0.7213, 2.94, 0.223, 277, 256, THE IDENTIFICATION AND PHARMACOLOGICAL CHARACTERIZATION OF 6-(TERT- BUTYLSULFONYL)-N-(5-FLUORO-1H-INDAZOL-3-YL)QUINOLIN-4-AMINE (GSK583) A HIGHLY POTENT AND SELECTIVE INHIBITOR OF RIP2 KINASE COMPOUND 3 COMPLEX
1220, d4d55A_, 0.7213, 2.97, 0.342, 260, 257, FOCAL ADHESION KINASE CATALYTIC DOMAIN
1221, d3prfB_, 0.7213, 2.58, 0.227, 262, 251, CRYSTAL STRUCTURE OF HUMAN B-RAF KINASE DOMAIN IN COMPLEX WITH A NON- OXIME FUROPYRIDINE INHIBITOR
1222, d3ik3B1, 0.7213, 3.36, 0.330, 285, 261, AP24534 A PAN-BCR-ABL INHIBITOR FOR CHRONIC MYELOID LEUKEMIA POTENTLY INHIBITS THE T315I MUTANT AND OVERCOMES MUTATION-BASED RESISTANCE
1223, d1zwsF_, 0.7213, 3.17, 0.180, 278, 261, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN DRP-1 KINASE
1224, d4njdA1, 0.7212, 3.40, 0.163, 289, 264, STRUCTURE OF P21-ACTIVATED KINASE 4 WITH A NOVEL INHIBITOR KY-04031
1225, d3my1A_, 0.7212, 3.41, 0.154, 314, 266, STRUCTURE OF CDK9/CYCLINT1 IN COMPLEX WITH DRB
1226, d3eqcA_, 0.7212, 3.52, 0.194, 312, 268, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN A TERNARY COMPLEX WITH COMPOUND 1 ATP-GS AND MG2P
1227, d5p9hA_, 0.7211, 2.75, 0.304, 264, 253, BTK1 COCRYSTALLIZED WITH RN983
1228, d4otfA1, 0.7211, 2.69, 0.307, 261, 251, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF BRUTON S TYROSINE KINASE WITH GDC0834
1229, d4jdjA_, 0.7211, 3.31, 0.183, 288, 263, CRYSTAL STRUCTURE OF SERINE/THREONINE-PROTEIN KINASE PAK 4 F461V MUTANT IN COMPLEX WITH PAKTIDE T PEPTIDE SUBSTRATE
1230, d5p9mA_, 0.7210, 2.96, 0.301, 271, 256, BTK1 BINDS COVALENTLY TO HY-15771 ONO-4059
1231, d3vo3A_, 0.7210, 3.19, 0.305, 303, 259, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN VEGFR2 WITH IMIDAZO[1 2-B]PYRIDAZINE DERIVATIVE
1232, d1rqqB_, 0.7210, 3.19, 0.292, 294, 260, CRYSTAL STRUCTURE OF THE INSULIN RECEPTOR KINASE IN COMPLEX WITH THE SH2 DOMAIN OF APS
1233, d2i1mA_, 0.7209, 3.48, 0.299, 311, 264, CFMS TYROSINE KINASE (TIE2 KID) IN COMPLEX WITH AN ARYLAMIDE INHIBITOR
1234, d1zwsC_, 0.7209, 3.02, 0.181, 278, 259, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN DRP-1 KINASE
1235, d5vefA_, 0.7208, 3.27, 0.183, 289, 263, PAK4 KINASE DOMAIN IN COMPLEX WITH FASUDIL
1236, d5fbnD_, 0.7208, 2.67, 0.294, 255, 252, BTK KINASE DOMAIN WITH INHIBITOR 1
1237, d4otqA_, 0.7208, 2.74, 0.312, 263, 253, CRYSTAL STRUCTURE OF BTK KINASE DOMAIN COMPLEXED WITH 1-[5-[3-(7-TERT- BUTYL-4-OXO-QUINAZOLIN-3-YL)-2-METHYL-PHENYL]-1-METHYL-2-OXO-3- PYRIDYL]-3-METHYL-UREA
1238, d1lufA_, 0.7208, 2.93, 0.323, 275, 254, CRYSTAL STRUCTURE OF THE MUSK TYROSINE KINASE: INSIGHTS INTO RECEPTOR AUTOREGULATION
1239, d5vedA_, 0.7207, 3.35, 0.182, 289, 264, PAK4 KINASE DOMAIN IN COMPLEX WITH STAUROSPORINE
1240, d5u9dA_, 0.7207, 2.92, 0.301, 271, 256, DISCOVERY OF A POTENT BTK INHIBITOR WITH A NOVEL BINDING MODE USING PARALLEL SELECTIONS WITH A DNA-ENCODED CHEMICAL LIBRARY
1241, d5ar8B_, 0.7207, 2.85, 0.206, 274, 252, RIP2 KINASE CATALYTIC DOMAIN (1 - 310) COMPLEX WITH BIPHENYLSULFONAMIDE
1242, d4xi2A2, 0.7207, 2.90, 0.294, 274, 255, CRYSTAL STRUCTURE OF AN AUTO-INHIBITED FORM OF BRUTON S TRYROSINE KINASE
1243, d4qmvA_, 0.7207, 3.44, 0.221, 288, 267, MST3 IN COMPLEX WITH PF-03814735 N-{2-[(1S4R)-6-{[4- (CYCLOBUTYLAMINO)-5-(TRIFLUOROMETHYL)PYRIMIDIN-2-YL]AMINO}-1234- TETRAHYDRO-14-EPIMINONAPHTHALEN-9-YL]-2-OXOETHYL}ACETAMIDE
1244, d4l7sB1, 0.7207, 2.30, 0.317, 248, 246, KINASE DOMAIN MUTANT OF HUMAN ITK IN COMPLEX WITH AN AMINOBENZOTHIAZOLE INHIBITOR
1245, d4fihA_, 0.7207, 3.34, 0.182, 291, 264, CATALYTIC DOMAIN OF HUMAN PAK4 WITH QKFTGLPRQW PEPTIDE
1246, d3qupA_, 0.7207, 1.98, 0.385, 241, 239, INHIBITOR BOUND STRUCTURE OF THE KINASE DOMAIN OF THE MURINE RECEPTOR TYROSINE KINASE TYRO3 (SKY)
1247, d3cd8A_, 0.7207, 2.88, 0.349, 278, 252, X-RAY STRUCTURE OF C-MET WITH TRIAZOLOPYRIDAZINE INHIBITOR.
1248, d3b2wA_, 0.7207, 2.66, 0.296, 261, 253, CRYSTAL STRUCTURE OF PYRIMIDINE AMIDE 11 BOUND TO LCK
1249, d1wvyA_, 0.7207, 2.87, 0.180, 273, 256, CRYSTAL STRUCTURES OF KINASE DOMAIN OF DAP KINASE IN COMPLEX WITH SMALL MOLECULAR INHIBITORS
1250, d1snxB_, 0.7207, 2.19, 0.311, 245, 244, CRYSTAL STRUCTURE OF APO INTERLEUKIN-2 TYROSINE KINASE CATALYTIC DOMAIN
1251, d5aacA_, 0.7206, 3.45, 0.263, 292, 266, STRUCTURE OF C1156Y MUTANT HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH CRIZOTINIB
1252, d4aszA1, 0.7205, 3.23, 0.280, 286, 261, CRYSTAL STRUCTURE OF APO TRKB KINASE DOMAIN
1253, d3slsA1, 0.7205, 3.48, 0.195, 289, 266, CRYSTAL STRUCTURE OF HUMAN MEK-1 KINASE IN COMPLEX WITH UCB1353770 AND AMPPNP
1254, d3eqbA1, 0.7205, 3.35, 0.185, 288, 265, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN A COMPLEX WITH LIGAND AND MGATP
1255, d1t45A_, 0.7205, 3.34, 0.298, 331, 262, STRUCTURAL BASIS FOR THE AUTOINHIBITION AND STI-571 INHIBITION OF C- KIT TYROSINE KINASE
1256, d5hlwA_, 0.7204, 3.27, 0.328, 284, 259, CRYSTAL STRUCTURE OF C-MET MUTANT Y1230H IN COMPLEX WITH COMPOUND 14
1257, d5bmsA1, 0.7204, 3.42, 0.177, 289, 265, CRYSTAL STRUCTURE OF P21-ACTIVATED KINASE 4 IN COMPLEX WITH AN INHIBITOR COMPOUND 29
1258, d2hy81_, 0.7204, 3.40, 0.180, 293, 267, PAK1 COMPLEX WITH ST2001
1259, d5jrqA1, 0.7203, 2.68, 0.227, 257, 251, BRAFV600E KINASE DOMAIN IN COMPLEX WITH CHEMICALLY LINKED VEMURAFENIB INHIBITOR VEM-6-VEM
1260, d5iuhA_, 0.7203, 3.21, 0.274, 285, 259, CRYSTAL STRUCTURE OF THE ANAPLASTIC LYMPHOMA KINASE (ALK) IN COMPLEX WITH 5D
1261, d4yhtB_, 0.7203, 2.63, 0.215, 258, 251, BRAF COMPLEXED WITH AN INHIBITOR
1262, d4e26B_, 0.7203, 2.74, 0.220, 264, 254, BRAF IN COMPLEX WITH AN ORGANIC INHIBITOR 7898734
1263, d3ppkA_, 0.7203, 2.70, 0.226, 262, 252, HUMAN B-RAF KINASE IN COMPLEX WITH A NON-OXIME FUROPYRIDINE INHIBITOR
1264, d5i9yA_, 0.7202, 3.41, 0.293, 287, 266, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH DASATINIB
1265, d4l67A_, 0.7202, 3.42, 0.174, 289, 264, CRYSTAL STRUCTURE OF CATALYTIC DOMAIN OF PAK4
1266, d3oezA_, 0.7202, 3.07, 0.287, 261, 258, CRYSTAL STRUCTURE OF THE L317I MUTANT OF THE CHICKEN C-SRC TYROSINE KINASE DOMAIN COMPLEXED WITH IMATINIB
1267, d3f3tB_, 0.7202, 2.94, 0.302, 259, 255, KINASE DOMAIN OF CSRC IN COMPLEX WITH INHIBITOR RL38 (TYPE III)
1268, d1wvxA_, 0.7202, 2.87, 0.180, 275, 256, CRYSTAL STRUCTURES OF KINASE DOMAIN OF DAP KINASE IN COMPLEX WITH SMALL MOLECULAR INHIBITORS
1269, d4otrA_, 0.7201, 2.75, 0.312, 263, 253, CRYSTAL STRUCTURE OF BTK KINASE DOMAIN COMPLEXED WITH 6-CYCLOPROPYL-2- [3-[5-[[5-(4-ETHYLPIPERAZIN-1-YL)-2-PYRIDYL]AMINO]-1-METHYL-6-OXO-3- PYRIDYL]-2-(HYDROXYMETHYL)PHENYL]-8-FLUORO-ISOQUINOLIN-1-ONE
1270, d4ogrI_, 0.7201, 3.26, 0.151, 318, 265, CRYSTAL STRUCTURE OF P-TEFB COMPLEX WITH AFF4 AND TAT
1271, d4fgbA_, 0.7201, 2.82, 0.203, 282, 256, CRYSTAL STRUCTURE OF HUMAN CALCIUM/CALMODULIN-DEPENDENT PROTEIN KINASE I APO FORM
1272, d3svvB_, 0.7201, 2.84, 0.285, 257, 253, CRYSTAL STRUCTURE OF T338C C-SRC COVALENTLY BOUND TO VINYLSULFONAMIDE- PYRAZOLOPYRIMIDINE 9
1273, d4ctbA_, 0.7200, 3.47, 0.263, 292, 266, STRUCTURE OF THE HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH THE INHIBITOR (5R)-8-AMINO-3-FLUORO-519-DIMETHYL-20-OXO-5181920- TETRAHYDRO-711-(AZENO)PYRIDO(2 1 :23)IMIDAZO(45-H)(2511) BENZOXADIAZACYCLOTETRADECINE-14-CARBONITRILE
1274, d3qlfB_, 0.7200, 2.93, 0.278, 258, 255, CRYSTAL STRUCTURE OF THE L317I MUTANT OF THE C-SRC TYROSINE KINASE DOMAIN COMPLEXED WITH PYRAZOLOPYRIMIDINE 5
1275, d3gubA1, 0.7200, 2.95, 0.179, 276, 257, CRYSTAL STRUCTURE OF DAPKL93G COMPLEXED WITH N6-(2- PHENYLETHYL)ADENOSINE
1276, d3f82A_, 0.7200, 2.96, 0.336, 278, 253, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF THE HEPATOCYTE GROWTH FACTOR RECEPTOR C-MET IN COMPLEX WITH N- (4-(2-AMINO-3-CHLOROPYRIDIN-4-YLOXY)-3-FLUOROPHENYL)-4- ETHOXY-1-(4-FLUOROPHENYL)-2-OXO-12-DIHYDROPYRIDINE-3- CARBOXAMIDE
1277, d1cmkE_, 0.7200, 3.74, 0.170, 348, 276, CRYSTAL STRUCTURES OF THE MYRISTYLATED CATALYTIC SUBUNIT OF CAMP- DEPENDENT PROTEIN KINASE REVEAL OPEN AND CLOSED CONFORMATIONS
1278, d4zlyA_, 0.7199, 2.86, 0.299, 270, 254, CRYSTAL STRUCTURE OF BRUTON S TYROSINE KINASE BOUND TO A CINNOLINE FRAGMENT
1279, d4yo4A1, 0.7199, 2.95, 0.179, 276, 257, CRYSTAL STRUCTURE OF DAPK1 CATALYTIC DOMAIN IN COMPLEX WITH THE HINGE BINDING FRAGMENT PHTHALAZINE
1280, d4rfyA_, 0.7199, 2.76, 0.312, 263, 253, CRYSTAL STRUCTURE OF BTK KINASE DOMAIN COMPLEXED WITH 6- (DIMETHYLAMINO)-2-[2-(HYDROXYMETHYL)-3-[1-METHYL-5-[[5-(MORPHOLINE-4- CARBONYL)-2-PYRIDYL]AMINO]-6-OXO-3-PYRIDYL]PHENYL]-34- DIHYDROISOQUINOLIN-1-ONE
1281, d4qqjA_, 0.7199, 3.19, 0.324, 282, 259, CRYSTAL STRUCTURE OF FGF RECEPTOR (FGFR) 4 KINASE DOMAIN HARBORING THE V550L GATE-KEEPER MUTATION
1282, d4jdkA_, 0.7199, 3.24, 0.179, 288, 262, CRYSTAL STRUCTURE OF SERINE/THREONINE-PROTEIN KINASE PAK 4 F461V MUTANT IN COMPLEX WITH PAKTIDE S PEPTIDE SUBSTRATE
1283, d3wzeA_, 0.7199, 2.99, 0.309, 298, 256, KDR IN COMPLEX WITH LIGAND SORAFENIB
1284, d3oy3A1, 0.7199, 3.14, 0.333, 283, 258, CRYSTAL STRUCTURE OF ABL T315I MUTANT KINASE DOMAIN BOUND WITH A DFG- OUT INHIBITOR AP24589
1285, d3eqhA_, 0.7199, 3.41, 0.195, 314, 266, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN A TERNARY COMPLEX WITH U0126 ADP AND MG2P
1286, d2yacA_, 0.7199, 3.31, 0.211, 290, 265, CRYSTAL STRUCTURE OF POLO-LIKE KINASE 1 IN COMPLEX WITH NMS-P937
1287, d4ymjA1, 0.7198, 2.82, 0.296, 267, 253, (R)-2-PHENYLPYRROLIDINE SUBSTITUTE IMIDAZOPYRIDAZINES: A NEW CLASS OF POTENT AND SELECTIVE PAN-TRK INHIBITORS
1288, d4qqtA_, 0.7198, 3.05, 0.319, 283, 257, CRYSTAL STRUCTURE OF FGF RECEPTOR (FGFR) 4 TYROSINE KINASE DOMAIN
1289, d3v01A1, 0.7198, 3.36, 0.189, 288, 265, DISCOVERY OF NOVEL ALLOSTERIC MEK INHIBITORS POSSESSING CLASSICAL AND NON-CLASSICAL BIDENTATE SER212 INTERACTIONS.
1290, d3uqfB_, 0.7198, 2.52, 0.298, 253, 248, C-SRC KINASE DOMAIN IN COMPLEX WITH BKI RM-1-89
1291, d3fc2A_, 0.7198, 3.31, 0.211, 293, 265, PLK1 IN COMPLEX WITH BI6727
1292, d1zwsG_, 0.7198, 3.20, 0.180, 278, 261, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN DRP-1 KINASE
1293, d1s9jA1, 0.7198, 3.35, 0.185, 288, 265, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN A COMPLEX WITH LIGAND AND MGATP
1294, d4j52A_, 0.7197, 3.31, 0.208, 293, 265, CRYSTAL STRUCTURE OF PLK1 IN COMPLEX WITH A PYRIMIDODIAZEPINONE INHIBITOR
1295, d3efkA_, 0.7197, 2.99, 0.332, 276, 253, STRUCTURE OF C-MET WITH PYRIMIDONE INHIBITOR 50
1296, d2rfnA_, 0.7197, 2.86, 0.344, 268, 250, X-RAY STRUCTURE OF C-MET WITH INHIBITOR.
1297, d5ut2A_, 0.7196, 2.72, 0.213, 273, 253, JAK2 JH2 IN COMPLEX WITH PRT062607
1298, d5ta6A_, 0.7196, 3.37, 0.203, 294, 266, CRYSTAL STRUCTURE OF PLK1 IN COMPLEX WITH A NOVEL 56- DIHYDROIMIDAZOLO[15-F]PTERIDINE INHIBITOR.
1299, d5nk5A_, 0.7196, 3.41, 0.320, 287, 266, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 1M
1300, d3zh8A_, 0.7196, 3.29, 0.163, 318, 264, A NOVEL SMALL MOLECULE APKC INHIBITOR
1301, d3vs7B3, 0.7196, 2.47, 0.302, 266, 248, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRAZOLO-PYRIMIDINE INHIBITOR 1-CYCLOPENTYL-3-(1H-PYRROLO[23-B]PYRIDIN-5-YL)-1H- PYRAZOLO[34-D]PYRIMIDIN-4-AMINE
1302, d2rfnB_, 0.7196, 2.86, 0.344, 269, 250, X-RAY STRUCTURE OF C-MET WITH INHIBITOR.
1303, d4ypdA1, 0.7195, 2.96, 0.179, 276, 257, CRYSTAL STRUCTURE OF DAPK1 CATALYTIC DOMAIN IN COMPLEX WITH THE HINGE BINDING FRAGMENT 4-METHYLPYRIDAZINE
1304, d4yjpA_, 0.7195, 3.21, 0.357, 263, 258, THE KINASE DOMAIN OF HUMAN SPLEEN TYROSINE (SYK) IN COMPLEX WITH GTC000223
1305, d4u81A1, 0.7195, 3.29, 0.186, 288, 264, MEK1 KINASE BOUND TO SMALL MOLECULE INHIBITOR G659
1306, d4d4yB_, 0.7195, 3.04, 0.349, 260, 255, FOCAL ADHESION KINASE CATALYTIC DOMAIN
1307, d4aseA_, 0.7195, 3.19, 0.305, 305, 259, CRYSTAL STRUCTURE OF VEGFR2 (JUXTAMEMBRANE AND KINASE DOMAINS) IN COMPLEX WITH TIVOZANIB (AV-951)
1308, d3zh8B_, 0.7195, 3.38, 0.166, 317, 265, A NOVEL SMALL MOLECULE APKC INHIBITOR
1309, d3oy3B1, 0.7195, 3.17, 0.333, 283, 258, CRYSTAL STRUCTURE OF ABL T315I MUTANT KINASE DOMAIN BOUND WITH A DFG- OUT INHIBITOR AP24589
1310, d2b4sD_, 0.7195, 3.13, 0.303, 294, 261, CRYSTAL STRUCTURE OF A COMPLEX BETWEEN PTP1B AND THE INSULIN RECEPTOR TYROSINE KINASE
1311, d5hu9A1, 0.7194, 2.72, 0.331, 262, 251, CRYSTAL STRUCTURE OF ABL1 IN COMPLEX WITH CHMFL-074
1312, d4w8eA_, 0.7194, 3.49, 0.225, 290, 267, STRUCTURE OF MST3 WITH A PYRROLOPYRIMIDINE INHIBITOR (PF-06645342)
1313, d4crsA1, 0.7194, 3.50, 0.179, 329, 268, HUMAN PROTEIN KINASE N2 (PKN2 PRKCL2) IN COMPLEX WITH ATPGAMMAS
1314, d4bcgA_, 0.7194, 3.35, 0.155, 312, 265, STRUCTURE OF CDK9 IN COMPLEX WITH CYCLIN T AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
1315, d4or5A_, 0.7193, 3.51, 0.157, 319, 267, CRYSTAL STRUCTURE OF HIV-1 TAT COMPLEXED WITH HUMAN P-TEFB AND AFF4
1316, d4b9dB1, 0.7193, 2.81, 0.182, 291, 253, CRYSTAL STRUCTURE OF HUMAN NIMA-RELATED KINASE 1 (NEK1) WITH INHIBITOR.
1317, d4h1mA_, 0.7192, 2.93, 0.340, 256, 256, CRYSTAL STRUCTURE OF PYK2 WITH THE INDOLE 10C
1318, d3v04A1, 0.7192, 3.29, 0.186, 288, 264, DISCOVERY OF NOVEL ALLOSTERIC MEK INHIBITORS POSSESSING CLASSICAL AND NON-CLASSICAL BIDENTATE SER212 INTERACTIONS.
1319, d3emgA_, 0.7192, 2.81, 0.357, 255, 252, DISCOVERY AND SAR OF NOVEL 4-THIAZOLYL-2- PHENYLAMINOPYRIMIDINES AS POTENT INHIBITORS OF SPLEEN TYROSINE KINASE (SYK)
1320, d1snxA_, 0.7192, 2.23, 0.316, 245, 244, CRYSTAL STRUCTURE OF APO INTERLEUKIN-2 TYROSINE KINASE CATALYTIC DOMAIN
1321, d5o26A_, 0.7191, 2.95, 0.203, 271, 256, CRYSTAL STRUCTURE OF WNK3 KINASE DOMAIN IN A DIPHOSPHORYLATED STATE AND IN COMPLEX WITH AMP-PNP/MG2+
1322, d5nk7A_, 0.7191, 3.22, 0.294, 284, 262, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 2A
1323, d5ar7B_, 0.7191, 3.07, 0.222, 278, 257, RIP2 KINASE CATALYTIC DOMAIN (1 - 310) COMPLEX WITH BIARYL UREA
1324, d4figB_, 0.7191, 3.52, 0.184, 292, 266, CATALYTIC DOMAIN OF HUMAN PAK4
1325, d3zfxB_, 0.7191, 2.66, 0.315, 254, 251, CRYSTAL STRUCTURE OF EPHB1
1326, d3rhkB_, 0.7191, 3.02, 0.340, 299, 256, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF C-MET KINASE IN COMPLEX WITH ARQ 197
1327, d5kmnA1, 0.7190, 3.20, 0.292, 290, 260, TRKA JM-KINASE WITH 1-(2-METHYL-4-PHENYL-PYRIMIDIN-5-YL)-3-[[2- (TRIFLUOROMETHYL)PHENYL]METHYL]UREA
1328, d5f9eA1, 0.7190, 3.70, 0.180, 331, 272, STRUCTURE OF PROTEIN KINASE C THETA WITH COMPOUND 10: 22-DIMETHYL-7- (2-OXIDANYLIDENE-3~{H}-IMIDAZO[45-B]PYRIDIN-1-YL)-1-(PHENYLMETHYL)- 3~{H}-QUINAZOLIN-4-ONE
1329, d5e8uA1, 0.7190, 2.96, 0.163, 303, 257, TGF-BETA RECEPTOR TYPE 1 KINASE DOMAIN (T204DI211VY249FS280T Y282FS287NA350CL352F)
1330, d5ar4B_, 0.7189, 3.08, 0.209, 279, 258, RIP2 KINASE CATALYTIC DOMAIN (1 - 310) COMPLEX WITH SB-203580
1331, d1yrpB_, 0.7189, 2.90, 0.187, 275, 256, CATALYTIC DOMAIN OF HUMAN ZIP KINASE PHOSPHORYLATED AT THR265
1332, d1yrpA_, 0.7189, 2.90, 0.187, 275, 256, CATALYTIC DOMAIN OF HUMAN ZIP KINASE PHOSPHORYLATED AT THR265
1333, d5e8tA1, 0.7188, 2.88, 0.160, 300, 256, TGF-BETA RECEPTOR TYPE 1 KINASE DOMAIN (T204D)
1334, d5am7B_, 0.7188, 3.02, 0.332, 287, 256, FGFR1 MUTANT WITH AN INHIBITOR
1335, d4jdhA_, 0.7188, 3.21, 0.183, 289, 262, CRYSTAL STRUCTURE OF SERINE/THREONINE-PROTEIN KINASE PAK 4 IN COMPLEX WITH PAKTIDE T PEPTIDE SUBSTRATE
1336, d3b8qA1, 0.7188, 3.14, 0.300, 285, 257, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A NAPHTHAMIDE INHIBITOR
1337, d2p55A2, 0.7188, 3.31, 0.186, 288, 264, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN A COMPLEX WITH LIGAND AND MGATP
1338, d1fpuB1, 0.7188, 2.89, 0.340, 266, 253, CRYSTAL STRUCTURE OF ABL KINASE DOMAIN IN COMPLEX WITH A SMALL MOLECULE INHIBITOR
1339, d5d7aB_, 0.7187, 3.03, 0.168, 286, 256, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF TRAF2 AND NCK-INTERACTING PROTEIN KINASE WITH NCB-0846
1340, d4u80A_, 0.7187, 3.27, 0.186, 286, 263, MEK 1 KINASE BOUND TO G799
1341, d4mneC_, 0.7187, 2.65, 0.212, 260, 250, CRYSTAL STRUCTURE OF THE BRAF:MEK1 COMPLEX
1342, d4figA_, 0.7187, 3.52, 0.184, 292, 266, CATALYTIC DOMAIN OF HUMAN PAK4
1343, d4appA1, 0.7187, 3.49, 0.189, 290, 265, CRYSTAL STRUCTURE OF THE HUMAN P21-ACTIVATED KINASE 4 IN COMPLEX WITH (S)-N-(5-(3-BENZYL-1-METHYLPIPERAZINE-4- CARBONYL)-66-DIMETHYL-1456-TETRAHYDROPYRROLO(34-C) PYRAZOL-3-YL)-3-PHENOXYBENZAMIDE
1344, d4anlA_, 0.7187, 3.54, 0.267, 292, 266, STRUCTURE OF G1269A MUTANT ANAPLASTIC LYMPHOMA KINASE
1345, d2j0iA_, 0.7187, 3.26, 0.172, 289, 262, CRYSTAL STRUCTURE OF THE HUMAN P21-ACTIVATED KINASE 4
1346, d5fbnC_, 0.7186, 2.79, 0.296, 256, 253, BTK KINASE DOMAIN WITH INHIBITOR 1
1347, d4zsaB_, 0.7186, 3.16, 0.322, 282, 258, CRYSTAL STRUCTURE OF FGFR1 KINASE DOMAIN IN COMPLEX WITH 7N
1348, d3zfxG_, 0.7186, 2.58, 0.316, 253, 250, CRYSTAL STRUCTURE OF EPHB1
1349, d3prfA_, 0.7186, 2.58, 0.236, 262, 250, CRYSTAL STRUCTURE OF HUMAN B-RAF KINASE DOMAIN IN COMPLEX WITH A NON- OXIME FUROPYRIDINE INHIBITOR
1350, d2jdoA_, 0.7186, 3.46, 0.160, 314, 269, STRUCTURE OF PKB-BETA (AKT2) COMPLEXED WITH ISOQUINOLINE-5- SULFONIC ACID (2-(2-(4-CHLOROBENZYLOXY) ETHYLAMINO)ETHYL) AMIDE
1351, d5jsmB1, 0.7185, 2.64, 0.226, 259, 252, BRAFV600E KINASE DOMAIN IN COMPLEX WITH CHEMICALLY LINKED VEMURAFENIB INHIBITOR VEM-3-VEM
1352, d4m13A_, 0.7185, 2.80, 0.321, 264, 252, CRYSTAL STRUCTURE OF ITK IN COMPLEX WITH COMPOUND 8 [4- (CARBAMOYLAMINO)-1-(7-PROPOXYNAPHTHALEN-1-YL)-1H-PYRAZOLE-3- CARBOXAMIDE]
1353, d3kb7A_, 0.7185, 3.29, 0.216, 289, 264, CRYSTAL STRUCTURE OF POLO-LIKE KINASE 1 IN COMPLEX WITH A PYRAZOLOQUINAZOLINE INHIBITOR
1354, d3gu8A1, 0.7185, 2.97, 0.179, 276, 257, CRYSTAL STRUCTURE OF DAPKL93G WITH N6-CYCLOPENTYLADENOSINE
1355, d2yhvA_, 0.7185, 3.55, 0.271, 291, 266, STRUCTURE OF L1196M MUTANT ANAPLASTIC LYMPHOMA KINASE
1356, d2xikA_, 0.7185, 3.40, 0.242, 288, 265, STRUCTURE OF HUMAN YSK1 (YEAST SPS1-STE20-RELATED KINASE 1)
1357, d6babB_, 0.7184, 3.04, 0.154, 285, 259, THE STRUCTURE OF HUMAN CAMKII WITH BOUND INHIBITOR
1358, d5j5sB_, 0.7184, 2.81, 0.289, 258, 253, SRC KINASE IN COMPLEX WITH A SULFONAMIDE INHIBITOR
1359, d5am6B_, 0.7184, 3.07, 0.328, 280, 256, NATIVE FGFR1 WITH AN INHIBITOR
1360, d4nwmA_, 0.7184, 2.65, 0.312, 261, 250, CRYSTAL STRUCTURE OF BRUTON AGAMMAGLOBULINEMIA TYROSINE KINASE COMPLEXED WITH BMS-809959 AKA 4-TERT-BUTYL-N-[2-ME THYL-3-(6-{[4- (MORPHOLINE-4-CARBONYL)PHENYL]AMINO}-9H- PURIN-2-YL)PHENYL]BENZAMIDE
1361, d3zfxF_, 0.7184, 2.61, 0.316, 254, 250, CRYSTAL STRUCTURE OF EPHB1
1362, d3ocbB_, 0.7184, 3.64, 0.162, 319, 271, AKT1 KINASE DOMAIN WITH PYRROLOPYRIMIDINE INHIBITOR
1363, d3mj2A_, 0.7184, 2.50, 0.323, 259, 248, X-RAY CRYSTAL STRUCTURE OF ITK COMPLEXED WITH INHIBITOR BMS-509744
1364, d3gqlA_, 0.7184, 3.45, 0.307, 287, 264, CRYSTAL STRUCTURE OF ACTIVATED RECEPTOR TYROSINE KINASE IN COMPLEX WITH SUBSTRATES
1365, d5ut5A_, 0.7183, 2.71, 0.209, 272, 253, JAK2 JH2 IN COMPLEX WITH GLPG0634
1366, d5d7aC_, 0.7183, 2.98, 0.172, 286, 256, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF TRAF2 AND NCK-INTERACTING PROTEIN KINASE WITH NCB-0846
1367, d4qmyA_, 0.7183, 3.60, 0.228, 287, 268, MST3 IN COMPLEX WITH STAUROSPORINE
1368, d4ogrA_, 0.7183, 3.30, 0.158, 314, 265, CRYSTAL STRUCTURE OF P-TEFB COMPLEX WITH AFF4 AND TAT
1369, d1zwsB_, 0.7183, 3.06, 0.181, 278, 259, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN DRP-1 KINASE
1370, d5nk1A_, 0.7182, 3.23, 0.294, 284, 262, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 1K
1371, d5dg5A_, 0.7182, 3.14, 0.341, 297, 258, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF THE HEPATOCYTE GROWTH FACTOR RECEPTOR C-MET IN COMPLEX WITH ALTIRATINIB ANALOG DP- 4157
1372, d4m0zA_, 0.7182, 2.81, 0.321, 264, 252, CRYSTAL STRUCTURE OF ITK IN COMPLEX WITH COMPOUND 5 {4- (CARBAMOYLAMINO)-1-(7-METHOXYNAPHTHALEN-1-YL)-1H-PYRAZOLE-3- CARBOXAMIDE}
1373, d3sxrA1, 0.7182, 2.90, 0.290, 257, 255, CRYSTAL STRUCTURE OF BMX NON-RECEPTOR TYROSINE KINASE COMPLEX WITH DASATINIB
1374, d3qgyB1, 0.7182, 2.20, 0.321, 244, 243, CRYSTAL STRUCTURE OF ITK INHIBITOR COMPLEX
1375, d4m0yA_, 0.7181, 2.87, 0.313, 263, 252, CRYSTAL STRUCTURE OF ITK IN COMPLEX WITH COMPOUND 1 [4- (CARBAMOYLAMINO)-1-(NAPHTHALEN-1-YL)-1H-PYRAZOLE-3-CARBOXAMIDE]
1376, d3fzpA_, 0.7181, 3.01, 0.305, 259, 256, CRYSTAL STRUCTURE OF PYK2 COMPLEXED WITH ATPGS
1377, d3dgkA1, 0.7181, 2.98, 0.179, 276, 257, CRYSTAL STRUCTURE OF A GLYCINE-RICH LOOP MUTANT OF THE DEATH ASSOCIATED PROTEIN KINASE CATALYTIC DOMAIN
1378, d2bdfB_, 0.7181, 3.06, 0.301, 265, 259, SRC KINASE IN COMPLEX WITH INHIBITOR AP23451
1379, d1pkgB_, 0.7181, 2.74, 0.308, 277, 250, STRUCTURE OF A C-KIT KINASE PRODUCT COMPLEX
1380, d5uszA_, 0.7180, 2.72, 0.209, 272, 253, JAK2 JH2 IN COMPLEX WITH JNJ-7706621
1381, d4mcvA_, 0.7180, 3.25, 0.295, 267, 261, STAR 12 BOUND TO ANALOG-SENSITIVE SRC KINASE
1382, d1phkA_, 0.7180, 2.94, 0.205, 277, 258, TWO STRUCTURES OF THE CATALYTIC DOMAIN OF PHOSPHORYLASE KINASE: AN ACTIVE PROTEIN KINASE COMPLEXED WITH NUCLEOTIDE SUBSTRATE-ANALOGUE AND PRODUCT
1383, d4zk5A_, 0.7179, 3.09, 0.181, 286, 259, MAP4K4 IN COMPLEX WITH INHIBITOR GNE-495
1384, d4nwmB_, 0.7179, 2.67, 0.308, 261, 250, CRYSTAL STRUCTURE OF BRUTON AGAMMAGLOBULINEMIA TYROSINE KINASE COMPLEXED WITH BMS-809959 AKA 4-TERT-BUTYL-N-[2-ME THYL-3-(6-{[4- (MORPHOLINE-4-CARBONYL)PHENYL]AMINO}-9H- PURIN-2-YL)PHENYL]BENZAMIDE
1385, d3mv5A_, 0.7179, 3.52, 0.164, 315, 269, CRYSTAL STRUCTURE OF AKT-1-INHIBITOR COMPLEXES
1386, d3g6gA_, 0.7179, 3.09, 0.302, 264, 258, EQUALLY POTENT INHIBITION OF C-SRC AND ABL BY COMPOUNDS THAT RECOGNIZE INACTIVE KINASE CONFORMATIONS
1387, d3f3uB_, 0.7179, 2.98, 0.290, 259, 255, KINASE DOMAIN OF CSRC IN COMPLEX WITH INHIBITOR RL37 (TYPE III)
1388, d3a8xA1, 0.7179, 3.58, 0.162, 331, 271, CRYSTAL STRUCTURE OF PKCIOTA KINASE DOMAIN
1389, d5nk2A_, 0.7178, 3.42, 0.318, 290, 264, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 2B
1390, d4or5F_, 0.7178, 3.60, 0.152, 324, 269, CRYSTAL STRUCTURE OF HIV-1 TAT COMPLEXED WITH HUMAN P-TEFB AND AFF4
1391, d4d5hB_, 0.7178, 3.08, 0.349, 260, 255, FOCAL ADHESION KINASE CATALYTIC DOMAIN
1392, d4cmtA_, 0.7178, 3.46, 0.261, 284, 264, STRUCTURE OF THE HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH THE INHIBITOR 3-((1R)-1-(5-FLUORO-2-(2H-123-TRIAZOL-2-YL) PHENYL)ETHOXY)-5-(3-(METHYLSULFONYL)PHENYL)PYRIDIN-2-AMINE
1393, d4bcfA_, 0.7178, 3.28, 0.160, 307, 263, STRUCTURE OF CDK9 IN COMPLEX WITH CYCLIN T AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
1394, d3zlsA_, 0.7178, 3.58, 0.186, 315, 269, CRYSTAL STRUCTURE OF MEK1 IN COMPLEX WITH FRAGMENT 6
1395, d3g5dA_, 0.7178, 2.84, 0.304, 256, 253, KINASE DOMAIN OF CSRC IN COMPLEX WITH DASATINIB
1396, d5ia3A_, 0.7177, 3.19, 0.296, 275, 260, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH PD173955
1397, d4rfzA_, 0.7177, 2.75, 0.310, 263, 252, CRYSTAL STRUCTURE OF BTK KINASE DOMAIN COMPLEXED WITH 6- (DIMETHYLAMINO)-8-FLUORO-2-[2-(HYDROXYMETHYL)-3-[1-METHYL-5-[[5- (MORPHOLINE-4-CARBONYL)-2-PYRIDYL]AMINO]-6-OXO-3- PYRIDYL]PHENYL]ISOQUINOLIN-1-ONE
1398, d4q9zB_, 0.7177, 3.80, 0.164, 308, 274, HUMAN PROTEIN KINASE C THETA IN COMPLEX WITH COMPOUND35 ((1R)-9- (AZETIDIN-3-YLAMINO)-18-DIMETHYL-35-DIHYDRO[124]TRIAZINO[34- C][14]BENZOXAZIN-2(1H)-ONE)
1399, d4itjB_, 0.7177, 3.17, 0.219, 276, 256, CRYSTAL STRUCTURE OF RIP1 KINASE IN COMPLEX WITH NECROSTATIN-4
1400, d3gu6A1, 0.7177, 2.98, 0.179, 276, 257, CRYSTAL STRUCTURE OF DAPKQ23V-ADP
1401, d2yn8B_, 0.7177, 2.97, 0.293, 260, 256, EPHB4 KINASE DOMAIN INHIBITOR COMPLEX
1402, d2w4jA_, 0.7177, 2.98, 0.179, 276, 257, X-RAY STRUCTURE OF A DAP-KINASE 2-277
1403, d2bdjA_, 0.7177, 2.59, 0.293, 254, 249, SRC KINASE IN COMPLEX WITH INHIBITOR AP23464
1404, d5ut1A_, 0.7176, 2.64, 0.207, 272, 251, JAK2 JH2 IN COMPLEX WITH BI-D1870
1405, d4m15A_, 0.7176, 2.77, 0.323, 263, 251, CRYSTAL STRUCTURE OF ITK IN COMPLEX WITH COMPOUND 9 [4- (CARBAMOYLAMINO)-1-[7-(PROPAN-2-YLOXY)NAPHTHALEN-1-YL]-1H-PYRAZOLE-3- CARBOXAMIDE] AND ADP
1406, d3zosA_, 0.7176, 2.93, 0.298, 301, 255, STRUCTURE OF THE DDR1 KINASE DOMAIN IN COMPLEX WITH PONATINIB
1407, d5veeA_, 0.7175, 3.49, 0.174, 289, 265, PAK4 KINASE DOMAIN IN COMPLEX WITH FRAX486
1408, d5e8wA1, 0.7175, 3.04, 0.155, 302, 258, TGF-BETA RECEPTOR TYPE 1 KINASE DOMAIN (T204D) IN COMPLEX WITH STAUROSPORINE
1409, d5cwzA_, 0.7175, 3.01, 0.172, 284, 256, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN TRAF2 AND NCK- INTERACTING PROTEIN KINASE
1410, d3orxA_, 0.7175, 3.29, 0.210, 283, 262, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT INHIBITOR 1F8
1411, d5nkgA_, 0.7174, 3.27, 0.321, 292, 262, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 3D
1412, d5kmkA1, 0.7174, 2.93, 0.301, 302, 256, TRKA JM-KINASE WITH 2-FLUORO-{N}-[2-(4-FLUOROPHENYL)-6-METHYL-3- PYRIDYL]-4-(TRIFLUOROMETHYL)BENZAMIDE
1413, d3orxC_, 0.7174, 3.29, 0.210, 283, 262, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT INHIBITOR 1F8
1414, d1sm2A_, 0.7174, 2.25, 0.311, 245, 244, CRYSTAL STRUCTURE OF THE PHOSPHORYLATED INTERLEUKIN-2 TYROSINE KINASE CATALYTIC DOMAIN
1415, d5nkcA_, 0.7173, 3.37, 0.299, 286, 264, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 2H
1416, d5dh3B_, 0.7173, 3.55, 0.225, 283, 267, CRYSTAL STRUCTURE OF MST2 IN COMPLEX WITH XMU-MP-1
1417, d4ot5A_, 0.7173, 2.75, 0.310, 263, 252, CRYSTAL STRUCTURE OF BTK KINASE DOMAIN COMPLEXED WITH 4-TERT-BUTYL-N- (3-{8-[4-(4-METHYL-PIPERAZINE-1-CARBONYL)-PHENYLAMINO]-IMIDAZO[12- A]PYRAZIN-6-YL}-PHENYL)-BENZAMIDE
1418, d4m12A_, 0.7173, 2.82, 0.321, 264, 252, CRYSTAL STRUCTURE OF ITK IN COMPLEX WITH COMPOUND 7 [4- (CARBAMOYLAMINO)-1-(7-ETHOXYNAPHTHALEN-1-YL)-1H-PYRAZOLE-3- CARBOXAMIDE]
1419, d3gu5A1, 0.7173, 2.99, 0.179, 276, 257, CRYSTAL STRUCTURE OF DAPKQ23V-AMPPNP-MG2+
1420, d2rkuA_, 0.7173, 3.33, 0.204, 294, 265, STRUCTURE OF PLK1 IN COMPLEX WITH BI2536
1421, d1ql6A_, 0.7173, 3.07, 0.201, 281, 259, THE CATALYTIC MECHANISM OF PHOSPHORYLASE KINASE PROBED BY MUTATIONAL STUDIES
1422, d4nk9B_, 0.7172, 3.29, 0.308, 282, 260, CRYSTAL STRUCTURE OF HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN IN COMPLEX WITH PYRAZOLAMINOPYRIMIDINE 1
1423, d4bchA_, 0.7172, 3.40, 0.158, 308, 265, STRUCTURE OF CDK9 IN COMPLEX WITH CYCLIN T AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
1424, d4yhtA_, 0.7171, 2.59, 0.217, 256, 249, BRAF COMPLEXED WITH AN INHIBITOR
1425, d4mneG_, 0.7171, 2.47, 0.219, 259, 247, CRYSTAL STRUCTURE OF THE BRAF:MEK1 COMPLEX
1426, d3zh8C_, 0.7171, 3.25, 0.168, 312, 262, A NOVEL SMALL MOLECULE APKC INHIBITOR
1427, d3q4uA_, 0.7171, 2.77, 0.198, 298, 252, CRYSTAL STRUCTURE OF THE ACVR1 KINASE DOMAIN IN COMPLEX WITH LDN- 193189
1428, d5grnA_, 0.7170, 3.02, 0.297, 285, 256, CRYSTAL STRUCTURE OF PDGFRA IN COMPLEX WITH WQ-C-159
1429, d4ra5A1, 0.7170, 3.72, 0.176, 331, 272, HUMAN PROTEIN KINASE C THETA IN COMPLEX WITH LIGAND COMPOUND 11A (6- [(13-DIMETHYL-AZETIDIN-3-YL)-METHYL-AMINO]-4(R)-METHYL-7-PHENYL-2 10-DIHYDRO-9-OXA-124A-TRIAZA-PHENANTHREN-3-ONE)
1430, d1rw8A_, 0.7170, 3.00, 0.160, 301, 257, CRYSTAL STRUCTURE OF TGF-BETA RECEPTOR I KINASE WITH ATP SITE INHIBITOR
1431, d5swhB_, 0.7169, 2.97, 0.282, 261, 255, C-SRC V281C KINASE DOMAIN IN COMPLEX WITH RAO-IV-151
1432, d4d5kB_, 0.7169, 2.88, 0.349, 256, 252, FOCAL ADHESION KINASE CATALYTIC DOMAIN
1433, d3en4A_, 0.7169, 2.95, 0.286, 257, 255, TARGETED POLYPHARMACOLOGY: CRYSTAL STRUCTURE OF THE C-SRC KINASE DOMAIN IN COMPLEX WITH PP121 A MULTITARGETED KINASE INHIBITOR
1434, d2phkA_, 0.7169, 2.93, 0.191, 277, 257, THE CRYSTAL STRUCTURE OF A PHOSPHORYLASE KINASE PEPTIDE SUBSTRATE COMPLEX: KINASE SUBSTRATE RECOGNITION
1435, d2owbA_, 0.7169, 3.36, 0.215, 294, 265, STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN POLO-LIKE KINASE 1
1436, d1r0pA_, 0.7169, 3.43, 0.345, 301, 261, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF THE HEPATOCYTE GROWTH FACTOR RECEPTOR C-MET IN COMPLEX WITH THE MICROBIAL ALKALOID K-252A
1437, d5htiA_, 0.7168, 3.30, 0.340, 290, 259, CRYSTAL STRUCTURE OF C-MET KINASE DOMAIN IN COMPLEX WITH LXM108
1438, d4mcvB_, 0.7168, 3.29, 0.287, 265, 261, STAR 12 BOUND TO ANALOG-SENSITIVE SRC KINASE
1439, d4j53A_, 0.7168, 3.35, 0.211, 293, 265, CRYSTAL STRUCTURE OF PLK1 IN COMPLEX WITH TAK-960
1440, d4apcA1, 0.7168, 2.86, 0.178, 289, 253, CRYSTAL STRUCTURE OF HUMAN NIMA-RELATED KINASE 1 (NEK1)
1441, d5i9zA_, 0.7166, 3.05, 0.306, 273, 258, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH DANUSERTIB (PHA739358)
1442, d4yjuA_, 0.7166, 3.04, 0.333, 262, 255, THE KINASE DOMAIN OF HUMAN SPLEEN TYROSINE (SYK) IN COMPLEX WITH GTC000249
1443, d3wj6A_, 0.7166, 3.04, 0.328, 282, 256,  
1444, d3gu4A1, 0.7166, 3.00, 0.179, 276, 257, CRYSTAL STRUCTURE OF DAPKQ23V-AMPPNP
1445, d3g5dB_, 0.7166, 2.90, 0.303, 257, 254, KINASE DOMAIN OF CSRC IN COMPLEX WITH DASATINIB
1446, d2bdwB_, 0.7166, 3.48, 0.154, 309, 266, CRYSTAL STRUCTURE OF THE AUTO-INHIBITED KINASE DOMAIN OF CALCIUM/CALMODULIN ACTIVATED KINASE II
1447, d5nk3A_, 0.7165, 3.51, 0.303, 281, 267, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 1L
1448, d3eqiA_, 0.7165, 3.62, 0.190, 315, 268, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN A BINARY COMPLEX WITH ADP AND MG2P
1449, d3efkB_, 0.7165, 2.86, 0.337, 272, 249, STRUCTURE OF C-MET WITH PYRIMIDONE INHIBITOR 50
1450, d2vx1A_, 0.7165, 3.20, 0.292, 274, 260, EPHB4 KINASE DOMAIN INHIBITOR COMPLEX
1451, d1zwsA_, 0.7165, 3.10, 0.181, 278, 259, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN DRP-1 KINASE
1452, d5sysA_, 0.7164, 3.03, 0.289, 258, 256, C-SRC V281C BOUND TO N-[3-({6-[(1E)-2-CYANO-3-(METHYLAMINO)-3-OXOPROP- 1-EN-1-YL]-7-(2-METHOXYETHYL)-7H-PYRROLO[23-D]PYRIMIDIN-5- YL}ETHYNYL)-4-METHYLPHENYL]-3-(TRIFLUOROMETHYL)BENZAMIDE INHIBITOR
1453, d5j5sA_, 0.7164, 2.99, 0.286, 258, 255, SRC KINASE IN COMPLEX WITH A SULFONAMIDE INHIBITOR
1454, d5b7vA_, 0.7164, 3.04, 0.328, 282, 256, HUMAN FGFR1 KINASE IN COMPLEX WITH CH5183284
1455, d4ogrE_, 0.7164, 3.23, 0.153, 310, 262, CRYSTAL STRUCTURE OF P-TEFB COMPLEX WITH AFF4 AND TAT
1456, d4knbB_, 0.7164, 2.50, 0.344, 256, 244, C-MET IN COMPLEX WITH OSI LIGAND
1457, d3q53A_, 0.7164, 3.36, 0.192, 291, 265, STRUCTURE OF PHOSPHORYLATED PAK1 KINASE DOMAIN IN COMPLEX WITH ATP
1458, d3genA_, 0.7164, 2.82, 0.306, 264, 252, THE 1.6 A CRYSTAL STRUCTURE OF HUMAN BRUTON S TYROSINE KINASE BOUND TO A PYRROLOPYRIMIDINE-CONTAINING COMPOUND
1459, d3dfcB1, 0.7164, 3.02, 0.179, 276, 257, CRYSTAL STRUCTURE OF A GLYCINE-RICH LOOP MUTANT OF THE DEATH ASSOCIATED PROTEIN KINASE CATALYTIC DOMAIN WITH AMPPNP
1460, d4uwyA_, 0.7163, 3.07, 0.324, 296, 256, FGFR1 APO STRUCTURE
1461, d4pf4A1, 0.7163, 3.01, 0.179, 277, 257, 1.1A X-RAY STRUCTURE OF THE APO CATALYTIC DOMAIN OF DEATH-ASSOCIATED PROTEIN KINASE 1 AA 1-277
1462, d3t9tA_, 0.7163, 2.79, 0.320, 263, 250, CRYSTAL STRUCTURE OF BTK MUTANT (F435TK596R) COMPLEXED WITH IMIDAZO[15-A]QUINOXALINE
1463, d3eqdA_, 0.7163, 3.60, 0.190, 315, 268, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN A BINARY COMPLEX WITH ATP-GS AND MG2P
1464, d2vx0A_, 0.7163, 3.18, 0.300, 273, 260, EPHB4 KINASE DOMAIN INHIBITOR COMPLEX
1465, d2biyA_, 0.7163, 3.47, 0.211, 287, 266, STRUCTURE OF PDK1-S241A MUTANT KINASE DOMAIN
1466, d5nk4A_, 0.7162, 3.35, 0.300, 290, 263, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 2C
1467, d5kmjA_, 0.7162, 3.14, 0.301, 300, 259, TRKA JM-KINASE WITH {N}-(2-PYRIDYLMETHYL)-2-[2-(2-THIENYL)INDOL-1- YL]ACETAMIDE
1468, d5a4cA_, 0.7162, 3.24, 0.305, 294, 259, FGFR1 LIGAND COMPLEX
1469, d4q9zA1, 0.7162, 3.66, 0.174, 330, 270, HUMAN PROTEIN KINASE C THETA IN COMPLEX WITH COMPOUND35 ((1R)-9- (AZETIDIN-3-YLAMINO)-18-DIMETHYL-35-DIHYDRO[124]TRIAZINO[34- C][14]BENZOXAZIN-2(1H)-ONE)
1470, d4lueA3, 0.7162, 2.40, 0.307, 261, 244, CRYSTAL STRUCTURE OF HCK IN COMPLEX WITH 7-[TRANS-4-(4- METHYLPIPERAZIN-1-YL)CYCLOHEXYL]-5-(4-PHENOXYPHENYL)-7H-PYRROLO[23- D]PYRIMIDIN-4-AMINE (RESULTING FROM DISPLACEMENT OF SKF86002)
1471, d3orxD_, 0.7162, 3.25, 0.207, 282, 261, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT INHIBITOR 1F8
1472, d5nkdA_, 0.7161, 3.34, 0.300, 287, 263, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 2I
1473, d4txcA_, 0.7161, 2.98, 0.179, 276, 257, CRYSTAL STRUCTURE OF DAPK1 KINASE DOMAIN IN COMPLEX WITH A SMALL MOLECULE INHIBITOR
1474, d3q4uD_, 0.7161, 2.71, 0.179, 299, 251, CRYSTAL STRUCTURE OF THE ACVR1 KINASE DOMAIN IN COMPLEX WITH LDN- 193189
1475, d3q4uC_, 0.7161, 2.62, 0.180, 296, 250, CRYSTAL STRUCTURE OF THE ACVR1 KINASE DOMAIN IN COMPLEX WITH LDN- 193189
1476, d2wqbA_, 0.7161, 3.12, 0.304, 289, 257, STRUCTURE OF THE TIE2 KINASE DOMAIN IN COMPLEX WITH A THIAZOLOPYRIMIDINE INHIBITOR
1477, d5usqA_, 0.7160, 2.89, 0.161, 299, 255, ALK-5 KINASE INHIBITOR COMPLEX
1478, d5jsmC1, 0.7160, 2.61, 0.224, 259, 250, BRAFV600E KINASE DOMAIN IN COMPLEX WITH CHEMICALLY LINKED VEMURAFENIB INHIBITOR VEM-3-VEM
1479, d5jrsA1, 0.7160, 2.57, 0.320, 257, 247, CRYSTAL STRUCTURE OF BRUTON AGAMMAGLOBULINEMIA TYROSINE KINASE COMPLEXED WITH 4-[2-FLUORO-3-(4-OXO -34-DIHYDROQUINAZOLIN-3-YL) PHENYL]-7-(2-HYDROXYPROPAN-2-Y L)-9H-CARBAZOLE-1-CARBOXAMIDE
1480, d5friA1, 0.7160, 2.88, 0.157, 299, 255, ALK5 IN COMPLEX WITHA AN N-(4-ANILINO-2-PYRIDYL)ACETAMIDE INHIBITOR.
1481, d4v01B_, 0.7160, 3.06, 0.310, 275, 255, FGFR1 IN COMPLEX WITH PONATINIB (CO-CRYSTALLISATION).
1482, d3eqfA_, 0.7160, 3.43, 0.189, 314, 265, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN A BINARY COMPLEX WITH K252A AND MG2P
1483, d1jklA_, 0.7160, 3.01, 0.179, 280, 257, 1.6A X-RAY STRUCTURE OF BINARY COMPLEX OF A CATALYTIC DOMAIN OF DEATH-ASSOCIATED PROTEIN KINASE WITH ATP ANALOGUE
1484, d4qmsA_, 0.7159, 3.72, 0.227, 283, 269, MST3 IN COMPLEX WITH DASATINIB
1485, d4bcjA_, 0.7159, 3.44, 0.155, 309, 265, STRUCTURE OF CDK9 IN COMPLEX WITH CYCLIN T AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
1486, d2ijmB_, 0.7159, 3.16, 0.350, 261, 257, CRYSTAL STRUCTURE OF FOCAL ADHESION KINASE DOMAIN WITH 2 MOLECULES IN THE ASYMMETRIC UNIT COMPLEXED WITH ADP AND ATP
1487, d5ta8A_, 0.7158, 3.32, 0.208, 294, 264, CRYSTAL STRUCTURE OF PLK1 IN COMPLEX WITH A NOVEL 56- DIHYDROIMIDAZOLO[15-F]PTERIDINE INHIBITOR
1488, d5nk9A_, 0.7158, 3.23, 0.295, 285, 261, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 2E
1489, d4ithB_, 0.7158, 2.85, 0.216, 270, 250, CRYSTAL STRUCTURE OF RIP1 KINASE IN COMPLEX WITH NECROSTATIN-1 ANALOG
1490, d3uqgB_, 0.7158, 2.91, 0.296, 257, 253, C-SRC KINASE DOMAIN IN COMPLEX WITH BUMPLESS BKI ANALOG UW1243
1491, d3i5nA_, 0.7158, 3.21, 0.354, 280, 254, CRYSTAL STRUCTURE OF C-MET WITH TRIAZOLOPYRIDAZINE INHIBITOR 13
1492, d3gu7A1, 0.7158, 3.02, 0.179, 276, 257, CRYSTAL STRUCTURE OF DAPKQ23V-ADP-MG2+
1493, d3ccnA_, 0.7158, 2.86, 0.352, 275, 250, X-RAY STRUCTURE OF C-MET WITH TRIAZOLOPYRIDAZINE INHIBITOR.
1494, d2hk5A2, 0.7158, 3.11, 0.302, 268, 258, HCK KINASE IN COMPLEX WITH LCK TARGETTED INHIBITOR PG-1009247
1495, d4rg0A_, 0.7157, 2.77, 0.310, 263, 252, CRYSTAL STRUCTURE OF BTK KINASE DOMAIN COMPLEXED WITH 2-[8-FLUORO-2- [2-(HYDROXYMETHYL)-3-[1-METHYL-5-[[5-(4-METHYLPIPERAZIN-1-YL)-2- PYRIDYL]AMINO]-6-OXO-3-PYRIDYL]PHENYL]-1-OXO-34-DIHYDROISOQUINOLIN- 6-YL]-2-METHYL-PROPANENITRILE
1496, d4nk9A_, 0.7157, 3.30, 0.308, 281, 260, CRYSTAL STRUCTURE OF HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN IN COMPLEX WITH PYRAZOLAMINOPYRIMIDINE 1
1497, d2hznA2, 0.7157, 2.72, 0.336, 268, 250, ABL KINASE DOMAIN IN COMPLEX WITH NVP-AFG210
1498, d2fb8A_, 0.7157, 2.55, 0.225, 259, 249, STRUCTURE OF THE B-RAF KINASE DOMAIN BOUND TO SB-590885
1499, d1snuA_, 0.7157, 2.28, 0.311, 245, 244, CRYSTAL STRUCTURE OF THE UNPHOSPHORYLATED INTERLEUKIN-2 TYROSINE KINASE CATALYTIC DOMAIN
1500, d5nkfA_, 0.7156, 3.31, 0.321, 291, 262, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 3B
1501, d5e90A1, 0.7156, 2.93, 0.164, 300, 256, TGF-BETA RECEPTOR TYPE 1 KINASE DOMAIN (T204DI211VY249F S280T Y282FS287NA350CL352F) IN COMPLEX WITH 3-AMINO-6- [4-(2- HYDROXYETHYL)PHENYL]-N-[4-(MORPHOLIN-4-YL)PYRIDIN-3-YL]PYRAZINE-2- CARBOXAMIDE
1502, d5av0A_, 0.7156, 2.97, 0.180, 275, 256, CRYSTAL STRUCTURE OF DAPK1 IN COMPLEX WITH 73 4 - TRIHYDROXYISOFLAVONE.
1503, d4x2fA1, 0.7156, 3.04, 0.160, 302, 257, SELECTION OF FRAGMENTS FOR KINASE INHIBITOR DESIGN: DECORATION IS KEY
1504, d4fnwA_, 0.7156, 3.64, 0.258, 304, 267, CRYSTAL STRUCTURE OF THE APO F1174L ANAPLASTIC LYMPHOMA KINASE CATALYTIC DOMAIN
1505, d3zbfA_, 0.7156, 3.16, 0.324, 281, 259, STRUCTURE OF HUMAN ROS1 KINASE DOMAIN IN COMPLEX WITH CRIZOTINIB
1506, d3uqfA_, 0.7156, 3.06, 0.296, 260, 257, C-SRC KINASE DOMAIN IN COMPLEX WITH BKI RM-1-89
1507, d3tz8B_, 0.7156, 3.15, 0.291, 263, 258, KINASE DOMAIN OF CSRC IN COMPLEX WITH RL104
1508, d1snuB_, 0.7156, 2.07, 0.317, 241, 240, CRYSTAL STRUCTURE OF THE UNPHOSPHORYLATED INTERLEUKIN-2 TYROSINE KINASE CATALYTIC DOMAIN
1509, d4zjiA_, 0.7155, 2.97, 0.178, 278, 258, PAK1 IN COMPLEX WITH 2-CHLORO-5-ETHYL-8-FLUORO-11-(4-METHYLPIPERAZIN- 1-YL)-DIBENZODIAZEPINE
1510, d3f66A_, 0.7155, 3.21, 0.345, 288, 258, HUMAN C-MET KINASE IN COMPLEX WITH QUINOXALINE INHIBITOR
1511, d5nk6A_, 0.7154, 3.24, 0.295, 284, 261, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 2D
1512, d5kmlA1, 0.7154, 3.25, 0.292, 290, 260, TRKA JM-KINASE WITH 1-(5-METHYL-3-PHENYL-12-OXAZOL-4-YL)-3-[[2- (TRIFLUOROMETHYL)PHENYL]METHYL]UREA
1513, d5i9xA_, 0.7154, 3.36, 0.293, 284, 263, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH BOSUTINIB (SKI-606)
1514, d4x2nA1, 0.7154, 3.03, 0.160, 302, 257, SELECTION OF FRAGMENTS FOR KINASE INHIBITOR DESIGN: DECORATION IS KEY
1515, d4u45A_, 0.7154, 3.14, 0.185, 289, 260, MAP4K4 IN COMPLEX WITH INHIBITOR (COMPOUND 25)
1516, d4d4vA_, 0.7154, 2.85, 0.353, 256, 252, FOCAL ADHESION KINASE CATALYTIC DOMAIN
1517, d4agcA_, 0.7154, 3.25, 0.305, 304, 259, CRYSTAL STRUCTURE OF VEGFR2 (JUXTAMEMBRANE AND KINASE DOMAINS) IN COMPLEX WITH AXITINIB (AG-013736) (N-METHYL-2-( 3-((E)-2-PYRIDIN-2-YL-VINYL)-1H-INDAZOL-6-YLSULFANYL)- BENZAMIDE)
1518, d3h9rA_, 0.7154, 2.74, 0.190, 312, 252, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF TYPE I ACTIVIN RECEPTOR (ACVR1) IN COMPLEX WITH FKBP12 AND DORSOMORPHIN
1519, d2vwyA_, 0.7154, 3.27, 0.299, 274, 261, EPHB4 KINASE DOMAIN INHIBITOR COMPLEX
1520, d1j3hB_, 0.7154, 3.54, 0.166, 327, 271, CRYSTAL STRUCTURE OF APOENZYME CAMP-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT
1521, d5e8sA1, 0.7153, 2.90, 0.161, 299, 255, TGF-BETA RECEPTOR TYPE 1 KINASE DOMAIN (WT)
1522, d4mnfB_, 0.7153, 2.57, 0.226, 257, 248, CRYSTAL STRUCTURE OF BRAF-V600E BOUND TO GDC0879
1523, d3oxzA1, 0.7153, 2.85, 0.343, 267, 251, CRYSTAL STRUCTURE OF ABL KINASE DOMAIN BOUND WITH A DFG-OUT INHIBITOR AP24534
1524, d4x2gA1, 0.7152, 3.05, 0.160, 302, 257, SELECTION OF FRAGMENTS FOR KINASE INHIBITOR DESIGN: DECORATION IS KEY
1525, d2wotA_, 0.7152, 3.11, 0.159, 303, 258, ALK5 IN COMPLEX WITH 4-((56-DIMETHYL-2-(2-PYRIDYL)-3- PYRIDYL)OXY)-N-(345-TRIMETHOXYPHENYL)PYRIDIN-2-AMINE
1526, d1ig1A_, 0.7152, 3.03, 0.179, 280, 257, 1.8A X-RAY STRUCTURE OF TERNARY COMPLEX OF A CATALYTIC DOMAIN OF DEATH-ASSOCIATED PROTEIN KINASE WITH ATP ANALOGUE AND MN.
1527, d5jsmD1, 0.7151, 2.62, 0.224, 255, 250, BRAFV600E KINASE DOMAIN IN COMPLEX WITH CHEMICALLY LINKED VEMURAFENIB INHIBITOR VEM-3-VEM
1528, p4ib5A_, 0.7151, 3.13, 0.143, 331, 258, STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT IN COMPLEX WITH A CK2BETA-COMPETITIVE CYCLIC PEPTIDE
1529, d3ehaA1, 0.7151, 3.08, 0.179, 275, 257, CRYSTAL STRUCTURE OF DEATH ASSOCIATED PROTEIN KINASE COMPLEXED WITH AMPPNP
1530, d2zvaA1, 0.7151, 2.98, 0.315, 260, 257, LYN TYROSINE KINASE DOMAIN-DASATINIB COMPLEX
1531, d5ut0A_, 0.7150, 2.63, 0.208, 272, 250, JAK2 JH2 IN COMPLEX WITH AT9283
1532, d3mvhA_, 0.7150, 3.57, 0.164, 311, 268, CRYSTAL STRUCTURE OF AKT-1-INHIBITOR COMPLEXES
1533, d2e2bA1, 0.7150, 2.75, 0.340, 266, 250, CRYSTAL STRUCTURE OF THE C-ABL KINASE DOMAIN IN COMPLEX WITH INNO-406
1534, d5j87C_, 0.7149, 2.76, 0.308, 261, 250, DISCOVERY OF N-(3-(5-((3-ACRYLAMIDO-4-(MORPHOLINE-4-CARBONYL)PHENYL) AMINO)-1-METHYL-6-OXO-16-DIHYDROPYRIDIN-3-YL)-2-METHYLPHENYL)-4- (TERT-BUTYL)BENZAMIDE (CHMFL-BTK-01) AS A HIGHLY SELECTIVE IRREVERSIBLE BTK KINASE INHIBITOR
1535, d5av1A_, 0.7149, 2.98, 0.180, 275, 256, CRYSTAL STRUCTURE OF DAPK1 IN THE PRESENCE OF BROMIDE IONS.
1536, d4zp5A_, 0.7149, 3.08, 0.172, 284, 256, MAP4K4 IN COMPLEX WITH INHIBITOR
1537, d4yjtA_, 0.7149, 3.24, 0.333, 268, 258, THE KINASE DOMAIN OF HUMAN SPLEEN TYROSINE (SYK) IN COMPLEX WITH GTC000233
1538, d4xlvA_, 0.7149, 3.23, 0.300, 307, 260, CRYSTAL STRUCTURE OF THE ACTIVATED INSULIN RECEPTOR TYROSINE KINASE DIMER
1539, d4gk4A_, 0.7149, 3.31, 0.299, 275, 261, HUMAN EPHA3 KINASE DOMAIN IN COMPLEX WITH LIGAND 90
1540, d3f5gA1, 0.7149, 2.98, 0.180, 275, 256, CRYSTAL STRUCTURE OF DEATH ASSOCIATED PROTEIN KINASE IN COMPLEX WITH ADP AND MG2+
1541, d3eh9A1, 0.7149, 2.99, 0.180, 274, 256, CRYSTAL STRUCTURE OF DEATH ASSOCIATED PROTEIN KINASE COMPLEXED WITH ADP
1542, d4u40A_, 0.7148, 3.21, 0.177, 295, 260, MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE KINASE 4 (MAP4K4) BOUND TO AMPPNP
1543, d4bggA_, 0.7148, 2.66, 0.180, 296, 250, CRYSTAL STRUCTURE OF THE ACVR1 KINASE IN COMPLEX WITH LDN-213844
1544, d3wj6B_, 0.7148, 3.16, 0.309, 277, 256,  
1545, d3mi9A_, 0.7148, 3.62, 0.160, 328, 269, CRYSTAL STRUCTURE OF HIV-1 TAT COMPLEXED WITH HUMAN P-TEFB
1546, d1zwsE_, 0.7148, 3.31, 0.180, 278, 261, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN DRP-1 KINASE
1547, d5hesB_, 0.7147, 2.63, 0.235, 278, 247, HUMAN LEUCINE ZIPPER- AND STERILE ALPHA MOTIF-CONTAINING KINASE (ZAK MLT HCCS-4 MRK AZK MLTK) IN COMPLEX WITH VEMURAFENIB
1548, d5b7vB_, 0.7147, 3.16, 0.309, 277, 256, HUMAN FGFR1 KINASE IN COMPLEX WITH CH5183284
1549, d4qmxA_, 0.7147, 3.55, 0.228, 287, 267, MST3 IN COMPLEX WITH SARACATINIB
1550, d4bggB_, 0.7147, 2.65, 0.180, 293, 250, CRYSTAL STRUCTURE OF THE ACVR1 KINASE IN COMPLEX WITH LDN-213844
1551, d3zlxA_, 0.7147, 3.63, 0.194, 312, 268, CRYSTAL STRUCTURE OF MEK1 IN COMPLEX WITH FRAGMENT 18
1552, d5ut6A_, 0.7146, 2.62, 0.208, 272, 250, JAK2 JH2 IN COMPLEX WITH A DIAMINOPYRIMIDINE
1553, d4qnaA_, 0.7146, 3.67, 0.228, 284, 268, MST3 IN COMPLEX WITH 2-(46-DIAMINO-135-TRIAZIN-2-YL)PHENOL
1554, d4mxcA_, 0.7146, 3.21, 0.341, 290, 258, CRYSTAL STRUCTURE OF CMET IN COMPLEX WITH NOVEL INHIBITOR
1555, d4m14A_, 0.7146, 2.78, 0.320, 263, 250, CRYSTAL STRUCTURE OF ITK IN COMPLEX WITH COMPOUND 9 [4- (CARBAMOYLAMINO)-1-[7-(PROPAN-2-YLOXY)NAPHTHALEN-1-YL]-1H-PYRAZOLE-3- CARBOXAMIDE]
1556, d4eklA_, 0.7146, 3.63, 0.163, 329, 270, AKT1 WITH GDC0068
1557, d4d4vB_, 0.7146, 2.87, 0.351, 255, 251, FOCAL ADHESION KINASE CATALYTIC DOMAIN
1558, d3orxB_, 0.7146, 3.19, 0.208, 280, 259, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT INHIBITOR 1F8
1559, d3mtfB_, 0.7146, 2.82, 0.187, 298, 252, CRYSTAL STRUCTURE OF THE ACVR1 KINASE IN COMPLEX WITH A 2- AMINOPYRIDINE INHIBITOR
1560, d2fb8B_, 0.7146, 2.67, 0.224, 259, 250, STRUCTURE OF THE B-RAF KINASE DOMAIN BOUND TO SB-590885
1561, d5ut3A_, 0.7145, 2.70, 0.207, 272, 251, JAK2 JH2 IN COMPLEX WITH IKK-2 INHIBITOR VI
1562, d5i9wA_, 0.7145, 2.81, 0.320, 267, 253, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH ANP
1563, d5cwzB_, 0.7145, 2.97, 0.169, 284, 254, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN TRAF2 AND NCK- INTERACTING PROTEIN KINASE
1564, d3fzsA_, 0.7145, 2.89, 0.343, 254, 254, CRYSTAL STRUCTURE OF PYK2 COMPLEXED WITH BIRB796
1565, d2wotA1, 0.7145, 3.03, 0.160, 301, 257, ALK5 IN COMPLEX WITH 4-((56-DIMETHYL-2-(2-PYRIDYL)-3- PYRIDYL)OXY)-N-(345-TRIMETHOXYPHENYL)PYRIDIN-2-AMINE
1566, d1jksA_, 0.7145, 3.03, 0.179, 280, 257, 1.5A X-RAY STRUCTURE OF APO FORM OF A CATALYTIC DOMAIN OF DEATH-ASSOCIATED PROTEIN KINASE
1567, d1jkkA_, 0.7145, 3.05, 0.179, 277, 257, 2.4A X-RAY STRUCTURE OF TERNARY COMPLEX OF A CATALYTIC DOMAIN OF DEATH-ASSOCIATED PROTEIN KINASE WITH ATP ANALOGUE AND MG.
1568, d5oxgC1, 0.7144, 2.87, 0.198, 299, 253, CRYSTAL STRUCTURE OF THE ACVR1 (ALK2) KINASE IN COMPLEX WITH LDN- 212854
1569, d4nw5A1, 0.7144, 3.25, 0.184, 296, 261, RSK2 N-TERMINAL KINASE IN COMPLEX WITH 2-AMINO-7-SUBSTITUTED BENZOXAZOLE COMPOUND 8
1570, d3zlyA_, 0.7144, 3.60, 0.195, 310, 267, CRYSTAL STRUCTURE OF MEK1 IN COMPLEX WITH FRAGMENT 8
1571, d5kmoA1, 0.7143, 3.11, 0.296, 290, 257, TRKA JM-KINASE WITH 1-(2-METHYL-4-PHENYL-PYRIMIDIN-5-YL)-3-(2- PYRIDYL)UREA
1572, d4brxA_, 0.7143, 3.13, 0.335, 259, 257, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH A DIARYLAMINO-135-TRIAZINE INHIBITOR
1573, d4b9dA1, 0.7143, 2.90, 0.182, 286, 253, CRYSTAL STRUCTURE OF HUMAN NIMA-RELATED KINASE 1 (NEK1) WITH INHIBITOR.
1574, d3rwqA_, 0.7143, 3.34, 0.202, 283, 262, DISCOVERY OF A NOVEL POTENT AND SELECTIVE INHIBITOR OF 3- PHOSPHOINOSITIDE DEPENDENT KINASE (PDK1)
1575, d1agwA_, 0.7143, 3.13, 0.324, 278, 256, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FIBROBLAST GROWTH FACTOR RECEPTOR 1 IN COMPLEX WITH SU4984 INHIBITOR
1576, d5cenA_, 0.7142, 2.88, 0.236, 281, 254, CRYSTAL STRUCTURE OF DLK (KINASE DOMAIN)
1577, d5av3A_, 0.7142, 2.99, 0.180, 275, 256, CRYSTAL STRUCTURE OF DAPK1-KAEMPFEROL COMPLEX IN THE PRESENCE OF IODIDE IONS.
1578, d4ybjB_, 0.7142, 2.76, 0.291, 253, 251, TYPE II DASATINIB ANALOG CRYSTALLIZED WITH C-SRC KINASE
1579, d3sxrB1, 0.7142, 2.92, 0.289, 255, 253, CRYSTAL STRUCTURE OF BMX NON-RECEPTOR TYROSINE KINASE COMPLEX WITH DASATINIB
1580, d3qklA_, 0.7142, 3.55, 0.164, 317, 269, SPIROCHROMANE AKT INHIBITORS
1581, d2vwxA_, 0.7142, 3.16, 0.293, 274, 259, EPHB4 KINASE DOMAIN INHIBITOR COMPLEX
1582, d4gv1A1, 0.7141, 3.60, 0.164, 328, 269, PKB ALPHA IN COMPLEX WITH AZD5363
1583, d4c8bA_, 0.7141, 2.99, 0.206, 279, 253, STRUCTURE OF THE KINASE DOMAIN OF HUMAN RIPK2 IN COMPLEX WITH PONATINIB
1584, d3bu5A_, 0.7141, 3.19, 0.295, 291, 258, CRYSTAL STRUCTURE OF THE INSULIN RECEPTOR KINASE IN COMPLEX WITH IRS2 KRLB PEPTIDE AND ATP
1585, d2yakA_, 0.7141, 3.02, 0.183, 277, 257, STRUCTURE OF DEATH-ASSOCIATED PROTEIN KINASE 1 (DAPK1) IN COMPLEX WITH A RUTHENIUM OCTASPORINE LIGAND (OSV)
1586, d4ks7A_, 0.7140, 3.45, 0.186, 286, 263, PAK6 KINASE DOMAIN IN COMPLEX WITH PF-3758309
1587, d3zlwA_, 0.7140, 3.65, 0.190, 312, 268, CRYSTAL STRUCTURE OF MEK1 IN COMPLEX WITH FRAGMENT 3
1588, d3unkA_, 0.7140, 3.13, 0.183, 295, 257, CDK2 IN COMPLEX WITH INHIBITOR YL5-083
1589, d3qkmA_, 0.7140, 3.55, 0.164, 329, 269, SPIROCYCLIC SULFONAMIDES AS AKT INHIBITORS
1590, d4x0mA1, 0.7139, 3.06, 0.160, 302, 257, SELECTION OF FRAGMENTS FOR KINASE INHIBITOR DESIGN: DECORATION IS KEY
1591, d4pmmA1, 0.7139, 2.67, 0.308, 281, 250, THE STRUCTURE OF TRKA KINASE BOUND TO THE INHIBITOR N-(3-CYCLOPROPYL- 1-PHENYL-1H-PYRAZOL-5-YL)-2-{4-[3-METHOXY-4-(4-METHYL-1H-IMIDAZOL-1- YL)PHENYL]-1H-123-TRIAZOL-1-YL}ACETAMIDE
1592, d4h58B_, 0.7139, 2.73, 0.227, 262, 251, BRAF IN COMPLEX WITH COMPOUND 3
1593, d4bciA_, 0.7139, 3.40, 0.155, 308, 264, STRUCTURE OF CDK9 IN COMPLEX WITH CYCLIN T AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
1594, d3qkkA_, 0.7139, 3.63, 0.163, 326, 270, SPIROCHROMANE AKT INHIBITORS
1595, d3lq5A_, 0.7139, 3.41, 0.155, 307, 264, STRUCTURE OF CDK9/CYCLINT IN COMPLEX WITH S-CR8
1596, d3fztA_, 0.7139, 3.02, 0.318, 259, 255, CRYSTAL STRUCTURE OF PYK2 COMPLEXED WITH PF-4618433
1597, d3c4dA1, 0.7139, 2.51, 0.219, 257, 247,  
1598, d3aoxA_, 0.7139, 3.55, 0.264, 298, 265, X-RAY CRYSTAL STRUCTURE OF HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH CH5424802
1599, d1fgkA_, 0.7139, 3.19, 0.327, 278, 257, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FIBROBLAST GROWTH FACTOR RECEPTOR 1
1600, d2vwzA_, 0.7138, 3.29, 0.299, 274, 261, EPHB4 KINASE DOMAIN INHIBITOR COMPLEX
1601, d1jktB_, 0.7138, 3.11, 0.178, 276, 258, TETRAGONAL CRYSTAL FORM OF A CATALYTIC DOMAIN OF DEATH-ASSOCIATED PROTEIN KINASE
1602, d4ntsB_, 0.7137, 3.85, 0.167, 341, 276, APO STRUCTURE OF THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE
1603, d4dceB_, 0.7137, 3.36, 0.249, 284, 261, CRYSTAL STRUCTURE OF HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH A PIPERIDINE-CARBOXAMIDE INHIBITOR
1604, d2bdfA_, 0.7137, 2.99, 0.297, 261, 256, SRC KINASE IN COMPLEX WITH INHIBITOR AP23451
1605, d1yomB_, 0.7137, 2.94, 0.272, 261, 254, CRYSTAL STRUCTURE OF SRC KINASE DOMAIN IN COMPLEX WITH PURVALANOL A
1606, d1gngB_, 0.7137, 3.38, 0.179, 355, 262, GLYCOGEN SYNTHASE KINASE-3 BETA (GSK3) COMPLEX WITH FRATTIDE PEPTIDE
1607, d5nkbA_, 0.7136, 3.25, 0.295, 285, 261, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 4A
1608, d5hznE_, 0.7136, 3.37, 0.309, 296, 259, STRUCTURE OF NVP-AEW541 IN COMPLEX WITH IGF-1R KINASE
1609, d5bx0A_, 0.7136, 3.54, 0.195, 315, 267, AN AUTOMATED MICROSCALE THERMOPHORESIS SCREENING APPROACH FOR FRAGMENT-BASED LEAD DISCOVERY
1610, d4nw6A1, 0.7136, 3.26, 0.184, 296, 261, RSK2 N-TERMINAL KINASE IN COMPLEX WITH 2-AMINO-7-SUBSTITUTED BENZOXAZOLE COMPOUND 27
1611, d4kioC1, 0.7136, 2.47, 0.316, 249, 247, KINASE DOMAIN MUTANT OF HUMAN ITK IN COMPLEX WITH A COVALENTLY-BINDING INHIBITOR
1612, d4fnxA_, 0.7136, 3.59, 0.265, 292, 264, CRYSTAL STRUCTURE OF THE APO R1275Q ANAPLASTIC LYMPHOMA KINASE CATALYTIC DOMAIN
1613, d3of0B_, 0.7136, 2.70, 0.294, 251, 248, CRYSTAL STRUCTURE OF THE L317I MUTANT OF THE CHICKEN C-SRC TYROSINE KINASE DOMAIN
1614, d3cqwA_, 0.7136, 3.58, 0.164, 318, 269, CRYSTAL STRUCTURE OF AKT-1 COMPLEXED WITH SUBSTRATE PEPTIDE AND INHIBITOR
1615, d5njzA_, 0.7135, 3.07, 0.298, 273, 258, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 1G
1616, d5auxA_, 0.7135, 3.00, 0.180, 275, 256, CRYSTAL STRUCTURE OF DAPK1 IN COMPLEX WITH KAEMPFEROL.
1617, d3miaA_, 0.7135, 3.70, 0.148, 324, 270, CRYSTAL STRUCTURE OF HIV-1 TAT COMPLEXED WITH ATP-BOUND HUMAN P-TEFB
1618, d5uabA_, 0.7134, 2.88, 0.353, 288, 249, MET TYROSINE KINASE INHIBITION ENHANCES THE ANTITUMOR EFFICACY OF AN HGF ANTIBODY
1619, d4ks8A_, 0.7134, 3.32, 0.188, 286, 261, PAK6 KINASE DOMAIN IN COMPLEX WITH SUNITINIB
1620, d4gk3A_, 0.7134, 3.29, 0.300, 275, 260, HUMAN EPHA3 KINASE DOMAIN IN COMPLEX WITH LIGAND 87
1621, d3qlgA_, 0.7134, 3.12, 0.284, 259, 257, CRYSTAL STRUCTURE OF THE L317I MUTANT OF THE C-SRC TYROSINE KINASE DOMAIN COMPLEXED WITH DASATINIB
1622, d3f5uA1, 0.7134, 3.02, 0.180, 275, 256, CRYSTAL STRUCTURE OF THE DEATH ASSOCIATED PROTEIN KINASE IN COMPLEX WITH AMPPNP AND MG2+
1623, d5hznA_, 0.7133, 3.37, 0.309, 296, 259, STRUCTURE OF NVP-AEW541 IN COMPLEX WITH IGF-1R KINASE
1624, d5auvA_, 0.7133, 3.00, 0.180, 275, 256, CRYSTAL STRUCTURE OF DAPK1 IN COMPLEX WITH APIGENIN.
1625, d4yjsA_, 0.7133, 2.94, 0.355, 257, 251, THE KINASE DOMAIN OF HUMAN SPLEEN TYROSINE (SYK) IN COMPLEX WITH GTC000226
1626, d4aojA_, 0.7133, 2.91, 0.312, 260, 253, HUMAN TRKA IN COMPLEX WITH THE INHIBITOR AZ-23
1627, d3rhxB_, 0.7133, 3.16, 0.332, 275, 256, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF FGFR1 KINASE IN COMPLEX WITH ARQ 069
1628, d3o7lD_, 0.7133, 3.81, 0.175, 333, 275, CRYSTAL STRUCTURE OF PHOSPHOLAMBAN (1-19):PKA C-SUBUNIT:AMP-PNP:MG2+ COMPLEX
1629, d1py5A_, 0.7133, 3.12, 0.163, 301, 258, CRYSTAL STRUCTURE OF TGF-BETA RECEPTOR I KINASE WITH INHIBITOR
1630, d5kmmA1, 0.7132, 3.00, 0.301, 300, 256, TRKA JM-KINASE WITH 1-(2-METHYL-4-PHENYL-PYRIMIDIN-5-YL)-3-(1- NAPHTHYL)UREA
1631, d5av2A_, 0.7132, 3.01, 0.180, 275, 256, CRYSTAL STRUCTURE OF DAPK1-KAEMPFEROL COMPLEX IN THE PRESENCE OF BROMIDE IONS.
1632, d4obpA_, 0.7132, 3.19, 0.185, 285, 259, MAP4K4 IN COMPLEX WITH INHIBITOR (COMPOUND 29) 6-(2-FLUOROPYRIDIN-4- YL)PYRIDO[32-D]PYRIMIDIN-4-AMINE
1633, d4gg7A_, 0.7132, 3.34, 0.353, 278, 258, CRYSTAL STRUCTURE OF CMET IN COMPLEX WITH NOVEL INHIBITOR
1634, d4dglD_, 0.7132, 3.17, 0.147, 328, 258, CRYSTAL STRUCTURE OF THE CK2 TETRAMERIC HOLOENZYME
1635, d4x2kA1, 0.7131, 3.08, 0.160, 302, 257, SELECTION OF FRAGMENTS FOR KINASE INHIBITOR DESIGN: DECORATION IS KEY
1636, d4x2jA1, 0.7131, 3.08, 0.160, 302, 257, SELECTION OF FRAGMENTS FOR KINASE INHIBITOR DESIGN: DECORATION IS KEY
1637, d5ia0A_, 0.7130, 3.17, 0.302, 263, 258, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH ALISERTIB (MLN8237)
1638, d5ar4A_, 0.7130, 2.93, 0.224, 274, 254, RIP2 KINASE CATALYTIC DOMAIN (1 - 310) COMPLEX WITH SB-203580
1639, d3socA1, 0.7130, 2.65, 0.180, 296, 250, CRYSTAL STRUCTURE OF ACTIVIN RECEPTOR TYPE-IIA (ACVR2A) KINASE DOMAIN IN COMPLEX WITH A QUINAZOLIN
1640, d1tkiB_, 0.7130, 3.71, 0.130, 321, 270, AUTOINHIBITED SERINE KINASE DOMAIN OF THE GIANT MUSCLE PROTEIN TITIN
1641, d1tkiA_, 0.7130, 3.71, 0.130, 321, 270, AUTOINHIBITED SERINE KINASE DOMAIN OF THE GIANT MUSCLE PROTEIN TITIN
1642, d5e8zA1, 0.7129, 2.98, 0.160, 300, 256, TGF-BETA RECEPTOR TYPE 1 KINASE DOMAIN (T204D) IN COMPLEX WITH 3- AMINO-6-[4-(2-HYDROXYETHYL)PHENYL]-N-[4-(MORPHOLIN-4-YL)PYRIDIN-3- YL]PYRAZINE-2-CARBOXAMIDE
1643, d4gt5A_, 0.7129, 3.19, 0.304, 290, 260, CRYSTAL STRUCTURE OF THE INACTIVE TRKA KINASE DOMAIN
1644, d4d5kA_, 0.7129, 2.86, 0.347, 255, 251, FOCAL ADHESION KINASE CATALYTIC DOMAIN
1645, d4d4yA_, 0.7129, 2.86, 0.347, 255, 251, FOCAL ADHESION KINASE CATALYTIC DOMAIN
1646, d1iepB1, 0.7129, 2.78, 0.336, 270, 250, CRYSTAL STRUCTURE OF THE C-ABL KINASE DOMAIN IN COMPLEX WITH STI-571.
1647, d5di1A_, 0.7128, 3.27, 0.167, 285, 258, MAP4K4 IN COMPLEX WITH AN INHIBITOR
1648, d3ocbA_, 0.7128, 3.74, 0.166, 315, 271, AKT1 KINASE DOMAIN WITH PYRROLOPYRIMIDINE INHIBITOR
1649, d3c4cA1, 0.7128, 2.52, 0.219, 257, 247, B-RAF KINASE IN COMPLEX WITH PLX4720
1650, d3an0A_, 0.7128, 3.71, 0.190, 291, 268,  
1651, d5j95A_, 0.7127, 3.10, 0.172, 284, 256, MAP4K4 IN COMPLEX WITH INHIBITOR
1652, d5hznF_, 0.7127, 3.34, 0.302, 296, 258, STRUCTURE OF NVP-AEW541 IN COMPLEX WITH IGF-1R KINASE
1653, d4qmzA_, 0.7127, 3.59, 0.228, 286, 267, MST3 IN COMPLEX WITH SUNITINIB
1654, d3vvhC1, 0.7127, 3.25, 0.202, 282, 262, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN COMPLEX WITH AN INHIBITOR AND MGATP
1655, p2y4iC_, 0.7127, 3.73, 0.190, 313, 269, KSR2-MEK1 HETERODIMER
1656, d2etmA_, 0.7127, 3.23, 0.345, 262, 258, CRYSTAL STRUCTURE OF FOCAL ADHESION KINASE DOMAIN COMPLEXED WITH 7H-PYRROLO [23-D] PYRIMIDINE DERIVATIVE
1657, d5hznB_, 0.7126, 3.34, 0.302, 296, 258, STRUCTURE OF NVP-AEW541 IN COMPLEX WITH IGF-1R KINASE
1658, d5auwA_, 0.7126, 2.97, 0.184, 274, 255, CRYSTAL STRUCTURE OF DAPK1 IN COMPLEX WITH QUERCETIN.
1659, d4gg5A_, 0.7126, 3.25, 0.349, 274, 255, CRYSTAL STRUCTURE OF CMET IN COMPLEX WITH NOVEL INHIBITOR
1660, d3vn9A_, 0.7126, 3.71, 0.190, 291, 268, RIFINED CRYSTAL STRUCTURE OF NON-PHOSPHORYLATED MAP2K6 IN A PUTATIVE AUTO-INHIBITION STATE
1661, d5hznG_, 0.7125, 3.32, 0.302, 296, 258, STRUCTURE OF NVP-AEW541 IN COMPLEX WITH IGF-1R KINASE
1662, d5hznC_, 0.7125, 3.32, 0.302, 296, 258, STRUCTURE OF NVP-AEW541 IN COMPLEX WITH IGF-1R KINASE
1663, d5fg8A_, 0.7125, 3.05, 0.163, 269, 257, DROSOPHILA CAMKII-WT IN COMPLEX WITH A FRAGMENT OF THE EAG POTASSIUM CHANNEL AND MG2+/ADP
1664, d5auyA_, 0.7125, 3.02, 0.180, 275, 256, CRYSTAL STRUCTURE OF DAPK1 IN COMPLEX WITH MORIN.
1665, d4zjiB_, 0.7125, 2.93, 0.203, 276, 256, PAK1 IN COMPLEX WITH 2-CHLORO-5-ETHYL-8-FLUORO-11-(4-METHYLPIPERAZIN- 1-YL)-DIBENZODIAZEPINE
1666, d3warA_, 0.7125, 3.17, 0.143, 334, 258, CRYSTAL STRUCTURE OF HUMAN CK2A
1667, d1agwB_, 0.7125, 3.17, 0.332, 272, 256, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FIBROBLAST GROWTH FACTOR RECEPTOR 1 IN COMPLEX WITH SU4984 INHIBITOR
1668, d5uhnB_, 0.7124, 3.05, 0.336, 269, 253, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FGF RECEPTOR 2 HARBORING A N549H/E565A DOUBLE GAIN-OF-FUNCTION MUTATION
1669, d4ra5B_, 0.7124, 3.55, 0.169, 310, 267, HUMAN PROTEIN KINASE C THETA IN COMPLEX WITH LIGAND COMPOUND 11A (6- [(13-DIMETHYL-AZETIDIN-3-YL)-METHYL-AMINO]-4(R)-METHYL-7-PHENYL-2 10-DIHYDRO-9-OXA-124A-TRIAZA-PHENANTHREN-3-ONE)
1670, d4p2wB_, 0.7124, 2.77, 0.315, 253, 251,  
1671, d3a7iA_, 0.7124, 3.59, 0.228, 286, 267, HUMAN MST3 KINASE IN COMPLEX WITH ADENINE
1672, d5av4A_, 0.7123, 2.98, 0.180, 274, 255, CRYSTAL STRUCTURE OF DAPK1-GENISTEIN COMPLEX IN THE PRESENCE OF BROMIDE IONS.
1673, d4qmnA_, 0.7123, 3.69, 0.228, 283, 268, MST3 IN COMPLEX WITH BOSUTINIB
1674, d4c7tA_, 0.7123, 3.14, 0.344, 259, 256, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH A DIARYLAMINO-135-TRIAZINE INHIBITOR
1675, d4b6lA_, 0.7123, 3.50, 0.169, 281, 266, DISCOVERY OF ORAL POLO-LIKE KINASE (PLK) INHIBITORS WITH ENHANCED SELECTIVITY PROFILE USING RESIDUE TARGETED DRUG DESIGN
1676, d3qruA_, 0.7123, 2.98, 0.181, 295, 254, CDK2 IN COMPLEX WITH INHIBITOR NSK-MC1-12
1677, d2fgiA_, 0.7123, 3.09, 0.325, 274, 255, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FGF RECEPTOR 1 IN COMPLEX WITH INHIBITOR PD173074
1678, d5m56A_, 0.7122, 3.15, 0.120, 331, 258, MONOCLINIC COMPLEX STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT (ISOFORM CK2ALPHA ) WITH THE INHIBITOR 4 -CARBOXY-68-CHLORO- FLAVONOL (FLC21)
1679, d5ia0B_, 0.7122, 3.19, 0.308, 266, 260, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH ALISERTIB (MLN8237)
1680, d4o0tA_, 0.7122, 3.68, 0.187, 292, 268, BACK POCKET FLEXIBILITY PROVIDES GROUP-II PAK SELECTIVITY FOR TYPE 1 KINASE INHIBITORS
1681, d4mneE_, 0.7122, 3.43, 0.186, 286, 263, CRYSTAL STRUCTURE OF THE BRAF:MEK1 COMPLEX
1682, d3ow4B_, 0.7122, 3.60, 0.164, 317, 269, DISCOVERY OF DIHYDROTHIENO- AND DIHYDROFUROPYRIMIDINES AS POTENT PAN AKT INHIBITORS
1683, d3of0A_, 0.7122, 3.00, 0.290, 260, 255, CRYSTAL STRUCTURE OF THE L317I MUTANT OF THE CHICKEN C-SRC TYROSINE KINASE DOMAIN
1684, d2yjsA_, 0.7122, 3.62, 0.265, 286, 264, STRUCTURE OF C1156Y MUTANT ANAPLASTIC LYMPHOMA KINASE
1685, d5oxgB_, 0.7121, 2.70, 0.180, 296, 250, CRYSTAL STRUCTURE OF THE ACVR1 (ALK2) KINASE IN COMPLEX WITH LDN- 212854
1686, d4d58A_, 0.7121, 2.83, 0.336, 255, 250, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH BIS- ANILINO PYRIMIDINE INHIBITOR
1687, d3qtwA_, 0.7121, 2.96, 0.177, 294, 254, CDK2 IN COMPLEX WITH INHIBITOR RC-2-13
1688, d2pl0A_, 0.7121, 2.72, 0.289, 268, 249, LCK BOUND TO IMATINIB
1689, d4f64A_, 0.7120, 3.18, 0.324, 278, 256, CRYSTAL STRUCTURE OF HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN IN COMPLEX WITH COMPOUND 6
1690, d4dceA_, 0.7120, 3.54, 0.262, 288, 263, CRYSTAL STRUCTURE OF HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH A PIPERIDINE-CARBOXAMIDE INHIBITOR
1691, d4dawA_, 0.7120, 3.39, 0.192, 293, 265, CRYSTAL STRUCTURE OF PAK1 KINASE DOMAIN WITH THE RUTHENIUM PHTHALIMIDE COMPLEX
1692, d3vvhB1, 0.7120, 3.42, 0.189, 289, 265, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN COMPLEX WITH AN INHIBITOR AND MGATP
1693, d1s9iB_, 0.7120, 3.49, 0.216, 291, 264, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 2 (MEK2)IN A COMPLEX WITH LIGAND AND MGATP
1694, d5kwhB_, 0.7119, 3.18, 0.147, 331, 258, CRYSTAL STRUCTURE OF CK2
1695, d5ia1A_, 0.7119, 2.90, 0.298, 261, 255, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH MLN8054
1696, d5h9bA_, 0.7119, 3.02, 0.168, 269, 256, DROSOPHILA CAMKII-WT IN COMPLEX WITH A FRAGMENT OF THE EAG POTASSIUM CHANNEL AND MG2+/AMPPN
1697, d3qtxA_, 0.7119, 3.05, 0.180, 294, 255, CDK2 IN COMPLEX WITH INHIBITOR RC-2-35
1698, d3d7tB_, 0.7119, 3.28, 0.297, 265, 259, STRUCTURAL BASIS FOR THE RECOGNITION OF C-SRC BY ITS INACTIVATOR CSK
1699, d3cp9A1, 0.7119, 3.08, 0.312, 281, 253, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A PYRIDONE INHIBITOR
1700, d2jkkA_, 0.7119, 3.08, 0.341, 258, 255, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH BIS- ANILINO PYRIMIDINE INHIBITOR
1701, d1sm2B_, 0.7119, 2.15, 0.317, 241, 240, CRYSTAL STRUCTURE OF THE PHOSPHORYLATED INTERLEUKIN-2 TYROSINE KINASE CATALYTIC DOMAIN
1702, d5ku8B_, 0.7118, 3.18, 0.143, 331, 258, CRYSTAL STRUCTURE OF CK2
1703, d5h8eB_, 0.7118, 3.18, 0.143, 331, 258, CRYSTAL STRUCTURE OF CK2 WITH COMPOUND 7H
1704, d4f63A_, 0.7118, 3.23, 0.327, 278, 257, CRYSTAL STRUCTURE OF HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN IN COMPLEX WITH COMPOUND 1
1705, d3q9xB_, 0.7118, 3.18, 0.147, 330, 258, CRYSTAL STRUCTURE OF HUMAN CK2 ALPHA IN COMPLEX WITH EMODIN AT PH 6.5
1706, d3py0A_, 0.7118, 3.04, 0.188, 294, 255, CDK2 IN COMPLEX WITH INHIBITOR SU9516
1707, d3pxyA_, 0.7118, 2.98, 0.181, 294, 254, CDK2 IN COMPLEX WITH INHIBITOR JWS648
1708, d2exmA_, 0.7118, 3.24, 0.178, 298, 258, HUMAN CDK2 IN COMPLEX WITH ISOPENTENYLADENINE
1709, d1fgkB_, 0.7118, 3.18, 0.332, 272, 256, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FIBROBLAST GROWTH FACTOR RECEPTOR 1
1710, d5kmiA_, 0.7117, 2.97, 0.302, 300, 255, TRKA JM-KINASE WITH 1-(9{H}-FLUOREN-9-YL)-3-(2-METHYL-4-PHENYL- PYRIMIDIN-5-YL)UREA
1711, d4v01A_, 0.7117, 3.09, 0.311, 273, 254, FGFR1 IN COMPLEX WITH PONATINIB (CO-CRYSTALLISATION).
1712, d4agwA_, 0.7117, 2.94, 0.287, 258, 254, DISCOVERY OF A SMALL MOLECULE TYPE II INHIBITOR OF WILD- TYPE AND GATEKEEPER MUTANTS OF BCR-ABL PDGFRALPHA KIT AND SRC KINASES
1713, d2xh5A_, 0.7117, 3.57, 0.160, 316, 269, STRUCTURE OF 4-(4-TERT-BUTYLBENZYL)-1-(7H-PYRROLO(23-D) PYRIMIDIN-4-YL)PIPERIDIN-4-AMINE BOUND TO PKB
1714, d5tehA_, 0.7116, 2.99, 0.278, 261, 255, C-SRC V281C KINASE DOMAIN IN COMPLEX WITH RAO-IV-156
1715, d5h8bB_, 0.7116, 3.19, 0.147, 331, 258, CRYSTAL STRUCTURE OF CK2 WITH COMPOUND 2
1716, d4qmuA_, 0.7116, 3.56, 0.229, 286, 266, MST3 IN COMPLEX WITH JNJ-7706621 4-({5-AMINO-1-[(26-DIFLUOROPHENYL) CARBONYL]-1H-124-TRIAZOL-3-YL}AMINO)BENZENESULFONAMIDE
1717, d4otgA_, 0.7116, 3.79, 0.174, 322, 270, CRYSTAL STRUCTURE OF PRK1 CATALYTIC DOMAIN IN COMPLEX WITH LESTAURTINIB
1718, d3r9dA_, 0.7116, 3.02, 0.181, 294, 254, CDK2 IN COMPLEX WITH INHIBITOR RC-2-135
1719, d4fx3C_, 0.7115, 3.18, 0.165, 298, 260, CRYSTAL STRUCTURE OF THE CDK2/CYCLIN A COMPLEX WITH OXINDOLE INHIBITOR
1720, d4fx3A_, 0.7115, 3.23, 0.165, 298, 261, CRYSTAL STRUCTURE OF THE CDK2/CYCLIN A COMPLEX WITH OXINDOLE INHIBITOR
1721, p3u9cA_, 0.7115, 3.19, 0.143, 331, 258, STRUCTURE OF A C-TERMINAL DELETION MUTANT OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH THE ATP-COMPETITIVE INHIBITOR RESORUFIN
1722, d3qqkA_, 0.7115, 2.95, 0.182, 294, 253, CDK2 IN COMPLEX WITH INHIBITOR L4
1723, d3gvuA1, 0.7115, 2.62, 0.347, 261, 248, THE CRYSTAL STRUCTURE OF HUMAN ABL2 IN COMPLEX WITH GLEEVEC
1724, d3f3vB_, 0.7115, 3.17, 0.292, 262, 257, KINASE DOMAIN OF CSRC IN COMPLEX WITH INHIBITOR RL45 (TYPE II)
1725, d3cpcA1, 0.7115, 2.98, 0.299, 277, 251, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A PYRIDONE INHIBITOR
1726, d1pxnA_, 0.7115, 2.98, 0.181, 294, 254, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR 4-[4-(4-METHYL-2-METHYLAMINO-THIAZOL-5-YL)- PYRIMIDIN-2-YLAMINO]-PHENOL
1727, d1bygA_, 0.7115, 2.30, 0.309, 246, 243, KINASE DOMAIN OF HUMAN C-TERMINAL SRC KINASE (CSK) IN COMPLEX WITH INHIBITOR STAUROSPORINE
1728, d5dh3A_, 0.7114, 3.48, 0.226, 287, 266, CRYSTAL STRUCTURE OF MST2 IN COMPLEX WITH XMU-MP-1
1729, d3vw8A_, 0.7114, 3.35, 0.341, 303, 258, CRYSTAL STRUCTURE OF HUMAN C-MET KINASE DOMAIN WITH ITS INHIBITOR
1730, d3rpvA_, 0.7114, 3.00, 0.181, 294, 254, CDK2 IN COMPLEX WITH INHIBITOR RC-2-88
1731, d1uvrA_, 0.7114, 3.38, 0.202, 284, 262, STRUCTURE OF HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH BIM-8
1732, d1pf8A_, 0.7114, 3.26, 0.178, 298, 258, CRYSTAL STRUCTURE OF HUMAN CYCLIN-DEPENDENT KINASE 2 COMPLEXED WITH A NUCLEOSIDE INHIBITOR
1733, d5swhA_, 0.7113, 2.92, 0.295, 258, 254, C-SRC V281C KINASE DOMAIN IN COMPLEX WITH RAO-IV-151
1734, d4g2fA_, 0.7113, 3.28, 0.301, 275, 259, HUMAN EPHA3 KINASE DOMAIN IN COMPLEX WITH COMPOUND 7
1735, d3qtzA_, 0.7113, 3.06, 0.176, 294, 255, CDK2 IN COMPLEX WITH INHIBITOR RC-2-36
1736, d3ag9B_, 0.7113, 3.41, 0.181, 317, 265, COMPLEX OF PKA WITH THE BISUBSTRATE PROTEIN KINASE INHIBITOR ARC-1012
1737, d3a7fA_, 0.7113, 3.49, 0.223, 283, 265, HUMAN MST3 KINASE
1738, d4md7F_, 0.7112, 3.20, 0.147, 332, 258, CRYSTAL STRUCTURE OF FULL-LENGTH SYMMETRIC CK2 HOLOENZYME
1739, d3qqgA_, 0.7112, 3.04, 0.180, 294, 255, CDK2 IN COMPLEX WITH INHIBITOR L2-5
1740, d3at3A_, 0.7112, 3.14, 0.144, 332, 257, CRYSTAL STRUCTURE OF CK2ALPHA WITH PYRADINE DERIVATIVE
1741, d1h1wA_, 0.7112, 3.22, 0.204, 284, 260, HIGH RESOLUTION CRYSTAL STRUCTURE OF THE HUMAN PDK1 CATALYTIC DOMAIN
1742, d1fvvA_, 0.7112, 3.22, 0.157, 298, 261, THE STRUCTURE OF CDK2/CYCLIN A IN COMPLEX WITH AN OXINDOLE INHIBITOR
1743, d5h8eA_, 0.7111, 3.20, 0.147, 331, 258, CRYSTAL STRUCTURE OF CK2 WITH COMPOUND 7H
1744, d4d5hA_, 0.7111, 2.89, 0.339, 255, 251, FOCAL ADHESION KINASE CATALYTIC DOMAIN
1745, d2xmyA_, 0.7111, 3.06, 0.180, 295, 255, DISCOVERY AND CHARACTERISATION OF 2-ANILINO-4-(THIAZOL-5-YL) PYRIMIDINE TRANSCRIPTIONAL CDK INHIBITORS AS ANTICANCER AGENTS
1746, d1vjyA_, 0.7111, 2.94, 0.157, 299, 254, CRYSTAL STRUCTURE OF A NAPHTHYRIDINE INHIBITOR OF HUMAN TGF- BETA TYPE I RECEPTOR
1747, d5oxgA_, 0.7110, 2.73, 0.180, 293, 250, CRYSTAL STRUCTURE OF THE ACVR1 (ALK2) KINASE IN COMPLEX WITH LDN- 212854
1748, d4mnfA_, 0.7110, 2.50, 0.232, 257, 246, CRYSTAL STRUCTURE OF BRAF-V600E BOUND TO GDC0879
1749, d4md7H_, 0.7110, 3.20, 0.147, 330, 258, CRYSTAL STRUCTURE OF FULL-LENGTH SYMMETRIC CK2 HOLOENZYME
1750, d3wowA_, 0.7110, 3.24, 0.151, 334, 259, CRYSTAL STRUCTURE OF HUMAN CK2A WITH AMPPNP
1751, d3g6hB_, 0.7110, 3.15, 0.288, 259, 257, SRC THR338ILE INHIBITED IN THE DFG-ASP-OUT CONFORMATION
1752, d1szmA_, 0.7110, 3.41, 0.177, 317, 265, DUAL BINDING MODE OF BISINDOLYLMALEIMIDE 2 TO PROTEIN KINASE A (PKA)
1753, d4xg8C_, 0.7109, 2.81, 0.353, 254, 249, CRYSTAL STRUCTURE OF AN INHIBITOR-BOUND SYK
1754, d4ubaA_, 0.7109, 3.11, 0.144, 333, 257, LOW-SALT STRUCTURE OF PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH 4 - CARBOXY-68-BROMO-FLAVONOL (FLC26)
1755, d4ixpA_, 0.7109, 3.32, 0.188, 334, 261, CRYSTAL STRUCTURE OF MATERNAL EMBRYONIC LEUCINE ZIPPER KINASE (MELK)
1756, p3u9cB_, 0.7109, 3.12, 0.148, 331, 257, STRUCTURE OF A C-TERMINAL DELETION MUTANT OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH THE ATP-COMPETITIVE INHIBITOR RESORUFIN
1757, d2xnbA_, 0.7109, 3.11, 0.176, 296, 256, DISCOVERY AND CHARACTERISATION OF 2-ANILINO-4-(THIAZOL-5-YL) PYRIMIDINE TRANSCRIPTIONAL CDK INHIBITORS AS ANTICANCER AGENTS
1758, p6c3eA_, 0.7108, 2.64, 0.215, 258, 246, CRYSTAL STRUCTURE OF RIP1 KINASE BOUND TO INHIBITOR
1759, d5ax9C_, 0.7108, 2.98, 0.185, 282, 254, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN TRAF2 AND NCK- INTERACTING PROTEIN KINASE IN COMPLEX WITH COMPUND 9
1760, d5auzA_, 0.7108, 3.00, 0.180, 274, 255, CRYSTAL STRUCTURE OF DAPK1 IN COMPLEX WITH GENISTEIN.
1761, d4u3yB_, 0.7108, 3.58, 0.166, 300, 265, APO MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE KINASE 4 (MAP4K4)
1762, d3unjA_, 0.7108, 3.00, 0.185, 294, 254, CDK2 IN COMPLEX WITH INHIBITOR YL1-038-31
1763, d3qtuA_, 0.7108, 3.00, 0.181, 294, 254, CDK2 IN COMPLEX WITH INHIBITOR RC-2-132
1764, d2x4zA1, 0.7108, 3.52, 0.182, 289, 264, CRYSTAL STRUCTURE OF THE HUMAN P21-ACTIVATED KINASE 4 IN COMPLEX WITH PF-03758309
1765, d1xo2B_, 0.7108, 3.15, 0.163, 289, 258, CRYSTAL STRUCTURE OF A HUMAN CYCLIN-DEPENDENT KINASE 6 COMPLEX WITH A FLAVONOL INHIBITOR FISETIN
1766, d4asxB1, 0.7107, 2.86, 0.182, 296, 253, CRYSTAL STRUCTURE OF ACTIVIN RECEPTOR TYPE-IIA (ACVR2A) KINASE DOMAIN IN COMPLEX WITH DIHYDRO-BAUERINE C
1767, d3rk5A_, 0.7107, 3.01, 0.181, 294, 254, CDK2 IN COMPLEX WITH INHIBITOR RC-2-72
1768, d5o26B_, 0.7106, 3.00, 0.209, 265, 253, CRYSTAL STRUCTURE OF WNK3 KINASE DOMAIN IN A DIPHOSPHORYLATED STATE AND IN COMPLEX WITH AMP-PNP/MG2+
1769, d4yneA1, 0.7106, 2.77, 0.310, 276, 252, (R)-2-PHENYLPYRROLIDINE SUBSTITUTE IMIDAZOPYRIDAZINES: A NEW CLASS OF POTENT AND SELECTIVE PAN-TRK INHIBITORS
1770, d3uo5A_, 0.7106, 3.20, 0.181, 267, 260, AURORA A IN COMPLEX WITH YL1-038-31
1771, d3oomA_, 0.7106, 2.91, 0.174, 297, 253, CRYSTAL STRUCTURE OF THE ACVR1 KINASE DOMAIN IN COMPLEX WITH THE IMIDAZO[12-B]PYRIDAZINE INHIBITOR K00507
1772, d3my0M1, 0.7106, 3.04, 0.168, 297, 256, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
1773, d2qu6A1, 0.7106, 2.92, 0.312, 276, 250, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A BENZOXAZOLE INHIBITOR
1774, d5oy6B_, 0.7105, 2.76, 0.180, 292, 250, CRYSTAL STRUCTURE OF THE ACVR1 (ALK2) KINASE IN COMPLEX WITH CYCLICAL INHIBITOR OD36.
1775, d4wsqB_, 0.7105, 2.85, 0.143, 310, 251, CRYSTAL STRUCTURE OF ADAPTOR PROTEIN 2 ASSOCIATED KINASE (AAK1) IN COMPLEX WITH SMALL MOLECULE INHIBITOR
1776, d4md7G_, 0.7105, 3.20, 0.147, 332, 258, CRYSTAL STRUCTURE OF FULL-LENGTH SYMMETRIC CK2 HOLOENZYME
1777, d3ow4A_, 0.7105, 3.65, 0.167, 317, 270, DISCOVERY OF DIHYDROTHIENO- AND DIHYDROFUROPYRIMIDINES AS POTENT PAN AKT INHIBITORS
1778, d3at4A_, 0.7105, 3.20, 0.147, 331, 258, CRYSTAL STRUCTURE OF CK2ALPHA WITH PYRADINE DERIVERTIVE
1779, d2ou7A_, 0.7105, 3.39, 0.205, 292, 264, STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN POLO-LIKE KINASE 1
1780, d5osdA_, 0.7104, 3.14, 0.182, 266, 258, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
1781, d5h8bA_, 0.7104, 3.20, 0.147, 331, 258, CRYSTAL STRUCTURE OF CK2 WITH COMPOUND 2
1782, d5d11B_, 0.7104, 2.77, 0.312, 255, 250, KINASE DOMAIN OF CSRC IN COMPLEX WITH RL235
1783, d4r1yA_, 0.7104, 2.75, 0.350, 265, 246, IDENTIFICATION AND OPTIMIZATION OF PYRIDAZINONES AS POTENT AND SELECTIVE C-MET KINASE INHIBITOR
1784, d4kwpA_, 0.7104, 3.19, 0.147, 329, 258, CRYSTAL STRUCTURE OF HUMAN CK2-ALPHA IN COMPLEX WITH A BENZIMIDAZOLE INHIBITOR (K164) AT 1.25 A RESOLUTION
1785, d3qu0A_, 0.7104, 3.00, 0.181, 294, 254, CDK2 IN COMPLEX WITH INHIBITOR RC-2-38
1786, d3qqhA_, 0.7104, 3.07, 0.184, 294, 255, CDK2 IN COMPLEX WITH INHIBITOR L2-2
1787, d2ijmA_, 0.7104, 3.12, 0.352, 260, 256, CRYSTAL STRUCTURE OF FOCAL ADHESION KINASE DOMAIN WITH 2 MOLECULES IN THE ASYMMETRIC UNIT COMPLEXED WITH ADP AND ATP
1788, d1uwhA_, 0.7104, 2.98, 0.217, 264, 253, THE COMPLEX OF WILD TYPE B-RAF AND BAY439006
1789, d5itaB_, 0.7103, 2.38, 0.214, 252, 243, CRYSTAL STRUCTURE OF BRAF KINASE DOMAIN BOUND TO AZ-VEM
1790, d4wsqA_, 0.7103, 2.88, 0.143, 317, 252, CRYSTAL STRUCTURE OF ADAPTOR PROTEIN 2 ASSOCIATED KINASE (AAK1) IN COMPLEX WITH SMALL MOLECULE INHIBITOR
1791, d4v04A_, 0.7103, 3.20, 0.309, 290, 256, FGFR1 IN COMPLEX WITH PONATINIB.
1792, d3q52A_, 0.7103, 3.52, 0.192, 292, 266, STRUCTURE OF PHOSPHORYLATED PAK1 KINASE DOMAIN
1793, d1k9aF3, 0.7103, 2.87, 0.317, 264, 252, CRYSTAL STRUCTURE ANALYSIS OF FULL-LENGTH CARBOXYL-TERMINAL SRC KINASE AT 2.5 A RESOLUTION
1794, d4f64B_, 0.7102, 3.21, 0.332, 272, 256, CRYSTAL STRUCTURE OF HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN IN COMPLEX WITH COMPOUND 6
1795, d3qa0B_, 0.7102, 3.20, 0.147, 330, 258, CRYSTAL STRUCTURE OF THE APO-FORM OF HUMAN CK2 ALPHA AT PH 6.5
1796, d3g0fA_, 0.7102, 3.35, 0.298, 291, 258, KIT KINASE DOMAIN MUTANT D816H IN COMPLEX WITH SUNITINIB
1797, d3axwA_, 0.7102, 3.18, 0.143, 329, 258, CRYSTAL STRUCTURE OF HUMAN CK2ALPHA COMPLEXED WITH A POTENT INHIBITOR
1798, d1yomA_, 0.7102, 2.95, 0.276, 260, 254, CRYSTAL STRUCTURE OF SRC KINASE DOMAIN IN COMPLEX WITH PURVALANOL A
1799, d1jwhB_, 0.7102, 3.21, 0.151, 335, 258, CRYSTAL STRUCTURE OF HUMAN PROTEIN KINASE CK2 HOLOENZYME
1800, d5oxgD_, 0.7101, 2.79, 0.195, 293, 251, CRYSTAL STRUCTURE OF THE ACVR1 (ALK2) KINASE IN COMPLEX WITH LDN- 212854
1801, d4u44A_, 0.7101, 3.15, 0.182, 286, 258, MAP4K4 IN COMPLEX WITH INHIBITOR (COMPOUND 16)
1802, d4qmtA_, 0.7101, 3.64, 0.228, 284, 267, MST3 IN COMPLEX WITH HESPERADIN
1803, d4pp9B1, 0.7101, 2.38, 0.307, 246, 244, ITK KINASE DOMAIN WITH COMPOUND 1 (N-[1-(3-CYANOBENZYL)-1H-PYRAZOL-4- YL]-2H-INDAZOLE-3-CARBOXAMIDE)
1804, d4nkaA_, 0.7101, 3.14, 0.310, 279, 255, CRYSTAL STRUCTURE OF HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN IN COMPLEX WITH PYRAZOLAMINOPYRIMIDINE 2
1805, d4ludA3, 0.7101, 2.44, 0.300, 261, 243, CRYSTAL STRUCTURE OF HCK IN COMPLEX WITH THE FLUORESCENT COMPOUND SKF86002
1806, d3ti1A_, 0.7101, 3.10, 0.184, 294, 255, CDK2 IN COMPLEX WITH SUNITINIB
1807, d2jkqA_, 0.7101, 3.10, 0.345, 258, 255, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH BIS- ANILINO PYRIMIDINE INHIBITOR
1808, d1wvwA_, 0.7101, 3.03, 0.176, 275, 256, CRYSTAL STRUCTURES OF KINASE DOMAIN OF DAP KINASE IN COMPLEX WITH SMALL MOLECULAR INHIBITORS
1809, d1ds5A_, 0.7101, 3.23, 0.151, 328, 258, DIMERIC CRYSTAL STRUCTURE OF THE ALPHA SUBUNIT IN COMPLEX WITH TWO BETA PEPTIDES MIMICKING THE ARCHITECTURE OF THE TETRAMERIC PROTEIN KINASE CK2 HOLOENZYME.
1810, d5ar7A_, 0.7100, 3.19, 0.215, 278, 256, RIP2 KINASE CATALYTIC DOMAIN (1 - 310) COMPLEX WITH BIARYL UREA
1811, d4md7E_, 0.7100, 3.21, 0.147, 332, 258, CRYSTAL STRUCTURE OF FULL-LENGTH SYMMETRIC CK2 HOLOENZYME
1812, d4hvsA1, 0.7100, 3.22, 0.300, 323, 257, CRYSTAL STRUCTURE OF KIT KINASE DOMAIN WITH A SMALL MOLECULE INHIBITOR PLX647
1813, d4aojC_, 0.7100, 2.92, 0.312, 261, 253, HUMAN TRKA IN COMPLEX WITH THE INHIBITOR AZ-23
1814, d3zewB_, 0.7100, 2.73, 0.312, 252, 250, CRYSTAL STRUCTURE OF EPHB4 IN COMPLEX WITH STAUROSPORINE
1815, d3s00A_, 0.7100, 2.99, 0.186, 294, 253, CDK2 IN COMPLEX WITH INHIBITOR L4-14
1816, d3f3uA_, 0.7100, 3.20, 0.291, 261, 258, KINASE DOMAIN OF CSRC IN COMPLEX WITH INHIBITOR RL37 (TYPE III)
1817, d1gagA_, 0.7100, 3.39, 0.303, 300, 261, CRYSTAL STRUCTURE OF THE INSULIN RECEPTOR KINASE IN COMPLEX WITH A BISUBSTRATE INHIBITOR
1818, d5kwhA_, 0.7099, 3.21, 0.143, 331, 258, CRYSTAL STRUCTURE OF CK2
1819, d3v8tB1, 0.7099, 2.08, 0.322, 242, 239, CRYSTAL STRUCTURE OF INTERLEUKIN-2 INDUCIBLE T-CELL KINASE ITK CATALYTIC DOMAIN WITH THIENOPYRAZOLYLINDOLE INHIBITOR 477
1820, d3r8vA_, 0.7099, 3.00, 0.186, 294, 253, CDK2 IN COMPLEX WITH INHIBITOR RC-1-135
1821, d3qqjA_, 0.7099, 3.08, 0.176, 294, 255, CDK2 IN COMPLEX WITH INHIBITOR L2
1822, d3ql8A_, 0.7099, 2.98, 0.182, 294, 253, CDK2 IN COMPLEX WITH INHIBITOR JWS-6-260
1823, d1fpuA1, 0.7099, 3.01, 0.340, 271, 253, CRYSTAL STRUCTURE OF ABL KINASE DOMAIN IN COMPLEX WITH A SMALL MOLECULE INHIBITOR
1824, d5t1hB_, 0.7098, 3.20, 0.143, 331, 258, CRYSTAL STRUCTURE OF CK2
1825, d5t18A1, 0.7098, 2.76, 0.310, 259, 248, CRYSTAL STRUCTURE OF BRUTON AGAMMABULINEMIA TYROSINE KINASE COMPLEXED WITH BMS-986142 AKA (2S)-6-FLUORO-5-[3-(8-FLUORO-1-METHYL-24-DIOXO- 1234-TETRAHYDROQUINAZOLIN-3-YL)-2-METHYLPHENYL]-2-(2- HYDROXYPROPAN-2-YL)-2349-TETRAHYDRO-1H-CARBAZOLE-8-CARBOXAMIDE
1826, d5o21A_, 0.7098, 2.96, 0.194, 272, 252, CRYSTAL STRUCTURE OF WNK3 KINASE DOMAIN IN A MONOPHOSPHORYLATED STATE WITH CHLORIDE BOUND IN THE ACTIVE SITE
1827, d5hu3A_, 0.7098, 2.96, 0.157, 266, 254, DROSOPHILA CAMKII-D136N IN COMPLEX WITH A PHOSPHORYLATED FRAGMENT OF THE EAG POTASSIUM CHANNEL AND MG2+/ADP
1828, d5auuA_, 0.7098, 3.02, 0.180, 274, 255, CRYSTAL STRUCTURE OF DAPK1 IN COMPLEX WITH LUTEOLIN.
1829, d4ra4A_, 0.7098, 3.65, 0.183, 317, 268, CRYSTAL STRUCTURE OF HUMAN PROTEIN KINASE C ALPHA IN COMPLEX WITH COMPOUND 28 ((R)-6-((3S4S)-13-DIMETHYL-PIPERIDIN-4-YL)-7-(2-FLUORO- PHENYL)-4-METHYL-210-DIHYDRO-9-OXA-124A-TRIAZA-PHENANTHREN-3-ONE)
1830, d4kabB_, 0.7098, 3.11, 0.350, 258, 254, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH 3-METHYL-14- DIHYDRO-PYRAZOLO[45-C]PYRAZOLE
1831, d3wilA_, 0.7098, 3.15, 0.144, 331, 257, CRYSTAL STRUCTURE OF THE CK2ALPHA/COMPOUND3 COMPLEX
1832, d3vvhA1, 0.7098, 3.46, 0.186, 286, 263, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN COMPLEX WITH AN INHIBITOR AND MGATP
1833, d3ngaA_, 0.7098, 3.21, 0.143, 331, 258, HUMAN CK2 CATALYTIC DOMAIN IN COMPLEX WITH CX-4945
1834, d3my0B_, 0.7098, 3.05, 0.168, 295, 256, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
1835, d2wouA_, 0.7098, 2.92, 0.162, 299, 253, ALK5 IN COMPLEX WITH 4-((4-((26-DIMETHYL-3-PYRIDYL)OXY)-2- PYRIDYL)AMINO)BENZENESULFONAMIDE
1836, d1yhwA_, 0.7098, 3.53, 0.188, 293, 266, CRYSTAL STRUCTURE OF PAK1 KINASE DOMAIN WITH ONE POINT MUTATIONS (K299R)
1837, d1jktA_, 0.7098, 3.06, 0.179, 276, 257, TETRAGONAL CRYSTAL FORM OF A CATALYTIC DOMAIN OF DEATH-ASSOCIATED PROTEIN KINASE
1838, d4mneF_, 0.7097, 2.54, 0.220, 258, 246, CRYSTAL STRUCTURE OF THE BRAF:MEK1 COMPLEX
1839, d3ugcA_, 0.7097, 2.65, 0.310, 274, 248, STRUCTURAL BASIS OF JAK2 INHIBITION BY THE TYPE II INHIBTOR NVP-BBT594
1840, d3tn8A_, 0.7097, 3.38, 0.145, 304, 262, CDK9/CYCLIN T IN COMPLEX WITH CAN508
1841, d3rk9A_, 0.7097, 3.03, 0.181, 294, 254, CDK2 IN COMPLEX WITH INHIBITOR RC-2-74
1842, d3mtfA_, 0.7097, 2.87, 0.175, 296, 252, CRYSTAL STRUCTURE OF THE ACVR1 KINASE IN COMPLEX WITH A 2- AMINOPYRIDINE INHIBITOR
1843, p3be9A_, 0.7097, 3.20, 0.143, 327, 258, STRUCTURE-BASED DESIGN AND SYNTHESIS OF NOVEL MACROCYCLIC PYRAZOLO[15-A] [135]TRIAZINE COMPOUNDS AS POTENT INHIBITORS OF PROTEIN KINASE CK2 AND THEIR ANTICANCER ACTIVITIES
1844, d5c03B_, 0.7096, 2.62, 0.202, 260, 248, CRYSTAL STRUCTURE OF KINASE
1845, d4xcuA1, 0.7096, 3.38, 0.327, 287, 260, CRYSTAL STRUCTURE OF FGFR4 WITH AN IRREVERSIBLE INHIBITOR
1846, d4jajA_, 0.7096, 3.11, 0.182, 265, 258, CRYSTAL STRUCTURE OF AURORA KINASE A IN COMPLEX WITH BENZO[C][1 8]NAPHTHYRIDIN-6(5H)-ONE
1847, d4eqcA1, 0.7096, 3.48, 0.192, 292, 265, CRYSTAL STRUCTURE OF PAK1 KINASE DOMAIN IN COMPLEX WITH FRAX597 INHIBITOR
1848, d3wikA_, 0.7096, 3.20, 0.143, 334, 258, CRYSTAL STRUCTURE OF THE CK2ALPHA/COMPOUND10 COMPLEX
1849, d3uodA_, 0.7096, 3.23, 0.181, 266, 260, AURORA A IN COMPLEX WITH RPM1693
1850, d3mb6A_, 0.7096, 3.22, 0.151, 329, 258, HUMAN CK2 CATALYTIC DOMAIN IN COMPLEX WITH A DIFURANE DERIVATIVE INHIBITOR (CPA)
1851, d3ckxA_, 0.7096, 3.48, 0.228, 276, 263, CRYSTAL STRUCTURE OF STERILE 20-LIKE KINASE 3 (MST3 STK24) IN COMPLEX WITH STAUROSPORINE
1852, d4qmwA_, 0.7095, 3.60, 0.229, 286, 266, MST3 IN COMPLEX WITH PP-121 1-CYCLOPENTYL-3-(1H-PYRROLO[23- B]PYRIDIN-5-YL)-1H-PYRAZOLO[34-D]PYRIMIDIN-4-AMINE
1853, d3r28A_, 0.7095, 3.09, 0.169, 294, 255, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-140
1854, d3ngaB_, 0.7095, 3.22, 0.143, 331, 258, HUMAN CK2 CATALYTIC DOMAIN IN COMPLEX WITH CX-4945
1855, d5o21B_, 0.7094, 2.86, 0.199, 273, 251, CRYSTAL STRUCTURE OF WNK3 KINASE DOMAIN IN A MONOPHOSPHORYLATED STATE WITH CHLORIDE BOUND IN THE ACTIVE SITE
1856, d4ybjA_, 0.7094, 2.98, 0.289, 255, 253, TYPE II DASATINIB ANALOG CRYSTALLIZED WITH C-SRC KINASE
1857, p4nh1B_, 0.7094, 3.20, 0.143, 332, 258, CRYSTAL STRUCTURE OF A HETEROTETRAMERIC CK2 HOLOENZYME COMPLEX CARRYING THE ANDANTE-MUTATION IN CK2BETA AND CONSISTENT WITH PROPOSED MODELS OF AUTOINHIBITION AND TRANS-AUTOPHOSPHORYLATION
1858, d4f63B_, 0.7094, 3.18, 0.333, 271, 255, CRYSTAL STRUCTURE OF HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN IN COMPLEX WITH COMPOUND 1
1859, d3my0A1, 0.7094, 3.02, 0.169, 295, 255, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
1860, d3at2A_, 0.7094, 3.22, 0.143, 334, 258, CRYSTAL STRUCTURE OF CK2ALPHA
1861, d2i0yA_, 0.7094, 3.12, 0.311, 289, 254, CFMS TYROSINE KINASE (FGF KID) IN COMPLEX WITH AN ARYLAMIDE INHIBITOR
1862, d1ds5D_, 0.7094, 3.24, 0.151, 328, 258, DIMERIC CRYSTAL STRUCTURE OF THE ALPHA SUBUNIT IN COMPLEX WITH TWO BETA PEPTIDES MIMICKING THE ARCHITECTURE OF THE TETRAMERIC PROTEIN KINASE CK2 HOLOENZYME.
1863, d5tobA_, 0.7093, 2.52, 0.336, 245, 244, SELECTIVITY SWITCH BETWEEN FAK AND PYK2: MACROCYCLIZATION OF FAK INHIBITORS IMPROVES PYK2 POTENCY
1864, d3rk7A_, 0.7093, 3.04, 0.181, 294, 254, CDK2 IN COMPLEX WITH INHIBITOR RC-2-71
1865, d3rjcA_, 0.7093, 3.02, 0.181, 294, 254, CDK2 IN COMPLEX WITH INHIBITOR L4-12
1866, d3qzgA_, 0.7093, 3.03, 0.181, 294, 254, CDK2 IN COMPLEX WITH INHIBITOR JWS-6-76
1867, d3f3wA_, 0.7093, 3.18, 0.296, 261, 257, DRUG RESISTANT CSRC KINASE DOMAIN IN COMPLEX WITH INHIBITOR RL45 (TYPE II)
1868, p2pvnA_, 0.7093, 3.22, 0.147, 327, 258, STRUCTURE-BASED DESIGN OF PYRAZOLO[15-A][135]TRIAZINE DERIVATIVES AS POTENT INHIBITORS OF PROTEIN KINASE CK2
1869, d5hq0A1, 0.7092, 2.98, 0.184, 289, 255, TERNARY COMPLEX OF HUMAN PROTEINS CDK1 CYCLIN B AND CKS2 BOUND TO AN INHIBITOR
1870, d4y72A1, 0.7092, 2.98, 0.184, 289, 255, HUMAN CDK1/CYCLINB1/CKS2 WITH INHIBITOR
1871, p4nh1A_, 0.7092, 3.21, 0.143, 330, 258, CRYSTAL STRUCTURE OF A HETEROTETRAMERIC CK2 HOLOENZYME COMPLEX CARRYING THE ANDANTE-MUTATION IN CK2BETA AND CONSISTENT WITH PROPOSED MODELS OF AUTOINHIBITION AND TRANS-AUTOPHOSPHORYLATION
1872, p4gubA_, 0.7092, 3.24, 0.143, 329, 258, CASEIN KINASE II BOUND TO INHIBITOR
1873, d4c8bB_, 0.7092, 3.02, 0.206, 281, 253, STRUCTURE OF THE KINASE DOMAIN OF HUMAN RIPK2 IN COMPLEX WITH PONATINIB
1874, d3zm4A_, 0.7092, 3.63, 0.195, 309, 266, CRYSTAL STRUCTURE OF MEK1 IN COMPLEX WITH FRAGMENT 1
1875, d2fgiB_, 0.7092, 3.23, 0.332, 272, 256, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FGF RECEPTOR 1 IN COMPLEX WITH INHIBITOR PD173074
1876, d1uu7A_, 0.7092, 3.24, 0.208, 280, 259, STRUCTURE OF HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH BIM-2
1877, d4zjjA_, 0.7091, 2.94, 0.176, 280, 255, PAK1 IN COMPLEX WITH (S)-N-(TERT-BUTYL)-3-((2-CHLORO-5-ETHYL-8-FLUORO- DIBENZODIAZEPIN-11-YL)AMINO)PYRROLIDINE-1-CARBOXAMIDE
1878, p4md8F_, 0.7091, 3.22, 0.147, 332, 258, CRYSTAL STRUCTURE OF FULL-LENGTH SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E)
1879, d4fnzA_, 0.7091, 3.56, 0.251, 287, 263, CRYSTAL STRUCTURE OF HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH PIPERIDINE-CARBOXAMIDE INHIBITOR 2
1880, d4agdA_, 0.7091, 3.49, 0.307, 303, 261, CRYSTAL STRUCTURE OF VEGFR2 (JUXTAMEMBRANE AND KINASE DOMAINS) IN COMPLEX WITH SUNITINIB (SU11248) (N-2- DIETHYLAMINOETHYL)-5-((Z)-(5-FLUORO-2-OXO-1H-INDOL-3- YLIDENE)METHYL)-24-DIMETHYL-1H-PYRROLE-3-CARBOXAMIDE)
1881, d3q9xA_, 0.7091, 3.21, 0.143, 330, 258, CRYSTAL STRUCTURE OF HUMAN CK2 ALPHA IN COMPLEX WITH EMODIN AT PH 6.5
1882, d3q4uB1, 0.7091, 2.84, 0.172, 298, 250, CRYSTAL STRUCTURE OF THE ACVR1 KINASE DOMAIN IN COMPLEX WITH LDN- 193189
1883, d3cthA_, 0.7091, 3.63, 0.326, 295, 264, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF THE HEPATOCYTE GROWTH FACTOR RECEPTOR C-MET IN COMPLEX WITH A AMINOPYRIDINE BASED INHIBITOR
1884, d3u87A_, 0.7090, 3.21, 0.147, 329, 258, STRUCTURE OF A CHIMERIC CONSTRUCT OF HUMAN CK2ALPHA AND HUMAN CK2ALPHA  IN COMPLEX WITH A NON-HYDROLYSABLE ATP-ANALOGUE
1885, d3s0oA_, 0.7090, 3.08, 0.165, 293, 254, CDK2 IN COMPLEX WITH INHIBITOR RC-1-138
1886, d3qhwC1, 0.7090, 3.20, 0.167, 295, 258, STRUCTURE OF A PCDK2/CYCLINA TRANSITION-STATE MIMIC
1887, d3q9zB_, 0.7090, 3.22, 0.147, 332, 258, CRYSTAL STRUCTURE OF HUMAN CK2 ALPHA IN COMPLEX WITH QUINALIZARIN AT PH 6.5
1888, d3dtwA1, 0.7090, 3.12, 0.291, 281, 254, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A BENZISOXAZOLE INHIBITOR
1889, p5x02A_, 0.7089, 3.21, 0.345, 305, 255, CRYSTAL STRUCTURE OF THE FLT3 KINASE DOMAIN BOUND TO THE INHIBITOR FF- 10101
1890, d5sysB_, 0.7089, 3.17, 0.285, 258, 256, C-SRC V281C BOUND TO N-[3-({6-[(1E)-2-CYANO-3-(METHYLAMINO)-3-OXOPROP- 1-EN-1-YL]-7-(2-METHOXYETHYL)-7H-PYRROLO[23-D]PYRIMIDIN-5- YL}ETHYNYL)-4-METHYLPHENYL]-3-(TRIFLUOROMETHYL)BENZAMIDE INHIBITOR
1891, d5os5A_, 0.7089, 3.17, 0.182, 267, 258, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
1892, d5itaA_, 0.7089, 2.49, 0.209, 250, 244, CRYSTAL STRUCTURE OF BRAF KINASE DOMAIN BOUND TO AZ-VEM
1893, d5hznH_, 0.7089, 3.50, 0.309, 303, 259, STRUCTURE OF NVP-AEW541 IN COMPLEX WITH IGF-1R KINASE
1894, d4deeA_, 0.7089, 3.16, 0.181, 271, 259, AURORA A IN COMPLEX WITH ADP
1895, d3r8uA_, 0.7089, 3.15, 0.173, 294, 255, CDK2 IN COMPLEX WITH INHIBITOR RC-1-132
1896, d3qtiA_, 0.7089, 3.37, 0.333, 292, 258, C-MET KINASE IN COMPLEX WITH NVP-BVU972
1897, d3my0U1, 0.7089, 3.03, 0.169, 284, 255, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
1898, d2wouA1, 0.7089, 2.92, 0.162, 297, 253, ALK5 IN COMPLEX WITH 4-((4-((26-DIMETHYL-3-PYRIDYL)OXY)-2- PYRIDYL)AMINO)BENZENESULFONAMIDE
1899, d1ykrA_, 0.7089, 3.32, 0.174, 298, 258, CRYSTAL STRUCTURE OF CDK2 WITH AN AMINOIMIDAZO PYRIDINE INHIBITOR
1900, d1ds5C_, 0.7089, 3.25, 0.151, 328, 258, DIMERIC CRYSTAL STRUCTURE OF THE ALPHA SUBUNIT IN COMPLEX WITH TWO BETA PEPTIDES MIMICKING THE ARCHITECTURE OF THE TETRAMERIC PROTEIN KINASE CK2 HOLOENZYME.
1901, d3qhwA1, 0.7088, 3.20, 0.167, 295, 258, STRUCTURE OF A PCDK2/CYCLINA TRANSITION-STATE MIMIC
1902, d3my0L1, 0.7088, 3.02, 0.169, 295, 255, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
1903, d2yn8A_, 0.7088, 2.82, 0.299, 253, 251, EPHB4 KINASE DOMAIN INHIBITOR COMPLEX
1904, d1yhvA_, 0.7088, 3.54, 0.188, 293, 266, CRYSTAL STRUCTURE OF PAK1 KINASE DOMAIN WITH TWO POINT MUTATIONS (K299R T423E)
1905, d1pxpA_, 0.7088, 3.08, 0.181, 294, 254, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR N-[4-(24-DIMETHYL-THIAZOL-5-YL)-PYRIMIDIN-2-YL]- N N -DIMETHYL-BENZENE-14-DIAMINE
1906, d1ir3A_, 0.7088, 3.39, 0.303, 300, 261, PHOSPHORYLATED INSULIN RECEPTOR TYROSINE KINASE IN COMPLEX WITH PEPTIDE SUBSTRATE AND ATP ANALOG
1907, d5fm3A_, 0.7087, 3.24, 0.336, 276, 256, CRYSTAL STRUCTURE OF HYPER-PHOSPHORYLATED RET KINASE DOMAIN WITH (PROXIMAL) JUXTAMEMBRANE SEGMENT
1908, d5dfpA_, 0.7087, 3.49, 0.192, 292, 265, CRYSTAL STRUCTURE OF PAK1 IN COMPLEX WITH AN INHIBITOR COMPOUND FRAX1036
1909, d5autA_, 0.7087, 3.04, 0.180, 274, 255, CRYSTAL STRUCTURE OF DAPK1 IN COMPLEX WITH ANS.
1910, d3r8lA_, 0.7087, 3.09, 0.181, 294, 254, CDK2 IN COMPLEX WITH INHIBITOR L3-4
1911, d3gqlC_, 0.7087, 3.23, 0.337, 275, 258, CRYSTAL STRUCTURE OF ACTIVATED RECEPTOR TYROSINE KINASE IN COMPLEX WITH SUBSTRATES
1912, d1pxoA_, 0.7087, 3.11, 0.176, 294, 255, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR [4-(2-AMINO-4-METHYL-THIAZOL-5-YL)-PYRIMIDIN-2- YL]-(3-NITRO-PHENYL)-AMINE
1913, d5hznD_, 0.7086, 3.50, 0.309, 304, 259, STRUCTURE OF NVP-AEW541 IN COMPLEX WITH IGF-1R KINASE
1914, d4rwiB_, 0.7086, 3.20, 0.332, 280, 256, CRYSTAL STRUCTURE OF V561M FGFR1 GATEKEEPER MUTATION (C488A C584S V561M) APO
1915, d4rlkA_, 0.7086, 3.24, 0.143, 327, 258, CRYSTAL STRUCTURE OF Z. MAYS CK2ALPHA IN COMPLEX WITH THE ATP- COMPETITIVE INHIBITOR 4-[(E)-(FLUOREN-9-YLIDENEHYDRAZINYLIDENE)- METHYL] BENZOATE
1916, p4md9H_, 0.7086, 3.16, 0.144, 328, 257, CRYSTAL STRUCTURE OF SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E TRUNCATED AT AA 336)
1917, d4f0iA_, 0.7086, 2.88, 0.310, 284, 252, CRYSTAL STRUCTURE OF APO TRKA
1918, d3rm7A_, 0.7086, 3.09, 0.181, 294, 254, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-91
1919, d3r8zA_, 0.7086, 3.04, 0.182, 290, 253, CDK2 IN COMPLEX WITH INHIBITOR RC-1-136
1920, d3cs9A_, 0.7086, 2.61, 0.344, 264, 247, HUMAN ABL KINASE IN COMPLEX WITH NILOTINIB
1921, d1yolA_, 0.7086, 2.81, 0.280, 256, 250, CRYSTAL STRUCTURE OF SRC KINASE DOMAIN IN COMPLEX WITH CGP77675
1922, d1iepA1, 0.7086, 2.77, 0.341, 270, 249, CRYSTAL STRUCTURE OF THE C-ABL KINASE DOMAIN IN COMPLEX WITH STI-571.
1923, d1h1pA1, 0.7086, 3.32, 0.166, 295, 259, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH THE INHIBITOR NU2058
1924, d5ku8A_, 0.7085, 3.23, 0.147, 328, 258, CRYSTAL STRUCTURE OF CK2
1925, d4zjjB_, 0.7085, 2.90, 0.197, 277, 254, PAK1 IN COMPLEX WITH (S)-N-(TERT-BUTYL)-3-((2-CHLORO-5-ETHYL-8-FLUORO- DIBENZODIAZEPIN-11-YL)AMINO)PYRROLIDINE-1-CARBOXAMIDE
1926, d4k8aB_, 0.7085, 3.13, 0.345, 258, 255, FRAGMENT-BASED DISCOVERY OF FOCAL ADHESION KINASE INHIBITORS
1927, d2qi8A_, 0.7085, 2.80, 0.320, 255, 250, CRYSTAL STRUCTURE OF DRUG RESISTANT SRC KINASE DOMAIN
1928, p5n9lA_, 0.7084, 3.15, 0.148, 329, 257, CRYSTAL STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT IN COMPLEX WITH THE ATP-COMPETITIVE DIBENZOFURAN INHIBITOR TF (4B)
1929, d4u40B_, 0.7084, 3.50, 0.174, 299, 264, MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE KINASE 4 (MAP4K4) BOUND TO AMPPNP
1930, p4md8G_, 0.7084, 3.23, 0.147, 332, 258, CRYSTAL STRUCTURE OF FULL-LENGTH SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E)
1931, d4jboA_, 0.7084, 3.08, 0.183, 266, 257, NOVEL AURORA KINASE INHIBITORS REVEAL MECHANISMS OF HURP IN NUCLEATION OF CENTROSOMAL AND KINETOCHORE MICROTUBULES
1932, d4imyE_, 0.7084, 3.48, 0.151, 313, 265, THE AFF4 SCAFFOLD BINDS HUMAN P-TEFB ADJACENT TO HIV TAT
1933, d3r0tA_, 0.7084, 3.22, 0.151, 327, 258, CRYSTAL STRUCTURE OF HUMAN PROTEIN KINASE CK2 ALPHA SUBUNIT IN COMPLEX WITH THE INHIBITOR CX-5279
1934, d3qzfA_, 0.7084, 3.00, 0.182, 294, 253, CDK2 IN COMPLEX WITH INHIBITOR JWS-6-52
1935, d3qrtA_, 0.7084, 2.99, 0.182, 294, 253, CDK2 IN COMPLEX WITH INHIBITOR NSK-MC2-55
1936, d3qa0A_, 0.7084, 3.23, 0.143, 330, 258, CRYSTAL STRUCTURE OF THE APO-FORM OF HUMAN CK2 ALPHA AT PH 6.5
1937, d3q04A_, 0.7084, 3.18, 0.144, 328, 257, CRYSTAL STRUCTURE OF THE APO-FORM OF HUMAN CK2 ALPHA AT PH 8.5
1938, d3my0N1, 0.7084, 3.03, 0.169, 299, 255, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
1939, d1h1pC1, 0.7084, 3.35, 0.165, 295, 260, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH THE INHIBITOR NU2058
1940, d5e8xA_, 0.7083, 3.10, 0.160, 304, 257, TGF-BETA RECEPTOR TYPE 1 KINASE DOMAIN (T204DI211VY249FS280T Y282FS287NA350CL352F) IN COMPLEX WITH STAUROSPORINE
1941, d3u87B_, 0.7083, 3.22, 0.147, 329, 258, STRUCTURE OF A CHIMERIC CONSTRUCT OF HUMAN CK2ALPHA AND HUMAN CK2ALPHA  IN COMPLEX WITH A NON-HYDROLYSABLE ATP-ANALOGUE
1942, d3tiyA_, 0.7083, 3.03, 0.178, 293, 253, CDK2 IN COMPLEX WITH NSC 35676
1943, d3rniA_, 0.7083, 3.18, 0.173, 294, 255, CDK2 IN COMPLEX WITH INHIBITOR RC-3-86
1944, d5oy6A_, 0.7082, 2.80, 0.196, 291, 250, CRYSTAL STRUCTURE OF THE ACVR1 (ALK2) KINASE IN COMPLEX WITH CYCLICAL INHIBITOR OD36.
1945, d4gcjA1, 0.7082, 3.04, 0.185, 298, 254, CDK2 IN COMPLEX WITH INHIBITOR RC-3-89
1946, d3tizA_, 0.7082, 3.08, 0.185, 293, 254, CDK2 IN COMPLEX WITH NSC 111848
1947, d3qtqA_, 0.7082, 3.07, 0.181, 294, 254, CDK2 IN COMPLEX WITH INHIBITOR RC-1-137
1948, d3qhrC1, 0.7082, 3.20, 0.167, 295, 258, STRUCTURE OF A PCDK2/CYCLINA TRANSITION-STATE MIMIC
1949, d3qhrA1, 0.7082, 3.20, 0.167, 295, 258, STRUCTURE OF A PCDK2/CYCLINA TRANSITION-STATE MIMIC
1950, d2f57B1, 0.7082, 3.49, 0.175, 293, 263, CRYSTAL STRUCTURE OF THE HUMAN P21-ACTIVATED KINASE 5
1951, d5xy1A1, 0.7081, 2.71, 0.313, 252, 249, CRYSTAL STRUCTURE OF LYN KINASE DOMAIN IN COMPLEX WITH N-(1H-INDAZOL- 6-YL)-8-(PIPERIDIN-4-YLOXY)-6-PROPYLQUINAZOLIN-2-AMINE
1952, d2a0cX_, 0.7081, 3.01, 0.182, 294, 253, HUMAN CDK2 IN COMPLEX WITH OLOMOUCINE II A NOVEL 269- TRISUBSTITUTED PURINE CYCLIN-DEPENDENT KINASE INHIBITOR
1953, d1lp4A_, 0.7081, 3.24, 0.143, 327, 258, CRYSTAL STRUCTURE OF A BINARY COMPLEX OF THE CATALYTIC SUBUNIT OF PROTEIN KINASE CK2 WITH MG-AMPPNP
1954, p5n9nA_, 0.7080, 3.09, 0.145, 329, 256, CRYSTAL STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT IN COMPLEX WITH THE ATP-COMPETITIVE TIGHT-BINDING DIBENZOFURAN INHIBITOR TF85 (4A)
1955, d4r7hA_, 0.7080, 3.24, 0.294, 308, 255, CRYSTAL STRUCTURE OF FMS KINASE DOMAIN WITH A SMALL MOLECULAR INHIBITOR PLX3397
1956, d4dgnA_, 0.7080, 3.24, 0.143, 325, 258, CRYSTAL STRUCTURE OF MAIZE CK2 IN COMPLEX WITH THE INHIBITOR LUTEOLIN
1957, d4bxaA_, 0.7080, 3.16, 0.148, 331, 257,  
1958, d3q9wA_, 0.7080, 3.25, 0.147, 328, 258, CRYSTAL STRUCTURE OF HUMAN CK2 ALPHA IN COMPLEX WITH EMODIN AT PH 8.5
1959, d3lm0A1, 0.7080, 2.91, 0.183, 271, 252, CRYSTAL STRUCTURE OF HUMAN SERINE/THREONINE KINASE 17B (STK17B)
1960, d2zv8A1, 0.7080, 2.86, 0.317, 256, 252, LYN TYROSINE KINASE DOMAIN-AMP-PNP COMPLEX
1961, d5hzeA_, 0.7079, 3.55, 0.189, 305, 264, MEK1 ADOPTS DFG-OUT CONFORMATION WHEN BOUND TO AN ANALOG OF E6201.
1962, d5c03A_, 0.7079, 2.61, 0.202, 260, 247, CRYSTAL STRUCTURE OF KINASE
1963, d4ypsA1, 0.7079, 2.70, 0.302, 275, 248, (R)-2-PHENYLPYRROLIDINE SUBSTITUTE IMIDAZOPYRIDAZINES: A NEW CLASS OF POTENT AND SELECTIVE PAN-TRK INHIBITORS
1964, p4md8H_, 0.7079, 3.23, 0.147, 331, 258, CRYSTAL STRUCTURE OF FULL-LENGTH SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E)
1965, d3pe2A_, 0.7079, 3.19, 0.144, 327, 257, CRYSTAL STRUCTURE OF HUMAN PROTEIN KINASE CK2 IN COMPLEX WITH THE INHIBITOR CX-5011
1966, d4rqvA_, 0.7078, 3.55, 0.197, 288, 264, CRYSTAL STRUCTURE OF PDK1 IN COMPLEX WITH ATP AND THE PIF-POCKET LIGAND RS2
1967, d4pmpA1, 0.7078, 2.71, 0.306, 276, 248, THE STRUCTURE OF TRKA KINASE BOUND TO THE INHIBITOR 1-CYCLOPROPYL-1- [3-(13-THIAZOL-2-YL)BENZYL]-3-[4-(TRIFLUOROMETHOXY)PHENYL]UREA
1968, d4d4sA_, 0.7078, 2.95, 0.347, 255, 251, FOCAL ADHESION KINASE CATALYTIC DOMAIN
1969, d3v5lD1, 0.7078, 2.25, 0.307, 244, 241, CRYSTAL STRUCTURE OF INTERLEUKIN-2 INDUCIBLE T-CELL KINASE ITK CATALYTIC DOMAIN WITH THIENOPYRAZOLYLINDOLE INHIBITOR 542
1970, d3r7vA_, 0.7078, 3.11, 0.181, 294, 254, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-9
1971, d3qqfA_, 0.7078, 3.16, 0.176, 294, 255, CDK2 IN COMPLEX WITH INHIBITOR L1
1972, d3pxrA_, 0.7078, 3.14, 0.173, 294, 255, APO CDK2 CRYSTALLIZED FROM JEFFAMINE
1973, d5cqwB_, 0.7077, 3.24, 0.147, 331, 258, TETRAGONAL COMPLEX STRUCTURE OF PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH A BENZOTRIAZOLE-BASED INHIBITOR GENERATED BY CLICK-CHEMISTRY
1974, d4bxaB_, 0.7077, 3.25, 0.147, 331, 258,  
1975, d3u6jA1, 0.7077, 3.46, 0.307, 305, 261, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A PYRAZOLONE INHIBITOR
1976, d3rp0C_, 0.7077, 3.23, 0.147, 329, 258,  
1977, d3r9hA_, 0.7077, 3.01, 0.182, 294, 253, CDK2 IN COMPLEX WITH INHIBITOR RC-2-142
1978, d3r7eA_, 0.7077, 3.17, 0.176, 294, 255, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-67
1979, d3krjA_, 0.7077, 3.22, 0.303, 304, 254, CFMS TYROSINE KINASE IN COMPLEX WITH 4-CYANO-1H-IMIDAZOLE-2-CARBOXYLIC ACID (2-CYCLOHEX-1-ENYL-4-PIPERIDIN-4-YL-PHENYL)-AMIDE
1980, d1fgiB_, 0.7077, 3.29, 0.328, 272, 256, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FIBROBLAST GROWTH FACTOR RECEPTOR 1 IN COMPLEX WITH SU5402 INHIBITOR
1981, d1dawA_, 0.7077, 3.24, 0.143, 327, 258, CRYSTAL STRUCTURE OF A BINARY COMPLEX OF PROTEIN KINASE CK2 (ALPHA-SUBUNIT) AND MG-AMPPNP
1982, d5cqwA_, 0.7076, 3.25, 0.143, 331, 258, TETRAGONAL COMPLEX STRUCTURE OF PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH A BENZOTRIAZOLE-BASED INHIBITOR GENERATED BY CLICK-CHEMISTRY
1983, d4dgmA_, 0.7076, 3.25, 0.143, 326, 258, CRYSTAL STRUCTURE OF MAIZE CK2 IN COMPLEX WITH THE INHIBITOR APIGENIN
1984, d4agwB_, 0.7076, 3.01, 0.280, 257, 254, DISCOVERY OF A SMALL MOLECULE TYPE II INHIBITOR OF WILD- TYPE AND GATEKEEPER MUTANTS OF BCR-ABL PDGFRALPHA KIT AND SRC KINASES
1985, d4ae9A_, 0.7076, 3.62, 0.175, 321, 269, STRUCTURE AND FUNCTION OF THE HUMAN SPERM-SPECIFIC ISOFORM OF PROTEIN KINASE A (PKA) CATALYTIC SUBUNIT C ALPHA 2
1986, d3r1sA_, 0.7076, 3.17, 0.173, 294, 255, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-127
1987, d3qxoA_, 0.7076, 3.00, 0.186, 294, 253, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-84
1988, d3qgwA_, 0.7076, 2.40, 0.309, 244, 243, CRYSTAL STRUCTURE OF ITK KINASE BOUND TO AN INHIBITOR
1989, d3q9zA_, 0.7076, 3.16, 0.144, 332, 257, CRYSTAL STRUCTURE OF HUMAN CK2 ALPHA IN COMPLEX WITH QUINALIZARIN AT PH 6.5
1990, d3pe1A_, 0.7076, 3.24, 0.147, 327, 258, CRYSTAL STRUCTURE OF HUMAN PROTEIN KINASE CK2 ALPHA SUBUNIT IN COMPLEX WITH THE INHIBITOR CX-4945
1991, d1ds5B_, 0.7076, 3.27, 0.151, 328, 258, DIMERIC CRYSTAL STRUCTURE OF THE ALPHA SUBUNIT IN COMPLEX WITH TWO BETA PEPTIDES MIMICKING THE ARCHITECTURE OF THE TETRAMERIC PROTEIN KINASE CK2 HOLOENZYME.
1992, d5os4A_, 0.7075, 3.10, 0.180, 264, 256, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
1993, p4md8E_, 0.7075, 3.24, 0.147, 332, 258, CRYSTAL STRUCTURE OF FULL-LENGTH SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E)
1994, d4ebvA1, 0.7075, 3.20, 0.337, 261, 255, STRUCTURE OF FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH NOVEL ALLOSTERIC INHIBITOR
1995, p2pvhA_, 0.7075, 3.25, 0.147, 327, 258, STRUCTURE-BASED DESIGN OF PYRAZOLO[15-A][135]TRIAZINE DERIVATIVES AS POTENT INHIBITORS OF PROTEIN KINASE CK2
1996, d2hyyA_, 0.7075, 2.67, 0.344, 263, 247, HUMAN ABL KINASE DOMAIN IN COMPLEX WITH IMATINIB (STI571 GLIVEC)
1997, d5t1hA_, 0.7074, 3.25, 0.147, 331, 258, CRYSTAL STRUCTURE OF CK2
1998, d3r73A_, 0.7074, 3.03, 0.186, 294, 253, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-164
1999, d1okyA_, 0.7074, 3.22, 0.209, 281, 258, STRUCTURE OF HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH STAUROSPORINE
2000, d4xx9A_, 0.7073, 3.60, 0.201, 288, 264, CRYSTAL STRUCTURE OF PDK1 IN COMPLEX WITH ATP AND THE PIF-POCKET LIGAND RF4
2001, d4rwkB_, 0.7073, 3.31, 0.333, 282, 258, CRYSTAL STRUCTURE OF V561M FGFR1 GATEKEEPER MUTATION (C488A C584S V561M) IN COMPLEX WITH N-{3-[2-(35-DIMETHOXYPHENYL)ETHYL]-1H- PYRAZOL-5-YL}-4-[(3R5S)-35-DIMETHYLPIPERAZIN-1-YL]BENZAMIDE (AZD4547)
2002, d4aw1A_, 0.7073, 3.50, 0.203, 283, 261, HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH ALLOSTERIC COMPOUND PS210 BOUND TO THE PIF-POCKET
2003, d3qxpA_, 0.7073, 3.01, 0.183, 294, 252, CDK2 IN COMPLEX WITH INHIBITOR RC-3-89
2004, d3ofmA_, 0.7073, 3.26, 0.124, 325, 259, STRUCTURE OF A HUMAN CK2ALPHA PRIME THE PARALOG ISOFORM OF THE CATALYTIC SUBUNIT OF PROTEIN KINASE CK2 FROM HOMO SAPIENS
2005, d3ms9B1, 0.7073, 2.67, 0.340, 267, 247, ABL KINASE IN COMPLEX WITH IMATINIB AND A FRAGMENT (FRAG1) IN THE MYRISTATE POCKET
2006, d3c13A_, 0.7073, 3.22, 0.144, 328, 257, LOW PH-VALUE CRYSTAL STRUCTURE OF EMODIN IN COMPLEX WITH THE CATALYTIC SUBUNIT OF PROTEIN KINASE CK2
2007, d4nksB_, 0.7072, 3.22, 0.333, 271, 255, CRYSTAL STRUCTURE OF HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN IN COMPLEX WITH PYRAZOLAMINOPYRIMIDINE 3
2008, d3rp0B_, 0.7072, 3.24, 0.147, 329, 258,  
2009, d5orpA_, 0.7071, 3.10, 0.180, 264, 256, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
2010, d3r6xA_, 0.7071, 3.04, 0.186, 294, 253, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-158
2011, d3r1qA_, 0.7071, 3.13, 0.173, 294, 255, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-102
2012, d3qzhA_, 0.7071, 3.14, 0.169, 294, 255, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-124
2013, d3qx4A_, 0.7071, 3.12, 0.181, 294, 254, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-78
2014, d3mb7A_, 0.7071, 3.27, 0.147, 330, 258, HUMAN CK2 CATALYTIC DOMAIN IN COMPLEX WITH A DIFURANE DERIVATIVE INHIBITOR (AMR)
2015, d3g0fB_, 0.7071, 3.25, 0.297, 293, 256, KIT KINASE DOMAIN MUTANT D816H IN COMPLEX WITH SUNITINIB
2016, d1dayA_, 0.7071, 3.26, 0.140, 327, 258, CRYSTAL STRUCTURE OF A BINARY COMPLEX OF PROTEIN KINASE CK2 (ALPHA-SUBUNIT) AND MG-GMPPNP
2017, d5os6A_, 0.7070, 3.10, 0.180, 264, 256, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
2018, d3royA_, 0.7070, 3.14, 0.169, 294, 255, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-154
2019, d3lvpC_, 0.7070, 3.39, 0.297, 293, 259, CRYSTAL STRUCTURE OF BISPHOSPHORYLATED IGF1-R KINASE DOMAIN (2P) IN COMPLEX WITH A BIS-AZAINDOLE INHIBITOR
2020, d3a7jA_, 0.7070, 3.69, 0.228, 286, 267, HUMAN MST3 KINASE IN COMPLEX WITH MNADP
2021, d5ax9A_, 0.7069, 3.04, 0.182, 282, 253, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN TRAF2 AND NCK- INTERACTING PROTEIN KINASE IN COMPLEX WITH COMPUND 9
2022, d3ce3A_, 0.7069, 3.61, 0.326, 293, 261, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF THE HEPATOCYTE GROWTH FACTOR RECEPTOR C-MET IN COMPLEX WITH A PYRROLOPYRIDINEPYRIDONE BASED INHIBITOR
2023, d5osfA_, 0.7068, 3.11, 0.180, 264, 256, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
2024, d5oseA_, 0.7068, 3.11, 0.180, 264, 256, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
2025, d5nkaA_, 0.7068, 3.17, 0.322, 271, 255, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 2G
2026, d5b0xA_, 0.7068, 3.23, 0.143, 329, 258, CRYSTAL STRUCTURE OF THE CK2A/BENZOIC ACID DERIVATIVE COMPLEX
2027, d4dgoA_, 0.7068, 3.27, 0.143, 325, 258, CRYSTAL STRUCTURE OF MAIZE CK2 IN COMPLEX WITH TYRPHOSTIN AG99
2028, d3d5uA_, 0.7068, 3.47, 0.193, 288, 264, CRYSTAL STRUCTURE OF A WILDTYPE POLO-LIKE KINASE 1 (PLK1) CATALYTIC DOMAIN.
2029, p2pvmA_, 0.7068, 3.26, 0.143, 327, 258, STRUCTURE-BASED DESIGN OF PYRAZOLO[15-A][135]TRIAZINE DERIVATIVES AS POTENT INHIBITORS OF PROTEIN KINASE CK2
2030, p2pvkA_, 0.7068, 3.25, 0.140, 327, 258, STRUCTURE-BASED DESIGN OF PYRAZOLO[15-A][135]TRIAZINE DERIVATIVES AS POTENT INHIBITORS OF PROTEIN KINASE CK2
2031, d5uglB_, 0.7067, 3.20, 0.327, 271, 254, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 TYROSINE KINASE DOMAIN HARBORING THE D650V ACTIVATING MUTATION
2032, d5orvA_, 0.7067, 3.11, 0.180, 264, 256, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
2033, d5motA_, 0.7067, 3.24, 0.151, 328, 258, CRYSTAL STRUCTURE OF CK2ALPHA WITH ZT0627 BOUND
2034, d4deaA_, 0.7067, 3.25, 0.181, 266, 260, AURORA A IN COMPLEX WITH YL1-038-18
2035, d4bxbA_, 0.7067, 3.22, 0.144, 328, 257,  
2036, d3tz9B_, 0.7067, 3.11, 0.295, 259, 254, KINASE DOMAIN OF CSRC IN COMPLEX WITH RL130
2037, d3f3vA_, 0.7067, 3.22, 0.292, 261, 257, KINASE DOMAIN OF CSRC IN COMPLEX WITH INHIBITOR RL45 (TYPE II)
2038, d3dkgA_, 0.7067, 3.30, 0.339, 281, 254, STRUCTURE OF MUTANT(Y1248L) MET RECEPTOR TYROSINE KINASE IN COMPLEX WITH INHIBITOR SGX-523
2039, d3bqcA_, 0.7067, 3.22, 0.144, 328, 257, HIGH PH-VALUE CRYSTAL STRUCTURE OF EMODIN IN COMPLEX WITH THE CATALYTIC SUBUNIT OF PROTEIN KINASE CK2
2040, d1uwhB_, 0.7067, 3.03, 0.217, 264, 253, THE COMPLEX OF WILD TYPE B-RAF AND BAY439006
2041, d5orzA_, 0.7066, 3.10, 0.180, 264, 256, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
2042, d5oroA_, 0.7066, 3.10, 0.180, 264, 256, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
2043, d5mohA_, 0.7066, 3.17, 0.148, 326, 257, CRYSTAL STRUCTURE OF CK2ALPHA WITH ZT0583 BOUND.
2044, d5cquA_, 0.7066, 3.22, 0.144, 328, 257, MONOCLINIC COMPLEX STRUCTURE OF PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH A BENZOTRIAZOLE-BASED INHIBITOR GENERATED BY CLICK-CHEMISTRY
2045, d4fbxA_, 0.7066, 3.24, 0.151, 333, 258, COMPLEX STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT CRYSTALLIZED IN THE PRESENCE OF A BISUBSTRATE INHIBITOR
2046, d3qwkA_, 0.7066, 3.04, 0.182, 294, 253, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-150
2047, d3q4tA1, 0.7066, 2.66, 0.190, 294, 248, CRYSTAL STRUCTURE OF ACTIVIN RECEPTOR TYPE-IIA (ACVR2A) KINASE DOMAIN IN COMPLEX WITH DORSOMORPHIN
2048, d3cp9B_, 0.7066, 2.85, 0.306, 269, 248, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A PYRIDONE INHIBITOR
2049, d3b8rA1, 0.7066, 3.15, 0.300, 282, 253, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A NAPHTHAMIDE INHIBITOR
2050, d2i0vA_, 0.7066, 3.40, 0.300, 303, 257, C-FMS TYROSINE KINASE IN COMPLEX WITH A QUINOLONE INHIBITOR
2051, d2hiwA1, 0.7066, 3.02, 0.336, 270, 253, CRYSTAL STRUCTURE OF INACTIVE CONFORMATION ABL KINASE CATALYTIC DOMAIN COMPLEXED WITH TYPE II INHIBITOR
2052, d2b54A_, 0.7066, 3.30, 0.178, 298, 258, HUMAN CYCLIN DEPENDENT KINASE 2 (CKD2)COMPLEXED WITH DIN- 232305
2053, d1lpuA_, 0.7066, 3.26, 0.143, 327, 258, LOW TEMPERATURE CRYSTAL STRUCTURE OF THE APO-FORM OF THE CATALYTIC SUBUNIT OF PROTEIN KINASE CK2 FROM ZEA MAYS
2054, p5owlB_, 0.7065, 3.26, 0.147, 332, 258, LOW SALT STRUCTURE OF HUMAN PROTEIN KINASE CK2ALPHA IN COMPLEX WITH 3- AMINOPROPYL-4;5;6;7-TETRABROMOBENZIMIDAZOL 
2055, d5ornA_, 0.7065, 3.11, 0.180, 264, 256, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
2056, d4ez3A_, 0.7065, 3.09, 0.186, 294, 253, CDK2 IN COMPLEX WITH NSC 134199
2057, d3pxkA_, 0.7065, 3.03, 0.349, 256, 252, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH PYRROLO[23- D]THIAZOLE
2058, d3kmwA_, 0.7065, 2.97, 0.209, 268, 254, CRYSTAL STRUCTURE OF THE ILK/ALPHA-PARVIN CORE COMPLEX (MGATP)
2059, p2pvlA_, 0.7065, 3.25, 0.147, 327, 258, STRUCTURE-BASED DESIGN OF PYRAZOLO[15-A][135]TRIAZINE DERIVATIVES AS POTENT INHIBITORS OF PROTEIN KINASE CK2
2060, d4yjqA_, 0.7064, 3.22, 0.335, 264, 254, SYK KINASE DOMAIN IN COMPLEX WITH INHIBITOR GTC000224
2061, d4wunA_, 0.7064, 3.14, 0.307, 282, 254, STRUCTURE OF FGFR1 IN COMPLEX WITH AZD4547 (N-{3-[2-(35- DIMETHOXYPHENYL)ETHYL]-1H-PYRAZOL-5-YL}-4-[(3R5S)-35- DIMETHYLPIPERAZIN-1-YL]BENZAMIDE) AT 1.65 ANGSTROM
2062, d3tz8A_, 0.7064, 3.26, 0.291, 261, 258, KINASE DOMAIN OF CSRC IN COMPLEX WITH RL104
2063, d3repA_, 0.7064, 3.05, 0.208, 268, 255, CRYSTAL STRUCTURE OF THE ILK/ALPHA-PARVIN CORE COMPLEX (MNATP)
2064, d3raiA_, 0.7064, 3.13, 0.177, 294, 254, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-160
2065, d3my0E1, 0.7064, 3.02, 0.165, 293, 254, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
2066, d3a8xB1, 0.7064, 3.51, 0.177, 325, 266, CRYSTAL STRUCTURE OF PKCIOTA KINASE DOMAIN
2067, d5os0A_, 0.7063, 3.11, 0.180, 264, 256, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
2068, d4f65A_, 0.7063, 3.35, 0.307, 279, 257, CRYSTAL STRUCTURE OF HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN IN COMPLEX WITH COMPOUND 8
2069, d3g0eA1, 0.7063, 3.17, 0.305, 330, 256, KIT KINASE DOMAIN IN COMPLEX WITH SUNITINIB
2070, d3el7A_, 0.7063, 2.98, 0.295, 254, 251, CRYSTAL STRUCTURE OF C-SRC IN COMPLEX WITH PYRAZOLOPYRIMIDINE 3
2071, d2qo9A_, 0.7063, 3.45, 0.303, 277, 261, HUMAN EPHA3 KINASE AND JUXTAMEMBRANE REGION PHOSPHORYLATED AMP-PNP BOUND
2072, d1zogA_, 0.7063, 3.24, 0.151, 325, 258, CRYSTAL STRUCTURE OF PROTEIN KINASE CK2 IN COMPLEX WITH TBB- DERIVATIVES
2073, d1pxjA_, 0.7063, 3.05, 0.182, 294, 253, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR 4-(24-DIMETHYL-THIAZOL-5-YL)-PYRIMIDIN-2-YLAMINE
2074, p5n9kA_, 0.7062, 3.19, 0.144, 329, 257, CRYSTAL STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT IN COMPLEX WITH THE ATP-COMPETITIVE TIGHT-BINDING DIBENZOFURAN INHIBITOR TF107 (5)
2075, d4yjvA_, 0.7062, 3.19, 0.341, 263, 252, THE KINASE DOMAIN OF HUMAN SPLEEN TYROSINE (SYK) IN COMPLEX WITH GTC000250
2076, d4w9xA_, 0.7062, 2.97, 0.143, 300, 252, CRYSTAL STRUCTURE OF BMP-2-INDUCIBLE KINASE IN COMPLEX WITH BARICITINIB
2077, d4kd1A_, 0.7062, 3.31, 0.174, 298, 259, CDK2 IN COMPLEX WITH DINACICLIB
2078, d3socB1, 0.7062, 2.98, 0.187, 294, 252, CRYSTAL STRUCTURE OF ACTIVIN RECEPTOR TYPE-IIA (ACVR2A) KINASE DOMAIN IN COMPLEX WITH A QUINAZOLIN
2079, d2qq7A_, 0.7062, 2.72, 0.316, 251, 247, CRYSTAL STRUCTURE OF DRUG RESISTANT SRC KINASE DOMAIN WITH IRREVERSIBLE INHIBITOR
2080, d2p2iB_, 0.7062, 2.73, 0.305, 263, 246, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A NICOTINAMIDE INHIBITOR
2081, d5os1A_, 0.7061, 3.11, 0.180, 264, 256, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
2082, d5li9A1, 0.7061, 3.76, 0.160, 328, 269, STRUCTURE OF A NUCLEOTIDE-BOUND FORM OF PKCIOTA CORE KINASE DOMAIN
2083, d3zfxC_, 0.7061, 2.62, 0.317, 248, 246, CRYSTAL STRUCTURE OF EPHB1
2084, d3qwjA_, 0.7061, 3.03, 0.182, 294, 253, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-142
2085, d3qlfA_, 0.7061, 2.67, 0.285, 249, 246, CRYSTAL STRUCTURE OF THE L317I MUTANT OF THE C-SRC TYROSINE KINASE DOMAIN COMPLEXED WITH PYRAZOLOPYRIMIDINE 5
2086, d3owkA_, 0.7061, 3.24, 0.148, 330, 257, HUMAN CK2 CATALYTIC DOMAIN IN COMPLEX WITH A BENZOPYRIDOINDOLE DERIVATIVE INHIBITOR
2087, d3kxgA_, 0.7061, 3.26, 0.147, 326, 258, CRYSTAL STRUCTURE OF Z. MAYS CK2 KINASE ALPHA SUBUNIT IN COMPLEX WITH THE INHIBITOR 34567-PENTABROMO-1H-INDAZOLE (K64)
2088, d2wxvA1, 0.7061, 3.36, 0.153, 298, 262, STRUCTURE OF CDK2-CYCLIN A WITH A PYRAZOLO(43-H) QUINAZOLINE-3-CARBOXAMIDE INHIBITOR
2089, d1yolB_, 0.7061, 2.92, 0.279, 253, 251, CRYSTAL STRUCTURE OF SRC KINASE DOMAIN IN COMPLEX WITH CGP77675
2090, d5vamA_, 0.7060, 3.05, 0.217, 269, 254, BRAF IN COMPLEX WITH RAF709
2091, d5oy6C_, 0.7060, 2.84, 0.196, 291, 250, CRYSTAL STRUCTURE OF THE ACVR1 (ALK2) KINASE IN COMPLEX WITH CYCLICAL INHIBITOR OD36.
2092, d5os3A_, 0.7060, 3.11, 0.180, 264, 256, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
2093, d5anjA_, 0.7060, 3.23, 0.164, 291, 256, CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH N-(9H-PURIN-6-YL) THIOPHENE-2-CARBOXAMIDE  PROCESSED WITH THE CRYSTALDIRECT AUTOMATED MOUNTING AND CRYO-COOLING TECHNOLOGY
2094, d3r1yA_, 0.7060, 3.20, 0.176, 294, 255, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-134
2095, d3qziA_, 0.7060, 3.16, 0.173, 294, 255, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-126
2096, d3pzhA_, 0.7060, 3.28, 0.143, 327, 258, CRYSTAL STRUCTURE OF MAIZE CK2 ALPHA IN COMPLEX WITH EMODIN AT 1.92 A RESOLUTION
2097, d3my0R1, 0.7060, 3.02, 0.169, 293, 254, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
2098, d3my0G1, 0.7060, 3.02, 0.169, 293, 254, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
2099, d5nk0A_, 0.7059, 3.24, 0.319, 273, 257, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 1J
2100, d4imyA_, 0.7059, 3.52, 0.151, 314, 265, THE AFF4 SCAFFOLD BINDS HUMAN P-TEFB ADJACENT TO HIV TAT
2101, d3rkbA_, 0.7059, 3.13, 0.182, 294, 253, CDK2 IN COMPLEX WITH INHIBITOR RC-2-73
2102, d3nrmA_, 0.7059, 3.11, 0.183, 263, 257, IMIDAZO[12-A]PYRAZINE-BASED AURORA KINASE INHIBITORS
2103, d5orwA_, 0.7058, 3.12, 0.180, 264, 256, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
2104, d5orrA_, 0.7058, 3.11, 0.180, 264, 256, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
2105, d5e8yA_, 0.7058, 2.95, 0.202, 298, 252, TGF-BETA RECEPTOR TYPE 2 KINASE DOMAIN (E431AR433AE485AK488AR493A R495A) IN COMPLEX WITH STAUROSPORINE
2106, p4md9M_, 0.7058, 3.25, 0.147, 331, 258, CRYSTAL STRUCTURE OF SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E TRUNCATED AT AA 336)
2107, d4asxA1, 0.7058, 2.87, 0.184, 295, 250, CRYSTAL STRUCTURE OF ACTIVIN RECEPTOR TYPE-IIA (ACVR2A) KINASE DOMAIN IN COMPLEX WITH DIHYDRO-BAUERINE C
2108, d3my0F1, 0.7058, 3.04, 0.169, 293, 254, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
2109, d2qocA_, 0.7058, 3.30, 0.309, 283, 259, HUMAN EPHA3 KINASE DOMAIN PHOSPHORYLATED AMP-PNP BOUND STRUCTURE
2110, d5p9lA_, 0.7057, 2.90, 0.305, 252, 249, BTK1 IN COMPLEX WITH CC 292
2111, d4cnhA_, 0.7057, 3.60, 0.268, 285, 261, STRUCTURE OF THE HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH THE INHIBITOR 3-((1R)-1-(5-FLUORO-2- METHOXYPHENYL)ETHOXY)-5-(1-METHYL-1H-123-TRIAZOL-5-YL) PYRIDIN-2-AMINE
2112, d2ofvA2, 0.7057, 2.29, 0.289, 243, 239, CRYSTAL STRUCTURE OF AMINOQUINAZOLINE 1 BOUND TO LCK
2113, d1zohA_, 0.7057, 3.28, 0.147, 326, 258, CRYSTAL STRUCTURE OF PROTEIN KINASE CK2 IN COMPLEX WITH TBB- DERIVATIVES INHIBITORS
2114, d1m2qA_, 0.7057, 3.27, 0.151, 327, 258, CRYSTAL STRUCTURE OF 18-DI-HYDROXY-4-NITRO-XANTEN-9- ONE/CK2 KINASE COMPLEX
2115, d5oryA_, 0.7056, 3.12, 0.180, 264, 256, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
2116, d3my0H1, 0.7056, 3.04, 0.173, 293, 254, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
2117, d3kxmA_, 0.7056, 3.27, 0.147, 326, 258, CRYSTAL STRUCTURE OF Z. MAYS CK2 KINASE ALPHA SUBUNIT IN COMPLEX WITH THE INHIBITOR K74
2118, d2g9xC2, 0.7056, 3.32, 0.166, 273, 259, STRUCTURE OF THR 160 PHOSPHORYLATED CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR NU6271
2119, d1hckA_, 0.7056, 3.23, 0.180, 294, 255, HUMAN CYCLIN-DEPENDENT KINASE 2
2120, d4p2wA_, 0.7055, 2.77, 0.323, 250, 248,  
2121, p4md9G_, 0.7055, 3.21, 0.148, 329, 257, CRYSTAL STRUCTURE OF SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E TRUNCATED AT AA 336)
2122, d3up2A_, 0.7055, 3.26, 0.181, 266, 260, AURORA A IN COMPLEX WITH RPM1686
2123, d3pvgA_, 0.7055, 3.28, 0.143, 326, 258, CRYSTAL STRUCTURE OF Z. MAYS CK2 ALPHA SUBUNIT IN COMPLEX WITH THE INHIBITOR 4567-TETRABROMO-1-CARBOXYMETHYLBENZIMIDAZOLE (K68)
2124, d3kxjA_, 0.7055, 3.28, 0.143, 326, 258,  
2125, d3hmmA_, 0.7055, 2.87, 0.167, 293, 251, STRUCTURE OF ALK5 + GW855857
2126, d2qobA_, 0.7055, 3.44, 0.305, 279, 259, HUMAN EPHA3 KINASE DOMAIN BASE STRUCTURE
2127, d5orxA_, 0.7054, 3.13, 0.180, 264, 256, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
2128, d5orsA_, 0.7054, 3.12, 0.180, 264, 256, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
2129, d5ackA_, 0.7054, 3.55, 0.198, 286, 263, HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH ALLOSTERIC COMPOUND 7 BOUND TO THE PIF-POCKET
2130, d4uxqA_, 0.7054, 3.17, 0.314, 286, 255, FGFR4 IN COMPLEX WITH PONATINIB
2131, d4uwyB_, 0.7054, 3.15, 0.328, 273, 253, FGFR1 APO STRUCTURE
2132, d4pmsA1, 0.7054, 2.87, 0.308, 279, 250, THE STRUCTURE OF TRKA KINASE BOUND TO THE INHIBITOR 4-NAPHTHALEN-1-YL- 1-[(5-PHENYL-124-OXADIAZOL-3-YL)METHYL]-1H-PYRROLO[32-C]PYRIDINE- 2-CARBOXYLIC ACID
2133, d4p5qA_, 0.7054, 3.34, 0.302, 275, 258, HUMAN EPHA3 KINASE DOMAIN IN COMPLEX WITH QUINOXALINE DERIVATIVES
2134, d4cegA_, 0.7054, 3.04, 0.180, 264, 255, CRYSTAL STRUCTURE OF AURORA A 122-403 C290A C393A BOUND TO ADP
2135, d3owjA_, 0.7054, 3.25, 0.144, 328, 257, HUMAN CK2 CATALYTIC DOMAIN IN COMPLEX WITH A PYRIDOCARBAZOLE DERIVATIVE INHIBITOR
2136, d3my0Q1, 0.7054, 3.05, 0.169, 293, 254, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
2137, d3ky2B_, 0.7054, 3.48, 0.341, 280, 258, CRYSTAL STRUCTURE OF FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN
2138, d2qokA_, 0.7054, 3.47, 0.304, 281, 260, HUMAN EPHA3 KINASE AND JUXTAMEMBRANE REGION Y596F:Y602F:S768A TRIPLE MUTANT
2139, d1lr4A_, 0.7054, 3.28, 0.143, 327, 258, ROOM TEMPERATURE CRYSTAL STRUCTURE OF THE APO-FORM OF THE CATALYTIC SUBUNIT OF PROTEIN KINASE CK2 FROM ZEA MAYS
2140, d5bpyB1, 0.7053, 2.62, 0.314, 246, 245, CRYSTAL STRUCTURE OF BRUTON AGAMMAGLOBULINEMIA TYROSINE KINASE COMPLEXED WITH BMS-824171 AKA 6-[(3R)-3-(4-TERT-BU TYLBENZAMIDO) PIPERIDIN-1-YL]-2-{[4-(MORPHOLINE-4-CARBONYL) PHENYL]AMINO}PYRIDINE- 3-CARBOXAMIDE
2141, d4ubaB_, 0.7053, 3.26, 0.151, 333, 258, LOW-SALT STRUCTURE OF PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH 4 - CARBOXY-68-BROMO-FLAVONOL (FLC26)
2142, d1pxiA_, 0.7053, 3.16, 0.181, 294, 254, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR 4-(25-DICHLORO-THIOPHEN-3-YL)-PYRIMIDIN-2- YLAMINE
2143, d4fkuA_, 0.7052, 3.17, 0.177, 293, 254, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH OXINDOLE INHIBITOR
2144, d3tzmA_, 0.7052, 2.93, 0.163, 295, 252, TGF-BETA RECEPTOR TYPE 1 IN COMPLEX WITH SB431542
2145, d3my0S1, 0.7052, 3.05, 0.177, 293, 254, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
2146, d3cpbA1, 0.7052, 3.15, 0.302, 278, 252, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A BISAMIDE INHIBITOR
2147, d2cchC2, 0.7052, 3.26, 0.171, 295, 258, THE CRYSTAL STRUCTURE OF CDK2 CYCLIN A IN COMPLEX WITH A SUBSTRATE PEPTIDE DERIVED FROM CDC MODIFIED WITH A GAMMA- LINKED ATP ANALOGUE
2148, d1k3aA_, 0.7052, 3.42, 0.291, 288, 258, STRUCTURE OF THE INSULIN-LIKE GROWTH FACTOR 1 RECEPTOR KINASE
2149, d4mneA_, 0.7051, 3.26, 0.189, 286, 259, CRYSTAL STRUCTURE OF THE BRAF:MEK1 COMPLEX
2150, d4itiB_, 0.7051, 2.94, 0.213, 270, 249, CRYSTAL STRUCTURE OF RIP1 KINASE IN COMPLEX WITH NECROSTATIN-3 ANALOG
2151, d3tucA_, 0.7051, 2.96, 0.333, 257, 252, CRYSTAL STRUCTURE OF SYK KINASE DOMAIN WITH 1-BENZYL-N-(5-(67- DIMETHOXYQUINOLIN-4-YLOXY)PYRIDIN-2-YL)-2-OXO-12-DIHYDROPYRIDINE-3- CARBOXAMIDE
2152, d5cspA_, 0.7050, 3.30, 0.151, 327, 258, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 5 BOUND
2153, d4rllA_, 0.7050, 3.15, 0.145, 329, 256, CRYSTAL STRUCTURE OF HUMAN CK2ALPHA IN COMPLEX WITH THE ATP- COMPETITIVE INHIBITOR 4-[(E)-(FLUOREN-9-YLIDENEHYDRAZINYLIDENE)- METHYL] BENZOATE
2154, p4ib5C_, 0.7050, 3.27, 0.147, 332, 258, STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT IN COMPLEX WITH A CK2BETA-COMPETITIVE CYCLIC PEPTIDE
2155, d3v8wB1, 0.7050, 2.08, 0.312, 240, 237, CRYSTAL STRUCTURE OF INTERLEUKIN-2 INDUCIBLE T-CELL KINASE ITK CATALYTIC DOMAIN WITH THIENOPYRAZOLYLINDOLE INHIBITOR 469
2156, d3rp0A_, 0.7050, 3.23, 0.144, 329, 257,  
2157, d3qgyA1, 0.7050, 2.45, 0.309, 244, 243, CRYSTAL STRUCTURE OF ITK INHIBITOR COMPLEX
2158, d1gngA_, 0.7050, 3.50, 0.172, 348, 262, GLYCOGEN SYNTHASE KINASE-3 BETA (GSK3) COMPLEX WITH FRATTIDE PEPTIDE
2159, p5omyA_, 0.7049, 3.28, 0.151, 332, 258, HIGH-SALT STRUCTURE OF PROTEIN KINASE CK2 CATALYTIC SUBUNIT (ISOFORM CK2ALPHA) IN COMPLEX WITH THE INDENOINDOLE-TYPE INHIBITOR 4P
2160, d5ek7B_, 0.7049, 3.35, 0.307, 286, 257, STRUCTURE OF THE AUTOINHIBITED EPHA2 JMS-KD
2161, d4u42A_, 0.7049, 2.93, 0.171, 282, 252, MAP4K4 T181E MUTANT BOUND TO INHIBITOR COMPOUND 1
2162, d3rp0D_, 0.7049, 3.24, 0.148, 329, 257,  
2163, d3q4tB1, 0.7049, 2.94, 0.179, 293, 251, CRYSTAL STRUCTURE OF ACTIVIN RECEPTOR TYPE-IIA (ACVR2A) KINASE DOMAIN IN COMPLEX WITH DORSOMORPHIN
2164, d3f3tA_, 0.7049, 3.23, 0.288, 261, 257, KINASE DOMAIN OF CSRC IN COMPLEX WITH INHIBITOR RL38 (TYPE III)
2165, d2oxyA_, 0.7049, 3.27, 0.143, 327, 258, PROTEIN KINASE CK2 IN COMPLEX WITH TETRABROMOBENZOIMIDAZOLE DERIVATIVES K17 K22 AND K32
2166, d2eufB_, 0.7049, 3.15, 0.156, 282, 257, X-RAY STRUCTURE OF HUMAN CDK6-VCYCLIN IN COMPLEX WITH THE INHIBITOR PD0332991
2167, d1ctpE_, 0.7049, 3.79, 0.191, 332, 272, STRUCTURE OF THE MAMMALIAN CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE AND AN INHIBITOR PEPTIDE DISPLAYS AN OPEN CONFORMATION
2168, d5d12B_, 0.7048, 2.85, 0.312, 253, 250, KINASE DOMAIN OF CSRC IN COMPLEX WITH RL40
2169, d5csvA_, 0.7048, 3.27, 0.147, 327, 258, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 6 BOUND
2170, d4tyjA1, 0.7048, 3.35, 0.329, 275, 255, STRUCTURAL ANALYSIS OF THE HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 4 KINASE
2171, d4mneD_, 0.7048, 3.26, 0.189, 285, 259, CRYSTAL STRUCTURE OF THE BRAF:MEK1 COMPLEX
2172, p4md9P_, 0.7048, 3.25, 0.151, 328, 258, CRYSTAL STRUCTURE OF SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E TRUNCATED AT AA 336)
2173, p4ib5B_, 0.7048, 3.27, 0.147, 329, 258, STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT IN COMPLEX WITH A CK2BETA-COMPETITIVE CYCLIC PEPTIDE
2174, d4i4fA_, 0.7048, 2.91, 0.344, 255, 250, STRUCTURE OF FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH AN ALLOSTERIC BINDING PYRAZOLOBENZOTHIAZINE COMPOUND.
2175, d3v5jB1, 0.7048, 2.00, 0.314, 239, 236, CRYSTAL STRUCTURE OF INTERLEUKIN-2 INDUCIBLE T-CELL KINASE ITK CATALYTIC DOMAIN WITH THIENOPYRAZOLYLINDOLE INHIBITOR 090
2176, d2qc6A_, 0.7048, 3.30, 0.147, 326, 258, PROTEIN KINASE CK2 IN COMPLEX WITH DBC
2177, p2pvjA_, 0.7048, 3.28, 0.140, 326, 258, STRUCTURE-BASED DESIGN OF PYRAZOLO[15-A][135]TRIAZINE DERIVATIVES AS POTENT INHIBITORS OF PROTEIN KINASE CK2
2178, d5oy6D_, 0.7047, 2.85, 0.196, 292, 250, CRYSTAL STRUCTURE OF THE ACVR1 (ALK2) KINASE IN COMPLEX WITH CYCLICAL INHIBITOR OD36.
2179, d5hlnB_, 0.7047, 3.48, 0.172, 346, 262, X-RAY CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH CHIR99021
2180, d4rqkA_, 0.7047, 3.50, 0.202, 285, 262, CRYSTAL STRUCTURE OF PDK1 IN COMPLEX WITH ATP AND THE PIF-POCKET LIGAND RS1
2181, p4md9E_, 0.7047, 3.30, 0.151, 329, 258, CRYSTAL STRUCTURE OF SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E TRUNCATED AT AA 336)
2182, d4eolA1, 0.7047, 3.18, 0.163, 293, 257, THR 160 PHOSPHORYLATED CDK2 H84S Q85M K89D - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR RO3306
2183, d3fxzA_, 0.7047, 3.56, 0.189, 292, 265, CRYSTAL STRUCTURE OF PAK1 KINASE DOMAIN WITH RUTHENIUM COMPLEX LAMBDA-FL172
2184, d2helA_, 0.7047, 3.03, 0.320, 256, 253, CRYSTAL STRUCTURE OF A MUTANT EPHA4 KINASE DOMAIN (Y742A)
2185, d5uq0A_, 0.7046, 3.15, 0.308, 266, 253, FGFR1 KINASE DOMAIN COMPLEX WITH FRAGMENT 22-DIMETHYL-23- DIHYDROBENZOFURAN-7-CARBOXAMIDE
2186, d5n1vB_, 0.7046, 3.27, 0.143, 331, 258, CRYSTAL STRUCTURE OF THE PROTEIN KINASE CK2 CATALYTIC SUBUNIT IN COMPLEX WITH PYRAZOLO-PYRIMIDINE MACROCYCLIC LIGAND
2187, d5lvlA_, 0.7046, 3.50, 0.202, 285, 262, HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH COMPOUND PS653 BOUND TO THE ATP-BINDING SITE
2188, d4aojB_, 0.7046, 2.96, 0.302, 258, 252, HUMAN TRKA IN COMPLEX WITH THE INHIBITOR AZ-23
2189, d2oxdA_, 0.7046, 3.28, 0.151, 325, 258, PROTEIN KINASE CK2 IN COMPLEX WITH TETRABROMOBENZOIMIDAZOLE K17 K22 AND K32 INHIBITORS
2190, d1jamA_, 0.7046, 3.31, 0.147, 327, 258, CRYSTAL STRUCTURE OF APO-FORM OF Z. MAYS CK2 PROTEIN KINASE ALPHA SUBUNIT
2191, d5dt3A_, 0.7045, 3.05, 0.180, 263, 255, AURORA A KINASE IN COMPLEX WITH ATP IN SPACE GROUP P6122
2192, d5d11A_, 0.7045, 2.88, 0.304, 254, 250, KINASE DOMAIN OF CSRC IN COMPLEX WITH RL235
2193, d5cu6A_, 0.7045, 3.31, 0.151, 327, 258, CRYSTAL STRUCTURE OF CK2ALPHA
2194, p4md9F_, 0.7045, 3.23, 0.148, 327, 257, CRYSTAL STRUCTURE OF SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E TRUNCATED AT AA 336)
2195, d4ficA_, 0.7045, 2.57, 0.291, 251, 244, KINASE DOMAIN OF CSRC IN COMPLEX WITH A HINGE REGION-BINDING FRAGMENT
2196, d3tudA1, 0.7045, 3.00, 0.336, 255, 253, CRYSTAL STRUCTURE OF SYK KINASE DOMAIN WITH N-(4-METHYL-3-(8-METHYL-7- OXO-2-(PHENYLAMINO)-78-DIHYDROPYRIDO[23-D]PYRIMIDIN-6-YL)PHENYL)-3- (TRIFLUOROMETHYL)BENZAMIDE
2197, d3blrA_, 0.7045, 3.48, 0.148, 300, 263, CRYSTAL STRUCTURE OF HUMAN CDK9/CYCLINT1 IN COMPLEX WITH FLAVOPIRIDOL
2198, d3b8qB_, 0.7045, 2.98, 0.316, 271, 250, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A NAPHTHAMIDE INHIBITOR
2199, d3a8wB1, 0.7045, 3.66, 0.160, 324, 268, CRYSTAL STRUCTURE OF PKCIOTA KINASE DOMAIN
2200, d2qu6B_, 0.7045, 2.86, 0.308, 260, 247, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A BENZOXAZOLE INHIBITOR
2201, d2pvrA_, 0.7045, 3.30, 0.147, 328, 258, CRYSTAL STRUCTURE OF THE CATALYTIC SUBUNIT OF PROTEIN KINASE CK2 (C- TERMINAL DELETION MUTANT 1-335) IN COMPLEX WITH TWO SULFATE IONS
2202, d5e91A_, 0.7044, 2.95, 0.203, 297, 251, TGF-BETA RECEPTOR TYPE 2 KINASE DOMAIN (E431AR433AE485AK488AR493A R495A) IN COMPLEX WITH 3-AMINO-6-[4-(2- HYDROXYETHYL)PHENYL]-N-[4- (MORPHOLIN-4-YL)PYRIDIN-3-YL] PYRAZINE-2-CARBOXAMIDE
2203, d5c01B_, 0.7044, 2.64, 0.206, 260, 247, CRYSTAL STRUCTURE OF KINASE
2204, d1pw2A_, 0.7044, 3.18, 0.177, 294, 254, APO STRUCTURE OF HUMAN CYCLIN-DEPENDENT KINASE 2
2205, p5otyA_, 0.7043, 3.24, 0.152, 327, 257, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH CAM4712
2206, p5ooiA_, 0.7043, 3.19, 0.121, 329, 257, STRUCTURE OF PROTEIN KINASE CK2 CATALYTIC SUBUNIT (ISOFORM CK2ALPHA ) IN COMPLEX WITH THE INDENOINDOLE-TYPE INHIBITOR 4P
2207, d5if1A_, 0.7043, 3.34, 0.157, 298, 261, CRYSTAL STRUCTURE APO CDK2/CYCLIN A
2208, d5dr2A1, 0.7043, 3.12, 0.184, 263, 256, AURORA A KINASE IN COMPLEX WITH AA30 AND ATP IN SPACE GROUP P6122
2209, d4i3zC_, 0.7043, 3.40, 0.165, 295, 260, STRUCTURE OF PCDK2/CYCLINA BOUND TO ADP AND 2 MAGNESIUM IONS
2210, d4i3zA_, 0.7043, 3.40, 0.165, 295, 260, STRUCTURE OF PCDK2/CYCLINA BOUND TO ADP AND 2 MAGNESIUM IONS
2211, d2oxxA_, 0.7043, 3.29, 0.151, 325, 258, PROTEIN KINASE CK2 IN COMPLEX WITH TETRABROMOBENZOIMIDAZOLE DERIVATIVES K17 K22 AND K32
2212, d2jedB1, 0.7043, 3.55, 0.174, 315, 265, THE CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF THE PROTEIN KINASE C THETA IN COMPLEX WITH NVP-XAA228 AT 2.32A RESOLUTION.
2213, d5ikwA_, 0.7042, 3.00, 0.139, 297, 252, CRYSTAL STRUCTURE OF BMP-2-INDUCIBLE KINASE IN COMPLEX WITH AN INDAZOLE INHIBITOR
2214, d5fboA_, 0.7042, 2.89, 0.300, 255, 250, BTK-INHIBITOR CO-STRUCTURE
2215, d5dn3A_, 0.7042, 3.14, 0.183, 264, 257, AURORA A IN COMPLEX WITH ATP AND AA35.
2216, d4ae6A_, 0.7042, 3.60, 0.176, 319, 267, STRUCTURE AND FUNCTION OF THE HUMAN SPERM-SPECIFIC ISOFORM OF PROTEIN KINASE A (PKA) CATALYTIC SUBUNIT CALPHA 2
2217, p3e3bX_, 0.7042, 3.12, 0.129, 334, 256, CRYSTAL STRUCTURE OF CATALYTIC SUBUNIT OF HUMAN PROTEIN KINASE CK2ALPHA PRIME WITH A POTENT INDAZOLE-DERIVATIVE INHIBITOR
2218, d2hwoA_, 0.7042, 2.79, 0.285, 251, 246, CRYSTAL STRUCTURE OF SRC KINASE DOMAIN IN COMPLEX WITH COVALENT INHIBITOR
2219, d5orlA_, 0.7041, 3.04, 0.180, 264, 255, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
2220, d4ii5C_, 0.7041, 3.40, 0.165, 295, 260, STRUCTURE OF PCDK2/CYCLINA BOUND TO ADP AND 1 MAGNESIUM ION
2221, d4ii5A_, 0.7041, 3.40, 0.165, 295, 260, STRUCTURE OF PCDK2/CYCLINA BOUND TO ADP AND 1 MAGNESIUM ION
2222, p5owlA_, 0.7040, 3.24, 0.144, 331, 257, LOW SALT STRUCTURE OF HUMAN PROTEIN KINASE CK2ALPHA IN COMPLEX WITH 3- AMINOPROPYL-4;5;6;7-TETRABROMOBENZIMIDAZOL 
2223, d5nqcA_, 0.7040, 3.40, 0.150, 331, 260, CK2ALPHA IN COMPLEX WITH NMR154
2224, d4j1rD_, 0.7040, 3.52, 0.188, 345, 261, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH INHIBITOR 15R
2225, d4j1rB_, 0.7040, 3.52, 0.184, 346, 261, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH INHIBITOR 15R
2226, d4j1rA_, 0.7040, 3.52, 0.184, 343, 261, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH INHIBITOR 15R
2227, d4anmA1, 0.7040, 3.29, 0.143, 327, 258, COMPLEX OF CK2 WITH A CDC7 INHIBITOR
2228, d3my0I1, 0.7040, 3.02, 0.166, 292, 253, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
2229, d3kxnA_, 0.7040, 3.29, 0.147, 327, 258, CRYSTAL STRUCTURE OF Z. MAYS CK2 KINASE ALPHA SUBUNIT IN COMPLEX WITH THE INHIBITOR TETRAIODOBENZIMIDAZOLE (K88)
2230, d5vamB_, 0.7039, 2.77, 0.226, 260, 248, BRAF IN COMPLEX WITH RAF709
2231, d5hngA_, 0.7039, 3.25, 0.206, 280, 257, DISCOVERY OF NOVEL 7-AZAINDOLES AS PDK1 INHIBITORS
2232, d4utdA_, 0.7039, 3.04, 0.180, 266, 255, STRUCTURE OF DEPHOSPHORYLATED AURORA A (122-403) BOUND TO AMPPCP IN AN ACTIVE CONFORMATION
2233, d4debA_, 0.7039, 3.25, 0.181, 264, 259, AURORA A IN COMPLEX WITH RK2-17-01
2234, d3tz9A_, 0.7039, 3.28, 0.284, 261, 257, KINASE DOMAIN OF CSRC IN COMPLEX WITH RL130
2235, d3rpoA_, 0.7039, 3.23, 0.173, 294, 255, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-156
2236, d3qgwB_, 0.7039, 2.12, 0.312, 240, 237, CRYSTAL STRUCTURE OF ITK KINASE BOUND TO AN INHIBITOR
2237, d3q9yA_, 0.7039, 3.24, 0.148, 327, 257, CRYSTAL STRUCTURE OF HUMAN CK2 ALPHA IN COMPLEX WITH QUINALIZARIN AT PH 8.5
2238, d3eflB_, 0.7039, 2.81, 0.308, 263, 247, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH MOTESANIB
2239, d1hclA_, 0.7039, 3.26, 0.173, 294, 255, HUMAN CYCLIN-DEPENDENT KINASE 2
2240, d5ortA_, 0.7038, 3.14, 0.180, 264, 256, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
2241, d5ek7A_, 0.7038, 3.42, 0.310, 286, 258, STRUCTURE OF THE AUTOINHIBITED EPHA2 JMS-KD
2242, d4j1rC_, 0.7038, 3.53, 0.184, 344, 261, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH INHIBITOR 15R
2243, d3ddpC1, 0.7038, 3.23, 0.159, 297, 258, STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR CR8
2244, d2xbaA_, 0.7038, 3.58, 0.269, 283, 260, STRUCTURE OF HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH PHA-E429
2245, d2uzdA_, 0.7038, 3.36, 0.162, 295, 259, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
2246, d5f94B_, 0.7037, 3.55, 0.172, 349, 262, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH COMPOUND 15: 2- [(CYCLOPROPYLCARBONYL)AMINO]-N-(4-METHOXYPYRIDIN-3-YL)PYRIDINE-4- CARBOXAMIDE
2247, d5aneA_, 0.7037, 3.10, 0.182, 294, 253, CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH 6-METHOXY-7H- PURINE PROCESSED WITH THE CRYSTALDIRECT AUTOMATED MOUNTING AND CRYO-COOLING TECHNOLOGY
2248, d4qmlA_, 0.7037, 3.57, 0.231, 280, 264, MST3 IN COMPLEX WITH AMP-PNP
2249, d4pp9A1, 0.7037, 2.44, 0.309, 245, 243, ITK KINASE DOMAIN WITH COMPOUND 1 (N-[1-(3-CYANOBENZYL)-1H-PYRAZOL-4- YL]-2H-INDAZOLE-3-CARBOXAMIDE)
2250, d4gu9B_, 0.7037, 3.25, 0.346, 255, 254, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH (2-FLUORO- PHENYL)-(1H-PYRAZOLO[34-D]PYRIMIDIN-4-YL)-AMINE
2251, d3my0V1, 0.7037, 2.91, 0.171, 281, 251, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
2252, d3my0C1, 0.7037, 3.05, 0.169, 298, 254, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
2253, d3bhyA1, 0.7037, 3.09, 0.201, 267, 254, CRYSTAL STRUCTURE OF HUMAN DEATH ASSOCIATED PROTEIN KINASE 3 (DAPK3) IN COMPLEX WITH A BETA-CARBOLINE LIGAND
2254, p5os8A_, 0.7036, 3.23, 0.148, 327, 257, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 11
2255, d5m4cA_, 0.7036, 3.28, 0.143, 329, 258, COMPLEX STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH A THIENO[23-D]PYRIMIDIN INHIBITOR CRYSTALLIZED UNDER LOW-SALT CONDITIONS
2256, d5cu0A_, 0.7036, 3.26, 0.148, 327, 257, CRYSTAL STRUCTURE OF CK2ALPHA WITH 2-HYDROXY-5-METHYLBENZOIC ACID AND N-(3-(3-CHLORO-4-(PHENYL)BENZYLAMINO)PROPYL)ACETAMIDE BOUND
2257, d4yjrA_, 0.7036, 3.21, 0.341, 263, 252, SYK KINASE DOMAIN IN COMPLEX WITH INHIBITOR GTC000225
2258, d4twoA_, 0.7036, 3.40, 0.301, 278, 259, HUMAN EPHA3 KINASE DOMAIN IN COMPLEX WITH COMPOUND 164
2259, d4rfmA1, 0.7036, 2.69, 0.313, 248, 246, ITK KINASE DOMAIN IN COMPLEX WITH COMPOUND 1 N-{1-[(11-DIOXO-1-THIAN- 2-YL)(PHENYL)METHYL]-1H- PYRAZOL-4-YL}-55-DIFLUORO-5A-METHYL-1H4H 4AH5H5AH6H-CYCLOPROPA[F]INDAZOLE-3-CARBOXAMIDE
2260, d3fwqB_, 0.7036, 3.49, 0.149, 334, 261, INACTIVE CONFORMATION OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT
2261, d2zv9A1, 0.7036, 2.87, 0.319, 255, 251, LYN TYROSINE KINASE DOMAIN-PP2 COMPLEX
2262, d5movA_, 0.7035, 3.21, 0.148, 325, 257, CRYSTAL STRUCTURE OF CK2ALPHA WITH ZT0633 BOUND
2263, d4bggC_, 0.7035, 2.76, 0.182, 279, 247, CRYSTAL STRUCTURE OF THE ACVR1 KINASE IN COMPLEX WITH LDN-213844
2264, d3qx2A_, 0.7035, 3.24, 0.176, 294, 255, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-190
2265, d5ur1A_, 0.7034, 3.23, 0.311, 278, 254, FGFR1 KINASE DOMAIN COMPLEX WITH SN37333 IN REVERSIBLE BINDING MODE
2266, d5jt2A1, 0.7034, 2.71, 0.231, 253, 247, BRAFV600E KINASE DOMAIN IN COMPLEX WITH CHEMICALLY LINKED VEMURAFENIB INHIBITOR VEM-BISAMIDE
2267, d5i3oA_, 0.7034, 3.02, 0.139, 302, 252, CRYSTAL STRUCTURE OF BMP-2-INDUCIBLE KINASE IN COMPLEX WITH AN INDAZOLE INHIBITOR
2268, d5deyA_, 0.7034, 3.79, 0.190, 295, 268, CRYSTAL STRUCTURE OF PAK1 IN COMPLEX WITH AN INHIBITOR COMPOUND G-5555
2269, d3r8pA_, 0.7034, 3.09, 0.182, 294, 253, CDK2 IN COMPLEX WITH INHIBITOR NSK-MC1-6
2270, d2wihA1, 0.7034, 3.38, 0.156, 298, 262, STRUCTURE OF CDK2-CYCLIN A WITH PHA-848125
2271, d1uu8A_, 0.7034, 3.27, 0.206, 277, 257, STRUCTURE OF HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH BIM-1
2272, d1f0qA_, 0.7034, 3.30, 0.151, 329, 258, CRYSTAL STRUCTURE OF THE ALPHA SUBUNIT OF PROTEIN KINASE CK2 IN COMPLEX WITH THE NUCLEOTIDE COMPETITIVE INHIBITOR EMODIN
2273, d4eokA1, 0.7033, 3.15, 0.160, 292, 256, THR 160 PHOSPHORYLATED CDK2 H84S Q85M K89D - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR NU6102
2274, d3r71A_, 0.7033, 3.24, 0.173, 294, 255, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-162
2275, d3og7B_, 0.7033, 2.69, 0.231, 254, 247, B-RAF KINASE V600E ONCOGENIC MUTANT IN COMPLEX WITH PLX4032
2276, d2qi8B_, 0.7033, 2.72, 0.301, 249, 246, CRYSTAL STRUCTURE OF DRUG RESISTANT SRC KINASE DOMAIN
2277, d5m4fA_, 0.7032, 3.28, 0.143, 330, 258, COMPLEX STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH THE INHIBITOR 4 -CARBOXY-68-CHLORO-FLAVONOL (FLC21) CRYSTALLIZED UNDER LOW-SALT CONDITIONS
2278, d5hieB_, 0.7032, 2.82, 0.217, 259, 249, BRAF KINASE DOMAIN B3AC LOOP DELETION MUTANT IN COMPLEX WITH DABRAFENIB
2279, d5e92A_, 0.7032, 3.04, 0.202, 298, 252, TGF-BETA RECEPTOR TYPE 2 KINASE DOMAIN (E431AR433AE485AK488AR493A R495A) IN COMPLEX WITH AMPPNP
2280, d4u44B_, 0.7032, 3.61, 0.175, 296, 263, MAP4K4 IN COMPLEX WITH INHIBITOR (COMPOUND 16)
2281, d4o0sA_, 0.7032, 3.20, 0.183, 265, 257, CRYSTAL STRUCTURES OF HUMAN KINASE AURORA A
2282, d3ii5A_, 0.7032, 2.82, 0.225, 262, 249, THE COMPLEX OF WILD-TYPE B-RAF WITH PYRAZOLO PYRIMIDINE INHIBITOR
2283, d5cu2A_, 0.7031, 3.25, 0.152, 328, 257, CRYSTAL STRUCTURE OF CK2ALPHA WITH 2-HYDROXY-5-METHYLBENZOIC ACID AND (METHYL 4-((3-(3-CHLORO-4-(PHENYL)BENZYLAMINO)PROPYL)AMINO)-4- OXOBUTANOAT BOUND
2284, p4md9K_, 0.7031, 3.25, 0.156, 328, 257, CRYSTAL STRUCTURE OF SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E TRUNCATED AT AA 336)
2285, d3qtiB_, 0.7031, 3.23, 0.336, 280, 253, C-MET KINASE IN COMPLEX WITH NVP-BVU972
2286, d3c1xA_, 0.7031, 3.52, 0.326, 290, 258, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF THE HEPATOCYTE GROWTH FACTOR RECEPTOR C-MET IN COMPLEX WITH A PYRROLOTRIAZINE BASED INHIBITOR
2287, d5dnrA_, 0.7030, 3.11, 0.184, 264, 256, AURORA A KINASE IN COMPLEX WITH ATP IN SPACE GROUP P41212
2288, d5ct7A_, 0.7030, 2.78, 0.223, 257, 247, BRAF IN COMPLEX WITH RAF265
2289, p4md9L_, 0.7030, 3.32, 0.147, 328, 258, CRYSTAL STRUCTURE OF SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E TRUNCATED AT AA 336)
2290, p4lfiB_, 0.7030, 3.31, 0.147, 371, 258, CRYSTAL STRUCTURE OF SCCK2 ALPHA IN COMPLEX WITH GMPPNP
2291, p4lfiA_, 0.7030, 3.31, 0.147, 370, 258, CRYSTAL STRUCTURE OF SCCK2 ALPHA IN COMPLEX WITH GMPPNP
2292, p3o17B_, 0.7030, 3.01, 0.193, 357, 254, CRYSTAL STRUCTURE OF JNK1-ALPHA1 ISOFORM
2293, d3bz3A_, 0.7030, 3.41, 0.345, 259, 258, CRYSTAL STRUCTURE ANALYSIS OF FOCAL ADHESION KINASE WITH A METHANESULFONAMIDE DIAMINOPYRIMIDINE INHIBITOR
2294, d2e2bB1, 0.7030, 2.63, 0.348, 258, 244, CRYSTAL STRUCTURE OF THE C-ABL KINASE DOMAIN IN COMPLEX WITH INNO-406
2295, d5n1vA_, 0.7029, 3.30, 0.147, 331, 258, CRYSTAL STRUCTURE OF THE PROTEIN KINASE CK2 CATALYTIC SUBUNIT IN COMPLEX WITH PYRAZOLO-PYRIMIDINE MACROCYCLIC LIGAND
2296, d4hw7A_, 0.7029, 3.30, 0.295, 289, 254, CRYSTAL STRUCTURE OF FMS KINASE DOMAIN WITH A SMALL MOLECULAR INHIBITOR PLX647-OME
2297, d4a06A_, 0.7029, 3.28, 0.205, 282, 258, HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH ALLOSTERIC ACTIVATOR PS114 BOUND TO THE PIF-POCKET
2298, d3rpsA_, 0.7029, 3.27, 0.148, 334, 257, STRUCTURE OF HUMAN CK2ALPHA IN COMPLEX WITH THE ATP-COMPETITIVE INHIBITOR 3-(4567-TETRABROMO-1H-BENZOTRIAZOL-1-YL)PROPAN-1-OL
2299, d2hiwB1, 0.7029, 3.01, 0.337, 270, 252, CRYSTAL STRUCTURE OF INACTIVE CONFORMATION ABL KINASE CATALYTIC DOMAIN COMPLEXED WITH TYPE II INHIBITOR
2300, d5i3rA_, 0.7028, 3.03, 0.139, 302, 252, CRYSTAL STRUCTURE OF BMP-2-INDUCIBLE KINASE IN COMPLEX WITH AN INDAZOLE INHIBITOR
2301, d4rwjB_, 0.7028, 3.38, 0.319, 282, 257, CRYSTAL STRUCTURE OF FGFR1 (C488A C584S) IN COMPLEX WITH AZD4547 (N- {3-[2-(35-DIMETHOXYPHENYL)ETHYL]-1H-PYRAZOL-5-YL}-4-[(3R5S)-35- DIMETHYLPIPERAZIN-1-YL]BENZAMIDE)
2302, d4rvtB_, 0.7028, 3.76, 0.170, 297, 265, MAP4K4 IN COMPLEX WITH A PYRIDIN-2(1H)-ONE DERIVATIVE
2303, d4rvtA_, 0.7028, 3.07, 0.163, 281, 252, MAP4K4 IN COMPLEX WITH A PYRIDIN-2(1H)-ONE DERIVATIVE
2304, d4o0rA_, 0.7028, 3.58, 0.196, 293, 265, BACK POCKET FLEXIBILITY PROVIDES GROUP-II PAK SELECTIVITY FOR TYPE 1 KINASE INHIBITORS
2305, d4l44A_, 0.7028, 3.60, 0.175, 321, 263, CRYSTAL STRUCTURES OF HUMAN P70S6K1-T389A (FORM II)
2306, d3sc1A_, 0.7028, 3.21, 0.211, 278, 256, NOVEL ISOQUINOLONE PDK1 INHIBITORS DISCOVERED THROUGH FRAGMENT-BASED LEAD DISCOVERY
2307, d3r7yA_, 0.7028, 3.17, 0.173, 294, 254, CDK2 IN COMPLEX WITH INHIBITOR KVR-2-88
2308, d2qluA1, 0.7028, 3.01, 0.184, 295, 250, CRYSTAL STRUCTURE OF ACTIVIN RECEPTOR TYPE II KINASE DOMAIN FROM HUMAN
2309, d1om1A_, 0.7028, 3.31, 0.151, 325, 258, CRYSTAL STRUCTURE OF MAIZE CK2 ALPHA IN COMPLEX WITH IQA
2310, d1m2rA_, 0.7028, 3.31, 0.155, 327, 258, CRYSTAL STRUCTURE OF 58-DI-AMINO-14-DI-HYDROXY- ANTHRAQUINONE/CK2 KINASE COMPLEX
2311, d1j91B_, 0.7028, 3.38, 0.139, 327, 259, CRYSTAL STRUCTURE OF Z. MAYS CK2 KINASE ALPHA SUBUNIT IN COMPLEX WITH THE ATP-COMPETITIVE INHIBITOR 4567- TETRABROMOBENZOTRIAZOLE
2312, d1j91A_, 0.7028, 3.31, 0.147, 327, 258, CRYSTAL STRUCTURE OF Z. MAYS CK2 KINASE ALPHA SUBUNIT IN COMPLEX WITH THE ATP-COMPETITIVE INHIBITOR 4567- TETRABROMOBENZOTRIAZOLE
2313, d5mmrA_, 0.7027, 3.28, 0.148, 326, 257, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-((2-CHLORO-[11 -BIPHENYL]-4-YL) METHYL)BUTANE-14-DIAMINE BOUND
2314, d5ct7B_, 0.7027, 2.55, 0.221, 254, 244, BRAF IN COMPLEX WITH RAF265
2315, d5csxA_, 0.7027, 2.89, 0.229, 261, 249, CRYSTAL STRUCTURE OF B-RAF IN COMPLEX WITH BI 882370
2316, d4mf1A1, 0.7027, 2.18, 0.310, 241, 239, ITK KINASE DOMAIN IN COMPLEX WITH BENZOTHIAZOLE INHIBITOR 12B (1S2S)- 2-{4-[(DIMETHYLAMINO)METHYL]PHENYL}-N-[6-(1H-PYRAZOL-4-YL)-13- BENZOTHIAZOL-2-YL]CYCLOPROPANECARBOXAMIDE
2317, d3v8wA1, 0.7027, 2.21, 0.311, 241, 238, CRYSTAL STRUCTURE OF INTERLEUKIN-2 INDUCIBLE T-CELL KINASE ITK CATALYTIC DOMAIN WITH THIENOPYRAZOLYLINDOLE INHIBITOR 469
2318, d3rpsB_, 0.7027, 3.32, 0.151, 334, 258, STRUCTURE OF HUMAN CK2ALPHA IN COMPLEX WITH THE ATP-COMPETITIVE INHIBITOR 3-(4567-TETRABROMO-1H-BENZOTRIAZOL-1-YL)PROPAN-1-OL
2319, d3gqlB_, 0.7027, 3.32, 0.307, 276, 257, CRYSTAL STRUCTURE OF ACTIVATED RECEPTOR TYROSINE KINASE IN COMPLEX WITH SUBSTRATES
2320, d3d94A_, 0.7027, 3.29, 0.304, 288, 253, CRYSTAL STRUCTURE OF THE INSULIN-LIKE GROWTH FACTOR-1 RECEPTOR KINASE IN COMPLEX WITH PQIP
2321, d2zjwA_, 0.7027, 3.25, 0.144, 332, 257, CRYSTAL STRUCTURE OF HUMAN CK2 ALPHA COMPLEXED WITH ELLAGIC ACID
2322, d1uv5A_, 0.7027, 3.52, 0.164, 348, 262, GLYCOGEN SYNTHASE KINASE 3 BETA COMPLEXED WITH 6-BROMOINDIRUBIN-3 -OXIME
2323, d1ol7A_, 0.7027, 3.13, 0.180, 261, 255, STRUCTURE OF HUMAN AURORA-A 122-403 PHOSPHORYLATED ON THR287 THR288
2324, d1mq4A_, 0.7027, 3.10, 0.184, 261, 255, CRYSTAL STRUCTURE OF AURORA-A PROTEIN KINASE
2325, d1m2pA_, 0.7027, 3.32, 0.151, 325, 258, CRYSTAL STRUCTURE OF 18-DI-HYDROXY-4-NITRO- ANTHRAQUINONE/CK2 KINASE COMPLEX
2326, d4pteB_, 0.7026, 3.57, 0.167, 347, 263, STRUCTURE OF A CARVOXAMIDE COMPOUND (15) (N-[4-(ISOQUINOLIN-7-YL) PYRIDIN-2-YL]CYCLOPROPANECARBOXAMIDE) TO GSK3B
2327, d4l46A_, 0.7026, 3.78, 0.180, 317, 266, CRYSTAL STRUCTURES OF HUMAN P70S6K1-WT
2328, d3zrmA_, 0.7026, 3.53, 0.179, 344, 262, IDENTIFICATION OF 2-(4-PYRIDYL)THIENOPYRIDINONES AS GSK- 3BETA INHIBITORS
2329, d2zv7A1, 0.7026, 2.88, 0.315, 256, 251, LYN TYROSINE KINASE DOMAIN APO FORM
2330, d2qonA_, 0.7026, 3.53, 0.306, 281, 258, HUMAN EPHA3 KINASE AND JUXTAMEMBRANE REGION Y596F:Y602F:Y742A TRIPLE MUTANT
2331, p5otzA_, 0.7025, 3.25, 0.148, 327, 257, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 1
2332, d5ho8A_, 0.7025, 3.15, 0.212, 278, 255, DISCOVERY OF NOVEL 7-AZAINDOLES AS PDK1 INHIBITORS
2333, d5cu0B_, 0.7025, 3.28, 0.144, 325, 257, CRYSTAL STRUCTURE OF CK2ALPHA WITH 2-HYDROXY-5-METHYLBENZOIC ACID AND N-(3-(3-CHLORO-4-(PHENYL)BENZYLAMINO)PROPYL)ACETAMIDE BOUND
2334, d3my0D1, 0.7025, 3.04, 0.170, 297, 253, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
2335, d3f3wB_, 0.7025, 3.29, 0.292, 260, 257, DRUG RESISTANT CSRC KINASE DOMAIN IN COMPLEX WITH INHIBITOR RL45 (TYPE II)
2336, d2y7jA_, 0.7025, 3.09, 0.179, 284, 257, STRUCTURE OF HUMAN PHOSPHORYLASE KINASE GAMMA 2
2337, d2oxyB_, 0.7025, 3.32, 0.143, 327, 258, PROTEIN KINASE CK2 IN COMPLEX WITH TETRABROMOBENZOIMIDAZOLE DERIVATIVES K17 K22 AND K32
2338, d5mo4A3, 0.7024, 3.09, 0.316, 271, 253, ABL1 KINASE (T334I_D382N) IN COMPLEX WITH ASCIMINIB AND NILOTINIB
2339, d5ct0A_, 0.7024, 3.29, 0.144, 326, 257, CRYSTAL STRUCTURE OF CK2ALPHA WITH 3-(3-CHLORO-4-(PHENYL)BENZYLAMINO) PROPAN-1-OL BOUND
2340, d3uo4A_, 0.7024, 3.27, 0.178, 266, 259, AURORA A IN COMPLEX WITH RPM1680
2341, d2gsfA_, 0.7024, 3.47, 0.301, 281, 259, THE HUMAN EPHA3 RECEPTOR TYROSINE KINASE AND JUXTAMEMBRANE REGION
2342, p6gihA_, 0.7023, 3.25, 0.153, 324, 255, CRYSTAL STRUCTURE OF CK2ALPHA WITH CAM187 BOUND 
2343, d4w9wA_, 0.7023, 3.02, 0.143, 306, 252, CRYSTAL STRUCTURE OF BMP-2-INDUCIBLE KINASE IN COMPLEX WITH SMALL MOLECULE AZD-7762
2344, d4bn1A_, 0.7023, 3.13, 0.184, 261, 255, CRYSTAL STRUCTURE OF V174M MUTANT OF AURORA-A KINASE
2345, d3fl5A_, 0.7023, 3.32, 0.143, 324, 258, PROTEIN KINASE CK2 IN COMPLEX WITH THE INHIBITOR QUINALIZARIN
2346, d3a8wA1, 0.7023, 3.50, 0.170, 323, 264, CRYSTAL STRUCTURE OF PKCIOTA KINASE DOMAIN
2347, d1pjkA_, 0.7023, 3.29, 0.144, 331, 257, CRYSTAL STRUCTURE OF A C-TERMINAL DELETION MUTANT OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT
2348, d1na7A_, 0.7023, 3.25, 0.140, 326, 257, CRYSTAL STRUCTURE OF THE CATALYTIC SUBUNIT OF HUMAN PROTEIN KINASE CK2
2349, d5ci7A_, 0.7022, 3.01, 0.202, 276, 252, STRUCTURE OF ULK1 BOUND TO A SELECTIVE INHIBITOR
2350, d4yznA_, 0.7022, 3.19, 0.239, 269, 255, HUMANIZED ROCO4 BOUND TO COMPOUND 19
2351, d3q6uA1, 0.7022, 3.29, 0.333, 281, 255, STRUCTURE OF THE APO MET RECEPTOR KINASE IN THE DUALLY-PHOSPHORYLATED ACTIVATED STATE
2352, d3h30B_, 0.7022, 3.45, 0.150, 333, 260, CRYSTAL STRUCTURE OF THE CATALYTIC SUBUNIT OF HUMAN PROTEIN KINASE CK2 WITH 56-DICHLORO-1-BETA-D- RIBOFURANOSYLBENZIMIDAZOLE
2353, d3fy0A_, 0.7022, 3.66, 0.189, 292, 265, CRYSTAL STRUCTURE OF PAK1 KINASE DOMAIN WITH RUTHENIUM COMPLEX DW1
2354, d2clqA_, 0.7022, 2.74, 0.210, 263, 248, STRUCTURE OF MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE 2 5
2355, d1vywA1, 0.7022, 3.42, 0.156, 298, 262, STRUCTURE OF CDK2/CYCLIN A WITH PNU-292137
2356, d5h8gA_, 0.7021, 3.21, 0.141, 324, 256, CRYSTAL STRUCTURE OF CK2 WITH COMPOUND 7B
2357, d4eolC1, 0.7021, 3.39, 0.165, 296, 260, THR 160 PHOSPHORYLATED CDK2 H84S Q85M K89D - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR RO3306
2358, d3kxhA_, 0.7021, 3.32, 0.143, 326, 258, CRYSTAL STRUCTURE OF Z. MAYS CK2 KINASE ALPHA SUBUNIT IN COMPLEX WITH THE INHIBITOR (2-DYMETHYLAMMINO-4567-TETRABROMOBENZOIMIDAZOL-1YL- ACETIC ACID (K66)
2359, d2reiA1, 0.7021, 3.19, 0.312, 274, 253, KINASE DOMAIN OF HUMAN EPHRIN TYPE-A RECEPTOR 7 (EPHA7)
2360, d5m4uA_, 0.7020, 3.20, 0.121, 332, 256, ORTHORHOMBIC COMPLEX STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT (ISOFORM CK2ALPHA ) WITH THE INHIBITOR 4 -CARBOXY-68-CHLORO- FLAVONOL (FLC21)
2361, d4j71A_, 0.7020, 3.57, 0.176, 347, 262, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH INHIBITOR 1R
2362, d3u4uA_, 0.7020, 3.29, 0.140, 327, 257, CASEIN KINASE 2 IN COMPLEX WITH AZ-INHIBITOR
2363, d3rm6A_, 0.7020, 3.23, 0.173, 293, 254, CDK2 IN COMPLEX WITH INHIBITOR KVR-2-80
2364, d3od6X_, 0.7020, 3.06, 0.198, 344, 252, CRYSTAL STRUCTURE OF P38ALPHA Y323T ACTIVE MUTANT
2365, d4ptgB_, 0.7019, 3.52, 0.176, 332, 262, STRUCTURE OF A CARBOXAMINE COMPOUND (26) (2-{2-[(CYCLOPROPYLCARBONYL) AMINO]PYRIDIN-4-YL}-4-METHOXYPYRIMIDINE-5-CARBOXAMIDE) TO GSK3B
2366, d4gu6B_, 0.7019, 3.27, 0.341, 258, 255, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH N-{3-[(5-CYANO- 2-PHENYL-1H-PYRROLO[23-B]PYRIDIN-4-YLAMINO)- METHYL]-PYRIDIN-2-YL}- N-METHYL-METHANESULFONAMIDE
2367, d3zrkA_, 0.7019, 3.55, 0.179, 345, 262, IDENTIFICATION OF 2-(4-PYRIDYL)THIENOPYRIDINONES AS GSK-3BETA INHIBITORS
2368, d3up7A_, 0.7019, 3.27, 0.181, 264, 259, AURORA A IN COMPLEX WITH YL1-038-09
2369, d5cswB_, 0.7018, 2.74, 0.228, 252, 246, B-RAF IN COMPLEX WITH DABRAFENIB
2370, d4r7iA_, 0.7018, 3.30, 0.295, 290, 254, CRYSTAL STRUCTURE OF FMS KINASE DOMAIN WITH A SMALL MOLECULAR INHIBITOR GLEEVEC
2371, d2vwvA_, 0.7018, 3.03, 0.304, 255, 250, EPHB4 KINASE DOMAIN INHIBITOR COMPLEX
2372, d2c6tA_, 0.7018, 3.32, 0.167, 295, 258, CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR
2373, d1finA_, 0.7018, 3.43, 0.145, 298, 262, CYCLIN A-CYCLIN-DEPENDENT KINASE 2 COMPLEX
2374, d5mo7A_, 0.7017, 3.30, 0.148, 327, 257, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
2375, d4kspA_, 0.7017, 2.74, 0.228, 257, 246, CRYSTAL STRUCTURE OF HUMAN B-RAF BOUND TO A DFG-OUT INHIBITOR TAK-632
2376, d3lokA_, 0.7017, 2.67, 0.307, 248, 244, DRUG RESISTANT CSRC KINASE DOMAIN IN COMPLEX WITH COVALENT INHIBITOR PD168393
2377, d1uwjA_, 0.7017, 3.02, 0.219, 264, 251, THE COMPLEX OF MUTANT V599E B-RAF AND BAY439006
2378, p6ehuB_, 0.7016, 3.32, 0.152, 327, 257, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 32
2379, d4wovA_, 0.7016, 2.65, 0.207, 258, 246, CRYSTAL STRUCTURE OF TYROSINE KINASE 2 JH2 (PSEUDO KINASE DOMAIN) COMPLEXED WITH BMS-066 AKA 2-METHOXY-N-({6-[3-METHYL-7-(METHYLAMINO)- 35810-TETRAAZATRICYCLO[7.3.0.0 6]DODECA-1(9)2(6)4711-PENTAEN- 11-YL]PYRIDIN-2-YL}METHY L)ACETAMIDE
2380, d4eoiC1, 0.7016, 3.31, 0.167, 295, 258, THR 160 PHOSPHORYLATED CDK2 K89D Q131E - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR RO3306
2381, d4aw5A_, 0.7016, 3.07, 0.306, 261, 252, COMPLEX OF THE EPHB4 KINASE DOMAIN WITH AN OXINDOLE INHIBITOR
2382, d3qqlA_, 0.7016, 3.22, 0.181, 294, 254, CDK2 IN COMPLEX WITH INHIBITOR L3
2383, d3owlA_, 0.7016, 3.26, 0.148, 330, 257, HUMAN CK2 CATALYTIC DOMAIN IN COMPLEX WITH A BENZOPYRIDOINDOLE DERIVATIVE INHIBITOR
2384, d2y7jB_, 0.7016, 3.15, 0.187, 281, 256, STRUCTURE OF HUMAN PHOSPHORYLASE KINASE GAMMA 2
2385, d2clxA_, 0.7016, 3.09, 0.183, 293, 252, 4-ARYLAZO-35-DIAMINO-1H-PYRAZOLE CDK INHIBITORS: SAR STUDY CRYSTAL STRUCTURE IN COMPLEX WITH CDK2 SELECTIVITY AND CELLULAR EFFECTS
2386, d5mmfA_, 0.7015, 3.30, 0.148, 326, 257, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 7 BOUND
2387, d5iexA_, 0.7015, 3.05, 0.175, 285, 251, CRYSTAL STRUCTURE OF (RS)-S-{4-[(5-BROMO-4-{[(2R3R)-2-HYDROXY-1- METHYLPROPYL]OXY}- PYRIMIDIN-2-YL)AMINO]PHENYL}-S- CYCLOPROPYLSULFOXIMIDE BOUND TO CDK2
2388, d5f94A_, 0.7015, 3.56, 0.164, 346, 262, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH COMPOUND 15: 2- [(CYCLOPROPYLCARBONYL)AMINO]-N-(4-METHOXYPYRIDIN-3-YL)PYRIDINE-4- CARBOXAMIDE
2389, d4zp5B_, 0.7015, 3.85, 0.165, 300, 266, MAP4K4 IN COMPLEX WITH INHIBITOR
2390, d4lueB3, 0.7015, 2.39, 0.314, 256, 239, CRYSTAL STRUCTURE OF HCK IN COMPLEX WITH 7-[TRANS-4-(4- METHYLPIPERAZIN-1-YL)CYCLOHEXYL]-5-(4-PHENOXYPHENYL)-7H-PYRROLO[23- D]PYRIMIDIN-4-AMINE (RESULTING FROM DISPLACEMENT OF SKF86002)
2391, d4kabA_, 0.7015, 3.18, 0.337, 255, 252, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH 3-METHYL-14- DIHYDRO-PYRAZOLO[45-C]PYRAZOLE
2392, d3o2mB_, 0.7015, 2.99, 0.182, 358, 253, CRYSTAL STRUCTURE OF JNK1-ALPHA1 ISOFORM COMPLEX WITH A BIARYL TETRAZOL (A-82118)
2393, d3lm5A1, 0.7015, 3.03, 0.179, 267, 252, CRYSTAL STRUCTURE OF HUMAN SERINE/THREONINE KINASE 17B (STK17B) IN COMPLEX WITH QUERCETIN
2394, d2rkpA_, 0.7015, 3.52, 0.149, 334, 261,  
2395, d2c6iA_, 0.7015, 3.09, 0.179, 292, 252, CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR
2396, d1zoeA_, 0.7015, 3.34, 0.147, 325, 258, CRYSTAL STRUCTURE OF PROTEIN KINASE CK2 IN COMPLEX WITH TBB- DERIVATIVES INHIBITORS
2397, d1pyxA_, 0.7015, 3.53, 0.164, 343, 262, GSK-3 BETA COMPLEXED WITH AMP-PNP
2398, d5m56B_, 0.7014, 3.30, 0.120, 328, 258, MONOCLINIC COMPLEX STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT (ISOFORM CK2ALPHA ) WITH THE INHIBITOR 4 -CARBOXY-68-CHLORO- FLAVONOL (FLC21)
2399, d5hieA_, 0.7014, 2.78, 0.198, 258, 248, BRAF KINASE DOMAIN B3AC LOOP DELETION MUTANT IN COMPLEX WITH DABRAFENIB
2400, d5cu2B_, 0.7014, 3.22, 0.145, 325, 256, CRYSTAL STRUCTURE OF CK2ALPHA WITH 2-HYDROXY-5-METHYLBENZOIC ACID AND (METHYL 4-((3-(3-CHLORO-4-(PHENYL)BENZYLAMINO)PROPYL)AMINO)-4- OXOBUTANOAT BOUND
2401, d4kaoB_, 0.7014, 3.19, 0.344, 254, 253, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH 1-(5-TERT- BUTYL-2-P-TOLYL-2H-PYRAZOL-3-YL)-3-(4-PYRIDIN-3- YL-PHENYL)-UREA
2402, d3f69B_, 0.7014, 3.23, 0.145, 282, 256, CRYSTAL STRUCTURE OF THE MYCOBACTERIUM TUBERCULOSIS PKNB MUTANT KINASE DOMAIN IN COMPLEX WITH KT5720
2403, d2og8A_, 0.7014, 2.61, 0.295, 246, 244, CRYSTAL STRUCTURE OF AMINOQUINAZOLINE 36 BOUND TO LCK
2404, d5modA_, 0.7013, 3.30, 0.152, 327, 257, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
2405, d5cx9A_, 0.7013, 3.28, 0.152, 328, 257, CRYSTAL STRUCTURE OF CK2ALPHA WITH (METHYL 4-((3-(3-CHLORO-4-(PHENYL) BENZYLAMINO)PROPYL)AMINO)-4-OXOBUTANOATE BOUND
2406, d5cswA_, 0.7013, 2.67, 0.216, 254, 245, B-RAF IN COMPLEX WITH DABRAFENIB
2407, d4ptcA_, 0.7013, 3.55, 0.168, 342, 262, STRUCTURE OF A CARBOXAMIDE COMPOUND (3) (2-{2-[(CYCLOPROPYLCARBONYL) AMINO]PYRIDIN-4-YL}-4-OXO-4H-1LAMBDA~4~3-THIAZOLE-5-CARBOXAMIDE) TO GSK3B
2408, d4j8nC_, 0.7013, 3.20, 0.179, 266, 257, AURORA A KINASE APO
2409, d4imyC_, 0.7013, 3.46, 0.153, 310, 262, THE AFF4 SCAFFOLD BINDS HUMAN P-TEFB ADJACENT TO HIV TAT
2410, d4dymA_, 0.7013, 2.91, 0.196, 293, 250, CRYSTAL STRUCTURE OF THE ACVR1 KINASE DOMAIN IN COMPLEX WITH THE IMIDAZO[12-B]PYRIDAZINE INHIBITOR K00135
2411, d3mssB1, 0.7013, 2.66, 0.348, 260, 244, ABL KINASE IN COMPLEX WITH IMATINIB AND FRAGMENT (FRAG2) IN THE MYRISTATE SITE
2412, d2xchA_, 0.7013, 3.31, 0.206, 278, 257, CRYSTAL STRUCTURE OF PDK1 IN COMPLEX WITH A PYRAZOLOQUINAZOLINE INHIBITOR
2413, d1y8yA_, 0.7013, 3.14, 0.183, 292, 252, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A PYRAZOLO[1 5-A]PYRIMIDINE INHIBITOR
2414, d1pxmA_, 0.7013, 2.99, 0.184, 290, 250, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR 3-[4-(24-DIMETHYL-THIAZOL-5-YL)-PYRIMIDIN-2- YLAMINO]-PHENOL
2415, d5moeA_, 0.7012, 3.22, 0.148, 325, 256, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
2416, d4j8nB_, 0.7012, 3.20, 0.179, 266, 257, AURORA A KINASE APO
2417, d4itiA_, 0.7012, 3.18, 0.215, 272, 251, CRYSTAL STRUCTURE OF RIP1 KINASE IN COMPLEX WITH NECROSTATIN-3 ANALOG
2418, d3nunA_, 0.7012, 3.25, 0.203, 278, 256, PHOSPHOINOSITIDE-DEPENDENT KINASE-1 (PDK1) WITH LEAD COMPOUND
2419, d3my0T1, 0.7012, 3.01, 0.167, 291, 252, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
2420, d5c01A_, 0.7011, 2.66, 0.203, 258, 246, CRYSTAL STRUCTURE OF KINASE
2421, d4mneH_, 0.7011, 3.35, 0.189, 275, 259, CRYSTAL STRUCTURE OF THE BRAF:MEK1 COMPLEX
2422, d4j8nA_, 0.7011, 3.20, 0.179, 266, 257, AURORA A KINASE APO
2423, d3lq8A_, 0.7011, 3.17, 0.343, 278, 251, STRUCTURE OF THE KINASE DOMAIN OF C-MET BOUND TO XL880 (GSK1363089)
2424, d2v0dA_, 0.7011, 3.14, 0.183, 292, 252, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
2425, d6b8uA_, 0.7010, 2.76, 0.224, 253, 246, CRYSTALS STRUCTURE OF B-RAF KINASE DOMAIN IN COMPLEX WITH AN IMIDAZOPYRIDINYL BENZAMIDE INHIBITOR
2426, d5mpjA_, 0.7010, 3.28, 0.148, 326, 257, 1-(2-CHLORO-[11 -BIPHENYL]-4-YL)-N-METHYLETHANAMINE
2427, d5ieyA_, 0.7010, 3.13, 0.179, 286, 252, CRYSTAL STRUCTURE OF A CDK INHIBITOR BOUND TO CDK2
2428, d5h3qA_, 0.7010, 3.37, 0.295, 302, 258, CRYSTAL STRUCTURE OF TRKA KINASE WITH LIGAND
2429, d4eonA1, 0.7010, 3.45, 0.157, 297, 261, THR 160 PHOSPHORYLATED CDK2 H84S Q85M Q131E - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR RO3306
2430, d3zrlB_, 0.7010, 3.50, 0.184, 347, 261, IDENTIFICATION OF 2-(4-PYRIDYL)THIENOPYRIDINONES AS GSK-3BETA INHIBITORS
2431, d3o2mA_, 0.7010, 3.00, 0.194, 358, 253, CRYSTAL STRUCTURE OF JNK1-ALPHA1 ISOFORM COMPLEX WITH A BIARYL TETRAZOL (A-82118)
2432, d3mssD1, 0.7010, 2.66, 0.348, 260, 244, ABL KINASE IN COMPLEX WITH IMATINIB AND FRAGMENT (FRAG2) IN THE MYRISTATE SITE
2433, d3lvpD_, 0.7010, 3.04, 0.304, 282, 250, CRYSTAL STRUCTURE OF BISPHOSPHORYLATED IGF1-R KINASE DOMAIN (2P) IN COMPLEX WITH A BIS-AZAINDOLE INHIBITOR
2434, d3kc3E_, 0.7010, 2.83, 0.141, 287, 249, MK2 COMPLEXED TO INHIBITOR N4-(7-(BENZOFURAN-2-YL)-1H-INDAZOL-5-YL) PYRIMIDINE-24-DIAMINE
2435, d1ymiA_, 0.7010, 3.47, 0.154, 334, 260,  
2436, d4ptcB_, 0.7009, 3.50, 0.168, 347, 262, STRUCTURE OF A CARBOXAMIDE COMPOUND (3) (2-{2-[(CYCLOPROPYLCARBONYL) AMINO]PYRIDIN-4-YL}-4-OXO-4H-1LAMBDA~4~3-THIAZOLE-5-CARBOXAMIDE) TO GSK3B
2437, d4erwA_, 0.7009, 3.12, 0.183, 292, 252, CDK2 IN COMPLEX WITH STAUROSPORINE
2438, d4eopC1, 0.7009, 3.38, 0.162, 295, 259, THR 160 PHOSPHORYLATED CDK2 Q131E - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR RO3306
2439, d3d5wA_, 0.7009, 3.54, 0.183, 284, 263, CRYSTAL STRUCTURE OF A PHOSPHORYLATED POLO-LIKE KINASE 1 (PLK1) CATALYTIC DOMAIN IN COMPLEX WITH ADP.
2440, d3bw5A_, 0.7009, 3.47, 0.154, 334, 260,  
2441, d3bhhD1, 0.7009, 3.36, 0.148, 285, 257, CRYSTAL STRUCTURE OF HUMAN CALCIUM/CALMODULIN-DEPENDENT PROTEIN KINASE IIB ISOFORM 1 (CAMK2B)
2442, d3b8rB_, 0.7009, 2.86, 0.300, 267, 247, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A NAPHTHAMIDE INHIBITOR
2443, d2c6kA_, 0.7009, 3.15, 0.179, 292, 252, CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR
2444, d5ho7A_, 0.7008, 3.22, 0.211, 280, 256, DISCOVERY OF NOVEL 7-AZAINDOLES AS PDK1 INHIBITORS
2445, d5cyiA1, 0.7008, 3.43, 0.157, 297, 261, CDK2/CYCLIN A COVALENT COMPLEX WITH 6-(CYCLOHEXYLMETHOXY)-N-(4- (VINYLSULFONYL)PHENYL)-9H-PURIN-2-AMINE (NU6300)
2446, d5clpB_, 0.7008, 3.30, 0.152, 327, 257, CRYSTAL STRUCTURE OF CK2ALPHA WITH 34-DICHLOROPHENETHYLAMINE BOUND
2447, d3zrmB_, 0.7008, 3.49, 0.180, 347, 261, IDENTIFICATION OF 2-(4-PYRIDYL)THIENOPYRIDINONES AS GSK- 3BETA INHIBITORS
2448, d3w8lB_, 0.7008, 3.27, 0.148, 326, 257, CRYSTAL STRUCTURE OF HUMAN CK2 IN COMPLEX WITH INOSITOL HEXAKISPHOSPHATE
2449, d3mssA1, 0.7008, 2.63, 0.352, 260, 244, ABL KINASE IN COMPLEX WITH IMATINIB AND FRAGMENT (FRAG2) IN THE MYRISTATE SITE
2450, d3ms9A1, 0.7008, 2.63, 0.348, 261, 244, ABL KINASE IN COMPLEX WITH IMATINIB AND A FRAGMENT (FRAG1) IN THE MYRISTATE POCKET
2451, d2cchA2, 0.7008, 3.37, 0.154, 295, 259, THE CRYSTAL STRUCTURE OF CDK2 CYCLIN A IN COMPLEX WITH A SUBSTRATE PEPTIDE DERIVED FROM CDC MODIFIED WITH A GAMMA- LINKED ATP ANALOGUE
2452, p5w5qB_, 0.7007, 3.75, 0.174, 297, 264, MAP4K4 IN COMPLEX WITH INHIBITOR COMPOUND 12 (N3-METHYL-10-(3-METHYL- 3-(5-METHYLOXAZOL-2-YL)BUT-1-YN-1-YL)-6;7-DIHYDRO-5H-5;7- METHANOBENZO[C]IMIDAZO[1;2-A]AZEPINE-2;3-DICARBOXAMIDE) 
2453, d5mo8A_, 0.7007, 3.30, 0.152, 325, 257, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
2454, d5lvoA_, 0.7007, 3.55, 0.198, 285, 262, HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH ALLOSTERIC COMPOUND PSE10 BOUND TO THE PIF-POCKET
2455, d4eokC1, 0.7007, 3.36, 0.158, 296, 259, THR 160 PHOSPHORYLATED CDK2 H84S Q85M K89D - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR NU6102
2456, d4bggD_, 0.7007, 2.93, 0.180, 286, 250, CRYSTAL STRUCTURE OF THE ACVR1 KINASE IN COMPLEX WITH LDN-213844
2457, d2r7iB_, 0.7007, 3.20, 0.154, 322, 254, CRYSTAL STRUCTURE OF CATALYTIC SUBUNIT OF PROTEIN KINASE CK2
2458, d1fq1B_, 0.7007, 3.29, 0.174, 295, 258, CRYSTAL STRUCTURE OF KINASE ASSOCIATED PHOSPHATASE (KAP) IN COMPLEX WITH PHOSPHO-CDK2
2459, p5oulA_, 0.7006, 3.29, 0.148, 327, 257, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 9
2460, d5nkiA_, 0.7006, 3.04, 0.304, 268, 253, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 4B
2461, d5mo7B_, 0.7006, 3.15, 0.149, 325, 255, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
2462, d5mo5A_, 0.7006, 3.23, 0.152, 326, 256, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
2463, d5lvnA_, 0.7006, 3.47, 0.196, 283, 260, HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH ADENOSINE BOUND TO THE ATP- BINDING SITE
2464, d5ctpB_, 0.7006, 3.32, 0.148, 327, 257, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(3-CHLORO-4-(PHENYL) BENZYLAMINO)PROPYL)ACETAMIDE BOUND
2465, d4j71B_, 0.7006, 3.58, 0.179, 347, 262, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH INHIBITOR 1R
2466, d4ebwA_, 0.7006, 3.32, 0.329, 259, 255, STRUCTURE OF FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH NOVEL ALLOSTERIC INHIBITOR
2467, d3zrkB_, 0.7006, 3.63, 0.175, 348, 263, IDENTIFICATION OF 2-(4-PYRIDYL)THIENOPYRIDINONES AS GSK-3BETA INHIBITORS
2468, d3pwdA_, 0.7006, 3.34, 0.151, 327, 258, CRYSTAL STRUCTURE OF MAIZE CK2 IN COMPLEX WITH NBC (Z1)
2469, d3my0P_, 0.7006, 3.08, 0.166, 290, 253, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
2470, d2bujA1, 0.7006, 3.42, 0.190, 283, 258, CRYSTAL STRUCTURE OF THE HUMAN SERINE-THREONINE KINASE 16 IN COMPLEX WITH STAUROSPORINE
2471, d1h1rC1, 0.7006, 3.33, 0.163, 295, 258, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH THE INHIBITOR NU6086
2472, d3r8mA_, 0.7005, 3.01, 0.195, 286, 251, CDK2 IN COMPLEX WITH INHIBITOR L3-3
2473, d3db6A_, 0.7005, 3.57, 0.189, 287, 264, CRYSTAL STRUCTURE OF AN ACTIVATED (THR->ASP) POLO-LIKE KINASE 1 (PLK1) CATALYTIC DOMAIN IN COMPLEX WITH COMPOUND 902
2474, d1h1sC1, 0.7005, 3.33, 0.167, 295, 258, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH THE INHIBITOR NU6102
2475, d5cvhA_, 0.7004, 3.31, 0.144, 327, 257, CRYSTAL STRUCTURE OF CK2ALPHA
2476, d4eonC1, 0.7004, 3.39, 0.158, 296, 259, THR 160 PHOSPHORYLATED CDK2 H84S Q85M Q131E - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR RO3306
2477, d4dedA_, 0.7004, 3.36, 0.181, 265, 260, AURORA A IN COMPLEX WITH YL1-038-21
2478, d3zrlA_, 0.7004, 3.57, 0.179, 345, 262, IDENTIFICATION OF 2-(4-PYRIDYL)THIENOPYRIDINONES AS GSK-3BETA INHIBITORS
2479, d3rcjA_, 0.7004, 3.32, 0.209, 281, 258, RAPID PREPARATION OF TRIAZOLYL SUBSTITUTED NH-HETEROCYCLIC KINASE INHIBITORS VIA ONE-POT SONOGASHIRA COUPLING TMS-DEPROTECTION CUAAC SEQUENCE
2480, d3p08A_, 0.7004, 2.94, 0.306, 252, 245, CRYSTAL STRUCTURE OF THE HUMAN BTK KINASE DOMAIN
2481, d3bhuC1, 0.7004, 3.36, 0.167, 269, 258, STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR MERIOLIN 5
2482, d2y7jC_, 0.7004, 3.13, 0.175, 284, 257, STRUCTURE OF HUMAN PHOSPHORYLASE KINASE GAMMA 2
2483, d2c4gA2, 0.7004, 3.48, 0.149, 297, 262, STRUCTURE OF CDK2-CYCLIN A WITH PHA-533514
2484, d2bpmA2, 0.7004, 3.44, 0.153, 298, 262, STRUCTURE OF CDK2-CYCLIN A WITH PHA-630529
2485, d5f95B_, 0.7003, 3.54, 0.172, 338, 262, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH COMPOUND 18: 2- [(CYCLOPROPYLCARBONYL)AMINO]-N-(4-PHENYLPYRIDIN-3-YL)PYRIDINE-4- CARBOXAMIDE
2486, d5ct0B_, 0.7003, 3.25, 0.148, 326, 256, CRYSTAL STRUCTURE OF CK2ALPHA WITH 3-(3-CHLORO-4-(PHENYL)BENZYLAMINO) PROPAN-1-OL BOUND
2487, d4wnpC_, 0.7003, 3.02, 0.202, 271, 252, STRUCTURE OF ULK1 BOUND TO A POTENT INHIBITOR
2488, d4eqmE_, 0.7003, 2.81, 0.165, 268, 248, STRUCTURAL ANALYSIS OF STAPHYLOCOCCUS AUREUS SERINE/THREONINE KINASE PKNB
2489, d3qcqA_, 0.7003, 3.21, 0.204, 276, 255, PHOSPHOINOSITIDE-DEPENDENT KINASE-1 (PDK1) KINASE DOMAIN WITH 6-(3- AMINO-1H-INDAZOL-6-YL)-N4-ETHYL-24-PYRIMIDINEDIAMINE
2490, d3pj8A1, 0.7003, 3.09, 0.183, 287, 252, STRUCTURE OF CDK2 IN COMPLEX WITH A PYRAZOLO[43-D]PYRIMIDINE BIOISOSTERE OF ROSCOVITINE.
2491, d3bhtC1, 0.7003, 3.35, 0.167, 269, 258, STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR MERIOLIN 3
2492, d1pxlA_, 0.7003, 2.98, 0.185, 290, 249, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR [4-(24-DIMETHYL-THIAZOL-5-YL)-PYRIMIDIN-2-YL]- (4-TRIFLUOROMETHYL-PHENYL)-AMINE
2493, d3hrfA_, 0.7002, 3.42, 0.208, 284, 259, CRYSTAL STRUCTURE OF HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH AN ALLOSTERIC ACTIVATOR BOUND TO THE PIF-POCKET
2494, d3a7gA_, 0.7002, 3.74, 0.222, 289, 266, HUMAN MST3 KINASE
2495, d1r1wA_, 0.7002, 3.39, 0.343, 287, 254, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF THE HEPATOCYTE GROWTH FACTOR RECEPTOR C-MET
2496, d5ia5A_, 0.7001, 3.33, 0.324, 273, 256, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH GOLVATINIB (E7050)
2497, d5ew3B_, 0.7001, 2.95, 0.312, 266, 247, HUMAN VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2 (KDR) KINASE DOMAIN IN COMPLEX WITH AAL993
2498, p4mwhA_, 0.7001, 3.31, 0.148, 371, 257, CRYSTAL STRUCTURE OF SCCK2 ALPHA IN COMPLEX WITH ATP
2499, d3mssC1, 0.7001, 2.65, 0.348, 260, 244, ABL KINASE IN COMPLEX WITH IMATINIB AND FRAGMENT (FRAG2) IN THE MYRISTATE SITE
2500, d2r7iD_, 0.7001, 3.21, 0.154, 322, 254, CRYSTAL STRUCTURE OF CATALYTIC SUBUNIT OF PROTEIN KINASE CK2
2501, d4wnoA_, 0.7000, 3.13, 0.197, 272, 254, STRUCTURE OF ULK1 BOUND TO AN INHIBITOR
2502, d4ntsA_, 0.7000, 4.02, 0.157, 341, 274, APO STRUCTURE OF THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE
2503, p4fi1A_, 0.7000, 3.31, 0.148, 371, 257, CRYSTAL STRUCTURE OF SCCK2 ALPHA IN COMPLEX WITH ATP
2504, d4eqmF_, 0.7000, 2.82, 0.169, 268, 248, STRUCTURAL ANALYSIS OF STAPHYLOCOCCUS AUREUS SERINE/THREONINE KINASE PKNB
2505, d3tt0B_, 0.7000, 3.20, 0.332, 272, 253, CO-STRUCTURE OF FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN WITH 3-(26-DICHLORO-35-DIMETHOXY-PHENYL)-1-{6-[4-(4-ETHYL-PIPERAZIN-1- YL)-PHENYLAMINO]-PYRIMIDIN-4-YL}-1-METHYL-UREA (BGJ398)
2506, d3rwpA_, 0.7000, 3.37, 0.202, 277, 257, DISCOVERY OF A NOVEL POTENT AND SELECTIVE INHIBITOR OF 3- PHOSPHOINOSITIDE DEPENDENT KINASE (PDK1)
2507, d3r83A_, 0.7000, 3.30, 0.176, 294, 255, CDK2 IN COMPLEX WITH INHIBITOR KVR-2-92
2508, d3m1sA_, 0.7000, 3.57, 0.168, 348, 262, STRUCTURE OF RUTHENIUM HALF-SANDWICH COMPLEX BOUND TO GLYCOGEN SYNTHASE KINASE 3
2509, d2wpaA1, 0.7000, 3.44, 0.156, 298, 262, OPTIMISATION OF 66-DIMETHYL PYRROLO 34-C PYRAZOLES: IDENTIFICATION OF PHA-793887 A POTENT CDK INHIBITOR SUITABLE FOR INTRAVENOUS DOSING
2510, d1unlB_, 0.7000, 3.18, 0.145, 292, 255, STRUCTURAL MECHANISM FOR THE INHIBITION OF CD5-P25 FROM THE ROSCOVITINE ALOISINE AND INDIRUBIN.
2511, d5mo6A_, 0.6999, 3.25, 0.148, 325, 256, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
2512, d5mmfB_, 0.6999, 3.25, 0.148, 325, 256, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 7 BOUND
2513, d5cu4A_, 0.6999, 3.28, 0.152, 327, 257, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 10 BOUND
2514, d4itjA_, 0.6999, 3.10, 0.217, 261, 249, CRYSTAL STRUCTURE OF RIP1 KINASE IN COMPLEX WITH NECROSTATIN-4
2515, d3m1sB_, 0.6999, 3.52, 0.169, 349, 261, STRUCTURE OF RUTHENIUM HALF-SANDWICH COMPLEX BOUND TO GLYCOGEN SYNTHASE KINASE 3
2516, d3juhB_, 0.6999, 3.49, 0.146, 334, 260, CRYSTAL STRUCTURE OF A MUTANT OF HUMAN PROTEIN KINASE CK2ALPHA WITH ALTERED COSUBSTRATE SPECIFICITY
2517, d3juhA_, 0.6999, 3.49, 0.154, 334, 260, CRYSTAL STRUCTURE OF A MUTANT OF HUMAN PROTEIN KINASE CK2ALPHA WITH ALTERED COSUBSTRATE SPECIFICITY
2518, d3ewhA1, 0.6999, 3.63, 0.307, 295, 261, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A PYRIDYL-PYRIMIDINE BENZIMIDAZOLE INHIBITOR
2519, d3cpcB_, 0.6999, 2.75, 0.311, 262, 244, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A PYRIDONE INHIBITOR
2520, p2h96B_, 0.6999, 2.99, 0.202, 357, 252, DISCOVERY OF POTENT HIGHLY SELECTIVE AND ORALLY BIOAVAILABLE PYRIDINE CARBOXAMIDE C-JUN NH2-TERMINAL KINASE INHIBITORS
2521, d1qmzC1, 0.6999, 3.38, 0.167, 295, 258, PHOSPHORYLATED CDK2-CYCLYIN A-SUBSTRATE PEPTIDE COMPLEX
2522, d5cx9B_, 0.6998, 3.25, 0.145, 325, 256, CRYSTAL STRUCTURE OF CK2ALPHA WITH (METHYL 4-((3-(3-CHLORO-4-(PHENYL) BENZYLAMINO)PROPYL)AMINO)-4-OXOBUTANOATE BOUND
2523, d4eqmD_, 0.6998, 2.83, 0.169, 268, 248, STRUCTURAL ANALYSIS OF STAPHYLOCOCCUS AUREUS SERINE/THREONINE KINASE PKNB
2524, d3h9oA_, 0.6998, 3.18, 0.209, 275, 254, PHOSPHOINOSITIDE-DEPENDENT PROTEIN KINASE 1 (PDK-1) IN COMPLEX WITH COMPOUND 9
2525, d5os2A_, 0.6997, 3.09, 0.182, 261, 253, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
2526, d4wnpA_, 0.6997, 3.05, 0.202, 273, 253, STRUCTURE OF ULK1 BOUND TO A POTENT INHIBITOR
2527, d1qmzA1, 0.6997, 3.38, 0.167, 295, 258, PHOSPHORYLATED CDK2-CYCLYIN A-SUBSTRATE PEPTIDE COMPLEX
2528, d1jstC_, 0.6997, 3.48, 0.153, 297, 261, PHOSPHORYLATED CYCLIN-DEPENDENT KINASE-2 BOUND TO CYCLIN A
2529, d5mo8B_, 0.6996, 3.25, 0.152, 324, 256, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
2530, d5dewA_, 0.6996, 3.89, 0.190, 295, 268, CRYSTAL STRUCTURE OF PAK1 IN COMPLEX WITH AN INHIBITOR COMPOUND 5
2531, d4lynA_, 0.6996, 3.06, 0.179, 287, 251, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 (CDK2-WT) COMPLEX WITH (2S)-N-(5-(((5-TERT-BUTYL-13-OXAZOL-2-YL)METHYL)SULFANYL)-13- THIAZOL-2-YL)-2-PHENYLPROPANAMIDE
2532, d4cxaA_, 0.6996, 3.83, 0.144, 329, 270, CRYSTAL STRUCTURE OF THE HUMAN CDK12-CYCLIN K COMPLEX BOUND TO AMPPNP
2533, d3zonA_, 0.6996, 2.71, 0.203, 261, 246, HUMAN TYK2 PSEUDOKINASE DOMAIN BOUND TO A KINASE INHIBITOR
2534, d3sayA_, 0.6996, 3.57, 0.176, 347, 261, CRYSTAL STRUCTURE OF HUMAN GLYCOGEN SYNTHASE KINASE 3 BETA (GSK3B) IN COMPLEX WITH INHIBITOR 142
2535, d3qcsA_, 0.6996, 3.22, 0.204, 276, 255, PHOSPHOINOSITIDE-DEPENDENT KINASE-1 (PDK1) KINASE DOMAIN WITH 6-[2- AMINO-6-(4-MORPHOLINYL)-4-PYRIMIDINYL]-1H-INDAZOL-3-AMINE
2536, d2b53A_, 0.6996, 3.23, 0.165, 294, 254, HUMAN CYCLIN DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH DIN- 234325
2537, d1uwjB_, 0.6996, 3.02, 0.223, 263, 251, THE COMPLEX OF MUTANT V599E B-RAF AND BAY439006
2538, d1oguC1, 0.6996, 3.36, 0.167, 269, 258, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH A 2-ARYLAMINO-4-CYCLOHEXYLMETHYL-5-NITROSO-6-AMINOPYRIMIDINE INHIBITOR
2539, d1h8fB_, 0.6996, 3.57, 0.172, 350, 261, GLYCOGEN SYNTHASE KINASE 3 BETA.
2540, d1h8fA_, 0.6996, 3.57, 0.172, 352, 261, GLYCOGEN SYNTHASE KINASE 3 BETA.
2541, d5mowA1, 0.6995, 3.26, 0.145, 326, 256, CRYSTAL STRUCTURE OF CK2ALPHA WITH ZT0432 BOUND
2542, d5hieC_, 0.6995, 2.59, 0.213, 253, 244, BRAF KINASE DOMAIN B3AC LOOP DELETION MUTANT IN COMPLEX WITH DABRAFENIB
2543, d4fc0A_, 0.6995, 2.73, 0.228, 254, 246, CRYSTAL STRUCTURE OF HUMAN KINASE DOMAIN OF B-RAF WITH A DFG-OUT INHIBITOR
2544, d3nusA_, 0.6995, 3.30, 0.207, 276, 256, PHOSPHOINOSITIDE-DEPENDENT KINASE-1 (PDK1) WITH FRAGMENT8
2545, d3f7zB1, 0.6995, 3.49, 0.173, 338, 260, X-RAY CO-CRYSTAL STRUCTURE OF GLYCOGEN SYNTHASE KINASE 3BETA IN COMPLEX WITH AN INHIBITOR
2546, d1q3wA_, 0.6995, 3.59, 0.164, 344, 262, GSK-3 BETA COMPLEXED WITH ALSTERPAULLONE
2547, d5mpjB_, 0.6994, 3.25, 0.148, 324, 256, 1-(2-CHLORO-[11 -BIPHENYL]-4-YL)-N-METHYLETHANAMINE
2548, d5hlnA_, 0.6994, 3.59, 0.168, 346, 262, X-RAY CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH CHIR99021
2549, d5cvhB_, 0.6994, 3.25, 0.145, 324, 256, CRYSTAL STRUCTURE OF CK2ALPHA
2550, d4ptgA_, 0.6994, 3.64, 0.175, 333, 263, STRUCTURE OF A CARBOXAMINE COMPOUND (26) (2-{2-[(CYCLOPROPYLCARBONYL) AMINO]PYRIDIN-4-YL}-4-METHOXYPYRIMIDINE-5-CARBOXAMIDE) TO GSK3B
2551, d3my0O1, 0.6994, 3.04, 0.167, 296, 252, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
2552, d2zm3B2, 0.6994, 3.58, 0.292, 295, 260, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND ISOQUINOLINEDIONE INHIBITOR
2553, d2y6oA_, 0.6994, 3.21, 0.305, 263, 256, CRYSTAL STRUCTURE OF EPHA4 KINASE DOMAIN IN COMPLEX WITH DASATINIB.
2554, d2w1hA_, 0.6993, 3.05, 0.180, 283, 250, FRAGMENT-BASED DISCOVERY OF THE PYRAZOL-4-YL UREA (AT9283) A MULTI-TARGETED KINASE INHIBITOR WITH POTENT AURORA KINASE ACTIVITY
2555, d2o5kA1, 0.6993, 3.54, 0.172, 350, 262, CRYSTAL STRUCTURE OF GSK3BETA IN COMPLEX WITH A BENZOIMIDAZOL INHIBITOR
2556, d1p4fA_, 0.6993, 2.97, 0.180, 269, 250, DEATH ASSOCIATED PROTEIN KINASE CATALYTIC DOMAIN WITH BOUND INHIBITOR FRAGMENT
2557, d3uliA_, 0.6992, 3.16, 0.179, 286, 252, HUMAN CYCLIN DEPENDENT KINASE 2 (CDK2) BOUND TO AZABENZIMIDAZOLE DERIVATIVE
2558, d3lvpB_, 0.6992, 3.55, 0.291, 295, 261, CRYSTAL STRUCTURE OF BISPHOSPHORYLATED IGF1-R KINASE DOMAIN (2P) IN COMPLEX WITH A BIS-AZAINDOLE INHIBITOR
2559, d3gb2A_, 0.6992, 3.59, 0.168, 340, 262, GSK3BETA INHIBITOR COMPLEX
2560, d2uzlA_, 0.6992, 3.43, 0.158, 295, 259, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
2561, d2iw8C2, 0.6992, 3.23, 0.173, 264, 255, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2-CYCLIN A F82H-L83V- H84D MUTANT WITH AN O6-CYCLOHEXYLMETHYLGUANINE INHIBITOR
2562, d2c4gC2, 0.6992, 3.51, 0.153, 298, 262, STRUCTURE OF CDK2-CYCLIN A WITH PHA-533514
2563, d2bkzA2, 0.6992, 3.46, 0.156, 298, 262, STRUCTURE OF CDK2-CYCLIN A WITH PHA-404611
2564, d1okzA_, 0.6992, 3.22, 0.212, 276, 255, STRUCTURE OF HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH UCN-01
2565, d4p2kA_, 0.6991, 3.24, 0.316, 259, 253, STRUCTURE OF EPHRIN TYPE-A RECEPTOR 2
2566, d3qd3A_, 0.6991, 3.36, 0.202, 278, 257, PHOSPHOINOSITIDE-DEPENDENT KINASE-1 (PDK1) KINASE DOMAIN WITH 11- DIMETHYLETHYL {(3R6S)-1-[2-AMINO-6-(3-AMINO-1H-INDAZOL-6-YL)-4- PYRIMIDINYL]-6-METHYL-3-PIPERIDINYL}CARBAMATE
2567, d2dwbA_, 0.6991, 3.08, 0.182, 259, 253, AURORA-A KINASE COMPLEXED WITH AMPPNP
2568, d2c69A_, 0.6991, 3.11, 0.175, 292, 251, CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR
2569, d5j95B_, 0.6990, 3.70, 0.168, 300, 262, MAP4K4 IN COMPLEX WITH INHIBITOR
2570, d5hlpA_, 0.6990, 3.62, 0.176, 337, 262, X-RAY CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH BRD3937
2571, d5f95A_, 0.6990, 3.59, 0.168, 345, 262, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH COMPOUND 18: 2- [(CYCLOPROPYLCARBONYL)AMINO]-N-(4-PHENYLPYRIDIN-3-YL)PYRIDINE-4- CARBOXAMIDE
2572, d5cyiC1, 0.6990, 3.46, 0.154, 295, 260, CDK2/CYCLIN A COVALENT COMPLEX WITH 6-(CYCLOHEXYLMETHOXY)-N-(4- (VINYLSULFONYL)PHENYL)-9H-PURIN-2-AMINE (NU6300)
2573, d5cshA_, 0.6990, 3.27, 0.148, 324, 256, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 4 BOUND
2574, d3v5lB1, 0.6990, 2.13, 0.326, 239, 236, CRYSTAL STRUCTURE OF INTERLEUKIN-2 INDUCIBLE T-CELL KINASE ITK CATALYTIC DOMAIN WITH THIENOPYRAZOLYLINDOLE INHIBITOR 542
2575, d3h30A_, 0.6990, 3.48, 0.150, 333, 260, CRYSTAL STRUCTURE OF THE CATALYTIC SUBUNIT OF HUMAN PROTEIN KINASE CK2 WITH 56-DICHLORO-1-BETA-D- RIBOFURANOSYLBENZIMIDAZOLE
2576, d3bhhC1, 0.6990, 3.46, 0.151, 284, 258, CRYSTAL STRUCTURE OF HUMAN CALCIUM/CALMODULIN-DEPENDENT PROTEIN KINASE IIB ISOFORM 1 (CAMK2B)
2577, d2wmbC1, 0.6990, 3.28, 0.167, 265, 257, STRUCTURAL AND THERMODYNAMIC CONSEQUENCES OF CYCLIZATION OF PEPTIDE LIGANDS FOR THE RECRUITMENT SITE OF CYCLIN A
2578, d1pyxB_, 0.6990, 3.55, 0.164, 338, 262, GSK-3 BETA COMPLEXED WITH AMP-PNP
2579, d1oi9C1, 0.6990, 3.39, 0.158, 295, 259, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH A 6-CYCLOHEXYLMETHYLOXY-2-ANILINO-PURINE INHIBITOR
2580, d1j1bB_, 0.6990, 3.64, 0.175, 364, 263, BINARY COMPLEX STRUCTURE OF HUMAN TAU PROTEIN KINASE I WITH AMPPNP
2581, d5jt2B1, 0.6989, 2.48, 0.227, 250, 242, BRAFV600E KINASE DOMAIN IN COMPLEX WITH CHEMICALLY LINKED VEMURAFENIB INHIBITOR VEM-BISAMIDE
2582, d5f9eB_, 0.6989, 3.45, 0.172, 293, 262, STRUCTURE OF PROTEIN KINASE C THETA WITH COMPOUND 10: 22-DIMETHYL-7- (2-OXIDANYLIDENE-3~{H}-IMIDAZO[45-B]PYRIDIN-1-YL)-1-(PHENYLMETHYL)- 3~{H}-QUINAZOLIN-4-ONE
2583, d5cvgA_, 0.6989, 3.24, 0.153, 326, 255, CRYSTAL STRUCTURE OF CK2ALPHA WITH A NOVEL CLOSED CONFORMATION OF THE AD LOOP
2584, d4j8nD_, 0.6989, 3.19, 0.180, 265, 256, AURORA A KINASE APO
2585, d4eosC1, 0.6989, 3.37, 0.167, 295, 258, THR 160 PHOSPHORYLATED CDK2 WT - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR RO3306
2586, d4bcoC1, 0.6989, 3.33, 0.167, 268, 257, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
2587, d1q41A_, 0.6989, 3.62, 0.179, 339, 262, GSK-3 BETA COMPLEXED WITH INDIRUBIN-3 -MONOXIME
2588, d5mmrB_, 0.6988, 3.24, 0.152, 325, 256, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-((2-CHLORO-[11 -BIPHENYL]-4-YL) METHYL)BUTANE-14-DIAMINE BOUND
2589, d4u43B_, 0.6988, 3.79, 0.171, 302, 263, MAP4K4 IN COMPLEX WITH INHIBITOR (COMPOUND 6)
2590, d4u3zA_, 0.6988, 3.26, 0.176, 282, 255, APO MAP4K4 T181E PHOSPHOMIMETIC MUTANT
2591, d3a7gB_, 0.6988, 3.75, 0.225, 290, 267, HUMAN MST3 KINASE
2592, d2x7fB_, 0.6988, 3.39, 0.182, 288, 258, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN TRAF2- AND NCK-INTERACTING KINASE WITH WEE1CHK1 INHIBITOR
2593, d2iw8A1, 0.6988, 3.30, 0.160, 296, 257, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2-CYCLIN A F82H-L83V- H84D MUTANT WITH AN O6-CYCLOHEXYLMETHYLGUANINE INHIBITOR
2594, d1uu9A_, 0.6988, 3.25, 0.215, 276, 256, STRUCTURE OF HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH BIM-3
2595, d1q5kB_, 0.6988, 3.63, 0.167, 344, 263, CRYSTAL STRUCTURE OF GLYCOGEN SYNTHASE KINASE 3 IN COMPLEXED WITH INHIBITOR
2596, d1fvvC_, 0.6988, 3.50, 0.149, 298, 262, THE STRUCTURE OF CDK2/CYCLIN A IN COMPLEX WITH AN OXINDOLE INHIBITOR
2597, d4u41B_, 0.6987, 3.64, 0.176, 297, 262, MAP4K4 BOUND TO INHIBITOR COMPOUND 1
2598, d3qcxA_, 0.6987, 3.23, 0.204, 276, 255, PHOSPHOINOSITIDE-DEPENDENT KINASE-1 (PDK1) KINASE DOMAIN WITH 6-{2- AMINO-6-[(3R)-3-METHYL-4-MORPHOLINYL]-4-PYRIMIDINYL}-1H-INDAZOL-3- AMINE
2599, d3og7A_, 0.6987, 2.47, 0.224, 247, 241, B-RAF KINASE V600E ONCOGENIC MUTANT IN COMPLEX WITH PLX4032
2600, d5cvfA_, 0.6986, 3.26, 0.145, 325, 255, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 5 BOUND
2601, d4oboB_, 0.6986, 3.65, 0.176, 297, 262, MAP4K4 IN COMPLEX WITH INHIBITOR (COMPOUND 22) 6-(3-CHLOROPHENYL) QUINAZOLIN-4-AMINE
2602, d4f65B_, 0.6986, 3.40, 0.312, 279, 256, CRYSTAL STRUCTURE OF HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN IN COMPLEX WITH COMPOUND 8
2603, d4bcoA1, 0.6986, 3.37, 0.158, 297, 259, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
2604, d3nuyA_, 0.6986, 3.31, 0.207, 276, 256, PHOSPHOINOSITIDE-DEPENDENT KINASE-1 (PDK1) WITH FRAGMENT17
2605, d3nuuA_, 0.6986, 3.30, 0.207, 276, 256, PHOSPHOINOSITIDE-DEPENDENT KINASE-1 (PDK1) WITH FRAGMENT11
2606, d3gxlA_, 0.6986, 2.82, 0.165, 285, 248, ALK-5 KINASE COMPLEX WITH GW857175
2607, d3byuA_, 0.6986, 2.83, 0.294, 256, 248, CO-CRYSTAL STRUCTURE OF LCK AND AMINOPYRIMIDINE REVERSE AMIDE 23
2608, d2hz0B_, 0.6986, 2.32, 0.359, 243, 237, ABL KINASE DOMAIN IN COMPLEX WITH NVP-AEG082
2609, d5moeB_, 0.6985, 3.21, 0.145, 323, 255, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
2610, d2pe0A_, 0.6985, 3.35, 0.207, 275, 256, CRYSTAL STRUCTURE OF HUMAN PHOSPHOINOSITIDE-DEPENDENT PROTEIN KINASE 1 (PDK1) 5-HYDROXY-3-[1-(1H-PYRROL-2-YL)-ETH-(Z)-YLIDENE]-13-DIHYDRO- INDOL-2-ONE COMPLEX
2611, d1w8cA_, 0.6985, 3.15, 0.183, 290, 251, CO-CRYSTAL STRUCTURE OF 6-CYCLOHEXYLMETHOXY-8-ISOPROPYL-9H- PURIN-2-YLAMINE AND MONOMERIC CDK2
2612, d6bqpA1, 0.6984, 3.12, 0.175, 262, 252, CRYSTAL STRUCTURE OF THE HUMAN CAMKK2B IN COMPLEX WITH CRENOLANIB
2613, d5di1B_, 0.6984, 3.74, 0.163, 300, 263, MAP4K4 IN COMPLEX WITH AN INHIBITOR
2614, d4oboA_, 0.6984, 3.18, 0.171, 275, 252, MAP4K4 IN COMPLEX WITH INHIBITOR (COMPOUND 22) 6-(3-CHLOROPHENYL) QUINAZOLIN-4-AMINE
2615, d2iw9C2, 0.6984, 3.28, 0.168, 267, 256, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2-CYCLIN A COMPLEXED WITH A BISANILINOPYRIMIDINE INHIBITOR
2616, d5valB_, 0.6983, 2.92, 0.219, 254, 247, BRAF IN COMPLEX WITH N-(3-(TERT-BUTYL)PHENYL)-4-METHYL-3-(6- MORPHOLINOPYRIMIDIN-4-YL)BENZAMIDE
2617, d4gu9A_, 0.6983, 3.02, 0.347, 252, 248, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH (2-FLUORO- PHENYL)-(1H-PYRAZOLO[34-D]PYRIMIDIN-4-YL)-AMINE
2618, d2uzoA_, 0.6983, 3.07, 0.184, 290, 250, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
2619, d4ct1A_, 0.6982, 3.50, 0.200, 283, 260, HUMAN PDK1-PKCZETA KINASE CHIMERA IN COMPLEX WITH ALLOSTERIC COMPOUND PS315 BOUND TO THE PIF-POCKET
2620, d3v5qB1, 0.6982, 2.93, 0.294, 262, 248, DISCOVERY OF A SELECTIVE TRK INHIBITOR WITH EFFICACY IN RODENT CANCER TUMOR MODELS
2621, d1gy3A_, 0.6982, 3.51, 0.154, 295, 260, PCDK2/CYCLIN A IN COMPLEX WITH MGADP NITRATE AND PEPTIDE SUBSTRATE
2622, p6ehuA_, 0.6981, 3.40, 0.156, 327, 257, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 32
2623, d5mo6B_, 0.6981, 3.27, 0.148, 324, 256, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
2624, d4ztlD_, 0.6981, 3.02, 0.209, 285, 249, IRAK4-INHIBITOR CO-STRUCTURE
2625, d3sqqA_, 0.6981, 2.94, 0.185, 288, 248, CDK2 IN COMPLEX WITH INHIBITOR RC-3-96
2626, d3my0W1, 0.6981, 2.97, 0.172, 280, 250, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
2627, d3dtwB_, 0.6981, 2.97, 0.310, 269, 248, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A BENZISOXAZOLE INHIBITOR
2628, d2uzlC_, 0.6981, 3.36, 0.159, 295, 258, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
2629, d1q5kA_, 0.6981, 3.64, 0.167, 345, 263, CRYSTAL STRUCTURE OF GLYCOGEN SYNTHASE KINASE 3 IN COMPLEXED WITH INHIBITOR
2630, d1gy3C_, 0.6981, 3.44, 0.158, 295, 259, PCDK2/CYCLIN A IN COMPLEX WITH MGADP NITRATE AND PEPTIDE SUBSTRATE
2631, d4nusA_, 0.6980, 3.57, 0.194, 301, 263, RSK2 N-TERMINAL KINASE IN COMPLEX WITH LJH685
2632, d3du8A_, 0.6980, 3.59, 0.172, 336, 262, CRYSTAL STRUCTURE OF GSK-3 BETA IN COMPLEX WITH NMS-869553A
2633, d3bhuA1, 0.6980, 3.26, 0.160, 295, 257, STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR MERIOLIN 5
2634, d1h0uA_, 0.6980, 3.16, 0.183, 291, 251,  
2635, d5ievA_, 0.6979, 3.05, 0.180, 284, 250, CRYSTAL STRUCTURE OF BAY 1000394 (RONICICLIB) BOUND TO CDK2
2636, d5cu3B_, 0.6979, 3.20, 0.157, 324, 255, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 10 BOUND
2637, d3zzwB_, 0.6979, 2.83, 0.297, 265, 246, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF ROR2
2638, d3p86A_, 0.6979, 2.52, 0.235, 250, 243, CRYSTAL STRUCTURE OF CTR1 KINASE DOMAIN MUTANT D676N IN COMPLEX WITH STAUROSPORINE
2639, d1pxkA_, 0.6979, 3.03, 0.185, 290, 249, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR N-[4-(24-DIMETHYL-THIAZOL-5-YL)PYRIMIDIN-2-YL]- N -HYDROXYIMINOFORMAMIDE
2640, d1i09A_, 0.6979, 3.53, 0.177, 338, 260, STRUCTURE OF GLYCOGEN SYNTHASE KINASE-3 (GSK3B)
2641, d5te0A_, 0.6978, 3.08, 0.143, 316, 252, CRYSTAL STRUCTURE OF ADAPTOR PROTEIN 2 ASSOCIATED KINASE (AAK1) IN COMPLEX WITH BIBF 1120
2642, d5mp8A_, 0.6978, 3.28, 0.148, 325, 256, CRYSTAL STRUCTURE OF CK2ALPHA WITH ZT0432 BOUND
2643, d4wnpD_, 0.6978, 3.12, 0.202, 272, 253, STRUCTURE OF ULK1 BOUND TO A POTENT INHIBITOR
2644, d3p08B_, 0.6978, 2.87, 0.305, 258, 243, CRYSTAL STRUCTURE OF THE HUMAN BTK KINASE DOMAIN
2645, d4qo9B_, 0.6977, 3.72, 0.238, 285, 265, MST3 IN COMPLEX WITH DANUSERTIB
2646, d4mwiA_, 0.6977, 2.82, 0.176, 266, 250, CRYSTAL STRUCTURE OF THE HUMAN MLKL PSEUDOKINASE DOMAIN
2647, d3sayB_, 0.6977, 3.59, 0.169, 347, 261, CRYSTAL STRUCTURE OF HUMAN GLYCOGEN SYNTHASE KINASE 3 BETA (GSK3B) IN COMPLEX WITH INHIBITOR 142
2648, d3i4bA_, 0.6977, 3.63, 0.167, 359, 263, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH A PYRIMIDYLPYRROLE INHIBITOR
2649, d2jldA_, 0.6977, 3.57, 0.169, 349, 261, EXTREMELY TIGHT BINDING OF RUTHENIUM COMPLEX TO GLYCOGEN SYNTHASE KINASE 3
2650, d1e1xA_, 0.6977, 3.12, 0.184, 290, 250, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR NU6027
2651, d5imeA1, 0.6976, 3.39, 0.191, 279, 256, CRYSTAL STRUCTURE OF P21-ACTIVATED KINASE 1 (PAK1) IN COMPLEX WITH COMPOUND 9
2652, d2c5nA_, 0.6976, 3.42, 0.154, 296, 260, DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND  INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN
2653, d5mowB_, 0.6975, 3.27, 0.148, 324, 256, CRYSTAL STRUCTURE OF CK2ALPHA WITH ZT0432 BOUND
2654, d5l6oA_, 0.6975, 2.93, 0.323, 267, 248, EPHB3 KINASE DOMAIN COVALENTLY BOUND TO AN IRREVERSIBLE INHIBITOR (COMPOUND 3)
2655, d4eojC1, 0.6975, 3.38, 0.163, 278, 258, THR 160 PHOSPHORYLATED CDK2 H84S Q85M K89D - HUMAN CYCLIN A3 COMPLEX WITH ATP
2656, d4cfwA1, 0.6975, 3.45, 0.158, 297, 260, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6- CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
2657, d4btmB_, 0.6975, 3.63, 0.160, 293, 263, TTBK1 IN COMPLEX WITH INHIBITOR
2658, d4bcpA1, 0.6975, 3.39, 0.158, 297, 259, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
2659, d3v5lC1, 0.6975, 2.40, 0.321, 242, 240, CRYSTAL STRUCTURE OF INTERLEUKIN-2 INDUCIBLE T-CELL KINASE ITK CATALYTIC DOMAIN WITH THIENOPYRAZOLYLINDOLE INHIBITOR 542
2660, d3a7hA_, 0.6975, 3.74, 0.215, 289, 265, HUMAN MST3 KINASE IN COMPLEX WITH ATP
2661, d2zm3D2, 0.6975, 3.59, 0.293, 292, 259, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND ISOQUINOLINEDIONE INHIBITOR
2662, d2y7jD_, 0.6975, 3.19, 0.184, 281, 256, STRUCTURE OF HUMAN PHOSPHORYLASE KINASE GAMMA 2
2663, d2r7iA_, 0.6975, 3.17, 0.150, 322, 253, CRYSTAL STRUCTURE OF CATALYTIC SUBUNIT OF PROTEIN KINASE CK2
2664, d4nm0A1, 0.6974, 3.53, 0.169, 355, 261, CRYSTAL STRUCTURE OF PEPTIDE INHIBITOR-FREE GSK-3/AXIN COMPLEX
2665, d3v5jA1, 0.6974, 2.19, 0.314, 239, 236, CRYSTAL STRUCTURE OF INTERLEUKIN-2 INDUCIBLE T-CELL KINASE ITK CATALYTIC DOMAIN WITH THIENOPYRAZOLYLINDOLE INHIBITOR 090
2666, d3iopA_, 0.6974, 3.05, 0.214, 275, 252, PDK-1 IN COMPLEX WITH THE INHIBITOR COMPOUND-8I
2667, d3gxjA_, 0.6974, 2.94, 0.164, 288, 250,  
2668, d3a7hB_, 0.6974, 3.67, 0.230, 290, 265, HUMAN MST3 KINASE IN COMPLEX WITH ATP
2669, d2iw6C2, 0.6974, 3.34, 0.167, 294, 257, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2-CYCLIN A COMPLEXED WITH A BISANILINOPYRIMIDINE INHIBITOR
2670, p2g01B_, 0.6974, 3.11, 0.193, 356, 254, PYRAZOLOQUINOLONES AS NOVEL SELECTIVE JNK1 INHIBITORS
2671, d2c6oA_, 0.6974, 3.13, 0.183, 290, 251, CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR
2672, d5ceoA_, 0.6973, 2.84, 0.239, 269, 247, DLK IN COMPLEX WITH INHIBITOR 2-((6-(33-DIFLUOROPYRROLIDIN-1-YL)-4- (1-(OXETAN-3-YL)PIPERIDIN-4-YL)PYRIDIN-2-YL)AMINO)ISONICOTINONITRILE
2673, d4usdA_, 0.6973, 3.01, 0.180, 268, 250, HUMAN STK10 (LOK) WITH SB-633825
2674, d3mpmA_, 0.6973, 2.94, 0.277, 257, 249, LCK COMPLEXED WITH A PYRAZOLOPYRIMIDINE
2675, d3i4bB_, 0.6973, 3.62, 0.167, 347, 263, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH A PYRIMIDYLPYRROLE INHIBITOR
2676, d3du8B_, 0.6973, 3.62, 0.172, 339, 262, CRYSTAL STRUCTURE OF GSK-3 BETA IN COMPLEX WITH NMS-869553A
2677, d1h0vA_, 0.6973, 3.07, 0.184, 288, 250, HUMAN CYCLIN DEPENDENT PROTEIN KINASE 2 IN COMPLEX WITH THE INHIBITOR 2-AMINO-6-[(R)-PYRROLIDINO-5 -YL]METHOXYPURINE
2678, d1b39A_, 0.6973, 3.03, 0.185, 290, 249, HUMAN CYCLIN-DEPENDENT KINASE 2 PHOSPHORYLATED ON THR 160
2679, d5mo5B_, 0.6972, 3.28, 0.148, 325, 256, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
2680, d5cu3A_, 0.6972, 3.20, 0.153, 325, 255, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 10 BOUND
2681, d4kioD1, 0.6972, 2.27, 0.315, 240, 238, KINASE DOMAIN MUTANT OF HUMAN ITK IN COMPLEX WITH A COVALENTLY-BINDING INHIBITOR
2682, d4fkoA_, 0.6972, 3.02, 0.189, 291, 249, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH THIAZOLYLPYRIMIDINE INHIBITOR
2683, d3zzwA_, 0.6972, 3.02, 0.288, 269, 250, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF ROR2
2684, d3ddpA1, 0.6972, 3.51, 0.154, 296, 260, STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR CR8
2685, d5hlpB_, 0.6971, 3.64, 0.176, 335, 262, X-RAY CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH BRD3937
2686, d2uzeA_, 0.6971, 3.45, 0.158, 295, 259, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
2687, d2c6lA_, 0.6971, 3.08, 0.180, 291, 250, CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR
2688, d1h1qC1, 0.6971, 3.45, 0.154, 295, 259, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH THE INHIBITOR NU6094
2689, d5lqfA1, 0.6970, 2.95, 0.187, 284, 251, CDK1/CYCLINB1/CKS2 IN COMPLEX WITH NU6102
2690, d4bcnA1, 0.6970, 3.38, 0.158, 295, 259, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
2691, d3v5lA1, 0.6970, 2.11, 0.328, 238, 235, CRYSTAL STRUCTURE OF INTERLEUKIN-2 INDUCIBLE T-CELL KINASE ITK CATALYTIC DOMAIN WITH THIENOPYRAZOLYLINDOLE INHIBITOR 542
2692, d2uzeC_, 0.6970, 3.40, 0.154, 295, 259, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
2693, d2g9xA2, 0.6970, 3.32, 0.167, 297, 257, STRUCTURE OF THR 160 PHOSPHORYLATED CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR NU6271
2694, d1j1cB_, 0.6970, 3.66, 0.171, 364, 263, BINARY COMPLEX STRUCTURE OF HUMAN TAU PROTEIN KINASE I WITH ADP
2695, d4dbnA_, 0.6969, 2.88, 0.223, 257, 247, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN B-RAF WITH A [1 3]THIAZOLO[54-B]PYRIDINE DERIVATIVE
2696, d4aw0A_, 0.6969, 3.55, 0.200, 283, 260, HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH ALLOSTERIC COMPOUND PS182 BOUND TO THE PIF-POCKET
2697, d3iecD_, 0.6969, 3.25, 0.215, 311, 256, HELICOBACTER PYLORI CAGA INHIBITS PAR1/MARK FAMILY KINASES BY MIMICKING HOST SUBSTRATES
2698, d2jldB_, 0.6969, 3.60, 0.164, 349, 262, EXTREMELY TIGHT BINDING OF RUTHENIUM COMPLEX TO GLYCOGEN SYNTHASE KINASE 3
2699, d1q3wB_, 0.6969, 3.61, 0.160, 341, 262, GSK-3 BETA COMPLEXED WITH ALSTERPAULLONE
2700, d1i09B_, 0.6969, 3.57, 0.169, 341, 261, STRUCTURE OF GLYCOGEN SYNTHASE KINASE-3 (GSK3B)
2701, d1gz8A_, 0.6969, 3.17, 0.183, 290, 251, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR 2-AMINO-6-(3 -METHYL-2 -OXO)BUTOXYPURINE
2702, d5cs6A_, 0.6968, 3.37, 0.152, 327, 257, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 3 BOUND
2703, d4k8aA_, 0.6968, 3.02, 0.355, 251, 248, FRAGMENT-BASED DISCOVERY OF FOCAL ADHESION KINASE INHIBITORS
2704, d4ct2A_, 0.6968, 3.25, 0.201, 277, 254, HUMAN PDK1-PKCZETA KINASE CHIMERA
2705, d4acgA_, 0.6968, 3.61, 0.160, 350, 262, GSK3B IN COMPLEX WITH INHIBITOR
2706, d3dy7A_, 0.6968, 2.96, 0.195, 260, 251, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN A COMPLEX WITH LIGAND AND MGATP
2707, d2auhA1, 0.6968, 3.51, 0.293, 294, 259, CRYSTAL STRUCTURE OF THE GRB14 BPS REGION IN COMPLEX WITH THE INSULIN RECEPTOR TYROSINE KINASE
2708, d1ol1C_, 0.6968, 3.40, 0.158, 296, 259, CYCLIN A BINDING GROOVE INHIBITOR H-CIT-CIT-LEU-ILE-(P-F-PHE)-NH2
2709, d3ionA_, 0.6967, 3.01, 0.215, 274, 251, PDK1 IN COMPLEX WITH COMPOUND 8H
2710, d3iecB_, 0.6967, 3.39, 0.216, 313, 259, HELICOBACTER PYLORI CAGA INHIBITS PAR1/MARK FAMILY KINASES BY MIMICKING HOST SUBSTRATES
2711, d2fumA_, 0.6967, 2.84, 0.161, 263, 248, CATALYTIC DOMAIN OF PROTEIN KINASE PKNB FROM MYCOBACTERIUM TUBERCULOSIS IN COMPLEX WITH MITOXANTRONE
2712, d5ctpA_, 0.6966, 3.30, 0.152, 324, 256, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(3-CHLORO-4-(PHENYL) BENZYLAMINO)PROPYL)ACETAMIDE BOUND
2713, d4zy4A_, 0.6966, 3.53, 0.195, 288, 261, CRYSTAL STRUCTURE OF P21 ACTIVATED KINASE 1 IN COMPLEX WITH AN INHIBITOR COMPOUND 4
2714, d4obqB_, 0.6966, 3.61, 0.173, 293, 260, MAP4K4 IN COMPLEX WITH INHIBITOR (COMPOUND 31) N-[3-(4- AMINOQUINAZOLIN-6-YL)-5-FLUOROPHENYL]-2-(PYRROLIDIN-1-YL)ACETAMIDE
2715, d4eevA_, 0.6966, 3.39, 0.341, 283, 255, CRYSTAL STRUCTURE OF C-MET IN COMPLEX WITH LY2801653
2716, d4c3fA_, 0.6966, 2.95, 0.281, 257, 249, STRUCTURE OF LCK IN COMPLEX WITH A COMPOUND DISCOVERED BY VIRTUAL FRAGMENT LINKING
2717, d3q3bA_, 0.6966, 3.65, 0.167, 344, 263, 6-AMINO-4-(PYRIMIDIN-4-YL)PYRIDONES: NOVEL GLYCOGEN SYNTHASE KINASE-3 INHIBITORS
2718, d1oiyC1, 0.6966, 3.35, 0.167, 295, 258, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH A 6-CYCLOHEXYLMETHYLOXY-2-ANILINO-PURINE INHIBITOR
2719, d4kioA1, 0.6965, 2.10, 0.328, 238, 235, KINASE DOMAIN MUTANT OF HUMAN ITK IN COMPLEX WITH A COVALENTLY-BINDING INHIBITOR
2720, d4grbA_, 0.6965, 3.38, 0.144, 327, 257, CASEIN KINASE 2 (CK2) BOUND TO INHIBITOR
2721, d4achA_, 0.6965, 3.58, 0.169, 350, 261, GSK3B IN COMPLEX WITH INHIBITOR
2722, d3lfnA_, 0.6965, 3.04, 0.189, 285, 249, CRYSTAL STRUCTURE OF CDK2 WITH SAR57 AN AMINOINDAZOLE TYPE INHIBITOR
2723, d3f7zA1, 0.6965, 3.65, 0.179, 338, 262, X-RAY CO-CRYSTAL STRUCTURE OF GLYCOGEN SYNTHASE KINASE 3BETA IN COMPLEX WITH AN INHIBITOR
2724, d1okuC_, 0.6965, 3.42, 0.154, 296, 260,  
2725, d1j1bA_, 0.6965, 3.64, 0.164, 354, 262, BINARY COMPLEX STRUCTURE OF HUMAN TAU PROTEIN KINASE I WITH AMPPNP
2726, d1h26C1, 0.6965, 3.34, 0.172, 266, 256, CDK2/CYCLIN A IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM P53
2727, d5kbqA_, 0.6964, 3.62, 0.193, 289, 264, PAK1 IN COMPLEX WITH BIS-ANILINO PYRIMIDINE INHIBITOR
2728, d5ceqA_, 0.6964, 2.86, 0.239, 269, 247, DLK IN COMPLEX WITH INHIBITOR 2-((1-CYCLOPENTYL-5-(1-(OXETAN-3-YL) PIPERIDIN-4-YL)-1H-PYRAZOL-3-YL)AMINO)ISONICOTINONITRILE
2729, d4eopA1, 0.6964, 3.33, 0.156, 294, 257, THR 160 PHOSPHORYLATED CDK2 Q131E - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR RO3306
2730, d3f88A_, 0.6964, 3.62, 0.179, 340, 262, GLYCOGEN SYNTHASE KINASE 3BETA INHIBITOR COMPLEX
2731, d3c4dB1, 0.6964, 2.74, 0.220, 256, 245,  
2732, d3bhtA2, 0.6964, 3.28, 0.160, 295, 257, STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR MERIOLIN 3
2733, d1q41B_, 0.6964, 3.61, 0.172, 343, 262, GSK-3 BETA COMPLEXED WITH INDIRUBIN-3 -MONOXIME
2734, d1jpaA_, 0.6964, 3.28, 0.303, 273, 254, CRYSTAL STRUCTURE OF UNPHOSPHORYLATED EPHB2 RECEPTOR TYROSINE KINASE AND JUXTAMEMBRANE REGION
2735, d5modB_, 0.6963, 3.29, 0.152, 324, 256, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
2736, p3o17A_, 0.6963, 3.07, 0.206, 357, 253, CRYSTAL STRUCTURE OF JNK1-ALPHA1 ISOFORM
2737, d2fysA_, 0.6963, 3.23, 0.168, 348, 256, CRYSTAL STRUCTURE OF ERK2 COMPLEX WITH KIM PEPTIDE DERIVED FROM MKP3
2738, d1xjdA_, 0.6963, 3.10, 0.178, 280, 253, CRYSTAL STRUCTURE OF PKC-THETA COMPLEXED WITH STAUROSPORINE AT 2A RESOLUTION
2739, d5ia4A_, 0.6962, 3.24, 0.320, 269, 253, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH FORETINIB (XL880)
2740, d4zk5B_, 0.6962, 3.60, 0.173, 294, 260, MAP4K4 IN COMPLEX WITH INHIBITOR GNE-495
2741, d4pqnA_, 0.6962, 2.33, 0.324, 240, 238, ITK KINASE DOMAIN WITH COMPOUND GNE-9822
2742, d4h58C_, 0.6962, 2.94, 0.218, 272, 248, BRAF IN COMPLEX WITH COMPOUND 3
2743, d4fkqA_, 0.6962, 3.04, 0.181, 283, 249, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH OXINDOLE INHIBITOR
2744, d3sd0B_, 0.6962, 3.61, 0.168, 349, 262, IDENTIFICATION OF A GLYCOGEN SYNTHASE KINASE-3B INHIBITOR THAT ATTENUATES HYPERACTIVITY IN CLOCK MUTANT MICE
2745, d3l1sA_, 0.6962, 3.62, 0.172, 336, 262, 3-ARYL-4-(ARYLHYDRAZONO)-1H-PYRAZOL-5-ONES: HIGHLY LIGAND EFFICIENT AND POTENT INHIBITORS OF GSK3
2746, d3iecC_, 0.6962, 3.30, 0.210, 311, 257, HELICOBACTER PYLORI CAGA INHIBITS PAR1/MARK FAMILY KINASES BY MIMICKING HOST SUBSTRATES
2747, d3f88B_, 0.6962, 3.60, 0.169, 340, 261, GLYCOGEN SYNTHASE KINASE 3BETA INHIBITOR COMPLEX
2748, d3bhvC1, 0.6962, 3.31, 0.167, 269, 257, STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR VARIOLIN B
2749, d2y6mA_, 0.6962, 3.22, 0.306, 262, 255, CRYSTAL STRUCTURE OF EPHA4 KINASE DOMAIN
2750, d3c4cB1, 0.6961, 2.81, 0.211, 256, 246, B-RAF KINASE IN COMPLEX WITH PLX4720
2751, d2zm3A2, 0.6961, 3.56, 0.300, 299, 260, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND ISOQUINOLINEDIONE INHIBITOR
2752, d2c5vC_, 0.6961, 3.45, 0.154, 296, 260, DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN
2753, d6bleA1, 0.6960, 3.17, 0.175, 263, 252, CRYSTAL STRUCTURE OF THE HUMAN CAMKK2B IN COMPLEX WITH CP673451
2754, d5vo2A_, 0.6960, 2.85, 0.239, 269, 247, DLK IN COMPLEX WITH INHIBITOR 5-(1-ISOPROPYL-5-(1-(OXETAN-3-YL) PIPERIDIN-4-YL)-1H-PYRAZOL-3-YL)-3-(TRIFLUOROMETHYL)PYRIDIN-2-AMINE (COMPOUND 7)
2755, d5bvkA_, 0.6960, 2.95, 0.305, 278, 249, FRAGMENT-BASED DISCOVERY OF POTENT AND SELECTIVE DDR1/2 INHIBITORS
2756, d4u41A_, 0.6960, 3.22, 0.171, 275, 252, MAP4K4 BOUND TO INHIBITOR COMPOUND 1
2757, d4eoiA1, 0.6960, 3.32, 0.156, 293, 257, THR 160 PHOSPHORYLATED CDK2 K89D Q131E - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR RO3306
2758, d3ggfA_, 0.6960, 3.40, 0.236, 275, 258, CRYSTAL STRUCTURE OF HUMAN SERINE/THREONINE-PROTEIN KINASE MST4 IN COMPLEX WITH AN QUINAZOLIN
2759, d1z5mA_, 0.6960, 3.22, 0.213, 275, 254, CRYSTAL STRUCTURE OF N1-[3-[[5-BROMO-2-[[3-[(1-PYRROLIDINYLCARBONYL) AMINO]PHENYL]AMINO]-4-PYRIMIDINYL]AMINO]PROPYL]-22- DIMETHYLPROPANEDIAMIDE COMPLEXED WITH HUMAN PDK1
2760, d1q4lA_, 0.6960, 3.60, 0.169, 342, 261, GSK-3 BETA COMPLEXED WITH INHIBITOR I-5
2761, d5hieD_, 0.6959, 2.66, 0.201, 253, 244, BRAF KINASE DOMAIN B3AC LOOP DELETION MUTANT IN COMPLEX WITH DABRAFENIB
2762, d4eomC1, 0.6959, 3.34, 0.167, 271, 257, THR 160 PHOSPHORYLATED CDK2 H84S Q85M Q131E - HUMAN CYCLIN A3 COMPLEX WITH ATP
2763, d4cfwC1, 0.6959, 3.50, 0.154, 295, 260, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6- CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
2764, d4btjB_, 0.6959, 3.66, 0.160, 293, 263, TTBK1 IN COMPLEX WITH ATP
2765, d3rzbA_, 0.6959, 2.97, 0.181, 282, 248, CDK2 IN COMPLEX WITH INHIBITOR RC-2-23
2766, d3iggA_, 0.6959, 3.15, 0.184, 290, 250, NOVEL CDK-5 INHIBITORS - CRYSTAL STRUCTURE OF INHIBITOR EFQ WITH CDK-2
2767, d1oiuC1, 0.6959, 3.37, 0.172, 264, 256, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH A 6-CYCLOHEXYLMETHYLOXY-2-ANILINO-PURINE INHIBITOR
2768, d4zy5B_, 0.6958, 3.71, 0.163, 287, 264, CRYSTAL STRUCTURE OF P21-ACTIVATED KINASE 1 IN COMPLEX WITH AN INHIBITOR COMPOUND 17
2769, d4u45B_, 0.6958, 3.67, 0.172, 295, 261, MAP4K4 IN COMPLEX WITH INHIBITOR (COMPOUND 25)
2770, d3r9oA_, 0.6958, 2.97, 0.185, 282, 248, CDK2 IN COMPLEX WITH INHIBITOR RC-2-143
2771, d3kc3B_, 0.6958, 2.81, 0.158, 290, 247, MK2 COMPLEXED TO INHIBITOR N4-(7-(BENZOFURAN-2-YL)-1H-INDAZOL-5-YL) PYRIMIDINE-24-DIAMINE
2772, d3f5xC_, 0.6958, 3.54, 0.149, 298, 262, CDK-2-CYCLIN COMPLEX WITH INDAZOLE INHIBITOR 9 BOUND AT ITS ACTIVE SITE
2773, d3dogA1, 0.6958, 3.39, 0.159, 296, 258, STRUCTURE OF THR 160 PHOSPHORYLATED CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR N-&-N1
2774, d3blhA1, 0.6958, 3.26, 0.160, 291, 256, CRYSTAL STRUCTURE OF HUMAN CDK9/CYCLINT1
2775, d2zm3C2, 0.6958, 3.56, 0.293, 295, 259, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND ISOQUINOLINEDIONE INHIBITOR
2776, d2c5vA_, 0.6958, 3.45, 0.158, 296, 260, DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN
2777, d1urcC_, 0.6958, 3.41, 0.158, 296, 259, CYCLIN A BINDING GROOVE INHIBITOR ACE-ARG-LYS-LEU-PHE-GLY
2778, d1h1rA1, 0.6958, 3.38, 0.155, 295, 258, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH THE INHIBITOR NU6086
2779, d5vo1A_, 0.6957, 2.85, 0.243, 269, 247, DLK IN COMPLEX WITH COMPOUND 10 (5-(1-ISOPROPYL-5-(3-(OXETAN-3-YL)-3- AZABICYCLO[3.1.0]HEXAN-6-YL)-1H-PYRAZOL-3-YL)-3-(TRIFLUOROMETHYL) PYRIDIN-2-AMINE)
2780, d4yfiC_, 0.6957, 2.81, 0.193, 269, 243, TNNI3K COMPLEXED WITH INHIBITOR 1
2781, d4oa9A_, 0.6957, 3.24, 0.190, 280, 252,  
2782, d3eknA_, 0.6957, 3.37, 0.298, 297, 258, INSULIN RECEPTOR KINASE COMPLEXED WITH AN INHIBITOR
2783, d3dogC1, 0.6957, 3.29, 0.173, 266, 255, STRUCTURE OF THR 160 PHOSPHORYLATED CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR N-&-N1
2784, d3d14A1, 0.6957, 3.10, 0.183, 257, 252, CRYSTAL STRUCTURE OF MOUSE AURORA A (ASN186->GLY LYS240->ARG MET302- >LEU) IN COMPLEX WITH 1-{5-[2-(THIENO[32-D]PYRIMIDIN-4-YLAMINO)- ETHYL]- THIAZOL-2-YL}-3-(3-TRIFLUOROMETHYL-PHENYL)-UREA
2785, d3bysA_, 0.6957, 2.76, 0.293, 255, 246, CO-CRYSTAL STRUCTURE OF LCK AND AMINOPYRIMIDINE AMIDE 10B
2786, p2gmxB_, 0.6957, 3.18, 0.200, 357, 255, SELECTIVE AMINOPYRIDINE-BASED C-JUN N-TERMINAL KINASE INHIBITORS WITH CELLULAR ACTIVITY
2787, d2c6mA_, 0.6957, 3.11, 0.180, 290, 250, CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR
2788, d5o23B1, 0.6956, 3.22, 0.195, 276, 251, CRYSTAL STRUCTURE OF WNK3 KINASE DOMAIN IN A MONOPHOSPHORYLATED APO STATE
2789, d5lvmA_, 0.6956, 3.54, 0.196, 283, 260, HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH ADENINE BOUND TO THE ATP- BINDING SITE
2790, d4l45A_, 0.6956, 3.67, 0.176, 317, 262, CRYSTAL STRUCTURES OF HUMAN P70S6K1-T389E
2791, d3l1sB_, 0.6956, 3.59, 0.153, 330, 262, 3-ARYL-4-(ARYLHYDRAZONO)-1H-PYRAZOL-5-ONES: HIGHLY LIGAND EFFICIENT AND POTENT INHIBITORS OF GSK3
2792, d2qoqA_, 0.6956, 3.57, 0.305, 284, 256, HUMAN EPHA3 KINASE AND JUXTAMEMBRANE REGION BASE AMP-PNP BOUND STRUCTURE
2793, p2g01A_, 0.6956, 3.17, 0.185, 355, 254, PYRAZOLOQUINOLONES AS NOVEL SELECTIVE JNK1 INHIBITORS
2794, d2b52A_, 0.6956, 2.92, 0.186, 283, 247, HUMAN CYCLIN DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH DPH- 042562
2795, d5uyjA1, 0.6955, 3.40, 0.180, 279, 256, CRYSTAL STRUCTURE OF THE HUMAN CAMKK2B
2796, d5kx7B_, 0.6955, 3.06, 0.217, 286, 249, IRAK4-INHIBITOR CO-STRUCTURE
2797, d5i3oB_, 0.6955, 3.15, 0.139, 302, 252, CRYSTAL STRUCTURE OF BMP-2-INDUCIBLE KINASE IN COMPLEX WITH AN INDAZOLE INHIBITOR
2798, d4pteA_, 0.6955, 3.59, 0.169, 341, 261, STRUCTURE OF A CARVOXAMIDE COMPOUND (15) (N-[4-(ISOQUINOLIN-7-YL) PYRIDIN-2-YL]CYCLOPROPANECARBOXAMIDE) TO GSK3B
2799, d1jwhA_, 0.6955, 3.40, 0.147, 336, 258, CRYSTAL STRUCTURE OF HUMAN PROTEIN KINASE CK2 HOLOENZYME
2800, d1h1sA1, 0.6955, 3.45, 0.166, 295, 259, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH THE INHIBITOR NU6102
2801, d5hkmA_, 0.6954, 2.98, 0.212, 272, 250, DISCOVERY OF NOVEL 7-AZAINDOLES AS PDK1 INHIBITORS
2802, d4nstA_, 0.6954, 3.86, 0.152, 322, 269, CRYSTAL STRUCTURE OF HUMAN CDK12/CYCLIN K IN COMPLEX WITH ADP-ALUMINUM FLUORIDE
2803, d4acdB_, 0.6954, 3.64, 0.164, 350, 262, GSK3B IN COMPLEX WITH INHIBITOR
2804, d3en7A_, 0.6954, 2.62, 0.290, 247, 241, TARGETED POLYPHARMACOLOGY: CRYSTAL STRUCTURE OF THE C-SRC KINASE DOMAIN IN COMPLEX WITH S1 A MULTITARGETED KINASE INHIBITOR
2805, d2xyuA_, 0.6954, 3.21, 0.307, 260, 254, CRYSTAL STRUCTURE OF EPHA4 KINASE DOMAIN IN COMPLEX WITH VUF 12058
2806, d2wxvC1, 0.6954, 3.53, 0.149, 298, 262, STRUCTURE OF CDK2-CYCLIN A WITH A PYRAZOLO(43-H) QUINAZOLINE-3-CARBOXAMIDE INHIBITOR
2807, d2uzbA_, 0.6954, 3.46, 0.151, 295, 259, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
2808, d2pe1A_, 0.6954, 3.37, 0.211, 275, 256, CRYSTAL STRUCTURE OF HUMAN PHOSPHOINOSITIDE-DEPENDENT PROTEIN KINASE 1 (PDK1) {2-OXO-3-[1-(1H-PYRROL-2-YL)-ETH-(Z)-YLIDENE]-23-DIHYDRO-1H- INDOL-5-YL}-UREA {BX-517} COMPLEX
2809, d2fumB_, 0.6954, 2.79, 0.154, 262, 247, CATALYTIC DOMAIN OF PROTEIN KINASE PKNB FROM MYCOBACTERIUM TUBERCULOSIS IN COMPLEX WITH MITOXANTRONE
2810, d2cciC2, 0.6954, 3.43, 0.167, 295, 258, CRYSTAL STRUCTURE OF PHOSPHO-CDK2 CYCLIN A IN COMPLEX WITH A PEPTIDE CONTAINING BOTH THE SUBSTRATE AND RECRUITMENT SITES OF CDC6
2811, d5jt2C1, 0.6953, 2.58, 0.231, 247, 242, BRAFV600E KINASE DOMAIN IN COMPLEX WITH CHEMICALLY LINKED VEMURAFENIB INHIBITOR VEM-BISAMIDE
2812, d4l43A_, 0.6953, 3.61, 0.176, 316, 261, CRYSTAL STRUCTURES OF HUMAN P70S6K1-T389A (FORM I)
2813, d3sd0A_, 0.6953, 3.57, 0.172, 350, 261, IDENTIFICATION OF A GLYCOGEN SYNTHASE KINASE-3B INHIBITOR THAT ATTENUATES HYPERACTIVITY IN CLOCK MUTANT MICE
2814, d3kc3F_, 0.6953, 2.93, 0.141, 293, 249, MK2 COMPLEXED TO INHIBITOR N4-(7-(BENZOFURAN-2-YL)-1H-INDAZOL-5-YL) PYRIMIDINE-24-DIAMINE
2815, d2r3rA_, 0.6953, 3.10, 0.181, 290, 249, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
2816, d2r3pA_, 0.6953, 3.06, 0.185, 289, 249, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
2817, d2r3oA_, 0.6953, 3.07, 0.185, 289, 249, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
2818, d2c68A_, 0.6953, 3.12, 0.184, 290, 250, CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR
2819, d1ol5A_, 0.6953, 3.26, 0.185, 263, 254, STRUCTURE OF AURORA-A 122-403 PHOSPHORYLATED ON THR287 THR288 AND BOUND TO TPX2 1-43
2820, d5to8A_, 0.6952, 2.97, 0.328, 250, 247, SELECTIVITY SWITCH BETWEEN FAK AND PYK2: MACROCYCLIZATION OF FAK INHIBITORS IMPROVES PYK2 POTENCY
2821, d5e8vA_, 0.6952, 3.08, 0.192, 296, 250, TGF-BETA RECEPTOR TYPE 2 KINASE DOMAIN (E431AR433AE485AK488AR493A R495A)
2822, d4wovB_, 0.6952, 2.65, 0.209, 256, 244, CRYSTAL STRUCTURE OF TYROSINE KINASE 2 JH2 (PSEUDO KINASE DOMAIN) COMPLEXED WITH BMS-066 AKA 2-METHOXY-N-({6-[3-METHYL-7-(METHYLAMINO)- 35810-TETRAAZATRICYCLO[7.3.0.0 6]DODECA-1(9)2(6)4711-PENTAEN- 11-YL]PYRIDIN-2-YL}METHY L)ACETAMIDE
2823, d4iq6B_, 0.6952, 3.66, 0.164, 332, 262, GSK-3BETA WITH INHIBITOR 6-CHLORO-N-CYCLOHEXYL-4-(1H-PYRROLO[23- B]PYRIDIN-3-YL)PYRIDIN-2-AMINE
2824, d4eooC1, 0.6952, 3.48, 0.158, 295, 259, THR 160 PHOSPHORYLATED CDK2 Q131E - HUMAN CYCLIN A3 COMPLEX WITH ATP
2825, d3fwqA_, 0.6952, 3.49, 0.151, 334, 259, INACTIVE CONFORMATION OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT
2826, d2r3iA_, 0.6952, 3.10, 0.181, 289, 249, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
2827, d2nryB_, 0.6952, 3.19, 0.211, 286, 251, CRYSTAL STRUCTURE OF IRAK-4
2828, d4achB_, 0.6951, 3.63, 0.164, 350, 262, GSK3B IN COMPLEX WITH INHIBITOR
2829, d3dlsA_, 0.6951, 3.55, 0.158, 285, 259, CRYSTAL STRUCTURE OF HUMAN PAS KINASE BOUND TO ADP
2830, d5nhjA_, 0.6950, 3.31, 0.168, 345, 256, HUMAN ERK2 WITH AN ERK1/2 INHIBITOR
2831, d4ub7A_, 0.6950, 3.34, 0.148, 334, 256, HIGH-SALT STRUCTURE OF PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH 4 - CARBOXY-68-BROMO-FLAVONOL (FLC26) SHOWING AN EXTREME DISTORTION OF THE ATP-BINDING LOOP COMBINED WITH A PI-HALOGEN BOND
2832, d4gk2A_, 0.6950, 3.20, 0.303, 265, 251, HUMAN EPHA3 KINASE DOMAIN IN COMPLEX WITH LIGAND 66
2833, d4cqeA_, 0.6950, 2.56, 0.227, 250, 242, B-RAF KINASE V600E MUTANT IN COMPLEX WITH  A DIARYLTHIAZOLE B-RAF INHIBITOR
2834, d4acdA_, 0.6950, 3.64, 0.164, 350, 262, GSK3B IN COMPLEX WITH INHIBITOR
2835, d2qlqA_, 0.6950, 2.54, 0.287, 245, 240, CRYSTAL STRUCTURE OF SRC KINASE DOMAIN WITH COVALENT INHIBITOR RL3
2836, d2bujB1, 0.6950, 3.41, 0.187, 277, 257, CRYSTAL STRUCTURE OF THE HUMAN SERINE-THREONINE KINASE 16 IN COMPLEX WITH STAUROSPORINE
2837, d1wccA_, 0.6950, 3.00, 0.181, 283, 248, SCREENING FOR FRAGMENT BINDING BY X-RAY CRYSTALLOGRAPHY
2838, d1b38A_, 0.6950, 3.08, 0.185, 290, 249, HUMAN CYCLIN-DEPENDENT KINASE 2
2839, d5v24B_, 0.6949, 2.98, 0.205, 263, 249, STRUCTURE-BASED DRUG DESIGN OF NOVEL ASK1 INHIBITORS USING A FULLY INTEGRATED LEAD OPTIMIZATION STRATEGY
2840, d4mf1B1, 0.6949, 2.47, 0.306, 244, 242, ITK KINASE DOMAIN IN COMPLEX WITH BENZOTHIAZOLE INHIBITOR 12B (1S2S)- 2-{4-[(DIMETHYLAMINO)METHYL]PHENYL}-N-[6-(1H-PYRAZOL-4-YL)-13- BENZOTHIAZOL-2-YL]CYCLOPROPANECARBOXAMIDE
2841, d2vtmA_, 0.6949, 3.07, 0.185, 290, 249, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
2842, d5drdA_, 0.6948, 3.04, 0.183, 259, 251, AURORA A KINASE IN COMPLEX WITH ATP IN SPACE GROUP P6122
2843, d4p5zA_, 0.6948, 3.23, 0.294, 267, 252, HUMAN EPHA3 KINASE DOMAIN IN COMPLEX WITH QUINOXALINE DERIVATIVES
2844, d3pupB_, 0.6948, 3.65, 0.164, 347, 262, STRUCTURE OF GLYCOGEN SYNTHASE KINASE 3 BETA (GSK3B) IN COMPLEX WITH A RUTHENIUM OCTASPORINE LIGAND (OS1)
2845, d2c5pA_, 0.6948, 3.46, 0.158, 296, 260,  
2846, d1okuA_, 0.6948, 3.47, 0.154, 296, 260,  
2847, d1h1qA1, 0.6948, 3.50, 0.151, 295, 259, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH THE INHIBITOR NU6094
2848, d5uy6A1, 0.6947, 3.37, 0.180, 280, 255, CRYSTAL STRUCTURE OF THE HUMAN CAMKK2B
2849, d4tygA1, 0.6947, 3.53, 0.322, 290, 258, STRUCTURAL ANALYSIS OF THE HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 4 KINASE
2850, d2zoqB_, 0.6947, 3.20, 0.150, 351, 253, STRUCTURAL DISSECTION OF HUMAN MITOGEN-ACTIVATED KINASE ERK1
2851, d2vtrA_, 0.6947, 3.06, 0.185, 290, 249, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
2852, d2r3fA_, 0.6947, 3.22, 0.179, 290, 251, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
2853, d1jpaB_, 0.6947, 3.18, 0.311, 269, 251, CRYSTAL STRUCTURE OF UNPHOSPHORYLATED EPHB2 RECEPTOR TYROSINE KINASE AND JUXTAMEMBRANE REGION
2854, d5uq2A_, 0.6946, 3.53, 0.149, 296, 261, CRYSTAL STRUCTURE OF HUMAN CDK2-SPY1 COMPLEX
2855, d4rzvB1, 0.6946, 2.60, 0.215, 254, 242, CRYSTAL STRUCTURE OF THE BRAF (R509H) KINASE DOMAIN MONOMER BOUND TO VEMURAFENIB
2856, d3wblA_, 0.6946, 3.02, 0.181, 283, 248, CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH PYRAZOLOPYRIMIDINE INHIBITOR
2857, d2wevA_, 0.6946, 3.46, 0.158, 296, 260, TRUNCATION AND OPTIMISATION OF PEPTIDE INHIBITORS OF CDK2 CYCLIN A THROUGH STRUCTURE GUIDED DESIGN
2858, d2hwpA_, 0.6946, 2.73, 0.281, 245, 242, CRYSTAL STRUCTURE OF SRC KINASE DOMAIN IN COMPLEX WITH COVALENT INHIBITOR PD168393
2859, d5uoxA_, 0.6945, 2.98, 0.201, 263, 249, STRUCTURE-BASED DESIGN OF ASK1 INHIBITORS AS POTENTIAL FIRST-IN-CLASS AGENTS FOR HEART FAILURE
2860, d5lqfD1, 0.6945, 2.90, 0.185, 282, 249, CDK1/CYCLINB1/CKS2 IN COMPLEX WITH NU6102
2861, d5cepA_, 0.6945, 2.88, 0.243, 269, 247, DLK IN COMPLEX WITH INHIBITOR N-(1-ISOPROPYL-5-(PIPERIDIN-4-YL)-1H- PYRAZOL-3-YL)-4-(TRIFLUOROMETHYL)PYRIDIN-2-AMINE
2862, d4ztmD_, 0.6945, 2.96, 0.211, 282, 246, IRAK4-INHIBITOR CO-STRUCTURE
2863, d4a07A_, 0.6945, 3.42, 0.205, 282, 258, HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH ALLOSTERIC ACTIVATOR PS171 BOUND TO THE PIF-POCKET
2864, d3qtrA_, 0.6945, 3.00, 0.185, 282, 248, CDK2 IN COMPLEX WITH INHIBITOR RC-1-148
2865, d2pe2A_, 0.6945, 3.32, 0.208, 275, 255, CRYSTAL STRUCTURE OF HUMAN PHOSPHOINOSITIDE-DEPENDENT PROTEIN KINASE 1 (PDK1) 3-{5-[2-OXO-5-UREIDO-12-DIHYDRO-INDOL-(3Z)-YLIDENEMETHYL]-1H- PYRROL-3-YL}-N-(2-PIPERIDIN-1-YL-ETHYL)-BENZAMIDE COMPLEX
2866, d1e1vA_, 0.6945, 3.08, 0.181, 290, 249, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR NU2058
2867, d5lpvA_, 0.6944, 3.10, 0.188, 282, 250, CRYSTAL STRUCTURE OF THE BRI1 KINASE DOMAIN (865-1160) IN COMPLEX WITH AMPPNP AND MN FROM ARABIDOPSIS THALIANA
2868, d4nksA_, 0.6944, 3.24, 0.311, 265, 251, CRYSTAL STRUCTURE OF HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN IN COMPLEX WITH PYRAZOLAMINOPYRIMIDINE 3
2869, d4cfuC1, 0.6944, 3.42, 0.167, 269, 258, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6- CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
2870, d3kc3L_, 0.6944, 2.83, 0.158, 291, 247, MK2 COMPLEXED TO INHIBITOR N4-(7-(BENZOFURAN-2-YL)-1H-INDAZOL-5-YL) PYRIMIDINE-24-DIAMINE
2871, d2c5xC_, 0.6944, 3.44, 0.158, 296, 259, DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN
2872, d2c5oC_, 0.6944, 3.51, 0.154, 296, 260, DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND  INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN
2873, d1zrzA_, 0.6944, 3.48, 0.162, 310, 260, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF ATYPICAL PROTEIN KINASE C-IOTA
2874, d5nevA1, 0.6943, 3.43, 0.159, 294, 258, CDK2/CYCLIN A IN COMPLEX WITH COMPOUND 73
2875, d5ax9B_, 0.6943, 3.30, 0.178, 274, 253, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN TRAF2 AND NCK- INTERACTING PROTEIN KINASE IN COMPLEX WITH COMPUND 9
2876, d4bcnC1, 0.6943, 3.40, 0.167, 293, 257, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
2877, d3pupA_, 0.6943, 3.66, 0.164, 346, 262, STRUCTURE OF GLYCOGEN SYNTHASE KINASE 3 BETA (GSK3B) IN COMPLEX WITH A RUTHENIUM OCTASPORINE LIGAND (OS1)
2878, d2vtlA_, 0.6943, 3.08, 0.185, 290, 249, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
2879, d2uzbC_, 0.6943, 3.34, 0.156, 292, 257, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
2880, d2i40A_, 0.6943, 3.20, 0.161, 291, 255, CDK2/CYCLIN A COMPLEXED WITH A THIOPHENE CARBOXAMIDE INHIBITOR
2881, d1ol2C_, 0.6943, 3.47, 0.158, 296, 259, CYCLIN A BINDING GROOVE INHIBITOR H-ARG-ARG-LEU-ASN-(P-F-PHE)-NH2
2882, d1o9uA_, 0.6943, 3.57, 0.169, 349, 260, GLYCOGEN SYNTHASE KINASE 3 BETA COMPLEXED WITH AXIN PEPTIDE
2883, d5ajqA_, 0.6942, 3.33, 0.173, 280, 255, HUMAN LOK (STK10) IN COMPLEX WITH BOSUTINIB
2884, d4nstC_, 0.6942, 3.80, 0.149, 317, 268, CRYSTAL STRUCTURE OF HUMAN CDK12/CYCLIN K IN COMPLEX WITH ADP-ALUMINUM FLUORIDE
2885, d4accB_, 0.6942, 3.66, 0.164, 350, 262, GSK3B IN COMPLEX WITH INHIBITOR
2886, d3v5qA1, 0.6942, 2.83, 0.298, 260, 245, DISCOVERY OF A SELECTIVE TRK INHIBITOR WITH EFFICACY IN RODENT CANCER TUMOR MODELS
2887, d3eidA_, 0.6942, 3.32, 0.152, 292, 257, CDK2/CYCLINA COMPLEXED WITH A PYRAZOLOPYRIDAZINE INHIBITOR
2888, d3dtcA_, 0.6942, 1.96, 0.310, 245, 232, CRYSTAL STRUCTURE OF MIXED-LINEAGE KINASE MLK1 COMPLEXED WITH COMPOUND 16
2889, d3ddqC1, 0.6942, 3.32, 0.173, 265, 255, STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR ROSCOVITINE
2890, d3ddqA1, 0.6942, 3.45, 0.151, 295, 258, STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR ROSCOVITINE
2891, d2r7iC_, 0.6942, 3.21, 0.155, 321, 252, CRYSTAL STRUCTURE OF CATALYTIC SUBUNIT OF PROTEIN KINASE CK2
2892, d2jboA_, 0.6942, 2.95, 0.149, 295, 249, PROTEIN KINASE MK2 IN COMPLEX WITH AN INHIBITOR (CRYSTAL FORM-1 SOAKING)
2893, d2c5pC_, 0.6942, 3.47, 0.158, 296, 259,  
2894, d1h28C1, 0.6942, 3.43, 0.167, 295, 258, CDK2/CYCLIN A IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM P107
2895, d1h0wA_, 0.6942, 2.96, 0.182, 283, 247, HUMAN CYCLIN DEPENDENT PROTEIN KINASE 2 IN COMPLEX WITH THE INHIBITOR 2-AMINO-6-[CYCLOHEX-3-ENYL]METHOXYPURINE
2896, d1di8A_, 0.6942, 3.08, 0.185, 283, 249, THE STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 (CDK2) IN COMPLEX WITH 4-[3-HYDROXYANILINO]-67-DIMETHOXYQUINAZOLINE
2897, d4oacA_, 0.6941, 3.28, 0.190, 280, 252,  
2898, d4f1mA1, 0.6941, 3.27, 0.225, 274, 253, CRYSTAL STRUCTURE OF THE G1179S ROCO4 KINASE DOMAIN BOUND TO APPCP FROM D. DISCOIDEUM.
2899, d4acgB_, 0.6941, 3.63, 0.160, 350, 262, GSK3B IN COMPLEX WITH INHIBITOR
2900, d2v22C_, 0.6941, 3.40, 0.163, 296, 258, REPLACE: A STRATEGY FOR ITERATIVE DESIGN OF CYCLIN BINDING GROOVE INHIBITORS
2901, p2h96A_, 0.6941, 3.20, 0.188, 358, 255, DISCOVERY OF POTENT HIGHLY SELECTIVE AND ORALLY BIOAVAILABLE PYRIDINE CARBOXAMIDE C-JUN NH2-TERMINAL KINASE INHIBITORS
2902, d5v19B_, 0.6940, 2.78, 0.207, 260, 246, STRUCTURE-BASED DRUG DESIGN OF NOVEL ASK1 INHIBITORS USING A FULLY INTEGRATED LEAD OPTIMIZATION STRATEGY
2903, d4zy5A_, 0.6940, 3.57, 0.188, 283, 260, CRYSTAL STRUCTURE OF P21-ACTIVATED KINASE 1 IN COMPLEX WITH AN INHIBITOR COMPOUND 17
2904, d4xs2A_, 0.6940, 3.09, 0.213, 283, 249, IRAK4-INHIBITOR CO-STRUCTURE
2905, d4nm7A1, 0.6940, 3.56, 0.153, 354, 261, CRYSTAL STRUCTURE OF GSK-3/AXIN COMPLEX BOUND TO PHOSPHORYLATED WNT RECEPTOR LRP6 E-MOTIF
2906, p4jqeA_, 0.6940, 3.59, 0.138, 369, 261, CRYSTAL STRUCTURE OF SCCK2 ALPHA IN COMPLEX WITH AMPPN
2907, d4iq6A_, 0.6940, 3.58, 0.169, 324, 260, GSK-3BETA WITH INHIBITOR 6-CHLORO-N-CYCLOHEXYL-4-(1H-PYRROLO[23- B]PYRIDIN-3-YL)PYRIDIN-2-AMINE
2908, d4bicA_, 0.6940, 2.71, 0.212, 260, 245, CRYSTAL STRUCTURES OF ASK1-INHIBITOR COMPLEXES
2909, d3qtsA_, 0.6940, 2.97, 0.190, 282, 247, CDK2 IN COMPLEX WITH INHIBITOR RC-2-12
2910, d2c5oA_, 0.6940, 3.50, 0.154, 296, 260, DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND  INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN
2911, d1oi9A1, 0.6940, 3.43, 0.155, 294, 258, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH A 6-CYCLOHEXYLMETHYLOXY-2-ANILINO-PURINE INHIBITOR
2912, d1j1cA_, 0.6940, 3.69, 0.167, 354, 263, BINARY COMPLEX STRUCTURE OF HUMAN TAU PROTEIN KINASE I WITH ADP
2913, d1h28A1, 0.6940, 3.43, 0.155, 295, 258, CDK2/CYCLIN A IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM P107
2914, d5lmkA1, 0.6939, 3.37, 0.156, 295, 257, STRUCTURE OF PHOPSHO-CDK2-CYCLIN A IN COMPLEX WITH AN ATP-COMPETITIVE INHIBITOR
2915, d5i3rB_, 0.6939, 3.17, 0.139, 302, 252, CRYSTAL STRUCTURE OF BMP-2-INDUCIBLE KINASE IN COMPLEX WITH AN INDAZOLE INHIBITOR
2916, d4cqeB_, 0.6939, 2.56, 0.224, 248, 241, B-RAF KINASE V600E MUTANT IN COMPLEX WITH  A DIARYLTHIAZOLE B-RAF INHIBITOR
2917, d4afjA_, 0.6939, 3.55, 0.181, 342, 259, 5-ARYL-4-CARBOXAMIDE-13-OXAZOLES: POTENT AND SELECTIVE GSK-3 INHIBITORS
2918, d4accA_, 0.6939, 3.64, 0.164, 350, 262, GSK3B IN COMPLEX WITH INHIBITOR
2919, d3rprA_, 0.6939, 2.99, 0.190, 282, 247, CDK2 IN COMPLEX WITH INHIBITOR RC-2-49
2920, d3r9nA_, 0.6939, 2.98, 0.190, 282, 247, CDK2 IN COMPLEX WITH INHIBITOR RC-2-21
2921, d3q96A_, 0.6939, 2.85, 0.224, 253, 246, B-RAF KINASE DOMAIN IN COMPLEX WITH A TETRAHYDRONAPHTHALENE INHIBITOR
2922, d3dlsD_, 0.6939, 3.48, 0.152, 284, 257, CRYSTAL STRUCTURE OF HUMAN PAS KINASE BOUND TO ADP
2923, d5lmkC1, 0.6938, 3.26, 0.173, 264, 255, STRUCTURE OF PHOPSHO-CDK2-CYCLIN A IN COMPLEX WITH AN ATP-COMPETITIVE INHIBITOR
2924, d5kziA_, 0.6938, 3.18, 0.167, 273, 252, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH AN IMIDAZOPYRIDAZINE INHIBITOR.
2925, d3is5F1, 0.6938, 3.02, 0.209, 259, 249, CRYSTAL STRUCTURE OF CDPK KINASE DOMAIN FROM TOXOPLASMA GONDII TGME49_018720
2926, d3f5xA_, 0.6938, 3.53, 0.149, 297, 261, CDK-2-CYCLIN COMPLEX WITH INDAZOLE INHIBITOR 9 BOUND AT ITS ACTIVE SITE
2927, d4yfiA_, 0.6937, 2.80, 0.194, 268, 242, TNNI3K COMPLEXED WITH INHIBITOR 1
2928, d4eoqC1, 0.6937, 3.33, 0.167, 271, 257, THR 160 PHOSPHORYLATED CDK2 WT - HUMAN CYCLIN A3 COMPLEX WITH ATP
2929, d3orzB_, 0.6937, 3.34, 0.204, 278, 255, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT ACTIVATOR 2A2
2930, d2r7bA_, 0.6937, 3.07, 0.215, 274, 251, CRYSTAL STRUCTURE OF THE PHOSPHOINOSITIDE-DEPENDENT KINASE- 1 (PDK-1)CATALYTIC DOMAIN BOUND TO A DIBENZONAPHTHYRIDINE INHIBITOR
2931, d2ofvB2, 0.6937, 2.22, 0.277, 243, 235, CRYSTAL STRUCTURE OF AMINOQUINAZOLINE 1 BOUND TO LCK
2932, d2bkzC2, 0.6937, 3.54, 0.157, 297, 261, STRUCTURE OF CDK2-CYCLIN A WITH PHA-404611
2933, d6b16A_, 0.6936, 3.56, 0.196, 285, 260, P21-ACTIVATED KINASE 1 IN COMPLEX WITH A 4-AZAINDOLE INHIBITOR
2934, d5mrdA_, 0.6936, 3.51, 0.205, 283, 259, HUMAN PDK1-PKCIOTA KINASE CHIMERA IN COMPLEX WITH ALLOSTERIC COMPOUND PS267 BOUND TO THE PIF-POCKET
2935, d4dbnB_, 0.6936, 2.90, 0.220, 263, 246, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN B-RAF WITH A [1 3]THIAZOLO[54-B]PYRIDINE DERIVATIVE
2936, d1r0eB_, 0.6936, 3.62, 0.169, 344, 261, GLYCOGEN SYNTHASE KINASE-3 BETA IN COMPLEX WITH 3-INDOLYL-4- ARYLMALEIMIDE INHIBITOR
2937, d5objA_, 0.6935, 3.09, 0.183, 260, 252, AURORA A KINASE IN COMPLEX WITH 2-(3-FLUOROPHENYL)QUINOLINE-4- CARBOXYLIC ACID AND ATP
2938, d5jrqB1, 0.6935, 2.62, 0.237, 245, 241, BRAFV600E KINASE DOMAIN IN COMPLEX WITH CHEMICALLY LINKED VEMURAFENIB INHIBITOR VEM-6-VEM
2939, d4kspB_, 0.6935, 2.85, 0.216, 256, 245, CRYSTAL STRUCTURE OF HUMAN B-RAF BOUND TO A DFG-OUT INHIBITOR TAK-632
2940, d4ez7A1, 0.6935, 3.21, 0.173, 298, 254, CDK2 IN COMPLEX WITH STAUROSPORINE AND 2 MOLECULES OF 8-ANILINO-1- NAPHTHALENE SULFONIC ACID
2941, d3orzD_, 0.6935, 3.37, 0.195, 278, 256, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT ACTIVATOR 2A2
2942, d3kc3A_, 0.6935, 2.86, 0.146, 288, 247, MK2 COMPLEXED TO INHIBITOR N4-(7-(BENZOFURAN-2-YL)-1H-INDAZOL-5-YL) PYRIMIDINE-24-DIAMINE
2943, d2wevC_, 0.6935, 3.47, 0.158, 296, 259, TRUNCATION AND OPTIMISATION OF PEPTIDE INHIBITORS OF CDK2 CYCLIN A THROUGH STRUCTURE GUIDED DESIGN
2944, d2r3hA_, 0.6935, 3.05, 0.185, 289, 248, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
2945, d2c5yA_, 0.6935, 3.15, 0.176, 290, 250, DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN
2946, d1q4lB_, 0.6935, 3.60, 0.161, 337, 261, GSK-3 BETA COMPLEXED WITH INHIBITOR I-5
2947, d3rahA_, 0.6934, 3.00, 0.190, 282, 247, CDK2 IN COMPLEX WITH INHIBITOR RC-2-22
2948, d3qcyA_, 0.6934, 3.34, 0.208, 275, 255, PHOSPHOINOSITIDE-DEPENDENT KINASE-1 (PDK1) KINASE DOMAIN WITH 4-[2- AMINO-6-(3-AMINO-1H-INDAZOL-6-YL)-4-PYRIMIDINYL]-N-PHENYL-2- MORPHOLINECARBOXAMIDE
2949, d3hrcA_, 0.6934, 3.54, 0.197, 279, 259, CRYSTAL STRUCTURE OF A MUTANT OF HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH ATP
2950, d1y91A_, 0.6934, 3.06, 0.185, 286, 248, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A PYRAZOLO[1 5-A]PYRIMIDINE INHIBITOR
2951, d1r0eA_, 0.6934, 3.62, 0.169, 344, 261, GLYCOGEN SYNTHASE KINASE-3 BETA IN COMPLEX WITH 3-INDOLYL-4- ARYLMALEIMIDE INHIBITOR
2952, d1p5eC1, 0.6934, 3.51, 0.158, 295, 259, THE STRUCTURE OF PHOSPHO-CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR 4567-TETRABROMOBENZOTRIAZOLE (TBS)
2953, d1oiyA1, 0.6934, 3.30, 0.164, 292, 256, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH A 6-CYCLOHEXYLMETHYLOXY-2-ANILINO-PURINE INHIBITOR
2954, d5m4iA_, 0.6933, 3.37, 0.148, 331, 256, COMPLEX STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH THE INHIBITOR 4 -CARBOXY-68-CHLORO-FLAVONOL (FLC21) CRYSTALLIZED UNDER HIGH-SALT CONDITIONS
2955, d5l2wA1, 0.6933, 3.22, 0.157, 296, 254, THE X-RAY CO-CRYSTAL STRUCTURE OF HUMAN CDK2/CYCLINE AND DINACICLIB.
2956, d5kx8C_, 0.6933, 3.13, 0.216, 287, 250, IRAK4-INHIBITOR CO-STRUCTURE
2957, d4nm5A1, 0.6933, 3.60, 0.161, 360, 261, CRYSTAL STRUCTURE OF GSK-3/AXIN COMPLEX BOUND TO PHOSPHORYLATED WNT RECEPTOR LRP6 C-MOTIF
2958, d4nifB_, 0.6933, 3.21, 0.169, 349, 254, HETERODIMERIC STRUCTURE OF ERK2 AND RSK1
2959, d4fkvA_, 0.6933, 3.02, 0.185, 282, 248, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH OXINDOLE INHIBITOR
2960, d4cfnC1, 0.6933, 3.44, 0.163, 293, 258, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6-CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
2961, d1oiuA1, 0.6933, 3.30, 0.160, 293, 256, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH A 6-CYCLOHEXYLMETHYLOXY-2-ANILINO-PURINE INHIBITOR
2962, d1mqbA_, 0.6933, 3.25, 0.311, 263, 254, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE
2963, d1ke8A_, 0.6933, 2.99, 0.186, 282, 247, CYCLIN-DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH 4-{[(2-OXO- 12-DIHYDRO-3H-INDOL-3-YLIDENE)METHYL]AMINO}-N-(13- THIAZOL-2-YL)BENZENESULFONAMIDE
2964, d5deyB_, 0.6932, 3.60, 0.173, 281, 260, CRYSTAL STRUCTURE OF PAK1 IN COMPLEX WITH AN INHIBITOR COMPOUND G-5555
2965, d4wunB_, 0.6932, 3.31, 0.310, 268, 252, STRUCTURE OF FGFR1 IN COMPLEX WITH AZD4547 (N-{3-[2-(35- DIMETHOXYPHENYL)ETHYL]-1H-PYRAZOL-5-YL}-4-[(3R5S)-35- DIMETHYLPIPERAZIN-1-YL]BENZAMIDE) AT 1.65 ANGSTROM
2966, d4nifE_, 0.6932, 3.21, 0.169, 348, 254, HETERODIMERIC STRUCTURE OF ERK2 AND RSK1
2967, d4kioB1, 0.6932, 2.13, 0.329, 237, 234, KINASE DOMAIN MUTANT OF HUMAN ITK IN COMPLEX WITH A COVALENTLY-BINDING INHIBITOR
2968, d4f1tA1, 0.6932, 3.19, 0.221, 267, 253, CRYSTAL STRUCTURE OF THE ROCO4 KINASE DOMAIN FROM D. DISCOIDEUM BOUND TO THE ROCK INHIBITOR H1152
2969, d4aotA1, 0.6932, 3.04, 0.185, 276, 249, CRYSTAL STRUCTURE OF HUMAN SERINE THREONINE KINASE-10 (LOK) BOUND TO GW830263A
2970, d2xckA_, 0.6932, 3.10, 0.210, 275, 252, CRYSTAL STRUCTURE OF PDK1 IN COMPLEX WITH A PYRAZOLOQUINAZOLINE INHIBITOR
2971, d3qd4A_, 0.6931, 3.29, 0.205, 276, 254, PHOSPHOINOSITIDE-DEPENDENT KINASE-1 (PDK1) KINASE DOMAIN WITH 11- DIMETHYLETHYL{(3R5R)-1-[2-AMINO-6-(3-AMINO-1H-INDAZOL-6-YL)-4- PYRIMIDINYL]-5-METHYL-3-PIPERIDINYL}CARBAMATE
2972, d5d9lA_, 0.6930, 3.56, 0.187, 299, 262, RSK2 N-TERMINAL KINASE IN COMPLEX WITH BIS-PHENOL PYRAZOLE
2973, d4eosA1, 0.6930, 3.29, 0.152, 293, 256, THR 160 PHOSPHORYLATED CDK2 WT - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR RO3306
2974, d3miyA1, 0.6930, 2.16, 0.319, 237, 235, X-RAY CRYSTAL STRUCTURE OF ITK COMPLEXED WITH SUNITINIB
2975, d3iecA_, 0.6930, 3.31, 0.215, 311, 256, HELICOBACTER PYLORI CAGA INHIBITS PAR1/MARK FAMILY KINASES BY MIMICKING HOST SUBSTRATES
2976, d3dj7A_, 0.6930, 3.15, 0.183, 257, 252, CRYSTAL STRUCTURE OF THE MOUSE AURORA-A CATALYTIC DOMAIN (ASN186->GLY LYS240->ARG MET302->LEU) IN COMPLEX WITH COMPOUND 130.
2977, d2ow3A_, 0.6930, 3.61, 0.185, 346, 260, GLYCOGEN SYNTHASE KINASE-3 BETA IN COMPLEX WITH BIS- (INDOLE)MALEIMIDE PYRIDINOPHANE INHIBITOR
2978, d2henD1, 0.6930, 3.13, 0.312, 258, 250, CRYSTAL STRUCTURE OF THE EPHB2 RECEPTOR KINASE DOMAIN IN COMPLEX WITH ADP
2979, d2c5xA_, 0.6930, 3.50, 0.154, 296, 260, DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN
2980, p5v62A_, 0.6929, 3.16, 0.154, 349, 253, PHOSPHO-ERK2 BOUND TO BIVALENT INHIBITOR SBP3
2981, d3my5C1, 0.6929, 3.36, 0.172, 265, 256, CDK2/CYCLINA IN COMPLEX WITH DRB
2982, d2x7fC_, 0.6929, 3.31, 0.180, 285, 255, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN TRAF2- AND NCK-INTERACTING KINASE WITH WEE1CHK1 INHIBITOR
2983, d2qvsE_, 0.6929, 3.75, 0.158, 323, 266, CRYSTAL STRUCTURE OF TYPE IIA HOLOENZYME OF CAMP-DEPENDENT PROTEIN KINASE
2984, d4wo5A1, 0.6928, 2.69, 0.215, 250, 242, CRYSTAL STRUCTURE OF A BRAF KINASE DOMAIN MONOMER
2985, d4cfvA1, 0.6928, 3.53, 0.150, 297, 260, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6- CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
2986, d4cfmA1, 0.6928, 3.45, 0.163, 295, 258, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6- CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
2987, d3q3bB_, 0.6928, 3.67, 0.164, 341, 262, 6-AMINO-4-(PYRIMIDIN-4-YL)PYRIDONES: NOVEL GLYCOGEN SYNTHASE KINASE-3 INHIBITORS
2988, d3ns9A_, 0.6928, 3.09, 0.177, 289, 249, CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH INHIBITOR BS-194
2989, d2ow3B_, 0.6928, 3.60, 0.185, 351, 260, GLYCOGEN SYNTHASE KINASE-3 BETA IN COMPLEX WITH BIS- (INDOLE)MALEIMIDE PYRIDINOPHANE INHIBITOR
2990, d2henB1, 0.6928, 3.13, 0.312, 258, 250, CRYSTAL STRUCTURE OF THE EPHB2 RECEPTOR KINASE DOMAIN IN COMPLEX WITH ADP
2991, d5valA_, 0.6927, 2.81, 0.220, 254, 245, BRAF IN COMPLEX WITH N-(3-(TERT-BUTYL)PHENYL)-4-METHYL-3-(6- MORPHOLINOPYRIMIDIN-4-YL)BENZAMIDE
2992, d5acbC_, 0.6927, 3.83, 0.148, 324, 270, CRYSTAL STRUCTURE OF THE HUMAN CDK12-CYCLINK COMPLEX
2993, d4usdB_, 0.6927, 3.07, 0.185, 267, 249, HUMAN STK10 (LOK) WITH SB-633825
2994, d2oibA_, 0.6927, 2.91, 0.217, 280, 244, CRYSTAL STRUCTURE OF IRAK4 KINASE DOMAIN APO FORM
2995, d2ogvA_, 0.6927, 3.55, 0.293, 317, 256, CRYSTAL STRUCTURE OF THE AUTOINHIBITED HUMAN C-FMS KINASE DOMAIN
2996, d4ztmA_, 0.6926, 3.19, 0.211, 287, 251, IRAK4-INHIBITOR CO-STRUCTURE
2997, d4oabA_, 0.6926, 3.17, 0.192, 279, 250,  
2998, d2c5tC_, 0.6926, 3.43, 0.163, 296, 258,  
2999, d2c5nC_, 0.6926, 3.48, 0.158, 296, 259, DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND  INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN
3000, d1oguA1, 0.6926, 3.38, 0.152, 293, 257, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH A 2-ARYLAMINO-4-CYCLOHEXYLMETHYL-5-NITROSO-6-AMINOPYRIMIDINE INHIBITOR
3001, d1ke9A_, 0.6926, 3.09, 0.185, 281, 248, CYCLIN-DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH 3-{[4- ({[AMINO(IMINO)METHYL]AMINOSULFONYL)ANILINO]METHYLENE}-2- OXO-23-DIHYDRO-1H-INDOLE
3002, d5mp8B_, 0.6925, 3.28, 0.150, 323, 254, CRYSTAL STRUCTURE OF CK2ALPHA WITH ZT0432 BOUND
3003, d5he0A2, 0.6925, 3.79, 0.165, 346, 266, BOVINE GRK2 IN COMPLEX WITH GBETAGAMMA SUBUNITS AND CCG215022
3004, d4f1oA1, 0.6925, 3.47, 0.219, 274, 256, CRYSTAL STRUCTURE OF THE L1180T MUTANT ROCO4 KINASE DOMAIN FROM D. DISCOIDEUM BOUND TO APPCP
3005, d4eorC1, 0.6925, 3.41, 0.168, 269, 256, THR 160 PHOSPHORYLATED CDK2 WT - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR NU6102
3006, d2x6dA_, 0.6925, 2.97, 0.188, 255, 250, AURORA-A BOUND TO AN INHIBITOR
3007, d2rl5A1, 0.6925, 3.49, 0.305, 290, 256, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A 23-DIHYDRO-14-BENZOXAZINE INHIBITOR
3008, d2iw6A1, 0.6925, 3.42, 0.156, 291, 257, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2-CYCLIN A COMPLEXED WITH A BISANILINOPYRIMIDINE INHIBITOR
3009, d1mruB_, 0.6925, 3.11, 0.159, 271, 251, INTRACELLULAR SER/THR PROTEIN KINASE DOMAIN OF MYCOBACTERIUM TUBERCULOSIS PKNB.
3010, d5dt4A_, 0.6924, 3.08, 0.183, 259, 251, AURORA A KINASE IN COMPLEX WITH AA35 AND ATP IN SPACE GROUP P6122
3011, d5cshB_, 0.6924, 3.28, 0.150, 323, 253, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 4 BOUND
3012, d4fkrA_, 0.6924, 3.05, 0.185, 282, 248, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH OXINDOLE INHIBITOR
3013, d2qo2A_, 0.6924, 3.43, 0.303, 282, 254, HUMAN EPHA3 KINASE AND JUXTAMEMBRANE REGION DEPHOSPHORYLATED APO STRUCTURE
3014, d1urcA_, 0.6924, 3.50, 0.154, 296, 260, CYCLIN A BINDING GROOVE INHIBITOR ACE-ARG-LYS-LEU-PHE-GLY
3015, d1ke5A_, 0.6924, 2.99, 0.186, 281, 247, CDK2 COMPLEXED WITH N-METHYL-4-{[(2-OXO-12-DIHYDRO-3H- INDOL-3-YLIDENE)METHYL]AMINO}BENZENESULFONAMIDE
3016, d3kc3I_, 0.6923, 2.90, 0.141, 295, 248, MK2 COMPLEXED TO INHIBITOR N4-(7-(BENZOFURAN-2-YL)-1H-INDAZOL-5-YL) PYRIMIDINE-24-DIAMINE
3017, d3bhvA1, 0.6923, 3.34, 0.160, 295, 257, STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR VARIOLIN B
3018, d2wihC1, 0.6923, 3.60, 0.153, 298, 262, STRUCTURE OF CDK2-CYCLIN A WITH PHA-848125
3019, d2whaC_, 0.6923, 3.44, 0.167, 296, 258,  
3020, d1vywC1, 0.6923, 3.55, 0.153, 298, 261, STRUCTURE OF CDK2/CYCLIN A WITH PNU-292137
3021, d1uu3A_, 0.6923, 3.31, 0.212, 276, 255, STRUCTURE OF HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH LY333531
3022, p5v61A_, 0.6922, 3.13, 0.151, 348, 252, PHOSPHO-ERK2 BOUND TO BIVALENT INHIBITOR SBP2
3023, d5jrsB1, 0.6922, 2.54, 0.326, 239, 239, CRYSTAL STRUCTURE OF BRUTON AGAMMAGLOBULINEMIA TYROSINE KINASE COMPLEXED WITH 4-[2-FLUORO-3-(4-OXO -34-DIHYDROQUINAZOLIN-3-YL) PHENYL]-7-(2-HYDROXYPROPAN-2-Y L)-9H-CARBAZOLE-1-CARBOXAMIDE
3024, d4twnA1, 0.6922, 3.58, 0.319, 275, 257, HUMAN EPHA3 KINASE DOMAIN IN COMPLEX WITH BIRB796
3025, d4qo9A_, 0.6922, 3.68, 0.237, 280, 262, MST3 IN COMPLEX WITH DANUSERTIB
3026, d4nfnA_, 0.6922, 3.74, 0.163, 293, 264, HUMAN TAU TUBULIN KINASE 1 (TTBK1) COMPLEXED WITH 3-({5-[(4-AMINO-4- METHYLPIPERIDIN-1-YL)METHYL]PYRROLO[21-F][124]TRIAZIN-4-YL}AMINO)- 5-BROMOPHENOL
3027, d4fkwA_, 0.6921, 2.90, 0.167, 280, 246, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH OXINDOLE INHIBITOR
3028, d3r7iA_, 0.6921, 3.01, 0.186, 282, 247, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-74
3029, d3dzqA_, 0.6921, 3.33, 0.300, 268, 253, HUMAN EPHA3 KINASE DOMAIN IN COMPLEX WITH INHIBITOR AWL-II- 38.3
3030, d2wpaC1, 0.6921, 3.61, 0.156, 298, 262, OPTIMISATION OF 66-DIMETHYL PYRROLO 34-C PYRAZOLES: IDENTIFICATION OF PHA-793887 A POTENT CDK INHIBITOR SUITABLE FOR INTRAVENOUS DOSING
3031, d2w06A_, 0.6921, 3.03, 0.186, 282, 247, STRUCTURE OF CDK2 IN COMPLEX WITH AN IMIDAZOLYL PYRIMIDINE COMPOUND 5C
3032, d2f57A1, 0.6921, 3.54, 0.178, 290, 259, CRYSTAL STRUCTURE OF THE HUMAN P21-ACTIVATED KINASE 5
3033, d1fvtA_, 0.6921, 3.01, 0.186, 282, 247, THE STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 (CDK2) IN COMPLEX WITH AN OXINDOLE INHIBITOR
3034, d4fklA_, 0.6920, 3.13, 0.177, 290, 249, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH THIAZOLYLPYRIMIDINE INHIBITOR
3035, d3ii5B_, 0.6920, 2.88, 0.228, 257, 246, THE COMPLEX OF WILD-TYPE B-RAF WITH PYRAZOLO PYRIMIDINE INHIBITOR
3036, d2p2hA1, 0.6920, 3.43, 0.318, 289, 255, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A PYRIDINYL-TRIAZINE INHIBITOR
3037, d4dhfA_, 0.6919, 3.17, 0.183, 258, 252, STRUCTURE OF AURORA A MUTANT BOUND TO BIOGENIDEC CPD 15
3038, d3py1A1, 0.6919, 3.34, 0.169, 298, 254, CDK2 TERNARY COMPLEX WITH SU9516 AND ANS
3039, d3naxA_, 0.6919, 3.29, 0.184, 278, 255, PDK1 IN COMPLEX WITH INHIBITOR MP7
3040, d2og8B2, 0.6919, 2.78, 0.291, 247, 244, CRYSTAL STRUCTURE OF AMINOQUINAZOLINE 36 BOUND TO LCK
3041, d5nk8A_, 0.6918, 3.15, 0.320, 266, 250, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 2F
3042, d4zy4B_, 0.6918, 3.74, 0.175, 292, 263, CRYSTAL STRUCTURE OF P21 ACTIVATED KINASE 1 IN COMPLEX WITH AN INHIBITOR COMPOUND 4
3043, d4zs0A_, 0.6918, 3.17, 0.183, 257, 252, HUMAN AURORA A CATALYTIC DOMAIN BOUND TO SB-6-OH
3044, d4yo6D_, 0.6918, 3.11, 0.213, 285, 249, IRAK4-INHIBITOR CO-STRUCTURE
3045, d3pixA_, 0.6918, 3.27, 0.303, 268, 251, CRYSTAL STRUCTURE OF BTK KINASE DOMAIN COMPLEXED WITH 2-ISOPROPYL-7- (4-METHYL-PIPERAZIN-1-YL)-4-(5-METHYL-2H-PYRAZOL-3-YLAMINO)-2H- PHTHALAZIN-1-ONE
3046, d3fz1A_, 0.6918, 3.11, 0.185, 284, 248, CRYSTAL STRUCTURE OF A BENZTHIOPHENE INHIBITOR BOUND TO HUMAN CYCLIN-DEPENDENT KINASE-2 (CDK-2)
3047, d1okwC_, 0.6918, 3.49, 0.154, 296, 259, CYCLIN A BINDING GROOVE INHIBITOR AC-ARG-ARG-LEU-ASN-(M-CL-PHE)-NH2
3048, d1j3hA_, 0.6918, 3.87, 0.169, 329, 267, CRYSTAL STRUCTURE OF APOENZYME CAMP-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT
3049, d1h08A_, 0.6918, 3.11, 0.185, 283, 248, CDK2 IN COMPLEX WITH A DISUBSTITUTED 2 4-BIS ANILINO PYRIMIDINE CDK4 INHIBITOR
3050, d5jkgA_, 0.6917, 3.14, 0.320, 266, 250, THE CRYSTAL STRUCTURE OF FGFR4 KINASE DOMAIN IN COMPLEX WITH LY2874455
3051, d1rjbA_, 0.6917, 3.20, 0.339, 298, 248, CRYSTAL STRUCTURE OF FLT3
3052, d5c9cA_, 0.6916, 2.85, 0.224, 254, 245, CRYSTAL STRUCTURE OF BRAF(V600E) IN COMPLEX WITH LY3009120 COMPND
3053, d4pdoB_, 0.6916, 2.93, 0.302, 261, 245, STRUCTURE OF EPHRIN TYPE-A RECEPTOR 2
3054, d3e5aA_, 0.6916, 3.42, 0.187, 264, 256, CRYSTAL STRUCTURE OF AURORA A IN COMPLEX WITH VX-680 AND TPX2
3055, d3blqA_, 0.6916, 3.56, 0.165, 295, 260, CRYSTAL STRUCTURE OF HUMAN CDK9/CYCLINT1 IN COMPLEX WITH ATP
3056, d2whbC_, 0.6916, 3.59, 0.146, 296, 261, TRUNCATION AND OPTIMISATION OF PEPTIDE INHIBITORS OF CDK2 CYCLIN A THROUGH STRUCTURE GUIDED DESIGN
3057, d2uueC_, 0.6916, 3.42, 0.151, 296, 258, REPLACE: A STRATEGY FOR ITERATIVE DESIGN OF CYCLIN BINDING GROOVE INHIBITORS
3058, d2cciA2, 0.6916, 3.41, 0.171, 295, 257, CRYSTAL STRUCTURE OF PHOSPHO-CDK2 CYCLIN A IN COMPLEX WITH A PEPTIDE CONTAINING BOTH THE SUBSTRATE AND RECRUITMENT SITES OF CDC6
3059, p6g97A_, 0.6915, 3.26, 0.154, 344, 254, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
3060, d5nhhA_, 0.6915, 3.32, 0.153, 348, 255, HUMAN ERK2 WITH AN ERK1/2 INHIBITOR
3061, d5i8aA1, 0.6915, 2.58, 0.304, 265, 240, TRKA WITH (6~{R})-3-METHYLSULFANYL-6-PHENYL-1-(1~{H}-PYRAZOL-3-YL)-6 7-DIHYDRO-5~{H}-THIENO[34-C]PYRIDIN-4-ONE
3062, d4oa2A_, 0.6915, 3.33, 0.182, 280, 253,  
3063, d4mtaA_, 0.6915, 3.22, 0.171, 273, 252, CRYSTAL STRUCTURE OF PIM-1 KINASE DOMAIN IN COMPLEX WITH 2-METHYL-5- PHENYLFURAN-3-CARBOXYLIC ACID
3064, d3qd0A_, 0.6915, 3.33, 0.205, 274, 254, PHOSPHOINOSITIDE-DEPENDENT KINASE-1 (PDK1) KINASE DOMAIN WITH (2R5S)- 1-[2-AMINO-6-(3-AMINO-1H-INDAZOL-6-YL)-4-PYRIMIDINYL]-6-METHYL-N- PHENYL-3-PIPERIDINECARBOXAMIDE
3065, d3orzC_, 0.6915, 3.33, 0.205, 276, 254, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT ACTIVATOR 2A2
3066, d3orzA_, 0.6915, 3.33, 0.205, 276, 254, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT ACTIVATOR 2A2
3067, d3ctjA_, 0.6915, 3.61, 0.323, 289, 257, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF THE HEPATOCYTE GROWTH FACTOR RECEPTOR C-MET IN COMPLEX WITH A AMINOPYRIDINE BASED INHIBITOR
3068, d2wmbA1, 0.6915, 3.40, 0.163, 295, 257, STRUCTURAL AND THERMODYNAMIC CONSEQUENCES OF CYCLIZATION OF PEPTIDE LIGANDS FOR THE RECRUITMENT SITE OF CYCLIN A
3069, d5dewB_, 0.6914, 3.70, 0.161, 281, 261, CRYSTAL STRUCTURE OF PAK1 IN COMPLEX WITH AN INHIBITOR COMPOUND 5
3070, d4pdoA_, 0.6914, 2.93, 0.302, 261, 245, STRUCTURE OF EPHRIN TYPE-A RECEPTOR 2
3071, d4dhfB_, 0.6914, 3.16, 0.183, 258, 252, STRUCTURE OF AURORA A MUTANT BOUND TO BIOGENIDEC CPD 15
3072, d2vv9A_, 0.6914, 2.81, 0.184, 279, 244, CDK2 IN COMPLEX WITH AN IMIDAZOLE PIPERAZINE
3073, d2iw9A2, 0.6914, 3.29, 0.153, 292, 255, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2-CYCLIN A COMPLEXED WITH A BISANILINOPYRIMIDINE INHIBITOR
3074, d1v0bA_, 0.6914, 3.09, 0.156, 286, 250, CRYSTAL STRUCTURE OF THE T198A MUTANT OF PFPK5
3075, d6b8uB_, 0.6913, 2.66, 0.223, 248, 242, CRYSTALS STRUCTURE OF B-RAF KINASE DOMAIN IN COMPLEX WITH AN IMIDAZOPYRIDINYL BENZAMIDE INHIBITOR
3076, d4k0yA_, 0.6913, 3.27, 0.174, 274, 253, STRUCTURE OF PIM-1 KINASE BOUND TO N-(4-FLUOROPHENYL)-7-HYDROXY-5- (PIPERIDIN-4-YL)PYRAZOLO[15-A]PYRIMIDINE-3-CARBOXAMIDE
3077, d4fc0B_, 0.6913, 2.94, 0.215, 263, 246, CRYSTAL STRUCTURE OF HUMAN KINASE DOMAIN OF B-RAF WITH A DFG-OUT INHIBITOR
3078, p4f9bA_, 0.6913, 3.27, 0.134, 318, 253, HUMAN CDC7 KINASE IN COMPLEX WITH DBF4 AND PHA767491
3079, d4bcmA1, 0.6913, 3.34, 0.160, 292, 256, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
3080, d3r7uA_, 0.6913, 3.03, 0.182, 282, 247, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-75
3081, d3lvpA_, 0.6913, 3.43, 0.294, 289, 255, CRYSTAL STRUCTURE OF BISPHOSPHORYLATED IGF1-R KINASE DOMAIN (2P) IN COMPLEX WITH A BIS-AZAINDOLE INHIBITOR
3082, d3f5pT1, 0.6913, 3.71, 0.292, 294, 260, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
3083, d3f5pM1, 0.6913, 3.73, 0.293, 294, 259, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
3084, d3be2A1, 0.6913, 3.47, 0.314, 285, 255, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A BENZAMIDE INHIBITOR
3085, d2wipA1, 0.6913, 3.38, 0.156, 293, 257, STRUCTURE OF CDK2-CYCLIN A COMPLEXED WITH 8-ANILINO-1- METHYL-45-DIHYDRO-1H-PYRAZOLO[43-H] QUINAZOLINE-3- CARBOXYLIC ACID
3086, d2ds1A_, 0.6913, 3.18, 0.176, 290, 250, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE CDK4 INHIBITOR
3087, d1pkdC1, 0.6913, 3.52, 0.151, 295, 259, THE CRYSTAL STRUCTURE OF UCN-01 IN COMPLEX WITH PHOSPHO- CDK2/CYCLIN A
3088, d1e9hC1, 0.6913, 3.52, 0.154, 295, 259, THR 160 PHOSPHORYLATED CDK2 - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR INDIRUBIN-5-SULPHONATE BOUND
3089, d5ur1B_, 0.6912, 3.37, 0.312, 265, 253, FGFR1 KINASE DOMAIN COMPLEX WITH SN37333 IN REVERSIBLE BINDING MODE
3090, d5efqA_, 0.6912, 3.89, 0.145, 321, 269, CRYSTAL STRUCTURE OF HUMAN CDK13/CYCLIN K IN COMPLEX WITH ADP-ALUMINUM FLUORIDE
3091, d5dgzA_, 0.6912, 3.22, 0.171, 273, 252, DISCOVERY OF 35-SUBSTITUTED 6-AZAINDAZOLES AS POTENT PAN-PIM INHIBITORS
3092, p4jr7A_, 0.6912, 3.30, 0.146, 367, 253, CRYSTAL STRUCTURE OF SCCK2 ALPHA IN COMPLEX WITH GMPPNP
3093, p4fmqA_, 0.6912, 3.28, 0.173, 350, 255, CRYSTAL STRUCTURE OF HUMAN ERK2 COMPLEXED WITH A MAPK DOCKING PEPTIDE
3094, d3f2aA_, 0.6912, 3.45, 0.173, 276, 255, CRYSTAL STRUCTURE OF HUMAN PIM-1 IN COMPLEX WITH DAPPA
3095, d2x1nC_, 0.6912, 3.46, 0.151, 296, 259, TRUNCATION AND OPTIMISATION OF PEPTIDE INHIBITORS OF CDK2 CYCLIN A THROUGH STRUCTURE GUIDED DESIGN
3096, d2nruA_, 0.6912, 3.23, 0.206, 293, 252, CRYSTAL STRUCTURE OF IRAK-4
3097, d4oa6A_, 0.6911, 3.29, 0.179, 279, 252,  
3098, d4ek5A_, 0.6911, 3.05, 0.186, 289, 247, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH AMINOPYRAZOLE INHIBITOR
3099, d3krwA2, 0.6911, 3.85, 0.169, 349, 267, HUMAN GRK2 IN COMPLEX WITH GBETGAMMA SUBUNITS AND BALANOL (SOAK)
3100, d2qodA_, 0.6911, 3.46, 0.291, 274, 254, HUMAN EPHA3 KINASE AND JUXTAMEMBRANE REGION Y602F MUTANT
3101, d2qo7A_, 0.6911, 3.52, 0.307, 278, 254, HUMAN EPHA3 KINASE AND JUXTAMEMBRANE REGION DEPHOSPHORYLATED AMP-PNP BOUND
3102, p2no3A_, 0.6911, 3.32, 0.184, 357, 255, NOVEL 4-ANILINOPYRIMIDINES AS POTENT JNK1 INHIBITORS
3103, d4ty1A_, 0.6910, 3.22, 0.167, 273, 252, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH AN AMINOOXADIAZOLE-INDOLE INHIBITOR.
3104, d4pnkA2, 0.6910, 3.80, 0.165, 350, 266, G PROTEIN-COUPLED RECEPTOR KINASE 2 IN COMPLEX WITH GSK180736A
3105, d4bcmC1, 0.6910, 3.55, 0.154, 293, 259, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
3106, d2w9zB_, 0.6910, 3.04, 0.178, 287, 247, CRYSTAL STRUCTURE OF CDK4 IN COMPLEX WITH A D-TYPE CYCLIN
3107, d2qoiA_, 0.6910, 3.46, 0.291, 274, 254, HUMAN EPHA3 KINASE AND JUXTAMEMBRANE REGION Y596F:Y602F DOUBLE MUTANT
3108, d5nhoA_, 0.6909, 3.33, 0.165, 343, 255, HUMAN ERK2 WITH AN ERK1/2 INHIBITOR
3109, d5diaA_, 0.6909, 3.22, 0.167, 273, 252, PIM1 IN COMPLEX WITH CPD36 ((1S3S)-N1-(6-(5-(PYRIDIN-3-YL)-1H- PYRAZOLO[34-C]PYRIDIN-3-YL)PYRIDIN-2-YL)CYCLOHEXANE-13-DIAMINE)
3110, d3tnwA1, 0.6909, 3.40, 0.155, 294, 258, STRUCTURE OF CDK2/CYCLIN A IN COMPLEX WITH CAN508
3111, d3lfsA_, 0.6909, 3.15, 0.181, 290, 249, CRYSTAL STRUCTURE OF CDK2 WITH SAR37 AN AMINOINDAZOLE TYPE INHIBITOR
3112, d2oi4X_, 0.6909, 3.23, 0.174, 275, 253, CRYSTAL STRUCTURE OF HUMAN PIM1 IN COMPLEX WITH FLUORINATED RUTHENIUM PYRIDOCARBAZOLE
3113, d1xqzA_, 0.6909, 3.34, 0.173, 277, 254, CRYSTAL STRUCTURE OF HPIM-1 KINASE AT 2.1 A RESOLUTION
3114, d1w98A2, 0.6909, 3.29, 0.154, 296, 254, THE STRUCTURAL BASIS OF CDK2 ACTIVATION BY CYCLIN E
3115, d4fv7A_, 0.6908, 3.22, 0.146, 342, 253, CRYSTAL STRUCTURE OF THE ERK2 COMPLEXED WITH E94
3116, d3krxA2, 0.6908, 3.89, 0.161, 349, 267, HUMAN GRK2 IN COMPLEX WITH GBETGAMMA SUBUNITS AND BALANOL (CO-CRYSTAL)
3117, d2whbA_, 0.6908, 3.55, 0.150, 296, 260, TRUNCATION AND OPTIMISATION OF PEPTIDE INHIBITORS OF CDK2 CYCLIN A THROUGH STRUCTURE GUIDED DESIGN
3118, d5v60A_, 0.6907, 3.14, 0.151, 347, 252, PHOSPHO-ERK2 BOUND TO AMP-PCP
3119, d5bvwA_, 0.6907, 3.11, 0.312, 274, 250, FRAGMENT-BASED DISCOVERY OF POTENT AND SELECTIVE DDR1/2 INHIBITORS
3120, d4wnpB_, 0.6907, 3.23, 0.197, 272, 254, STRUCTURE OF ULK1 BOUND TO A POTENT INHIBITOR
3121, d4obpB_, 0.6907, 3.68, 0.170, 290, 259, MAP4K4 IN COMPLEX WITH INHIBITOR (COMPOUND 29) 6-(2-FLUOROPYRIDIN-4- YL)PYRIDO[32-D]PYRIMIDIN-4-AMINE
3122, d4bcpC1, 0.6907, 3.38, 0.157, 266, 255, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
3123, d3sw7A_, 0.6907, 2.84, 0.180, 278, 244, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH THIAZOLYLPYRIMIDINE INHIBITOR
3124, d3idpA_, 0.6907, 2.92, 0.224, 255, 246, B-RAF V600E KINASE DOMAIN IN COMPLEX WITH AN AMINOISOQUINOLINE INHIBITOR
3125, d2whaA_, 0.6907, 3.49, 0.154, 296, 259,  
3126, d2jgzA_, 0.6907, 3.26, 0.157, 288, 254, CRYSTAL STRUCTURE OF PHOSPHO-CDK2 IN COMPLEX WITH CYCLIN B
3127, d4n70A_, 0.6906, 3.23, 0.167, 274, 252, PIM1 COMPLEXED WITH A PYRIDYLCARBOXAMIDE
3128, d4lghB_, 0.6906, 2.79, 0.283, 247, 244, CRYSTAL STRUCTURE OF 1NM-PP1 BOUND TO ANALOG-SENSITIVE SRC KINASE
3129, d4knbD_, 0.6906, 3.01, 0.351, 247, 242, C-MET IN COMPLEX WITH OSI LIGAND
3130, d4eojA1, 0.6906, 3.36, 0.156, 293, 256, THR 160 PHOSPHORYLATED CDK2 H84S Q85M K89D - HUMAN CYCLIN A3 COMPLEX WITH ATP
3131, d3dlsC_, 0.6906, 3.60, 0.160, 281, 257, CRYSTAL STRUCTURE OF HUMAN PAS KINASE BOUND TO ADP
3132, d2oh4A1, 0.6906, 3.46, 0.310, 296, 255, CRYSTAL STRUCTURE OF VEGFR2 WITH A BENZIMIDAZOLE-UREA INHIBITOR
3133, d1finC_, 0.6906, 3.57, 0.157, 298, 261, CYCLIN A-CYCLIN-DEPENDENT KINASE 2 COMPLEX
3134, d6b16B_, 0.6905, 3.55, 0.174, 281, 258, P21-ACTIVATED KINASE 1 IN COMPLEX WITH A 4-AZAINDOLE INHIBITOR
3135, d5xvuB_, 0.6905, 3.49, 0.148, 321, 257, CRYSTAL STRUCTURE OF THE PROTEIN KINASE CK2 CATALYTIC DOMAIN FROM PLASMODIUM FALCIPARUM BOUND TO ATP
3136, d5uorB_, 0.6905, 3.00, 0.206, 262, 248, STRUCTURE-BASED DESIGN OF ASK1 INHIBITORS AS POTENTIAL FIRST-IN-CLASS AGENTS FOR HEART FAILURE
3137, d4tyeA_, 0.6905, 3.79, 0.314, 292, 261, STRUCTURAL ANALYSIS OF THE HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 4 KINASE
3138, d4cfuA1, 0.6905, 3.37, 0.160, 295, 257, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6- CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
3139, d4afjB_, 0.6905, 3.64, 0.178, 346, 259, 5-ARYL-4-CARBOXAMIDE-13-OXAZOLES: POTENT AND SELECTIVE GSK-3 INHIBITORS
3140, d3d15A_, 0.6905, 3.13, 0.183, 256, 251, CRYSTAL STRUCTURE OF MOUSE AURORA A (ASN186->GLY LYS240->ARG MET302- >LEU) IN COMPLEX WITH 1-(3-CHLORO-PHENYL)-3-{5-[2-(THIENO[32- D]PYRIMIDIN-4-YLAMINO)- ETHYL]-THIAZOL-2-YL}-UREA [SNS-314]
3141, d2v22A_, 0.6905, 3.54, 0.150, 296, 260, REPLACE: A STRATEGY FOR ITERATIVE DESIGN OF CYCLIN BINDING GROOVE INHIBITORS
3142, d2nruB_, 0.6905, 3.27, 0.206, 294, 253, CRYSTAL STRUCTURE OF IRAK-4
3143, d1ke7A_, 0.6905, 2.98, 0.187, 281, 246, CYCLIN-DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH 3-{[(22- DIOXIDO-13-DIHYDRO-2-BENZOTHIEN-5-YL)AMINO]METHYLENE}-5- (13-OXAZOL-5-YL)-13-DIHYDRO-2H-INDOL-2-ONE
3144, d4yc3A1, 0.6904, 3.36, 0.175, 294, 257, CDK1/CYCLINB1/CKS2 APO
3145, d4qteA_, 0.6904, 3.38, 0.164, 348, 256, STRUCTURE OF ERK2 IN COMPLEX WITH VTX-11E 4-{2-[(2-CHLORO-4- FLUOROPHENYL)AMINO]-5-METHYLPYRIMIDIN-4-YL}-N-[(1S)-1-(3- CHLOROPHENYL)-2-HYDROXYETHYL]-1H-PYRROLE-2-CARBOXAMIDE
3146, d1q3dA_, 0.6904, 3.66, 0.169, 339, 261, GSK-3 BETA COMPLEXED WITH STAUROSPORINE
3147, d1k9aD3, 0.6904, 3.31, 0.310, 268, 252, CRYSTAL STRUCTURE ANALYSIS OF FULL-LENGTH CARBOXYL-TERMINAL SRC KINASE AT 2.5 A RESOLUTION
3148, d5u6iA_, 0.6903, 3.28, 0.154, 339, 254, DISCOVERY OF MLI-2 AN ORALLY AVAILABLE AND SELECTIVE LRRK2 INHIBITOR THAT REDUCES BRAIN KINASE ACTIVITY
3149, d2wfyC_, 0.6903, 3.50, 0.158, 296, 259, TRUNCATION AND OPTIMISATION OF PEPTIDE INHIBITORS OF CDK2 CYCLIN A THROUGH STRUCTURE GUIDED DESIGN
3150, d2bpmC2, 0.6903, 3.62, 0.149, 298, 262, STRUCTURE OF CDK2-CYCLIN A WITH PHA-630529
3151, d1w0xC_, 0.6903, 2.94, 0.184, 280, 245, CRYSTAL STRUCTURE OF HUMAN CDK2 IN COMPLEX WITH THE INHIBITOR OLOMOUCINE.
3152, d5v82A_, 0.6902, 3.16, 0.179, 273, 251, PIM1 KINASE IN COMPLEX WITH CPD17 (1-(6-(44-DIFLUOROPIPERIDIN-3-YL) PYRIDIN-2-YL)-6-(6-METHYLPYRAZIN-2-YL)-1H-PYRAZOLO[43-C]PYRIDINE)
3153, d5kx8D_, 0.6902, 3.05, 0.206, 283, 247, IRAK4-INHIBITOR CO-STRUCTURE
3154, d4y73C_, 0.6902, 3.19, 0.219, 290, 251, CRYSTAL STRUCTURE OF IRAK4 KINASE DOMAIN WITH INHIBITOR
3155, d4wrsA_, 0.6902, 3.28, 0.166, 273, 253, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH AN AZASPIRO PYRAZINYL-INDAZOLE INHIBITOR.
3156, d4mblA_, 0.6902, 3.28, 0.170, 274, 253, DISCOVERY OF PYRAZOLO[15A]PYRIMIDINE-BASED PIM1 INHIBITORS
3157, d4aotB1, 0.6902, 3.35, 0.178, 277, 253, CRYSTAL STRUCTURE OF HUMAN SERINE THREONINE KINASE-10 (LOK) BOUND TO GW830263A
3158, d3w8lA_, 0.6902, 3.39, 0.145, 326, 256, CRYSTAL STRUCTURE OF HUMAN CK2 IN COMPLEX WITH INOSITOL HEXAKISPHOSPHATE
3159, d2qlqB_, 0.6902, 2.76, 0.305, 248, 243, CRYSTAL STRUCTURE OF SRC KINASE DOMAIN WITH COVALENT INHIBITOR RL3
3160, p2no3B_, 0.6902, 3.24, 0.185, 357, 254, NOVEL 4-ANILINOPYRIMIDINES AS POTENT JNK1 INHIBITORS
3161, d2c6tC_, 0.6902, 3.49, 0.163, 295, 258, CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR
3162, d1blxA_, 0.6902, 3.18, 0.167, 305, 251, P19INK4D/CDK6 COMPLEX
3163, d5nevC1, 0.6901, 3.42, 0.167, 295, 257, CDK2/CYCLIN A IN COMPLEX WITH COMPOUND 73
3164, d4f0fA1, 0.6901, 3.34, 0.224, 274, 255, CRYSTAL STRUCTURE OF THE ROCO4 KINASE DOMAIN BOUND TO APPCP FROM D. DISCOIDEUM
3165, d3qc4A_, 0.6901, 3.56, 0.171, 276, 257, PDK1 IN COMPLEX WITH DFG-OUT INHIBITOR XXX
3166, d3nszA_, 0.6901, 3.47, 0.148, 327, 257, HUMAN CK2 CATALYTIC DOMAIN IN COMPLEX WITH AMPPN
3167, d3nayB_, 0.6901, 3.23, 0.209, 278, 253, PDK1 IN COMPLEX WITH INHIBITOR MP6
3168, d3ha6A1, 0.6901, 3.38, 0.184, 262, 255, CRYSTAL STRUCTURE OF AURORA A IN COMPLEX WITH TPX2 AND COMPOUND 10
3169, d2x1nA_, 0.6901, 3.58, 0.154, 296, 260, TRUNCATION AND OPTIMISATION OF PEPTIDE INHIBITORS OF CDK2 CYCLIN A THROUGH STRUCTURE GUIDED DESIGN
3170, d2qofA_, 0.6901, 3.51, 0.291, 280, 254, HUMAN EPHA3 KINASE AND JUXTAMEMBRANE REGION Y596F MUTANT
3171, d5l6pA_, 0.6900, 3.33, 0.316, 274, 253, EPHB3 KINASE DOMAIN COVALENTLY BOUND TO AN IRREVERSIBLE INHIBITOR (COMPOUND 6)
3172, d5dosA_, 0.6900, 3.11, 0.183, 259, 251, AURORA A KINASE IN COMPLEX WITH AA35 AND ATP IN SPACE GROUP P6122
3173, d4u3zB_, 0.6900, 3.63, 0.174, 294, 259, APO MAP4K4 T181E PHOSPHOMIMETIC MUTANT
3174, d4ditA_, 0.6900, 3.53, 0.167, 328, 257, CRYSTAL STRUCTURE OF GSK3BETA IN COMPLEX WITH A IMIDAZOPYRIDINE INHIBITOR
3175, d2x7fA_, 0.6900, 3.30, 0.182, 276, 253, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN TRAF2- AND NCK-INTERACTING KINASE WITH WEE1CHK1 INHIBITOR
3176, d2nruD_, 0.6900, 3.31, 0.225, 293, 253, CRYSTAL STRUCTURE OF IRAK-4
3177, d1q3dB_, 0.6900, 3.64, 0.173, 339, 260, GSK-3 BETA COMPLEXED WITH STAUROSPORINE
3178, d1okvC_, 0.6900, 3.47, 0.167, 296, 258, CYCLIN A BINDING GROOVE INHIBITOR H-ARG-ARG-LEU-ILE-PHE-NH2
3179, d5drbA_, 0.6899, 3.34, 0.226, 273, 252, CRYSTAL STRUCTURE OF WNK1 IN COMPLEX WITH WNK463
3180, d4ficB_, 0.6899, 2.80, 0.289, 245, 242, KINASE DOMAIN OF CSRC IN COMPLEX WITH A HINGE REGION-BINDING FRAGMENT
3181, p3vuhA_, 0.6899, 3.21, 0.210, 355, 252, CRYSTAL STRUCTURE OF A CYSTEINE-DEFICIENT MUTANT M3 IN MAP KINASE JNK1
3182, d1yxtA_, 0.6899, 3.37, 0.169, 274, 254, CRYSTAL STRUCTURE OF KINASE PIM1 IN COMPLEX WITH AMPPNP
3183, d5ipjA_, 0.6898, 3.22, 0.167, 273, 252, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH A QUINAZOLINONE-PYRROLOPYRROLONE INHIBITOR.
3184, d5if1C_, 0.6898, 3.54, 0.150, 296, 260, CRYSTAL STRUCTURE APO CDK2/CYCLIN A
3185, d4fkiA_, 0.6898, 3.13, 0.185, 287, 248, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH AMINOPYRAZOLE INHIBITOR
3186, d4alvA_, 0.6898, 3.23, 0.171, 274, 252, BENZOFUROPYRIMIDINONE INHIBITORS OF PIM-1
3187, p3vugA_, 0.6898, 3.21, 0.210, 356, 252, CRYSTAL STRUCTURE OF A CYSTEINE-DEFICIENT MUTANT M2 IN MAP KINASE JNK1
3188, d3rmfA_, 0.6898, 2.85, 0.189, 278, 244, CDK2 IN COMPLEX WITH INHIBITOR RC-2-33
3189, d2xj0A_, 0.6898, 3.17, 0.171, 274, 251, PROTEIN KINASE PIM-1 IN COMPLEX WITH FRAGMENT-4 FROM CRYSTALLOGRAPHIC FRAGMENT SCREEN
3190, d2qooA_, 0.6898, 3.48, 0.291, 273, 254, HUMAN EPHA3 KINASE AND JUXTAMEMBRANE REGION Y596F:Y602F:Y742F TRIPLE MUTANT
3191, d1ckjB_, 0.6898, 3.67, 0.145, 293, 262, CASEIN KINASE I DELTA TRUNCATION MUTANT CONTAINING RESIDUES 1-317 COMPLEX WITH BOUND TUNGSTATE
3192, d5dhjA_, 0.6897, 3.22, 0.171, 273, 252, PIM1 IN COMPLEX WITH CPD4 (3-METHYL-5-(PYRIDIN-3-YL)-1H-PYRAZOLO[34- C]PYRIDINE)
3193, d4jx7A_, 0.6897, 3.30, 0.170, 274, 253, CRYSTAL STRUCTURE OF PIM1 KINASE IN COMPLEX WITH INHIBITOR 2-[(TRANS- 4-AMINOCYCLOHEXYL)AMINO]-4-{[3-(TRIFLUOROMETHYL) PHENYL]AMINO}PYRIDO[43-D]PYRIMIDIN-5(6H)-ONE
3194, d4cfnA1, 0.6897, 3.45, 0.148, 293, 257, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6-CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
3195, d3is5B1, 0.6897, 2.97, 0.191, 255, 246, CRYSTAL STRUCTURE OF CDPK KINASE DOMAIN FROM TOXOPLASMA GONDII TGME49_018720
3196, d3cjgA_, 0.6897, 3.34, 0.317, 280, 252, CRYSTAL STRUCTURE OF VEGFR2 IN COMPLEX WITH A 345-TRIMETHOXY ANILINE CONTAINING PYRIMIDINE
3197, d3cjfA_, 0.6897, 3.33, 0.310, 276, 252, CRYSTAL STRUCTURE OF VEGFR2 IN COMPLEX WITH A 345-TRIMETHOXY ANILINE CONTAINING PYRIMIDINE
3198, d2w17A_, 0.6897, 2.89, 0.188, 278, 245, CDK2 IN COMPLEX WITH THE IMIDAZOLE PYRIMIDINE AMIDE COMPOUND (S)-8B
3199, d2uzdC_, 0.6897, 3.43, 0.171, 295, 257, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
3200, d4ztnA_, 0.6896, 3.20, 0.212, 286, 250, IRAK4-INHIBITOR CO-STRUCTURE
3201, d4eomA1, 0.6896, 3.41, 0.160, 294, 257, THR 160 PHOSPHORYLATED CDK2 H84S Q85M Q131E - HUMAN CYCLIN A3 COMPLEX WITH ATP
3202, d3my5A1, 0.6896, 3.41, 0.148, 294, 257, CDK2/CYCLINA IN COMPLEX WITH DRB
3203, d6bkuA1, 0.6895, 3.21, 0.187, 264, 251, CRYSTAL STRUCTURE OF THE HUMAN CAMKK2B BOUND TO GSK650394
3204, d5k5nB_, 0.6895, 3.53, 0.180, 334, 256, CRYSTAL STRUCTURE OF GSK-3BETA COMPLEXED WITH PF-04802367 A HIGHLY SELECTIVE BRAIN-PENETRANT KINASE INHIBITOR
3205, d4wt6A_, 0.6895, 3.34, 0.170, 273, 253, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH A THIADIAZOLAMINE-INDOLE INHIBITOR.
3206, d4krcA_, 0.6895, 3.43, 0.156, 297, 256, CRYSTAL STRUCTURE OF PHO85-PCL10-ATP-GAMMA-S COMPLEX
3207, d4eorA1, 0.6895, 3.26, 0.157, 292, 254, THR 160 PHOSPHORYLATED CDK2 WT - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR NU6102
3208, d2vwwA_, 0.6895, 3.14, 0.297, 253, 249, EPHB4 KINASE DOMAIN INHIBITOR COMPLEX
3209, d1h27C1, 0.6895, 3.44, 0.167, 290, 257, CDK2/CYCLIN A IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM P27
3210, d3c4eD_, 0.6894, 3.31, 0.166, 273, 253, PIM-1 KINASE DOMAIN IN COMPLEX WITH 3-AMINOPHENYL-7- AZAINDOLE
3211, d2wmaA1, 0.6894, 3.45, 0.151, 295, 258, STRUCTURAL AND THERMODYNAMIC CONSEQUENCES OF CYCLIZATION OF PEPTIDE LIGANDS FOR THE RECRUITMENT SITE OF CYCLIN A
3212, d2i40C_, 0.6894, 3.52, 0.151, 296, 259, CDK2/CYCLIN A COMPLEXED WITH A THIOPHENE CARBOXAMIDE INHIBITOR
3213, d1h26A1, 0.6894, 3.51, 0.159, 295, 258, CDK2/CYCLIN A IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM P53
3214, d1ckiB_, 0.6894, 3.68, 0.145, 286, 262, RECOMBINANT CASEIN KINASE I DELTA TRUNCATION MUTANT CONTAINING RESIDUES 1-317
3215, d5k4jA1, 0.6893, 3.02, 0.187, 281, 246, CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH COMPOUND 22
3216, d5eolA_, 0.6893, 3.24, 0.167, 273, 252, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH A MACROCYCLIC QUINOXALINE-PYRROLODIHYDROPIPERIDINONE INHIBITOR
3217, d4ztlC_, 0.6893, 3.08, 0.215, 282, 247, IRAK4-INHIBITOR CO-STRUCTURE
3218, d4o0tB_, 0.6893, 3.54, 0.163, 280, 258, BACK POCKET FLEXIBILITY PROVIDES GROUP-II PAK SELECTIVITY FOR TYPE 1 KINASE INHIBITORS
3219, d4k18A_, 0.6893, 3.34, 0.177, 277, 254, STRUCTURE OF PIM-1 KINASE BOUND TO 5-(4-CYANOBENZYL)-N-(4- FLUOROPHENYL)-7-HYDROXYPYRAZOLO[15-A]PYRIMIDINE-3-CARBOXAMIDE
3220, d4dtkA_, 0.6893, 3.23, 0.175, 273, 252, NOVEL AND SELECTIVE PAN-PIM KINASE INHIBITOR
3221, d3vc4A_, 0.6893, 3.28, 0.170, 274, 253, EXPLOITATION OF HYDROGEN BONDING CONSTRAINTS AND FLAT HYDROPHOBIC ENERGY LANDSCAPES IN PIM-1 KINASE NEEDLE SCREENING AND INHIBITOR DESIGN
3222, d3cpbB_, 0.6893, 2.92, 0.316, 263, 244, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A BISAMIDE INHIBITOR
3223, d2xj2A_, 0.6893, 3.10, 0.172, 273, 250, PROTEIN KINASE PIM-1 IN COMPLEX WITH SMALL MOLECULE INHIBITOR
3224, d2vtiA_, 0.6893, 2.96, 0.188, 280, 245, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
3225, d1ke6A_, 0.6893, 2.95, 0.184, 280, 245, CYCLIN-DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH N-METHYL-{4- [2-(7-OXO-67-DIHYDRO-8H-[13]THIAZOLO[54-E]INDOL-8- YLIDENE)HYDRAZINO]PHENYL}METHANESULFONAMIDE
3226, d4y73A_, 0.6892, 3.24, 0.223, 289, 251, CRYSTAL STRUCTURE OF IRAK4 KINASE DOMAIN WITH INHIBITOR
3227, p3vuiA_, 0.6892, 3.23, 0.210, 355, 252, CRYSTAL STRUCTURE OF A CYSTEINE-DEFICIENT MUTANT M2 IN MAP KINASE JNK1
3228, d3r00A_, 0.6892, 3.21, 0.175, 274, 252, THE DISCOVERY OF NOVEL BENZOFURAN-2-CARBOXYLIC ACIDS AS POTENT PIM-1 INHIBITORS
3229, d2oibD_, 0.6892, 3.11, 0.201, 288, 249, CRYSTAL STRUCTURE OF IRAK4 KINASE DOMAIN APO FORM
3230, d1sykA_, 0.6892, 4.00, 0.152, 348, 270, CRYSTAL STRUCTURE OF E230Q MUTANT OF CAMP-DEPENDENT PROTEIN KINASE REVEALS UNEXPECTED APOENZYME CONFORMATION
3231, d3piyA_, 0.6891, 3.07, 0.312, 262, 247, CRYSTAL STRUCTURE OF BTK KINASE DOMAIN COMPLEXED WITH R406
3232, d3f5pI1, 0.6891, 3.77, 0.292, 293, 260, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
3233, p2gmxA_, 0.6891, 3.26, 0.206, 357, 253, SELECTIVE AMINOPYRIDINE-BASED C-JUN N-TERMINAL KINASE INHIBITORS WITH CELLULAR ACTIVITY
3234, d1ol1A_, 0.6891, 3.55, 0.158, 296, 260, CYCLIN A BINDING GROOVE INHIBITOR H-CIT-CIT-LEU-ILE-(P-F-PHE)-NH2
3235, d5k7gD_, 0.6890, 2.95, 0.212, 283, 245, IRAK4 IN COMPLEX WITH AZ3862
3236, d5dwrA_, 0.6890, 3.21, 0.167, 273, 251, IDENTIFICATION OF N-(4-((1R3S5S)-3-AMINO-5-METHYLCYCLOHEXYL)PYRIDIN- 3-YL)-6-(26-DIFLUOROPHENYL)-5-FLUOROPICOLINAMIDE (PIM447) A POTENT AND SELECTIVE PROVIRAL INSERTION SITE OF MOLONEY MURINE LEUKEMIA (PIM) 12 AND 3 KINASE INHIBITOR IN CLINICAL TRIALS FOR HEMATOLOGICAL MALIGNANCIES
3237, d3rpyA_, 0.6890, 2.81, 0.189, 277, 243, CDK2 IN COMPLEX WITH INHIBITOR RC-2-40
3238, d3cs9B_, 0.6890, 2.71, 0.342, 247, 243, HUMAN ABL KINASE IN COMPLEX WITH NILOTINIB
3239, d3bgzA_, 0.6890, 3.11, 0.168, 267, 250, HUMAN PIM-1 KINASE IN COMPLEX WITH DIPHENYL INDOLE INHIBITOR VX3
3240, d2vtoA_, 0.6890, 3.09, 0.190, 283, 247, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
3241, d2uueA_, 0.6890, 3.57, 0.154, 296, 260, REPLACE: A STRATEGY FOR ITERATIVE DESIGN OF CYCLIN BINDING GROOVE INHIBITORS
3242, d2o64A_, 0.6890, 3.39, 0.173, 274, 254, CRYSTAL STRUCTURE OF PIM1 WITH QUERCETAGETIN
3243, d2jkoA_, 0.6890, 3.29, 0.355, 256, 251, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH BIS- ANILINO PYRIMIDINE INHIBITOR
3244, d2clqB_, 0.6890, 2.79, 0.213, 259, 244, STRUCTURE OF MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE 2 5
3245, d2bzhB_, 0.6890, 3.25, 0.174, 275, 253, CRYSTAL STRUCTURE OF THE HUMAN PIM1 IN COMPLEX WITH A RUTHENIUM ORGANOMETALLIC LIGAND RU1
3246, d4yo6A_, 0.6889, 3.20, 0.216, 286, 250, IRAK4-INHIBITOR CO-STRUCTURE
3247, d4i4eA_, 0.6889, 3.20, 0.340, 254, 250, STRUCTURE OF FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH HINGE BINDING PYRAZOLOBENZOTHIAZINE COMPOUND.
3248, d4au8B_, 0.6889, 2.89, 0.158, 277, 247, CRYSTAL STRUCTURE OF COMPOUND 4A IN COMPLEX WITH CDK5 SHOWING AN UNUSUAL BINDING MODE TO THE HINGE REGION VIA A WATER MOLECULE
3249, d5efqC_, 0.6888, 3.89, 0.146, 325, 268, CRYSTAL STRUCTURE OF HUMAN CDK13/CYCLIN K IN COMPLEX WITH ADP-ALUMINUM FLUORIDE
3250, d4qp8B_, 0.6888, 3.08, 0.164, 337, 250, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH 2-(1H-PYRAZOL-4-YL)-7- (PYRIDIN-3-YL)-5H-PYRROLO[23-B]PYRAZINE
3251, d4alwA_, 0.6888, 3.26, 0.167, 273, 252, BENZOFUROPYRIMIDINONE INHIBITORS OF PIM-1
3252, d3wzdA_, 0.6888, 3.19, 0.301, 278, 249, KDR IN COMPLEX WITH LIGAND LENVATINIB
3253, p3vudA_, 0.6888, 3.28, 0.198, 355, 253, CRYSTAL STRUCTURE OF A CYSTEINE-DEFICIENT MUTANT M1 IN MAP KINASE JNK1
3254, d3uimA_, 0.6888, 3.04, 0.184, 291, 245, STRUCTURAL BASIS FOR THE IMPACT OF PHOSPHORYLATION ON PLANT RECEPTOR- LIKE KINASE BAK1 ACTIVATION
3255, d3kc3H_, 0.6888, 2.95, 0.146, 290, 247, MK2 COMPLEXED TO INHIBITOR N4-(7-(BENZOFURAN-2-YL)-1H-INDAZOL-5-YL) PYRIMIDINE-24-DIAMINE
3256, d2vwuA_, 0.6888, 3.17, 0.297, 253, 249, EPHB4 KINASE DOMAIN INHIBITOR COMPLEX
3257, d2pzyC_, 0.6888, 3.04, 0.145, 307, 248, STRUCTURE OF MK2 COMPLEXED WITH COMPOUND 76
3258, d1ol2A_, 0.6888, 3.55, 0.154, 296, 260, CYCLIN A BINDING GROOVE INHIBITOR H-ARG-ARG-LEU-ASN-(P-F-PHE)-NH2
3259, d5m44A_, 0.6887, 3.42, 0.156, 329, 256, COMPLEX STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH A THIENO[23-D]PYRIMIDIN INHIBITOR CRYSTALLIZED UNDER HIGH-SALT CONDITIONS
3260, d5iisA_, 0.6887, 3.39, 0.170, 273, 253, DESIGN SYNTHESIS AND STRUCTURE ACTIVITY RELATIONSHIP OF POTENT PAN- PIM KINASE INHIBITORS DERIVED FROM THE PYRIDYL-AMIDE SCAFFOLD
3261, d4zy6A_, 0.6887, 3.65, 0.189, 284, 259, CRYSTAL STRUCTURE OF P21-ACTIVATED KINASE 1 IN COMPLEX WITH AN INHIBITOR COMPOUND 29
3262, d4ztnD_, 0.6887, 3.14, 0.213, 285, 249, IRAK4-INHIBITOR CO-STRUCTURE
3263, p4ux9D_, 0.6887, 3.05, 0.189, 344, 249, CRYSTAL STRUCTURE OF JNK1 BOUND TO A MKK7 DOCKING MOTIF
3264, d2c5tA_, 0.6887, 3.57, 0.154, 296, 260,  
3265, d5xvuC_, 0.6886, 3.48, 0.152, 321, 256, CRYSTAL STRUCTURE OF THE PROTEIN KINASE CK2 CATALYTIC DOMAIN FROM PLASMODIUM FALCIPARUM BOUND TO ATP
3266, d5ke0A_, 0.6886, 3.35, 0.153, 340, 255, DISCOVERY OF 1-1H-PYRAZOLO 43-C PYRIDINE-6-YL UREA INHIBITORS OF EXTRACELLULAR SIGNAL REGULATED KINASE ERK FOR THE TREATMENT OF CANCERS
3267, d4xhkB_, 0.6886, 3.16, 0.171, 269, 251, PIM1 KINASE IN COMPLEX WITH COMPOUND 1S
3268, d4pmtA1, 0.6886, 2.78, 0.306, 269, 242, THE STRUCTURE OF TRKA KINASE BOUND TO THE INHIBITOR N~4~-(4-MORPHOLIN- 4-YLPHENYL)-N~6~-(PYRIDIN-3-YLMETHYL)PYRIDO[32-D]PYRIMIDINE-46- DIAMINE
3269, d3sw4A_, 0.6886, 2.98, 0.184, 279, 245, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH THIAZOLYLPYRIMIDINE INHIBITOR
3270, d3f5pG1, 0.6886, 3.77, 0.292, 298, 260, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
3271, d3dlsE_, 0.6886, 3.64, 0.152, 282, 257, CRYSTAL STRUCTURE OF HUMAN PAS KINASE BOUND TO ADP
3272, d2objA_, 0.6886, 3.23, 0.167, 272, 251, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH INHIBITOR
3273, d5dt0A_, 0.6885, 3.13, 0.183, 259, 251, AURORA A KINASE IN COMPLEX WITH JNJ-7706621 IN SPACE GROUP P6122
3274, d4wsyA_, 0.6885, 3.25, 0.167, 273, 252, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH A THIAZOLAMINE-INDAZOLE INHIBITOR.
3275, d3f5pD1, 0.6885, 3.77, 0.292, 296, 260, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
3276, d1yxuD_, 0.6885, 3.32, 0.174, 273, 253, CRYSTAL STRUCTURE OF KINASE PIM1 IN COMPLEX WITH AMP
3277, d1pkdA1, 0.6885, 3.58, 0.154, 295, 259, THE CRYSTAL STRUCTURE OF UCN-01 IN COMPLEX WITH PHOSPHO- CDK2/CYCLIN A
3278, d4n6zA_, 0.6884, 3.07, 0.165, 272, 249, PIM1 COMPLEXED WITH A PYRIDYLCARBOXAMIDE
3279, d4maoA_, 0.6884, 2.82, 0.193, 298, 244, RSK2 T493M C-TERMINAL KINASE DOMAIN IN COMPLEX WITH RMM58
3280, d3f5pS1, 0.6884, 3.78, 0.292, 294, 260, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
3281, d3f5pC1, 0.6884, 3.77, 0.292, 300, 260, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
3282, d3d5xA_, 0.6884, 3.51, 0.182, 279, 258, CRYSTAL STRUCTURE OF AN ACTIVATED (THR->ASP) POLO-LIKE KINASE 1 (PLK1) CATALYTIC DOMAIN IN COMPLEX WITH WORTMANNIN.
3283, d2chlA_, 0.6884, 3.88, 0.127, 298, 267, STRUCTURE OF CASEIN KINASE 1 GAMMA 3
3284, d3vbqA_, 0.6883, 3.13, 0.172, 271, 250, EXPLOITATION OF HYDROGEN BONDING CONSTRAINTS AND FLAT HYDROPHOBIC ENERGY LANDSCAPES IN PIM-1 KINASE NEEDLE SCREENING AND INHIBITOR DESIGN
3285, d3a2cF_, 0.6883, 3.03, 0.158, 287, 247, CRYSTAL STRUCTURE OF A PYRAZOLOPYRIMIDINE INHIBITOR COMPLEX BOUND TO MAPKAP KINASE-2 (MK2)
3286, d5w5jB_, 0.6882, 2.42, 0.212, 257, 236, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES
3287, d5kgdA_, 0.6882, 3.24, 0.171, 273, 252, CRYSTAL STRUCTURE OF PIM1 WITH INHIBITOR: 2-PYRIDIN-3-YL-1~{H}- BENZIMIDAZOLE
3288, d4twcA_, 0.6882, 3.86, 0.140, 293, 265, 2-BENZAMIDO-N-(1H-BENZO[D]IMIDAZOL-2-YL)THIAZOLE-4- CARBOXAMIDE DERIVATIVES AS POTENT INHIBITORS OF CK1D/E
3289, d3lw0B_, 0.6882, 3.28, 0.308, 292, 250, IGF-1RK IN COMPLEX WITH LIGAND MSC1609119A-1
3290, d3f5pA1, 0.6882, 3.77, 0.292, 298, 260, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
3291, d3dpkA_, 0.6882, 3.35, 0.308, 279, 250, CFMS TYROSINE KINASE IN COMPLEX WITH A PYRIDOPYRIMIDINONE INHIBITOR
3292, p5oo0A_, 0.6881, 3.20, 0.177, 288, 249, CDK2(WT) COVALENT ADDUCT WITH D28 AT C177
3293, d5d10B_, 0.6881, 2.91, 0.305, 247, 243, KINASE DOMAIN OF CSRC IN COMPLEX WITH RL236
3294, d4l3lA_, 0.6881, 3.57, 0.181, 291, 259, CRYSTAL STRUCTURES OF HUMAN P70S6K1 KINASE DOMAIN (ZINC ANOMALOUS)
3295, d3v5wA2, 0.6881, 4.00, 0.164, 355, 268, HUMAN G PROTEIN-COUPLED RECEPTOR KINASE 2 IN COMPLEX WITH SOLUBLE GBETAGAMMA SUBUNITS AND PAROXETINE
3296, d3kc3K_, 0.6881, 2.87, 0.147, 280, 245, MK2 COMPLEXED TO INHIBITOR N4-(7-(BENZOFURAN-2-YL)-1H-INDAZOL-5-YL) PYRIMIDINE-24-DIAMINE
3297, d3f5pK1, 0.6881, 3.73, 0.295, 292, 258, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
3298, d5lpzA_, 0.6880, 3.28, 0.175, 283, 251, CRYSTAL STRUCTURE OF THE BRI1 KINASE DOMAIN (865-1196) IN COMPLEX WITH ADP FROM ARABIDOPSIS THALIANA
3299, d5ko1A_, 0.6880, 2.93, 0.177, 265, 249, PSEUDOKINASE DOMAIN OF MLKL BOUND TO COMPOUND 4.
3300, d4fkgA_, 0.6880, 3.11, 0.186, 286, 247, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH AMINOPYRAZOLE INHIBITOR
3301, d4aluA_, 0.6880, 3.31, 0.166, 274, 253, BENZOFUROPYRIMIDINONE INHIBITORS OF PIM-1
3302, d3jpvA_, 0.6880, 3.15, 0.171, 273, 251, CRYSTAL STRUCTURE OF HUMAN PROTO-ONCOGENE SERINE THREONINE KINASE (PIM1) IN COMPLEX WITH A CONSENSUS PEPTIDE AND A PYRROLO[23- A]CARBAZOLE LIGAND
3303, d3dlsF_, 0.6880, 3.54, 0.148, 281, 256, CRYSTAL STRUCTURE OF HUMAN PAS KINASE BOUND TO ADP
3304, d2xj1A_, 0.6880, 3.23, 0.167, 273, 251, PROTEIN KINASE PIM-1 IN COMPLEX WITH SMALL MOLECULE INIBITOR
3305, d5lpwA_, 0.6879, 3.23, 0.185, 280, 249, CRYSTAL STRUCTURE OF THE APO-BRI1 KINASE DOMAIN (865-1160)
3306, d3f5pH1, 0.6879, 3.78, 0.292, 298, 260, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
3307, d2vtpA_, 0.6879, 3.07, 0.191, 281, 246, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
3308, d4m8tA_, 0.6878, 2.84, 0.189, 303, 244, RSK2 T493M C-TERMINAL KINASE DOMAIN IN COMPLEX WITH 3-(3-(1H-PYRAZOL- 4-YL)PHENYL)-2-CYANOACRYLAMIDE
3309, p4h3qA_, 0.6878, 3.31, 0.169, 352, 255, CRYSTAL STRUCTURE OF HUMAN ERK2 COMPLEXED WITH A MAPK DOCKING PEPTIDE
3310, d3lw0A_, 0.6878, 3.34, 0.311, 292, 251, IGF-1RK IN COMPLEX WITH LIGAND MSC1609119A-1
3311, d3f5pB1, 0.6878, 3.77, 0.292, 297, 260, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
3312, d3cs9D_, 0.6878, 3.00, 0.341, 263, 246, HUMAN ABL KINASE IN COMPLEX WITH NILOTINIB
3313, d5xvuA_, 0.6877, 3.53, 0.152, 321, 257, CRYSTAL STRUCTURE OF THE PROTEIN KINASE CK2 CATALYTIC DOMAIN FROM PLASMODIUM FALCIPARUM BOUND TO ATP
3314, d5t1sA_, 0.6877, 3.18, 0.217, 280, 249, IRAK4 KINASE - COMPOUND 1 CO-STRUCTURE
3315, d5kx8A_, 0.6877, 3.19, 0.213, 285, 249, IRAK4-INHIBITOR CO-STRUCTURE
3316, d4n6yA_, 0.6877, 3.26, 0.171, 273, 252, PIM1 COMPLEXED WITH A PHENYLCARBOXAMIDE
3317, d4jg7A_, 0.6877, 3.22, 0.186, 307, 247, STRUCTURE OF RSK2 CTD BOUND TO 3-(3-(1H-PYRROLO[23-B]PYRIDINE-3- CARBONYL)PHENYL)-2-CYANOACRYLAMIDE
3318, p3vukA_, 0.6877, 3.30, 0.202, 355, 253, CRYSTAL STRUCTURE OF A CYSTEINE-DEFICIENT MUTANT M5 IN MAP KINASE JNK1
3319, d3q4zA1, 0.6877, 3.63, 0.198, 281, 258, STRUCTURE OF UNPHOSPHORYLATED PAK1 KINASE DOMAIN
3320, d3lw0D_, 0.6877, 3.35, 0.311, 292, 251, IGF-1RK IN COMPLEX WITH LIGAND MSC1609119A-1
3321, d3lw0C_, 0.6877, 3.35, 0.311, 292, 251, IGF-1RK IN COMPLEX WITH LIGAND MSC1609119A-1
3322, d2zoqA_, 0.6877, 3.40, 0.169, 351, 255, STRUCTURAL DISSECTION OF HUMAN MITOGEN-ACTIVATED KINASE ERK1
3323, d5lpbA_, 0.6876, 3.16, 0.190, 280, 248, CRYSTAL STRUCTURE OF THE BRI1 KINASE DOMAIN (865-1160) IN COMPLEX WITH ADP FROM ARABIDOPSIS THALIANA
3324, d4iz5D_, 0.6876, 3.25, 0.165, 347, 254, STRUCTURE OF THE COMPLEX BETWEEN ERK2 PHOSPHOMIMETIC MUTANT AND PEA-15
3325, d3ralA_, 0.6876, 2.85, 0.189, 277, 243, CDK2 IN COMPLEX WITH INHIBITOR RC-2-34
3326, d3q96B_, 0.6876, 2.94, 0.224, 262, 245, B-RAF KINASE DOMAIN IN COMPLEX WITH A TETRAHYDRONAPHTHALENE INHIBITOR
3327, d3nayA_, 0.6876, 3.31, 0.202, 278, 253, PDK1 IN COMPLEX WITH INHIBITOR MP6
3328, d3f5pR1, 0.6876, 3.81, 0.292, 293, 260, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
3329, d2oibC_, 0.6876, 2.94, 0.213, 278, 244, CRYSTAL STRUCTURE OF IRAK4 KINASE DOMAIN APO FORM
3330, d2nruC_, 0.6876, 3.49, 0.227, 293, 255, CRYSTAL STRUCTURE OF IRAK-4
3331, d4iz5C_, 0.6875, 3.25, 0.165, 347, 254, STRUCTURE OF THE COMPLEX BETWEEN ERK2 PHOSPHOMIMETIC MUTANT AND PEA-15
3332, d4iz5B_, 0.6875, 3.25, 0.165, 347, 254, STRUCTURE OF THE COMPLEX BETWEEN ERK2 PHOSPHOMIMETIC MUTANT AND PEA-15
3333, d4iz5A_, 0.6875, 3.25, 0.165, 347, 254, STRUCTURE OF THE COMPLEX BETWEEN ERK2 PHOSPHOMIMETIC MUTANT AND PEA-15
3334, d4d9uA_, 0.6875, 3.22, 0.181, 307, 248, RSK2 C-TERMINAL KINASE DOMAIN (E)-TERT-BUTYL 3-(4-AMINO-7-(3- HYDROXYPROPYL)-5-P-TOLYL-7H-PYRROLO[23-D]PYRIMIDIN-6-YL)-2- CYANOACRYLATE
3335, d4bznA_, 0.6875, 3.32, 0.167, 272, 252, CRYSTAL STRUCTURE OF PIM1 IN COMPLEX WITH A PYRROLO(12-A) PYRAZINONE INHIBITOR
3336, d3tnwC_, 0.6875, 3.51, 0.156, 291, 257, STRUCTURE OF CDK2/CYCLIN A IN COMPLEX WITH CAN508
3337, d3s1hA_, 0.6875, 2.85, 0.189, 277, 243, CDK2 IN COMPLEX WITH INHIBITOR RC-2-39
3338, d2w99B_, 0.6875, 3.09, 0.178, 291, 247, CRYSTAL STRUCTURE OF CDK4 IN COMPLEX WITH A D-TYPE CYCLIN
3339, d2r3jA_, 0.6875, 2.92, 0.189, 278, 244, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
3340, d1yxxA_, 0.6875, 3.38, 0.165, 274, 254, CRYSTAL STRUCTURE OF KINASE PIM1 IN COMPLEX WITH (3E)-3-[(4- HYDROXYPHENYL)IMINO]-1H-INDOL-2(3H)-ONE
3341, d1giiA_, 0.6875, 3.00, 0.184, 279, 245, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE CDK4 INHIBITOR
3342, d4obqA_, 0.6874, 3.14, 0.165, 275, 248, MAP4K4 IN COMPLEX WITH INHIBITOR (COMPOUND 31) N-[3-(4- AMINOQUINAZOLIN-6-YL)-5-FLUOROPHENYL]-2-(PYRROLIDIN-1-YL)ACETAMIDE
3343, d5k7gC_, 0.6873, 3.17, 0.215, 283, 247, IRAK4 IN COMPLEX WITH AZ3862
3344, d4as0A_, 0.6873, 3.16, 0.171, 273, 251, CYCLOMETALATED PHTHALIMIDES AS PROTEIN KINASE INHIBITORS
3345, d3d2iA_, 0.6873, 3.14, 0.180, 255, 250, CRYSTAL STRUCTURE OF MOUSE AURORA A (ASN186->GLY LYS240- >ARG MET302->LEU) IN COMPLEX WITH 1-{5-[2-(1-METHYL-1H- PYRAZOLO[43-D]PYRIMIDIN-7-YLAMINO)-ETHYL]-THIAZOL-2-YL}-3- (3-TRIFLUOROMETHYL-PHENYL)-UREA
3346, d5u94A_, 0.6872, 3.09, 0.169, 263, 249, CRYSTAL STRUCTURE OF THE MYCOBACTERIUM TUBERCULOSIS PASTA KINASE PKNB IN COMPLEX WITH THE POTENTIAL THERAPUTIC KINASE INHIBITOR GSK690693.
3347, d5ih5A_, 0.6872, 3.78, 0.148, 286, 263, HUMAN CASEIN KINASE 1 ISOFORM DELTA (KINASE DOMAIN) IN COMPLEX WITH EPIBLASTIN A
3348, d5he2A2, 0.6872, 3.93, 0.165, 353, 267, BOVINE GRK2 IN COMPLEX WITH GBETAGAMMA SUBUNITS AND CCG224406
3349, d5clpA_, 0.6872, 3.30, 0.155, 322, 252, CRYSTAL STRUCTURE OF CK2ALPHA WITH 34-DICHLOROPHENETHYLAMINE BOUND
3350, d4yomB1, 0.6872, 3.00, 0.194, 320, 248, STRUCTURE OF SAD KINASE
3351, d4qnyA_, 0.6872, 3.27, 0.169, 333, 255, CRYSTAL STRUCTURE OF MAPK FROM LEISHMANIA DONOVANI LDBPK_331470
3352, d3ggfB_, 0.6872, 3.49, 0.249, 270, 257, CRYSTAL STRUCTURE OF HUMAN SERINE/THREONINE-PROTEIN KINASE MST4 IN COMPLEX WITH AN QUINAZOLIN
3353, d1ckiA_, 0.6872, 3.61, 0.153, 292, 261, RECOMBINANT CASEIN KINASE I DELTA TRUNCATION MUTANT CONTAINING RESIDUES 1-317
3354, d5o23A_, 0.6871, 2.95, 0.195, 269, 246, CRYSTAL STRUCTURE OF WNK3 KINASE DOMAIN IN A MONOPHOSPHORYLATED APO STATE
3355, d4qq5A1, 0.6871, 3.46, 0.325, 272, 252, CRYSTAL STRUCTURE OF FGF RECEPTOR (FGFR) 4 KINASE HARBORING THE V550L GATE-KEEPER MUTATION IN COMPLEX WITH FIIN-2 AN IRREVERSIBLE TYROSINE KINASE INHIBITOR CAPABLE OF OVERCOMING FGFR KINASE GATE-KEEPER MUTATIONS
3356, d4k1bA_, 0.6871, 3.26, 0.171, 273, 252, STRUCTURE OF PIM-1 KINASE BOUND TO N-(5-(2-FLUOROPHENYL)-1H-PYRROLO[2 3-B]PYRIDIN-3-YL)-5-((((3R4R)-3-FLUOROPIPERIDIN-4-YL)METHYL)AMINO) PYRAZOLO[15-A]PYRIMIDINE-3-CARBOXAMIDE
3357, d3lfqA_, 0.6871, 3.19, 0.177, 289, 249, CRYSTAL STRUCTURE OF CDK2 WITH SAR60 AN AMINOINDAZOLE TYPE INHIBITOR
3358, d3f5pL1, 0.6871, 3.76, 0.293, 292, 259, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
3359, d3dlsB_, 0.6871, 3.70, 0.156, 280, 257, CRYSTAL STRUCTURE OF HUMAN PAS KINASE BOUND TO ADP
3360, d2r64A_, 0.6871, 2.95, 0.189, 279, 244, CRYSTAL STRUCTURE OF A 3-AMINOINDAZOLE COMPOUND WITH CDK2
3361, d2oicD_, 0.6871, 3.18, 0.218, 284, 248, CRYSTAL STRUCTURE OF IRAK4 KINASE DOMAIN COMPLEXED WITH STAUROSPORINE
3362, d5c9cB_, 0.6870, 2.90, 0.225, 251, 244, CRYSTAL STRUCTURE OF BRAF(V600E) IN COMPLEX WITH LY3009120 COMPND
3363, d4yp8C_, 0.6870, 3.21, 0.212, 287, 250, IRAK4-INHIBITOR CO-STRUCTURE
3364, d4jg8A_, 0.6870, 2.96, 0.188, 300, 245, STRUCTURE OF RSK2 T493M CTD MUTANT BOUND TO 2-CYANO-N-(1-HYDROXY-2- METHYLPROPAN-2-YL)-3-(3-(345-TRIMETHOXYPHENYL)-1H-INDAZOL-5-YL) ACRYLAMIDE
3365, d4j7bA_, 0.6870, 3.53, 0.209, 284, 258, CRYSTAL STRUCTURE OF POLO-LIKE KINASE 1
3366, d4bhnA_, 0.6870, 2.67, 0.207, 256, 242, CRYSTAL STRUCTURES OF ASK1-INHIBITOR COMPLEXES
3367, d3rakA_, 0.6870, 2.83, 0.185, 277, 243, CDK2 IN COMPLEX WITH INHIBITOR RC-2-32
3368, d2wmaC1, 0.6870, 3.48, 0.164, 264, 256, STRUCTURAL AND THERMODYNAMIC CONSEQUENCES OF CYCLIZATION OF PEPTIDE LIGANDS FOR THE RECRUITMENT SITE OF CYCLIN A
3369, d2welA_, 0.6870, 3.32, 0.157, 304, 254, CRYSTAL STRUCTURE OF SU6656-BOUND CALCIUM/CALMODULIN- DEPENDENT PROTEIN KINASE II DELTA IN COMPLEX WITH CALMODULIN
3370, d2r3mA_, 0.6870, 2.93, 0.189, 278, 244, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
3371, d1h07A_, 0.6870, 3.01, 0.183, 285, 246, CDK2 IN COMPLEX WITH A DISUBSTITUTED 4 6-BIS ANILINO PYRIMIDINE CDK4 INHIBITOR
3372, d4tw9A_, 0.6869, 3.93, 0.143, 290, 266, DIFLUORO-DIOXOLO-BENZOIMIDAZOL-BENZAMIDES AS POTENT INHIBITORS OF CK1DELTA AND EPSILON WITH NANOMOLAR INHIBITORY ACTIVITY ON CANCER CELL PROLIFERATION
3373, d4l3jA_, 0.6869, 3.59, 0.174, 291, 258, CRYSTAL STRUCTURES OF HUMAN P70S6K1 KINASE DOMAIN
3374, d4jx3A_, 0.6869, 3.38, 0.173, 274, 254, CRYSTAL STRUCTURE OF PIM1 KINASE
3375, d3r01A_, 0.6869, 3.32, 0.166, 274, 253, THE DISCOVERY OF NOVEL BENZOFURAN-2-CARBOXYLIC ACIDS AS POTENT PIM-1 INHIBITORS
3376, d2pzyB_, 0.6869, 2.88, 0.147, 283, 245, STRUCTURE OF MK2 COMPLEXED WITH COMPOUND 76
3377, d2j2iB_, 0.6869, 3.16, 0.171, 273, 251, CRYSTAL STRUCTURE OF THE HUMAB PIM1 IN COMPLEX WITH LY333531
3378, d1h25C1, 0.6869, 3.44, 0.161, 277, 255, CDK2/CYCLIN A IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM RETINOBLASTOMA-ASSOCIATED PROTEIN
3379, d5vuaB_, 0.6868, 3.25, 0.163, 270, 251, PIM1 KINASE IN COMPLEX WITH A BENZOFURANONE INHIBITOR
3380, d4yffB_, 0.6868, 2.98, 0.198, 264, 243, TNNI3K COMPLEXED WITH INHIBITOR 2
3381, d4m67A_, 0.6868, 2.91, 0.177, 264, 248, CRYSTAL STRUCTURE OF THE HUMAN MLKL KINASE-LIKE DOMAIN
3382, d4acmA_, 0.6868, 2.90, 0.189, 277, 244, CDK2 IN COMPLEX WITH 3-AMINO-6-(4-{[2-(DIMETHYLAMINO)ETHYL] SULFAMOYL}-PHENYL)-N-PYRIDIN-3-YLPYRAZINE-2-CARBOXAMIDE
3383, d3f5pF1, 0.6868, 3.80, 0.292, 298, 260, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
3384, d1okwA_, 0.6868, 3.56, 0.154, 296, 259, CYCLIN A BINDING GROOVE INHIBITOR AC-ARG-ARG-LEU-ASN-(M-CL-PHE)-NH2
3385, d4yffA_, 0.6867, 2.89, 0.202, 264, 242, TNNI3K COMPLEXED WITH INHIBITOR 2
3386, d4xh6A_, 0.6867, 3.27, 0.171, 273, 252, CRYSTAL STRUCTURE OF PROTO-ONCOGENE KINASE PIM1 BOUND TO HISPIDULIN
3387, d4btmA_, 0.6867, 3.76, 0.160, 292, 262, TTBK1 IN COMPLEX WITH INHIBITOR
3388, d3qriA1, 0.6867, 2.99, 0.341, 270, 246, THE CRYSTAL STRUCTURE OF HUMAN ABL1 KINASE DOMAIN IN COMPLEX WITH DCC- 2036
3389, d2xizA_, 0.6867, 3.25, 0.167, 273, 251, PROTEIN KINASE PIM-1 IN COMPLEX WITH FRAGMENT-3 FROM CRYSTALLOGRAPHIC FRAGMENT SCREEN
3390, d5uitB_, 0.6866, 3.07, 0.215, 283, 246, CRYSTAL STRUCTURE OF IRAK4 IN COMPLEX WITH COMPOUND 14
3391, d2r3qA_, 0.6866, 3.07, 0.187, 286, 246, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
3392, d2pzyA_, 0.6866, 2.98, 0.146, 291, 246, STRUCTURE OF MK2 COMPLEXED WITH COMPOUND 76
3393, d2f2cB_, 0.6866, 3.16, 0.159, 280, 251, X-RAY STRUCTURE OF HUMAN CDK6-VCYCLINWITH THE INHIBITOR AMINOPURVALANOL
3394, d1eh4A_, 0.6866, 3.87, 0.151, 293, 265, BINARY COMPLEX OF CASEIN KINASE-1 FROM S. POMBE WITH AN ATP COMPETITIVE INHIBITOR IC261
3395, d5lpyA_, 0.6865, 3.21, 0.185, 282, 248, CRYSTAL STRUCTURE OF THE BRI1 KINASE DOMAIN (865-1160) IN COMPLEX WITH ATP FROM ARABIDOPSIS THALIANA
3396, d5kgeA_, 0.6865, 3.28, 0.167, 273, 252, CRYSTAL STRUCTURE OF PIM1 WITH INHIBITOR: 5-(34-DICHLOROPHENYL)- 1~{H}-PYRAZOL-3-AMINE
3397, d5fp6A_, 0.6865, 2.96, 0.176, 278, 245, STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH SMALL-MOLECULE LIGAND 3-(47-DICHLORO-1H-INDOL-3-YL)PROP-2-YN-1-OL (AT17833) IN AN ALTERNATE BINDING SITE.
3398, d4i6fA_, 0.6865, 3.89, 0.140, 285, 265, SELECTIVE & BRAIN-PERMEABLE POLO-LIKE KINASE-2 (PLK-2) INHIBITORS THAT REDUCE -SYNUCLEIN PHOSPHORYLATION IN RAT BRAIN
3399, d4enxA_, 0.6865, 3.20, 0.164, 266, 250, CRYSTAL STRUCTURE OF PIM-1 KINASE IN COMPLEX WITH INHIBITOR (2E5Z)-2- (2-CHLOROPHENYLIMINO)-5-(4-HYDROXY-3-NITROBENZYLIDENE)THIAZOLIDIN-4- ONE
3400, d4bzdA_, 0.6865, 2.86, 0.177, 277, 243, STRUCTURE OF CDK2 IN COMPLEX WITH A BENZIMIDAZOPYRIMIDINE
3401, d4btjA_, 0.6865, 3.72, 0.156, 292, 262, TTBK1 IN COMPLEX WITH ATP
3402, d2vtsA_, 0.6865, 3.11, 0.187, 282, 246, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
3403, d2r3kA_, 0.6865, 2.85, 0.189, 277, 243, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
3404, d1vzoA_, 0.6865, 3.30, 0.209, 319, 253, THE STRUCTURE OF THE N-TERMINAL KINASE DOMAIN OF MSK1 REVEALS A NOVEL AUTOINHIBITORY CONFORMATION FOR A DUAL KINASE PROTEIN
3405, d5uklA2, 0.6864, 4.09, 0.167, 353, 269, HUMAN GRK2 IN COMPLEX WITH GBETAGAMMA SUBUNITS AND CCG222886 (14BD)
3406, d4p4cA_, 0.6864, 3.26, 0.296, 266, 250, HUMAN EPHA3 KINASE DOMAIN IN COMPLEX WITH QUINOXALINE DERIVATIVES
3407, d4ithA_, 0.6864, 2.57, 0.225, 247, 236, CRYSTAL STRUCTURE OF RIP1 KINASE IN COMPLEX WITH NECROSTATIN-1 ANALOG
3408, d4ek4A_, 0.6864, 3.15, 0.186, 287, 247, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH AMINOPYRAZOLE INHIBITOR
3409, d3jxwA_, 0.6864, 3.35, 0.166, 274, 253, DISCOVERY OF 3H-BENZO[45]THIENO[32-D]PYRIMIDIN-4-ONES AS POTENT HIGHLY SELECTIVE AND ORALLY BIOAVAILABLE PIM KINASES INHIBITORS
3410, d2a1aB1, 0.6864, 3.05, 0.160, 266, 244, PKR KINASE DOMAIN-EIF2ALPHA COMPLEX
3411, d1jstA_, 0.6864, 3.64, 0.153, 297, 261, PHOSPHORYLATED CYCLIN-DEPENDENT KINASE-2 BOUND TO CYCLIN A
3412, d5up3A_, 0.6863, 2.79, 0.209, 258, 244, STRUCTURE-BASED DESIGN OF ASK1 INHIBITORS AS POTENTIAL FIRST-IN-CLASS AGENTS FOR HEART FAILURE
3413, d4qtbB_, 0.6863, 3.43, 0.165, 348, 255, STRUCTURE OF HUMAN ERK1 IN COMPLEX WITH SCH772984 REVEALING A NOVEL INHIBITOR-INDUCED BINDING POCKET
3414, d3orxG_, 0.6863, 3.42, 0.197, 274, 254, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT INHIBITOR 1F8
3415, d3bgpA_, 0.6863, 3.26, 0.167, 272, 251, HUMAN PIM-1 COMPLEXED WITH A BENZOISOXAZOLE INHIBITOR VX1
3416, d2r3gA_, 0.6863, 3.08, 0.187, 287, 246, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
3417, d4krdA_, 0.6862, 3.48, 0.156, 294, 256, CRYSTAL STRUCTURE OF PHO85-PCL10 COMPLEX
3418, d3bgqA_, 0.6862, 3.16, 0.168, 272, 250, HUMAN PIM-1 KINASE IN COMPLEX WITH AN TRIAZOLO PYRIDAZINE INHIBITOR VX2
3419, d1jsvA_, 0.6862, 3.05, 0.184, 287, 245, THE STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 (CDK2) IN COMPLEX WITH 4-[(6-AMINO-4-PYRIMIDINYL) AMINO]BENZENESULFONAMIDE
3420, d5kgiA_, 0.6861, 3.18, 0.175, 273, 251, CRYSTAL STRUCTURE OF PIM1 WITH INHIBITOR 2-[34-BIS(CHLORANYL) PHENOXY]ETHANAMINE
3421, d5hx6A_, 0.6861, 3.24, 0.218, 259, 248, CRYSTAL STRUCTURE OF RIP1 KINASE WITH A BENZO[B][14]OXAZEPIN-4-ONE
3422, d4qp7A_, 0.6861, 3.12, 0.164, 337, 250, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH 2-(1H-PYRAZOL-4-YL)-5H- PYRROLO[23-B]PYRAZINE
3423, d4l42A_, 0.6861, 3.50, 0.173, 299, 255, CRYSTAL STRUCTURES OF HUMAN P70S6K1-PIF
3424, d4eooA1, 0.6861, 3.44, 0.148, 292, 256, THR 160 PHOSPHORYLATED CDK2 Q131E - HUMAN CYCLIN A3 COMPLEX WITH ATP
3425, d4ek8A_, 0.6861, 3.06, 0.192, 280, 245, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH THIAZOLYLPYRIMIDINE INHIBITOR
3426, d4cfmC1, 0.6861, 3.33, 0.174, 265, 253, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6- CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
3427, d3orxE_, 0.6861, 3.42, 0.193, 274, 254, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT INHIBITOR 1F8
3428, d4wa9A1, 0.6860, 2.56, 0.359, 236, 234, THE CRYSTAL STRUCTURE OF HUMAN ABL1 WILD TYPE KINASE DOMAIN IN COMPLEX WITH AXITINIB
3429, d4nfmA_, 0.6860, 3.82, 0.155, 293, 264, HUMAN TAU TUBULIN KINASE 1 (TTBK1)
3430, d4i6bA_, 0.6860, 3.89, 0.140, 285, 265, SELECTIVE & BRAIN-PERMEABLE POLO-LIKE KINASE-2 (PLK-2) INHIBITORS THAT REDUCE -SYNUCLEIN PHOSPHORYLATION IN RAT BRAIN
3431, d2wfyA_, 0.6860, 3.57, 0.158, 295, 259, TRUNCATION AND OPTIMISATION OF PEPTIDE INHIBITORS OF CDK2 CYCLIN A THROUGH STRUCTURE GUIDED DESIGN
3432, d2o3pA_, 0.6860, 3.47, 0.173, 274, 255, CRYSTAL STRUCTURE OF PIM1 WITH QUERCETIN
3433, d1ob3A_, 0.6860, 2.99, 0.159, 277, 246, STRUCTURE OF P. FALCIPARUM PFPK5
3434, d5k5nA_, 0.6859, 3.50, 0.176, 331, 255, CRYSTAL STRUCTURE OF GSK-3BETA COMPLEXED WITH PF-04802367 A HIGHLY SELECTIVE BRAIN-PENETRANT KINASE INHIBITOR
3435, d5jq5A_, 0.6859, 3.07, 0.175, 287, 246, CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH INHIBITOR ICEC0942
3436, d4yc6E_, 0.6859, 3.23, 0.181, 285, 249, CDK1/CKS1
3437, d4qnyB_, 0.6859, 3.34, 0.172, 339, 256, CRYSTAL STRUCTURE OF MAPK FROM LEISHMANIA DONOVANI LDBPK_331470
3438, d4i5pA_, 0.6859, 3.89, 0.140, 284, 265, SELECTIVE & BRAIN-PERMEABLE POLO-LIKE KINASE-2 (PLK-2) INHIBITORS THAT REDUCE -SYNUCLEIN PHOSPHORYLATION IN RAT BRAIN
3439, d4eqmB_, 0.6859, 3.22, 0.168, 269, 250, STRUCTURAL ANALYSIS OF STAPHYLOCOCCUS AUREUS SERINE/THREONINE KINASE PKNB
3440, d3r02A_, 0.6859, 3.22, 0.171, 271, 251, THE DISCOVERY OF NOVEL BENZOFURAN-2-CARBOXYLIC ACIDS AS POTENT PIM-1 INHIBITORS
3441, d3e3pA_, 0.6859, 3.37, 0.179, 337, 252, GLYCOGEN SYNTHASE KINASE FROM LEISHMANIA MAJOR
3442, d4fkpA_, 0.6858, 2.98, 0.189, 279, 244, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH OXINDOLE INHIBITOR
3443, d4eoqA1, 0.6858, 3.43, 0.148, 293, 256, THR 160 PHOSPHORYLATED CDK2 WT - HUMAN CYCLIN A3 COMPLEX WITH ATP
3444, d4ek3A_, 0.6858, 3.21, 0.177, 287, 248, CRYSTAL STRUCTURE OF APO CDK2
3445, d4bzoA_, 0.6858, 3.26, 0.175, 272, 251, CRYSTAL STRUCTURE OF PIM1 IN COMPLEX WITH A PYRROLO- PYRAZINONE INHIBITOR
3446, d3zduA_, 0.6858, 3.21, 0.181, 297, 248, CRYSTAL STRUCTURE OF THE HUMAN CDKL3 KINASE DOMAIN
3447, d3pxfA1, 0.6858, 3.51, 0.168, 298, 256, CDK2 IN COMPLEX WITH TWO MOLECULES OF 8-ANILINO-1-NAPHTHALENE SULFONATE
3448, d3idpB_, 0.6858, 3.04, 0.215, 256, 246, B-RAF V600E KINASE DOMAIN IN COMPLEX WITH AN AMINOISOQUINOLINE INHIBITOR
3449, d3ezvA_, 0.6858, 2.82, 0.182, 277, 242, CDK-2 WITH INDAZOLE INHIBITOR 9 BOUND AT ITS ACTIVE SITE
3450, d2uznA_, 0.6858, 2.98, 0.193, 279, 244, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
3451, d5t1tC_, 0.6857, 3.20, 0.209, 286, 249, IRAK4 KINASE - COMPOUND 1 CO-STRUCTURE
3452, d4i6hA_, 0.6857, 3.91, 0.140, 285, 265, SELECTIVE & BRAIN-PERMEABLE POLO-LIKE KINASE-2 (PLK-2) INHIBITORS THAT REDUCE ALPHA-SYNUCLEIN PHOSPHORYLATION IN RAT BRAIN
3453, d4g17A1, 0.6857, 3.99, 0.131, 301, 268, CRYSTAL STRUCTURE OF CK1G3 WITH 2-[(4-TERT-BUTYLPHENYL)AMINO]-1H- BENZIMIDAZOLE-6-CARBONITRILE
3454, d3otuA_, 0.6857, 3.27, 0.210, 276, 252, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT ACTIVATOR JS30
3455, p3hdmA_, 0.6857, 3.42, 0.173, 285, 255, CRYSTAL STRUCTURE OF SERUM AND GLUCOCORTICOID-REGULATED KINASE 1 IN COMPLEX WITH COMPOUND 1
3456, d3f5pE1, 0.6857, 3.81, 0.292, 298, 260, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
3457, d1yi3A_, 0.6857, 3.22, 0.168, 267, 250, CRYSTAL STRUCTURE OF PIM-1 BOUND TO LY294002
3458, d5ukkA2, 0.6856, 4.08, 0.164, 348, 269, HUMAN GRK2 IN COMPLEX WITH HUMAN G-BETA-GAMMA SUBUNITS AND CCG211998 (14AK)
3459, d4y73D_, 0.6856, 3.40, 0.222, 288, 252, CRYSTAL STRUCTURE OF IRAK4 KINASE DOMAIN WITH INHIBITOR
3460, d4rj3A_, 0.6856, 3.19, 0.178, 287, 247, CDK2 WITH EGFR INHIBITOR COMPOUND 8
3461, d3wi6E_, 0.6856, 2.87, 0.156, 283, 244, CRYSTAL STRUCTURE OF MAPKAP KINASE-2 (MK2) IN COMPLEX WITH NON- SELECTIVE INHIBITOR
3462, d3wi6C_, 0.6856, 2.87, 0.156, 283, 244, CRYSTAL STRUCTURE OF MAPKAP KINASE-2 (MK2) IN COMPLEX WITH NON- SELECTIVE INHIBITOR
3463, d3ulzA_, 0.6856, 3.10, 0.180, 291, 245, CRYSTAL STRUCTURE OF APO BAK1
3464, d3kc3J_, 0.6856, 2.93, 0.147, 288, 245, MK2 COMPLEXED TO INHIBITOR N4-(7-(BENZOFURAN-2-YL)-1H-INDAZOL-5-YL) PYRIMIDINE-24-DIAMINE
3465, d4qqcA1, 0.6855, 3.52, 0.321, 271, 252, CRYSTAL STRUCTURE OF FGF RECEPTOR (FGFR) 4 KINASE DOMAIN IN COMPLEX WITH FIIN-2 AN IRREVERSIBLE TYROSINE KINASE INHIBITOR CAPABLE OF OVERCOMING FGFR KINASE GATE-KEEPER MUTATIONS
3466, d4eqmC_, 0.6855, 3.24, 0.168, 269, 250, STRUCTURAL ANALYSIS OF STAPHYLOCOCCUS AUREUS SERINE/THREONINE KINASE PKNB
3467, d3wi6F_, 0.6855, 2.88, 0.156, 283, 244, CRYSTAL STRUCTURE OF MAPKAP KINASE-2 (MK2) IN COMPLEX WITH NON- SELECTIVE INHIBITOR
3468, d5aniA_, 0.6854, 3.08, 0.179, 280, 246, CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH 6-CHLORO-7H- PURINE PROCESSED WITH THE CRYSTALDIRECT AUTOMATED MOUNTING AND CRYO-COOLING TECHNOLOGY
3469, d4mbiA_, 0.6854, 3.40, 0.169, 274, 254, DISCOVERY OF PYRAZOLO[15A]PYRIMIDINE-BASED PIM1 INHIBITORS
3470, d4dglC_, 0.6854, 3.59, 0.143, 334, 258, CRYSTAL STRUCTURE OF THE CK2 TETRAMERIC HOLOENZYME
3471, d3umwA_, 0.6854, 3.07, 0.165, 264, 248, CRYSTAL STRUCTURE OF PIM1 KINASE IN COMPLEX WITH INHIBITOR (Z)-2-[(1H- INDAZOL-3-YL)METHYLENE]-6-METHOXY-7-(PIPERAZIN-1-YLMETHYL)BENZOFURAN- 3(2H)-ONE
3472, d3s2pA_, 0.6854, 2.97, 0.189, 279, 244, CRYSTAL STRUCTURE OF CDK2 WITH A 2-AMINOPYRIMIDINE COMPOUND
3473, d3bwfA_, 0.6854, 3.20, 0.175, 273, 251, CRYSTAL STRUCTURE OF THE HUMAN PIM1 IN COMPLEX WITH AN OSMIUM COMPOUND
3474, d2bzjA_, 0.6854, 3.19, 0.171, 273, 251, CRYSTAL STRUCTURE OF THE HUMAN PIM1 IN COMPLEX WITH A RUTHENIUM ORGANOMETALLIC LIGAND RU3
3475, d1yxvA_, 0.6854, 3.30, 0.167, 274, 252, CRYSTAL STRUCTURE OF KINASE PIM1 IN COMPLEX WITH 34-DIHYDROXY-1- METHYLQUINOLIN-2(1H)-ONE
3476, d5uiuB_, 0.6853, 3.11, 0.211, 287, 247, CRYSTAL STRUCTURE OF IRAK4 IN COMPLEX WITH COMPOUND 30
3477, d5ih6A_, 0.6853, 3.83, 0.148, 286, 263, HUMAN CASEIN KINASE 1 ISOFORM DELTA (KINASE DOMAIN) IN COMPLEX WITH EPIBLASTIN A DERIVATIVE
3478, d5d10A_, 0.6853, 3.00, 0.286, 248, 245, KINASE DOMAIN OF CSRC IN COMPLEX WITH RL236
3479, d4zy6B_, 0.6853, 3.66, 0.171, 280, 258, CRYSTAL STRUCTURE OF P21-ACTIVATED KINASE 1 IN COMPLEX WITH AN INHIBITOR COMPOUND 29
3480, d4twcB_, 0.6853, 3.89, 0.147, 292, 265, 2-BENZAMIDO-N-(1H-BENZO[D]IMIDAZOL-2-YL)THIAZOLE-4- CARBOXAMIDE DERIVATIVES AS POTENT INHIBITORS OF CK1D/E
3481, d4izaA_, 0.6853, 3.29, 0.173, 346, 254, STRUCTURE OF DUALLY PHOSPHORYLATED ERK2 BOUND TO THE PEA-15 DEATH EFFECTOR DOMAIN
3482, d4eqmA_, 0.6853, 3.24, 0.168, 269, 250, STRUCTURAL ANALYSIS OF STAPHYLOCOCCUS AUREUS SERINE/THREONINE KINASE PKNB
3483, d3wi6B_, 0.6853, 2.88, 0.156, 283, 244, CRYSTAL STRUCTURE OF MAPKAP KINASE-2 (MK2) IN COMPLEX WITH NON- SELECTIVE INHIBITOR
3484, d3r04A_, 0.6853, 3.22, 0.167, 271, 251, THE DISCOVERY OF NOVEL BENZOFURAN-2-CARBOXYLIC ACIDS AS POTENT PIM-1 INHIBITORS
3485, d3dcvA_, 0.6853, 3.28, 0.179, 273, 251, CRYSTAL STRUCTURE OF HUMAN PIM1 KINASE COMPLEXED WITH 4-(4- HYDROXY-3-METHYL-PHENYL)-6-PHENYLPYRIMIDIN-2(1H)-ONE
3486, d2erkA_, 0.6853, 3.23, 0.151, 351, 252, PHOSPHORYLATED MAP KINASE ERK2
3487, d1ckpA_, 0.6853, 2.98, 0.189, 279, 244, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR PURVALANOL B
3488, d5kggA_, 0.6852, 3.30, 0.171, 273, 252, CRYSTAL STRUCTURE OF PIM1 WITH INHIBITOR: 2-(5-CHLORANYL-1~{H}-INDOL- 3-YL)ETHANAMINE
3489, d4qp4A_, 0.6852, 3.13, 0.164, 337, 250, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH N-CYCLOHEXYL-9H-PURIN-6- AMINE
3490, d4bghA_, 0.6852, 2.78, 0.187, 275, 241, CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH PAN-CDK INHIBITOR
3491, d3orxH_, 0.6852, 3.44, 0.197, 274, 254, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT INHIBITOR 1F8
3492, d2nryD_, 0.6852, 3.03, 0.208, 282, 245, CRYSTAL STRUCTURE OF IRAK-4
3493, d2j9mA_, 0.6852, 2.75, 0.183, 275, 240, CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH MACROCYCLIC AMINOPYRIMIDINE
3494, d1yxuA_, 0.6852, 3.43, 0.165, 273, 254, CRYSTAL STRUCTURE OF KINASE PIM1 IN COMPLEX WITH AMP
3495, d5telA_, 0.6851, 3.37, 0.178, 273, 253, PIM-1 KINASE IN COMPLEX WITH A 7-AZAINDOLE
3496, d4yffD_, 0.6851, 2.87, 0.221, 257, 240, TNNI3K COMPLEXED WITH INHIBITOR 2
3497, d4yc6A_, 0.6851, 3.21, 0.177, 285, 249, CDK1/CKS1
3498, d4g16A1, 0.6851, 3.98, 0.131, 301, 268, CRYSTAL STRUCTURE OF CK1G3 WITH 2-[(4-{[3-(TRIFLUOROMETHYL)PYRIDIN2- YL]OXY}PHENYL)AMINO]-1H-BENZIMIDAZOLE-6-CARBONITRILE
3499, d3vbvA_, 0.6851, 3.33, 0.163, 268, 252, EXPLOITATION OF HYDROGEN BONDING CONSTRAINTS AND FLAT HYDROPHOBIC ENERGY LANDSCAPES IN PIM-1 KINASE NEEDLE SCREENING AND INHIBITOR DESIGN
3500, d1p5eA1, 0.6851, 3.55, 0.151, 295, 258, THE STRUCTURE OF PHOSPHO-CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR 4567-TETRABROMOBENZOTRIAZOLE (TBS)
3501, d4ll5A_, 0.6850, 3.21, 0.171, 268, 251, CRYSTAL STRUCTURE OF PIM-1 IN COMPLEX WITH THE FLUORESCENT COMPOUND SKF86002
3502, d1ckjA_, 0.6850, 3.64, 0.149, 296, 261, CASEIN KINASE I DELTA TRUNCATION MUTANT CONTAINING RESIDUES 1-317 COMPLEX WITH BOUND TUNGSTATE
3503, d5he3A2, 0.6849, 3.88, 0.170, 346, 265, BOVINE GRK2 IN COMPLEX WITH GBETAGAMMA SUBUNITS AND CCG224411
3504, d4yfiB_, 0.6849, 3.10, 0.217, 262, 244, TNNI3K COMPLEXED WITH INHIBITOR 1
3505, d3pxzA1, 0.6849, 3.50, 0.173, 298, 255, CDK2 TERNARY COMPLEX WITH JWS648 AND ANS
3506, d2bcjA3, 0.6849, 3.91, 0.170, 348, 265, CRYSTAL STRUCTURE OF G PROTEIN-COUPLED RECEPTOR KINASE 2 IN COMPLEX WITH GALPHA-Q AND GBETAGAMMA SUBUNITS
3507, d5t1tD_, 0.6848, 3.12, 0.215, 283, 247, IRAK4 KINASE - COMPOUND 1 CO-STRUCTURE
3508, d5nhpA_, 0.6848, 3.44, 0.165, 338, 255, HUMAN ERK2 WITH AN ERK1/2 INHIBITOR
3509, d3qriB_, 0.6848, 2.82, 0.346, 262, 243, THE CRYSTAL STRUCTURE OF HUMAN ABL1 KINASE DOMAIN IN COMPLEX WITH DCC- 2036
3510, d3is5A1, 0.6848, 2.94, 0.204, 254, 245, CRYSTAL STRUCTURE OF CDPK KINASE DOMAIN FROM TOXOPLASMA GONDII TGME49_018720
3511, d2vtaA_, 0.6848, 2.94, 0.189, 278, 243, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
3512, d2nryC_, 0.6848, 3.04, 0.217, 280, 244, CRYSTAL STRUCTURE OF IRAK-4
3513, d2bdwA_, 0.6848, 3.78, 0.153, 309, 262, CRYSTAL STRUCTURE OF THE AUTO-INHIBITED KINASE DOMAIN OF CALCIUM/CALMODULIN ACTIVATED KINASE II
3514, d5nhlA_, 0.6847, 3.43, 0.165, 345, 255, HUMAN ERK2 WITH AN ERK1/2 INHIBITOR
3515, d5imeB_, 0.6847, 3.36, 0.170, 280, 253, CRYSTAL STRUCTURE OF P21-ACTIVATED KINASE 1 (PAK1) IN COMPLEX WITH COMPOUND 9
3516, d4yc6C_, 0.6847, 3.22, 0.177, 285, 249, CDK1/CKS1
3517, d4qp9A_, 0.6847, 3.13, 0.168, 335, 250, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH 7-(1-PROPYL-1H-PYRAZOL-4- YL)-2-(PYRIDIN-4-YL)-5H-PYRROLO[23-B]PYRAZINE
3518, d4a7cA_, 0.6847, 3.33, 0.171, 273, 252, CRYSTAL STRUCTURE OF PIM1 KINASE WITH ETP46546
3519, d3ig7A_, 0.6847, 2.96, 0.189, 278, 243, NOVEL CDK-5 INHIBITORS - CRYSTAL STRUCTURE OF INHIBITOR EFP WITH CDK-2
3520, d2qq7B_, 0.6847, 2.71, 0.308, 244, 240, CRYSTAL STRUCTURE OF DRUG RESISTANT SRC KINASE DOMAIN WITH IRREVERSIBLE INHIBITOR
3521, d5ukmA2, 0.6846, 4.15, 0.163, 353, 270, BOVINE GRK2 IN COMPLEX WITH HUMAN GBETAGAMMA SUBUNITS AND CCG258208 (14AS)
3522, d4ztlA_, 0.6846, 2.93, 0.210, 280, 243, IRAK4-INHIBITOR CO-STRUCTURE
3523, d4mygB_, 0.6846, 3.35, 0.209, 335, 254, MAPK13 ACTIVE FORM
3524, d3e3pB_, 0.6846, 3.32, 0.179, 337, 251, GLYCOGEN SYNTHASE KINASE FROM LEISHMANIA MAJOR
3525, d2weiA1, 0.6846, 3.53, 0.197, 269, 254, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF CRYPTOSPORIDIUM PARVUM CALCIUM DEPENDENT PROTEIN KINASE IN COMPLEX WITH 3- MB-PP1
3526, d2b9iA_, 0.6846, 3.17, 0.159, 338, 251, CRYSTAL STRUCTURE OF FUS3 WITH A DOCKING MOTIF FROM MSG5
3527, d5mhqA1, 0.6845, 3.08, 0.183, 288, 246, CCT068127 IN COMPLEX WITH CDK2
3528, d5l4qA_, 0.6845, 2.93, 0.152, 293, 243, CRYSTAL STRUCTURE OF ADAPTOR PROTEIN 2 ASSOCIATED KINASE 1 (AAK1) IN COMPLEX WITH LKB1 (AAK1 DUAL INHIBITOR)
3529, d4o0wA_, 0.6845, 3.21, 0.183, 259, 251, CRYSTAL STRUCTURES OF HUMAN KINASE AURORA A
3530, d4hgsA1, 0.6845, 3.96, 0.134, 301, 268, CRYSTAL STRUCTURE OF CK1GS WITH COMPOUND 13
3531, d4cfvC1, 0.6845, 3.43, 0.161, 263, 254, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6- CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
3532, p3zu7A_, 0.6845, 3.26, 0.162, 344, 253, CRYSTAL STRUCTURE OF A DESIGNED SELECTED ANKYRIN REPEAT PROTEIN IN COMPLEX WITH THE MAP KINASE ERK2
3533, d3r22A_, 0.6845, 3.15, 0.189, 255, 249, DESIGN SYNTHESIS AND BIOLOGICAL EVALUATION OF PYRAZOLOPYRIDINE- SULFONAMIDES AS POTENT MULTIPLE-MITOTIC KINASE (MMK) INHIBITORS (PART I)
3534, d3orxF_, 0.6845, 3.45, 0.197, 274, 254, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT INHIBITOR 1F8
3535, d2cjmC_, 0.6845, 3.51, 0.163, 294, 257, MECHANISM OF CDK INHIBITION BY ACTIVE SITE PHOSPHORYLATION: CDK2 Y15P T160P IN COMPLEX WITH CYCLIN A STRUCTURE
3536, d5uiqC_, 0.6844, 3.07, 0.207, 280, 246, CRYSTAL STRUCTURE OF IRAK4 IN COMPLEX WITH COMPOUND 9
3537, d5ih4A_, 0.6844, 3.82, 0.148, 286, 263, HUMAN CASEIN KINASE 1 ISOFORM DELTA APO (KINASE DOMAIN)
3538, d4rpvA_, 0.6844, 3.29, 0.171, 273, 252, CO-CRYSTAL STRUCTURE OF PIM1 WITH COMPOUND 3
3539, d3f5pJ1, 0.6844, 3.80, 0.293, 292, 259, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
3540, d1yxuC_, 0.6844, 3.36, 0.162, 272, 253, CRYSTAL STRUCTURE OF KINASE PIM1 IN COMPLEX WITH AMP
3541, d1yxuB_, 0.6844, 3.41, 0.165, 273, 254, CRYSTAL STRUCTURE OF KINASE PIM1 IN COMPLEX WITH AMP
3542, d5l4qB_, 0.6843, 2.82, 0.149, 287, 242, CRYSTAL STRUCTURE OF ADAPTOR PROTEIN 2 ASSOCIATED KINASE 1 (AAK1) IN COMPLEX WITH LKB1 (AAK1 DUAL INHIBITOR)
3543, d5dpvA_, 0.6843, 3.15, 0.184, 257, 250, AURORA A KINASE IN COMPLEX WITH AA35 AND JNJ-7706621 IN SPACE GROUP P6122
3544, d4yp8D_, 0.6843, 3.30, 0.220, 285, 250, IRAK4-INHIBITOR CO-STRUCTURE
3545, d4hnfB_, 0.6843, 3.76, 0.149, 290, 262, CRYSTAL STRUCTURE OF CK1D IN COMPLEX WITH PF4800567
3546, d4bieA_, 0.6843, 2.73, 0.219, 257, 242, CRYSTAL STRUCTURES OF ASK1-INHIBITOR COMPLEXES
3547, d3jyaA_, 0.6843, 3.37, 0.174, 274, 253, DISCOVERY OF 3H-BENZO[45]THIENO[32-D]PYRIMIDIN-4-ONES AS POTENT HIGHLY SELECTIVE AND ORALLY BIOAVAILABLE PIM KINASES INHIBITORS
3548, d2xiyA_, 0.6843, 3.28, 0.171, 273, 251, PROTEIN KINASE PIM-1 IN COMPLEX WITH FRAGMENT-2 FROM CRYSTALLOGRAPHIC FRAGMENT SCREEN
3549, d2iztA_, 0.6843, 3.89, 0.120, 296, 266, STRUCTURE OF CASEIN KINASE GAMMA 3 IN COMPLEX WITH INHIBITOR
3550, d2hyyB1, 0.6843, 2.46, 0.360, 252, 236, HUMAN ABL KINASE DOMAIN IN COMPLEX WITH IMATINIB (STI571 GLIVEC)
3551, d1vr2A_, 0.6843, 3.41, 0.298, 275, 252, HUMAN VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2 (KDR) KINASE DOMAIN
3552, d1h00A_, 0.6843, 3.03, 0.193, 278, 244, CDK2 IN COMPLEX WITH A DISUBSTITUTED 4 6-BIS ANILINO PYRIMIDINE CDK4 INHIBITOR
3553, d5l8lA_, 0.6842, 3.38, 0.180, 263, 256, AURORA-A KINASE DOMAIN IN COMPLEX WITH VNAR-D01 (CRYSTAL FORM 1)
3554, d4rc4A_, 0.6842, 3.27, 0.167, 272, 251, CRYSTAL STRUCTURE OF SER/THR KINASE PIM1 IN COMPLEX WITH MITOXANTRONE DERIVATIVES
3555, d1h24C1, 0.6842, 3.62, 0.151, 292, 258, CDK2/CYCLIN A IN COMPLEX WITH A 9 RESIDUE RECRUITMENT PEPTIDE FROM E2F
3556, d5vubB_, 0.6841, 3.24, 0.164, 269, 250, PIM1 KINASE IN COMPLEX WITH A BENZOFURANONE INHIBITOR
3557, d4ztnC_, 0.6841, 3.14, 0.211, 284, 247, IRAK4-INHIBITOR CO-STRUCTURE
3558, d4un0C_, 0.6841, 3.70, 0.152, 308, 263, CRYSTAL STRUCTURE OF THE HUMAN CDK12-CYCLINK COMPLEX
3559, d3vbtA_, 0.6841, 3.34, 0.163, 267, 252, EXPLOITATION OF HYDROGEN BONDING CONSTRAINTS AND FLAT HYDROPHOBIC ENERGY LANDSCAPES IN PIM-1 KINASE NEEDLE SCREENING AND INHIBITOR DESIGN
3560, d5he1A2, 0.6840, 3.83, 0.170, 342, 264, HUMAN GRK2 IN COMPLEX WITH GBETAGAMMA SUBUNITS AND CCG224062
3561, p3zuvC_, 0.6840, 3.22, 0.155, 357, 251, CRYSTAL STRUCTURE OF A DESIGNED SELECTED ANKYRIN REPEAT PROTEIN IN COMPLEX WITH THE PHOSPHORYLATED MAP KINASE ERK2
3562, d3v8tA1, 0.6840, 2.27, 0.313, 236, 233, CRYSTAL STRUCTURE OF INTERLEUKIN-2 INDUCIBLE T-CELL KINASE ITK CATALYTIC DOMAIN WITH THIENOPYRAZOLYLINDOLE INHIBITOR 477
3563, d3octA_, 0.6840, 2.73, 0.310, 244, 242, CRYSTAL STRUCTURE OF BRUTON S TYROSINE KINASE MUTANT V555R IN COMPLEX WITH DASATINIB
3564, d1xr1A_, 0.6840, 3.53, 0.173, 277, 255, CRYSTAL STRUCTURE OF HPIM-1 KINASE IN COMPLEX WITH AMP-PNP AT 2.1 A RESOLUTION
3565, d1e9hA_, 0.6840, 3.63, 0.158, 295, 259, THR 160 PHOSPHORYLATED CDK2 - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR INDIRUBIN-5-SULPHONATE BOUND
3566, d6bqqA1, 0.6839, 3.45, 0.181, 269, 254, CRYSTAL STRUCTURE OF THE HUMAN CAMKK2B IN COMPLEX WITH BI2526
3567, d5opbA_, 0.6839, 3.25, 0.157, 262, 249, STRUCTURE OF CHK1 10-PT. MUTANT COMPLEX WITH INDAZOLE LRRK2 INHIBITOR
3568, d3miyB1, 0.6839, 2.37, 0.318, 238, 236, X-RAY CRYSTAL STRUCTURE OF ITK COMPLEXED WITH SUNITINIB
3569, d2np8A_, 0.6839, 3.07, 0.181, 256, 248, STRUCTURAL BASIS FOR THE INHIBITION OF AURORA A KINASE BY A NOVEL CLASS OF HIGH AFFINITY DISUBSTITUTED PYRIMIDINE INHIBITORS
3570, d1k9aC3, 0.6839, 3.25, 0.313, 266, 249, CRYSTAL STRUCTURE ANALYSIS OF FULL-LENGTH CARBOXYL-TERMINAL SRC KINASE AT 2.5 A RESOLUTION
3571, d5kgkA_, 0.6838, 3.30, 0.171, 273, 252, CRYSTAL STRUCTURE OF PIM1 WITH INHIBITOR: 3-(4-METHOXYPHENYL)-1~{H}- PYRAZOL-5-AMINE
3572, d5k00A_, 0.6838, 3.12, 0.185, 311, 248, MELK IN COMPLEX WITH NVS-MELK5
3573, d5aadA_, 0.6838, 2.97, 0.187, 252, 246, AURORA A KINASE BOUND TO AN IMIDAZOPYRIDINE INHIBITOR (7A)
3574, d4hglA1, 0.6838, 3.99, 0.134, 301, 268, CRYSTAL STRUCTURE OF CK1G3 WITH COMPOUND 1
3575, d3vbxA_, 0.6838, 3.34, 0.167, 268, 252, EXPLOITATION OF HYDROGEN BONDING CONSTRAINTS AND FLAT HYDROPHOBIC ENERGY LANDSCAPES IN PIM-1 KINASE NEEDLE SCREENING AND INHIBITOR DESIGN
3576, d5kcxA_, 0.6837, 3.35, 0.167, 272, 252, PIM-1 KINASE IN COMPLEX WITH A SELECTIVE N-SUBSTITUTED 7-AZAINDOLE INHIBITOR
3577, d4j7bD_, 0.6837, 3.50, 0.199, 281, 256, CRYSTAL STRUCTURE OF POLO-LIKE KINASE 1
3578, d3wi6D_, 0.6837, 2.86, 0.156, 282, 243, CRYSTAL STRUCTURE OF MAPKAP KINASE-2 (MK2) IN COMPLEX WITH NON- SELECTIVE INHIBITOR
3579, d3dkoA1, 0.6837, 3.37, 0.316, 272, 250, COMPLEX BETWEEN THE KINASE DOMAIN OF HUMAN EPHRIN TYPE-A RECEPTOR 7 (EPHA7) AND INHIBITOR ALW-II-49-7
3580, d2r3lA_, 0.6837, 2.84, 0.186, 275, 242, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
3581, d1gihA_, 0.6837, 2.85, 0.190, 276, 242, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE CDK4 INHIBITOR
3582, d5vucB_, 0.6836, 3.09, 0.161, 269, 248, PIM1 KINASE IN COMPLEX WITH A BENZOFURANONE INHIBITOR
3583, d5op2A_, 0.6836, 3.19, 0.153, 263, 248, STRUCTURE OF CHK1 10-PT. MUTANT COMPLEX WITH ARYLBENZAMIDE LRRK2 INHIBITOR
3584, d5c1qB_, 0.6836, 3.21, 0.167, 273, 251, SERINE/THREONINE-PROTEIN KINASE PIM-1
3585, d4ztmC_, 0.6836, 3.12, 0.215, 282, 246, IRAK4-INHIBITOR CO-STRUCTURE
3586, d4yfiD_, 0.6836, 3.07, 0.218, 261, 243, TNNI3K COMPLEXED WITH INHIBITOR 1
3587, d3qyiA_, 0.6836, 3.26, 0.178, 346, 253,  
3588, d2wqnA_, 0.6836, 3.04, 0.183, 259, 246, STRUCTURE OF ADP-BOUND HUMAN NEK7
3589, d1h06A_, 0.6836, 2.92, 0.189, 277, 243,  
3590, d1buhA_, 0.6836, 3.27, 0.173, 287, 249, CRYSTAL STRUCTURE OF THE HUMAN CDK2 KINASE COMPLEX WITH CELL CYCLE-REGULATORY PROTEIN CKSHS1
3591, d5es1A_, 0.6835, 3.20, 0.196, 304, 250, CRYSTAL STRUCTURE OF MICROTUBULE AFFINITY-REGULATING KINASE 4 CATALYTIC DOMAIN IN COMPLEX WITH A PYRAZOLOPYRIMIDINE INHIBITOR
3592, d4jbpA_, 0.6835, 3.04, 0.190, 255, 247, NOVEL AURORA KINASE INHIBITORS REVEAL MECHANISMS OF HURP IN NUCLEATION OF CENTROSOMAL AND KINETOCHORE MICROTUBULES
3593, d4i41A_, 0.6835, 3.28, 0.167, 272, 251, CRYSTAL STRUCTURE OF HUMAN SER/THR KINASE PIM1 IN COMPLEX WITH MITOXANTRONE
3594, d4d9tA_, 0.6835, 3.03, 0.180, 299, 245, RSK2 C-TERMINAL KINASE DOMAIN WITH INHIBITOR (E)-METHYL 3-(4-AMINO-7- (3-HYDROXYPROPYL)-5-P-TOLYL-7H-PYRROLO[23-D]PYRIMIDIN-6-YL)-2- CYANOACRYLATE
3595, p3zuvA_, 0.6835, 3.26, 0.151, 357, 252, CRYSTAL STRUCTURE OF A DESIGNED SELECTED ANKYRIN REPEAT PROTEIN IN COMPLEX WITH THE PHOSPHORYLATED MAP KINASE ERK2
3596, d2r3nA_, 0.6835, 2.80, 0.183, 275, 241, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
3597, d5turA_, 0.6834, 3.42, 0.174, 270, 253, PIM-1 KINASE IN COMPLEX WITH A 7-AZAINDOLE
3598, d5nhvA_, 0.6834, 3.52, 0.168, 345, 256, HUMAN ERK2 WITH AN ERK1/2 INHIBITOR
3599, d4fkjA_, 0.6833, 2.90, 0.194, 278, 242, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH AMINOPYRAZOLE INHIBITOR
3600, d3kc3C_, 0.6833, 2.85, 0.149, 281, 242, MK2 COMPLEXED TO INHIBITOR N4-(7-(BENZOFURAN-2-YL)-1H-INDAZOL-5-YL) PYRIMIDINE-24-DIAMINE
3601, d5t1tA_, 0.6832, 3.12, 0.215, 283, 246, IRAK4 KINASE - COMPOUND 1 CO-STRUCTURE
3602, d5buiA_, 0.6832, 3.16, 0.165, 338, 248, ERK2 COMPLEXED WITH 2-PYRIDIYL TETRAHYDROAZAINDAZOLE
3603, d1yhsA_, 0.6832, 3.23, 0.168, 267, 250, CRYSTAL STRUCTURE OF PIM-1 BOUND TO STAUROSPORINE
3604, d1vyzA_, 0.6832, 3.06, 0.189, 279, 244, STRUCTURE OF CDK2 COMPLEXED WITH PNU-181227
3605, d5tx5A_, 0.6831, 3.27, 0.219, 259, 247, RIP1 KINASE ( FLAG 1-294 C34A C127A C233A C240A) WITH GSK772
3606, d5t1sB_, 0.6831, 3.06, 0.213, 282, 244, IRAK4 KINASE - COMPOUND 1 CO-STRUCTURE
3607, d5dr9A_, 0.6831, 3.12, 0.185, 257, 249, AURORA A KINASE IN COMPLEX WITH AA29 AND JNJ-7706621 IN SPACE GROUP P6122
3608, d2vthA_, 0.6831, 2.97, 0.185, 278, 243, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN
3609, d2qolA_, 0.6831, 3.52, 0.291, 271, 251, HUMAN EPHA3 KINASE AND JUXTAMEMBRANE REGION Y596:Y602:S768G TRIPLE MUTANT
3610, d1h27A1, 0.6831, 3.57, 0.159, 295, 258, CDK2/CYCLIN A IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM P27
3611, d5d9kB_, 0.6830, 3.23, 0.195, 280, 251, RSK2 N-TERMINAL KINASE IN COMPLEX WITH BI-D1870
3612, d4lmuA_, 0.6830, 3.23, 0.164, 265, 250, CRYSTAL STRUCTURE OF PIM1 IN COMPLEX WITH THE INHIBITOR QUERCETIN (RESULTING FROM DISPLACEMENT OF SKF86002)
3613, d4kbkB_, 0.6830, 3.78, 0.149, 289, 262, CK1D IN COMPLEX WITH (3S)-3-{4-[3-(4-FLUOROPHENYL)-1-METHYL-1H- PYRAZOL-4-YL]PYRIDIN-2-YL}MORPHOLINE INHIBITOR
3614, d3wi6A_, 0.6830, 2.87, 0.156, 282, 243, CRYSTAL STRUCTURE OF MAPKAP KINASE-2 (MK2) IN COMPLEX WITH NON- SELECTIVE INHIBITOR
3615, d3py3A1, 0.6830, 3.64, 0.167, 352, 257, CRYSTAL STRUCTURE OF PHOSPHORYLATED P38ALPHA MAP KINASE
3616, d2vtjA_, 0.6830, 2.81, 0.187, 276, 241, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
3617, d1v0pA_, 0.6830, 3.03, 0.159, 277, 246, STRUCTURE OF P. FALCIPARUM PFPK5-PURVALANOL B LIGAND COMPLEX
3618, d1h25A1, 0.6830, 3.54, 0.160, 292, 256, CDK2/CYCLIN A IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM RETINOBLASTOMA-ASSOCIATED PROTEIN
3619, d3kc3G_, 0.6829, 2.85, 0.152, 276, 243, MK2 COMPLEXED TO INHIBITOR N4-(7-(BENZOFURAN-2-YL)-1H-INDAZOL-5-YL) PYRIMIDINE-24-DIAMINE
3620, d3is5C1, 0.6829, 2.93, 0.193, 254, 244, CRYSTAL STRUCTURE OF CDPK KINASE DOMAIN FROM TOXOPLASMA GONDII TGME49_018720
3621, d3uzpA_, 0.6828, 3.92, 0.148, 292, 264, CRYSTAL STRUCTURE OF CK1D WITH PF670462 FROM P21 CRYSTAL FORM
3622, d2gphA_, 0.6828, 3.39, 0.153, 345, 255, DOCKING MOTIF INTERACTIONS IN THE MAP KINASE ERK2
3623, d1xwsA_, 0.6828, 3.37, 0.166, 273, 253, CRYSTAL STRUCTURE OF THE HUMAN PIM1 KINASE DOMAIN
3624, d5horA_, 0.6827, 2.90, 0.346, 247, 237, CRYSTAL STRUCTURE OF C-MET-M1250T IN COMPLEX WITH SAR125844.
3625, d4qtbA_, 0.6827, 3.48, 0.165, 351, 255, STRUCTURE OF HUMAN ERK1 IN COMPLEX WITH SCH772984 REVEALING A NOVEL INHIBITOR-INDUCED BINDING POCKET
3626, d4lg4C_, 0.6827, 3.65, 0.222, 288, 261, STRUCTURAL BASIS FOR AUTOACTIVATION OF HUMAN MST2 KINASE AND ITS REGULATION BY RASSF5
3627, d4bckA1, 0.6827, 3.64, 0.162, 296, 259, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
3628, d3fdnA_, 0.6827, 3.13, 0.189, 261, 249, STRUCTURE-BASED DRUG DESIGN OF NOVEL AURORA KINASE A INHIBITORS: STRUCTURE BASIS FOR POTENCY AND SPECIFICITY
3629, d2c47D1, 0.6827, 3.79, 0.137, 289, 262, STRUCTURE OF CASEIN KINASE 1 GAMMA 2
3630, d4yp8A_, 0.6826, 3.17, 0.219, 284, 247, IRAK4-INHIBITOR CO-STRUCTURE
3631, d4au8A1, 0.6826, 2.85, 0.160, 274, 244, CRYSTAL STRUCTURE OF COMPOUND 4A IN COMPLEX WITH CDK5 SHOWING AN UNUSUAL BINDING MODE TO THE HINGE REGION VIA A WATER MOLECULE
3632, d2b55A_, 0.6826, 2.82, 0.183, 276, 241, HUMAN CYCLIN DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH INDENOPYRAXOLE DIN-101312
3633, d1v1kA_, 0.6826, 2.93, 0.189, 277, 243, CDK2 IN COMPLEX WITH A DISUBSTITUTED 4 6-BIS ANILINO PYRIMIDINE CDK4 INHIBITOR
3634, d4yo6C_, 0.6825, 3.24, 0.205, 286, 249, IRAK4-INHIBITOR CO-STRUCTURE
3635, d4bicB_, 0.6825, 2.88, 0.217, 259, 244, CRYSTAL STRUCTURES OF ASK1-INHIBITOR COMPLEXES
3636, d3pvwA2, 0.6825, 3.87, 0.169, 343, 266, BOVINE GRK2 IN COMPLEX WITH GBETAGAMMA SUBUNITS AND A SELECTIVE KINASE INHIBITOR (CMPD103A)
3637, d2xixA_, 0.6825, 3.28, 0.172, 272, 250, PROTEIN KINASE PIM-1 IN COMPLEX WITH FRAGMENT-1 FROM CRYSTALLOGRAPHIC FRAGMENT SCREEN
3638, d5mqvC_, 0.6824, 3.80, 0.149, 288, 262, CRYSTAL STRUCTURE OF HUMAN CASEIN KINASE I DELTA IN COMPLEX WITH 4-(2 5-DIMETHOXYPHENYL)-N-(4-(5-(4-FLUORPHENYL)-2-(METHYLTHIO)-1H- IMIDAZOL-4-YL)-PYRIDIN-2-YL)-1-METHYL-1H-PYRROLE-2-CARBOXAMIDE
3639, d4rmzA_, 0.6824, 3.22, 0.218, 284, 248, CRYSTAL STRUCTURE OF IRAK-4
3640, d4r6vA1, 0.6824, 3.53, 0.327, 271, 251, CRYSTAL STRUCTURE OF FGF RECEPTOR (FGFR) 4 KINASE HARBORING THE V550L GATE-KEEPER MUTATION IN COMPLEX WITH FIIN-3 AN IRREVERSIBLE TYROSINE KINASE INHIBITOR CAPABLE OF OVERCOMING FGFR KINASE GATE-KEEPER MUTATIONS
3641, d4bibA_, 0.6824, 2.65, 0.212, 254, 240, CRYSTAL STRUCTURES OF ASK1-INHIBITOR COMPLEXES
3642, d2w05A_, 0.6824, 2.83, 0.183, 276, 241, STRUCTURE OF CDK2 IN COMPLEX WITH AN IMIDAZOLYL PYRIMIDINE COMPOUND 5B
3643, d2o63A_, 0.6824, 3.53, 0.173, 274, 255, CRYSTAL STRUCTURE OF PIM1 WITH MYRICETIN
3644, d1mp8A_, 0.6824, 3.29, 0.341, 252, 249, CRYSTAL STRUCTURE OF FOCAL ADHESION KINASE (FAK)
3645, d1gzkA_, 0.6824, 3.09, 0.171, 271, 245, MOLECULAR MECHANISM FOR THE REGULATION OF PROTEIN KINASE B/ AKT BY HYDROPHOBIC MOTIF PHOSPHORYLATION
3646, p6g93A_, 0.6823, 3.44, 0.165, 343, 254, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
3647, d5t1sC_, 0.6823, 3.17, 0.206, 284, 247, IRAK4 KINASE - COMPOUND 1 CO-STRUCTURE
3648, d4y73B_, 0.6823, 3.27, 0.221, 289, 249, CRYSTAL STRUCTURE OF IRAK4 KINASE DOMAIN WITH INHIBITOR
3649, d4rc2A_, 0.6823, 3.28, 0.171, 272, 251, CRYSTAL STRUCTURE OF SER/THR KINASE PIM1 IN COMPLEX WITH MITOXANTRONE DERIVATIVES
3650, d4nifA_, 0.6823, 2.93, 0.160, 313, 243, HETERODIMERIC STRUCTURE OF ERK2 AND RSK1
3651, d3uysC_, 0.6823, 3.83, 0.145, 286, 262, CRYSTAL STRUCTURE OF APO HUMAN CK1D
3652, d3pj2A_, 0.6823, 2.99, 0.291, 248, 244, CRYSTAL STRUCTURE OF BTK KINASE DOMAIN COMPLEXED WITH 2-[4-(2- DIETHYLAMINO-ETHOXY)-PHENYLAMINO]-6-(4-FLUORO-PHENOXY)-8-METHYL-8H- PYRIDO[23-D]PYRIMIDIN-7-ONE
3653, d2pzyD_, 0.6823, 3.01, 0.143, 288, 245, STRUCTURE OF MK2 COMPLEXED WITH COMPOUND 76
3654, d5jznA_, 0.6822, 3.18, 0.168, 268, 250, CRYSTAL STRUCTURE OF DCLK1-KD IN COMPLEX WITH NVP-TAE684
3655, d4yffC_, 0.6822, 2.86, 0.222, 258, 239, TNNI3K COMPLEXED WITH INHIBITOR 2
3656, d4lggB_, 0.6822, 2.98, 0.280, 245, 243, STRUCTURE OF 3MB-PP1 BOUND TO ANALOG-SENSITIVE SRC KINASE
3657, d3vbyA_, 0.6822, 3.36, 0.163, 267, 252, EXPLOITATION OF HYDROGEN BONDING CONSTRAINTS AND FLAT HYDROPHOBIC ENERGY LANDSCAPES IN PIM-1 KINASE NEEDLE SCREENING AND INHIBITOR DESIGN
3658, d5oq8A_, 0.6821, 3.19, 0.154, 261, 247, STRUCTURE OF CHK1 12-PT. MUTANT COMPLEX WITH ARYLBENZAMIDE LRRK2 INHIBITOR
3659, d4xs2B_, 0.6821, 3.01, 0.215, 278, 242, IRAK4-INHIBITOR CO-STRUCTURE
3660, d4prjA_, 0.6821, 3.06, 0.187, 251, 246, AURORA A KINASE DOMAIN WITH COMPOUND 2 (N-[1-(3-CYANOBENZYL)-1H- PYRAZOL-4-YL]-6-(1H-PYRAZOL-4-YL)-1H-INDAZOLE-3-CARBOXAMIDE)
3661, d4lghA_, 0.6821, 2.67, 0.282, 243, 238, CRYSTAL STRUCTURE OF 1NM-PP1 BOUND TO ANALOG-SENSITIVE SRC KINASE
3662, d3we4A_, 0.6821, 3.61, 0.175, 286, 257, CRYSTAL STRUCTURE OF S6K1 KINASE DOMAIN IN COMPLEX WITH A PYRIMIDINE DERIVATIVE PF-4708671 2-{[4-(5-ETHYLPYRIMIDIN-4-YL)PIPERAZIN-1- YL]METHYL}-5-(TRIFLUOROMETHYL)-1H-BENZIMIDAZOLE
3663, d3vw6A_, 0.6821, 2.71, 0.207, 255, 241, CRYSTAL STRUCTURE OF HUMAN APOPTOSIS SIGNAL-REGULATING KINASE 1 (ASK1) WITH IMIDAZOPYRIDINE INHIBITOR
3664, d3cikA2, 0.6821, 3.96, 0.165, 347, 266, HUMAN GRK2 IN COMPLEX WITH GBETAGAMMA SUBUNITS
3665, d5toeA_, 0.6820, 3.44, 0.174, 272, 253, PIM-1 KINASE IN COMPLEX WITH A 7-AZAINDOLE
3666, d5dr6A_, 0.6820, 3.14, 0.185, 257, 249, AURORA A KINASE IN COMPLEX WITH AA30 AND JNJ-7706621 IN SPACE GROUP P6122
3667, d5ar8A_, 0.6820, 2.82, 0.215, 255, 237, RIP2 KINASE CATALYTIC DOMAIN (1 - 310) COMPLEX WITH BIPHENYLSULFONAMIDE
3668, d4ztmB_, 0.6820, 2.91, 0.212, 280, 241, IRAK4-INHIBITOR CO-STRUCTURE
3669, d4k9yA_, 0.6820, 3.46, 0.335, 271, 251, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH 1-[4-(6-AMINO- PURIN-9-YL)-PHENYL]-3-(5-TERT-BUTYL-2-P-TOLYL-2H-PYRAZOL-3-YL)-UREA
3670, d4jjrB_, 0.6820, 3.71, 0.151, 283, 259, A P21 CRYSTAL FORM OF MAMMALIAN CASEIN KINASE 1 DELTA
3671, d4enyA_, 0.6820, 3.08, 0.166, 261, 247, CRYSTAL STRUCTURE OF PIM-1 KINASE IN COMPLEX WITH (2E5Z)-2-(2- CHLOROPHENYLIMINO)-5-(4-HYDROXY-3-METHOXYBENZYLIDENE)THIAZOLIDIN-4- ONE
3672, d3pyyB1, 0.6820, 2.71, 0.354, 244, 237, DISCOVERY AND CHARACTERIZATION OF A CELL-PERMEABLE SMALL-MOLECULE C- ABL KINASE ACTIVATOR THAT BINDS TO THE MYRISTOYL BINDING SITE
3673, d3krlA_, 0.6820, 3.38, 0.309, 281, 249, CFMS TYROSINE KINASE IN COMPLEX WITH 5-CYANO-FURAN-2-CARBOXYLIC ACID [4-(4-METHYL-PIPERAZIN-1-YL)-2-PIPERIDIN-1-YL-PHENYL]-AMIDE
3674, d1eh4B_, 0.6820, 3.88, 0.148, 293, 264, BINARY COMPLEX OF CASEIN KINASE-1 FROM S. POMBE WITH AN ATP COMPETITIVE INHIBITOR IC261
3675, p6g9aA_, 0.6819, 3.43, 0.165, 341, 254, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
3676, d5d9kA_, 0.6819, 3.33, 0.194, 280, 252, RSK2 N-TERMINAL KINASE IN COMPLEX WITH BI-D1870
3677, d4yc6G_, 0.6819, 3.28, 0.177, 285, 249, CDK1/CKS1
3678, d4bbmA1, 0.6819, 3.59, 0.213, 306, 254, CRYSTAL STRUCTURE OF THE HUMAN CDKL2 KINASE DOMAIN WITH BOUND TCS 2312
3679, d3uytC_, 0.6819, 3.91, 0.144, 286, 264, CRYSTAL STRUCTURE OF CK1D WITH PF670462 FROM P1 CRYSTAL FORM
3680, d3jy0A_, 0.6819, 3.38, 0.167, 275, 252, DISCOVERY OF 3H-BENZO[45]THIENO[32-D]PYRIMIDIN-4-ONES AS POTENT HIGHLY SELECTIVE AND ORALLY BIOAVAILABLE PIM KINASES INHIBITORS
3681, d3cqeA_, 0.6819, 3.08, 0.161, 258, 248, WEE1 KINASE COMPLEX WITH INHIBITOR PD074291
3682, d3c4eC_, 0.6819, 3.39, 0.166, 272, 253, PIM-1 KINASE DOMAIN IN COMPLEX WITH 3-AMINOPHENYL-7- AZAINDOLE
3683, d2bziB_, 0.6819, 3.21, 0.172, 272, 250, CRYSTAL STRUCTURE OF THE HUMAN PIM1 IN COMPLEX WITH A RUTHENIUM ORGANOMETALLIC LIGAND RU2
3684, d1ywvA_, 0.6819, 3.48, 0.165, 274, 254, CRYSTAL STRUCTURES OF PROTO-ONCOGENE KINASE PIM1: A TARGET OF ABERRANT SOMATIC HYPERMUTATIONS IN DIFFUSE LARGE CELL LYMPHOMA
3685, d1gzoA_, 0.6819, 3.10, 0.171, 271, 245, STRUCTURE OF PROTEIN KINASE B UNPHOSPHORYLATED
3686, d6brcA1, 0.6818, 3.38, 0.187, 263, 252, CRYSTAL STRUCTURE OF THE HUMAN CAMKK2B IN COMPLEX WITH AP26113-ANALOG (ALK-IN-1)
3687, d3pvuA2, 0.6818, 3.83, 0.166, 340, 265, BOVINE GRK2 IN COMPLEX WITH GBETAGAMMA SUBUNITS AND A SELECTIVE KINASE INHIBITOR (CMPD101)
3688, d3f3zA_, 0.6818, 3.31, 0.161, 271, 254, CRYSTAL STRUCTURE OF CRYPTOSPORIDIUM PARVUM CALCIUM DEPENDENT PROTEIN KINASE CGD7_1840 IN PRESENCE OF INDIRUBIN E804
3689, d5anoA_, 0.6817, 2.93, 0.190, 277, 242, CRYSTAL STRUCTURE OF CDK2 PROCESSED WITH THE CRYSTALDIRECT AUTOMATED MOUNTING AND CRYO-COOLING TECHNOLOGY
3690, d3mvjB_, 0.6817, 3.82, 0.174, 320, 264, HUMAN CYCLIC AMP-DEPENDENT PROTEIN KINASE PKA INHIBITOR COMPLEX
3691, d3c4eA_, 0.6817, 3.48, 0.161, 273, 254, PIM-1 KINASE DOMAIN IN COMPLEX WITH 3-AMINOPHENYL-7- AZAINDOLE
3692, d1okvA_, 0.6817, 3.67, 0.154, 295, 260, CYCLIN A BINDING GROOVE INHIBITOR H-ARG-ARG-LEU-ILE-PHE-NH2
3693, d4nj3A_, 0.6816, 3.00, 0.189, 277, 243, MODULATING THE INTERACTION BETWEEN CDK2 AND CYCLIN A WITH A QUINOLINE- BASED INHIBITOR
3694, d4nifD_, 0.6816, 2.95, 0.160, 313, 243, HETERODIMERIC STRUCTURE OF ERK2 AND RSK1
3695, d4fktA_, 0.6816, 3.12, 0.193, 278, 244, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH OXINDOLE INHIBITOR
3696, d3c4eB_, 0.6816, 3.42, 0.166, 273, 253, PIM-1 KINASE DOMAIN IN COMPLEX WITH 3-AMINOPHENYL-7- AZAINDOLE
3697, d1irkA_, 0.6816, 3.44, 0.307, 303, 254, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF THE HUMAN INSULIN RECEPTOR
3698, d5jq8A_, 0.6815, 3.09, 0.176, 278, 244, CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH INHIBITOR ICEC0943
3699, d2c30A_, 0.6815, 3.66, 0.180, 289, 256, CRYSTAL STRUCTURE OF THE HUMAN P21-ACTIVATED KINASE 6
3700, d5uitA_, 0.6814, 3.19, 0.211, 284, 247, CRYSTAL STRUCTURE OF IRAK4 IN COMPLEX WITH COMPOUND 14
3701, d5t1sD_, 0.6814, 3.09, 0.216, 281, 245, IRAK4 KINASE - COMPOUND 1 CO-STRUCTURE
3702, d1yxsA_, 0.6814, 3.45, 0.174, 274, 253, CRYSTAL STRUCTURE OF KINASE PIM1 WITH P123M MUTATION
3703, d4xs2D_, 0.6813, 3.06, 0.209, 277, 244, IRAK4-INHIBITOR CO-STRUCTURE
3704, d3mygA_, 0.6813, 3.10, 0.190, 252, 247, AURORA A KINASE COMPLEXED WITH SCH 1473759
3705, d2xruA_, 0.6813, 3.07, 0.190, 253, 247, AURORA-A T288E COMPLEXED WITH PHA-828300
3706, d2qr8A_, 0.6813, 2.96, 0.180, 298, 244, 2.0A X-RAY STRUCTURE OF C-TERMINAL KINASE DOMAIN OF P90 RIBOSOMAL S6 KINASE 2 (RSK2)
3707, d1mruA_, 0.6813, 3.18, 0.161, 269, 249, INTRACELLULAR SER/THR PROTEIN KINASE DOMAIN OF MYCOBACTERIUM TUBERCULOSIS PKNB.
3708, d3zfyA_, 0.6812, 3.26, 0.312, 260, 247, CRYSTAL STRUCTURE OF EPHB3
3709, d3lokB_, 0.6812, 2.74, 0.301, 242, 239, DRUG RESISTANT CSRC KINASE DOMAIN IN COMPLEX WITH COVALENT INHIBITOR PD168393
3710, d3d7tA_, 0.6812, 2.91, 0.302, 249, 245, STRUCTURAL BASIS FOR THE RECOGNITION OF C-SRC BY ITS INACTIVATOR CSK
3711, d2b9hA_, 0.6812, 3.13, 0.157, 337, 249, CRYSTAL STRUCTURE OF FUS3 WITH A DOCKING MOTIF FROM STE7
3712, d1x8bA_, 0.6812, 3.07, 0.158, 259, 247, STRUCTURE OF HUMAN WEE1A KINASE: KINASE DOMAIN COMPLEXED WITH INHIBITOR PD0407824
3713, d5x17B_, 0.6811, 3.90, 0.148, 289, 263, CRYSTAL STRUCTURE OF MURINE CK1D IN COMPLEX WITH ADP
3714, p3v3vA_, 0.6811, 3.28, 0.199, 351, 251, STRUCTURAL AND FUNCTIONAL ANALYSIS OF QUERCETAGETIN A NATURAL JNK1 INHIBITOR
3715, d2bheA_, 0.6811, 2.76, 0.180, 274, 239, HUMAN CYCLIN DEPENDENT PROTEIN KINASE 2 IN COMPLEX WITH THE INHIBITOR 5-BROMO-INDIRUBINE
3716, d2b9fA_, 0.6811, 3.16, 0.149, 337, 249, CRYSTAL STRUCTURE OF NON-PHOSPHORYLATED FUS3
3717, d5o13A_, 0.6810, 3.21, 0.177, 270, 249, CRYSTAL STRUCTURE OF PIM1 KINASE IN COMPLEX WITH SMALL-MOLECULE INHIBITOR
3718, d4ek6A_, 0.6810, 3.04, 0.193, 278, 243, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH AMINOPYRAZOLE INHIBITOR
3719, d3qc4B1, 0.6810, 3.29, 0.168, 268, 250, PDK1 IN COMPLEX WITH DFG-OUT INHIBITOR XXX
3720, d2hwoB_, 0.6810, 2.71, 0.290, 242, 238, CRYSTAL STRUCTURE OF SRC KINASE DOMAIN IN COMPLEX WITH COVALENT INHIBITOR
3721, d5texA_, 0.6809, 3.44, 0.174, 274, 253, PIM-1 KINASE IN COMPLEX WITH A 7-AZAINDOLE
3722, d5mqvF_, 0.6809, 3.79, 0.146, 286, 261, CRYSTAL STRUCTURE OF HUMAN CASEIN KINASE I DELTA IN COMPLEX WITH 4-(2 5-DIMETHOXYPHENYL)-N-(4-(5-(4-FLUORPHENYL)-2-(METHYLTHIO)-1H- IMIDAZOL-4-YL)-PYRIDIN-2-YL)-1-METHYL-1H-PYRROLE-2-CARBOXAMIDE
3723, d5hhwA_, 0.6809, 3.45, 0.299, 306, 254, CRYSTAL STRUCTURE OF INSULIN RECEPTOR KINASE DOMAIN IN COMPLEX WITH CIS-(R)-7-(3-(AZETIDIN-1-YLMETHYL)CYCLOBUTYL)-5-(3-((TETRAHYDRO-2H- PYRAN-2-YL)METHOXY)PHENYL)-7H-PYRROLO[23-D]PYRIMIDIN-4-AMINE.
3724, d5acbD_, 0.6809, 3.79, 0.160, 319, 263, CRYSTAL STRUCTURE OF THE HUMAN CDK12-CYCLINK COMPLEX
3725, d4mygA_, 0.6809, 3.17, 0.185, 335, 249, MAPK13 ACTIVE FORM
3726, d3we8A_, 0.6809, 3.34, 0.171, 273, 252, PIM-1 KINASE IN COMPLEX WITH RUTHENIUM-BASED INHIBITOR
3727, d2hyyD1, 0.6809, 2.61, 0.360, 251, 236, HUMAN ABL KINASE DOMAIN IN COMPLEX WITH IMATINIB (STI571 GLIVEC)
3728, d2henA1, 0.6809, 3.29, 0.309, 258, 249, CRYSTAL STRUCTURE OF THE EPHB2 RECEPTOR KINASE DOMAIN IN COMPLEX WITH ADP
3729, d2b9jA_, 0.6809, 3.11, 0.157, 337, 249, CRYSTAL STRUCTURE OF FUS3 WITH A DOCKING MOTIF FROM FAR1
3730, d1gznA_, 0.6809, 3.20, 0.167, 271, 246, STRUCTURE OF PKB KINASE DOMAIN
3731, d1f5qA_, 0.6809, 3.49, 0.148, 296, 256, CRYSTAL STRUCTURE OF MURINE GAMMA HERPESVIRUS CYCLIN COMPLEXED TO HUMAN CYCLIN DEPENDENT KINASE 2
3732, d4joaA_, 0.6808, 3.12, 0.283, 250, 244, CRYSTAL STRUCTURE OF HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH 7-AZAINDOLE BASED INHIBITOR
3733, d4ic7A_, 0.6808, 3.48, 0.156, 355, 256, CRYSTAL STRUCTURE OF THE ERK5 KINASE DOMAIN IN COMPLEX WITH AN MKK5 BINDING FRAGMENT
3734, d5cs6B_, 0.6807, 3.22, 0.153, 316, 248, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 3 BOUND
3735, d5bvnA_, 0.6807, 3.29, 0.297, 278, 249, FRAGMENT-BASED DISCOVERY OF POTENT AND SELECTIVE DDR1/2 INHIBITORS
3736, d4qp3B_, 0.6807, 3.41, 0.165, 331, 254, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH (S)-2-((9H-PURIN-6-YL) AMINO)-3-PHENYLPROPAN-1-OL
3737, d1g5sA_, 0.6807, 2.80, 0.183, 275, 240, CRYSTAL STRUCTURE OF HUMAN CYCLIN DEPENDENT KINASE 2 (CDK2) IN COMPLEX WITH THE INHIBITOR H717
3738, d4fg9B_, 0.6806, 3.20, 0.179, 279, 246, CRYSTAL STRUCTURE OF HUMAN CALCIUM/CALMODULIN-DEPENDENT PROTEIN KINASE I 1-320 IN COMPLEX WITH ATP
3739, d3t9iA_, 0.6806, 3.22, 0.165, 273, 249, PIM1 COMPLEXED WITH A NOVEL 36-DISUBSTITUTED INDOLE AT 2.6 ANG RESOLUTION
3740, d3m11A_, 0.6806, 3.02, 0.187, 256, 246, CRYSTAL STRUCTURE OF AURORA A KINASE COMPLEXED WITH INHIBITOR
3741, d5mqvA_, 0.6805, 3.74, 0.146, 286, 260, CRYSTAL STRUCTURE OF HUMAN CASEIN KINASE I DELTA IN COMPLEX WITH 4-(2 5-DIMETHOXYPHENYL)-N-(4-(5-(4-FLUORPHENYL)-2-(METHYLTHIO)-1H- IMIDAZOL-4-YL)-PYRIDIN-2-YL)-1-METHYL-1H-PYRROLE-2-CARBOXAMIDE
3742, d5e1sA_, 0.6805, 3.28, 0.292, 284, 250, THE CRYSTAL STRUCTURE OF INSR TYROSINE KINASE IN COMPLEX WITH THE INHIBITOR BI 885578
3743, d4cxaC_, 0.6805, 3.91, 0.162, 330, 266, CRYSTAL STRUCTURE OF THE HUMAN CDK12-CYCLIN K COMPLEX BOUND TO AMPPNP
3744, d3uokB_, 0.6805, 3.28, 0.190, 265, 248, AURORA A IN COMPLEX WITH YL5-81-1
3745, d3tubA_, 0.6805, 3.22, 0.352, 253, 250, CRYSTAL STRUCTURE OF SYK KINASE DOMAIN WITH 1-(5-(67- DIMETHOXYQUINOLIN-4-YLOXY)PYRIDIN-2-YL)-3-((1R2S)-2- PHENYLCYCLOPROPYL)UREA
3746, d5uq0B_, 0.6804, 3.24, 0.313, 256, 246, FGFR1 KINASE DOMAIN COMPLEX WITH FRAGMENT 22-DIMETHYL-23- DIHYDROBENZOFURAN-7-CARBOXAMIDE
3747, d3qrkA1, 0.6804, 3.05, 0.347, 268, 245, THE CRYSTAL STRUCTURE OF HUMAN ABL1 KINASE DOMAIN IN COMPLEX WITH DP- 987
3748, d3a99A_, 0.6804, 3.39, 0.175, 273, 252, STRUCTURE OF PIM-1 KINASE CRYSTALLIZED IN THE PRESENCE OF P27KIP1 CARBOXY-TERMINAL PEPTIDE
3749, d2henC1, 0.6804, 3.29, 0.309, 258, 249, CRYSTAL STRUCTURE OF THE EPHB2 RECEPTOR KINASE DOMAIN IN COMPLEX WITH ADP
3750, d1o6yA_, 0.6804, 3.03, 0.167, 260, 246, CATALYTIC DOMAIN OF PKNB KINASE FROM MYCOBACTERIUM TUBERCULOSIS
3751, d4ztnB_, 0.6803, 3.13, 0.213, 282, 244, IRAK4-INHIBITOR CO-STRUCTURE
3752, d2a4lA_, 0.6803, 3.20, 0.179, 286, 246, HUMAN CYCLIN-DEPENDENT KINASE 2 IN COMPLEX WITH ROSCOVITINE
3753, d3f69A_, 0.6802, 3.15, 0.138, 270, 246, CRYSTAL STRUCTURE OF THE MYCOBACTERIUM TUBERCULOSIS PKNB MUTANT KINASE DOMAIN IN COMPLEX WITH KT5720
3754, d2wipC1, 0.6802, 3.52, 0.149, 291, 255, STRUCTURE OF CDK2-CYCLIN A COMPLEXED WITH 8-ANILINO-1- METHYL-45-DIHYDRO-1H-PYRAZOLO[43-H] QUINAZOLINE-3- CARBOXYLIC ACID
3755, d2c47B_, 0.6802, 3.77, 0.138, 289, 261, STRUCTURE OF CASEIN KINASE 1 GAMMA 2
3756, d4iaaA_, 0.6801, 3.31, 0.167, 272, 251, CRYSTAL STRUCTURE OF SER/THR KINASE PIM1 IN COMPLEX WITH THIORIDAZINE
3757, d2z2wA_, 0.6801, 3.12, 0.161, 260, 248, HUMAND WEE1 KINASE COMPLEXED WITH INHIBITOR PF0335770
3758, d2bikB_, 0.6801, 3.29, 0.171, 272, 251, HUMAN PIM1 PHOSPHORYLATED ON SER261
3759, d4fg9A_, 0.6800, 3.14, 0.188, 278, 245, CRYSTAL STRUCTURE OF HUMAN CALCIUM/CALMODULIN-DEPENDENT PROTEIN KINASE I 1-320 IN COMPLEX WITH ATP
3760, d3pscA2, 0.6799, 3.89, 0.174, 344, 264, BOVINE GRK2 IN COMPLEX WITH GBETAGAMMA SUBUNITS
3761, d2o65A_, 0.6799, 3.60, 0.173, 274, 255, CRYSTAL STRUCTURE OF PIM1 WITH PENTAHYDROXYFLAVONE
3762, d1h01A_, 0.6799, 3.25, 0.174, 286, 247, CDK2 IN COMPLEX WITH A DISUBSTITUTED 2 4-BIS ANILINO PYRIMIDINE CDK4 INHIBITOR
3763, d5tkdB_, 0.6798, 2.59, 0.210, 247, 238, CRYSTAL STRUCTURE OF TYROSINE KINASE 2 JH2 (PSEUDO KINASE DOMAIN) COMPLEXED WITH 6-[(35-DIMETHYLPHE NYL)AMINO]-8- (METHYLAMINO) IMIDAZO[12-B]PYRIDAZINE-3-CARBO XAMIDE
3764, d5aagA_, 0.6798, 3.09, 0.186, 253, 247, AURORA A KINASE BOUND TO AN IMIDAZOPYRIDINE INHIBITOR (14B)
3765, d4tw9B_, 0.6798, 3.89, 0.144, 289, 264, DIFLUORO-DIOXOLO-BENZOIMIDAZOL-BENZAMIDES AS POTENT INHIBITORS OF CK1DELTA AND EPSILON WITH NANOMOLAR INHIBITORY ACTIVITY ON CANCER CELL PROLIFERATION
3766, d4fg8B_, 0.6798, 2.92, 0.189, 268, 243, CRYSTAL STRUCTURE OF HUMAN CALCIUM/CALMODULIN-DEPENDENT PROTEIN KINASE I 1-315 IN COMPLEX WITH ATP
3767, d2w96B_, 0.6798, 3.01, 0.185, 267, 243, CRYSTAL STRUCTURE OF CDK4 IN COMPLEX WITH A D-TYPE CYCLIN
3768, d5jznB_, 0.6797, 3.26, 0.179, 266, 251, CRYSTAL STRUCTURE OF DCLK1-KD IN COMPLEX WITH NVP-TAE684
3769, d3uokA_, 0.6797, 3.21, 0.190, 265, 247, AURORA A IN COMPLEX WITH YL5-81-1
3770, d2izsA_, 0.6797, 4.00, 0.131, 298, 267, STRUCTURE OF CASEIN KINASE GAMMA 3 IN COMPLEX WITH INHIBITOR
3771, d5o11A_, 0.6796, 3.21, 0.165, 268, 248, CRYSTAL STRUCTURE OF PIM1 KINASE IN COMPLEX WITH SMALL-MOLECULE INHIBITOR
3772, d5hd7A_, 0.6796, 3.53, 0.161, 347, 255, DISSECTING THERAPEUTIC RESISTANCE TO ERK INHIBITION RAT MUTANT SCH772984 IN COMPLEX WITH (3R)-1-(2-OXO-2-{4-[4-(PYRIMIDIN-2-YL) PHENYL]PIPERAZIN-1-YL}ETHYL)-N-[3-(PYRIDIN-4-YL)-2H-INDAZOL-5- YL]PYRROLIDINE-3-CARBOXAMIDE
3773, d4o0rB_, 0.6796, 3.55, 0.193, 282, 254, BACK POCKET FLEXIBILITY PROVIDES GROUP-II PAK SELECTIVITY FOR TYPE 1 KINASE INHIBITORS
3774, d4btkA_, 0.6796, 3.75, 0.162, 287, 260, TTBK1 IN COMPLEX WITH INHIBITOR
3775, d3uohB_, 0.6796, 3.21, 0.190, 264, 247, AURORA A IN COMPLEX WITH RPM1722
3776, d3uohA_, 0.6796, 3.21, 0.190, 264, 247, AURORA A IN COMPLEX WITH RPM1722
3777, d3uixA_, 0.6796, 3.29, 0.164, 266, 250, CRYSTAL STRUCTURE OF PIM1 KINASE IN COMPLEX WITH SMALL MOLECULE INHIBITOR
3778, d3le6A_, 0.6796, 3.17, 0.176, 283, 245, THE STRUCTURE OF CYCLIN DEPENDENT KINASE 2 (CKD2) WITH A PYRAZOLOBENZODIAZEPINE INHIBITOR
3779, d5aafA_, 0.6795, 3.18, 0.190, 254, 248, AURORA A KINASE BOUND TO AN IMIDAZOPYRIDINE INHIBITOR (14A)
3780, d4ibmA_, 0.6795, 3.56, 0.286, 301, 252, CRYSTAL STRUCTURE OF INSULIN RECEPTOR KINASE DOMAIN IN COMPLEX WITH AN INHIBITOR IRFIN-1
3781, d5w84A_, 0.6794, 2.93, 0.212, 279, 241, CRYSTAL STRUCTURE OF IRAK-4 WITH A 46-DIAMINONICOTINAMIDE INHIBITOR (COMPOUND NUMBER 4)
3782, d4medA_, 0.6794, 3.32, 0.167, 272, 251, CRYSTAL STRUCTURE OF SER/THR KINASE PIM1 IN COMPLEX WITH THIORIDAZINE DERIVATIVES
3783, d4fksA_, 0.6794, 2.91, 0.191, 275, 241, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH OXINDOLE INHIBITOR
3784, d4cjyC_, 0.6794, 3.70, 0.146, 303, 261,  
3785, d1ym7D3, 0.6794, 3.97, 0.174, 340, 265, G PROTEIN-COUPLED RECEPTOR KINASE 2 (GRK2)
3786, d1yi4A_, 0.6794, 3.34, 0.175, 267, 251, STRUCTURE OF PIM-1 BOUND TO ADENOSINE
3787, p6gdqA_, 0.6793, 3.41, 0.166, 339, 253, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
3788, d4byiA_, 0.6793, 3.21, 0.189, 254, 249, AURORA A KINASE BOUND TO A HIGHLY SELECTIVE IMIDAZOPYRIDINE INHIBITOR
3789, d3etaB_, 0.6793, 3.42, 0.308, 292, 250, KINASE DOMAIN OF INSULIN RECEPTOR COMPLEXED WITH A PYRROLO PYRIDINE INHIBITOR
3790, d5w4wC_, 0.6792, 3.93, 0.148, 284, 263, IDENTIFICATION AND PROFILING OF A SELECTIVE AND BRAIN PENETRANT RADIOLIGAND FOR IN VIVO TARGET OCCUPANCY MEASUREMENT OF CASEIN KINASE 1 (CK1) INHIBITORS
3791, d5uiuA_, 0.6792, 3.34, 0.221, 286, 249, CRYSTAL STRUCTURE OF IRAK4 IN COMPLEX WITH COMPOUND 30
3792, d5obrA_, 0.6792, 3.18, 0.177, 255, 248, AURORA A KINASE IN COMPLEX WITH 2-(3-CHLORO-5-FLUOROPHENYL)QUINOLINE- 4-CARBOXYLIC ACID AND JNJ-7706621
3793, d4q9sA_, 0.6792, 3.30, 0.337, 252, 249, CRYSTAL STRUCTURE OF HUMAN FOCAL ADHESION KINASE (FAK) BOUND TO COMPOUND1 (35-DIHYDRO[124]TRIAZINO[34-C][14]BENZOXAZIN-2(1H)- ONE)
3794, d3k5uA_, 0.6792, 3.14, 0.190, 260, 248, IDENTIFICATION SAR STUDIES AND X-RAY COCRYSTAL ANALYSIS OF A NOVEL FURANO-PYRIMIDINE AURORA KINASE A INHIBITOR
3795, d2vtqA_, 0.6792, 2.79, 0.184, 274, 239, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
3796, d2izuA_, 0.6792, 3.99, 0.124, 297, 266, STRUCTURE OF CASEIN KINASE GAMMA 3 IN COMPLEX WITH INHIBITOR
3797, d2hyyC1, 0.6792, 2.70, 0.359, 249, 237, HUMAN ABL KINASE DOMAIN IN COMPLEX WITH IMATINIB (STI571 GLIVEC)
3798, d4zloA_, 0.6791, 3.54, 0.182, 277, 253, SERINE/THREONINE-PROTEIN KINASE PAK1 COMPLEXED WITH A DIBENZODIAZEPINE: IDENTIFICATION OF AN ALLOSTERIC SITE ON PAK1
3799, d4bidA_, 0.6791, 2.71, 0.208, 254, 240, CRYSTAL STRUCTURES OF ASK1-INHIBITOR COMPLEXES
3800, d5ih9A_, 0.6790, 3.12, 0.191, 308, 246, MELK IN COMPLEX WITH NVS-MELK8A
3801, d4qp1B_, 0.6790, 3.39, 0.162, 343, 253, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH N-CYCLOHEXYL-9H-PURIN-6- AMINE
3802, d1unlA_, 0.6790, 3.55, 0.141, 292, 256, STRUCTURAL MECHANISM FOR THE INHIBITION OF CD5-P25 FROM THE ROSCOVITINE ALOISINE AND INDIRUBIN.
3803, d4rc3A_, 0.6789, 3.30, 0.172, 271, 250, CRYSTAL STRUCTURE OF SER/THR KINASE PIM1 IN COMPLEX WITH MITOXANTRONE DERIVATIVES
3804, d3w55A_, 0.6789, 3.04, 0.163, 335, 246, THE STRUCTURE OF ERK2 IN COMPLEX WITH FR148083
3805, d2e14A_, 0.6789, 3.04, 0.163, 335, 246,  
3806, d1ym7C3, 0.6789, 3.92, 0.170, 346, 264, G PROTEIN-COUPLED RECEPTOR KINASE 2 (GRK2)
3807, d5mqvE_, 0.6788, 3.78, 0.146, 287, 260, CRYSTAL STRUCTURE OF HUMAN CASEIN KINASE I DELTA IN COMPLEX WITH 4-(2 5-DIMETHOXYPHENYL)-N-(4-(5-(4-FLUORPHENYL)-2-(METHYLTHIO)-1H- IMIDAZOL-4-YL)-PYRIDIN-2-YL)-1-METHYL-1H-PYRROLE-2-CARBOXAMIDE
3808, d3en6B_, 0.6788, 2.62, 0.281, 239, 235, TARGETED POLYPHARMACOLOGY: CRYSTAL STRUCTURE OF THE C-SRC KINASE DOMAIN IN COMPLEX WITH PP102 A MULTITARGETED KINASE INHIBITOR
3809, d1ywnA_, 0.6788, 3.38, 0.301, 279, 249, VEGFR2 IN COMPLEX WITH A NOVEL 4-AMINO-FURO[23-D]PYRIMIDINE
3810, d1h24A1, 0.6788, 3.59, 0.164, 292, 256, CDK2/CYCLIN A IN COMPLEX WITH A 9 RESIDUE RECRUITMENT PEPTIDE FROM E2F
3811, d5hd4A_, 0.6787, 3.55, 0.165, 347, 255, DISSECTING THERAPEUTIC RESISTANCE TO ERK INHIBITION RAT WILD TYPE SCH772984 IN COMPLEX WITH (3R)-1-(2-OXO-2-{4-[4-(PYRIMIDIN-2-YL) PHENYL]PIPERAZIN-1-YL}ETHYL)-N-[3-(PYRIDIN-4-YL)-2H-INDAZOL-5- YL]PYRROLIDINE-3-CARBOXAMIDE
3812, d3q4zB_, 0.6787, 3.47, 0.166, 279, 253, STRUCTURE OF UNPHOSPHORYLATED PAK1 KINASE DOMAIN
3813, d4jbqA_, 0.6786, 3.23, 0.189, 257, 249, NOVEL AURORA KINASE INHIBITORS REVEAL MECHANISMS OF HURP IN NUCLEATION OF CENTROSOMAL AND KINETOCHORE MICROTUBULES
3814, d3pyyA1, 0.6786, 2.70, 0.354, 251, 237, DISCOVERY AND CHARACTERIZATION OF A CELL-PERMEABLE SMALL-MOLECULE C- ABL KINASE ACTIVATOR THAT BINDS TO THE MYRISTOYL BINDING SITE
3815, d2zv2A_, 0.6786, 3.17, 0.179, 256, 246, CRYSTAL STRUCTURE OF HUMAN CALCIUM/CALMODULIN-DEPENDENT PROTEIN KINASE KINASE 2 BETA CAMKK2 KINASE DOMAIN IN COMPLEX WITH STO-609
3816, d4ic7D_, 0.6785, 3.53, 0.156, 353, 256, CRYSTAL STRUCTURE OF THE ERK5 KINASE DOMAIN IN COMPLEX WITH AN MKK5 BINDING FRAGMENT
3817, d1dm2A_, 0.6785, 2.85, 0.175, 274, 240, HUMAN CYCLIN-DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR HYMENIALDISINE
3818, d5m57A1, 0.6784, 2.77, 0.167, 253, 240, NEK2 BOUND TO ARYLAMINOPURINE 6
3819, d5eymB_, 0.6784, 3.41, 0.202, 292, 252, MEK1 IN COMPLEX WITH BI 847325
3820, d5cwzC_, 0.6784, 2.90, 0.170, 271, 241, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN TRAF2 AND NCK- INTERACTING PROTEIN KINASE
3821, d5aaeA_, 0.6784, 3.14, 0.190, 252, 247, AURORA A KINASE BOUND TO AN IMIDAZOPYRIDINE INHIBITOR (14D)
3822, d3uo6A_, 0.6784, 3.16, 0.191, 264, 246, AURORA A IN COMPLEX WITH YL5-083
3823, d2vtnA_, 0.6784, 2.79, 0.176, 274, 239, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
3824, d1jowB_, 0.6784, 3.08, 0.163, 277, 246, CRYSTAL STRUCTURE OF A COMPLEX OF HUMAN CDK6 AND A VIRAL CYCLIN
3825, d3uo6B_, 0.6783, 3.16, 0.191, 264, 246, AURORA A IN COMPLEX WITH YL5-083
3826, d2xngA_, 0.6783, 3.04, 0.188, 253, 245, STRUCTURE OF AURORA-A BOUND TO A SELECTIVE IMIDAZOPYRAZINE INHIBITOR
3827, d1ym7A3, 0.6783, 4.03, 0.169, 347, 266, G PROTEIN-COUPLED RECEPTOR KINASE 2 (GRK2)
3828, d1wzyA_, 0.6783, 3.44, 0.173, 350, 254, CRYSTAL STRUCTURE OF HUMAN ERK2 COMPLEXED WITH A PYRAZOLOPYRIDAZINE DERIVATIVE
3829, d1oirA_, 0.6783, 3.39, 0.169, 286, 249, IMIDAZOPYRIDINES: A POTENT AND SELECTIVE CLASS OF CYCLIN-DEPENDENT KINASE INHIBITORS IDENTIFIED THROUGH STRUCTURE-BASED HYBRIDISATION
3830, d2izrA_, 0.6782, 4.02, 0.135, 298, 267, STRUCTURE OF CASEIN KINASE GAMMA 3 IN COMPLEX WITH INHIBITOR
3831, d2c47A_, 0.6782, 3.76, 0.138, 288, 260, STRUCTURE OF CASEIN KINASE 1 GAMMA 2
3832, d4xs2C_, 0.6781, 3.17, 0.215, 281, 246, IRAK4-INHIBITOR CO-STRUCTURE
3833, d4lm5A_, 0.6781, 3.23, 0.173, 264, 249, CRYSTAL STRUCTURE OF PIM1 IN COMPLEX WITH 2-{4-[(3-AMINOPROPYL) AMINO]QUINAZOLIN-2-YL}PHENOL (RESULTING FROM DISPLACEMENT OF SKF86002)
3834, d4bcqC1, 0.6781, 3.50, 0.169, 291, 254, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
3835, d3pxqA1, 0.6781, 3.25, 0.165, 294, 248, CDK2 IN COMPLEX WITH 3 MOLECULES OF 8-ANILINO-1-NAPHTHALENE SULFONATE
3836, d1ym7B3, 0.6781, 4.04, 0.169, 347, 266, G PROTEIN-COUPLED RECEPTOR KINASE 2 (GRK2)
3837, d1howA_, 0.6781, 3.35, 0.155, 346, 251, THE X-RAY CRYSTAL STRUCTURE OF SKY1P AN SR PROTEIN KINASE IN YEAST
3838, d5eymA_, 0.6780, 3.42, 0.198, 292, 252, MEK1 IN COMPLEX WITH BI 847325
3839, d4rblA_, 0.6780, 3.31, 0.172, 271, 250, CRYSTAL STRUCTURE OF SER/THR KINASE PIM1 IN COMPLEX WITH MITOXANTRONE DERIVATIVES
3840, d4lg4B_, 0.6780, 3.46, 0.209, 284, 253, STRUCTURAL BASIS FOR AUTOACTIVATION OF HUMAN MST2 KINASE AND ITS REGULATION BY RASSF5
3841, d4bf2A_, 0.6780, 2.64, 0.223, 253, 238, CRYSTAL STRUCTURES OF ASK1-INHIBITOR COMPLEXES
3842, d3h0zA_, 0.6780, 2.96, 0.189, 248, 243, AURORA A IN COMPLEX WITH A BISANILINOPYRIMIDINE
3843, d3a2cB_, 0.6780, 3.04, 0.152, 277, 243, CRYSTAL STRUCTURE OF A PYRAZOLOPYRIMIDINE INHIBITOR COMPLEX BOUND TO MAPKAP KINASE-2 (MK2)
3844, d2wqmA_, 0.6780, 3.03, 0.193, 258, 244, STRUCTURE OF APO HUMAN NEK7
3845, d2btrA_, 0.6780, 2.91, 0.192, 275, 240, STRUCTURE OF CDK2 COMPLEXED WITH PNU-198873
3846, d4bibB_, 0.6779, 2.95, 0.230, 258, 244, CRYSTAL STRUCTURES OF ASK1-INHIBITOR COMPLEXES
3847, d3c7qA_, 0.6779, 3.58, 0.298, 286, 252, STRUCTURE OF VEGFR2 KINASE DOMAIN IN COMPLEX WITH BIBF1120
3848, d3ag9A_, 0.6779, 4.12, 0.162, 323, 265, COMPLEX OF PKA WITH THE BISUBSTRATE PROTEIN KINASE INHIBITOR ARC-1012
3849, d2btsA_, 0.6779, 2.91, 0.175, 274, 240, STRUCTURE OF CDK2 COMPLEXED WITH PNU-230032
3850, d4hniA_, 0.6778, 3.57, 0.153, 284, 255, CRYSTAL STRUCTURE OF CK1E IN COMPLEX WITH PF4800567
3851, d4bidB_, 0.6778, 2.91, 0.230, 258, 243, CRYSTAL STRUCTURES OF ASK1-INHIBITOR COMPLEXES
3852, p3nieA_, 0.6778, 3.42, 0.198, 369, 252, CRYSTAL STRUCTURE OF PF11_0147
3853, d2bhhA_, 0.6778, 2.77, 0.176, 274, 239, HUMAN CYCLIN DEPENDENT PROTEIN KINASE 2 IN COMPLEX WITH THE INHIBITOR 4-HYDROXYPIPERINDINESULFONYL-INDIRUBINE
3854, d5mqvB_, 0.6777, 3.79, 0.150, 287, 260, CRYSTAL STRUCTURE OF HUMAN CASEIN KINASE I DELTA IN COMPLEX WITH 4-(2 5-DIMETHOXYPHENYL)-N-(4-(5-(4-FLUORPHENYL)-2-(METHYLTHIO)-1H- IMIDAZOL-4-YL)-PYRIDIN-2-YL)-1-METHYL-1H-PYRROLE-2-CARBOXAMIDE
3855, d5m51A1, 0.6777, 2.78, 0.171, 253, 240, NEK2 BOUND TO ARYLAMINOPURINE COMPOUND 8
3856, d5k76B_, 0.6777, 3.12, 0.213, 281, 244, IRAK4 IN COMPLEX WITH COMPOUND 28
3857, d1csnA_, 0.6777, 3.98, 0.140, 293, 264, BINARY COMPLEX OF CASEIN KINASE-1 WITH MGATP
3858, d3tl8D_, 0.6776, 3.49, 0.191, 306, 251, THE AVRPTOB-BAK1 COMPLEX REVEALS TWO STRUCTURALLY SIMILAR KINASEINTERACTING DOMAINS IN A SINGLE TYPE III EFFECTOR
3859, d3r21A_, 0.6775, 3.21, 0.185, 254, 248, DESIGN SYNTHESIS AND BIOLOGICAL EVALUATION OF PYRAZOLOPYRIDINE- SULFONAMIDES AS POTENT MULTIPLE-MITOTIC KINASE (MMK) INHIBITORS (PART I)
3860, d3amyA_, 0.6775, 3.38, 0.155, 318, 251, CRYSTAL STRUCTURE OF HUMAN CK2 ALPHA COMPLEXED WITH APIGENIN
3861, d4xj0B_, 0.6774, 3.47, 0.161, 338, 254, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH AN INHIBITOR 14K
3862, d2w9fB_, 0.6774, 3.01, 0.182, 261, 242, CRYSTAL STRUCTURE OF CDK4 IN COMPLEX WITH A D-TYPE CYCLIN
3863, d1p4oB_, 0.6774, 3.54, 0.311, 314, 251, STRUCTURE OF APO UNACTIVATED IGF-1R KINASE DOMAIN AT 1.5A RESOLUTION.
3864, d5jzjA_, 0.6773, 3.18, 0.181, 271, 249, CRYSTAL STRUCTURE OF DCLK1-KD IN COMPLEX WITH AMPPN
3865, d3cr0A_, 0.6773, 3.13, 0.166, 257, 247, WEE1 KINASE COMPLEX WITH INHIBITOR PD259_809
3866, d3bi6A_, 0.6773, 3.16, 0.161, 258, 248, WEE1 KINASE COMPLEX WITH INHIBITOR PD352396
3867, d1sykB_, 0.6773, 3.96, 0.159, 323, 264, CRYSTAL STRUCTURE OF E230Q MUTANT OF CAMP-DEPENDENT PROTEIN KINASE REVEALS UNEXPECTED APOENZYME CONFORMATION
3868, d1q99B_, 0.6773, 3.43, 0.159, 364, 252, CRYSTAL STRUCTURE OF THE SACCHAROMYCES CEREVISIAE SR PROTEIN KINSAE SKY1P COMPLEXED WITH THE NON-HYDROLYZABLE ATP ANALOGUE AMP-PNP
3869, d2fumD_, 0.6772, 2.96, 0.165, 258, 243, CATALYTIC DOMAIN OF PROTEIN KINASE PKNB FROM MYCOBACTERIUM TUBERCULOSIS IN COMPLEX WITH MITOXANTRONE
3870, d1p4oA_, 0.6772, 3.54, 0.311, 308, 251, STRUCTURE OF APO UNACTIVATED IGF-1R KINASE DOMAIN AT 1.5A RESOLUTION.
3871, d4rzvA1, 0.6771, 2.54, 0.225, 245, 236, CRYSTAL STRUCTURE OF THE BRAF (R509H) KINASE DOMAIN MONOMER BOUND TO VEMURAFENIB
3872, d4rmzB_, 0.6771, 3.17, 0.220, 282, 245, CRYSTAL STRUCTURE OF IRAK-4
3873, d4lggA_, 0.6771, 2.85, 0.280, 241, 239, STRUCTURE OF 3MB-PP1 BOUND TO ANALOG-SENSITIVE SRC KINASE
3874, d4d1xA_, 0.6771, 2.91, 0.184, 274, 239, CDK2 IN COMPLEX WITH LUCIFERIN
3875, d3uolB_, 0.6771, 3.30, 0.186, 263, 247, AURORA A IN COMPLEX WITH SO2-162
3876, d3uolA_, 0.6771, 3.30, 0.186, 263, 247, AURORA A IN COMPLEX WITH SO2-162
3877, d3umxA_, 0.6771, 3.11, 0.167, 261, 246, CRYSTAL STRUCTURE OF PIM1 KINASE IN COMPLEX WITH INHIBITOR (Z)-2-[(1H- INDOL-3-YL)METHYLENE]-7-(AZEPAN-1-YLMETHYL)-6-HYDROXYBENZOFURAN- 3(2H)-ONE
3878, d3g33C_, 0.6771, 3.05, 0.185, 291, 243, CRYSTAL STRUCTURE OF CDK4/CYCLIN D3
3879, d3a2cJ_, 0.6771, 3.02, 0.153, 275, 242, CRYSTAL STRUCTURE OF A PYRAZOLOPYRIMIDINE INHIBITOR COMPLEX BOUND TO MAPKAP KINASE-2 (MK2)
3880, d4usfB1, 0.6769, 3.68, 0.188, 283, 255, HUMAN SLK WITH SB-440719
3881, d4o0uA_, 0.6769, 3.28, 0.180, 259, 250, CRYSTAL STRUCTURES OF HUMAN KINASE AURORA A
3882, d3unzB_, 0.6769, 3.21, 0.187, 263, 246, AURORA A IN COMPLEX WITH RPM1679
3883, d3unzA_, 0.6769, 3.21, 0.187, 263, 246, AURORA A IN COMPLEX WITH RPM1679
3884, d5mqvD_, 0.6768, 3.81, 0.146, 287, 260, CRYSTAL STRUCTURE OF HUMAN CASEIN KINASE I DELTA IN COMPLEX WITH 4-(2 5-DIMETHOXYPHENYL)-N-(4-(5-(4-FLUORPHENYL)-2-(METHYLTHIO)-1H- IMIDAZOL-4-YL)-PYRIDIN-2-YL)-1-METHYL-1H-PYRROLE-2-CARBOXAMIDE
3885, d5hx6B_, 0.6768, 3.31, 0.217, 264, 244, CRYSTAL STRUCTURE OF RIP1 KINASE WITH A BENZO[B][14]OXAZEPIN-4-ONE
3886, d4bckC1, 0.6768, 3.53, 0.165, 291, 254, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
3887, d3cs9C_, 0.6768, 2.75, 0.343, 243, 239, HUMAN ABL KINASE IN COMPLEX WITH NILOTINIB
3888, d2yexA_, 0.6768, 3.45, 0.175, 269, 252, SYNTHESIS AND EVALUATION OF TRIAZOLONES AS CHECKPOINT KINASE 1 INHIBITORS
3889, d2pk9A_, 0.6768, 3.28, 0.148, 287, 250, STRUCTURE OF THE PHO85-PHO80 CDK-CYCLIN COMPLEX OF THE PHOSPHATE-RESPONSIVE SIGNAL TRANSDUCTION PATHWAY
3890, d2a19B1, 0.6768, 3.08, 0.169, 261, 243, PKR KINASE DOMAIN- EIF2ALPHA- AMP-PNP COMPLEX.
3891, d4jjrA_, 0.6767, 3.77, 0.147, 284, 258, A P21 CRYSTAL FORM OF MAMMALIAN CASEIN KINASE 1 DELTA
3892, d3o23A_, 0.6767, 3.47, 0.311, 293, 251, HUMAN UNPHOSPHORYLATED IGF1-R KINASE DOMAIN IN COMPLEX WITH AN HYDANTOIN INHIBITOR
3893, d4qp6B_, 0.6766, 3.44, 0.166, 334, 253, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH 5H-PYRROLO[23-B]PYRAZINE
3894, d3wf7A_, 0.6766, 3.58, 0.177, 288, 254, CRYSTAL STRUCTURE OF S6K1 KINASE DOMAIN IN COMPLEX WITH A PURINE DERIVATIVE 1-(9H-PURIN-6-YL)-N-[3-(TRIFLUOROMETHYL)PHENYL]PIPERIDINE- 4-CARBOXAMIDE
3895, d3a2cL_, 0.6766, 3.02, 0.153, 276, 242, CRYSTAL STRUCTURE OF A PYRAZOLOPYRIMIDINE INHIBITOR COMPLEX BOUND TO MAPKAP KINASE-2 (MK2)
3896, d2yerA_, 0.6766, 3.45, 0.159, 268, 251, SYNTHESIS AND EVALUATION OF TRIAZOLONES AS CHECKPOINT KINASE 1 INHIBITORS
3897, d1v0oA_, 0.6766, 3.07, 0.156, 276, 243, STRUCTURE OF P. FALCIPARUM PFPK5-INDIRUBIN-5-SULPHONATE LIGAND COMPLEX
3898, p4e3cC1, 0.6765, 3.30, 0.168, 290, 250, X-RAY CRYSTAL STRUCTURE OF HUMAN IKK2 IN AN ACTIVE CONFORMATION
3899, d3o0gA_, 0.6765, 3.59, 0.145, 289, 256, CRYSTAL STRUCTURE OF CDK5:P25 IN COMPLEX WITH AN ATP ANALOGUE
3900, d3ma6B_, 0.6765, 3.17, 0.202, 266, 248, CRYSTAL STRUCTURE OF KINASE DOMAIN OF TGCDPK1 IN PRESENCE OF 3BRB-PP1
3901, d3g33A_, 0.6765, 3.18, 0.176, 291, 244, CRYSTAL STRUCTURE OF CDK4/CYCLIN D3
3902, d4p90A_, 0.6764, 3.33, 0.201, 272, 249, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN PAK1 IN COMPLEX WITH COMPOUND 15
3903, d4jg6A_, 0.6764, 2.90, 0.192, 302, 240, RSK2 CTD BOUND TO 2-CYANO-3-(1H-INDAZOL-5-YL)ACRYLAMIDE
3904, d4bhnB_, 0.6764, 2.88, 0.215, 257, 242, CRYSTAL STRUCTURES OF ASK1-INHIBITOR COMPLEXES
3905, d5oq7A_, 0.6763, 3.16, 0.159, 259, 245, STRUCTURE OF CHK1 8-PT. MUTANT COMPLEX WITH ARYLBENZAMIDE LRRK2 INHIBITOR
3906, d5flfE_, 0.6763, 3.37, 0.328, 258, 247, DISEASE LINKED MUTATION IN FGFR
3907, d4kbcB_, 0.6763, 3.59, 0.145, 277, 256, CK1D IN COMPLEX WITH {4-[3-(4-FLUOROPHENYL)-1H-PYRAZOL-4-YL]PYRIDIN-2- YL}METHANOL INHIBITOR
3908, d3r2bA_, 0.6763, 2.81, 0.151, 272, 239, MK2 KINASE BOUND TO COMPOUND 5B
3909, d1gijA_, 0.6762, 2.84, 0.188, 273, 239, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE CDK4 INHIBITOR
3910, d1aq1A_, 0.6762, 2.97, 0.162, 277, 241, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR STAUROSPORINE
3911, d5k7gA_, 0.6761, 2.89, 0.222, 277, 239, IRAK4 IN COMPLEX WITH AZ3862
3912, d4hgtA_, 0.6761, 3.75, 0.148, 283, 257, CRYSTAL STRUCTURE OF CK1D WITH COMPOUND 13
3913, d3gc0A_, 0.6761, 3.03, 0.174, 278, 242, STRUCTURE OF THE CMGC CDK KINASE FROM GIARDIA LAMBLIA IN COMPLEX WITH AMP
3914, d4qp2B_, 0.6760, 3.45, 0.166, 329, 253, CRYSTAL STRUCTURE OF ERKS IN COMPLEX WITH 5-CHLOROBENZO[D]OXAZOL-2- AMINE
3915, p4h3pA_, 0.6760, 3.33, 0.159, 342, 251, CRYSTAL STRUCTURE OF HUMAN ERK2 COMPLEXED WITH A MAPK DOCKING PEPTIDE
3916, d4aaaA1, 0.6759, 3.18, 0.196, 290, 245, CRYSTAL STRUCTURE OF THE HUMAN CDKL2 KINASE DOMAIN
3917, d3dfaA1, 0.6758, 3.41, 0.193, 262, 249, CRYSTAL STRUCTURE OF KINASE DOMAIN OF CALCIUM-DEPENDENT PROTEIN KINASE CGD3_920 FROM CRYPTOSPORIDIUM PARVUM
3918, d1urwA_, 0.6758, 2.94, 0.196, 274, 240, CDK2 IN COMPLEX WITH AN IMIDAZO[12-B]PYRIDAZINE
3919, d4lg4A_, 0.6757, 3.80, 0.219, 289, 260, STRUCTURAL BASIS FOR AUTOACTIVATION OF HUMAN MST2 KINASE AND ITS REGULATION BY RASSF5
3920, d3r2bJ_, 0.6757, 2.82, 0.151, 272, 239, MK2 KINASE BOUND TO COMPOUND 5B
3921, d3r2bB_, 0.6757, 2.81, 0.151, 272, 239, MK2 KINASE BOUND TO COMPOUND 5B
3922, d3r2bG_, 0.6756, 2.82, 0.151, 272, 239, MK2 KINASE BOUND TO COMPOUND 5B
3923, d5bvoA_, 0.6755, 3.28, 0.310, 276, 248, FRAGMENT-BASED DISCOVERY OF POTENT AND SELECTIVE DDR1/2 INHIBITORS
3924, d4u42B_, 0.6755, 3.13, 0.169, 265, 243, MAP4K4 T181E MUTANT BOUND TO INHIBITOR COMPOUND 1
3925, d4ynzB1, 0.6754, 3.23, 0.202, 316, 248, STRUCTURE OF THE N-TERMINAL DOMAIN OF SAD
3926, d4qyyA_, 0.6754, 3.61, 0.165, 337, 255, DISCOVERY OF NOVEL DUAL MECHANISM ERK INHIBITORS BY AFFINITY SELECTION SCREENING OF AN INACTIVE KINASE STATE
3927, d4qpaA_, 0.6754, 3.43, 0.166, 331, 253, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH 7-(1-BENZYL-1H-PYRAZOL-4- YL)-2-(PYRIDIN-4-YL)-5H-PYRROLO[23-B]PYRAZINE
3928, d3uojB_, 0.6754, 3.22, 0.187, 263, 246, AURORA A IN COMPLEX WITH RPM1715
3929, d3uojA_, 0.6754, 3.22, 0.187, 263, 246, AURORA A IN COMPLEX WITH RPM1715
3930, d5l8kA_, 0.6753, 3.55, 0.180, 266, 255, AURORA-A KINASE DOMAIN IN COMPLEX WITH VNAR-D01 (CRYSTAL FORM 2)
3931, d4d4rB_, 0.6753, 3.73, 0.337, 270, 252, FOCAL ADHESION KINASE CATALYTIC DOMAIN
3932, d3bqrA1, 0.6753, 3.18, 0.189, 273, 244, CRYSTAL STRUCTURE OF HUMAN DEATH ASSOCIATED PROTEIN KINASE 3 (DAPK3) IN COMPLEX WITH AN IMIDAZO-PYRIDAZINE LIGAND
3933, d3a2cE_, 0.6753, 3.05, 0.153, 276, 242, CRYSTAL STRUCTURE OF A PYRAZOLOPYRIMIDINE INHIBITOR COMPLEX BOUND TO MAPKAP KINASE-2 (MK2)
3934, d2vu3A_, 0.6753, 2.97, 0.175, 285, 240, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
3935, d5ajqB_, 0.6752, 3.19, 0.180, 267, 245, HUMAN LOK (STK10) IN COMPLEX WITH BOSUTINIB
3936, d4fg8A_, 0.6752, 2.83, 0.201, 263, 239, CRYSTAL STRUCTURE OF HUMAN CALCIUM/CALMODULIN-DEPENDENT PROTEIN KINASE I 1-315 IN COMPLEX WITH ATP
3937, p3nieB_, 0.6752, 3.42, 0.195, 367, 251, CRYSTAL STRUCTURE OF PF11_0147
3938, d5fqdF_, 0.6751, 4.08, 0.151, 294, 265, STRUCTURAL BASIS OF LENALIDOMIDE INDUCED CK1A DEGRADATION BY THE CRL4CRBN UBIQUITIN LIGASE
3939, d1r78A_, 0.6751, 2.85, 0.163, 273, 239, CDK2 COMPLEX WITH A 4-ALKYNYL OXINDOLE INHIBITOR
3940, d5x17A_, 0.6750, 3.91, 0.141, 290, 262, CRYSTAL STRUCTURE OF MURINE CK1D IN COMPLEX WITH ADP
3941, d3zfyB_, 0.6750, 3.17, 0.313, 255, 243, CRYSTAL STRUCTURE OF EPHB3
3942, d3nizA1, 0.6750, 3.24, 0.169, 284, 249, CRYPTOSPORIDIUM PARVUM CYCLIN-DEPENDENT KINASE CGD5_2510 WITH ADP BOUND.
3943, d5fqdC_, 0.6749, 4.08, 0.151, 294, 265, STRUCTURAL BASIS OF LENALIDOMIDE INDUCED CK1A DEGRADATION BY THE CRL4CRBN UBIQUITIN LIGASE
3944, d6brcB_, 0.6748, 3.34, 0.189, 260, 249, CRYSTAL STRUCTURE OF THE HUMAN CAMKK2B IN COMPLEX WITH AP26113-ANALOG (ALK-IN-1)
3945, d3wf9A_, 0.6748, 3.60, 0.180, 287, 255, CRYSTAL STRUCTURE OF S6K1 KINASE DOMAIN IN COMPLEX WITH A QUINOLINE DERIVATIVE 1-OXO-1-[(4-SULFAMOYLPHENYL)AMINO]PROPAN-2-YL-2-METHYL-1 234-TETRAHYDROACRIDINE-9-CARBOXYLATE
3946, d3r2bL_, 0.6748, 2.85, 0.151, 272, 239, MK2 KINASE BOUND TO COMPOUND 5B
3947, d3r2bI_, 0.6748, 2.84, 0.151, 272, 239, MK2 KINASE BOUND TO COMPOUND 5B
3948, d3r2bF_, 0.6748, 2.84, 0.151, 272, 239, MK2 KINASE BOUND TO COMPOUND 5B
3949, d3oriB_, 0.6748, 3.29, 0.145, 267, 249, MYCOBACTERIUM TUBERCULOSIS PKNB KINASE DOMAIN L33D MUTANT (CRYSTAL FORM 1)
3950, d5we8B_, 0.6747, 3.33, 0.205, 272, 244, CRYSTAL STRUCTURE OF WNK1 IN COMPLEX WITH N-{(3R)-1-[(4-CHLOROPHENYL) METHYL]PYRROLIDIN-3-YL}-2-(3-METHOXYPHENYL)-N-METHYLQUINOLINE-4- CARBOXAMIDE (COMPOUND 8)
3951, d5nguA_, 0.6747, 3.46, 0.162, 339, 253, HUMAN ERK2 WITH AN ERK1/2 INHIBITOR
3952, d3a2cC_, 0.6747, 3.08, 0.153, 273, 242, CRYSTAL STRUCTURE OF A PYRAZOLOPYRIMIDINE INHIBITOR COMPLEX BOUND TO MAPKAP KINASE-2 (MK2)
3953, d2e9oA_, 0.6747, 3.48, 0.151, 269, 251, STRUCTURE OF H-CHK1 COMPLEXED WITH AA582939
3954, d4xj0A_, 0.6746, 3.52, 0.165, 345, 254, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH AN INHIBITOR 14K
3955, d3r2bK_, 0.6746, 2.83, 0.151, 272, 239, MK2 KINASE BOUND TO COMPOUND 5B
3956, d3r2bH_, 0.6746, 2.84, 0.151, 272, 239, MK2 KINASE BOUND TO COMPOUND 5B
3957, d3r2bC_, 0.6746, 2.84, 0.151, 272, 239, MK2 KINASE BOUND TO COMPOUND 5B
3958, d3ezrA_, 0.6746, 2.81, 0.168, 273, 238, CDK-2 WITH INDAZOLE INHIBITOR 17 BOUND AT ITS ACTIVE SITE
3959, d3dxnA_, 0.6746, 3.34, 0.210, 258, 248, CRYSTAL STRUCTURE OF THE CALCIUM-DEPENDENT KINASE FROM TOXOPLASMA GONDII 541.M00134 KINASE DOMAIN.
3960, d2csnA_, 0.6746, 3.96, 0.141, 293, 263, BINARY COMPLEX OF CASEIN KINASE-1 WITH CKI7
3961, d4feqA_, 0.6745, 1.96, 0.381, 224, 223, INHIBITOR BOUND STRUCTURE OF THE KINASE DOMAIN OF THE MURINE RECEPTOR TYROSINE KINASE TYRO3 (SKY)
3962, d3wf8A_, 0.6745, 3.65, 0.180, 287, 256, CRYSTAL STRUCTURE OF S6K1 KINASE DOMAIN IN COMPLEX WITH A QUINOLINE DERIVATIVE 2-OXO-2-[(4-SULFAMOYLPHENYL)AMINO]ETHYL 78910- TETRAHYDRO-6H-CYCLOHEPTA[B]QUINOLINE-11-CARBOXYLATE
3963, d3r2bD_, 0.6745, 2.84, 0.151, 272, 239, MK2 KINASE BOUND TO COMPOUND 5B
3964, d1q99A_, 0.6745, 3.46, 0.146, 354, 253, CRYSTAL STRUCTURE OF THE SACCHAROMYCES CEREVISIAE SR PROTEIN KINSAE SKY1P COMPLEXED WITH THE NON-HYDROLYZABLE ATP ANALOGUE AMP-PNP
3965, d1omwA3, 0.6745, 3.96, 0.170, 344, 264, CRYSTAL STRUCTURE OF THE COMPLEX BETWEEN G PROTEIN-COUPLED RECEPTOR KINASE 2 AND HETEROTRIMERIC G PROTEIN BETA 1 AND GAMMA 2 SUBUNITS
3966, d1oitA_, 0.6745, 2.90, 0.188, 273, 239, IMIDAZOPYRIDINES: A POTENT AND SELECTIVE CLASS OF CYCLIN-DEPENDENT KINASE INHIBITORS IDENTIFIED THROUGH STRUCTURE-BASED HYBRIDISATION
3967, d3a2cD_, 0.6744, 3.18, 0.156, 277, 244, CRYSTAL STRUCTURE OF A PYRAZOLOPYRIMIDINE INHIBITOR COMPLEX BOUND TO MAPKAP KINASE-2 (MK2)
3968, d3r2bE_, 0.6743, 2.85, 0.151, 272, 239, MK2 KINASE BOUND TO COMPOUND 5B
3969, d3pizA_, 0.6742, 2.94, 0.311, 245, 241, CRYSTAL STRUCTURE OF BTK KINASE DOMAIN COMPLEXED WITH (5-AMINO-1-O- TOLYL-1H-PYRAZOL-4-YL)-[3-(1-METHANESULFONYL-PIPERIDIN-4-YL)-PHENYL]- METHANONE
3970, d2in6A_, 0.6742, 3.07, 0.167, 256, 245, WEE1 KINASE COMPLEX WITH INHIBITOR PD311839
3971, d1i44A_, 0.6742, 3.41, 0.307, 282, 251, CRYSTALLOGRAPHIC STUDIES OF AN ACTIVATION LOOP MUTANT OF THE INSULIN RECEPTOR TYROSINE KINASE
3972, d3eidC_, 0.6741, 3.53, 0.141, 290, 255, CDK2/CYCLINA COMPLEXED WITH A PYRAZOLOPYRIDAZINE INHIBITOR
3973, d1q8zB_, 0.6741, 3.58, 0.153, 364, 255, THE APOENZYME STRUCTURE OF THE YEAST SR PROTEIN KINASE SKY1P
3974, d1cm8B_, 0.6741, 3.34, 0.194, 327, 248, PHOSPHORYLATED MAP KINASE P38-GAMMA
3975, d3sv0A_, 0.6740, 3.99, 0.144, 294, 263, CRYSTAL STRUCTURE OF CASEIN KINASE-1 LIKE PROTEIN IN PLANT
3976, d2w1gA1, 0.6740, 3.20, 0.186, 254, 247, STRUCTURE DETERMINATION OF AURORA KINASE IN COMPLEX WITH INHIBITOR
3977, d1cm8A_, 0.6740, 3.34, 0.194, 327, 248, PHOSPHORYLATED MAP KINASE P38-GAMMA
3978, d2fumC_, 0.6739, 2.86, 0.150, 254, 240, CATALYTIC DOMAIN OF PROTEIN KINASE PKNB FROM MYCOBACTERIUM TUBERCULOSIS IN COMPLEX WITH MITOXANTRONE
3979, d5we8A_, 0.6738, 3.48, 0.203, 270, 246, CRYSTAL STRUCTURE OF WNK1 IN COMPLEX WITH N-{(3R)-1-[(4-CHLOROPHENYL) METHYL]PYRROLIDIN-3-YL}-2-(3-METHOXYPHENYL)-N-METHYLQUINOLINE-4- CARBOXAMIDE (COMPOUND 8)
3980, d5mrbA1, 0.6738, 3.23, 0.170, 259, 247, CRYSTAL STRUCTURE OF HUMAN MPS1 (TTK) IN COMPLEX WITH CPD-5
3981, d5andA_, 0.6738, 2.98, 0.192, 273, 239, CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH 2-IMIDAZOL-1-YL-1H- BENZIMIDAZOLE PROCESSED WITH THE CRYSTALDIRECT AUTOMATED MOUNTING AND CRYO-COOLING TECHNOLOGY
3982, d3en7B_, 0.6738, 2.69, 0.277, 237, 235, TARGETED POLYPHARMACOLOGY: CRYSTAL STRUCTURE OF THE C-SRC KINASE DOMAIN IN COMPLEX WITH S1 A MULTITARGETED KINASE INHIBITOR
3983, d2jd5A_, 0.6738, 3.42, 0.151, 353, 252, SKY1P BOUND TO NPL3P-DERIVED SUBSTRATE PEPTIDE
3984, d1q8zA_, 0.6737, 3.46, 0.150, 354, 253, THE APOENZYME STRUCTURE OF THE YEAST SR PROTEIN KINASE SKY1P
3985, d5tx5B_, 0.6736, 3.35, 0.218, 263, 243, RIP1 KINASE ( FLAG 1-294 C34A C127A C233A C240A) WITH GSK772
3986, d3oriA_, 0.6736, 3.31, 0.145, 267, 249, MYCOBACTERIUM TUBERCULOSIS PKNB KINASE DOMAIN L33D MUTANT (CRYSTAL FORM 1)
3987, d1h4lA_, 0.6736, 3.18, 0.142, 278, 246, STRUCTURE AND REGULATION OF THE CDK5-P25(NCK5A) COMPLEX
3988, d5tkdA_, 0.6735, 2.66, 0.203, 248, 237, CRYSTAL STRUCTURE OF TYROSINE KINASE 2 JH2 (PSEUDO KINASE DOMAIN) COMPLEXED WITH 6-[(35-DIMETHYLPHE NYL)AMINO]-8- (METHYLAMINO) IMIDAZO[12-B]PYRIDAZINE-3-CARBO XAMIDE
3989, d5kbqB_, 0.6735, 3.59, 0.163, 273, 251, PAK1 IN COMPLEX WITH BIS-ANILINO PYRIMIDINE INHIBITOR
3990, p4e3cF1, 0.6735, 3.39, 0.171, 290, 251, X-RAY CRYSTAL STRUCTURE OF HUMAN IKK2 IN AN ACTIVE CONFORMATION
3991, d3a2cH_, 0.6735, 3.11, 0.152, 275, 243, CRYSTAL STRUCTURE OF A PYRAZOLOPYRIMIDINE INHIBITOR COMPLEX BOUND TO MAPKAP KINASE-2 (MK2)
3992, d4zjiD_, 0.6734, 3.61, 0.187, 280, 256, PAK1 IN COMPLEX WITH 2-CHLORO-5-ETHYL-8-FLUORO-11-(4-METHYLPIPERAZIN- 1-YL)-DIBENZODIAZEPINE
3993, d4ae6B_, 0.6734, 4.13, 0.160, 321, 263, STRUCTURE AND FUNCTION OF THE HUMAN SPERM-SPECIFIC ISOFORM OF PROTEIN KINASE A (PKA) CATALYTIC SUBUNIT CALPHA 2
3994, d3uytA_, 0.6734, 3.90, 0.142, 287, 261, CRYSTAL STRUCTURE OF CK1D WITH PF670462 FROM P1 CRYSTAL FORM
3995, d2w1fA1, 0.6734, 3.16, 0.187, 253, 246, STRUCTURE DETERMINATION OF AURORA KINASE IN COMPLEX WITH INHIBITOR
3996, p5nzzE_, 0.6733, 3.44, 0.184, 343, 250, CRYSTAL STRUCTURE OF PHOSPHORYLATED P38AMAPK IN COMPLEX WITH TAB1 
3997, d4bieB_, 0.6733, 2.94, 0.219, 257, 242, CRYSTAL STRUCTURES OF ASK1-INHIBITOR COMPLEXES
3998, d3gbzA_, 0.6733, 2.87, 0.172, 274, 239, STRUCTURE OF THE CMGC CDK KINASE FROM GIARDIA LAMBLIA
3999, d2fvdA_, 0.6733, 3.06, 0.179, 284, 240, CYCLIN DEPENDENT KINASE 2 (CDK2) WITH DIAMINOPYRIMIDINE INHIBITOR
4000, d5k75C_, 0.6732, 3.21, 0.216, 282, 245, IRAK4 IN COMPLEX WITH COMPOUND 1
4001, d4tn6A_, 0.6732, 4.11, 0.143, 292, 265, CK1D IN COMPLEX WITH INHIBITOR
4002, d4hyhA_, 0.6732, 3.28, 0.158, 263, 247, X-RAY CRYSTAL STRUCTURE OF COMPOUND 39 BOUND TO HUMAN CHK1 KINASE DOMAIN
4003, d2e9uA_, 0.6732, 3.51, 0.151, 269, 251, STRUCTURE OF H-CHK1 COMPLEXED WITH A780125
4004, d5ihcA_, 0.6731, 3.06, 0.177, 305, 243, MELK IN COMPLEX WITH NVS-MELK12B
4005, d3etaA_, 0.6731, 3.37, 0.306, 293, 248, KINASE DOMAIN OF INSULIN RECEPTOR COMPLEXED WITH A PYRROLO PYRIDINE INHIBITOR
4006, d3a2cG_, 0.6731, 3.04, 0.158, 273, 241, CRYSTAL STRUCTURE OF A PYRAZOLOPYRIMIDINE INHIBITOR COMPLEX BOUND TO MAPKAP KINASE-2 (MK2)
4007, d2ywpA_, 0.6731, 3.54, 0.151, 269, 252, CRYSTAL STRUCTURE OF CHK1 WITH A UREA INHIBITOR
4008, d2jd5B_, 0.6731, 3.68, 0.152, 360, 256, SKY1P BOUND TO NPL3P-DERIVED SUBSTRATE PEPTIDE
4009, d1unhA_, 0.6730, 3.12, 0.143, 276, 244, STRUCTURAL MECHANISM FOR THE INHIBITION OF CDK5-P25 BY ROSCOVITINE ALOISINE AND INDIRUBIN.
4010, d1di9A_, 0.6730, 3.55, 0.191, 348, 251, THE STRUCTURE OF P38 MITOGEN-ACTIVATED PROTEIN KINASE IN COMPLEX WITH 4-[3-METHYLSULFANYLANILINO]-67- DIMETHOXYQUINAZOLINE
4011, d5t1tB_, 0.6729, 3.10, 0.220, 280, 241, IRAK4 KINASE - COMPOUND 1 CO-STRUCTURE
4012, d5jzjB_, 0.6729, 3.16, 0.178, 261, 247, CRYSTAL STRUCTURE OF DCLK1-KD IN COMPLEX WITH AMPPN
4013, d3kc3D_, 0.6729, 2.94, 0.154, 269, 241, MK2 COMPLEXED TO INHIBITOR N4-(7-(BENZOFURAN-2-YL)-1H-INDAZOL-5-YL) PYRIMIDINE-24-DIAMINE
4014, d2vttA_, 0.6729, 2.82, 0.190, 272, 237, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
4015, d5k4iA_, 0.6728, 3.07, 0.164, 336, 244, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH COMPOUND 22
4016, p4ux9A_, 0.6728, 3.21, 0.186, 343, 247, CRYSTAL STRUCTURE OF JNK1 BOUND TO A MKK7 DOCKING MOTIF
4017, d3ma6A_, 0.6728, 3.53, 0.186, 267, 253, CRYSTAL STRUCTURE OF KINASE DOMAIN OF TGCDPK1 IN PRESENCE OF 3BRB-PP1
4018, d5nttA1, 0.6727, 3.53, 0.167, 268, 252, CRYSTAL STRUCTURE OF HUMAN MPS1 (TTK) C604Y MUTANT IN COMPLEX WITH NMS-P715
4019, d5eakA_, 0.6727, 3.29, 0.197, 305, 249, OPTIMIZATION OF MICROTUBULE AFFINITY REGULATING KINASE (MARK) INHIBITORS WITH IMPROVED PHYSICAL PROPERTIES
4020, d4hniB_, 0.6727, 3.56, 0.154, 284, 253, CRYSTAL STRUCTURE OF CK1E IN COMPLEX WITH PF4800567
4021, d4usfA1, 0.6726, 3.66, 0.186, 275, 253, HUMAN SLK WITH SB-440719
4022, d4fuxA_, 0.6726, 3.56, 0.166, 342, 253, CRYSTAL STRUCTURE OF THE ERK2 COMPLEXED WITH E75
4023, d2aypA_, 0.6726, 3.39, 0.169, 268, 249, CRYSTAL STRUCTURE OF CHK1 WITH AN INDOL INHIBITOR
4024, d1q97B_, 0.6726, 3.65, 0.157, 361, 255, THE STRUCTURE OF THE SACCHAROMYCES CEREVISIAE SR PROTEIN KINASE SKY1P WITH BOUND ATP
4025, d2fgaA_, 0.6725, 3.46, 0.151, 269, 251,  
4026, d2cmwA_, 0.6725, 4.16, 0.127, 294, 267, STRUCTURE OF HUMAN CASEIN KINASE 1 GAMMA-1 IN COMPLEX WITH 2-(2-HYDROXYETHYLAMINO)-6-(3-CHLOROANILINO)-9- ISOPROPYLPURINE (CASP TARGET)
4027, d1p14A_, 0.6725, 3.22, 0.291, 287, 247, CRYSTAL STRUCTURE OF A CATALYTIC-LOOP MUTANT OF THE INSULIN RECEPTOR TYROSINE KINASE
4028, d6bu6D_, 0.6724, 4.01, 0.144, 318, 264, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A BIS- DIFLUOROPHENOL-AMINOPYRIDINE INHIBITOR
4029, d2wzjD_, 0.6724, 3.47, 0.193, 313, 249, CATALYTIC AND UBA DOMAIN OF KINASE MARK2/(PAR-1) K82R T208E DOUBLE MUTANT
4030, d2fysB_, 0.6724, 3.27, 0.177, 338, 249, CRYSTAL STRUCTURE OF ERK2 COMPLEX WITH KIM PEPTIDE DERIVED FROM MKP3
4031, d6eimB_, 0.6723, 3.52, 0.167, 295, 251, HUMAN STK10 BOUND TO GW683134A
4032, d5w4wD_, 0.6722, 3.85, 0.143, 287, 259, IDENTIFICATION AND PROFILING OF A SELECTIVE AND BRAIN PENETRANT RADIOLIGAND FOR IN VIVO TARGET OCCUPANCY MEASUREMENT OF CASEIN KINASE 1 (CK1) INHIBITORS
4033, d5k75B_, 0.6722, 3.21, 0.217, 274, 244, IRAK4 IN COMPLEX WITH COMPOUND 1
4034, d5ih8A_, 0.6722, 3.16, 0.189, 306, 244, MELK IN COMPLEX WITH NVS-MELK1
4035, d4kaoA_, 0.6722, 3.43, 0.341, 252, 246, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH 1-(5-TERT- BUTYL-2-P-TOLYL-2H-PYRAZOL-3-YL)-3-(4-PYRIDIN-3- YL-PHENYL)-UREA
4036, d3h0yA_, 0.6722, 3.09, 0.189, 250, 244, AURORA A IN COMPLEX WITH A BISANILINOPYRIMIDINE
4037, d3en5A_, 0.6722, 2.76, 0.284, 238, 236, TARGETED POLYPHARMACOLOGY: CRYSTAL STRUCTURE OF THE C-SRC KINASE DOMAIN IN COMPLEX WITH PP494 A MULTITARGETED KINASE INHIBITOR
4038, d2hwpB_, 0.6722, 2.79, 0.292, 239, 236, CRYSTAL STRUCTURE OF SRC KINASE DOMAIN IN COMPLEX WITH COVALENT INHIBITOR PD168393
4039, d1w82A_, 0.6722, 3.57, 0.183, 351, 251, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH SMALL MOLECULE INHIBITOR
4040, d1m7nB_, 0.6722, 3.44, 0.309, 299, 249, CRYSTAL STRUCTURE OF UNACTIVATED APO INSULIN-LIKE GROWTH FACTOR-1 RECEPTOR KINASE DOMAIN
4041, d4kbkC_, 0.6721, 3.90, 0.150, 280, 260, CK1D IN COMPLEX WITH (3S)-3-{4-[3-(4-FLUOROPHENYL)-1-METHYL-1H- PYRAZOL-4-YL]PYRIDIN-2-YL}MORPHOLINE INHIBITOR
4042, d4c2wB_, 0.6721, 3.80, 0.156, 277, 257, CRYSTAL STRUCTURE OF AURORA B IN COMPLEX WITH AMP-PNP
4043, d3uytB_, 0.6721, 3.91, 0.150, 286, 260, CRYSTAL STRUCTURE OF CK1D WITH PF670462 FROM P1 CRYSTAL FORM
4044, d2bvaB_, 0.6721, 3.64, 0.179, 274, 251, CRYSTAL STRUCTURE OF THE HUMAN P21-ACTIVATED KINASE 4
4045, d1zy5A1, 0.6721, 3.41, 0.186, 269, 247, CRYSTAL STRUCTURE OF EIF2ALPHA PROTEIN KINASE GCN2: R794G HYPERACTIVATING MUTANT COMPLEXED WITH AMPPNP.
4046, d1p2aA_, 0.6721, 2.82, 0.190, 271, 237, THE STRUCTURE OF CYCLIN DEPENDENT KINASE 2 (CKD2) WITH A TRISUBSTITUTED NAPHTHOSTYRIL INHIBITOR
4047, d4fv6A_, 0.6720, 2.99, 0.165, 332, 242, CRYSTAL STRUCTURE OF THE ERK2 COMPLEXED WITH E57
4048, d4c2vA_, 0.6720, 3.70, 0.152, 270, 256, AURORA B KINASE IN COMPLEX WITH THE SPECIFIC INHIBITOR BARASERTIB
4049, d2c47C_, 0.6720, 3.74, 0.140, 282, 257, STRUCTURE OF CASEIN KINASE 1 GAMMA 2
4050, d1mryA_, 0.6720, 3.06, 0.161, 270, 242, CRYSTAL STRUCTURE OF AN INACTIVE AKT2 KINASE DOMAIN
4051, d1f5qC_, 0.6719, 3.51, 0.151, 288, 252, CRYSTAL STRUCTURE OF MURINE GAMMA HERPESVIRUS CYCLIN COMPLEXED TO HUMAN CYCLIN DEPENDENT KINASE 2
4052, d5w4wA_, 0.6718, 4.02, 0.144, 291, 263, IDENTIFICATION AND PROFILING OF A SELECTIVE AND BRAIN PENETRANT RADIOLIGAND FOR IN VIVO TARGET OCCUPANCY MEASUREMENT OF CASEIN KINASE 1 (CK1) INHIBITORS
4053, d5k75D_, 0.6718, 3.19, 0.213, 280, 244, IRAK4 IN COMPLEX WITH COMPOUND 1
4054, d4c3rA_, 0.6718, 3.13, 0.180, 252, 245, STRUCTURE OF DEPHOSPHORYLATED AURORA A (122-403) BOUND TO AMPPCP
4055, d3my0X_, 0.6718, 2.89, 0.176, 257, 239, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
4056, d3kk8A_, 0.6718, 3.90, 0.155, 283, 258, CAMKII SUBSTRATE COMPLEX A
4057, d2jfmA_, 0.6718, 3.31, 0.191, 287, 246, CRYSTAL STRUCTURE OF HUMAN STE20-LIKE KINASE (UNLIGANDED FORM)
4058, d3my0K_, 0.6717, 2.95, 0.175, 261, 240, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
4059, d1m7nA_, 0.6717, 3.45, 0.309, 299, 249, CRYSTAL STRUCTURE OF UNACTIVATED APO INSULIN-LIKE GROWTH FACTOR-1 RECEPTOR KINASE DOMAIN
4060, d1h4lB_, 0.6717, 3.21, 0.142, 278, 246, STRUCTURE AND REGULATION OF THE CDK5-P25(NCK5A) COMPLEX
4061, d5ap7A1, 0.6716, 3.28, 0.166, 253, 247, NATURALLY OCCURRING MUTATIONS IN THE MPS1 GENE PREDISPOSE CELLS TO KINASE INHIBITOR DRUG RESISTANCE.
4062, d4wo5B1, 0.6716, 2.40, 0.228, 241, 232, CRYSTAL STRUCTURE OF A BRAF KINASE DOMAIN MONOMER
4063, d3w8qA_, 0.6716, 3.37, 0.188, 318, 250, STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1)
4064, d3vbwA_, 0.6716, 3.36, 0.165, 264, 248, EXPLOITATION OF HYDROGEN BONDING CONSTRAINTS AND FLAT HYDROPHOBIC ENERGY LANDSCAPES IN PIM-1 KINASE NEEDLE SCREENING AND INHIBITOR DESIGN
4065, d2z7rA_, 0.6716, 2.99, 0.186, 265, 242, CRYSTAL STRUCTURE OF THE N-TERMINAL KINASE DOMAIN OF HUMAN RSK1 BOUND TO STAUROSPORINE
4066, d2vgoB_, 0.6716, 3.77, 0.152, 277, 256, CRYSTAL STRUCTURE OF AURORA B KINASE IN COMPLEX WITH REVERSINE INHIBITOR
4067, d2e9nA_, 0.6716, 3.58, 0.147, 269, 252, STRUCTURE OF H-CHK1 COMPLEXED WITH A767085
4068, d1unhB_, 0.6716, 3.13, 0.143, 276, 244, STRUCTURAL MECHANISM FOR THE INHIBITION OF CDK5-P25 BY ROSCOVITINE ALOISINE AND INDIRUBIN.
4069, p6g9hA_, 0.6714, 3.58, 0.166, 343, 253, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
4070, d4tn6B_, 0.6714, 3.92, 0.149, 285, 261, CK1D IN COMPLEX WITH INHIBITOR
4071, d4ae9B_, 0.6714, 4.06, 0.161, 321, 261, STRUCTURE AND FUNCTION OF THE HUMAN SPERM-SPECIFIC ISOFORM OF PROTEIN KINASE A (PKA) CATALYTIC SUBUNIT C ALPHA 2
4072, d3ormA_, 0.6714, 3.41, 0.149, 266, 249, MYCOBACTERIUM TUBERCULOSIS PKNB KINASE DOMAIN D76A MUTANT
4073, d1g3nE_, 0.6714, 2.90, 0.158, 293, 241, STRUCTURE OF A P18(INK4C)-CDK6-K-CYCLIN TERNARY COMPLEX
4074, d2qnjB1, 0.6713, 3.46, 0.202, 321, 252, KINASE AND UBIQUITIN-ASSOCIATED DOMAINS OF MARK3/PAR-1
4075, d5fdpA_, 0.6712, 3.44, 0.291, 285, 247, STRUCTURE OF DDR1 RECEPTOR TYROSINE KINASE IN COMPLEX WITH D2099 INHIBITOR AT 2.25 ANGSTROMS RESOLUTION.
4076, d3i60A_, 0.6712, 3.05, 0.165, 335, 243, CRYSTAL STRUCTURE OF ERK2 BOUND TO (S)-4-(2-(2-CHLOROPHENYLAMINO)-5- METHYLPYRIMIDIN-4-YL)-N-(2-HYDROXY-1-PHENYLETHYL)-1H-PYRROLE-2- CARBOXAMIDE
4077, d3ekkA_, 0.6712, 3.30, 0.290, 285, 248, INSULIN RECEPTOR KINASE COMPLEXED WITH AN INHIBITOR
4078, d2oibB_, 0.6712, 3.24, 0.213, 278, 244, CRYSTAL STRUCTURE OF IRAK4 KINASE DOMAIN APO FORM
4079, d5w4wB_, 0.6711, 4.03, 0.144, 291, 263, IDENTIFICATION AND PROFILING OF A SELECTIVE AND BRAIN PENETRANT RADIOLIGAND FOR IN VIVO TARGET OCCUPANCY MEASUREMENT OF CASEIN KINASE 1 (CK1) INHIBITORS
4080, d4c2vB_, 0.6711, 3.78, 0.156, 280, 256, AURORA B KINASE IN COMPLEX WITH THE SPECIFIC INHIBITOR BARASERTIB
4081, d3tl8G_, 0.6711, 3.44, 0.189, 301, 249, THE AVRPTOB-BAK1 COMPLEX REVEALS TWO STRUCTURALLY SIMILAR KINASEINTERACTING DOMAINS IN A SINGLE TYPE III EFFECTOR
4082, d3erkA_, 0.6711, 3.60, 0.166, 350, 253, THE COMPLEX STRUCTURE OF THE MAP KINASE ERK2/SB220025
4083, d3comB_, 0.6711, 3.87, 0.208, 279, 260, CRYSTAL STRUCTURE OF MST1 KINASE
4084, d2f9gA_, 0.6711, 3.14, 0.159, 332, 245, CRYSTAL STRUCTURE OF FUS3 PHOSPHORYLATED ON TYR182
4085, d4aguB_, 0.6710, 2.99, 0.190, 276, 242, CRYSTAL STRUCTURE OF THE HUMAN CDKL1 KINASE DOMAIN
4086, d2cjmA_, 0.6710, 3.45, 0.151, 285, 251, MECHANISM OF CDK INHIBITION BY ACTIVE SITE PHOSPHORYLATION: CDK2 Y15P T160P IN COMPLEX WITH CYCLIN A STRUCTURE
4087, d1wbsA_, 0.6710, 3.67, 0.187, 351, 252, IDENTIFICATION OF NOVEL P38 ALPHA MAP KINASE INHIBITORS USING FRAGMENT-BASED LEAD GENERATION.
4088, d4tthB_, 0.6709, 2.98, 0.162, 256, 241, CRYSTAL STRUCTURE OF A CDK6/VCYCLIN COMPLEX WITH INHIBITOR BOUND
4089, d4b8mB_, 0.6709, 3.79, 0.156, 279, 256, AURORA B KINASE IN COMPLEX WITH VX-680
4090, d3a2cA_, 0.6709, 3.08, 0.154, 274, 241, CRYSTAL STRUCTURE OF A PYRAZOLOPYRIMIDINE INHIBITOR COMPLEX BOUND TO MAPKAP KINASE-2 (MK2)
4091, d2ydiA_, 0.6709, 3.62, 0.158, 279, 253, DISCOVERY OF CHECKPOINT KINASE INHIBITOR AZD7762 BY STRUCTURE BASED DESIGN AND OPTIMIZATION OF THIOPHENE CARBOXAMIDE UREAS
4092, d2gdoA_, 0.6709, 3.44, 0.153, 269, 248, 4-(AMINOALKYLAMINO)-3-BENZIMIDAZOLE-QUINOLINONES AS POTENT CHK1 INHIBITORS
4093, d1g3nA_, 0.6709, 2.91, 0.158, 293, 241, STRUCTURE OF A P18(INK4C)-CDK6-K-CYCLIN TERNARY COMPLEX
4094, d1fotA_, 0.6709, 3.78, 0.190, 299, 258, STRUCTURE OF THE UNLIGANDED CAMP-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT FROM SACCHAROMYCES CEREVISIAE
4095, d5k72A_, 0.6708, 2.96, 0.222, 277, 239, IRAK4 IN COMPLEX WITH COMPOUND 21
4096, d5k3yB_, 0.6708, 3.84, 0.152, 277, 257, CRYSTAL STRUCTURE OF AURORAB/INCENP IN COMPLEX WITH BI 811283
4097, d3ztxA_, 0.6708, 3.83, 0.154, 269, 259, AURORA KINASE SELECTIVE INHIBITORS IDENTIFIED USING A TAXOL- INDUCED CHECKPOINT SENSITIVITY SCREEN.
4098, d2wzjB_, 0.6708, 3.38, 0.194, 310, 248, CATALYTIC AND UBA DOMAIN OF KINASE MARK2/(PAR-1) K82R T208E DOUBLE MUTANT
4099, p6g91A_, 0.6707, 3.54, 0.166, 344, 253, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
4100, d5k72C_, 0.6707, 3.09, 0.216, 277, 241, IRAK4 IN COMPLEX WITH COMPOUND 21
4101, d4qp1A_, 0.6707, 3.52, 0.166, 342, 253, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH N-CYCLOHEXYL-9H-PURIN-6- AMINE
4102, d2vgpB_, 0.6707, 3.82, 0.156, 277, 257, CRYSTAL STRUCTURE OF AURORA B KINASE IN COMPLEX WITH A AMINOTHIAZOLE INHIBITOR
4103, d1wbwA_, 0.6707, 3.78, 0.193, 351, 254, IDENTIFICATION OF NOVEL P38 ALPHA MAP KINASE INHIBITORS USING FRAGMENT-BASED LEAD GENERATION.
4104, d5uirA_, 0.6706, 3.05, 0.217, 270, 240, CRYSTAL STRUCTURE OF IRAK4 IN COMPLEX WITH COMPOUND 11
4105, d5larA_, 0.6706, 3.87, 0.179, 350, 257, CRYSTAL STRUCTURE OF P38 ALPHA MAPK14 IN COMPLEX WITH VPC00628
4106, d4aguA_, 0.6706, 3.04, 0.193, 277, 243, CRYSTAL STRUCTURE OF THE HUMAN CDKL1 KINASE DOMAIN
4107, p3n9xB_, 0.6706, 3.42, 0.187, 362, 251, CRYSTAL STRUCTURE OF MAP KINASE FROM PLASMODIUM BERGHEI PB000659.00.0
4108, d5uoxB_, 0.6705, 2.86, 0.208, 252, 240, STRUCTURE-BASED DESIGN OF ASK1 INHIBITORS AS POTENTIAL FIRST-IN-CLASS AGENTS FOR HEART FAILURE
4109, d3a2cK_, 0.6705, 3.02, 0.150, 273, 240, CRYSTAL STRUCTURE OF A PYRAZOLOPYRIMIDINE INHIBITOR COMPLEX BOUND TO MAPKAP KINASE-2 (MK2)
4110, d2j51A_, 0.6705, 3.40, 0.190, 288, 247, CRYSTAL STRUCTURE OF HUMAN STE20-LIKE KINASE BOUND TO 5- AMINO-3-((4-(AMINOSULFONYL)PHENYL)AMINO)-N-(26- DIFLUOROPHENYL)-1H-124-TRIAZOLE-1-CARBOTHIOAMIDE
4111, d2e9vA_, 0.6705, 3.37, 0.165, 268, 248, STRUCTURE OF H-CHK1 COMPLEXED WITH A859017
4112, d1wboA_, 0.6705, 3.78, 0.193, 351, 254, FRAGMENT BASED P38 INHIBITORS
4113, d6bu6A_, 0.6704, 4.00, 0.121, 322, 264, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A BIS- DIFLUOROPHENOL-AMINOPYRIDINE INHIBITOR
4114, d4ynzA1, 0.6704, 3.06, 0.205, 306, 244, STRUCTURE OF THE N-TERMINAL DOMAIN OF SAD
4115, d4xp3A_, 0.6704, 3.57, 0.166, 339, 253, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH AN INHIBITOR
4116, d4p41B_, 0.6704, 2.99, 0.162, 256, 241,  
4117, d3zfmA_, 0.6704, 3.20, 0.305, 248, 243, CRYSTAL STRUCTURE OF EPHB2
4118, d3txoA_, 0.6704, 3.70, 0.179, 317, 252, PKC ETA KINASE IN COMPLEX WITH A NAPHTHYRIDINE
4119, d2bfxA_, 0.6704, 3.82, 0.156, 269, 257, MECHANISM OF AURORA-B ACTIVATION BY INCENP AND INHIBITION BY HESPERADIN.
4120, d5kx8B_, 0.6703, 3.01, 0.209, 278, 239, IRAK4-INHIBITOR CO-STRUCTURE
4121, d4zjiC_, 0.6703, 3.51, 0.190, 281, 253, PAK1 IN COMPLEX WITH 2-CHLORO-5-ETHYL-8-FLUORO-11-(4-METHYLPIPERAZIN- 1-YL)-DIBENZODIAZEPINE
4122, d4qp8A_, 0.6703, 3.20, 0.166, 335, 247, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH 2-(1H-PYRAZOL-4-YL)-7- (PYRIDIN-3-YL)-5H-PYRROLO[23-B]PYRAZINE
4123, d3oriD_, 0.6703, 3.43, 0.161, 267, 249, MYCOBACTERIUM TUBERCULOSIS PKNB KINASE DOMAIN L33D MUTANT (CRYSTAL FORM 1)
4124, d3a2cI_, 0.6703, 3.12, 0.149, 275, 242, CRYSTAL STRUCTURE OF A PYRAZOLOPYRIMIDINE INHIBITOR COMPLEX BOUND TO MAPKAP KINASE-2 (MK2)
4125, d2duvA_, 0.6702, 2.86, 0.194, 272, 237, STRUCTURE OF CDK2 WITH A 3-HYDROXYCHROMONES
4126, d5w85A_, 0.6701, 3.17, 0.219, 278, 242, CRYSTAL STRUCTURE OF IRAK-4 WITH A 46-DIAMINONICOTINAMIDE INHIBITOR (COMPOUND NUMBER 9)
4127, d5vc4A_, 0.6701, 3.43, 0.155, 261, 251, CRYSTAL STRUCTURE OF HUMAN WEE1 KINASE DOMAIN IN COMPLEX WITH BOSUTINIB-ISOMER
4128, d3oriC_, 0.6701, 3.48, 0.149, 267, 249, MYCOBACTERIUM TUBERCULOSIS PKNB KINASE DOMAIN L33D MUTANT (CRYSTAL FORM 1)
4129, d1zysA_, 0.6701, 3.56, 0.167, 271, 252, CO-CRYSTAL STRUCTURE OF CHECKPOINT KINASE CHK1 WITH A PYRROLO-PYRIDINE INHIBITOR
4130, d1zy4A1, 0.6701, 3.37, 0.187, 269, 246, CRYSTAL STRUCTURE OF EIF2ALPHA PROTEIN KINASE GCN2: R794G HYPERACTIVATING MUTANT IN APO FORM.
4131, d1tvoA_, 0.6701, 3.63, 0.165, 350, 254, THE STRUCTURE OF ERK2 IN COMPLEX WITH A SMALL MOLECULE INHIBITOR
4132, p6g8xA_, 0.6700, 3.63, 0.165, 338, 254, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
4133, p5nzzF_, 0.6700, 3.61, 0.183, 341, 251, CRYSTAL STRUCTURE OF PHOSPHORYLATED P38AMAPK IN COMPLEX WITH TAB1 
4134, d5ankA_, 0.6700, 3.07, 0.179, 273, 240, CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH 246-TRIOXO-1- PHENYL-HEXAHYDROPYRIMIDINE-5-CARBOXAMIDE PROCESSED WITH THE CRYSTALDIRECT AUTOMATED MOUNTING AND CRYO-COOLING TECHNOLOGY
4135, d4fv8A_, 0.6700, 3.01, 0.165, 333, 242, CRYSTAL STRUCTURE OF THE ERK2 COMPLEXED WITH E63
4136, d4kbcA_, 0.6699, 3.97, 0.142, 288, 260, CK1D IN COMPLEX WITH {4-[3-(4-FLUOROPHENYL)-1H-PYRAZOL-4-YL]PYRIDIN-2- YL}METHANOL INHIBITOR
4137, d4kbaC_, 0.6699, 3.80, 0.155, 277, 258, CK1D IN COMPLEX WITH 9-[3-(4-FLUOROPHENYL)-1-METHYL-1H-PYRAZOL-4-YL]- 2345-TETRAHYDROPYRIDO[23-F][14]OXAZEPINE INHIBITOR
4138, d4kb8C_, 0.6698, 3.82, 0.155, 277, 258, CK1D IN COMPLEX WITH 1-{4-[3-(4-FLUOROPHENYL)-1-METHYL-1H-PYRAZOL-4- YL]PYRIDIN-2-YL}-N-METHYLMETHANAMINE LIGAND
4139, d3tl8A_, 0.6698, 3.50, 0.180, 300, 250, THE AVRPTOB-BAK1 COMPLEX REVEALS TWO STRUCTURALLY SIMILAR KINASEINTERACTING DOMAINS IN A SINGLE TYPE III EFFECTOR
4140, d3p86B_, 0.6698, 2.44, 0.228, 239, 232, CRYSTAL STRUCTURE OF CTR1 KINASE DOMAIN MUTANT D676N IN COMPLEX WITH STAUROSPORINE
4141, d2ojiA_, 0.6698, 3.61, 0.165, 344, 254, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH N-BENZYL-4-(4-(3- CHLOROPHENYL)-1H-PYRAZOL-3-YL)-1H-PYRROLE-2-CARBOXAMIDE
4142, d2cguA_, 0.6698, 3.46, 0.165, 263, 249, IDENTIFICATION OF CHEMICALLY DIVERSE CHK1 INHIBITORS BY RECEPTOR-BASED VIRTUAL SCREENING
4143, d2bfyA_, 0.6698, 3.93, 0.154, 270, 259, COMPLEX OF AURORA-B WITH INCENP AND HESPERADIN.
4144, d1ny3A_, 0.6698, 2.90, 0.159, 277, 239, CRYSTAL STRUCTURE OF ADP BOUND TO MAP KAP KINASE 2
4145, d1jqhA_, 0.6698, 3.80, 0.286, 291, 255, IGF-1 RECEPTOR KINASE DOMAIN
4146, d5d9hA_, 0.6697, 3.63, 0.197, 290, 249, CRYSTAL STRUCTURE OF SPAK (STK39) DIMER IN THE BASAL ACTIVITY STATE
4147, d2wzjF_, 0.6697, 3.51, 0.193, 310, 249, CATALYTIC AND UBA DOMAIN OF KINASE MARK2/(PAR-1) K82R T208E DOUBLE MUTANT
4148, d2vgoA_, 0.6697, 3.76, 0.156, 268, 256, CRYSTAL STRUCTURE OF AURORA B KINASE IN COMPLEX WITH REVERSINE INHIBITOR
4149, d5oq7B_, 0.6696, 3.06, 0.174, 256, 241, STRUCTURE OF CHK1 8-PT. MUTANT COMPLEX WITH ARYLBENZAMIDE LRRK2 INHIBITOR
4150, d5o12A_, 0.6696, 3.16, 0.168, 264, 244, CRYSTAL STRUCTURE OF PIM1 KINASE IN COMPLEX WITH SMALL-MOLECULE INHIBITOR
4151, d4aguC_, 0.6696, 3.11, 0.189, 278, 244, CRYSTAL STRUCTURE OF THE HUMAN CDKL1 KINASE DOMAIN
4152, d5fdxA_, 0.6695, 3.36, 0.298, 280, 245, STRUCTURE OF DDR1 RECEPTOR TYROSINE KINASE IN COMPLEX WITH D2164 INHIBITOR AT 2.65 ANGSTROMS RESOLUTION.
4153, d3h0zC_, 0.6695, 3.03, 0.183, 246, 241, AURORA A IN COMPLEX WITH A BISANILINOPYRIMIDINE
4154, d2jflA_, 0.6695, 3.43, 0.190, 286, 247, CRYSTAL STRUCTURE OF HUMAN STE20-LIKE KINASE ( DIPHOSPHORYLATED FORM) BOUND TO 5- AMINO-3-((4-( AMINOSULFONYL)PHENYL)AMINO)-N-(26- DIFLUOROPHENYL)-1H-12 4-TRIAZOLE-1-CARBOTHIOAMIDE
4155, d5opuA_, 0.6694, 3.21, 0.164, 261, 244, STRUCTURE OF CHK1 10-PT. MUTANT COMPLEX WITH PYRROLOPYRIDINE LRRK2 INHIBITOR
4156, d4xp2A_, 0.6694, 3.56, 0.166, 337, 253, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH AN INHIBITOR
4157, d2ojgA_, 0.6694, 3.64, 0.169, 337, 254, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH NN-DIMETHYL-4-(4- PHENYL-1H-PYRAZOL-3-YL)-1H-PYRROLE-2-CARBOXAMIDE
4158, d1jqhC_, 0.6694, 3.80, 0.286, 291, 255, IGF-1 RECEPTOR KINASE DOMAIN
4159, d5w85B_, 0.6693, 3.21, 0.218, 279, 243, CRYSTAL STRUCTURE OF IRAK-4 WITH A 46-DIAMINONICOTINAMIDE INHIBITOR (COMPOUND NUMBER 9)
4160, d5ukfA_, 0.6693, 3.95, 0.122, 322, 263, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE 1 BOUND TO AN OXINDOLE INHIBITOR
4161, d5op7A_, 0.6693, 3.25, 0.163, 261, 245, STRUCTURE OF CHK1 10-PT. MUTANT COMPLEX WITH PYRROLOPYRIMIDINE LRRK2 INHIBITOR
4162, d3zhpC1, 0.6693, 3.48, 0.227, 267, 251, HUMAN MST3 (STK24) IN COMPLEX WITH MO25BETA
4163, d3ma3A_, 0.6693, 3.32, 0.166, 266, 247, CRYSTAL STRUCTURE OF HUMAN PROTO-ONCOGENE SERINE THREONINE KINASE (PIM1) IN COMPLEX WITH A CONSENSUS PEPTIDE AND A NAPHTHO-DIFURAN LIGAND
4164, d3kmuA_, 0.6693, 3.15, 0.198, 253, 243, CRYSTAL STRUCTURE OF THE ILK/ALPHA-PARVIN CORE COMPLEX (APO)
4165, d2bfyB_, 0.6693, 3.79, 0.152, 278, 256, COMPLEX OF AURORA-B WITH INCENP AND HESPERADIN.
4166, p5nzzG_, 0.6692, 3.55, 0.183, 342, 251, CRYSTAL STRUCTURE OF PHOSPHORYLATED P38AMAPK IN COMPLEX WITH TAB1 
4167, p4d28C_, 0.6692, 3.45, 0.161, 279, 249, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF SNRK3.11 AT5G35410
4168, d2oicC_, 0.6692, 2.99, 0.206, 277, 238, CRYSTAL STRUCTURE OF IRAK4 KINASE DOMAIN COMPLEXED WITH STAUROSPORINE
4169, p4lopD_, 0.6691, 3.72, 0.169, 351, 255, STRUCTURAL BASIS OF AUTOACTIVATION OF P38 ALPHA INDUCED BY TAB1 (TETRAGONAL CRYSTAL FORM)
4170, d3k54A_, 0.6691, 3.03, 0.301, 243, 239, STRUCTURES OF HUMAN BRUTON S TYROSINE KINASE IN ACTIVE AND INACTIVE CONFORMATIONS SUGGESTS A MECHANISM OF ACTIVATION FOR TEC FAMILY KINASES.
4171, d5oneA_, 0.6690, 3.29, 0.191, 257, 246, CRYSTAL STRUCTURE OF AURORA-A IN COMPLEX WITH FMF-03-145-1 (COMPOUND 2)
4172, d5d9hB_, 0.6690, 3.79, 0.203, 293, 251, CRYSTAL STRUCTURE OF SPAK (STK39) DIMER IN THE BASAL ACTIVITY STATE
4173, d4nt4A1, 0.6690, 4.09, 0.128, 299, 265, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF GILGAMESH ISOFORM I FROM DROSOPHILA MELANOGASTER
4174, d4b8mA_, 0.6690, 3.73, 0.157, 270, 255, AURORA B KINASE IN COMPLEX WITH VX-680
4175, d3o71A_, 0.6690, 3.42, 0.163, 340, 252, CRYSTAL STRUCTURE OF ERK2/DCC PEPTIDE COMPLEX
4176, d2vrxA_, 0.6690, 3.76, 0.156, 268, 256, STRUCTURE OF AURORA B KINASE IN COMPLEX WITH ZM447439
4177, d2cgvA_, 0.6690, 3.48, 0.165, 264, 249, IDENTIFICATION OF CHEMICALLY DIVERSE CHK1 INHIBITORS BY RECEPTOR-BASED VIRTUAL SCREENING
4178, d5vc6A_, 0.6689, 3.45, 0.160, 259, 250, CRYSTAL STRUCTURE OF HUMAN WEE1 KINASE DOMAIN IN COMPLEX WITH PHA- 848125
4179, d4d4rA_, 0.6689, 3.34, 0.331, 251, 245, FOCAL ADHESION KINASE CATALYTIC DOMAIN
4180, d2i6lA_, 0.6689, 2.99, 0.162, 292, 241, CRYSTAL STRUCTURE OF HUMAN MITOGEN ACTIVATED PROTEIN KINASE 6 (MAPK6)
4181, d2cgxA_, 0.6689, 3.49, 0.161, 265, 249, IDENTIFICATION OF CHEMICALLY DIVERSE CHK1 INHIBITORS BY RECEPTOR-BASED VIRTUAL SCREENING
4182, d1v0oB_, 0.6689, 3.10, 0.169, 274, 242, STRUCTURE OF P. FALCIPARUM PFPK5-INDIRUBIN-5-SULPHONATE LIGAND COMPLEX
4183, p6g9dA_, 0.6688, 3.57, 0.166, 345, 253, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
4184, d2x8dA_, 0.6688, 3.75, 0.161, 279, 254, DISCOVERY OF A NOVEL CLASS OF TRIAZOLONES AS CHECKPOINT KINASE INHIBITORS - HIT TO LEAD EXPLORATION
4185, d2e9vB_, 0.6688, 3.38, 0.165, 268, 248, STRUCTURE OF H-CHK1 COMPLEXED WITH A859017
4186, d5wdyA_, 0.6687, 3.12, 0.212, 260, 240, CRYSTAL STRUCTURE OF WNK1 IN COMPLEX WITH 1-CYCLOHEXYL-N-({6-FLUORO-1- [2-(3-METHOXYPHENYL)PYRIDIN-4-YL]-1H-INDOL-3-YL}METHYL)METHANAMINE (COMPOUND 6)
4187, d5lcjA_, 0.6687, 3.52, 0.167, 345, 252, IN-GEL ACTIVITY-BASED PROTEIN PROFILING OF A CLICKABLE COVALENT ERK 1/2 INHIBITOR
4188, d3uysD_, 0.6687, 3.77, 0.141, 284, 256, CRYSTAL STRUCTURE OF APO HUMAN CK1D
4189, d3mj1A1, 0.6687, 2.11, 0.329, 226, 225, X-RAY CRYSTAL STRUCTURE OF ITK COMPLEXED WITH INHIBITOR RO5191614
4190, d3en6A_, 0.6687, 2.56, 0.289, 236, 232, TARGETED POLYPHARMACOLOGY: CRYSTAL STRUCTURE OF THE C-SRC KINASE DOMAIN IN COMPLEX WITH PP102 A MULTITARGETED KINASE INHIBITOR
4191, d3e7oA_, 0.6687, 3.34, 0.184, 342, 250, CRYSTAL STRUCTURE OF JNK2
4192, p6g9mA_, 0.6686, 3.58, 0.166, 341, 253, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
4193, d4iz7A_, 0.6686, 3.44, 0.167, 344, 251, STRUCTURE OF NON-PHOSPHORYLATED ERK2 BOUND TO THE PEA-15 DEATH EFFECTOR DOMAIN
4194, d4dfyE_, 0.6686, 3.71, 0.179, 312, 257, CRYSTAL STRUCTURE OF R194A MUTANT OF CAMP-DEPENDENT PROTEIN KINASE WITH UNPHOSPHORYLATED ACTIVATION LOOP
4195, d3zhpD_, 0.6686, 3.45, 0.219, 264, 251, HUMAN MST3 (STK24) IN COMPLEX WITH MO25BETA
4196, p3teiA_, 0.6685, 3.34, 0.165, 339, 249, CRYSTAL STRUCTURE OF HUMAN ERK2 COMPLEXED WITH A MAPK DOCKING PEPTIDE
4197, d1q97A_, 0.6685, 3.52, 0.159, 351, 251, THE STRUCTURE OF THE SACCHAROMYCES CEREVISIAE SR PROTEIN KINASE SKY1P WITH BOUND ATP
4198, d4zzoA_, 0.6684, 3.60, 0.166, 339, 253, HUMAN ERK2 IN COMPLEX WITH AN IRREVERSIBLE INHIBITOR
4199, d4lg4E_, 0.6684, 3.59, 0.218, 275, 252, STRUCTURAL BASIS FOR AUTOACTIVATION OF HUMAN MST2 KINASE AND ITS REGULATION BY RASSF5
4200, d3op5A_, 0.6684, 4.00, 0.122, 320, 263, HUMAN VACCINIA-RELATED KINASE 1
4201, d3g51A_, 0.6684, 3.30, 0.197, 280, 244, STRUCTURAL DIVERSITY OF THE ACTIVE CONFORMATION OF THE N- TERMINAL KINASE DOMAIN OF P90 RIBOSOMAL S6 KINASE 2
4202, d3c9wA2, 0.6684, 3.25, 0.171, 335, 246, CRYSTAL STRUCTURE OF ERK-2 WITH HYPOTHEMYCIN COVALENTLY BOUND
4203, d4fv3A_, 0.6683, 3.59, 0.166, 346, 253, CRYSTAL STRUCTURE OF THE ERK2 COMPLEXED WITH EK6
4204, d2c3kA_, 0.6683, 3.36, 0.154, 262, 247, IDENTIFICATION OF A BURIED POCKET FOR POTENT AND SELECTIVE INHIBITION OF CHK1: PREDICTION AND VERIFICATION
4205, p5nzzH_, 0.6682, 3.48, 0.181, 335, 249, CRYSTAL STRUCTURE OF PHOSPHORYLATED P38AMAPK IN COMPLEX WITH TAB1 
4206, d5hniX_, 0.6682, 3.02, 0.350, 245, 234, CRYSTAL STRUCTURE OF CMET WT WITH COMPOUND 3
4207, d2qr7A_, 0.6682, 3.02, 0.179, 292, 240, 2.0A X-RAY STRUCTURE OF C-TERMINAL KINASE DOMAIN OF P90 RIBOSOMAL S6 KINASE 2: SE-MET DERIVATIVE
4208, d1lewA_, 0.6682, 3.62, 0.193, 341, 249, CRYSTAL STRUCTURE OF MAP KINASE P38 COMPLEXED TO THE DOCKING SITE ON ITS NUCLEAR SUBSTRATE MEF2A
4209, d6bruA_, 0.6681, 4.12, 0.135, 322, 266, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A (S)- 2-PHENYLAMINOPTERIDINONE INHIBITOR
4210, d3c9wB2, 0.6681, 3.26, 0.171, 335, 246, CRYSTAL STRUCTURE OF ERK-2 WITH HYPOTHEMYCIN COVALENTLY BOUND
4211, d1wbtA_, 0.6680, 3.71, 0.187, 351, 252, IDENTIFICATION OF NOVEL P38 ALPHA MAP KINASE INHIBITORS USING FRAGMENT-BASED LEAD GENERATION.
4212, d5ihaA_, 0.6679, 3.08, 0.191, 303, 241, MELK IN COMPLEX WITH NVS-MELK8F
4213, d5hniY_, 0.6679, 3.01, 0.350, 245, 234, CRYSTAL STRUCTURE OF CMET WT WITH COMPOUND 3
4214, d3oroA_, 0.6679, 3.52, 0.141, 272, 249, MYCOBACTERIUM TUBERCULOSIS PKNB KINASE DOMAIN L33D MUTANT (CRYSTAL FORM 4)
4215, d2hakF_, 0.6679, 3.53, 0.202, 318, 252, CATALYTIC AND UBIQUTIN-ASSOCIATED DOMAINS OF MARK1/PAR-1
4216, d2ghgA1, 0.6679, 3.62, 0.151, 269, 252, H-CHK1 COMPLEXED WITH A431994
4217, d4qpaB_, 0.6678, 3.64, 0.165, 345, 254, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH 7-(1-BENZYL-1H-PYRAZOL-4- YL)-2-(PYRIDIN-4-YL)-5H-PYRROLO[23-B]PYRAZINE
4218, d2xneA_, 0.6678, 2.94, 0.187, 246, 240, STRUCTURE OF AURORA-A BOUND TO AN IMIDAZOPYRAZINE INHIBITOR
4219, d2w1eA1, 0.6678, 3.21, 0.188, 252, 245, STRUCTURE DETERMINATION OF AURORA KINASE IN COMPLEX WITH INHIBITOR
4220, d5v5yA_, 0.6677, 3.43, 0.161, 259, 249, CRYSTAL STRUCTURE OF HUMAN WEE1 KINASE DOMAIN IN COMPLEX WITH MK1775
4221, d5uisB_, 0.6677, 3.02, 0.218, 274, 239, CRYSTAL STRUCTURE OF IRAK4 IN COMPLEX WITH COMPOUND 12
4222, d4zzmA_, 0.6677, 3.60, 0.166, 344, 253, HUMAN ERK2 IN COMPLEX WITH AN IRREVERSIBLE INHIBITOR
4223, d4ztrA_, 0.6677, 3.18, 0.189, 249, 244, HUMAN AURORA A CATALYTIC DOMAIN BOUND TO FK1141
4224, d2ojjA_, 0.6677, 3.64, 0.165, 344, 254, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH (S)-N-(1-(3- CHLORO-4-FLUOROPHENYL)-2-HYDROXYETHYL)-4-(4-(3- CHLOROPHENYL)-1H-PYRAZOL-3-YL)-1H-PYRROLE-2-CARBOXAMIDE
4225, d3pj3A_, 0.6676, 2.82, 0.301, 240, 236, CRYSTAL STRUCTURE OF BTK KINASE DOMAIN COMPLEXED WITH 2-METHYL-5-[(E)- (3-PHENYL-ACRYLOYL)AMINO]-N-(2-PHENYL-3H-IMIDAZO[45-B]PYRIDIN-6-YL)- BENZAMIDE
4226, d4xrlA_, 0.6675, 3.58, 0.162, 337, 253, CRYSTAL STRUCTURE AT ROOM TEMPERATURE OF ERK2 IN COMPLEX WITH AN INHIBITOR
4227, d4erkA_, 0.6675, 3.55, 0.167, 350, 252, THE COMPLEX STRUCTURE OF THE MAP KINASE ERK2/OLOMOUCINE
4228, d1ua2A_, 0.6675, 3.18, 0.167, 286, 240, CRYSTAL STRUCTURE OF HUMAN CDK7
4229, d5uiqD_, 0.6674, 3.01, 0.218, 271, 238, CRYSTAL STRUCTURE OF IRAK4 IN COMPLEX WITH COMPOUND 9
4230, d5k72D_, 0.6674, 3.10, 0.221, 276, 240, IRAK4 IN COMPLEX WITH COMPOUND 21
4231, d4qp7B_, 0.6674, 3.25, 0.170, 335, 247, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH 2-(1H-PYRAZOL-4-YL)-5H- PYRROLO[23-B]PYRAZINE
4232, p4looA_, 0.6674, 3.81, 0.165, 349, 255, STRUCTURAL BASIS OF AUTOACTIVATION OF P38 ALPHA INDUCED BY TAB1 (MONOCLINIC CRYSTAL FORM)
4233, d1zltA_, 0.6674, 3.67, 0.159, 272, 251, CRYSTAL STRUCTURE OF CHK1 COMPLEXED WITH A HYMENALDISINE ANALOG
4234, d1ouyA_, 0.6674, 3.81, 0.198, 350, 253, THE STRUCTURE OF P38 ALPHA IN COMPLEX WITH A DIHYDROPYRIDO- PYRIMIDINE INHIBITOR
4235, d5nhfA_, 0.6673, 3.59, 0.170, 339, 253, HUMAN ERK2 WITH AN ERK1/2 INHIBITOR
4236, p4ux9C_, 0.6673, 3.39, 0.186, 333, 247, CRYSTAL STRUCTURE OF JNK1 BOUND TO A MKK7 DOCKING MOTIF
4237, d2wzjC_, 0.6673, 3.45, 0.194, 310, 248, CATALYTIC AND UBA DOMAIN OF KINASE MARK2/(PAR-1) K82R T208E DOUBLE MUTANT
4238, d2p4iB_, 0.6673, 2.74, 0.332, 258, 232, EVOLUTION OF A HIGHLY SELECTIVE AND POTENT 2-(PYRIDIN-2-YL)- 135-TRIAZINE TIE-2 KINASE INHIBITOR
4239, d2oo8X_, 0.6673, 2.83, 0.336, 259, 232, SYNTHESIS STRUCTURAL ANALYSIS AND SAR STUDIES OF TRIAZINE DERIVATIVES AS POTENT SELECTIVE TIE-2 INHIBITORS
4240, d1zz2A_, 0.6673, 3.38, 0.191, 337, 246, TWO CLASSES OF P38ALPHA MAP KINASE INHIBITORS HAVING A COMMON DIPHENYLETHER CORE BUT EXHIBITING DIVERGENT BINDING MODES
4241, d4fv2A_, 0.6672, 3.61, 0.166, 344, 253, CRYSTAL STRUCTURE OF THE ERK2 COMPLEXED WITH EK5
4242, d4c2wA_, 0.6672, 3.86, 0.156, 268, 257, CRYSTAL STRUCTURE OF AURORA B IN COMPLEX WITH AMP-PNP
4243, d3pj1A_, 0.6672, 2.98, 0.315, 241, 238, CRYSTAL STRUCTURE OF BTK KINASE DOMAIN COMPLEXED WITH 3-(26-DICHLORO- PHENYL)-7-[4-(2-DIETHYLAMINO-ETHOXY)-PHENYLAMINO]-1-METHYL-34- DIHYDRO-1H-PYRIMIDO[45-D]PYRIMIDIN-2-ONE
4244, p6cpwA_, 0.6671, 3.55, 0.164, 328, 250, DISCOVERY OF 3(S)-THIOMETHYL PYRROLIDINE ERK INHIBITORS FOR ONCOLOGY 
4245, d5vdkA_, 0.6671, 3.33, 0.162, 260, 247, CRYSTAL STRUCTURE OF HUMAN WEE2 KINASE DOMAIN IN COMPLEX WITH MK1775
4246, d5ho6A_, 0.6671, 2.83, 0.359, 240, 231, CRYSTAL STRUCTURE OF CMET IN COMPLEX WITH CMPD.
4247, d5bujA_, 0.6671, 2.98, 0.162, 331, 240, ERK2 COMPLEXED WITH A N-H TETRAHYDROAZAINDAZOLE
4248, d4bcqA1, 0.6671, 3.61, 0.159, 289, 252, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
4249, d3vapA_, 0.6671, 3.19, 0.193, 249, 243, SYNTHESIS AND SAR STUDIES OF IMIDAZO-[12-A]-PYRAZINE AURORA KINASE INHIBITORS WITH IMPROVED OFF TARGET KINASE SELECTIVITY
4250, d2wtkC1, 0.6671, 3.55, 0.155, 261, 251, STRUCTURE OF THE HETEROTRIMERIC LKB1-STRADALPHA-MO25ALPHA COMPLEX
4251, d5w5jA_, 0.6670, 2.69, 0.216, 251, 231, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES
4252, d3qywA_, 0.6670, 3.62, 0.166, 340, 253, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH AN INHIBITOR
4253, d3fpqA_, 0.6670, 3.25, 0.215, 262, 242, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF WNK1
4254, d5uirB_, 0.6669, 3.06, 0.221, 273, 240, CRYSTAL STRUCTURE OF IRAK4 IN COMPLEX WITH COMPOUND 11
4255, d4ztsA_, 0.6668, 3.19, 0.176, 249, 244, HUMAN AURORA A CATALYTIC DOMAIN BOUND TO FK1142
4256, d4kbaB_, 0.6668, 3.85, 0.148, 285, 257, CK1D IN COMPLEX WITH 9-[3-(4-FLUOROPHENYL)-1-METHYL-1H-PYRAZOL-4-YL]- 2345-TETRAHYDROPYRIDO[23-F][14]OXAZEPINE INHIBITOR
4257, d3wf6A_, 0.6668, 3.37, 0.187, 277, 246, CRYSTAL STRUCTURE OF S6K1 KINASE DOMAIN IN COMPLEX WITH A PYRAZOLOPYRIMIDINE DERIVATIVE 4-[4-(1H-INDOL-3-YL)-36- DIHYDROPYRIDIN-1(2H)-YL]-1H-PYRAZOLO[34-D]PYRIMIDINE
4258, d5mz3A_, 0.6667, 3.61, 0.193, 350, 249, P38 ALPHA MUTANT C162S IN COMPLEX WITH CMPD2 [N-(4-METHYL-3-(4455- TETRAMETHYL-132-DIOXABOROLAN-2-YL)PHENYL)-3-(TRIFLUOROMETHYL) BENZAMIDE]
4259, d5bueA_, 0.6667, 2.98, 0.162, 329, 240, ERK2 COMPLEXED WITH N-BENZYLPYRIDONE TETRAHYDROAZAINDAZOLE
4260, d4b0gA_, 0.6667, 2.96, 0.187, 247, 240, COMPLEX OF AURORA-A BOUND TO AN IMIDAZOPYRIDINE-BASED INHIBITOR
4261, d2x8eA_, 0.6667, 3.27, 0.159, 259, 245, DISCOVERY OF A NOVEL CLASS OF TRIAZOLONES AS CHECKPOINT KINASE INHIBITORS - HIT TO LEAD EXPLORATION
4262, d1lezA_, 0.6667, 3.65, 0.193, 343, 249, CRYSTAL STRUCTURE OF MAP KINASE P38 COMPLEXED TO THE DOCKING SITE ON ITS ACTIVATOR MKK3B
4263, d1golA_, 0.6667, 3.66, 0.166, 357, 253, COORDINATES OF RAT MAP KINASE ERK2 WITH AN ARGININE MUTATION AT POSITION 52
4264, d5v24A_, 0.6666, 2.93, 0.213, 249, 239, STRUCTURE-BASED DRUG DESIGN OF NOVEL ASK1 INHIBITORS USING A FULLY INTEGRATED LEAD OPTIMIZATION STRATEGY
4265, d5uiqB_, 0.6666, 3.05, 0.221, 272, 240, CRYSTAL STRUCTURE OF IRAK4 IN COMPLEX WITH COMPOUND 9
4266, d5m53A1, 0.6666, 2.73, 0.196, 248, 235, NEK2 BOUND TO ARYLAMINOPURINE INHIBITOR 11
4267, d4fv1A_, 0.6666, 3.65, 0.166, 342, 253, CRYSTAL STRUCTURE OF THE ERK2 COMPLEXED WITH EK4
4268, d4aa4A_, 0.6666, 3.83, 0.177, 347, 254, P38ALPHA MAP KINASE BOUND TO CMPD 22
4269, d5vt1A1, 0.6665, 3.64, 0.187, 264, 252, CRYSTAL STRUCTURE OF THE HUMAN CAMKK2B BOUND TO A BENZAMIDE INHIBITOR
4270, d5bvdA_, 0.6665, 2.94, 0.163, 330, 239, TETRAHYDROPYRROLO-DIAZEPENONES AS INHIBITORS OF ERK2 KINASE
4271, d4qp4B_, 0.6665, 3.21, 0.175, 335, 246, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH N-CYCLOHEXYL-9H-PURIN-6- AMINE
4272, d2oidD_, 0.6665, 2.98, 0.219, 274, 237, CRYSTAL STRUCTURE OF IRAK4 KINASE DOMAIN COMPLEXED WITH AMPPNP
4273, d1q8yB_, 0.6665, 3.67, 0.150, 357, 253, THE STRUCTURE OF THE YEAST SR PROTEIN KINASE SKY1P WITH BOUND ADP
4274, p6g92A_, 0.6664, 3.56, 0.167, 343, 252, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
4275, d6bqlA1, 0.6664, 3.69, 0.179, 276, 252, CRYSTAL STRUCTURE OF THE HUMAN CAMKK2B IN COMPLEX WITH TAE-226
4276, d3wf5A_, 0.6664, 3.28, 0.192, 277, 245, CRYSTAL STRUCTURE OF S6K1 KINASE DOMAIN IN COMPLEX WITH A PYRAZOLOPYRIMIDINE DERIVATIVE 4-[4-(1H-BENZIMIDAZOL-2-YL)PIPERIDIN-1- YL]-1H-PYRAZOLO[34-D]PYRIMIDINE
4277, d2bfxB_, 0.6664, 3.78, 0.154, 275, 254, MECHANISM OF AURORA-B ACTIVATION BY INCENP AND INHIBITION BY HESPERADIN.
4278, d1ungA_, 0.6664, 3.53, 0.139, 288, 251, STRUCTURAL MECHANISM FOR THE INHIBITION OF CDK5-P25 BY ROSCOVITINE ALOISINE AND INDIRUBIN.
4279, d1jqhB_, 0.6664, 3.80, 0.287, 287, 254, IGF-1 RECEPTOR KINASE DOMAIN
4280, d5n93A1, 0.6663, 3.24, 0.171, 256, 245, TTK KINASE DOMAIN IN COMPLEX WITH TC-MPS1-12
4281, d2e9pA_, 0.6663, 3.53, 0.164, 269, 250, STRUCTURE OF H-CHK1 COMPLEXED WITH A771129
4282, d5vd2A_, 0.6662, 3.35, 0.157, 258, 248, CRYSTAL STRUCTURE OF HUMAN WEE1 KINASE DOMAIN IN COMPLEX WITH PF- 03814735
4283, d5bveA_, 0.6662, 2.94, 0.163, 330, 239, TETRAHYDROPYRROLO-DIAZEPENONES AS INHIBITORS OF ERK2 KINASE
4284, d4useA_, 0.6662, 3.75, 0.167, 286, 251, HUMAN STK10 (LOK) WITH SB-633825
4285, d2wzjE_, 0.6662, 3.48, 0.194, 310, 248, CATALYTIC AND UBA DOMAIN OF KINASE MARK2/(PAR-1) K82R T208E DOUBLE MUTANT
4286, d2hxlA_, 0.6662, 3.66, 0.160, 272, 250, CRYSTAL STRUCTURE OF CHEK1 IN COMPLEX WITH INHIBITOR 1
4287, p6ge0A_, 0.6661, 3.58, 0.167, 343, 252, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
4288, p5xyyA_, 0.6661, 3.87, 0.197, 350, 254, THE STRUCTURE OF P38 ALPHA IN COMPLEX WITH A TRIAZOL INHIBITOR
4289, d5oq5A_, 0.6661, 3.38, 0.174, 265, 247, STRUCTURE OF CHK1 8-PT. MUTANT COMPLEX WITH AMINOPYRIMIDO- BENZODIAZEPINONE LRRK2 INHIBITOR
4290, d5k7gB_, 0.6661, 3.03, 0.214, 275, 238, IRAK4 IN COMPLEX WITH AZ3862
4291, d5eakB_, 0.6661, 3.35, 0.210, 300, 248, OPTIMIZATION OF MICROTUBULE AFFINITY REGULATING KINASE (MARK) INHIBITORS WITH IMPROVED PHYSICAL PROPERTIES
4292, d4fv9A_, 0.6661, 2.99, 0.167, 331, 240, CRYSTAL STRUCTURE OF THE ERK2 COMPLEXED WITH E71
4293, d3vw6B_, 0.6661, 2.89, 0.213, 253, 239, CRYSTAL STRUCTURE OF HUMAN APOPTOSIS SIGNAL-REGULATING KINASE 1 (ASK1) WITH IMIDAZOPYRIDINE INHIBITOR
4294, d2zb0A_, 0.6661, 3.66, 0.191, 349, 251, CRYSTAL STRUCTURE OF P38 IN COMPLEX WITH BIPHENYL AMIDE INHIBITOR
4295, d2oscA_, 0.6661, 2.69, 0.343, 255, 230, SYNTHESIS STRUCTURAL ANALYSIS AND SAR STUDIES OF TRIAZINE DERIVATIVES AS POTENT SELECTIVE TIE-2 INHIBITORS
4296, d2ja0A_, 0.6661, 3.45, 0.187, 285, 246,  
4297, d2j4zA_, 0.6661, 3.40, 0.190, 263, 248, STRUCTURE OF AURORA-2 IN COMPLEX WITH PHA-680626
4298, d5tf9A_, 0.6660, 3.20, 0.213, 262, 239, CRYSTAL STRUCTURE OF WNK1 IN COMPLEX WITH MN2+AMPPNP AND WNK476
4299, p4ux9B_, 0.6660, 3.30, 0.184, 327, 245, CRYSTAL STRUCTURE OF JNK1 BOUND TO A MKK7 DOCKING MOTIF
4300, d4s33A_, 0.6660, 3.67, 0.165, 347, 254, ERK2 R65S MUTANT COMPLEXED WITH AMP-PNP
4301, d4fk3A1, 0.6660, 2.55, 0.216, 238, 231, B-RAF KINASE V600E ONCOGENIC MUTANT IN COMPLEX WITH PLX3203
4302, d3nlbA_, 0.6660, 3.40, 0.154, 261, 246, NOVEL KINASE PROFILE HIGHLIGHTS THE TEMPORAL BASIS OF CONTEXT DEPENDENT CHECKPOINT PATHWAYS TO CELL DEATH
4303, d3fe3B_, 0.6660, 3.66, 0.209, 317, 253, CRYSTAL STRUCTURE OF THE KINASE MARK3/PAR-1: T211A-S215A DOUBLE MUTANT
4304, d2w1dA1, 0.6660, 3.19, 0.184, 251, 244, STRUCTURE DETERMINATION OF AURORA KINASE IN COMPLEX WITH INHIBITOR
4305, d5vc3A_, 0.6659, 3.38, 0.153, 260, 249, CRYSTAL STRUCTURE OF HUMAN WEE1 KINASE DOMAIN IN COMPLEX WITH BOSUTINIB
4306, d5umoA_, 0.6659, 3.67, 0.171, 347, 252, STRUCTURE OF EXTRACELLULAR SIGNAL-REGULATED KINASE
4307, d1ua2D_, 0.6659, 3.20, 0.180, 286, 239, CRYSTAL STRUCTURE OF HUMAN CDK7
4308, d5k3yA_, 0.6658, 3.83, 0.152, 267, 256, CRYSTAL STRUCTURE OF AURORAB/INCENP IN COMPLEX WITH BI 811283
4309, d4bf2B_, 0.6658, 2.82, 0.224, 252, 237, CRYSTAL STRUCTURES OF ASK1-INHIBITOR COMPLEXES
4310, d1q8yA_, 0.6658, 3.57, 0.151, 351, 252, THE STRUCTURE OF THE YEAST SR PROTEIN KINASE SKY1P WITH BOUND ADP
4311, d4zznA_, 0.6657, 3.61, 0.166, 338, 253, HUMAN ERK2 IN COMPLEX WITH AN INHIBITOR
4312, d4x7qB_, 0.6656, 2.78, 0.194, 243, 237, PIM2 KINASE IN COMPLEX WITH COMPOUND 1S
4313, d4aacA_, 0.6655, 3.79, 0.182, 350, 253, P38ALPHA MAP KINASE BOUND TO CMPD 29
4314, d3uzpB_, 0.6655, 3.73, 0.142, 284, 254, CRYSTAL STRUCTURE OF CK1D WITH PF670462 FROM P21 CRYSTAL FORM
4315, d3tl8H_, 0.6655, 3.42, 0.190, 303, 247, THE AVRPTOB-BAK1 COMPLEX REVEALS TWO STRUCTURALLY SIMILAR KINASEINTERACTING DOMAINS IN A SINGLE TYPE III EFFECTOR
4316, p6g9nA_, 0.6654, 3.66, 0.166, 344, 253, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
4317, d4s34A_, 0.6654, 3.62, 0.170, 343, 253, ERK2 (I84A) IN COMPLEX WITH AMP-PNP
4318, d2hxqA_, 0.6654, 3.66, 0.160, 272, 250, CRYSTAL STRUCTURE OF CHEK1 IN COMPLEX WITH INHIBITOR 2
4319, p5lw1H_, 0.6653, 3.38, 0.185, 355, 248, CRYSTAL STRUCTURE OF DARPIN-DARPIN RIGID FUSION VARIANT DD_232_11_D12 IN COMPLEX JNK1A1 AND JIP1 PEPTIDE
4320, d3nnwA_, 0.6653, 3.59, 0.185, 349, 249, CRYSTAL STRUCTURE OF P38 ALPHA IN COMPLEX WITH DP802
4321, d3gc8A_, 0.6653, 3.37, 0.183, 347, 246, THE STRUCTURE OF P38BETA C162S IN COMPLEX WITH A DIHYDROQUINAZOLINONE
4322, d3d7zA_, 0.6653, 3.63, 0.172, 348, 250, CRYSTAL STRUCTURE OF P38 KINASE IN COMPLEX WITH A BIPHENYL AMIDE INHIBITOR
4323, d4yp8B_, 0.6652, 3.10, 0.222, 278, 239, IRAK4-INHIBITOR CO-STRUCTURE
4324, d4s2zA_, 0.6652, 3.66, 0.167, 346, 252, ERK2 INTRINSICALLY ACTIVE MUTANT R65S
4325, d1w83A_, 0.6652, 3.67, 0.188, 351, 250, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH SMALL MOLECULE INHIBITOR
4326, d5eykB_, 0.6651, 3.86, 0.152, 275, 256, CRYSTAL STRUCTURE OF AURORA B IN COMPLEX WITH BI 847325
4327, d4yo6B_, 0.6651, 3.00, 0.219, 277, 237, IRAK4-INHIBITOR CO-STRUCTURE
4328, d2oidB_, 0.6651, 3.15, 0.222, 272, 239, CRYSTAL STRUCTURE OF IRAK4 KINASE DOMAIN COMPLEXED WITH AMPPNP
4329, d1erkA_, 0.6651, 3.68, 0.166, 357, 253, STRUCTURE OF SIGNAL-REGULATED KINASE
4330, p5ax3A_, 0.6650, 3.21, 0.167, 329, 245, CRYSTAL STRUCTURE OF ERK2 COMPLEXED WITH ALLOSTERIC AND ATP- COMPETITIVE INHIBITORS.
4331, d2brnA_, 0.6650, 3.54, 0.161, 268, 248, STRUCTURE-BASED DESIGN OF NOVEL CHK1 INHIBITORS: INSIGHTS INTO HYDROGEN BONDING AND PROTEIN-LIGAND AFFINITY
4332, d1zycC1, 0.6650, 3.50, 0.182, 269, 247, CRYSTAL STRUCTURE OF EIF2ALPHA PROTEIN KINASE GCN2: WILD- TYPE IN APO FORM.
4333, d5vc5A_, 0.6649, 3.47, 0.160, 261, 250, CRYSTAL STRUCTURE OF HUMAN WEE1 KINASE DOMAIN IN COMPLEX WITH PD- 166285
4334, d5tf9B_, 0.6649, 3.17, 0.214, 266, 238, CRYSTAL STRUCTURE OF WNK1 IN COMPLEX WITH MN2+AMPPNP AND WNK476
4335, p5etaB_, 0.6649, 3.46, 0.201, 335, 244, STRUCTURE OF MAPK14 WITH BOUND THE KIM DOMAIN OF THE TOXOPLASMA PROTEIN GRA24
4336, p3n9xA_, 0.6649, 3.40, 0.193, 374, 249, CRYSTAL STRUCTURE OF MAP KINASE FROM PLASMODIUM BERGHEI PB000659.00.0
4337, d5n87A1, 0.6648, 3.30, 0.175, 252, 246, TTK KINASE DOMAIN IN COMPLEX WITH NTRC 0066-0
4338, d5kbrA_, 0.6648, 3.26, 0.194, 259, 242, PAK1 IN COMPLEX WITH 7-AZAINDOLE INHIBITOR
4339, d3mptA_, 0.6648, 3.59, 0.173, 347, 249, CRYSTAL STRUCTURE OF P38 KINASE IN COMPLEX WITH A PYRROLE-2- CARBOXAMIDE INHIBITOR
4340, d2vrxB_, 0.6648, 3.80, 0.154, 274, 254, STRUCTURE OF AURORA B KINASE IN COMPLEX WITH ZM447439
4341, d2iwiB_, 0.6648, 3.00, 0.183, 249, 240, CRYSTAL STRUCTURE OF THE HUMAN PIM2 IN COMPLEX WITH A RUTHENIUM ORGANOMETALLIC LIGAND RU1
4342, d1w84A_, 0.6648, 3.88, 0.189, 351, 254, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH SMALL MOLECULE INHIBITOR
4343, d1ia8A_, 0.6648, 3.66, 0.160, 272, 250, THE 1.7 A CRYSTAL STRUCTURE OF HUMAN CELL CYCLE CHECKPOINT KINASE CHK1
4344, d4xneA_, 0.6647, 3.58, 0.171, 344, 252, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH AN INHIBITOR
4345, d4s32A_, 0.6647, 3.67, 0.165, 346, 254, CRYSTAL STRUCTURE OF ERK2 AMP-PNP COMPLEX
4346, d6bu6B_, 0.6646, 4.03, 0.126, 307, 262, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A BIS- DIFLUOROPHENOL-AMINOPYRIDINE INHIBITOR
4347, d5uiqA_, 0.6646, 3.00, 0.219, 268, 237, CRYSTAL STRUCTURE OF IRAK4 IN COMPLEX WITH COMPOUND 9
4348, d4s31A_, 0.6646, 3.67, 0.167, 347, 252, CRYSTAL STRUCTURE OF MITOGEN-ACTIVATED PROTEIN KINASE 1 WTERK2 AT 1.45A
4349, d1szmB_, 0.6646, 4.11, 0.162, 320, 260, DUAL BINDING MODE OF BISINDOLYLMALEIMIDE 2 TO PROTEIN KINASE A (PKA)
4350, d4kiqA_, 0.6645, 3.42, 0.191, 338, 246, CRYSTAL STRUCTURE OF MITOGEN-ACTIVATED PROTEIN KINASE 14 (P38-H5) COMPLEX WITH ETHYL 6-((5-(CYCLOPROPYLCARBAMOYL)-2-METHYLPHENYL) CARBAMOYL)-1H-INDOLE-1-CARBOXYLATE
4351, d5angA_, 0.6644, 2.86, 0.191, 268, 235, CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH 7-HYDROXY-4-( MORPHOLINOMETHYL)CHROMEN-2-ONE PROCESSED WITH THE CRYSTALDIRECT AUTOMATED MOUNTING AND CRYO-COOLING TECHNOLOGY
4352, d4g6oA_, 0.6644, 3.66, 0.163, 339, 252, CRYSTAL STRUCTURE OF THE ERK2
4353, d5byyA_, 0.6643, 3.62, 0.159, 338, 252, ERK5 IN COMPLEX WITH SMALL MOLECULE
4354, d4kinB_, 0.6643, 3.56, 0.189, 341, 249, CRYSTAL STRUCTURE OF MITOGEN-ACTIVATED PROTEIN KINASE 14 (P38-H5) COMPLEX WITH 5-(2-CHLOROPHENYL)-N-(5-(CYCLOPROPYLCARBAMOYL)-2- METHYLPHENYL)-2-THIOPHENECARBOXAMIDE
4355, d3ztxB_, 0.6643, 3.86, 0.154, 272, 254, AURORA KINASE SELECTIVE INHIBITORS IDENTIFIED USING A TAXOL- INDUCED CHECKPOINT SENSITIVITY SCREEN.
4356, d2x9eA_, 0.6643, 3.16, 0.173, 253, 243, HUMAN MPS1 IN COMPLEX WITH NMS-P715
4357, d3p9jA_, 0.6642, 3.15, 0.189, 249, 243, AURORA A KINASE DOMAIN WITH PHTHALAZINONE PYRAZOLE INHIBITOR
4358, d3mvlB_, 0.6642, 3.45, 0.191, 339, 246, P38 ALPHA MAP KINASE COMPLEXED WITH PYRROLOTRIAZINE INHIBITOR 7K
4359, d3dakD_, 0.6642, 3.79, 0.209, 284, 249, CRYSTAL STRUCTURE OF DOMAIN-SWAPPED OSR1 KINASE DOMAIN
4360, d5op5A_, 0.6641, 3.24, 0.156, 259, 243, STRUCTURE OF CHK1 10-PT. MUTANT COMPLEX WITH PYRROLOPYRIMIDINE LRRK2 INHIBITOR
4361, d5lckA_, 0.6641, 3.57, 0.171, 345, 251, A CLICKABLE COVALENT ERK 1/2 INHIBITOR
4362, d4ka3A_, 0.6641, 3.60, 0.178, 340, 247, STRUCTURE OF MAP KINASE IN COMPLEX WITH A DOCKING PEPTIDE
4363, d5k7iA_, 0.6640, 2.91, 0.226, 272, 235, IRAK4 IN COMPLEX WITH AZ3864
4364, d5ap1A1, 0.6640, 3.27, 0.176, 264, 245, NATURALLY OCCURRING MUTATIONS IN THE MPS1 GENE PREDISPOSE CELLS TO KINASE INHIBITOR DRUG RESISTANCE.
4365, d4hyiA_, 0.6640, 3.55, 0.161, 269, 249, X-RAY CRYSTAL STRUCTURE OF COMPOUND 40 BOUND TO HUMAN CHK1 KINASE DOMAIN
4366, d4g6nA_, 0.6640, 3.65, 0.166, 341, 253, CRYSTAL STRUCTURE OF THE ERK2
4367, d3nnvA_, 0.6640, 3.59, 0.185, 348, 249, CRYSTAL STRUCTURE OF P38 ALPHA IN COMPLEX WITH DP437
4368, d3d2kA_, 0.6640, 2.99, 0.184, 245, 239, CRYSTAL STRUCTURE OF MOUSE AURORA A (ASN186->GLY LYS240- >ARG MET302->LEU) IN COMPLEX WITH [7-(2-{2-[3-(3-CHLORO- PHENYL)-UREIDO]-THIAZOL-5-YL}-ETHYLAMINO)-PYRAZOLO[43- D]PYRIMIDIN-1-YL]-ACETIC ACID
4369, d5v19A_, 0.6639, 2.87, 0.215, 250, 237, STRUCTURE-BASED DRUG DESIGN OF NOVEL ASK1 INHIBITORS USING A FULLY INTEGRATED LEAD OPTIMIZATION STRATEGY
4370, p5oatF_, 0.6639, 3.92, 0.140, 359, 257, PINK1 STRUCTURE
4371, d4xp0A_, 0.6639, 3.51, 0.140, 336, 250, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH AN INHIBITOR
4372, d2z7lA_, 0.6639, 3.66, 0.163, 329, 252, UNPHOSPHORYLATED MITOGEN ACTIVATED PROTEIN KINASE ERK2 IN COMPLEX WITH (4-{[5-CARBAMOYL-4-(3-METHYLANILINO)PYRIMIDIN 2-YL]AMINO}PHENYL)ACETIC ACID
4373, d2cgwA_, 0.6639, 3.52, 0.153, 262, 248, IDENTIFICATION OF CHEMICALLY DIVERSE CHK1 INHIBITORS BY RECEPTOR-BASED VIRTUAL SCREENING
4374, p4d28B_, 0.6638, 3.47, 0.165, 277, 248, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF SNRK3.11 AT5G35410
4375, d6bp0D_, 0.6637, 4.01, 0.142, 311, 260, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE 1 BOUND TO (R)- 2-PHENYLAMINOPTERIDINONE INHIBITOR
4376, d4zegA_, 0.6637, 3.38, 0.167, 260, 246, CRYSTAL STRUCTURE OF TTK KINASE DOMAIN IN COMPLEX WITH A PYRAZOLOPYRIMIDINE INHIBITOR
4377, d4bc6A_, 0.6637, 3.92, 0.166, 285, 253, CRYSTAL STRUCTURE OF HUMAN SERINE THREONINE KINASE-10 BOUND TO NOVEL BOSUTINIB ISOFORM 1 PREVIOUSLY THOUGHT TO BE BOSUTINIB
4378, p6gdmA_, 0.6636, 3.58, 0.139, 341, 251, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
4379, d1oukA_, 0.6636, 3.75, 0.175, 348, 252, THE STRUCTURE OF P38 ALPHA IN COMPLEX WITH A PYRIDINYLIMIDAZOLE INHIBITOR
4380, p5lw1B_, 0.6635, 3.40, 0.185, 355, 248, CRYSTAL STRUCTURE OF DARPIN-DARPIN RIGID FUSION VARIANT DD_232_11_D12 IN COMPLEX JNK1A1 AND JIP1 PEPTIDE
4381, d4gt3A_, 0.6635, 3.64, 0.166, 347, 253, ATP-BOUND FORM OF THE ERK2 KINASE
4382, d3op5B_, 0.6635, 4.03, 0.122, 319, 262, HUMAN VACCINIA-RELATED KINASE 1
4383, d3dakC_, 0.6635, 3.52, 0.216, 281, 245, CRYSTAL STRUCTURE OF DOMAIN-SWAPPED OSR1 KINASE DOMAIN
4384, d3qyzA_, 0.6634, 3.67, 0.166, 339, 253, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH AN INHIBITOR
4385, d1a06A_, 0.6634, 3.30, 0.182, 279, 247, CALMODULIN-DEPENDENT PROTEIN KINASE FROM RAT
4386, d6bp0B_, 0.6633, 3.96, 0.120, 304, 259, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE 1 BOUND TO (R)- 2-PHENYLAMINOPTERIDINONE INHIBITOR
4387, d4kb8B_, 0.6633, 3.90, 0.152, 285, 257, CK1D IN COMPLEX WITH 1-{4-[3-(4-FLUOROPHENYL)-1-METHYL-1H-PYRAZOL-4- YL]PYRIDIN-2-YL}-N-METHYLMETHANAMINE LIGAND
4388, d5ootA_, 0.6632, 3.30, 0.160, 260, 244, STRUCTURE OF CHK1 10-PT. MUTANT COMPLEX WITH AMINOPYRIMIDO- BENZODIAZEPINONE LRRK2 INHIBITOR
4389, d4ewqA_, 0.6632, 3.59, 0.171, 346, 251, HUMAN P38 ALPHA MAPK IN COMPLEX WITH A PYRIDAZINE BASED INHIBITOR
4390, d1ua2B_, 0.6632, 3.18, 0.172, 286, 239, CRYSTAL STRUCTURE OF HUMAN CDK7
4391, d5oopA_, 0.6631, 3.38, 0.163, 261, 245, STRUCTURE OF CHK1 10-PT. MUTANT COMPLEX WITH AMP-PNP
4392, d4zjjC_, 0.6631, 3.56, 0.184, 276, 250, PAK1 IN COMPLEX WITH (S)-N-(TERT-BUTYL)-3-((2-CHLORO-5-ETHYL-8-FLUORO- DIBENZODIAZEPIN-11-YL)AMINO)PYRROLIDINE-1-CARBOXAMIDE
4393, d4f0gA1, 0.6631, 3.17, 0.220, 260, 241, CRYSTAL STRUCTURE OF THE ROCO4 KINASE DOMAIN FROM D. DISCOIDEUM
4394, d6bruD_, 0.6630, 4.01, 0.142, 311, 260, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A (S)- 2-PHENYLAMINOPTERIDINONE INHIBITOR
4395, d3w16A_, 0.6630, 3.21, 0.193, 249, 243, STRUCTURE OF AURORA KINASE A COMPLEXED TO PYRAZOLE-AMINOQUINOLINE INHIBITOR III
4396, d3iphA_, 0.6630, 3.57, 0.177, 345, 248, CRYSTAL STRUCTURE OF P38 IN COMPLEX WITH A BIPHENYLAMIDE INHIBITOR
4397, d2vgpA_, 0.6630, 3.76, 0.154, 265, 253, CRYSTAL STRUCTURE OF AURORA B KINASE IN COMPLEX WITH A AMINOTHIAZOLE INHIBITOR
4398, d3dbqA_, 0.6629, 3.51, 0.165, 259, 248, CRYSTAL STRUCTURE OF TTK KINASE DOMAIN
4399, d5uvfA_, 0.6628, 4.02, 0.134, 317, 261, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO BI- D1870
4400, p4loqD_, 0.6628, 3.80, 0.157, 351, 254, STRUCTURAL BASIS OF AUTOACTIVATION OF P38 ALPHA INDUCED BY TAB1 (TETRAGONAL CRYSTAL FORM WITH BOUND SULPHATE)
4401, d4lg4F_, 0.6628, 3.78, 0.213, 276, 254, STRUCTURAL BASIS FOR AUTOACTIVATION OF HUMAN MST2 KINASE AND ITS REGULATION BY RASSF5
4402, d2ydkA_, 0.6628, 3.42, 0.163, 263, 246, DISCOVERY OF CHECKPOINT KINASE INHIBITOR AZD7762 BY STRUCTURE BASED DESIGN AND OPTIMIZATION OF THIOPHENE CARBOXAMIDE UREAS
4403, d5na0A1, 0.6627, 3.26, 0.171, 250, 245, TTK KINASE DOMAIN IN COMPLEX WITH A PEG-LINKED PYRIMIDO-INDOLIZINE
4404, d4i5hA_, 0.6627, 3.22, 0.174, 335, 242, CRYSTAL STRUCTURE OF A DOUBLE MUTANT RAT ERK2 COMPLEXED WITH A TYPE II QUINAZOLINE INHIBITOR
4405, d1bl6A_, 0.6627, 3.82, 0.190, 351, 253, THE COMPLEX STRUCTURE OF THE MAP KINASE P38/SB216995
4406, d4hnfA_, 0.6626, 4.07, 0.142, 289, 261, CRYSTAL STRUCTURE OF CK1D IN COMPLEX WITH PF4800567
4407, d3fmhA_, 0.6626, 3.60, 0.173, 347, 249, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH 6-(24-DIFLUORO-PHENOXY)- 8-METHYL-2-((R)-1-METHYL-2-TETRAZOL-2-YL-ETHYLAMINO)-8H-PYRIDO[23- D]PYRIMIDIN-7-ONE
4408, d4qp3A_, 0.6625, 3.48, 0.165, 339, 248, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH (S)-2-((9H-PURIN-6-YL) AMINO)-3-PHENYLPROPAN-1-OL
4409, d3fmeA1, 0.6625, 3.58, 0.205, 267, 249, CRYSTAL STRUCTURE OF HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 6 (MEK6) ACTIVATED MUTANT (S207D T211D)
4410, d5l2sA_, 0.6624, 2.76, 0.157, 263, 235, THE X-RAY CO-CRYSTAL STRUCTURE OF HUMAN CDK6 AND ABEMACICLIB.
4411, d4s30A_, 0.6624, 3.68, 0.171, 342, 251, ERK2 INTRINSICALLY ACTIVE MUTANT (I84A)
4412, d4qyhB_, 0.6624, 3.43, 0.155, 264, 245, CHK1 KINASE DOMAIN IN COMPLEX WITH DIAZACARBAZOLE GNE-783
4413, d3v6sA_, 0.6624, 3.43, 0.169, 349, 249, DISCOVERY OF POTENT AND SELECTIVE COVALENT INHIBITORS OF JNK
4414, d3nw6A_, 0.6624, 3.81, 0.291, 301, 251, CRYSTAL STRUCTURE OF INSULIN-LIKE GROWTH FACTOR 1 RECEPTOR (IGF-1R-WT) COMPLEX WITH A CARBON-LINKED PROLINE ISOSTERE INHIBITOR (11A)
4415, d3hmpA_, 0.6624, 3.48, 0.165, 258, 248, CRYSTAL STRUCTURE OF HUMAN MPS1 CATALYTIC DOMAIN IN COMPLEX WITH A QUINAZOLIN LIGAND COMPOUND 4
4416, d5fdxB_, 0.6623, 3.33, 0.312, 274, 240, STRUCTURE OF DDR1 RECEPTOR TYROSINE KINASE IN COMPLEX WITH D2164 INHIBITOR AT 2.65 ANGSTROMS RESOLUTION.
4417, p4lopA_, 0.6623, 3.72, 0.190, 351, 253, STRUCTURAL BASIS OF AUTOACTIVATION OF P38 ALPHA INDUCED BY TAB1 (TETRAGONAL CRYSTAL FORM)
4418, p4h3pD_, 0.6623, 3.39, 0.166, 338, 247, CRYSTAL STRUCTURE OF HUMAN ERK2 COMPLEXED WITH A MAPK DOCKING PEPTIDE
4419, d4byjA_, 0.6623, 3.13, 0.183, 246, 241, AURORA A KINASE BOUND TO A HIGHLY SELECTIVE IMIDAZOPYRIDINE INHIBITOR
4420, d3v6rA_, 0.6623, 3.35, 0.165, 349, 248, DISCOVERY OF POTENT AND SELECTIVE COVALENT INHIBITORS OF JNK
4421, d5oorA_, 0.6622, 3.37, 0.160, 273, 244, STRUCTURE OF CHK1 10-PT. MUTANT COMPLEX WITH STAUROSPORINE
4422, d4j8mA_, 0.6622, 3.52, 0.189, 265, 249, AURORA A IN COMPLEX WITH CD532
4423, d4aa5A_, 0.6622, 3.55, 0.181, 340, 248, P38ALPHA MAP KINASE BOUND TO CMPD 33
4424, d3fe3A_, 0.6622, 3.65, 0.210, 317, 252, CRYSTAL STRUCTURE OF THE KINASE MARK3/PAR-1: T211A-S215A DOUBLE MUTANT
4425, d3dakB_, 0.6622, 3.74, 0.215, 278, 247, CRYSTAL STRUCTURE OF DOMAIN-SWAPPED OSR1 KINASE DOMAIN
4426, d3dakA_, 0.6622, 3.59, 0.220, 279, 246, CRYSTAL STRUCTURE OF DOMAIN-SWAPPED OSR1 KINASE DOMAIN
4427, d2br1A_, 0.6622, 3.73, 0.159, 272, 251, STRUCTURE-BASED DESIGN OF NOVEL CHK1 INHIBITORS: INSIGHTS INTO HYDROGEN BONDING AND PROTEIN-LIGAND AFFINITY
4428, p5lw1E_, 0.6621, 3.42, 0.185, 355, 248, CRYSTAL STRUCTURE OF DARPIN-DARPIN RIGID FUSION VARIANT DD_232_11_D12 IN COMPLEX JNK1A1 AND JIP1 PEPTIDE
4429, d2wzjA_, 0.6621, 3.59, 0.193, 310, 249, CATALYTIC AND UBA DOMAIN OF KINASE MARK2/(PAR-1) K82R T208E DOUBLE MUTANT
4430, p4lopB_, 0.6620, 3.78, 0.169, 350, 254, STRUCTURAL BASIS OF AUTOACTIVATION OF P38 ALPHA INDUCED BY TAB1 (TETRAGONAL CRYSTAL FORM)
4431, d3mvlA_, 0.6620, 3.50, 0.187, 339, 246, P38 ALPHA MAP KINASE COMPLEXED WITH PYRROLOTRIAZINE INHIBITOR 7K
4432, d3is5E1, 0.6620, 2.82, 0.205, 243, 234, CRYSTAL STRUCTURE OF CDPK KINASE DOMAIN FROM TOXOPLASMA GONDII TGME49_018720
4433, d2brbA_, 0.6620, 3.64, 0.161, 272, 249, STRUCTURE-BASED DESIGN OF NOVEL CHK1 INHIBITORS: INSIGHTS INTO HYDROGEN BONDING AND PROTEIN-LIGAND AFFINITY
4434, d5ap4A1, 0.6619, 3.21, 0.173, 253, 243, NATURALLY OCCURRING MUTATIONS IN THE MPS1 GENE PREDISPOSE CELLS TO KINASE INHIBITOR DRUG RESISTANCE.
4435, d4o6eA_, 0.6619, 3.27, 0.171, 328, 245, DISCOVERY OF 5678-TETRAHYDROPYRIDO[34-D]PYRIMIDINE INHIBITORS OF ERK2
4436, d3nnuA_, 0.6619, 3.64, 0.185, 348, 249, CRYSTAL STRUCTURE OF P38 ALPHA IN COMPLEX WITH DP1376
4437, d1wbvA_, 0.6619, 3.77, 0.183, 351, 251, IDENTIFICATION OF NOVEL P38 ALPHA MAP KINASE INHIBITORS USING FRAGMENT-BASED LEAD GENERATION.
4438, d1wbnA_, 0.6619, 3.79, 0.187, 351, 251, FRAGMENT BASED P38 INHIBITORS
4439, d6bp0A_, 0.6618, 4.03, 0.134, 317, 261, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE 1 BOUND TO (R)- 2-PHENYLAMINOPTERIDINONE INHIBITOR
4440, d5uisA_, 0.6618, 2.96, 0.217, 269, 235, CRYSTAL STRUCTURE OF IRAK4 IN COMPLEX WITH COMPOUND 12
4441, d4xv9A1, 0.6618, 2.74, 0.228, 244, 232, B-RAF KINASE DOMAIN IN COMPLEX WITH PLX5568
4442, p4lopC_, 0.6618, 3.78, 0.158, 341, 253, STRUCTURAL BASIS OF AUTOACTIVATION OF P38 ALPHA INDUCED BY TAB1 (TETRAGONAL CRYSTAL FORM)
4443, d4iz7C_, 0.6618, 3.41, 0.173, 340, 248, STRUCTURE OF NON-PHOSPHORYLATED ERK2 BOUND TO THE PEA-15 DEATH EFFECTOR DOMAIN
4444, d4hgtB_, 0.6618, 3.63, 0.147, 280, 251, CRYSTAL STRUCTURE OF CK1D WITH COMPOUND 13
4445, d4dfyA_, 0.6618, 3.73, 0.176, 310, 255, CRYSTAL STRUCTURE OF R194A MUTANT OF CAMP-DEPENDENT PROTEIN KINASE WITH UNPHOSPHORYLATED ACTIVATION LOOP
4446, d3e92A_, 0.6618, 3.71, 0.176, 348, 250, CRYSTAL STRUCTURE OF P38 KINASE IN COMPLEX WITH A BIARYL AMIDE INHIBITOR
4447, d2zb1A_, 0.6618, 3.60, 0.173, 345, 248, CRYSTAL STRUCTURE OF P38 IN COMPLEX WITH BIPHENYL AMIDE INHIBITOR
4448, d2okrA_, 0.6618, 3.50, 0.196, 339, 245, CRYSTAL STRUCTURE OF THE P38A-MAPKAP KINASE 2 HETERODIMER
4449, d1bl7A_, 0.6618, 3.84, 0.190, 351, 253, THE COMPLEX STRUCTURE OF THE MAP KINASE P38/SB220025
4450, d4xrjA_, 0.6617, 3.62, 0.167, 344, 252, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH AN INHIBITOR
4451, d3dt1A2, 0.6617, 3.65, 0.168, 352, 250, P38 COMPLEXED WITH A QUINAZOLINE INHIBITOR
4452, d2onlB1, 0.6617, 3.49, 0.192, 339, 245, CRYSTAL STRUCTURE OF THE P38A-MAPKAP KINASE 2 HETERODIMER
4453, d2broA_, 0.6617, 3.67, 0.156, 272, 250, STRUCTURE-BASED DESIGN OF NOVEL CHK1 INHIBITORS: INSIGHTS INTO HYDROGEN BONDING AND PROTEIN-LIGAND AFFINITY
4454, d5opsA_, 0.6616, 3.18, 0.158, 258, 241, STRUCTURE OF CHK1 10-PT. MUTANT COMPLEX WITH PYRROLOPYRIDINE LRRK2 INHIBITOR
4455, d5n84A1, 0.6616, 3.35, 0.171, 253, 246, TTK KINASE DOMAIN IN COMPLEX WITH MPS-BAY2B
4456, d4kinD_, 0.6616, 3.54, 0.178, 339, 247, CRYSTAL STRUCTURE OF MITOGEN-ACTIVATED PROTEIN KINASE 14 (P38-H5) COMPLEX WITH 5-(2-CHLOROPHENYL)-N-(5-(CYCLOPROPYLCARBAMOYL)-2- METHYLPHENYL)-2-THIOPHENECARBOXAMIDE
4457, d1ua2C_, 0.6616, 3.21, 0.172, 286, 239, CRYSTAL STRUCTURE OF HUMAN CDK7
4458, d5uvfC_, 0.6615, 3.93, 0.125, 301, 257, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO BI- D1870
4459, d4xozA_, 0.6615, 3.60, 0.171, 341, 251, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH AN INHIBITOR
4460, d4fsuA_, 0.6615, 3.30, 0.156, 260, 243, CRYSTAL STRUCTURE OF THE CHK1
4461, d2uv2A1, 0.6615, 3.46, 0.189, 286, 244, CRYSTAL STRUCTURE OF HUMAN STE20-LIKE KINASE BOUND TO 4-(4-( 5-CYCLOPROPYL-1H-PYRAZOL-3-YLAMINO)-QUINAZOLIN-2-YLAMINO)- PHENYL)-ACETONITRILE
4462, d2io6A_, 0.6615, 3.11, 0.166, 252, 241, WEE1 KINASE COMPLEXED WITH INHIBITOR PD330961
4463, p6g9jA_, 0.6614, 3.66, 0.143, 347, 252, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
4464, d4bgqA_, 0.6614, 3.05, 0.162, 276, 240, CRYSTAL STRUCTURE OF THE HUMAN CDKL5 KINASE DOMAIN
4465, d3uytD_, 0.6613, 3.75, 0.154, 268, 254, CRYSTAL STRUCTURE OF CK1D WITH PF670462 FROM P1 CRYSTAL FORM
4466, d2jc6A_, 0.6613, 3.50, 0.171, 278, 245, CRYSTAL STRUCTURE OF HUMAN CALMODULIN-DEPENDENT PROTEIN KINASE 1D
4467, d1r3cA_, 0.6613, 3.77, 0.191, 349, 251, THE STRUCTURE OF P38ALPHA C162S MUTANT
4468, d5ap0A1, 0.6612, 3.27, 0.172, 250, 244, NATURALLY OCCURRING MUTATIONS IN THE MPS1 GENE PREDISPOSE CELLS TO KINASE INHIBITOR DRUG RESISTANCE.
4469, d2oj9A_, 0.6612, 3.83, 0.300, 295, 250, STRUCTURE OF IGF-1R KINASE DOMAIN COMPLEXED WITH A BENZIMIDAZOLE INHIBITOR
4470, d1pmeA_, 0.6612, 3.65, 0.155, 333, 251, STRUCTURE OF PENTA MUTANT HUMAN ERK2 MAP KINASE COMPLEXED WITH A SPECIFIC INHIBITOR OF HUMAN P38 MAP KINASE
4471, d5opvA_, 0.6611, 3.28, 0.156, 261, 243, STRUCTURE OF CHK1 10-PT. MUTANT COMPLEX WITH PYRROLOPYRIDINE LRRK2 INHIBITOR
4472, d4kiqC_, 0.6611, 3.42, 0.192, 338, 245, CRYSTAL STRUCTURE OF MITOGEN-ACTIVATED PROTEIN KINASE 14 (P38-H5) COMPLEX WITH ETHYL 6-((5-(CYCLOPROPYLCARBAMOYL)-2-METHYLPHENYL) CARBAMOYL)-1H-INDOLE-1-CARBOXYLATE
4473, d3wyxA_, 0.6611, 3.33, 0.167, 258, 245, CRYSTAL STRUCTURE OF HUMAN MPS1 CATALYTIC DOMAIN IN COMPLEX WITH 6- ((3-(CYANOMETHOXY)-4-(1-METHYL-1H-PYRAZOL-4-YL)PHENYL)AMINO)-2- (CYCLOHEXYLAMINO)NICOTINONITRILE
4474, d3r63A_, 0.6611, 3.69, 0.166, 347, 253, STRUCTURE OF ERK2 (SPE) MUTANT (S246E)
4475, d3nuxA_, 0.6611, 2.73, 0.158, 261, 234, CDK6 (MONOMERIC) IN COMPLEX WITH INHIBITOR
4476, d1nxkA_, 0.6611, 3.04, 0.155, 279, 238, CRYSTAL STRUCTURE OF STAUROSPORINE BOUND TO MAP KAP KINASE 2
4477, d4kiqD_, 0.6610, 3.48, 0.195, 338, 246, CRYSTAL STRUCTURE OF MITOGEN-ACTIVATED PROTEIN KINASE 14 (P38-H5) COMPLEX WITH ETHYL 6-((5-(CYCLOPROPYLCARBAMOYL)-2-METHYLPHENYL) CARBAMOYL)-1H-INDOLE-1-CARBOXYLATE
4478, d3qrjB1, 0.6610, 2.71, 0.365, 252, 233, THE CRYSTAL STRUCTURE OF HUMAN ABL1 KINASE DOMAIN T315I MUTANT IN COMPLEX WITH DCC-2036
4479, d3dajA_, 0.6610, 3.07, 0.183, 245, 240, CRYSTAL STRUCTURE OF AURORA A COMPLEXED WITH AN INHIBITOR DISCOVERED THROUGH SITE-DIRECTED DYNAMIC TETHERING
4480, d2okrD_, 0.6610, 3.58, 0.187, 339, 246, CRYSTAL STRUCTURE OF THE P38A-MAPKAP KINASE 2 HETERODIMER
4481, d2iwiA_, 0.6610, 3.01, 0.192, 244, 239, CRYSTAL STRUCTURE OF THE HUMAN PIM2 IN COMPLEX WITH A RUTHENIUM ORGANOMETALLIC LIGAND RU1
4482, d1m7qA_, 0.6610, 3.76, 0.195, 348, 251, CRYSTAL STRUCTURE OF P38 MAP KINASE IN COMPLEX WITH A DIHYDROQUINAZOLINONE INHIBITOR
4483, d4u9aA_, 0.6609, 3.04, 0.211, 272, 237, SULPHUR ANOMALOUS CRYSTAL STRUCTURE OF ASYMMETRIC IRAK4 DIMER
4484, d4qygB_, 0.6609, 3.46, 0.155, 264, 245, CHK1 KINASE DOMAIN IN COMPLEX WITH DIAZACARBAZOLE COMPOUND 14
4485, d1jvpP_, 0.6609, 3.10, 0.165, 268, 237, CRYSTAL STRUCTURE OF HUMAN CDK2 (UNPHOSPHORYLATED) IN COMPLEX WITH PKF049-365
4486, d6btwD_, 0.6608, 3.92, 0.140, 307, 257, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A PHENYL-PTERIDINONE INHIBITOR
4487, d5uorA_, 0.6608, 3.09, 0.209, 249, 239, STRUCTURE-BASED DESIGN OF ASK1 INHIBITORS AS POTENTIAL FIRST-IN-CLASS AGENTS FOR HEART FAILURE
4488, d5jt2D1, 0.6608, 2.46, 0.241, 232, 228, BRAFV600E KINASE DOMAIN IN COMPLEX WITH CHEMICALLY LINKED VEMURAFENIB INHIBITOR VEM-BISAMIDE
4489, d2c6dA_, 0.6608, 3.41, 0.192, 254, 245, AURORA A KINASE ACTIVATED MUTANT (T287D) IN COMPLEX WITH ADPNP
4490, d3ocgA_, 0.6607, 3.30, 0.189, 336, 243, P38 ALPHA KINASE COMPLEXED WITH A 5-AMINO-PYRAZOLE BASED INHIBITOR
4491, d2brmA_, 0.6606, 3.45, 0.150, 263, 246, STRUCTURE-BASED DESIGN OF NOVEL CHK1 INHIBITORS: INSIGHTS INTO HYDROGEN BONDING AND PROTEIN-LIGAND AFFINITY
4492, d5op4A_, 0.6605, 3.26, 0.161, 259, 242, STRUCTURE OF CHK1 10-PT. MUTANT COMPLEX WITH AMINOPYRIMIDINE LRRK2 INHIBITOR
4493, p4d28D_, 0.6605, 3.28, 0.161, 271, 242, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF SNRK3.11 AT5G35410
4494, d3bizA_, 0.6605, 3.13, 0.166, 250, 241, WEE1 KINASE COMPLEX WITH INHIBITOR PD331618
4495, d5nadA1, 0.6604, 3.35, 0.168, 253, 244, TTK KINASE DOMAIN IN COMPLEX WITH BAY 1217389
4496, d5ehlA1, 0.6604, 3.45, 0.165, 254, 248, RAPID DISCOVERY OF PYRIDO[34-D]PYRIMIDINE INHIBITORS OF MONOPOLAR SPINDLE KINASE 1 (MPS1) USING A STRUCTURE-BASED HYDRIDIZATION APPROACH
4497, d4fv4A_, 0.6604, 3.04, 0.163, 329, 239, CRYSTAL STRUCTURE OF THE ERK2 COMPLEXED WITH EK7
4498, d3ctqA_, 0.6604, 3.38, 0.198, 336, 243, STRUCTURE OF MAP KINASE P38 IN COMPLEX WITH A 1-O-TOLYL-12 3-TRIAZOLE-4-CARBOXAMIDE
4499, d2x8iA_, 0.6604, 3.40, 0.156, 261, 244, DISCOVERY OF A NOVEL CLASS OF TRIAZOLONES AS CHECKPOINT KINASE INHIBITORS - HIT TO LEAD EXPLORATION
4500, d2j7tA_, 0.6604, 3.75, 0.177, 285, 248, CRYSTAL STRUCTURE OF HUMAN SERINE THREONINE KINASE-10 BOUND TO SU11274
4501, d3qquA_, 0.6603, 3.62, 0.310, 285, 248, COCRYSTAL STRUCTURE OF UNPHOSPHORYLATED IGF WITH PYRIMIDINE 8
4502, d6btwA_, 0.6602, 4.05, 0.134, 317, 261, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A PHENYL-PTERIDINONE INHIBITOR
4503, d4u97A_, 0.6602, 3.15, 0.214, 272, 238, CRYSTAL STRUCTURE OF ASYMMETRIC IRAK4 DIMER
4504, d3qrjA1, 0.6602, 2.49, 0.367, 246, 229, THE CRYSTAL STRUCTURE OF HUMAN ABL1 KINASE DOMAIN T315I MUTANT IN COMPLEX WITH DCC-2036
4505, d3i5zA_, 0.6602, 3.09, 0.162, 331, 240, CRYSTAL STRUCTURE OF ERK2 BOUND TO (S)-N-(2-HYDROXY-1-PHENYLETHYL)-4- (5-METHYL-2-(PHENYLAMINO)PYRIMIDIN-4-YL)-1H-PYRROLE-2-CARBOXAMIDE
4506, d2rg6A_, 0.6602, 3.36, 0.186, 335, 242, PHENYLALANINE PYRROLOTRIAZINE P38 ALPHA MAP KINASE INHIBITOR COMPOUND 11J
4507, d1nxkC_, 0.6602, 3.14, 0.154, 294, 240, CRYSTAL STRUCTURE OF STAUROSPORINE BOUND TO MAP KAP KINASE 2
4508, d1nxkB_, 0.6602, 2.89, 0.153, 272, 236, CRYSTAL STRUCTURE OF STAUROSPORINE BOUND TO MAP KAP KINASE 2
4509, d5knjB_, 0.6601, 3.06, 0.182, 259, 242, PSEUDOKINASE DOMAIN OF MLKL BOUND TO COMPOUND 1.
4510, d4qygA_, 0.6601, 3.47, 0.155, 264, 245, CHK1 KINASE DOMAIN IN COMPLEX WITH DIAZACARBAZOLE COMPOUND 14
4511, d4kinC_, 0.6601, 3.47, 0.184, 338, 245, CRYSTAL STRUCTURE OF MITOGEN-ACTIVATED PROTEIN KINASE 14 (P38-H5) COMPLEX WITH 5-(2-CHLOROPHENYL)-N-(5-(CYCLOPROPYLCARBAMOYL)-2- METHYLPHENYL)-2-THIOPHENECARBOXAMIDE
4512, d3hv4B_, 0.6601, 3.49, 0.188, 338, 245, HUMAN P38 MAP KINASE IN COMPLEX WITH RL51
4513, d2rioB_, 0.6601, 3.17, 0.208, 395, 240, STRUCTURE OF THE DUAL ENZYME IRE1 REVEALS THE BASIS FOR CATALYSIS AND REGULATION OF NON-CONVENTIONAL SPLICING
4514, d2ozaB_, 0.6601, 3.61, 0.181, 340, 249, STRUCTURE OF P38ALPHA COMPLEX
4515, d4ztqA_, 0.6600, 3.20, 0.186, 247, 242, HUMAN AURORA A CATALYTIC DOMAIN BOUND TO FK932
4516, d4o6lB_, 0.6600, 3.41, 0.171, 256, 246, CRYSTAL STRUCTURE OF TTK KINASE DOMAIN WITH AN INHIBITOR: 401498 (N- [(1R)-1-(2-CHLOROPHENYL)PROPYL]-3-{4-[(1-METHYLPIPERIDIN-4-YL) OXY]PHENYL}-1H-INDAZOLE-5-CARBOXAMIDE)
4517, d2rioA_, 0.6600, 3.22, 0.207, 396, 241, STRUCTURE OF THE DUAL ENZYME IRE1 REVEALS THE BASIS FOR CATALYSIS AND REGULATION OF NON-CONVENTIONAL SPLICING
4518, d4kb8A_, 0.6599, 3.65, 0.159, 265, 251, CK1D IN COMPLEX WITH 1-{4-[3-(4-FLUOROPHENYL)-1-METHYL-1H-PYRAZOL-4- YL]PYRIDIN-2-YL}-N-METHYLMETHANAMINE LIGAND
4519, d3wyyA_, 0.6599, 3.37, 0.171, 258, 245, CRYSTAL STRUCTURE OF HUMAN MPS1 CATALYTIC DOMAIN IN COMPLEX WITH (E)- 3-(4-((6-(((3S5S7S)-ADAMANTAN-1-YL)AMINO)-4-AMINO-5-CYANOPYRIDIN-2- YL)AMINO)-2-(CYANOMETHOXY)PHENYL)-N-(2-METHOXYETHYL)ACRYLAMIDE
4520, d3gc9A_, 0.6599, 3.30, 0.169, 335, 243, THE STRUCTURE OF P38BETA C119S C162S IN COMPLEX WITH A DIHYDROQUINAZOLINONE INHIBITOR
4521, d1mrvA_, 0.6599, 3.08, 0.155, 261, 238, CRYSTAL STRUCTURE OF AN INACTIVE AKT2 KINASE DOMAIN
4522, d4ftiA_, 0.6598, 3.49, 0.155, 270, 245, CRYSTAL STRUCTURE OF THE CHK1
4523, d4qp6A_, 0.6597, 3.50, 0.169, 339, 248, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH 5H-PYRROLO[23-B]PYRAZINE
4524, d4kipB_, 0.6597, 3.49, 0.179, 338, 246, CRYSTAL STRUCTURE OF MITOGEN-ACTIVATED PROTEIN KINASE 14 (P38-H5) COMPLEX WITH 2-(2-CHLOROPHENYL)-N-(5-(CYCLOPROPYLCARBAMOYL)-2- METHYLPHENYL)-13-THIAZOLE-5-CARBOXAMIDE
4525, d4fv5A_, 0.6597, 3.10, 0.162, 330, 240, CRYSTAL STRUCTURE OF THE ERK2 COMPLEXED WITH EK9
4526, d4fv0A_, 0.6597, 3.66, 0.139, 341, 251, CRYSTAL STRUCTURE OF THE ERK2 COMPLEXED WITH EK3
4527, d3flzA_, 0.6597, 3.62, 0.169, 347, 248, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH 8-METHYL-6-PHENOXY-2- (TETRAHYDRO-PYRAN-4-YLAMINO)-8H-PYRIDO[23-D]PYRIMIDIN-7-ONE
4528, d3e93A_, 0.6597, 3.70, 0.194, 346, 248, CRYSTAL STRUCTURE OF P38 KINASE IN COMPLEX WITH A BIARYL AMIDE INHIBITOR
4529, d2j50B_, 0.6597, 3.27, 0.189, 249, 244, STRUCTURE OF AURORA-2 IN COMPLEX WITH PHA-739358
4530, d2j50A_, 0.6597, 3.27, 0.189, 249, 244, STRUCTURE OF AURORA-2 IN COMPLEX WITH PHA-739358
4531, d4ztlB_, 0.6596, 2.85, 0.216, 269, 232, IRAK4-INHIBITOR CO-STRUCTURE
4532, d4qyhA_, 0.6596, 3.48, 0.155, 264, 245, CHK1 KINASE DOMAIN IN COMPLEX WITH DIAZACARBAZOLE GNE-783
4533, d5fd2B_, 0.6595, 2.26, 0.218, 234, 225, B-RAF WILD-TYPE KINASE DOMAIN IN COMPLEX WITH A PURINYLPYRIDINYLAMINO- BASED INHIBITOR
4534, d5ci6B_, 0.6595, 3.34, 0.188, 350, 245, CRYSTAL STRUCTURE OF ARABIDOPSIS THALIANA MPK6
4535, d5bvfA_, 0.6595, 2.92, 0.161, 327, 236, TETRAHYDROPYRROLO-DIAZEPENONES AS INHIBITORS OF ERK2 KINASE
4536, d4n4sA_, 0.6595, 3.51, 0.156, 342, 250, A DOUBLE MUTANT RAT ERK2 IN COMPLEX WITH A PYRAZOLO[34-D]PYRIMIDINE INHIBITOR
4537, d3vquA_, 0.6595, 3.30, 0.168, 258, 244, CRYSTAL STRUCTURE OF HUMAN MPS1 CATALYTIC DOMAIN IN COMPLEX WITH 4- [(4-AMINO-5-CYANO-6-ETHOXYPYRIDIN-2- YL)AMINO]BENZAMIDE
4538, d3tkiA_, 0.6595, 3.58, 0.154, 272, 246, CRYSTAL STRUCTURE OF CHK1 IN COMPLEX WITH INHIBITOR S25
4539, d3kq7A_, 0.6595, 3.66, 0.185, 348, 249, STRUCTURE OF HUMAN P38ALPHA WITH N-[4-METHYL-3-(6-{[2-(1- METHYLPYRROLIDIN-2-YL)ETHYL]AMINO}PYRIDINE-3-AMIDO)PHENYL]- 2-(MORPHOLIN-4-YL)PYRIDINE-4-CARBOXAMIDE
4540, d3flyA_, 0.6595, 3.61, 0.169, 347, 248, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH 6-(24- DIFLUORO-PHENOXY)-2-ISOPROPYLAMINO-8-METHYL-8H-PYRIDO[23- D]PYRIMIDIN-7-ONE
4541, d2j4zB_, 0.6595, 3.48, 0.186, 269, 247, STRUCTURE OF AURORA-2 IN COMPLEX WITH PHA-680626
4542, d5uvfB_, 0.6594, 3.97, 0.127, 316, 259, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO BI- D1870
4543, d5oprA_, 0.6594, 3.27, 0.157, 258, 242, STRUCTURE OF CHK1 10-PT. MUTANT COMPLEX WITH AMINOPYRIDINE LRRK2 INHIBITOR
4544, d2onlA1, 0.6594, 3.48, 0.193, 338, 244, CRYSTAL STRUCTURE OF THE P38A-MAPKAP KINASE 2 HETERODIMER
4545, d4fsnA_, 0.6593, 3.46, 0.152, 270, 244, CRYSTAL STRUCTURE OF THE CHK1
4546, d3nw7A_, 0.6593, 3.80, 0.293, 297, 249, CRYSTAL STRUCTURE OF INSULIN-LIKE GROWTH FACTOR 1 RECEPTOR (IGF-1R-WT) COMPLEX WITH A CARBON-LINKED PROLINE ISOSTERE INHIBITOR (34)
4547, d3gcuB_, 0.6593, 3.44, 0.189, 337, 244, HUMAN P38 MAP KINASE IN COMPLEX WITH RL48
4548, d1zycD1, 0.6593, 3.45, 0.193, 254, 244, CRYSTAL STRUCTURE OF EIF2ALPHA PROTEIN KINASE GCN2: WILD- TYPE IN APO FORM.
4549, d3wzkA_, 0.6592, 3.38, 0.168, 258, 244, CRYSTAL STRUCTURE OF HUMAN MPS1 CATALYTIC DOMAIN IN COMPLEX WITH N- CYCLOPROPYL-4-(8-((THIOPHEN-2-YLMETHYL)AMINO)IMIDAZO[12-A]PYRAZIN-3- YL)BENZAMIDE
4550, d3hv5B_, 0.6592, 3.52, 0.184, 339, 245, HUMAN P38 MAP KINASE IN COMPLEX WITH RL24
4551, d3a62A_, 0.6592, 3.27, 0.194, 263, 242, CRYSTAL STRUCTURE OF PHOSPHORYLATED P70S6K1
4552, d4qyeA_, 0.6591, 3.49, 0.155, 271, 245, CHK1 KINASE DOMAIN IN COMPLEX WITH DIARYLPYRAZINE COMPOUND 1
4553, d4fg7A_, 0.6591, 2.96, 0.190, 250, 237, CRYSTAL STRUCTURE OF HUMAN CALCIUM/CALMODULIN-DEPENDENT PROTEIN KINASE I 1-293 IN COMPLEX WITH ATP
4554, d3my0J_, 0.6591, 2.64, 0.190, 252, 231, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
4555, d4b99A_, 0.6590, 3.59, 0.156, 335, 250, CRYSTAL STRUCTURE OF MAPK7 (ERK5) WITH INHIBITOR
4556, d3ot3A_, 0.6590, 3.33, 0.156, 259, 243, X-RAY CRYSTAL STRUCTURE OF COMPOUND 22K BOUND TO HUMAN CHK1 KINASE DOMAIN
4557, d4rvmA_, 0.6589, 3.40, 0.156, 264, 244, CHK1 KINASE DOMAIN WITH DIAZACARBAZOLE COMPOUND 19
4558, d4rvkA_, 0.6589, 3.40, 0.156, 264, 244, CHK1 KINASE DOMAIN WITH DIAZACARBAZOLE COMPOUND 8: N-[3-(6-CYANO-9H- PYRROLO[23-B:54-C ]DIPYRIDIN-3-YL)PHENYL]ACETAMIDE
4559, d3wzjA_, 0.6589, 3.28, 0.169, 257, 243, CRYSTAL STRUCTURE OF HUMAN MPS1 CATALYTIC DOMAIN IN COMPLEX WITH 4-(6- (CYCLOHEXYLAMINO)-8-(((TETRAHYDRO-2H-PYRAN-4-YL)METHYL)AMINO) IMIDAZO[12-B]PYRIDAZIN-3-YL)-N-CYCLOPROPYLBENZAMIDE
4560, d1kwpA_, 0.6589, 3.46, 0.156, 319, 244, CRYSTAL STRUCTURE OF MAPKAP2
4561, d5oq6A_, 0.6588, 3.29, 0.165, 257, 242, STRUCTURE OF CHK1 12-PT. MUTANT COMPLEX WITH AMINOPYRIMIDO- BENZODIAZEPINONE LRRK2 INHIBITOR
4562, d5dbxB_, 0.6588, 3.57, 0.204, 282, 245, CRYSTAL STRUCTURE OF MURINE SPAK(T243D) IN COMPLEX WITH AMPPNP
4563, d4ft3A_, 0.6588, 3.40, 0.156, 269, 243, CRYSTAL STRUCTURE OF THE CHK1
4564, d3oz6B_, 0.6588, 3.49, 0.165, 341, 248, CRYSTAL STRUCTURE OF MAPK FROM CRYPTOSPORIDIUM PARVUM CGD2_1960
4565, d3mvmA_, 0.6588, 3.32, 0.182, 335, 242, P38 ALPHA MAP KINASE COMPLEXED WITH PYRROLOTRIAZINE INHIBITOR 7V
4566, d5x18A_, 0.6586, 4.31, 0.140, 294, 265, CRYSTAL STRUCTURE OF CASEIN KINASE I HOMOLOG 1
4567, p4loqB_, 0.6586, 3.86, 0.158, 351, 253, STRUCTURAL BASIS OF AUTOACTIVATION OF P38 ALPHA INDUCED BY TAB1 (TETRAGONAL CRYSTAL FORM WITH BOUND SULPHATE)
4568, d4bi0A1, 0.6586, 3.35, 0.171, 251, 245, SCAFFOLD FOCUSED VIRTUAL SCREENING: PROSPECTIVE APPLICATION TO THE DISCOVERY OF TTK INHIBITOR
4569, d1pyeA_, 0.6586, 2.81, 0.172, 266, 232, CRYSTAL STRUCTURE OF CDK2 WITH INHIBITOR
4570, d2r0iB_, 0.6585, 3.40, 0.207, 300, 246, CRYSTAL STRUCTURE OF A KINASE MARK2/PAR-1 MUTANT
4571, d6eimA_, 0.6584, 3.48, 0.173, 286, 243, HUMAN STK10 BOUND TO GW683134A
4572, d4pwnA_, 0.6584, 2.91, 0.233, 245, 232, CRYSTAL STRUCTURE OF ACTIVE WNK1 KINASE
4573, d4kbkA_, 0.6584, 3.90, 0.145, 283, 255, CK1D IN COMPLEX WITH (3S)-3-{4-[3-(4-FLUOROPHENYL)-1-METHYL-1H- PYRAZOL-4-YL]PYRIDIN-2-YL}MORPHOLINE INHIBITOR
4574, d3s3iA_, 0.6584, 3.79, 0.175, 349, 251, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH SMALL MOLECULE INHIBITOR
4575, d2f49A_, 0.6584, 3.41, 0.162, 335, 247, CRYSTAL STRUCTURE OF FUS3 IN COMPLEX WITH A STE5 PEPTIDE
4576, d4qtdA_, 0.6583, 3.43, 0.166, 355, 247, STRUCTURE OF HUMAN JNK1 IN COMPLEX WITH SCH772984 AND THE AMPPNP- HYDROLYSED TRIPHOSPHATE REVEALING THE SECOND TYPE-I BINDING MODE
4577, d5ukfC_, 0.6582, 4.02, 0.127, 317, 260, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE 1 BOUND TO AN OXINDOLE INHIBITOR
4578, p5o7iA_, 0.6582, 3.77, 0.155, 340, 252, ERK5 IN COMPLEX WITH A PYRROLE INHIBITOR 
4579, d4qp2A_, 0.6582, 3.54, 0.165, 336, 248, CRYSTAL STRUCTURE OF ERKS IN COMPLEX WITH 5-CHLOROBENZO[D]OXAZOL-2- AMINE
4580, d4c4fA1, 0.6582, 3.31, 0.176, 250, 244, STRUCTURE-BASED DESIGN OF ORALLY BIOAVAILABLE PYRROLOPYRIDINE INHIBITORS OF THE MITOTIC KINASE MPS1
4581, d4kiqB_, 0.6581, 3.46, 0.192, 338, 245, CRYSTAL STRUCTURE OF MITOGEN-ACTIVATED PROTEIN KINASE 14 (P38-H5) COMPLEX WITH ETHYL 6-((5-(CYCLOPROPYLCARBAMOYL)-2-METHYLPHENYL) CARBAMOYL)-1H-INDOLE-1-CARBOXYLATE
4582, d4fk3B1, 0.6581, 2.80, 0.236, 241, 233, B-RAF KINASE V600E ONCOGENIC MUTANT IN COMPLEX WITH PLX3203
4583, d2qnjA1, 0.6581, 3.71, 0.190, 317, 252, KINASE AND UBIQUITIN-ASSOCIATED DOMAINS OF MARK3/PAR-1
4584, d4g34A1, 0.6580, 3.04, 0.195, 247, 236, CRYSTAL STRUCTURE OF GSK6924 BOUND TO PERK (R587-R1092 DELETE A660- T867) AT 2.70 A RESOLUTION
4585, d4c4eA1, 0.6580, 3.48, 0.171, 253, 246, STRUCTURE-BASED DESIGN OF ORALLY BIOAVAILABLE PYRROLOPYRIDINE INHIBITORS OF THE MITOTIC KINASE MPS1
4586, d3fpqB_, 0.6580, 3.45, 0.222, 263, 243, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF WNK1
4587, d4zsjA_, 0.6579, 3.93, 0.153, 344, 255, MITOGEN ACTIVATED PROTEIN KINASE 7 IN COMPLEX WITH INHIBITOR
4588, d4kipA_, 0.6579, 3.54, 0.183, 337, 246, CRYSTAL STRUCTURE OF MITOGEN-ACTIVATED PROTEIN KINASE 14 (P38-H5) COMPLEX WITH 2-(2-CHLOROPHENYL)-N-(5-(CYCLOPROPYLCARBAMOYL)-2- METHYLPHENYL)-13-THIAZOLE-5-CARBOXAMIDE
4589, p4loqA_, 0.6578, 3.90, 0.153, 352, 255, STRUCTURAL BASIS OF AUTOACTIVATION OF P38 ALPHA INDUCED BY TAB1 (TETRAGONAL CRYSTAL FORM WITH BOUND SULPHATE)
4590, d3comA_, 0.6577, 3.82, 0.211, 264, 251, CRYSTAL STRUCTURE OF MST1 KINASE
4591, d2vwiD_, 0.6577, 3.53, 0.206, 284, 243, STRUCTURE OF THE OSR1 KINASE A HYPERTENSION DRUG TARGET
4592, d2w5aA1, 0.6576, 3.33, 0.184, 259, 244, HUMAN NEK2 KINASE ADP-BOUND
4593, d4gvaA_, 0.6575, 3.73, 0.171, 345, 251, ADP-BOUND FORM OF THE ERK2 KINASE
4594, d4ft0A_, 0.6575, 3.49, 0.156, 266, 244, CRYSTAL STRUCTURE OF THE CHK1
4595, d5ehyA1, 0.6574, 3.33, 0.167, 251, 245, RAPID DISCOVERY OF PYRIDO[34-D]PYRIMIDINE INHIBITORS OF MONOPOLAR SPINDLE KINASE 1 (MPS1) USING A STRUCTURE-BASED HYDRIDIZATION APPROACH
4596, d5dbxA_, 0.6574, 3.58, 0.207, 284, 246, CRYSTAL STRUCTURE OF MURINE SPAK(T243D) IN COMPLEX WITH AMPPNP
4597, d4cv8A1, 0.6574, 3.43, 0.171, 252, 245, MPS1 KINASE WITH 3-AMINOPYRIDIN-2-ONE INHIBITORS
4598, d3gc9B_, 0.6574, 3.61, 0.174, 339, 247, THE STRUCTURE OF P38BETA C119S C162S IN COMPLEX WITH A DIHYDROQUINAZOLINONE INHIBITOR
4599, d1zycB1, 0.6574, 3.38, 0.207, 252, 242, CRYSTAL STRUCTURE OF EIF2ALPHA PROTEIN KINASE GCN2: WILD- TYPE IN APO FORM.
4600, d1bmkA_, 0.6574, 3.82, 0.190, 351, 252, THE COMPLEX STRUCTURE OF THE MAP KINASE P38/SB218655
4601, d5l2tA_, 0.6573, 2.72, 0.163, 261, 233, THE X-RAY CO-CRYSTAL STRUCTURE OF HUMAN CDK6 AND RIBOCICLIB.
4602, d4ibmB_, 0.6573, 3.65, 0.309, 294, 249, CRYSTAL STRUCTURE OF INSULIN RECEPTOR KINASE DOMAIN IN COMPLEX WITH AN INHIBITOR IRFIN-1
4603, d3w1fA_, 0.6573, 3.46, 0.167, 259, 246, CRYSTAL STRUCTURE OF HUMAN MPS1 CATALYTIC DOMAIN IN COMPLEX WITH 5-(5- ETHOXY-6-(1-METHYL-1H-PYRAZOL-4-YL)-1H-INDAZOL-3-YL)-2- METHYLBENZENESULFONAMIDE
4604, d2vwiC_, 0.6573, 3.33, 0.201, 270, 239, STRUCTURE OF THE OSR1 KINASE A HYPERTENSION DRUG TARGET
4605, d3p4kA_, 0.6572, 3.61, 0.200, 338, 245, THE THIRD CONFORMATION OF P38A MAP KINASE OBSERVED IN PHOSPHORYLATED P38A AND IN SOLUTION
4606, d3gfeA_, 0.6572, 3.69, 0.181, 352, 249, CRYSTAL STRUCTURE OF P38A MITOGEN-ACTIVATED PROTEIN KINASE IN COMPLEX WITH A PYRAZOLOPYRIDINONE INHIBITOR
4607, d1ol6A_, 0.6572, 3.17, 0.183, 245, 241, STRUCTURE OF UNPHOSPHORYLATED D274N MUTANT OF AURORA-A
4608, d1nxkD_, 0.6572, 3.08, 0.156, 277, 237, CRYSTAL STRUCTURE OF STAUROSPORINE BOUND TO MAP KAP KINASE 2
4609, d3o50B_, 0.6571, 3.25, 0.186, 249, 242, CRYSTAL STRUCTURE OF BENZAMIDE 9 BOUND TO AURORAA
4610, d4zsgA_, 0.6570, 3.80, 0.154, 347, 253, MITOGEN ACTIVATED PROTEIN KINASE 7 IN COMPLEX WITH INHIBITOR
4611, d4d2rA_, 0.6570, 3.86, 0.293, 300, 249, HUMAN IGF IN COMPLEX WITH A DYRK1B INHIBITOR
4612, d4cv9A1, 0.6570, 3.43, 0.167, 250, 245, MPS1 KINASE WITH 3-AMINOPYRIDIN-2-ONE INHIBITORS
4613, d2hy0A_, 0.6570, 3.60, 0.163, 272, 245, CRYSTAL STRUCTURE OF CHEK1 IN COMPLEX WITH INHIBITOR 22
4614, d2balA_, 0.6570, 3.69, 0.194, 337, 247, P38ALPHA MAP KINASE BOUND TO PYRAZOLOAMINE
4615, d1zycA1, 0.6570, 3.50, 0.184, 259, 245, CRYSTAL STRUCTURE OF EIF2ALPHA PROTEIN KINASE GCN2: WILD- TYPE IN APO FORM.
4616, d1f3mC_, 0.6570, 4.06, 0.187, 287, 256, CRYSTAL STRUCTURE OF HUMAN SERINE/THREONINE KINASE PAK1
4617, d5ljjA1, 0.6569, 3.28, 0.173, 260, 243, CRYSTAL STRUCTURE OF HUMAN MPS1 (TTK) IN COMPLEX WITH REVERSINE
4618, d4ftuA_, 0.6569, 3.49, 0.152, 270, 244, CRYSTAL STRUCTURE OF THE CHK1
4619, d2qg5A1, 0.6569, 3.87, 0.158, 268, 253, CRYPTOSPORIDIUM PARVUM CALCIUM DEPENDENT PROTEIN KINASE CGD7_1840
4620, d6btwB_, 0.6568, 3.92, 0.125, 301, 256, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A PHENYL-PTERIDINONE INHIBITOR
4621, d5tbeA_, 0.6568, 3.45, 0.168, 332, 244, HUMAN P38ALPHA MAP KINASE IN COMPLEX WITH DIBENZOSUBERONE COMPOUND 2
4622, d4m7iA1, 0.6568, 3.08, 0.191, 246, 236, CRYSTAL STRUCTURE OF GSK6157 BOUND TO PERK (R587-R1092 DELETE A660- T867) AT 2.34A RESOLUTION
4623, d3oxiA_, 0.6568, 3.09, 0.197, 322, 238, DESIGN AND SYNTHESIS OF DISUBSTITUTED THIOPHENE AND THIAZOLE BASED INHIBITORS OF JNK FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES
4624, d2qg5B1, 0.6568, 3.75, 0.156, 275, 250, CRYPTOSPORIDIUM PARVUM CALCIUM DEPENDENT PROTEIN KINASE CGD7_1840
4625, d5n9sA1, 0.6567, 3.52, 0.174, 256, 247, TTK KINASE DOMAIN IN COMPLEX WITH BAY 1161909
4626, p3vumA_, 0.6567, 3.18, 0.217, 347, 240, CRYSTAL STRUCTURE OF A CYSTEINE-DEFICIENT MUTANT M7 IN MAP KINASE JNK1
4627, d3r2yA_, 0.6567, 2.85, 0.150, 259, 233, MK2 KINASE BOUND TO COMPOUND 1
4628, d2c3lA_, 0.6567, 3.59, 0.154, 265, 246, IDENTIFICATION OF A BURIED POCKET FOR POTENT AND SELECTIVE INHIBITION OF CHK1: PREDICTION AND VERIFICATION
4629, d2brgA_, 0.6567, 3.36, 0.156, 257, 243, STRUCTURE-BASED DESIGN OF NOVEL CHK1 INHIBITORS: INSIGHTS INTO HYDROGEN BONDING AND PROTEIN-LIGAND AFFINITY
4630, d5k7iB_, 0.6566, 3.15, 0.229, 271, 236, IRAK4 IN COMPLEX WITH AZ3864
4631, d3sa0A_, 0.6566, 3.70, 0.144, 354, 250, COMPLEX OF ERK2 WITH NORATHYRIOL
4632, d3i81A_, 0.6566, 3.76, 0.298, 296, 248, CRYSTAL STRUCTURE OF INSULIN-LIKE GROWTH FACTOR 1 RECEPTOR (IGF-1R-WT) COMPLEX WITH BMS-754807 [1-(4-((5-CYCLOPROPYL- 1H-PYRAZOL-3-YL)AMINO)PYRROLO[21-F][124]TRIAZIN-2-YL)-N- (6-FLUORO-3-PYRIDINYL)-2-METHYL-L-PROLINAMIDE]
4633, d3fklA_, 0.6566, 3.79, 0.185, 344, 249, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH RO9552
4634, d2hogA_, 0.6566, 3.60, 0.167, 272, 245, CRYSTAL STRUCTURE OF CHEK1 IN COMPLEX WITH INHIBITOR 20
4635, d2c3jA_, 0.6566, 3.38, 0.160, 257, 243, IDENTIFICATION OF A BURIED POCKET FOR POTENT AND SELECTIVE INHIBITION OF CHK1: PREDICTION AND VERIFICATION
4636, d5byzA_, 0.6565, 3.81, 0.157, 348, 254, ERK5 IN COMPLEX WITH SMALL MOLECULE
4637, d4l7fA1, 0.6565, 3.37, 0.169, 343, 243, CO-CRYSTAL STRUCTURE OF JNK1 AND AX13587
4638, d4gsbA_, 0.6565, 3.63, 0.169, 343, 248, MONOCLINIC CRYSTAL FORM OF THE APO-ERK2
4639, d3nwwA_, 0.6565, 3.69, 0.190, 339, 248, P38 ALPHA KINASE COMPLEXED WITH A 2-AMINOTHIAZOL-5-YL-PYRIMIDINE BASED INHIBITOR
4640, d3hmoA_, 0.6565, 3.49, 0.166, 257, 247, CRYSTAL STRUCTURE OF HUMAN MPS1 CATALYTIC DOMAIN IN COMPLEX WITH THE INHIBITOR STAUROSPORINE
4641, d5l2iA_, 0.6564, 2.84, 0.154, 260, 234, THE X-RAY CO-CRYSTAL STRUCTURE OF HUMAN CDK6 AND PALBOCICLIB.
4642, d3flwA_, 0.6564, 3.61, 0.174, 345, 247, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH PAMAPIMOD
4643, d1yojA_, 0.6564, 2.61, 0.284, 233, 229, CRYSTAL STRUCTURE OF SRC KINASE DOMAIN
4644, d4bi1A1, 0.6563, 3.24, 0.169, 249, 242, SCAFFOLD FOCUSED VIRTUAL SCREENING: PROSPECTIVE APPLICATION TO THE DISCOVERY OF TTK INHIBITOR
4645, d3zz2A_, 0.6563, 3.79, 0.173, 281, 249,  
4646, d2w5bA1, 0.6563, 3.38, 0.167, 263, 245, HUMAN NEK2 KINASE ATPGAMMAS-BOUND
4647, d4js8A_, 0.6562, 3.37, 0.176, 259, 244, CRYSTAL STRUCTURE OF TTK KINASE DOMAIN WITH AN INHIBITOR: 401348
4648, d3gc8B_, 0.6562, 3.70, 0.173, 346, 248, THE STRUCTURE OF P38BETA C162S IN COMPLEX WITH A DIHYDROQUINAZOLINONE
4649, d2qkrA1, 0.6562, 2.93, 0.170, 269, 235, CRYPTOSPORIDIUM PARVUM CYCLIN-DEPENDENT KINASE CGD5_2510 WITH INDIRUBIN 3 -MONOXIME BOUND
4650, d2c6eA_, 0.6562, 3.45, 0.191, 251, 246, AURORA A KINASE ACTIVATED MUTANT (T287D) IN COMPLEX WITH A 5-AMINOPYRIMIDINYL QUINAZOLINE INHIBITOR
4651, d1nvqA_, 0.6562, 3.45, 0.156, 264, 244, THE COMPLEX STRUCTURE OF CHECKPOINT KINASE CHK1/UCN-01
4652, d5a6nA1, 0.6561, 3.26, 0.192, 270, 239, CRYSTAL STRUCTURE OF HUMAN DEATH ASSOCIATED PROTEIN KINASE 3 (DAPK3) IN COMPLEX WITH COMPOUND 2
4653, d2qg5D1, 0.6561, 3.80, 0.164, 267, 250, CRYPTOSPORIDIUM PARVUM CALCIUM DEPENDENT PROTEIN KINASE CGD7_1840
4654, d5etcA_, 0.6560, 3.85, 0.191, 355, 251, STRUCTURE OF INACTIVE MAPK14 WITH ORDERED ACTIVATION LOOP
4655, d4ft7A_, 0.6560, 3.55, 0.155, 270, 245, CRYSTAL STRUCTURE OF THE CHK1
4656, d3m42A_, 0.6560, 3.15, 0.155, 290, 238, CRYSTAL STRUCTURE OF MAPKAP KINASE 2 (MK2) COMPLEXED WITH A TETRACYCLIC ATP SITE INHIBITOR
4657, d2zazA_, 0.6560, 3.68, 0.194, 345, 247, CRYSTAL STRUCTURE OF P38 IN COMPLEX WITH 4-ANILINO QUINOLINE INHIBITOR
4658, d5ehoA1, 0.6559, 3.38, 0.171, 255, 245, RAPID DISCOVERY OF PYRIDO[34-D]PYRIMIDINE INHIBITORS OF MONOPOLAR SPINDLE KINASE 1 (MPS1) USING A STRUCTURE-BASED HYDRIDIZATION APPROACH
4659, d5fp5A_, 0.6558, 2.91, 0.190, 264, 232, STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH SMALL-MOLECULE LIGAND 4-FLUOROBENZOIC ACID (AT222) IN AN ALTERNATE BINDING SITE.
4660, d4kinA_, 0.6558, 3.58, 0.179, 338, 246, CRYSTAL STRUCTURE OF MITOGEN-ACTIVATED PROTEIN KINASE 14 (P38-H5) COMPLEX WITH 5-(2-CHLOROPHENYL)-N-(5-(CYCLOPROPYLCARBAMOYL)-2- METHYLPHENYL)-2-THIOPHENECARBOXAMIDE
4661, d4equB_, 0.6558, 3.72, 0.171, 282, 246, HUMAN STK-10 (LOK) KINASE DOMAIN IN DFG-OUT CONFORMATION WITH INHIBITOR DSA-7
4662, d4cvaA1, 0.6558, 3.35, 0.168, 250, 244, MPS1 KINASE WITH 3-AMINOPYRIDIN-2-ONE INHIBITORS
4663, d3op5C_, 0.6558, 3.93, 0.152, 308, 257, HUMAN VACCINIA-RELATED KINASE 1
4664, d1a9uA_, 0.6558, 3.98, 0.194, 351, 253, THE COMPLEX STRUCTURE OF THE MAP KINASE P38/SB203580
4665, d4qtaA_, 0.6557, 3.43, 0.167, 335, 245, STRUCTURE OF HUMAN ERK2 IN COMPLEX WITH SCH772984 REVEALING A NOVEL INHIBITOR-INDUCED BINDING POCKET
4666, p4loqC_, 0.6557, 3.76, 0.159, 337, 252, STRUCTURAL BASIS OF AUTOACTIVATION OF P38 ALPHA INDUCED BY TAB1 (TETRAGONAL CRYSTAL FORM WITH BOUND SULPHATE)
4667, d4xv2B1, 0.6556, 2.50, 0.229, 234, 227, B-RAF KINASE V600E ONCOGENIC MUTANT IN COMPLEX WITH DABRAFENIB
4668, d4qyfA_, 0.6556, 3.45, 0.156, 269, 244, CHK1 KINASE DOMAIN IN COMPLEX WITH AMINOPYRAZINE COMPOUND 13
4669, d4g31A1, 0.6556, 3.11, 0.191, 247, 236, CRYSTAL STRUCTURE OF GSK6414 BOUND TO PERK (R587-R1092 DELETE A660- T867) AT 2.28 A RESOLUTION
4670, d4ft9A_, 0.6556, 3.56, 0.156, 270, 244, CRYSTAL STRUCTURE OF THE CHK1
4671, d4ez5A_, 0.6556, 2.72, 0.155, 258, 232, CDK6 (MONOMERIC) IN COMPLEX WITH INHIBITOR
4672, d5ap3A1, 0.6555, 3.31, 0.177, 250, 243, NATURALLY OCCURRING MUTATIONS IN THE MPS1 GENE PREDISPOSE CELLS TO KINASE INHIBITOR DRUG RESISTANCE.
4673, d3u9nA_, 0.6555, 3.37, 0.177, 257, 243, X-RAY CRYSTAL STRUCTURE OF COMPOUND 1 BOUND TO HUMAN CHK1 KINASE DOMAIN
4674, d3qquB_, 0.6554, 3.67, 0.306, 288, 248, COCRYSTAL STRUCTURE OF UNPHOSPHORYLATED IGF WITH PYRIMIDINE 8
4675, d5o1vA_, 0.6553, 3.55, 0.225, 278, 240, CRYSTAL STRUCTURE OF WNK3 KINASE DOMAIN IN A MONOPHOSPHORYLATED APO STATE (A-LOOP SWAPPED)
4676, d4zloB_, 0.6553, 3.53, 0.210, 263, 243, SERINE/THREONINE-PROTEIN KINASE PAK1 COMPLEXED WITH A DIBENZODIAZEPINE: IDENTIFICATION OF AN ALLOSTERIC SITE ON PAK1
4677, d4fuyA_, 0.6553, 3.56, 0.142, 329, 247, CRYSTAL STRUCTURE OF THE ERK2 COMPLEXED WITH EK2
4678, d4czuD1, 0.6553, 3.63, 0.177, 296, 249, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF SNRK3.23 AT1G30270 T190D MUTANT
4679, d3o8uA_, 0.6553, 3.38, 0.182, 332, 242, CONFORMATIONAL PLASTICITY OF P38 MAP KINASE DFG MOTIF MUTANTS IN RESPONSE TO INHIBITOR BINDING
4680, d2pmiC_, 0.6553, 3.26, 0.145, 285, 242, STRUCTURE OF THE PHO85-PHO80 CDK-CYCLIN COMPLEX OF THE PHOSPHATE- RESPONSIVE SIGNAL TRANSDUCTION PATHWAY WITH BOUND ATP-GAMMA-S
4681, d4uzhA1, 0.6552, 3.29, 0.190, 250, 242, SAR156497 AN EXQUISITELY SELECTIVE INHIBITOR OF AURORA KINASES
4682, d4bi2A1, 0.6552, 3.34, 0.168, 250, 244, SCAFFOLD FOCUSED VIRTUAL SCREENING: PROSPECTIVE APPLICATION TO THE DISCOVERY OF TTK INHIBITOR
4683, d3u8wA_, 0.6552, 3.75, 0.172, 349, 250, CRYSTAL STRUCTURE OF P38A MITOGEN-ACTIVATED PROTEIN KINASE IN COMPLEX WITH A TRIAZOLOPYRIDAZINONE INHIBITOR
4684, d2wmrA_, 0.6552, 3.29, 0.158, 254, 241, CRYSTAL STRUCTURE OF CHECKPOINT KINASE 1 (CHK1) IN COMPLEX WITH INHIBITORS
4685, d1nvsA_, 0.6552, 3.46, 0.156, 264, 244, THE COMPLEX STRUCTURE OF CHECKPOINT KINASE CHK1/SB218078
4686, d4m68A_, 0.6551, 3.62, 0.193, 268, 249, CRYSTAL STRUCTURE OF THE MOUSE MLKL KINASE-LIKE DOMAIN
4687, d3ds6D_, 0.6551, 3.66, 0.173, 349, 249, P38 COMPLEX WITH A PHTHALAZINE INHIBITOR
4688, d1p38A_, 0.6551, 3.89, 0.183, 351, 252, THE STRUCTURE OF THE MAP KINASE P38 AT 2.1 ANGSTOMS RESOLUTION
4689, d4kbaA_, 0.6550, 3.65, 0.161, 263, 249, CK1D IN COMPLEX WITH 9-[3-(4-FLUOROPHENYL)-1-METHYL-1H-PYRAZOL-4-YL]- 2345-TETRAHYDROPYRIDO[23-F][14]OXAZEPINE INHIBITOR
4690, d4n0sA_, 0.6549, 3.68, 0.144, 348, 250, COMPLEX OF ERK2 WITH CAFFEIC ACID
4691, p3vulA_, 0.6549, 3.27, 0.216, 344, 241, CRYSTAL STRUCTURE OF A CYSTEINE-DEFICIENT MUTANT M1 IN MAP KINASE JNK1
4692, d3bv2A_, 0.6549, 3.49, 0.198, 337, 243, MORPHOLINO PYRROLOTRIAZINE P38 ALPHA MAP KINASE INHIBITOR COMPOUND 30
4693, d2jc6C_, 0.6549, 3.54, 0.180, 277, 244, CRYSTAL STRUCTURE OF HUMAN CALMODULIN-DEPENDENT PROTEIN KINASE 1D
4694, d5uisC_, 0.6548, 3.12, 0.225, 270, 236, CRYSTAL STRUCTURE OF IRAK4 IN COMPLEX WITH COMPOUND 12
4695, d4zxtA_, 0.6548, 3.73, 0.144, 348, 250, COMPLEX OF ERK2 WITH CATECHOL
4696, d4x7nA_, 0.6548, 3.41, 0.183, 259, 241, CO-CRYSTAL STRUCTURE OF PERK BOUND TO 4-[2-AMINO-4-METHYL-3-(2- METHYLQUINOLIN-6-YL)BENZOYL]-1-METHYL-25-DIPHENYL-12-DIHYDRO-3H- PYRAZOL-3-ONE INHIBITOR
4697, d4fsrA_, 0.6548, 3.58, 0.156, 269, 244, CRYSTAL STRUCTURE OF THE CHK1
4698, d3hv4A_, 0.6548, 3.56, 0.189, 339, 244, HUMAN P38 MAP KINASE IN COMPLEX WITH RL51
4699, d3tkhA_, 0.6547, 3.54, 0.156, 269, 243, CRYSTAL STRUCTURE OF CHK1 IN COMPLEX WITH INHIBITOR S01
4700, d6bp0C_, 0.6546, 4.09, 0.131, 315, 260, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE 1 BOUND TO (R)- 2-PHENYLAMINOPTERIDINONE INHIBITOR
4701, d4czuA1, 0.6546, 3.66, 0.177, 291, 249, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF SNRK3.23 AT1G30270 T190D MUTANT
4702, d1zzlA_, 0.6546, 3.87, 0.167, 351, 251, CRYSTAL STRUCTURE OF P38 WITH TRIAZOLOPYRIDINE
4703, d5fxsA1, 0.6545, 3.90, 0.285, 307, 249, IGFR-1R COMPLEX WITH A PYRIMIDINE INHIBITOR.
4704, d4zjjD_, 0.6545, 3.66, 0.193, 274, 249, PAK1 IN COMPLEX WITH (S)-N-(TERT-BUTYL)-3-((2-CHLORO-5-ETHYL-8-FLUORO- DIBENZODIAZEPIN-11-YL)AMINO)PYRROLIDINE-1-CARBOXAMIDE
4705, d3nw5A_, 0.6545, 3.74, 0.296, 302, 247, CRYSTAL STRUCTURE OF INSULIN-LIKE GROWTH FACTOR 1 RECEPTOR (IGF-1R-WT) COMPLEX WITH A CARBON-LINKED PROLINE ISOSTERE INHIBITOR (11B)
4706, d2z7sA_, 0.6545, 2.80, 0.185, 256, 232, CRYSTAL STRUCTURE OF THE N-TERMINAL KINASE DOMAIN OF HUMAN RSK1 BOUND TO PURVALNOL A
4707, d2z7qA_, 0.6545, 2.82, 0.194, 255, 232, CRYSTAL STRUCTURE OF THE N-TERMINAL KINASE DOMAIN OF HUMAN RSK-1 BOUND TO AMP-PCP
4708, d1zydA1, 0.6545, 3.55, 0.197, 268, 244, CRYSTAL STRUCTURE OF EIF2ALPHA PROTEIN KINASE GCN2: WILD- TYPE COMPLEXED WITH ATP.
4709, d6bruB_, 0.6544, 3.98, 0.125, 301, 256, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A (S)- 2-PHENYLAMINOPTERIDINONE INHIBITOR
4710, d4fszA_, 0.6544, 3.53, 0.156, 268, 243, CRYSTAL STRUCTURE OF THE CHK1
4711, d3uvrA_, 0.6543, 3.50, 0.196, 331, 245, HUMAN P38 MAP KINASE IN COMPLEX WITH KM064
4712, d3o50A_, 0.6543, 3.20, 0.183, 246, 240, CRYSTAL STRUCTURE OF BENZAMIDE 9 BOUND TO AURORAA
4713, d3nnxA_, 0.6543, 3.61, 0.189, 336, 243, CRYSTAL STRUCTURE OF PHOSPHORYLATED P38 ALPHA IN COMPLEX WITH DP802
4714, d3flsA_, 0.6543, 3.57, 0.176, 343, 245, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH 6-(24- DIFLUORO-PHENOXY)-2-((R)-2-METHANESULFONYL-1-METHYL- ETHYLAMINO)-8-METHYL-8H-PYRIDO[23-D]PYRIMIDIN-7-ONE
4715, d2yixA_, 0.6543, 3.91, 0.167, 351, 252, TRIAZOLOPYRIDINE INHIBITORS OF P38
4716, d5k75A_, 0.6542, 3.08, 0.221, 271, 235, IRAK4 IN COMPLEX WITH COMPOUND 1
4717, d5etiA1, 0.6542, 3.79, 0.173, 352, 249, STRUCTURE OF DEAD KINASE MAPK14
4718, d3lffA_, 0.6542, 3.52, 0.189, 335, 244, HUMAN P38 MAP KINASE IN COMPLEX WITH RL166
4719, d4kkeA_, 0.6541, 3.65, 0.152, 354, 250, THE CRYSTAL STRUCTURE OF AMP-BOUND JNK3
4720, d3p7cA_, 0.6541, 3.35, 0.203, 332, 241, P38 INHIBITOR-BOUND
4721, d2r0iA_, 0.6541, 3.50, 0.207, 300, 246, CRYSTAL STRUCTURE OF A KINASE MARK2/PAR-1 MUTANT
4722, d6bruC_, 0.6540, 4.10, 0.131, 315, 260, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A (S)- 2-PHENYLAMINOPTERIDINONE INHIBITOR
4723, d2c6eB_, 0.6540, 3.20, 0.179, 246, 240, AURORA A KINASE ACTIVATED MUTANT (T287D) IN COMPLEX WITH A 5-AMINOPYRIMIDINYL QUINAZOLINE INHIBITOR
4724, d5k76A_, 0.6539, 3.21, 0.224, 270, 237, IRAK4 IN COMPLEX WITH COMPOUND 28
4725, d6bu6C_, 0.6538, 4.04, 0.131, 315, 259, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A BIS- DIFLUOROPHENOL-AMINOPYRIDINE INHIBITOR
4726, d6btwC_, 0.6538, 4.01, 0.128, 315, 258, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A PHENYL-PTERIDINONE INHIBITOR
4727, p5o90A_, 0.6538, 3.73, 0.169, 330, 249, CRYSTAL STRUCTURE OF A P38ALPHA T185G MUTANT IN COMPLEX WITH TAB1 PEPTIDE.
4728, d3bv3A_, 0.6538, 3.65, 0.196, 338, 245, MORPHOLINO PYRROLOTRIAZINE P38 ALPHA MAP KINASE INHIBITOR COMPOUND 2
4729, d2fa2A_, 0.6538, 3.46, 0.162, 333, 247, CRYSTAL STRUCTURE OF FUS3 WITHOUT A PEPTIDE FROM STE5
4730, d1nvrA_, 0.6538, 3.49, 0.156, 264, 244, THE COMPLEX STRUCTURE OF CHECKPOINT KINASE CHK1/STAUROSPORINE
4731, d5n7vA1, 0.6537, 3.38, 0.172, 257, 244, TTK KINASE DOMAIN IN COMPLEX WITH MPI-0479605
4732, d1muoA_, 0.6537, 3.38, 0.189, 251, 243, CRYSTAL STRUCTURE OF AURORA-2 AN ONCOGENIC SERINE- THREONINE KINASE
4733, d4jikA_, 0.6536, 3.32, 0.170, 256, 241, X-RAY CRYSTAL STRUCTURE OF COMPOUND 22A (R)-2-(4-CHLOROPHENYL)-8- (PIPERIDIN-3-YLAMINO)IMIDAZO[12-C]PYRIMIDINE-5-CARBOXAMIDE BOUND TO HUMAN CHK1 KINASE DOMAIN
4734, d3mvmB_, 0.6536, 3.35, 0.183, 332, 240, P38 ALPHA MAP KINASE COMPLEXED WITH PYRROLOTRIAZINE INHIBITOR 7V
4735, d3aqvA_, 0.6536, 3.23, 0.178, 267, 241, HUMAN AMP-ACTIVATED PROTEIN KINASE ALPHA 2 SUBUNIT KINASE DOMAIN (T172D) COMPLEXED WITH COMPOUND C
4736, d4zslA_, 0.6535, 3.91, 0.158, 341, 253, MITOGEN ACTIVATED PROTEIN KINASE 7 IN COMPLEX WITH INHIBITOR
4737, d2bvaA_, 0.6535, 3.70, 0.182, 272, 247, CRYSTAL STRUCTURE OF THE HUMAN P21-ACTIVATED KINASE 4
4738, p4d28A_, 0.6534, 3.45, 0.164, 274, 244, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF SNRK3.11 AT5G35410
4739, d2rg5A_, 0.6534, 3.46, 0.186, 333, 242, PHENYLALANINE PYRROLOTRIAZINE P38 ALPHA MAP KINASE INHIBITOR COMPOUND 11B
4740, d1oiqA_, 0.6534, 2.87, 0.173, 264, 231, IMIDAZOPYRIDINES: A POTENT AND SELECTIVE CLASS OF CYCLIN-DEPENDENT KINASE INHIBITORS IDENTIFIED THROUGH STRUCTURE-BASED HYBRIDISATION
4741, d4kkhA_, 0.6533, 3.61, 0.157, 351, 249, THE CRYSTAL STRUCTURE OF INHIBITOR-BOUND JNK3
4742, d4ftjA_, 0.6533, 3.53, 0.153, 266, 242, CRYSTAL STRUCTURE OF THE CHK1
4743, d3odzX_, 0.6533, 3.48, 0.207, 335, 242, CRYSTAL STRUCTURE OF P38ALPHA Y323R ACTIVE MUTANT
4744, d3o0gB_, 0.6533, 2.87, 0.147, 264, 232, CRYSTAL STRUCTURE OF CDK5:P25 IN COMPLEX WITH AN ATP ANALOGUE
4745, d2zmcA_, 0.6533, 3.64, 0.165, 260, 249, CRYSTAL STRUCTURE OF HUMAN MITOTIC CHECKPOINT KINASE MPS1 CATALYTIC DOMAIN APO FORM
4746, d3orkA1, 0.6532, 3.58, 0.156, 272, 244, MYCOBACTERIUM TUBERCULOSIS PKNB KINASE DOMAIN L33D MUTANT (CRYSTAL FORM 2)
4747, d1zmwA_, 0.6532, 3.50, 0.199, 302, 246, CATALYTIC AND UBIQUTIN-ASSOCIATED DOMAINS OF MARK2/PAR-1: T208A/S212A INACTIVE DOUBLE MUTANT
4748, d4x7kA_, 0.6531, 3.44, 0.183, 260, 241, CO-CRYSTAL STRUCTURE OF PERK BOUND TO 4-{2-AMINO-3-[5-FLUORO-2- (METHYLAMINO)QUINAZOLIN-6-YL]-4-METHYLBENZOYL}-1-METHYL-25-DIPHENYL- 12-DIHYDRO-3H-PYRAZOL-3-ONE INHIBITOR
4749, d3ds6B_, 0.6531, 3.66, 0.173, 343, 248, P38 COMPLEX WITH A PHTHALAZINE INHIBITOR
4750, d5up3B_, 0.6530, 2.84, 0.215, 243, 233, STRUCTURE-BASED DESIGN OF ASK1 INHIBITORS AS POTENTIAL FIRST-IN-CLASS AGENTS FOR HEART FAILURE
4751, d1ungB_, 0.6530, 3.05, 0.157, 268, 236, STRUCTURAL MECHANISM FOR THE INHIBITION OF CDK5-P25 BY ROSCOVITINE ALOISINE AND INDIRUBIN.
4752, d3kgaA_, 0.6529, 3.13, 0.155, 290, 238, CRYSTAL STRUCTURE OF MAPKAP KINASE 2 (MK2) COMPLEXED WITH A POTENT 3-AMINOPYRAZOLE ATP SITE INHIBITOR
4753, d1zyjA_, 0.6529, 3.37, 0.183, 331, 240, HUMAN P38 MAP KINASE IN COMPLEX WITH INHIBITOR 1A
4754, d5d1jA_, 0.6528, 2.75, 0.170, 265, 230, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 (CDK2-WT) COMPLEX WITH N-[5-[[[5-(11-DIMETHYLETHYL)-2-OXAZOLYL] METHYL]THIO]-2-THIAZOLYL]- 4-PIPERIDINECARBOXAMIDE (BMS-387032)
4755, d3ptgA_, 0.6528, 3.35, 0.203, 340, 241, DESIGN AND SYNTHESIS OF A NOVEL ORALLY EFFICACIOUS TRI-SUBSTITUTED THIOPHENE BASED JNK INHIBITOR
4756, d3orpA_, 0.6528, 3.65, 0.147, 274, 245, MYCOBACTERIUM TUBERCULOSIS PKNB KINASE DOMAIN L33D MUTANT (CRYSTAL FORM 5)
4757, d3gcvA_, 0.6528, 3.59, 0.198, 338, 243, HUMAN P38 MAP KINASE IN COMPLEX WITH RL62
4758, d3flnC_, 0.6527, 3.55, 0.176, 343, 245, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH R1487
4759, d1w7hA_, 0.6527, 3.96, 0.191, 351, 251, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH SMALL MOLECULE INHIBITOR
4760, d4u97B_, 0.6526, 2.99, 0.196, 270, 230, CRYSTAL STRUCTURE OF ASYMMETRIC IRAK4 DIMER
4761, d3odyX_, 0.6526, 3.45, 0.203, 321, 241, CRYSTAL STRUCTURE OF P38ALPHA Y323Q ACTIVE MUTANT
4762, d1zmwB_, 0.6526, 3.45, 0.204, 302, 245, CATALYTIC AND UBIQUTIN-ASSOCIATED DOMAINS OF MARK2/PAR-1: T208A/S212A INACTIVE DOUBLE MUTANT
4763, d4u9aB_, 0.6525, 3.07, 0.199, 270, 231, SULPHUR ANOMALOUS CRYSTAL STRUCTURE OF ASYMMETRIC IRAK4 DIMER
4764, d3uysA_, 0.6525, 3.93, 0.146, 281, 253, CRYSTAL STRUCTURE OF APO HUMAN CK1D
4765, d3lauA1, 0.6525, 3.27, 0.187, 250, 241, CRYSTAL STRUCTURE OF AURORA2 KINASE IN COMPLEX WITH A GSK3BETA INHIBITOR
4766, d2f49B_, 0.6525, 3.45, 0.162, 337, 247, CRYSTAL STRUCTURE OF FUS3 IN COMPLEX WITH A STE5 PEPTIDE
4767, d5ei6A1, 0.6524, 3.53, 0.166, 261, 247, RAPID DISCOVERY OF PYRIDO[34-D]PYRIMIDINE INHIBITORS OF MONOPOLAR SPINDLE KINASE 1 (MPS1) USING A STRUCTURE-BASED HYDRIDIZATION APPROACH
4768, d4x7lA_, 0.6524, 3.45, 0.183, 260, 241, CO-CRYSTAL STRUCTURE OF PERK BOUND TO 4-{2-AMINO-4-METHYL-3-[2- (METHYLAMINO)-13-BENZOTHIAZOL-6-YL]BENZOYL}-1-METHYL-25-DIPHENYL-1 2-DIHYDRO-3H-PYRAZOL-3-ONE INHIBITOR
4769, d4kbkD_, 0.6524, 3.93, 0.146, 281, 253, CK1D IN COMPLEX WITH (3S)-3-{4-[3-(4-FLUOROPHENYL)-1-METHYL-1H- PYRAZOL-4-YL]PYRIDIN-2-YL}MORPHOLINE INHIBITOR
4770, d2y4pC_, 0.6524, 3.18, 0.182, 264, 236, DIMERIC STRUCTURE OF DAPK-1 CATALYTIC DOMAIN
4771, d4y46A_, 0.6523, 3.53, 0.157, 340, 248, PYRIDOPYRIMIDINONE DERIVATIVES AS POTENT AND SELECTIVE C-JUN N- TERMINAL KINASE (JNK) INHIBITORS
4772, d4othA_, 0.6523, 3.86, 0.190, 305, 248, CRYSTAL STRUCTURE OF PRK1 CATALYTIC DOMAIN IN COMPLEX WITH RO-31-8220
4773, d4fsyA_, 0.6523, 3.52, 0.157, 267, 242, CRYSTAL STRUCTURE OF THE CHK1
4774, d3d83A_, 0.6523, 3.70, 0.187, 347, 246, CRYSTAL STRUCTURE OF P38 KINASE IN COMPLEX WITH A BIPHENYL AMIDE INHIBITOR
4775, d3cohB_, 0.6523, 3.37, 0.177, 247, 243, CRYSTAL STRUCTURE OF AURORA-A IN COMPLEX WITH A PENTACYCLIC INHIBITOR
4776, d2ym6A_, 0.6523, 3.31, 0.154, 253, 240, CRYSTAL STRUCTURE OF CHECKPOINT KINASE 1 (CHK1) IN COMPLEX WITH INHIBITORS
4777, p4fzfB_, 0.6522, 2.92, 0.247, 245, 231, CRYSTAL STRUCTURE OF MST4-MO25 COMPLEX WITH DKI
4778, d3gcuA_, 0.6522, 3.61, 0.189, 339, 244, HUMAN P38 MAP KINASE IN COMPLEX WITH RL48
4779, d3fmjA_, 0.6522, 3.73, 0.171, 344, 246, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH 4-(5-METHYL-3-PHENYL- ISOXAZOL-4-YL)-PYRIMIDIN-2-YLAMINE
4780, d3ds6A_, 0.6522, 3.69, 0.169, 343, 248, P38 COMPLEX WITH A PHTHALAZINE INHIBITOR
4781, d4x7hA_, 0.6521, 3.37, 0.183, 256, 240, CO-CRYSTAL STRUCTURE OF PERK BOUND TO N-{5-[(67-DIMETHOXYQUINOLIN-4- YL)OXY]PYRIDIN-2-YL}-1-METHYL-3-OXO-2-PHENYL-5-(PYRIDIN-4-YL)-23- DIHYDRO-1H-PYRAZOLE-4-CARBOXAMIDE INHIBITOR
4782, d3pa3A_, 0.6521, 3.44, 0.169, 259, 243, X-RAY CRYSTAL STRUCTURE OF COMPOUND 70 BOUND TO HUMAN CHK1 KINASE DOMAIN
4783, d3p5kA_, 0.6521, 3.39, 0.195, 332, 241, P38 INHIBITOR-BOUND
4784, d3ckwA_, 0.6521, 3.60, 0.217, 255, 244, CRYSTAL STRUCTURE OF STERILE 20-LIKE KINASE 3 (MST3 STK24)
4785, d4xv2A1, 0.6520, 2.38, 0.227, 232, 225, B-RAF KINASE V600E ONCOGENIC MUTANT IN COMPLEX WITH DABRAFENIB
4786, d3hmnA_, 0.6520, 3.46, 0.171, 255, 245, CRYSTAL STRUCTURE OF HUMAN MPS1 CATALYTIC DOMAIN IN COMPLEX WITH ATP
4787, d2hakD_, 0.6520, 3.80, 0.187, 309, 251, CATALYTIC AND UBIQUTIN-ASSOCIATED DOMAINS OF MARK1/PAR-1
4788, d6b4wA_, 0.6519, 3.44, 0.171, 259, 245, TTK IN COMPLEX WITH INHIBITOR
4789, d4jt3A_, 0.6519, 3.49, 0.167, 254, 245, CRYSTAL STRUCTURE OF TTK KINASE DOMAIN WITH AN INHIBITOR: 400740
4790, d4c4iA1, 0.6519, 3.46, 0.171, 250, 245, STRUCTURE-BASED DESIGN OF ORALLY BIOAVAILABLE PYRROLOPYRIDINE INHIBITORS OF THE MITOTIC KINASE MPS1
4791, d3wzuA_, 0.6519, 3.73, 0.214, 270, 248, THE STRUCTURE OF MAP2K7 IN COMPLEX WITH 5Z-7-OXOZEAENOL
4792, d3cekA1, 0.6519, 3.57, 0.166, 252, 247, CRYSTAL STRUCTURE OF HUMAN DUAL SPECIFICITY PROTEIN KINASE (TTK)
4793, d5uvfD_, 0.6518, 3.91, 0.114, 296, 254, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO BI- D1870
4794, d3cohA_, 0.6518, 3.38, 0.177, 247, 243, CRYSTAL STRUCTURE OF AURORA-A IN COMPLEX WITH A PENTACYCLIC INHIBITOR
4795, d4c4jA1, 0.6517, 3.44, 0.176, 258, 244, STRUCTURE-BASED DESIGN OF ORALLY BIOAVAILABLE PYRROLOPYRIDINE INHIBITORS OF THE MITOTIC KINASE MPS1
4796, d3itzA1, 0.6517, 3.78, 0.177, 353, 248, CRYSTAL STRUCTURE OF P38A MITOGEN-ACTIVATED PROTEIN KINASE IN COMPLEX WITH A PYRAZOLOPYRIDAZINE INHIBITOR
4797, d4bhzA1, 0.6516, 3.31, 0.166, 248, 241, SCAFFOLD FOCUSED VIRTUAL SCREENING: PROSPECTIVE APPLICATION TO THE DISCOVERY OF TTK INHIBITOR
4798, d2zmdA_, 0.6516, 3.66, 0.165, 259, 248, CRYSTAL STRUCTURE OF HUMAN MPS1 CATALYTIC DOMAIN T686A MUTANT IN COMPLEX WITH SP600125 INHIBITOR
4799, d4ftrA_, 0.6515, 3.46, 0.154, 258, 241, CRYSTAL STRUCTURE OF THE CHK1
4800, d3pzeA_, 0.6515, 3.56, 0.167, 347, 246, JNK1 IN COMPLEX WITH INHIBITOR
4801, d3fknA_, 0.6515, 3.66, 0.175, 346, 246, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH RO7125
4802, d2o8yB_, 0.6515, 3.12, 0.209, 266, 235, APO IRAK4 KINASE DOMAIN
4803, d4hokM_, 0.6512, 4.21, 0.142, 291, 261, CRYSTAL STRUCTURE OF APO CK1E
4804, d2pkjA_, 0.6512, 3.44, 0.187, 332, 241,  
4805, d5dlsA_, 0.6511, 3.42, 0.165, 257, 242, IDENTIFICATION OF NOVEL IN VIVO ACTIVE CHK1 INHIBITORS UTILIZING STRUCTURE GUIDED DRUG DESIGN
4806, d4w4wA_, 0.6511, 3.58, 0.161, 349, 248, JNK2/3 IN COMPLEX WITH N-(2-METHYLPYRIDIN-4-YL)-3-{4- [(PHENYLCARBAMOYL)AMINO]-1H-PYRAZOL-1-YL}BENZAMIDE
4807, d4kkgA_, 0.6511, 3.66, 0.153, 353, 249, CRYSTAL STRUCTURE OF APO AND AMP-BOUND JNK3
4808, d3m2wA_, 0.6511, 3.10, 0.160, 290, 237, CRYSTAL STRUCTURE OF MAPKAK KINASE 2 (MK2) COMPLEXED WITH A SPIROAZETIDINE-TETRACYCLIC ATP SITE INHIBITOR
4809, d3bx5A_, 0.6511, 3.59, 0.176, 338, 245, P38 ALPHA MAP KINASE COMPLEXED WITH BMS-640994
4810, d1oz1A_, 0.6511, 3.76, 0.190, 344, 247, P38 MITOGEN-ACTIVATED KINASE IN COMPLEX WITH 4-AZAINDOLE INHIBITOR
4811, d5owrA_, 0.6510, 3.93, 0.169, 282, 248, HUMAN STK10 BOUND TO DASATINIB
4812, d5ew9A_, 0.6510, 3.50, 0.198, 257, 243, CRYSTAL STRUCTURE OF AURORA A KINASE DOMAIN BOUND TO MK-5108
4813, d3hv5A_, 0.6510, 3.61, 0.189, 339, 244, HUMAN P38 MAP KINASE IN COMPLEX WITH RL24
4814, d2zdtA_, 0.6510, 3.54, 0.159, 342, 246, CRYSTAL STRUCTURE OF HUMAN JNK3 COMPLEXED WITH AN ISOQUINOLONE INHIBITOR
4815, d1f3mD_, 0.6510, 4.16, 0.188, 285, 255, CRYSTAL STRUCTURE OF HUMAN SERINE/THREONINE KINASE PAK1
4816, d4o6lA_, 0.6509, 3.54, 0.176, 257, 244, CRYSTAL STRUCTURE OF TTK KINASE DOMAIN WITH AN INHIBITOR: 401498 (N- [(1R)-1-(2-CHLOROPHENYL)PROPYL]-3-{4-[(1-METHYLPIPERIDIN-4-YL) OXY]PHENYL}-1H-INDAZOLE-5-CARBOXAMIDE)
4817, d5o1vB_, 0.6508, 3.57, 0.218, 270, 239, CRYSTAL STRUCTURE OF WNK3 KINASE DOMAIN IN A MONOPHOSPHORYLATED APO STATE (A-LOOP SWAPPED)
4818, d4y5hA_, 0.6508, 3.67, 0.161, 349, 249, PYRIDOPYRIMIDINONE DERIVATIVES AS POTENT AND SELECTIVE C-JUN N- TERMINAL KINASE (JNK) INHIBITORS
4819, d4kbaD_, 0.6508, 3.91, 0.143, 274, 252, CK1D IN COMPLEX WITH 9-[3-(4-FLUOROPHENYL)-1-METHYL-1H-PYRAZOL-4-YL]- 2345-TETRAHYDROPYRIDO[23-F][14]OXAZEPINE INHIBITOR
4820, d2pmiA_, 0.6508, 3.32, 0.150, 284, 240, STRUCTURE OF THE PHO85-PHO80 CDK-CYCLIN COMPLEX OF THE PHOSPHATE- RESPONSIVE SIGNAL TRANSDUCTION PATHWAY WITH BOUND ATP-GAMMA-S
4821, d5eykA_, 0.6507, 3.88, 0.155, 263, 252, CRYSTAL STRUCTURE OF AURORA B IN COMPLEX WITH BI 847325
4822, d4cztA1, 0.6507, 3.65, 0.169, 289, 248, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF SNRK3.23 AT1G30270
4823, d2j90B_, 0.6507, 3.11, 0.198, 262, 232, CRYSTAL STRUCTURE OF HUMAN ZIP KINASE IN COMPLEX WITH A TETRACYCLIC PYRIDONE INHIBITOR (PYRIDONE 6)
4824, d1jsuA_, 0.6507, 3.65, 0.160, 285, 244, P27(KIP1)/CYCLIN A/CDK2 COMPLEX
4825, d4gh2A_, 0.6506, 3.49, 0.158, 266, 241, CRYSTAL STRUCTURE OF THE CHK1
4826, d3oz6A_, 0.6505, 3.71, 0.161, 343, 248, CRYSTAL STRUCTURE OF MAPK FROM CRYPTOSPORIDIUM PARVUM CGD2_1960
4827, d3mh0A_, 0.6505, 3.44, 0.183, 332, 241, MUTAGENESIS OF P38 MAP KINASE ESHTABLISHES KEY ROLES OF PHE169 IN FUNCTION AND STRUCTURAL DYNAMICS AND REVEALS A NOVEL DFG-OUT STATE
4828, d3mgyA_, 0.6505, 3.31, 0.189, 329, 238, MUTAGENESIS OF P38 MAP KINASE ESHTABLISHES KEY ROLES OF PHE169 IN FUNCTION AND STRUCTURAL DYNAMICS AND REVEALS A NOVEL DFG-OUT STATE
4829, d3gp0A1, 0.6505, 3.40, 0.193, 332, 238, CRYSTAL STRUCTURE OF HUMAN MITOGEN ACTIVATED PROTEIN KINASE 11 (P38 BETA) IN COMPLEX WITH NILOTINIB
4830, d4xv3A1, 0.6504, 2.43, 0.209, 232, 225, B-RAF KINASE V600E ONCOGENIC MUTANT IN COMPLEX WITH PLX7922
4831, d3qquD_, 0.6504, 3.80, 0.300, 292, 247, COCRYSTAL STRUCTURE OF UNPHOSPHORYLATED IGF WITH PYRIMIDINE 8
4832, d3p7aA_, 0.6504, 3.43, 0.195, 332, 241, P38 INHIBITOR-BOUND
4833, d1r39A_, 0.6504, 3.76, 0.178, 345, 247, THE STRUCTURE OF P38ALPHA
4834, d5a14A_, 0.6503, 3.39, 0.160, 284, 243, HUMAN CDK2 WITH TYPE II INHIBITOR
4835, d4kb8D_, 0.6503, 3.94, 0.146, 278, 253, CK1D IN COMPLEX WITH 1-{4-[3-(4-FLUOROPHENYL)-1-METHYL-1H-PYRAZOL-4- YL]PYRIDIN-2-YL}-N-METHYLMETHANAMINE LIGAND
4836, d3pa4A_, 0.6503, 3.42, 0.169, 257, 242, X-RAY CRYSTAL STRUCTURE OF COMPOUND 2A BOUND TO HUMAN CHK1 KINASE DOMAIN
4837, d3p7bA_, 0.6503, 3.41, 0.191, 332, 241, P38 INHIBITOR-BOUND
4838, d3hllA_, 0.6503, 3.61, 0.176, 337, 245, CRYSTAL STRUCTURE OF HUMAN P38ALPHA COMPLEXED WITH PH-797804
4839, d3fmkA_, 0.6503, 3.70, 0.174, 346, 247, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH 6-(24-DIFLUORO-PHENOXY)- 8-METHYL-2-((S)-1-METHYL-2-TETRAZOL-2-YL-ETHYLAMINO)-8H-PYRIDO[23- D]PYRIMIDIN-7-ONE
4840, d2pv5A_, 0.6503, 3.33, 0.189, 329, 238,  
4841, d4x7jA_, 0.6502, 3.46, 0.187, 257, 240, CO-CRYSTAL STRUCTURE OF PERK WITH 2-AMINO-N-[4-METHOXY-3- (TRIFLUOROMETHYL)PHENYL]-4-METHYL-3-[2-(METHYLAMINO)QUINAZOLIN-6- YL]BENZAMIDE INHIBITOR
4842, d4c4gA1, 0.6502, 3.29, 0.174, 247, 241, STRUCTURE-BASED DESIGN OF ORALLY BIOAVAILABLE PYRROLOPYRIDINE INHIBITORS OF THE MITOTIC KINASE MPS1
4843, d1yqjA2, 0.6502, 3.77, 0.190, 351, 248, CRYSTAL STRUCTURE OF P38 ALPHA IN COMPLEX WITH A SELECTIVE PYRIDAZINE INHIBITOR
4844, d3op5D_, 0.6501, 4.06, 0.141, 302, 256, HUMAN VACCINIA-RELATED KINASE 1
4845, d4auaA_, 0.6500, 2.64, 0.158, 256, 228, LIGANDED X-RAY CRYSTAL STRUCTURE OF CYCLIN DEPENDENT KINASE 6 (CDK6)
4846, d3rinA_, 0.6500, 3.95, 0.171, 349, 251, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH SMALL MOLECULE INHIBITOR
4847, d3p79A_, 0.6500, 3.46, 0.195, 332, 241, P38 INHIBITOR-BOUND
4848, d2lgcA1, 0.6500, 3.85, 0.153, 353, 249, JOINT NMR AND X-RAY REFINEMENT REVEALS THE STRUCTURE OF A NOVEL DIBENZO[AD]CYCLOHEPTENONE INHIBITOR/P38 MAP KINASE COMPLEX IN SOLUTION
4849, d5awmA_, 0.6499, 3.52, 0.167, 345, 245, THE CRYSTAL STRUCTURE OF JNK FROM DROSOPHILA MELANOGASTER REVEALS AN EVOLUTIONARILY CONSERVED TOPOLOGY WITH THAT OF MAMMALIAN JNK PROTEINS.
4850, d4fa2A_, 0.6499, 3.74, 0.182, 339, 247, HUMAN P38 ALPHA MITOGEN-ACTIVATED KINASE IN COMPLEX WITH SB239063
4851, d3uiuB_, 0.6499, 2.89, 0.166, 255, 229, CRYSTAL STRUCTURE OF APO-PKR KINASE DOMAIN
4852, d3uiuA_, 0.6499, 2.89, 0.166, 255, 229, CRYSTAL STRUCTURE OF APO-PKR KINASE DOMAIN
4853, d3qquC_, 0.6499, 3.84, 0.296, 293, 247, COCRYSTAL STRUCTURE OF UNPHOSPHORYLATED IGF WITH PYRIMIDINE 8
4854, d3gfwA1, 0.6499, 3.35, 0.174, 249, 242, CRYSTAL STRUCTURE OF HUMAN DUAL SPECIFICITY PROTEIN KINASE (TTK) IN COMPLEX WITH A PYROLO-PYRIDIN LIGAND
4855, d3flqA_, 0.6499, 3.75, 0.191, 345, 246, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH 6-(24- DIFLUORO-PHENOXY)-2-((S)-2-METHANESULFONYL-1-METHYL- ETHYLAMINO)-8-METHYL-8H-PYRIDO[23-D]PYRIMIDIN
4856, d2p4iA_, 0.6499, 2.69, 0.356, 252, 225, EVOLUTION OF A HIGHLY SELECTIVE AND POTENT 2-(PYRIDIN-2-YL)- 135-TRIAZINE TIE-2 KINASE INHIBITOR
4857, d3p78A_, 0.6498, 3.46, 0.195, 332, 241, P38 INHIBITOR-BOUND
4858, d5b2lA_, 0.6495, 4.09, 0.237, 288, 257, A CRUCIAL ROLE OF CYS218 IN THE STABILIZATION OF AN UNPRECEDENTED AUTO-INHIBITION FORM OF MAP2K7
4859, d2wtvB_, 0.6494, 3.55, 0.187, 261, 246, AURORA-A INHIBITOR STRUCTURE
4860, d3uvpA_, 0.6493, 3.52, 0.174, 334, 242, HUMAN P38 MAP KINASE IN COMPLEX WITH A BENZAMIDE SUBSTITUTED BENZOSUBERONE
4861, d2wtvC_, 0.6493, 3.55, 0.187, 261, 246, AURORA-A INHIBITOR STRUCTURE
4862, d5fxqA1, 0.6492, 3.90, 0.287, 301, 247, IGFR-1R COMPLEX WITH A PYRIMIDINE INHIBITOR.
4863, d5a6oA_, 0.6492, 3.18, 0.191, 265, 236, CRYSTAL STRUCTURE OF THE APO FORM OF THE UNPHOSPHORYLATED HUMAN DEATH ASSOCIATED PROTEIN KINASE 3 (DAPK3)
4864, d4w4xA_, 0.6492, 3.78, 0.155, 342, 251, JNK2/3 IN COMPLEX WITH 3-(4-{[(4-FLUOROPHENYL)CARBAMOYL]AMINO}-1H- PYRAZOL-1-YL)-N-(2-METHYLPYRIDIN-4-YL)BENZAMIDE
4865, d2fa2B_, 0.6491, 3.53, 0.159, 332, 245, CRYSTAL STRUCTURE OF FUS3 WITHOUT A PEPTIDE FROM STE5
4866, d5x18B_, 0.6490, 4.46, 0.129, 294, 264, CRYSTAL STRUCTURE OF CASEIN KINASE I HOMOLOG 1
4867, d4o2zA1, 0.6489, 3.56, 0.189, 357, 244, CRYSTAL STRUCTURE OF MPK3 FROM LEISHMANIA DONOVANI LDBPK_100540 IN THE PRESENCE OF NVP-BBT594
4868, d4cztD1, 0.6489, 3.73, 0.181, 296, 249, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF SNRK3.23 AT1G30270
4869, d3oefX_, 0.6489, 3.64, 0.193, 334, 244, CRYSTAL STRUCTURE OF Y323F INACTIVE MUTANT OF P38ALPHA MAP KINASE
4870, d3eljA_, 0.6489, 3.50, 0.167, 347, 245, JNK1 COMPLEXED WITH A BIS-ANILINO-PYRROLOPYRIMIDINE INHIBITOR.
4871, d5ap6A1, 0.6488, 3.50, 0.171, 259, 246, NATURALLY OCCURRING MUTATIONS IN THE MPS1 GENE PREDISPOSE CELLS TO KINASE INHIBITOR DRUG RESISTANCE.
4872, d4w4yA_, 0.6488, 3.78, 0.155, 350, 251, JNK2/3 IN COMPLEX WITH 3-(4-{[(4-METHYLPHENYL)CARBAMOYL]AMINO}-1H- PYRAZOL-1-YL)-N-(2-METHYLPYRIDIN-4-YL)BENZAMIDE
4873, d3f61A_, 0.6488, 3.53, 0.145, 271, 241, CRYSTAL STRUCTURE OF M. TUBERCULOSIS PKNB LEU33ASP/VAL222ASP DOUBLE MUTANT IN COMPLEX WITH ADP
4874, d1jnkA_, 0.6488, 3.62, 0.154, 346, 247, THE C-JUN N-TERMINAL KINASE (JNK3S) COMPLEXED WITH MGAMP-PNP
4875, d4awiA_, 0.6487, 3.52, 0.188, 352, 245, HUMAN JNK1ALPHA KINASE WITH 4-PHENYL-7-AZAINDOLE IKK2 INHIBITOR.
4876, d2vwiB_, 0.6487, 3.55, 0.213, 264, 239, STRUCTURE OF THE OSR1 KINASE A HYPERTENSION DRUG TARGET
4877, d2brhA_, 0.6487, 3.52, 0.153, 257, 242, STRUCTURE-BASED DESIGN OF NOVEL CHK1 INHIBITORS: INSIGHTS INTO HYDROGEN BONDING AND PROTEIN-LIGAND AFFINITY
4878, d1zydB1, 0.6487, 3.44, 0.200, 251, 240, CRYSTAL STRUCTURE OF EIF2ALPHA PROTEIN KINASE GCN2: WILD- TYPE COMPLEXED WITH ATP.
4879, d1zmuB_, 0.6487, 3.39, 0.211, 296, 242, CATALYTIC AND UBIQUTIN-ASSOCIATED DOMAINS OF MARK2/PAR-1: WILD TYPE
4880, d1wfcA_, 0.6487, 3.68, 0.180, 340, 245, STRUCTURE OF APO UNPHOSPHORYLATED P38 MITOGEN ACTIVATED PROTEIN KINASE P38 (P38 MAP KINASE) THE MAMMALIAN HOMOLOGUE OF THE YEAST HOG1 PROTEIN
4881, d1pmuA_, 0.6487, 3.63, 0.162, 342, 247, THE CRYSTAL STRUCTURE OF JNK3 IN COMPLEX WITH A PHENANTROLINE INHIBITOR
4882, d4lg4D_, 0.6486, 3.15, 0.221, 250, 235, STRUCTURAL BASIS FOR AUTOACTIVATION OF HUMAN MST2 KINASE AND ITS REGULATION BY RASSF5
4883, d3cgfA_, 0.6486, 3.57, 0.154, 346, 246, IRAK-4 INHIBITORS (PART II)- A STRUCTURE BASED ASSESSMENT OF IMIDAZO[12 A]PYRIDINE BINDING
4884, d2wtvD_, 0.6486, 3.63, 0.186, 262, 247, AURORA-A INHIBITOR STRUCTURE
4885, d2hakC_, 0.6486, 3.87, 0.163, 310, 251, CATALYTIC AND UBIQUTIN-ASSOCIATED DOMAINS OF MARK1/PAR-1
4886, d1v0bB_, 0.6486, 2.92, 0.182, 261, 231, CRYSTAL STRUCTURE OF THE T198A MUTANT OF PFPK5
4887, d2wtvA_, 0.6485, 3.64, 0.186, 262, 247, AURORA-A INHIBITOR STRUCTURE
4888, d5k72B_, 0.6483, 3.04, 0.225, 267, 231, IRAK4 IN COMPLEX WITH COMPOUND 21
4889, d4fsmA_, 0.6483, 3.50, 0.154, 265, 240, CRYSTAL STRUCTURE OF THE CHK1
4890, d3hecA_, 0.6483, 3.36, 0.185, 329, 238, P38 IN COMPLEX WITH IMATINIB
4891, d5lohA_, 0.6480, 3.08, 0.179, 248, 234, KINASE DOMAIN OF HUMAN GREATWALL
4892, d5ap5A1, 0.6480, 3.37, 0.174, 248, 242, NATURALLY OCCURRING MUTATIONS IN THE MPS1 GENE PREDISPOSE CELLS TO KINASE INHIBITOR DRUG RESISTANCE.
4893, d4tyhB_, 0.6480, 3.79, 0.178, 335, 247, TERNARY COMPLEX OF P38 AND MK2 WITH A P38 INHIBITOR
4894, d3v6rB_, 0.6480, 3.58, 0.154, 346, 246, DISCOVERY OF POTENT AND SELECTIVE COVALENT INHIBITORS OF JNK
4895, d3rocA_, 0.6480, 3.64, 0.171, 337, 245, CRYSTAL STRUCTURE OF HUMAN P38 ALPHA COMPLEXED WITH A PYRIMIDINONE COMPOUND
4896, d3fmmA_, 0.6480, 3.70, 0.171, 346, 246, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH RO6226
4897, d2ghmA_, 0.6480, 3.65, 0.171, 336, 245, MUTATED MAP KINASE P38 (MUS MUSCULUS) IN COMPLEX WITH INHBITOR PG-895449
4898, d4hokU_, 0.6479, 4.25, 0.135, 289, 259, CRYSTAL STRUCTURE OF APO CK1E
4899, d3kvxA_, 0.6479, 3.28, 0.184, 327, 239, JNK3 BOUND TO AMINOPYRIMIDINE INHIBITOR SR-3562
4900, d3fv8A_, 0.6479, 3.25, 0.176, 331, 239, JNK3 BOUND TO PIPERAZINE AMIDE INHIBITOR SR2774.
4901, d4f9yA_, 0.6478, 3.82, 0.161, 339, 248, HUMAN P38 ALPHA MAPK IN COMPLEX WITH A NOVEL AND SELECTIVE SMALL MOLECULE INHIBITOR
4902, p4btfA2, 0.6478, 3.80, 0.180, 297, 250, STRUCTURE OF MLKL
4903, d3hl7A_, 0.6478, 3.61, 0.180, 336, 245, CRYSTAL STRUCTURE OF HUMAN P38ALPHA COMPLEXED WITH SD-0006
4904, d3h10D_, 0.6478, 3.58, 0.188, 255, 245, AURORA A INHIBITOR COMPLEX
4905, d2qhmA_, 0.6478, 3.65, 0.152, 268, 243, CRYSTAL STRUCTURE OF CHEK1 IN COMPLEX WITH INHIBITOR 2A
4906, d4xv1A1, 0.6477, 2.46, 0.219, 228, 224, B-RAF KINASE V600E ONCOGENIC MUTANT IN COMPLEX WITH PLX7904
4907, d3h10A_, 0.6477, 3.70, 0.190, 268, 247, AURORA A INHIBITOR COMPLEX
4908, d3ds6C_, 0.6477, 3.78, 0.173, 349, 249, P38 COMPLEX WITH A PHTHALAZINE INHIBITOR
4909, d2x81A_, 0.6477, 3.28, 0.176, 242, 238, STRUCTURE OF AURORA A IN COMPLEX WITH MLN8054
4910, d2j90A1, 0.6477, 2.98, 0.194, 259, 232, CRYSTAL STRUCTURE OF HUMAN ZIP KINASE IN COMPLEX WITH A TETRACYCLIC PYRIDONE INHIBITOR (PYRIDONE 6)
4911, d5o2bA1, 0.6476, 3.64, 0.210, 268, 238, CRYSTAL STRUCTURE OF WNK3 KINASE DOMAIN IN A DIPHOSPHORYLATED STATE AND IN A COMPLEX WITH THE INHIBITOR PP-121
4912, d4czuC_, 0.6476, 3.87, 0.181, 281, 249, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF SNRK3.23 AT1G30270 T190D MUTANT
4913, d2xf0A_, 0.6476, 3.28, 0.160, 251, 237, CRYSTAL STRUCTURE OF CHECKPOINT KINASE 1 (CHK1) IN COMPLEX WITH INHIBITORS
4914, d3o8tA_, 0.6475, 3.48, 0.191, 332, 241, CONFORMATIONAL PLASTICITY OF P38 MAP KINASE DFG-MOTIF MUTANTS IN RESPONSE TO INHIBITOR BINDING
4915, d2qhnA_, 0.6475, 3.61, 0.153, 268, 242, CRYSTAL STRUCTURE OF CHEK1 IN COMPLEX WITH INHIBITOR 1A
4916, d3db8A_, 0.6474, 3.46, 0.207, 261, 242, CRYSTAL STRUCTURE OF AN ACTIVATED (THR->ASP) POLO-LIKE KINASE 1 (PLK1) CATALYTIC DOMAIN IN COMPLEX WITH COMPOUND 041
4917, d1oveA_, 0.6474, 3.93, 0.172, 349, 250, THE STRUCTURE OF P38 ALPHA IN COMPLEX WITH A DIHYDROQUINOLINONE
4918, d4fswA_, 0.6473, 3.43, 0.159, 265, 239, CRYSTAL STRUCTURE OF THE CHK1
4919, d2zduA_, 0.6473, 3.38, 0.154, 330, 241, CRYSTAL STRUCTURE OF HUMAN JNK3 COMPLEXED WITH AN ISOQUINOLONE INHIBITOR
4920, d2wajA_, 0.6473, 3.58, 0.154, 348, 246, CRYSTAL STRUCTURE OF HUMAN JNK3 COMPLEXED WITH A 1-ARYL-34- DIHYDROISOQUINOLINE INHIBITOR
4921, d4uynA_, 0.6472, 3.28, 0.192, 249, 240, SAR156497 AN EXQUISITELY SELECTIVE INHIBITOR OF AURORA KINASES
4922, d4fttA_, 0.6472, 3.62, 0.153, 266, 242, CRYSTAL STRUCTURE OF THE CHK1
4923, d4zthA_, 0.6471, 3.71, 0.171, 339, 245, STRUCTURE OF HUMAN P38AMAPK-ARYLPYRIDAZINYLPYRIDINE FRAGMENT COMPLEX USED IN INHIBITOR DISCOVERY
4924, d2hakE_, 0.6471, 3.76, 0.180, 318, 250, CATALYTIC AND UBIQUTIN-ASSOCIATED DOMAINS OF MARK1/PAR-1
4925, d4xoyA_, 0.6470, 3.60, 0.144, 326, 243, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH AN INHIBITOR
4926, d4ftcA_, 0.6470, 3.53, 0.154, 266, 240, CRYSTAL STRUCTURE OF THE CHK1
4927, d4ft5A_, 0.6470, 3.54, 0.162, 265, 240, CRYSTAL STRUCTURE OF THE CHK1
4928, d3h10B_, 0.6469, 3.69, 0.191, 267, 246, AURORA A INHIBITOR COMPLEX
4929, d2xrwA1, 0.6469, 3.23, 0.176, 346, 238, LINEAR BINDING MOTIFS FOR JNK AND FOR CALCINEURIN ANTAGONISTICALLY CONTROL THE NUCLEAR SHUTTLING OF NFAT4
4930, d2o8yA_, 0.6469, 3.19, 0.213, 269, 235, APO IRAK4 KINASE DOMAIN
4931, d4p90B_, 0.6467, 3.58, 0.169, 262, 242, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN PAK1 IN COMPLEX WITH COMPOUND 15
4932, d3w10A_, 0.6467, 3.53, 0.198, 263, 243, AURORA KINASE A COMPLEXED TO PYRAZOLE AMINOQUINOLINE I
4933, d3dbdA_, 0.6466, 3.48, 0.207, 261, 242, CRYSTAL STRUCTURE OF AN ACTIVATED (THR->ASP) POLO-LIKE KINASE 1 (PLK1) CATALYTIC DOMAIN IN COMPLEX WITH COMPOUND 094
4934, d4otiA_, 0.6465, 3.72, 0.189, 303, 244, CRYSTAL STRUCTURE OF PRK1 CATALYTIC DOMAIN IN COMPLEX WITH TOFACITINIB
4935, d4m69B_, 0.6465, 3.68, 0.178, 264, 247, CRYSTAL STRUCTURE OF THE MOUSE RIP3-MLKL COMPLEX
4936, d4eh2A_, 0.6465, 3.68, 0.176, 337, 244, HUMAN P38 MAP KINASE IN COMPLEX WITH NP-F1 AND RL87
4937, d2gtnA_, 0.6465, 3.63, 0.184, 337, 244, MUTATED MAP KINASE P38 (MUS MUSCULUS) IN COMPLEX WITH INHBITOR PG-951717
4938, d5fxrA1, 0.6464, 3.89, 0.289, 299, 246, IGFR-1R COMPLEX WITH A PYRIMIDINE INHIBITOR.
4939, d4izaC_, 0.6464, 3.49, 0.168, 335, 244, STRUCTURE OF DUALLY PHOSPHORYLATED ERK2 BOUND TO THE PEA-15 DEATH EFFECTOR DOMAIN
4940, d3kf7A_, 0.6464, 3.61, 0.176, 337, 244, CRYSTAL STRUCTURE OF HUMAN P38ALPHA COMPLEXED WITH A TRIAZOLOPYRIMIDINE COMPOUND
4941, d3ka0A_, 0.6464, 3.11, 0.163, 279, 233, MK2 COMPLEX WITH INHIBITOR 6-(5-(2-AMINOPYRIMIDIN-4-YLAMINO)-2- HYDROXYPHENYL)-N-METHYLBENZO[B]THIOPHENE-2-CARBOXAMIDE
4942, d2w5hA1, 0.6464, 3.35, 0.170, 257, 241, HUMAN NEK2 KINASE APO
4943, d5ei2A_, 0.6463, 3.46, 0.172, 256, 244, RAPID DISCOVERY OF PYRIDO[34-D]PYRIMIDINE INHIBITORS OF MONOPOLAR SPINDLE KINASE 1 (MPS1) USING A STRUCTURE-BASED HYDRIDIZATION APPROACH
4944, d2wmvA_, 0.6463, 3.26, 0.148, 251, 237, CRYSTAL STRUCTURE OF CHECKPOINT KINASE 1 (CHK1) IN COMPLEX WITH INHIBITORS
4945, d2jamA_, 0.6463, 3.34, 0.174, 279, 241, CRYSTAL STRUCTURE OF HUMAN CALMODULIN-DEPENDENT PROTEIN KINASE I G
4946, d4w4vA_, 0.6462, 3.75, 0.157, 342, 249, JNK2/3 IN COMPLEX WITH 3-(4-{[(2-CHLOROPHENYL)CARBAMOYL]AMINO}-1H- PYRAZOL-1-YL)-N-(2-METHYLPYRIDIN-4-YL)BENZAMIDE
4947, d4ftaA_, 0.6462, 3.41, 0.155, 264, 238, CRYSTAL STRUCTURE OF THE CHK1
4948, d2jamB_, 0.6462, 3.39, 0.174, 280, 242, CRYSTAL STRUCTURE OF HUMAN CALMODULIN-DEPENDENT PROTEIN KINASE I G
4949, d5mtxA_, 0.6460, 3.55, 0.178, 331, 242, DIBENZOOXEPINONE INHIBITOR 12B IN COMPLEX WITH P38 MAPK
4950, d4hokW_, 0.6460, 4.28, 0.139, 289, 259, CRYSTAL STRUCTURE OF APO CK1E
4951, d3fkoA_, 0.6460, 3.68, 0.176, 343, 245, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH RO3668
4952, d1ywrA_, 0.6460, 3.61, 0.180, 338, 245, CRYSTAL STRUCTURE ANALYSIS OF INACTIVE P38 KINASE DOMAIN IN COMPLEX WITH A MONOCYCLIC PYRAZOLONE INHIBITOR
4953, d4ehvA_, 0.6459, 3.68, 0.189, 337, 244, HUMAN P38 MAP KINASE IN COMPLEX WITH NP-F10 AND RL87
4954, d4d1zA_, 0.6459, 2.79, 0.186, 258, 226, CDK2 IN COMPLEX WITH A LUCIFERIN DERIVATE
4955, d3zxtC_, 0.6459, 3.10, 0.190, 259, 232, DIMERIC STRUCTURE OF DAPK-1 CATALYTIC DOMAIN IN COMPLEX WITH AMPPCP-MG
4956, d3f9nA_, 0.6459, 3.33, 0.155, 253, 238, CRYSTAL STRUCTURE OF CHK1 KINASE IN COMPLEX WITH INHIBITOR 38
4957, d2xeyA_, 0.6458, 3.33, 0.160, 252, 238, CRYSTAL STRUCTURE OF CHECKPOINT KINASE 1 (CHK1) IN COMPLEX WITH INHIBITORS
4958, d1zy5B1, 0.6458, 3.30, 0.191, 247, 236, CRYSTAL STRUCTURE OF EIF2ALPHA PROTEIN KINASE GCN2: R794G HYPERACTIVATING MUTANT COMPLEXED WITH AMPPNP.
4959, d4qd6B1, 0.6457, 2.10, 0.344, 241, 215, ITK KINASE DOMAIN IN COMPLEX WITH INHIBITOR COMPOUND
4960, d4f9wA_, 0.6456, 3.55, 0.189, 336, 243, HUMAN P38ALPHA MAPK IN COMPLEX WITH A NOVEL AND SELECTIVE SMALL MOLECULE INHIBITOR
4961, d4cztC_, 0.6455, 3.88, 0.169, 286, 248, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF SNRK3.23 AT1G30270
4962, d3zyaA1, 0.6455, 3.74, 0.163, 341, 245, HUMAN P38 MAP KINASE IN COMPLEX WITH 2-AMINO-PHENYLAMINO- DIBENZOSUBERONE
4963, d4hokS_, 0.6454, 4.24, 0.136, 286, 258, CRYSTAL STRUCTURE OF APO CK1E
4964, d4hokI_, 0.6454, 4.32, 0.138, 291, 260, CRYSTAL STRUCTURE OF APO CK1E
4965, d3hp2A_, 0.6454, 3.82, 0.198, 341, 247, CRYSTAL STRUCTURE OF HUMAN P38ALPHA COMPLEXED WITH A PYRIDINONE COMPOUND
4966, d5lohB_, 0.6453, 3.12, 0.174, 250, 235, KINASE DOMAIN OF HUMAN GREATWALL
4967, d4useB_, 0.6452, 3.75, 0.174, 278, 242, HUMAN STK10 (LOK) WITH SB-633825
4968, d3ttjA_, 0.6452, 3.65, 0.154, 333, 246, CRYSTAL STRUCTURE OF JNK3 COMPLEXED WITH CC-359 A JNK INHIBITOR FOR THE PREVENTION OF ISCHEMIA-REPERFUSION INJURY
4969, d1pmvA_, 0.6451, 3.60, 0.159, 347, 246, THE STRUCTURE OF JNK3 IN COMPLEX WITH A DIHYDROANTHRAPYRAZOLE INHIBITOR
4970, d5kbrB_, 0.6450, 3.49, 0.172, 260, 239, PAK1 IN COMPLEX WITH 7-AZAINDOLE INHIBITOR
4971, d4eh7A_, 0.6450, 3.69, 0.184, 337, 244, HUMAN P38 MAP KINASE IN COMPLEX WITH NP-F6 AND RL87
4972, d4xv1B1, 0.6448, 2.67, 0.230, 233, 226, B-RAF KINASE V600E ONCOGENIC MUTANT IN COMPLEX WITH PLX7904
4973, d3qudA_, 0.6448, 3.82, 0.182, 345, 247, HUMAN P38 MAP KINASE IN COMPLEX WITH 2-AMINO-PHENYLAMINO-BENZOPHENONE
4974, d2p33A_, 0.6448, 3.62, 0.154, 332, 246, SYNTHESIS AND SAR OF AMINOPYRIMIDINES AS NOVEL C-JUN N- TERMINAL KINASE (JNK) INHIBITORS
4975, d2o0uA_, 0.6448, 3.78, 0.157, 331, 248, CRYSTAL STRUCTURE OF HUMAN JNK3 COMPLEXED WITH N-{3-CYANO-6-[3-(1- PIPERIDINYL)PROPANOYL]-4567-TETRAHYDROTHIENO[23-C]PYRIDIN-2-YL}- 1-NAPHTHALENECARBOXAMIDE
4976, d4ftqA_, 0.6447, 3.24, 0.157, 254, 236, CRYSTAL STRUCTURE OF THE CHK1
4977, d3jvrA_, 0.6446, 3.52, 0.150, 258, 240, CHARACTERIZATION OF THE CHK1 ALLOSTERIC INHIBITOR BINDING SITE
4978, d3cgoA_, 0.6446, 3.63, 0.171, 332, 246, IRAK-4 INHIBITORS (PART II)- A STRUCTURE BASED ASSESSMENT OF IMIDAZO[12 A]PYRIDINE BINDING
4979, d2gfsA_, 0.6446, 3.76, 0.171, 344, 245, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH RO3201195
4980, d5uojA_, 0.6445, 4.01, 0.194, 343, 248, THE STRUCTURE OF THE MAP KINASE P38 AT 2.1 ANGSTROMS RESOLUTION
4981, d1zmvB_, 0.6445, 3.47, 0.207, 296, 242, CATALYTIC AND UBIQUTIN-ASSOCIATED DOMAINS OF MARK2/PAR-1: K82R MUTANT
4982, d1zmuA_, 0.6444, 3.42, 0.207, 293, 241, CATALYTIC AND UBIQUTIN-ASSOCIATED DOMAINS OF MARK2/PAR-1: WILD TYPE
4983, d3uvqA_, 0.6443, 3.64, 0.169, 333, 243, HUMAN P38 MAP KINASE IN COMPLEX WITH A DIBENZOSUBERONE DERIVATIVE
4984, d3ttiA_, 0.6442, 3.59, 0.155, 341, 245, CRYSTAL STRUCTURE OF JNK3 COMPLEXED WITH CC-930 AN ORALLY ACTIVE ANTI-FIBROTIC JNK INHIBITOR
4985, d3h9fA1, 0.6442, 3.50, 0.173, 256, 243, CRYSTAL STRUCTURE OF HUMAN DUAL SPECIFICITY PROTEIN KINASE (TTK) IN COMPLEX WITH A PYRIMIDO-DIAZEPIN LIGAND
4986, d4un0D_, 0.6441, 3.47, 0.173, 276, 243, CRYSTAL STRUCTURE OF THE HUMAN CDK12-CYCLINK COMPLEX
4987, p3lhjA_, 0.6441, 3.83, 0.179, 341, 246, CRYSTAL STRUCTURE OF P38A MITOGEN-ACTIVATED PROTEIN KINASE IN COMPLEX WITH A PYRAZOLOPYRIDINONE INHIBITOR.
4988, d2ydjA_, 0.6441, 3.31, 0.168, 252, 238, DISCOVERY OF CHECKPOINT KINASE INHIBITOR AZD7762 BY STRUCTURE BASED DESIGN AND OPTIMIZATION OF THIOPHENE CARBOXAMIDE UREAS
4989, d3gi3A_, 0.6440, 3.50, 0.192, 330, 239, CRYSTAL STRUCTURE OF A N-PHENYL-N -NAPHTHYLUREA ANALOG IN COMPLEX WITH P38 MAP KINASE
4990, d1zy4B1, 0.6440, 3.37, 0.191, 247, 236, CRYSTAL STRUCTURE OF EIF2ALPHA PROTEIN KINASE GCN2: R794G HYPERACTIVATING MUTANT IN APO FORM.
4991, d1kwpB_, 0.6440, 3.35, 0.148, 313, 236, CRYSTAL STRUCTURE OF MAPKAP2
4992, d4ftkA_, 0.6439, 3.52, 0.155, 263, 238, CRYSTAL STRUCTURE OF THE CHK1
4993, d3g90X_, 0.6439, 3.57, 0.152, 345, 244, JNK-3 BOUND TO (Z)-5-FLUORO-1-((6-FLUORO-4H-BENZO[D][13]DIOXIN-8-YL) METHYL)-3-(HYDROXYIMINO)INDOLIN-2-ONE
4994, d3fi4A_, 0.6439, 3.63, 0.165, 339, 242, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH RO4499
4995, d3dj6A_, 0.6439, 3.35, 0.185, 252, 238, CRYSTAL STRUCTURE OF THE MOUSE AURORA-A CATALYTIC DOMAIN (ASN186->GLY LYS240->ARG MET302->LEU) IN COMPLEX WITH COMPOUND 823.
4996, d2r0uA_, 0.6439, 3.64, 0.157, 269, 242, CRYSTAL STRUCTURE OF CHEK1 IN COMPLEX WITH INHIBITOR 54
4997, d1zxeC1, 0.6439, 3.62, 0.182, 265, 242, CRYSTAL STRUCTURE OF EIF2ALPHA PROTEIN KINASE GCN2: D835N INACTIVATING MUTANT IN APO FORM
4998, d4yr8C_, 0.6437, 3.10, 0.185, 318, 233, CRYSTAL STRUCTURE OF JNK IN COMPLEX WITH A REGULATOR PROTEIN
4999, d4eh8A_, 0.6437, 3.64, 0.174, 336, 242, HUMAN P38 MAP KINASE IN COMPLEX WITH NP-F7 AND RL87
5000, d1yw2A_, 0.6436, 3.94, 0.169, 341, 248, MUTATED MUS MUSCULUS P38 KINASE (MP38)
